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PREFACE 
The work featured in this thesis represents part of the research 1 perfonned 
throughout my doctoral studies. These results were harvested from the Laboratory of 
Cellular Neurobiology at the University of Québec à Trois-Rivières, Canada, but also 
from a collaborative effort with the Laboratory of Neurophannacology at the University 
of Cagliari, Italy, where 1 completed six months of research during my doctoral studies. 
This thesis is presented in the fonn of scientific articles and manuscripts: as of 
August 2018, two have been published and one has been submitted. It also refers to 
two reviews and one book chapter pertinent to the core subject and for which 1 am lead 
author. These can be found in the appendices. 
As per the authorization granted by the Cellular and Molecular Biology Graduate 
Program Committee on April 20th , 2017, this thesis is written entirely in English. 
A French surnmary of the thesis is provided in the following pages, and French 
surnrnaries of each of the articles are supplied at the beginning of the corresponding 
chapters. Please take note that the introduction and discussion sections are written in 
Canadian English, whereas the articles, manuscripts and reviews are written in American 
or British English, according to the language requirements specified by the editors of the 
scientific journals in which they were published or submitted. One of the reviews is also 
written in French. 
AlI abbreviations and acronyrns employed throughout the text or within figures are 
listed in the table provided for this purpose. Abbreviations in text are defined upon first 
encounter, except for common biochemical tenns or when the fluidity of the text is 
hindered. Within figures, abbreviations are described in the legend upon first encounter, 
regardless of whether the y were first introduced in the text, but are not defined in 
subsequent legends. It is important to note that each chapter that features an article 
stands alone within this thesis and may therefore present tenns or abbreviations that are 
inconsistent with the remainder of the text. 
x 
Last, 1 wish to mention that this thesis explores three distinct subject 
matters integrated in a single discourse: dopaminergic neurons, hyperglycaemia and the 
polyphenol resveratrol. Granted the broadness of the topics discussed herein, 
the introduction is accordingly lengthy, as 1 was committed to appropriately ventilate aIl 
dimensions impinging on the central hypothesis and on future perspectives. Likewise, 
owing to the multiple techniques and models used to achieve the objectives of this 
thesis, the methodology is meticulously described in the aim of guiding the reader 
through the numerous decisions made upstream of the results presented herein. 
RÉSUMÉ 
Au deuxième rang des maladies neurodégénératives les plus communes après la maladie 
d'Alzheimer, la maladie de Parkinson atteint quelque 1 % de la population âgée de plus 
de 60 ans. Cette pathologie est caractérisée par la perte des neurones dopaminergiques 
logés dans la substance noire pars compacta du mésencéphale, conduisant à une 
diminution de la dopamine dans le striaturn dorsal et à l' apparition de symptômes 
moteurs. Malgré d ' amples efforts dévoués à l'élucidation des ses mécanismes 
neuropathologiques, la neurodégénérescence sélective des neurones de la voie 
nigrostriée demeure incomprise. En effet, la voie dopaminergique mésocorticolimbique, 
provenant du mésencéphale au niveau de l'aire ventrale tegmentale et innervant le 
striaturn ventral et le cortex préfrontal, ne semble pas dégénérer. Une explication 
voudrait que les neurones de la voie nigrostriée expriment un phénotype distinct les 
rendant plus vulnérables au stress oxydant. Selon cette conjecture, les neurones 
dopaminergiques de la voie nigrostriée devraient exhiber une plus grande susceptibilité à 
toute source de stress oxydant. 
Dans cette optique, nous avons émis l' hypothèse que les neurones de la voie nigrostriée 
sont plus vulnérables au stress oxydant engendré par l 'hyperglycémie en comparaison, 
par exemple, à ceux de la voie mésocorticolimbique. En premier lieu, nous avons vérifié 
que de fortes concentrations de glucose pouvaient causer un stress oxydant menant à la 
dégénérescence de neurones dopaminergiques en culture. En effet, chez les cellules 
PCI2 différenciées en neurones dopaminergiques, ces conditions conduisaient à une 
hausse des niveaux de l'anion superoxyde, une espèce réactive de l' oxygène produite 
en excès dans les premiers instants suivant une hyperglycémie. En maintenant ces 
concentrations élevées sur une période de 96 h, les cellules neuronales PCI2 entraient en 
apoptose, tel que le confirmaient la fragmentation de l' ADN et l' altération des profils 
d'expression de plusieurs marqueurs apoptotiques. De plus, l'usage d ' un antioxydant 
éprouvé, le polyphénol resvératrol, abrogeait la hausse des niveaux d'anion superoxyde 
et la mort des cellules neuronales PCI2. 
Suite à la confirmation que de fortes concentrations de glucose pouvaient conduire à la 
mort de neurones dopaminergiques en culture, nous avons voulu vérifier notre hypothèse 
centrale dans un modèle rongeur d'hyperglycémie. Nous avons employé un paradigme 
bien connu qui fait appel à l' administration de streptozotocine, une toxine ciblant les 
cellules productrices d'insuline, afin de générer un modèle de rat exhibant une 
hyperglycémie pouvant être maintenue pour une durée de 6 mois. À l'aide de méthodes 
immunologiques, nous avons démontré qu 'une hyperglycémie chronique induisait la 
dégénérescence des neurones dopaminergiques de la substance noire pars compacta, 
mais pas de ceux de l' aire ventrale tegmentale. Conséquemment, nous observions 
une perte des terminaisons dopaminergiques dans le striatum dorsal qui n' était pas 
perceptible dans le striatum ventral. De plus, par microdialyse intracérébrale, nous avons 
confirmé une baisse des niveaux de dopamine explicitement dans le striatum 
dorsal. Cette neurodégénérescence était accompagnée de l' augmentation du nombre 
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d'astrocytes et de la perte de cellules microgliales au niveau de la substance noire pars 
compacta et du striatum, mais pas dans l'aire ventrale tegmentale. 
En complément, nous avons examiné les aspects comportementaux de notre modèle 
de rat hyperglycémique à l'aide de tests utilisés chez les rongeurs parkinsoniens. 
Nos résultats démontrent l'existence de déficits moteurs évoquant ceux retrouvés chez 
les patients parkinsoniens. Il était intéressant de constater que ces troubles moteurs ainsi 
que la baisse des niveaux de dopamine se manifestaient avant que ne soit perceptible la 
neurodégénérescence, indiquant un possible dysfonctionnement du système nigrostrié en 
amont de la mort neuronale. Puisque la dopamine occupe un rôle prépondérant dans 
la régulation des comportements sociaux, nous avons également procédé à l' étude 
des interactions entre paires de rats non-familiers, tout en nous attardant à leurs 
communications ultrasoniques dont les paramètres sont vraisemblablement modulés par 
la dopamine. Lors de ces rencontres sociales, nous avons découvert que les rats 
hyperglycémiques exhibaient une hyper-sociabilité et une agressivité accompagnées de 
l'accroissement du nombre de vocalisations ultrasoniques émises, suggérant l'existence 
d'un dysfonctionnement dopaminergique. L'intensité de ces témoignages hyper-réactifs 
était de plus corrélée au degré de perte d'innervation du striatum dorsal. 
La somme de ces résultats nous permet de conclure que les neurones de la 
voie nigrostriée exhibent une susceptibilité manifeste vis-à-vis de conditions 
hyperglycémiques soutenues. Ces démonstrations viennent en appui aux études 
épidémiologiques soulignant un risque accru de développer la maladie de Parkinson 
chez les patients diabétiques. 
Mots-clés: comportements sociaux anormaux, déficits moteurs, diabète, 
hyperglycémie, maladie de Parkinson, neurones dopaminergiques, stress oxydant, 
voie mésocorticolimbique, voie nigrostriée. 
SUMMARY 
Parkinson 's disease affects an estimated 1 % of the population over the age of 60 years, 
making it the second most cornrnon neurodegenerative disorder after Alzheimer's 
disease. Fundamentally, this pathology features a progressive loss of dopaminergic 
neurons harboured in the substantia nigra pars compacta of the midbrain, which leads 
to decreased dopamine release in the dorsal striatum responsible for the emergence of 
motor symptoms. Despite arduous efforts deployed to improve our understanding of 
the neuropathological underpinnings of this disease, researchers are still at loss as to 
why the nigrostriatal dopaminergic pathway undergoes preferential early degeneration 
compared, for instance, to the neighbouring mesocorticolimbic pathway originating 
from the ventral tegmental area in the midbrain and projecting to the ventral striatum 
and prefrontal cortex. Rapidly gaining momentum is a proposition providing that 
nigrostriatal dopaminergic neurons possess a distinctive phenotypic liability responsible 
for their relative susceptibility to oxidative stress. If this holds true, nigrostriatal 
dopaminergic neurons should be preferentially vulnerable to unspecific oxidative insults. 
On these bases, we hypothesized that nigrostriatal dopaminergic neurons are more 
vulnerable to hyperglycaemia-induced oxidative stress compared to other neuronal 
populations, expressly ones of the mesocorticolimbic pathway. We began by verifying 
that high glucose conditions are conducive to the death of dopaminergic neurons in 
culture and that this degeneration is linked to oxidative stress. When cultured in elevated 
yet physiological concentrations of glucose, differentiated dopaminergic neuronal PC12 
cells promptly exhibited high levels of superoxide anion, a key reactive oxygen species 
who se overproduction constitutes the earliest event in hyperglycaemia-induced oxidative 
stress. Sustained for 96 h, high glucose conditions led to the apoptotic death of neuronal 
PC12 cells substantiated by DNA fragmentation and altered expression profiles of 
various markers of apoptosis. Treating neuronal dopaminergic PC12 cells with a potent 
antioxidative polyphenol, resveratrol, attenuated the rise in superoxide anion levels and 
afforded protection against high glucose-induced apoptosis. 
After confirming that high glucose conditions elicit a state of oxidative stress leading to 
the death of dopaminergic neurons in culture, we set out to verify our central hypothesis 
in a rat model of long-term hyperglycaemia. We employed a well-known paradigm 
that utilizes streptozotocin, a toxin that targets insulin-producing pancreatic ~ cells, 
to generate a model presenting a hyperglycaemic phenotype that could be maintained for 
up to 6 months. Employing irnrnunohistochemical and immunoblotting techniques, 
we demonstrated that long-term hyperglycaemia in rats causes the degeneration of 
dopaminergic neurons in the substantia nigra pars compacta, but not in the ventral 
tegmental area. Accordingly, dopaminergic terminal fibres were less dense in the dorsal 
than in the ventral striatum of hyperglycaemic rats. Utilizing the intracerebral 
microdialysis technique, we also showed that dopamine release was diminished in the 
dorsal striatum, but not in the ventral striatum or in the prefrontal cortex. We further 
discovered a noticeable increase in astrocytes that was neuroanatomically coincidental to 
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a loss of microglial cells in the substantia nigra pars compacta and striatum, but not in 
the ventral tegrnental area. 
Behavioural alterations were assessed in a series of tasks destined to uncover motor 
deficits in rodent models of Parkinson's disease. Long-term hyperglycaemic rats 
manifested signs of bradykinesia and gait disturbances reminiscent of parkinsonian 
motor syrnptoms. Interestingly, motor deficits and dampened dorsostriatal dopamine 
release were apparent before neurodegeneration could be discerned, suggesting possible 
functional impairments of the nigrostriatal pathway upstream of neuronal death. 
Considering dopamine also exerts an important control on social behaviours, 
we examined interactions between pairs of unacquainted rats and analyzed dopamine-
regulated ultrasonic vocalizations known to reflect the subjects ' affective state. 
In particular, hyperglycaemic rats engaged in markedly hyper-sociable and hyper-
aggressive encounters, while emitting a greater number of ultrasonic vocalizations, 
evocative of a dopaminergic dysfunction. Remarkably, the intensity of these hyper-
reactive phenotypes correlated with the degree of dorsostriatal dopaminergic 
denervation. 
Taken together, our data expose the preferential vulnerability of the nigrostriatal 
pathway to sustained hyperglycaemia, supporting the physiological significance of their 
phenotypic liability to oxidative stress. Our findings further strengthen the apparent 
epidemiological link between pre-existing diabetes and an increased risk of developing 
Parkinson's disease. 
Keywords: abnormal social behaviours, diabetes, dopaminergic neurons, 
hyperglycaemia, mesocorticolimbic pathway, motor deficits, nigrostrial pathway, 
oxidative stress, Parkinson' s disease. 
TABLE OF CONTENTS 
ACKNOWLEDGMENTS ......................................................................................... vii 
PREFACE................................................................................................................... ix 
RÉSUMÉ..................................................................................................................... xi 
SUMMARY ................................................................................................................ xiii 
LIST OF T ABLES ..................................................................................................... xxiii 
LIST OF FIGURES ................................................................................................... xxv 
LIST OF ABBREVIATIONS AND ACRONYMS ................................................. xxix 
CHAPTERI 
INTRODUCTION ...................................................................................................... 1 
1.1 Dopaminergic neurons .... ............. ................... ........ .... .... ............. ........ ............... 1 
1.1.1 Dopamine metabolism and neurotransmission ... .... ........ ...... ........ .. ........ 3 
1.1.2 Central dopaminergic systems.......... ...... ........ ............. ... ............ .... ........ 9 
1.1.2.1 The nigrostriatal pathway .... ..... ... ..... . .... ....... . ... .... .. .. .... .. .... ...... Il 
1.1.2.2 The mesocorticolimbic pathway... ....... ....... .................. .... ...... .. 15 
1.1.2.3 Converging and diverging functions ... .. ...... ...... ........ .............. . 16 
1.1.3 Parkinson ' s disease ...... .... ......... .......... .... ........ ........ ........ .... .. ...... ... ..... .... 18 
1.1.3.1 Clinical symptomatology and treatments .. .... .. .................. ..... .. 19 
1.1.3.2 Prodrome and biomarkers.. .................. ............ ........ ............. .... 24 
1.1.3.3 Pathophysiology ........ .............. ...... .......................... ........ ........ . 26 
1.1.3.4 Vulnerability of the nigrostriatal pathway ......... ...... ........ ......... 31 
1.2 Hyperglycaemia in the central nervous system... ........ ........ ......... ..... .. ......... ....... 38 
1.2.1 Glucose as a preferential fuel for the brain ......... ..... ...... ..... ....... ... .......... 38 
1.2.2 Neuronal glucose transport .................... .... .... ................ ......... ...... .. ...... .. 39 
1.2.2.1 Transporters and kinetics ......... ...................... ... .. ... ......... .......... 39 
1.2.2.2 Physiological considerations .... ........ .... ... ........ ... ...................... 44 
1.2.3 Neuronal glucose metabolism. ..... .. ... ........ .......... .. .. .. ............... .... .... ....... 46 
1.2.3.1 Specifie metabolic fates ... .... .... .... ... .................... ........... ......... .. 48 
1.2.3.2 CUITent hypotheses in neuroenergetics..... ..... ........ ... .... ... ... .. .... 50 
XVI 
l.2.4 Neuronal oxidative stress in hyperglycaemia .................... ............ ........ . 54 
1.2.4.1 Mitochondrial mechanisms ................................ .............. .... ..... 55 
1.2.4.2 Rerouting mechanisms: polyol pathway and macromolecule 
glycation.. ................... .... ...... ...... .... ............. ................ ... .. .. ....... 60 
l.2.5 Vulnerability of the nigrostriatal pathway .................................. ...... .... .. 65 
1.2.5.1 Epidemiological basis: Parkinson 's disease in diabetic 
patients ... ...... ........ ........................ .... ............ .... ......... ...... ......... . 65 
1.2.5.2 Molecular and cellular bases.......................................... .. ........ . 68 
1.3 The antioxidative polyphenol resveratrol.................................. .......................... 72 
1.3.1 Background..... ............................... ..................... ...... .............................. 72 
1.3.1.1 Historical context...................................................................... 72 
1.3.1.2 Dietary origins ............ .......................... ................................ .... 74 
1.3.1.3 Structure, chemistry and antioxidative functions ...... ........ .. ..... 76 
1.3.2 Protection of dopaminergic neurons against oxidative stress .. ........ .... ... 78 
1.3.3 Direct putative targets ................................ .................... ............ ............. 81 
1.3.3.1 Ribosyldihydronicotinamide dehydrogenase (quinone) and 
oxidative stress.... ... ............................................. .... ..... ...... ....... 82 
1.3.3.2 Phosphodiesterases and the energy sensing axis .............. .. ...... 83 
1.3.3.3 Mammalian target of rapamycin and autophagy ...................... 85 
1.3.3.4 Other targets....... ...... ......... ........ .. .............................................. 87 
1.4 Research aims and hypotheses ............ ........ .. .. .. .............................. ............ .... .... 88 
1.4.1 Objective 1: Evaluate the degeneration of cultured dopaminergic 
neuronal cells in high glucose conditions ............ .............. .. ................... 89 
1.4.2 Objective 2: Determine the potential of the antioxidative polyphenol 
resveratrol to hamper the high glucose-induced degeneration of 
cultured dopaminergic neuronal cells ...... .... .. ........................................ . 90 
1.4.3 Objective 3: Characterize dopaminergic neurodegeneration in a rat 
model of long-term hyperglycaemia .......... .. ...................... .. ................... 90 
1.4.4 Objective 4: Assess the behavioural alterations resulting from 
nigrostriatal neurodegeneration in a rat model of long-term 
hyperglycaemia ............ ......... .. .... .... .... .... ...... ... ...... ........ .......... ............... 91 
1.5 Methodology .. .............. ........ ..... ... .. .... ............ ..... .. .... ...... ...................... .... ... .. .. ... 92 
l.5.1 Objective 1: Evaluate the degeneration of cultured dopaminergic 
neuronal cells in high glucose conditions .... ................ ...... .. .... .. ...... ....... 92 
XVll 
1.5.1.1 CeU culture. ...... ........................... ... ................ ............ ......... .... .. 92 
1.5.1.2 High glucose conditions ..... .... ............................ ..... .. ............... 94 
1.5.1.3 Superoxide anion quantification ............................. .................. 96 
1.5.1.4 Evaluation of apoptotic death ................... ....... .................... ..... 98 
1.5.2 Objective 2: Determine the potential of the antioxidative polyphenol 
resveratrol to hamper the high glucose-induced degeneration of 
cultured dopaminergic neuronal ceUs ..... ... ..... ........ .......... ..... ........... ...... 105 
1.5.2.1 Resveratrol treatments .......... .................... ........ ... ..... ........ ... ..... 105 
1.5.3 Objective 3: Characterize dopaminergic neurodegeneration in a rat 
model of long-term hyperglycaemia ....... ........ ................ ........ ................ 106 
1.5.3.1 Rat model of long-term hyperglycaemia .................................. 106 
1.5.3.2 Intracerebral glucose measurements ..... ........ ........ .... .... .... ........ 114 
1.5.3.3 Assessment of neurodegeneration ....... ......... ........ ............ ... ..... 116 
1.5.3.4 Assessment of glial profiles ....... .... .... ........ .......... .. ... ... ....... ..... . 117 
1.5.3.5 Intracerebral dopamine measurements ....... .... ... .......... ... ... .... ... 11 8 
1.5.4 Objective 4: Assess the behavioural alterations resulting from 
nigrostriatal neurodegeneration in a rat model of long-term 
hyperglycaemia ............ ............. ... ...... ..................... ... ..... ........................ 122 
1.5.4.1 Assessment of motor deficits ...... .... .... ..... ... ................ ........ ...... 122 
1.5.4.2 Evaluation of social behaviour ... ........ ......................... ........... .. 125 
CHAPTERII 
RESVERA TROL PROTECTS DOP AMINERGIC PC12 CELLS FROM 
HIGH GLUCOSE-INDUCED OXIDA TIVE STRESS AND APOPTOSIS: 
EFFECT ON P53 AND GLUCOSE-REGULATED PROTEIN 75 
LOCALIZA TION ...................................................................................................... 129 
2.1 Author contributions ......... .... ................. ..... ....... ... ........ .......... ... ....... ... ... .... ........ 129 
2.2 Résumé .... ...... .. ... ..... .. ......... ..... ............................................................................ 130 
2.3 Full article in English: Resveratrol protects dopaminergic PC12 ce Us from 
high glucose-induced oxidative stress and apoptosis: effect on p53 and 
glucose-regulated protein 75 localization ........................ .. .... ...... .. .. ..... ..... ......... 131 
Abstract...... .......... . ............... ....... ........... ........... .. ................... ................. ... ..... .... 131 
Introduction. ....... ........... .... ........... .... .................... ................... ...... ........ .............. 131 
Materials and methods. ........................................... ............................................ 134 
Drugs and chemicals .................... .......... ................... ....... ...... ... ....... ...... . 134 
Cell culture and treatments ...... .. ... ........ ......... .... ....... ....... ........ ......... ...... 135 
XVlll 
Detection of mitochondrial superoxide radical............... ...... .......... .. ...... 136 
Immunofluorescence and terminal deoxynucleotidyl transferase 
dUTP nick end labeling as say ............................ ............ ........ .... ..... ..... .. . 136 
Specific apoptotic DNA denaturation analysis ....... ...................... ......... . 137 
Protein extraction............ ........ ............ ........................... ........ ..... .... ....... . 137 
Electrophoresis and Western blotting analysis .......... ... .......................... 138 
Glucose-regulated prote in 75-p53 colocalization ................................... 139 
Statistical analysis .............. ........................ ............................................. 139 
Results ........................... ..... .. ..... ... ..... .... .... ................ .... ........ ....................... ....... 140 
Resveratrol rescues high glucose-induced production of superoxide ..... 140 
Resveratrol reduces high glucose-induced apoptosis ......... ............. ..... ... 141 
Resveratrol modulates p53 and glucose-regulated protein 75 
subcellular localization and colocalization ........................... ...... ..... ....... 146 
Discussion. ........ ........... ........ ..... ...... ............ .............. ............... ......... ...... ... .. ....... 149 
Acknowledgments ....... .......... .... ..... ...... .......... .... ...... ........... .......... .... ... ...... ........ 153 
References........ ................. .... ............. ............ ........ ...................................... ....... 154 
CHAPTERIII 
DOPAMINERGIC NEURODEGENERA TION IN A RA T MODEL OF 
LONG-TERM HYPERGL YCEMIA: PREFERENTIAL DEGENERA TION 
OF THE NIGROSTRIATAL MOTOR PATHWAY ............................................. 163 
3.1 Author contributions .................................................................................... ....... 163 
3.2 Résumé ......................................................................................................... ....... 164 
3.3 Full article in English: Dopaminergic neurodegeneration in a rat model of 
long-term hyperglycemia: preferential degeneration of the nigrostriatal 
motor pathway ....... .............. ........... .... .......... ....... ..... . .......... .... ...... .... .... .... .. ..... .. 165 
Abstract ..... ................ .... ....... ............... ................... .. ..... ...... ....... .. .... .............. .... . 165 
Introduction ...... ...... ........... ........... ..... .. ......... ....................... .......... ..... ................. 165 
Research design and methods ......... .... ..... ..... ... ... ..... ..... ............... .... ........ ...... .... . 167 
Subjects ............. ...... ......... ....... ........ ............ ............ .... ........ .... .. ........ .... .. 167 
Induction of long-term hyperglycemia ... ........................ ....... ... .............. 168 
Motor behavior assessments ... ................................... ........ .. ...... ........ ..... 168 
Cognitive behavior. .... ..... ... ..... ......................... ...... .... .... ....... .... .............. 169 
Sacrifices and tissue harvest .................................. ..... .... ............ ........... . 169 
X1X 
Immunohistochemistry ....... ...... ... .... .......... ......... ........ ........ ......... ...... .. ... 170 
Immunoblotting ....... .... ... .... .......... ....... .. ................. .............. ...... ..... ....... 171 
Intracerebral microdialysis in freely moving rats ................................... 171 
Brain tissue and microdialysate glucose concentrations......................... 173 
Statistical analyses .......... ................ ...... .... .... ........ ... ...................... ......... 173 
Results ..... ......................................... ... ..... ....... ...... ... ........ ........ .......................... 173 
Glucose concentrations increase in aU brain regions of interest........... .. 173 
Long-term hyperglycemia causes preferential degeneration of 
dopaminergic neurons in the substantia nigra pars compacta................. 174 
Long-term hyperglycemia causes preferential degeneration of 
dopaminergic fiber terminaIs in the dorsal striatum ............... ...... ... ....... 176 
Long-term hyperglycemia does not cal}se substantial 
neurodegeneration in the prefrontal cortex or in the hippocampus ..... .. . 179 
Long-term hyperglycemic rats display astrogliosis and loss of 
microglial cells in degenerated dopaminergic regions .......... ....... ......... 182 
Long-term hyperglycemic rats show altered motor behaviour .......... ..... 183 
Discussion ............ .......... ...... .... ............ ......... ..... ........ ......... ....... .... ........... .... ..... . 185 
Acknowledgments ............... ....... ..... ... ........................................... ....... .. .... ........ 188 
References .... .............................. ................. ........................... ............... ...... .... .. .. 189 
Supplementary data ..... .... .... .. ...... .......... ........ ............. ........ ............ ...... ......... ..... 195 
Metabolic follow-up and disease progression ... .... .... ..... .... ................ .... 195 
CHAPTERIV 
LONG-TERM HYPERGL YCAEMIA MODIFIES SOCIAL BEHA VIOUR 
AND EMISSION OF ULTRASONIC VOCALISATIONS IN RATS: 
A POSSIBLE EXPERIMENTAL MODEL OF AL TE RED SOCIABILITY 
IN DIABETES ............................................................................................................ 203 
4.1 Author contributions ........... ......... .... .. .. ............ ... .... .... .......... ......... .... ................. 203 
4.2 Résumé .... .... ... ........ .... ... ...... ... ...... ........ ........ .. ..... ........ ........... . ... ....... . ....... ........ .. 203 
4.3 Full article in English: Altered social behaviour in long-term hyperglycemic 
rats displaying dopaminergic striatal denervation: an ultrasonic vocalisation 
study .......... ............... ..... ... ................ .... ........ .. ..... .... ........... .... ........... ............. .... . 205 
Abstract ... ............... ................ ..................... ........ ......... ...... ..... .. ... ..... .... ........ .... .. 205 
Introduction. .... ...... ..... .. .. ......... .... ...... . .... ...... ........... ............... ............................ . 205 
Results ........ ....... .... ....... ....... .... .... ... ... ........... ............................................... ....... 207 
xx 
Occurrences of social behaviours and ultrasonic vocalisations ...... .. .... .. 207 
Behavioural covariance profile .......................................... .............. ...... . 209 
Behaviour-vocalisation covariance profile ........................ .. .................. . 211 
Magnitude of social interactivity and ultrasonic vocalisations in 
relation to the degree of striatal denervation, hypoinsulinaemia and 
glucose intolerance .. ...... ..... ........ ........ ................ ........ ................... ... ....... 212 
Discussion ........................................................................................ .. ................. 217 
Methods ... ........ .... ...... ..... ........... ........ ................... ........ ........ .... .... .... .. ..... ...... ..... 220 
Subjects ... ........ .......... ..... ...... ..... ............ ........ ........ ...... .. .... ......... ....... ...... 220 
Induction ofhyperglycaemia .............. .. .... .. ........ .. .... .... .. .. .. .... .... .... .. ...... 22 1 
Oral glucose intolerance test and baseline insulinemia .. .......... .. .... .. .. .... 22 1 
Ultrasonic vocalisations and social behaviour ........ ...... .. .......... .. ...... ...... 222 
Immunohistochemistry .... ... ............... .. ....... . ..... .......... ..... .. .... ................. 223 
Statistical analyses .... .. ........... ... ...... ... ..... ................ ........ ................ ...... .. 224 
Acknowledgments ... ......... .... ........ ....... ....... .................... .............. .. .. .. .... ............ 225 
References......... .......................... ........ ........ ........ ... .... ......................... .... ..... ....... 226 
CHAPTERV 
DISCUSSION ............................................................................................................. 235 
5.1 Objectives 1 and 2: In vitro , high glucose-induced oxidative stress leads to 
the death of dopaminergic neurons avertible by resveratrol treatments ...... .. .... . 235 
5.1 .1 Drawing parallels with Brownlee's theory .. ................................ .. .. .. ..... 235 
5.1.1.1 From oxidative stress to apoptosis ........................ .... .. .... .. .. ...... 236 
5.1.1.2 Paradoxical poly(adenosine diphosphate-ribose) polyrnerase 
inactivation ....... .... ...... ........ .... ........ ..... ............... ... ....... ...... .... .. . 238 
5.1.1.3 Validating Brownlee ' s model .. .. .. .... ...... ........ .. .............. .. .. .. .... . 239 
5.1.2 Resveratrol: partial antioxidative effects, but full neuroprotection .. ...... 241 
5.1.3 The relevance of glucose-regulated protein 75 in Parkinson 's di sease .. 243 
5.2 Objectives 3 and 4: In vivo, long-term hyperglycaemia causes preferential 
nigrostriatal dopaminergique neurodegeneration and consequential 
behavioural alterations .... ............................... ...... .............. ...... ... .... .. .. .. .... .. ........ 243 
5.2.1 Intracerebral glucose concentrations .. ................................ ...... .... .. ...... ... 244 
5.2.2 Altered glial profiles as an indicator of oxidative stress .... .. ................... 245 
5.2.3 Nigrostriatal dopaminergic neuronal death: beyond the validation of 
our hypothesis ................. ........ ...... ....... .......... ..... .... ..... ....... ... .... ....... ...... 249 
XXI 
5.2.3.1 Subtle neurodegeneration and motor deficits ........................... 249 
5.2.3.2 Time course of neurodegeneration ........................................... 251 
5.2.4 Hyper-aggressive and hyper-sociable manifestations .......... ...... ......... .... 252 
5.2.4.1 A possible relationship with nigrostriatal dopaminergic 
neurodegeneration.............. ......... ....... ... ........... ............. .. .... ..... . 253 
5.2.4.2 A possible relationship with phasic and tonic dopaminergic 
neurotransmission ... ......... .... .................... ........ .... .... ............ ..... 254 
5.2.5 Effects attributable to hypoinsulinaemia ................................................ 256 
5.2.5.1 Insulin in neurodegeneration ............ ................ ... ........ ........... .. 256 
5.2.5.2 Insulin in behaviour ...................................... ... ..... .................... 260 
5.2.6 Improving the model .... .......... .... .............................. ........ .... .. .... ............. 265 
5.3 Therapeutic perspectives ... ........ ....... ........... .... .... ........ ...... ...... ........ ......... ........... 266 
5.3.1 Implications for diabetic patients ........ .... .... ........ ........ ..... ... ........... ...... ... 267 
5.3 .2 Implications for parkinsonian patients ................... .......... ... ........ ......... ... 268 
5.3 .3 Employing resveratrol to therapeutic ends ............. ........ ... .. .. ..... ......... ... 271 
5.4 Concluding remarks ..... ...... ......... ...... ............................................. ............... ...... 271 
REFERENCES ........................................................................................................... 273 
APPENDIXA 
LA NEURO-INFLAMMA TION : DR JEKYLL OU MR HYDE? ....................... 389 
APPENDIXB 
OLD MOLECULES, NEW INSIGHTS: THERAPEUTIC 
CONSIDERATIONS FOR THE USE OF POL YPHENOLS IN 
NEURODEGENERATIVE DISEASES .................................................................. 411 
APPENDIXC 
PREVENTION OF NEUROINFLAMMATION BY RESVERA TROL: 
FOCUS ON EXPE~ENTAL MO DELS AND MOLECULAR 
MECHANISMS .......................................................................................................... 461 
APPENDIXD 
THE LINK BETWEEN PARKINSON'S DISEASE AND ATTENTION-
DEFICIT HYPERACTIVITY DISORDER: AN ACCOUNT OF THE 
EVIDENCE ................................................................................................................. 491 

LIST OF TABLES 
Table Page 
1.1 Projected prevalence of select neurological conditions in Canada .... ...... ... ... 24 
1.2 Markers of prodromal Parkinson' s disease ......... ........ ... ..... ........ .... ..... ...... .... 25 
1.3 List of monogenic Parkinson 's disease and parkinsonism ............................ 28 
1.4 Overview of the 26 genetic risk variants showing consistent association 
with Parkinson's disease in genome-wide association studies .... ......... ......... 33 
1.5 Glucose transporter expression sites and substrates . ... ........ ...... ............. ....... 40 
1.6 Glucose transport capacities of brain cells..................................................... 42 
1.7 Computed compartment glucose levels for the core (primary) model or 
the astrocyte-neuron lactate shuttle (ANLS)..... ............................................. 43 
1.8 Recent studies investigating the association between diabetes and 
Parkinson 's disease ...... ... ........ .... ....... ....................................... ... .. ................ 68 
1.9 Direct putative targets of resveratrol.............................. ... ............ ... ............ .. 82 
1.10 Animal models of diabetes ..... ............... ............... .... .... ...... .... ...... ............ ...... 108 
1.11 Ingredient lists of the rat diets provided by Harlan........ ................................ 113 
-------------------------------------------------------------------------------------------------
LIST OF FIGURES 
Figure Page 
1.1 The catecholamine biosynthetic pathway ... .. ..... .... .... ............. ............. .... ...... 5 
1.2 Tonic and phasic dopaminergic neurotransmission ...... ................................. 6 
1.3 Dopamine reuptake and catabolism ...... ............ ..... ........ .. ..... ...... .. .... ..... .. ...... 8 
lA Basal ganglia circuitry in decision-making. .... ....... ............ .. .. ..... .... .. .... ........ . 10 
1.5 A8- AI0 dopaminergic neuronal clusters in the rat brain .......................... .... 12 
1.6 Mesocorticolimbic and nigrostriatal projections .. ....... ......... ........ ..... ... ... .. .... 14 
1.7 The various forms ofParkinson's disease .... ........ ........ ........ .......... ....... ........ 20 
1.8 CUITent parkinsonian drug therapies ....................... .......... .... .... .... ........ ..... .... 22 
1.9 Braak staging of the progression of Parkinson's disease-related Lewy 
body pathology................. ...... ........... ...... ...... ........... ........ .. ..... ...... ...... ........... 30 
1.10 Disease mechanisms implicated in Parkinson ' s disease .............. ...... ....... .... . 34 
1.11 Crosstalk between aging and Parkinson' s disease. ...... .. ........ ... .... ... .. .... ..... ... 35 
1.12 Glucose and monocarboxylate transporters in the mammalian brain.... ...... .. 41 
1.13 Schematic representation of glucose metabolism and pertinent 
connecting pathways in neurons and astrocytes ........................... ................. 47 
1.14 A schematic representation of the astrocyte-neuron lactate shuttle theory... . 53 
1.15 Hyperglycaemia-induced generation of superoxide anion at the level of 
the mitochondrial electron transport chain ... .. ... .............. ...... ........ ... ... . ....... .. 57 
1.16 Detrimental activation of P ARP in response to DNA damage..... .. .... .. .. .. .. ... 58 
1.17 NAD in glucose metabolism .............. ........... .... ...... ...... ... .... ......... ... .... ......... . 61 
1.18 The chemistry of prote in gl ycation ....... .. .. ............. .......... ... ......... ........ .... ...... 63 
1.19 Resveratrol in the scientific literature ..... ...... :....... .... .... .. ..... ............ ..... .. .. ..... 74 
XXVI 
1.20 Frequently encountered polyphenols ....................... ...... ....... ........... ... ... ........ 75 
1.21 Resveratrol's putative direct scavenging mechanisms.......... ............. ............ 77 
1.22 Molecular mainstays of metabolic homeostasis.................... .... ......... ............ 85 
1.23 Metabolic regulation of cell growth and autophagy dynamics ... .. ......... ... .... . 87 
1.24 Characterization of dopaminergic neuronal cell cultures ..... ...... ..... ............. . 93 
1.25 Time-course and dose-response study of the toxicity of glucose on 
dopaminergic cells in culture .. .... .... ..... ........ ...... .... ...... ........ ..................... .... . 95 
1.26 Structure and fluorescent mechanism ofMitoSOXTM Red... ......................... 97 
1.27 Selectivity ofMitoSOXTM Red ............... ... ......... ... ..... ... ............. ........ ..... ...... 98 
1.28 The classic intrinsic and extrinsic pathways in apoptosis............ ...... ........... . 99 
1.29 Specificity with respect to temperature kinetics of formamide-induced 
DNA denaturation ........ ....... ........... ............ .... .... ........ ........ .. ........ ..... ......... .... 101 
1.30 Mitochondrial translocation of Bax followed by the formation of the 
mitochondrial permeability transition pore .................... ........... ..... ... ............. 103 
1.31 The multiple roles of GRP75 ............................ ... ..... ... ... ..... .......... ..... ... ... ..... 104 
1.32 Mechanisms of pancreatic B cel! death in chemical-induced diabetes ... ... .... . 111 
1.33 Metabolic follow-up of nicotinamide-streptozotocin or high fat-
streptozotocin treated rats ........................ .... ..... ........... .... ............... ..... ... ..... .. 112 
1.34 Schematic representation of solute ex changes during microdialysis 
experiments ......... ................... ................... ... ............................ .... ...... ............ 120 
1.35 Experimental setup of social behaviour assessments .... ........... .... ........... ....... 127 
2.1 RESV reduces HG-induced superoxide anion production DAergic 
PC12 cel!s ... ... ......... ...................................... ..................... ............... .... .. ....... 141 
2.2 RESV reduces HG-induced apoptosis in DAergic PC12 cel!s ..... ......... ........ 143 
2.3 RESV modulates the expression of apoptotic protein markers. ........ ...... ....... 145 
2.4 Effect ofRESV on the subcellular localization ofp53 and GRP75 ....... ....... 147 
2.5 RESV modulates p53 and GRP75 colocalization ........................ ..... ...... ....... 148 
XXVll 
3.1 Brain glucose concentrations in HG rats compared to CTRL rats................. 174 
3.2 Analyses ofmidbrain markers ofneurodegeneration in HG rats compared 
to CTRL rats .......................................................... .... ........ .................. .......... 175 
3.3 Analyses of striatal markers of neurodegeneration in HG rats compared 
to CTRL rats........ .................. ..... ...... ...... .... ... .... ........ ................ .................... 178 
3.4 Analyses of prefrontal markers of neurodegeneration in HG rats 
compared to CTRL rats .................. .... .................... ..................... ... ....... .... .... 180 
3.5 Analyses of hippocampal markers of neurodegeneration in HG rats 
compared to CTRL rats .............................................................................. ... 181 
3.6 Immunohistochemical analyses of astrocytes and microglial cells in the 
brains of HG rats compared to CTRL rats ..................................................... 183 
3.7 Behavioral assessments of HG rats compared to CTRL rats ...... ........ ....... .... 184 
4.1 Occurrences of social behaviours and USV s..... ..................... ...... ............ ..... 208 
4.2 Affiliative/exploratory and aggression behavioural covariance matrices ...... 210 
4.3 Behaviour-vocalisation covariance matrix ........ ...... ...... ..... .... .......... ......... .... 212 
4.4 Classification of long-term HG rats based on degree of striatal 
denervation, hypoinsulinaemia and glucose Intolerance ........................ . ...... 213 
4.5 Occurrences of social behaviours in relation to the degree of striatal 
denervation, hypoinsulinaemia or glucose Intolerance ....... ........ .... ...... ......... 215 
4.6 Numbers of ultrasonic vocalisations emitted in relation to the degree of 
striatal denervation, hypoinsulinaemia or glucose Intolerance. ................. .... 216 
4.7 Examples of sonograms of ultrasonic vocalisations ... .............. .... .... ........ ..... 223 
5.1 Totallevels ofp53 and GRP75 in neuronal PC12 cells treated with high 
glucose concentrations ......................... ............... .... .... .................... .... .... ..... .. 237 
5.2 Role ofGRP75 in oxidative stress-induced apoptosis ....... ......................... ... 238 
5.3 Dose-response curve depicting the quantitative features of hormesis ........... 242 
5.4 Metabolic activities of astrocytes and neurons .................. ........... ...... ........... 247 
5.5 Classification of long-term hyperglycaemic rats based on the degree of 
striatal denervation in multiple regions.............. ........ ...... ................. ........ ..... 253 
XXVlll 
5.6 Overview of insu lin and insulin-like peptide signalling in the brain .. .. ........ . 257 
5.7 Insulin content and binding in the brain of streptozotocin-treated rats...... .... 259 
5.8 Nigrostriatal dopaminergic neurodegeneration in relation to the degree of 
hypoinsulinaemia or glucose intolerance ........................ .. .. .............. .. ........ .. . 260 
5.9 lnsulin ' s action on the hypothalamus .................................... .. ............ .. ......... 262 
3-MT 
3-0MD 
4EBPl 
6-0HDA 
AADC 
Ac 
ac 
Acetyl-CoA 
ACMSD 
aCSF 
AD 
ADP 
ADPR 
Affin Chrom 
AGE 
AgRP 
Akt or AKT-l 
AMP 
AMPK 
AN69 
LIST OF ABBREVIA TIONS AND ACRONYMS 
3-Methoxytyramine 
3-0-Methyldopa 
Eukaryotic translation initiation factor 4E (eIF4E)-
binding protein 1 
6-H ydroxydopamine 
Aromatic amino acid decarboxylase 
Beta-amyloid 
Acetyl group 
Anterior commissure 
Acetyl coenzyme A 
Aminocarboxymuconate semialdehyde decarboxylase 
gene 
Artificial cerebrospinal fluid (CSF) 
Aldehyde dehydrogenase or autosomal dominant or 
Alzheimer's disease 
Adenosine diphosphate 
Adenosine diphosphate ribosyl 
Affinity chromatography 
Advanced glycation end-product 
Agouti-related protein 
Protein kinase B 
Adenosine monophosphate 
Adenosine monophosphate kinase 
Acrylonitrile 69 membrane 
xxx 
ANLS 
ANOVA 
AP-1 
Apaf-1 
APE1 /Ref-1 
Apo2L1TRAIL 
aq 
AR 
Arc 
ARE 
Arg 
ARN 
Atg13 
ATM 
ATP 
AUC 
Bad 
Bak 
Bax 
BBB 
BCKDK 
Bel-2 
Bel-XL 
BDNF 
BHE 
Astrocyte-neuron lactate shuttle 
Anal ysis of variance 
Activator prote in 1 
Apoptotic protease activating factor 1 
Apurinic/apyramidic endonuelease l /redox factor-1 
Apoptosis antigen 2 ligand/tumour necrosis factor 
(TNF)-related apoptosis-inducing ligand 
Cerebral aqueduct 
Autosomal recessive 
Arcuate nueleus 
Antioxidant response element 
Arginine 
Acide ribonucléique 
Autophagy-related protein 13 
Ataxia telangiectasia mutated serine/threonine kinase 
Adenosine triphosphate or adénosine triphosphate 
Area under curve 
B celllymphoma 2-associated death promoter 
B celllymphoma 2 homologous antagonist/killer 
B celllymphoma 2-associated X protein 
Blood-brain barrier 
Branched chain ketoacid dehydrogenase kinase gene 
B celllymphoma 2 
B celllymphoma-extra large 
Brain-derived neurotrophic factor 
Barrière hémato-encéphalique 
Bill 
Bim 
BSA 
BSLCR 
BSTl 
b.w. 
c-FLIP 
C6orfiO 
C 
CA 
CamKKB 
cAMP 
CART 
CB 
CBR1 
cc 
CCDC62 
CCL 
CCR6 
CD 
B celllymphoma 2 homology 3 (BH3) interacting-
domain death agoni st 
B cell Iymphoma 2-like protein 11 
Bovine serum albumin 
Barrière sang-liquide céphalo-rachidien 
Bone marrow stromal cell antigen 1 gene 
Body weight 
Cell 
XXXI 
First apoptosis signal receptor (Fas)-associated protein 
with death domain (FADD)-like interleukin-1-beta 
converting enzyme (lCE) (FLICE/caspase 8)-like 
inhibitory protein 
Chromosome 6 open reading frame 10 gene 
Cytoplasmic fraction 
Radio-carbon dioxide 
Cornu ammonis 
Calciurn/calmodulin-dependent protein kinase kinase 2 
or beta 
Cyc1ic adenosine monophosphate 
Cocaine and amphetamine regulated transcript 
Cytochalasin B 
Carbonyl reductase 1 
Corpus callosum 
Coiled-coil domain containing 62 gene 
Chemokine [C-C motif] ligand 
Chemokine [C-C motif] receptor type 6 
Cluster of differentiation 
XXXll 
CD200R 
CD95L 
cGMP 
CGRP 
Chem Prot 
CMH 
CN 
CNS 
CNTF 
co 
COMT 
cox 
CR 
CSF 
CSFIR 
CTC 
CTLA-4 
CTRL or Ctrl 
CX3CL 
CX3CR 
CXCL 
Cy3 
CYP 
Cytc 
Dl 
Cluster of differentiation 200 receptor 
Cluster of differentiation 95 ligand 
Cyclic guanosine monophosphate 
Calcitonin gene-re lated peptide 
Chemical proteomics 
Comp/ex majeur d 'histocompatibilité 
Caudate nucleus 
Central nervous system 
Ciliary neurotropic factor 
Coeruleus/subcoeruleus complex 
Catecho 1-0-meth y Itransferase 
Cyclooxygenase or cyclooxygénase 
Complement receptor 
Cerebrospinal fluid 
Colony stimulating factor 1 receptor 
Cerebellothalamocortical 
Cytotoxic T -1 ymphocyte-associated prote in 4 
Control 
Chemokine [C-X3-C motif] ligand or fractalkine 
Chemokine [C-X3-C motif] receptor 
Chemokine [C-X-C motif) ligand 
Cyanine 3 
Cytochrome P450 
Cytochrome c 
Dl-like dopamine (DA) receptor-expressing medium 
spmy neurons 
D2 
DIID2 DA-R 
DA 
DAB 
DAergic 
DAMP 
DAPI 
DAQ 
DAT 
dc 
DDC 
DDRGKI 
DG 
DRAP 
DISC 
DLS 
dm 
DMEM 
DMS 
DNA 
DOPA or L-DOPA 
DOPAC 
DOPAL 
DR4/DR5 
XXXlli 
D2-like dopamine (DA) receptor-expressing medium 
spmy neurons 
D l-like/D2-like dopamine (DA) receptors 
Dopamine 
3,3'-Diaminobenzidine 
Dopaminergic 
Damage-associated molecular pattern 
4',6-Diamidino-2-phen yi indole 
Dopamine quinones 
Dopamine transporter 
Dorsal, caudal or dorsocaudal 
3,4-Dihydroxyphenylalanine (DOPA) decarboxylase or 
diethyldithiocarbamate 
DDRGK domain containing 1 gene 
Dentate gyrus 
Dihydroxyacetone phosphate 
Death-inducing signalling complex 
Dorsolateral striatum 
Dorsal IX/X motor nucleus 
Dulbecco ' s Modified Eagle medium 
Dorsomedial striatum 
Deoxyribonucleic acid 
L-3 ,4-Dihydroxyphenylalanine 
3,4-Dihydroxyphenylacetic acid 
3,4-D ihydroxypheny lacetaldehyde 
Death receptor 4/5 
XXXIV 
DS or dStr 
dUTP 
e-
EGCG 
ELKI 
Enz Inhib 
Epacl or EPAC 
ER 
ERE 
ERK 
Ethidium 
f 
FI-ATPase 
F6P 
FAD 
FADD 
FAM47E 
Fas 
FasL 
FBS 
fc 
Dorsal striatum 
Deoxyuridine triphosphate 
Electron 
Epigallocatechin-3-gallate 
E26 transformation-specifie (ETS)-like transcription 
factor 
Enzyme inhibition assay 
Exchange factor directly activated by cyc1ic adenosine 
monophosphate 1 
Estrogen receptor 
Estrogen response element 
Extracellular signal-related kinase 
3,8-Diamino-5-ethyl-6-phenylphenanthridinium 
Fomix 
FI portion of adenosine triphosphatase (ATPase or 
A TP synthase) 
Fructose 6-phosphate 
Flavin adenine dinuc1eotide (F AD+ oxidized, F ADH2 
reduced) 
First apoptosis signal receptor (Fas)-associated death 
domain 
Family with sequence similarity 47 member E gene 
First apoptosis signal receptor ligand 
First apoptosis signal receptor (Fas) ligand or 
ligand Fas 
Fetal bovine serum 
First order sensory association areas and premotor 
areas and/or primary sensory and motor fields of 
the neocortex 
FcR~ 
FGF 
FIP200 
PITC 
Fluor 
FM 
fMRI 
FOXO 
Fox03a 
Freq 
Fru-2,6-P2 
F.U. 
G6P 
G6PD 
GA3P 
GABA 
GAK 
GAPDH 
GBA 
GCHl 
GDNF 
GFAP 
GI 
Fragment crystallizable region (Fc) receptor beta 
subunit 
Ferrous iron ion (reduced iron 2+) 
Ferric iron ion (reduced iron 3+) 
Fibroblast growth factor 
xxxv 
Retinoblastoma 1 (RBl)-inducible coiled-coil protein 1 
Fluorescein isothiocyanate 
Fluorescence assay 
Frequency modulated 
Functional magnetic resonance imaging 
Forkhead box 0 
Forkhead box 03 
Frequency 
Fructose 2,6-bisphosphate 
Fluorescence units 
Glucose 6-phosphate 
Glucose 6-phosphate dehydrogenase 
Glyceraldehyde 3-phosphate 
Gamma-aminobutyric acid 
Cyclin G associated kinase/auxilin-2 
Glyceraldehyde 3-phosphate dehydrogenase 
Beta-glucocerebrosidase gene 
Guanosine triphosphate (GTP) cyclohydrolase 1 gene 
Glial cell line-derived neurotrophic factor 
Glial fibrillary acidic prote in 
Gastrointestinal 
XXXVI 
Glc Glucose 
Glo Glyoxalase 
Glu Glutamate 
GLUT Glucose transporter 
GMP Guanosine monophosphate 
gp9lphox or Nox-2 Cytochrome b-245 heavy chain 
GPe External globus pallidus 
GPI Glucose 6-phosphate isomerase 
GPi Internai globus pallidus 
GPNMB Glycoprotein neuromedin B gene 
GRP75 or mtHSP70 or mot-2 Glucose-regulated prote in 75 or mortalin or 
mitochondrial heat shock protein 70 
GS· Glutathione (GSH) radical 
GSH Gamma-L-glutamyl-L-cysteinylglycine or glutathione 
GSHR Growth hormone secretagogue receptor or ghrelin 
receptor 
GSK-3 or GS3K 
GSSG or GSSH 
GSTPI 
GTP 
HAD 
Hb 
HbAlc 
HBSS 
hc 
Glycogen synthase kinase 3 
Glutathione disulphide 
Glutathione S-transferase P 
Guanosine triphosphate 
Hydrogen peroxide 
Human immunodeficiency virus-associated dementia 
Hemoglobin 
Glycated hemoglobin subunit alpha 1 
Hank ' s balanced salt solution 
High order sensory association areas and prefrontal 
areas of the neocortex 
XXXVll 
HDAC Histone deacetylase 
HDACI Histone deacetylase 1 
HDACi Histone deacetylase inhibitor 
HF High fat, high-fat diet or high fat-fed 
HG Hyperglycaemic or high glucose 
hg38 Human genome build 38 
HIV-l Human immunodeficiency virus-l 
HK Hexokinase 
HLA Human leucocyte antigen 
HLA-DQBl Major histocompatibility complex, class II, 
DQ beta 1 gene 
HMGBl High mobility group box 1 
HMIT H+/myo-inositol transporter 
HO-l Herne oxygenase-l 
HPC Hippocampus 
HPLC High-performance liquid chromatography 
HRP Horseradish peroxidase 
Hsp or HSP Heat shock protein 
HVA Homovanillic acid 
IAP Inhibitor of apoptosis proteins 
Thal Ionized calcium-binding adapter molecule 1 
ICso Half maximal inhibitory concentration 
ICAM Intercellular adhesion molecule 
IDO Indoleamine 2,3-dioxygenase 
IFN Interferon 
IGF Insulin-like growth factor 
XXXVlll 
IGFIR 
IGF2R 
IGFBP or IGFBF 
mc 
IL 
IL-IR 
iNOS 
INPP5F 
l.p. 
IPN 
IR or INSR 
IRS 
l.v. 
JAK 
JAM 
JC polyomavirus 
JNK 
k cat 
Keapl 
KIR 
KSRP 
Insulin-like growth factor receptor I 
Insulin-like growth factor receptor 2 
Insulin-like growth factor binding proteins 
Immunohistochemistry 
Infralimbic prefrontal cortex or interleukin or 
interleukine 
lnterleukin-I receptor 
Inducible nitric oxide synthase 
Inositol polyphosphate-5-phosphatase F gene 
Intraperitoneal 
Interpeduncular nucleus 
Insulin receptor 
Insulin receptor substrate 
Intravenous 
Janus kinase 
Junctional adhesion molecules 
John Cunningham polyomavirus 
c-Jun N-terminal kinases 
Maximum turnover rate 
Dissociation constant 
Kelch-like erythroid cell-derived protein with cap 'n' 
collar (CNC) homology (ECH)-associated prote in 1 
Inhibition constant 
Killer-cell immunoglobulin-like receptor 
Maximum affinity or Michaelis constant 
K homology (KH)-type splicing regulator protein 
LC-MS 
LCR 
LepR 
LFA 
LHA 
LKBl 
Lmxla/b 
LOPD 
LPS 
LRPl 
Lst8 
luc 
M 
MAC-l 
MANN 
MAO 
MA PK 
MAPT 
Mb 
mc 
MC4R 
MCCC1 
Mcl-l 
Liquid chromatography-mass spectrometry 
Liquide céphalo-rachidien 
Leptin receptor 
Lymphocyte function-associated antigen-l 
Lateral hypothalamic area 
Liver kinase B 1 
Linll , Isl-l and Mec-3 do main (LIM) homeobox 
transcription factor a/b 
Late-onset Parkinson's disease 
Lipopolysaccharide 
Low-density lipoprotein receptor-related protein 1 
Target of rapamycin complex subunit lethal with 
SEC 13 protein 8 
Leukotriene A4 hydrolase 
Luciferase 
Mitochondrial fraction 
Macrophage-l antigen 
D-Mannitol 
Monoamine oxidase 
Mitogen-activated protein kinase 
Microtubule-associated prote in tau gene 
Mega base pair 
Transentorhinal region and/or ectorhinal region 
(anteromedial temporal mesocortex) 
Melanocortin 4 receptor 
Methylcrotonoyl-coenzyme A carboxylase 1 gene 
XXXIX 
Induced myeloid leukemia cell differentiation protein 
xl 
MCP-l 
MCT 
MDM2 
MGor3MG 
MGO 
MHC 
MIR4697HG 
ml 
MMP 
mn-SOD 
mPGES-l 
MPO 
MPP+ 
MPTP 
rnRNA 
a-MSH 
MT 
mt 
mtDNA 
mTOR 
mTORCl 
MTT 
MVDI 
N 
NA 
Monocyte chemotactic protein-l 
Monocarbox ylate transporter 
Mouse double minute 2 homologue 
3 -0-Methylglucose 
Methylglyoxal 
Major histocompatibility complex 
Microribonuc1eic acid (miRNA) 4697 host gene 
Medial lemniscus 
Matrix metalloproteinases 
Manganese superoxide dismutase 
lnducible microsomal prostaglandin E synthase-l 
M yeloperoxidase 
I-Methyl-4-phenylpyridinium 
I-Methyl-4-phenyl-l ,2,3,6-tetrahydropyridine 
Messenger ribonuc1eic acid 
Alpha-melanocyte-stimulating hormone 
Mammillothalamic tract 
Mitochondria 
Mitochondrial DNA 
Mammalian target of rapamycin 
Mammalian target of rapamycin complex 1 
3-(4,5-Dimethylthiazol-2-yl)-2 ,5-diphenyltetrazolium 
bromide 
Diphosphomevalonate decarboxylase 
Nuc1ear fraction 
Nicotinamide 
NAcc orNAc 
NAD 
NADP 
NCAM 
NE 
NF-KB 
NGA neurons 
NGF 
NIB 
NK 
NO 
NOEL 
NOR 
Noxa 
NPY 
NQ02 
Nr4a2 or NUITl 
Nrf2 
NSERC 
NT3 
NTS 
Nucleus accumbens 
Nicotinamide adenine dinucleotide (NAD+ oxidized, 
NADH reduced) 
Nicotinamide adenine dinucleotide phosphate 
(NADP+ oxidized, NADPH reduced) 
Neural cell adhesion molecule 
Norepinephrine or noradrenaline 
xli 
Nuclear factor kappa-light-chain-enhancer of activated 
B cells 
Neuropeptide Y (NPY)/gamma-aminobutyric acid 
(GABA)/agouti-related protein neurons (AgRP) 
Nerve growth factor 
National Institute of Health 
Natural killer 
Nitric oxide 
Peroxynitrite 
No observed effect level 
Novel object recognition 
Phorbol-l2-myristate-13-acetate-induced protein 1 
Neuropeptide Y 
Ribosyldihydronicotinamide dehydrogenase (qui none) 
Nuclear receptor 4a2 
Nuclear factor erythroid-derived 2 like 2 
Natural Sciences and Engineering Research Council of 
Canada 
Neurotrophin-3 
Nucleus of the solitary tract 
xlii 
NUCKSl 
OGTT 
OH 
·OH 
OMIM 
OR 
OS 
OT 
Ox Phos 
P 
Porp 
p38MAPK or p38 MAPK 
p47phox 
p66Shc 
PAGvl 
PAMP 
PARK-A TP13A2 
PARK-DJl 
PARK-DNAJC6 
PARK-FBX07 
PARK-LRRK2 
PARK-parkin or PARK2 
Nuclear case in kinase and cyclin dependent kinase 
substrate 1 gene 
Superoxide anion 
Oral glucose tolerance test 
Hydroxyl radical 
Hydroxyl radical 
Online Mendelian Inheritance in Man 
Odds ratio 
Oxidative stress 
Olfactory tubercle 
Oxidative phosphorylation 
Phosphate group 
Probability 
p38 Mitogen-activated protein kinases 
Neutrophil cytosol factor 1 
66 kDa Proto-oncogene Src homologous-collagen 
homologue (Shc) adaptor protein 
Ventrolateral periaqueductal grey 
Pathogen-associated mo\ecular pattern 
Probable cation-transporting adenosine triphosphatase 
(ATPase) 13A2 gene 
Oncogene DJ-l gene 
Auxilin gene 
F-box only protein 7 gene 
Leucine-rich repeat kinase 2 gene 
Parkin gene 
PARK-PINKl 
PARK-SNCA 
PARK-SYNJl 
PARK-VPS35 
PARP or PARP-l 
PBS 
PC12 
PD 
PD-l 
PD-LI 
PDE 
PDH 
PET 
PFA 
PFC 
PFK 
Pfkfb3 
PGC-la 
PGE2 
PGP 
PI3K 
PIGD 
PKA 
Phosphatase and tensin homologue (PTEN)-induced 
putative kinase 1 gene 
Alpha-synuclein gene 
Synaptojanin 1 gene 
Vacuolar protein sorting-associated protein 35 gene 
Poly( adenosine diphosphate-ribose) polymerase 
Phosphate-buffered saline 
Pheochromocytoma cell line 12 
Parkinson's disease 
Prograrnmed cell death protein 1 
Programmed death-ligand 1 
Phosphodiesterase 
Pyruvate dehydrogenase 
Positron emission tomography 
Perifomical area 
Prefrontal cortex 
Phosphofructokinase 
xliii 
6-Phosphofructo-2-kinase/fructose-2 ,6-bisphosphatase 3 
Peroxisome proliferator-activated receptor gamma 
coactivator l-alpha 
Prostaglandin E2 
Proline glycine proline peptide 
Inorganic phosphate 
Phosphatidylinositol 3-kinase or phosphoinositide 
3-kinase 
Postural instability and gait difficulty 
Protein kinase A 
xliv 
PKC 
PKD 
PKM 
PL 
PLC 
PMVK 
POHEM 
POMC 
PPAR 
PPP 
PRR 
PSG 
PTP 
Puma 
Put 
PVN 
Q 
RAS 
RBC 
REM 
RESV 
RlPA 
RIT2 
RNA 
Protein kinase C 
Protein kinase D 
Pyruvate kinase isozymes 
Prelimbic prefrontal cortex 
Phospholipase C 
Phosphomevalonate kinase gene 
Population health model 
Pro-opiomelanocortin 
Peroxisome proliferator-activated receptor 
Pentose phosphate pathway 
Pattern-recognition receptors 
Parkinson's Study Group 
Penneability transition pore 
p53 upregulated modulator of apoptosis 
Putamen 
Paraventricular nucleus 
Quinone 
Free radical 
Rat sarcoma 
Red blood cell 
Rapid eye movement 
Resveratrol or trans-3,5,4'-trihydroxystilbene 
Radioimmunoprecipitation as say 
Ras-like without CAAX 2 gene 
Ribonuc\eic acid 
RNS 
ROH 
ROOH 
ROS 
RPMI 
RRF 
RT 
SCI 
SDFl 
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CHAPTERI 
INTRODUCTION 
Of all the intricate systems that make up the hurnan organism, no other has elicited 
more debate or has inspired such a vast array of theories regarding its functions than the 
central nervous system (CNS). An era's worth of research in neuroscience has amounted 
to our CUITent appreciation of the various temporal, spatial and thermodynamic 
circumstances that dictate neural outcomes in countless contexts. Nevertheless, 
particular modules of the CNS continue to galvanize neuroscientists, in particular the 
multifarious roles dopaminergic systems fulfil in health and disease. This thesis aims to 
address one specific aspect of dopaminergic neurons: their selective vulnerability in 
certain pathological settings, with a keen focus on the nigrostriatal dopaminergic 
pathway involved in Parkinson ' s disease. 
1.1 Dopaminergic neurons 
Possibly the most impressive feature of CNS dopaminergic neurons is their small 
population size, totalling approximately 200 000 cells per hemisphere in humans 
(Stark and Pakkenburg, 2004), weighed against the astonishing number of pro cesses 
the y carry out, for instance motor control, cue-related leaming, arousal, social play, 
mood modulation, endocrine regulation and many more. In fact, to sustain these 
functions, dopaminergic neurons make synapses with no fewer th an 200 million other 
neurons in the striatum, cortex, amygdala and other structures (Stark and Pakkenburg, 
2004). Emerging late in prenatal development, it is possible that dopamine holds a 
particular position in stabilizing and integrating various other brain circuits (Grace, 
2016). Conversely, dopaminergic neurons are phylogenetically ancient, occUITing in all 
mammals, birds, reptiles and insects, which allows assurnptions on their crucial role in 
2 
the adaptation of animal behaviour throughout evolution (Jones and Pilowski, 2002; 
Smeets and Gonzalez, 2000; Yamamoto and Vernier, 2011). 
Dopaminergic subpopulations were first described in the 1960s upon identification 
and classification of groups of catecholaminergic neurons (Dahlstr6m and Fuxe, 1964), 
later updated by others (H6kfelt et al., 1984). Of the designated A1-Al7 groups, 
it is understood today that only groups A8-All comprise proper dopaminergic neurons 
(Bj6rklund and Dunnett, 2007). By definition, dopaminergic neurons utilize the 
catecholamine neurotransmitter dopamine (3-hydroxytyramine) to communicate and, 
thus, express the rate-limiting enzyme of catecholamine biosynthesis, tyrosine 
hydroxylase (TH), as weIl as aromatic amino acid decarboxylase that ultimately 
produces dopamine (Bj6rklund and Dunnett, 2007). Conversely, they do not express the 
enzymes necessary for the conversion of dopamine to the succeeding catecholamines in 
the biosynthetic pathway, namely noradrenaline and adrenaline (Bj6rklund and Dunnett, 
2007). Several other ontological hallmarks are also exclusive to dopaminergic neurons, 
reviewed in greater detail by Arenas et al. (2015) 1 • 
Of equal importance to their role in the CNS, dopaminergic neurons occupy 
important functions in the enteric nervous system (Li et al., 2006). They are principally 
located in the submucosal plexus, only sparingly so in the myenteric plexus, and are 
distributed more densely in the small intestine in comparison to gastric or colonic tissues 
(Li et al., 2004). By secreting dopamine onto smooth muscle cells, dopaminergic 
neurons inhibit gastrointestinal motility (Li et al., 2006). Although the place he Id by 
dopaminergic neurons in the proper operation of the enteric nervous system is 
increasingly acknowledged (see for review Mittal et al., 2017), this thesis will focus on 
CNS dopaminergic neurons. 
1 The presence or absence of developmental factors, such as LIM homeobox transcnptlon factors 
(Lmx 1 a/b) or the late transcription factor nuclear receptor 4a2 (N r4a2 , better known as NUIT 1), 
determines neuronal identity by suppression of lateral fates or activation of dopaminergic ones. 
Today, human dopaminergic neurons can be prepared through direct reprogramming of pluripotent stem 
cells or somatic cells, for the purpose of disease modeling or regenerative therapies (Arenas et al., 
2015). 
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1.1.1 Dopamine metabolism and neurotransmission 
Dopamine was first described in the hum an brain in the 1950s by 
Kathleen Montagu (Montagu, 1957) and named after its previously achieved chemical 
synthe sis utilizing the precursor L-3 ,4-dihydroxyphenylalanine (L-DOPA) (Fahn, 2008). 
Arvid Carlsson and Nils-Âke Hillarp confirmed its identity as a neurotransmitter in the 
CNS (Carlsson et al., 1958), the former receiving the 2000 Nobel Prize in Physiology 
and Medicine for this demonstration (Benes, 2001). A host of researchers later 
confirmed dopamine ' s implication in Parkinson's disease2 (Bazelton et al. , 1967; 
Ehringer and Homykiewicz, 1960; Homykiewicz, 1966) and behavioural disorders, 
such as psychoses and addiction (Baldessarini, 1985). Advances in lesion models and 
dopamine visualization techniques further permitted the discovery of its role in a 
plethora of brain functions upon which were built entire fields still evolving rapidly 
today. 
Alongside noradrenaline and adrenaline, dopamine belongs to the catecholamine 
subcategory of monoamine neurotransmitters, aIl produced from amino acid metabolism 
and collectively important in various aspects of behaviour. The non-essential amino acid 
L-tyrosine is the precursor for catecholamines, easily obtained in a balanced diet or 
derived from L-phenylalanine hydroxylation in the liver, but not in the brain. 
Tyrosine must gain entry to the CNS via the large neutral amino acid transporter by 
competing with other amino acids (Duelli et al. , 2000). Once inside neurons, the first 
step consists in the hydroxylation of L-tyrosine to L-DOPA by the rate-limiting enzyme 
TH. Aromatic amino acid decarboxylase3 then promptly decarboxylates L-DOPA to 
dopamine. In adrenergic neurons, dopamine is further hydroxylated into noradrenaline, 
which is in tum methylated to yield adrenaline (see for review of catecholamine 
biosynthetic pathways Daubner et al., 2011) (Figure 1.1). Whereas dopamine is 
produced in the cytosol of neurons, noradrenaline and adrenaline are mainly synthesized 
in synaptic vesicles. In order to access these vesicles for transformation into other 
2 Parkinson ' s disease is later described in section 1.1.3 . 
3 This enzyme is also referred to as DOPA decarboxylase despite its lack of substrate specificity. 
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catecholamines or for storage until its release, dopamine must use vesicular monoamine 
transporter 2 (VMAT2) (Cartier et al., 2010; Eiden et al., 2004). To reduce dopamine's 
presence in the cytosol, TH and aromatic amino acid decarboxylase are accordingly 
complexed to the cytosolic portion of VMAT2, ensuring rapid vesicular uptake and 
stabilization of dopamine by the acidic environment (Guillot and Miller, 2009). 
This mechanism is important considering that lingering cytosolic dopamine undergoes 
deleterious auto-oxidation reactions (see for review Segura-Aguilar et al., 2014) , 
which yield dopamine-derived quinones known to react with nucleophilic components in 
cells like cysteine residues of proteins (Belluzzi et al. , 2012). Quinones also participate 
in the synthesis of neuromelanin, a pigmented melanin analogue responsible for the dark 
coloration of certain catecholamine-rich structures4 (Sulzer et al. , 2000). 
Dopaminergic neurotransmission occurs by phasic or tonic release (Grace, 2000) 
(Figure 1.2). Phasic firing involves quick spiking activity produced in dopaminergic 
neurons in response to a proper stimulus-mediated action potential (Grace and Bunney, 
1984a) or to presynaptic receptor activation by neighbouring neurons (Rice et al., 20 I l). 
Phasic bursts of dopamine carry proper information to targets and provide them with 
spiking currents necessary for long-term potentiation (Wickens et al., 1996). 
In opposition, tonic firing represents the slower baseline pacemaker activity of 
dopaminergic neurons (Grace and Bunney, 1984b) and rather fulfil a modulatory role 
by regulating postsynaptic targets that are innervated by other afferents. Once secreted, 
dopamine binds G-protein linked metabotropic receptors that exist in five types 
(Missale et al., 1998) and in heterocomplexes with other dopamine or non-dopamine 
receptors (Borroto-Escuela et al., 2017), allowing for a great number of outcomes at the 
postsynaptic membrane. Dopamine receptors can be conveniently separated into the 
stimulatory, low-affinity Dl-like (Dl and D5) and inhibitory, high-affinity D2-like 
(D2-D4) families. It is commonly accepted that D2-like receptors are more sensitive to 
tonic neurotransmission than D l-like receptors that rather transduce phasic bursts 
4 Neuromelanin's role in health and disease is unclear. On the one hand, it chelates transition metals like 
iron ions and may therefore protect catecholaminergic neurons from Fenton reactions that produce 
reactive oxygen species (ROS). However, under certain circumstances, neuromelanin also departs itself 
from these metals, acting thereby as an agent of neurotoxicity (Segura-Aguilar et al. , 20 14). 
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(Dreyer et al. , 2010), but paradigms have been shifting in recent years (Yapo et al., 
2017). 
Figure 1.1 
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The catecholamine biosynthetic pathway. 
(From Wikimedia Commons: https://commons.wikimedia.org/wikilFile: 
Biosynthese _ Catecholamine.svg.) 
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Figure 1.2 
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Tonie and phasie dopaminergic neurotransmission. 
Top: Constant low levels of extracellular dopamine are ensured by 
tonic release, dependent on slow irregular firing and modulated by 
glutamatergic afferents. Release mainly occurs extrasynaptically where 
catechol-O-methyltransferase ensures dopamine degradation. Bottom: 
Phasic dopamine neurotransmission is triggered by burst firing of 
dopaminergic neurons, which release very high levels of dopamine into 
the synaptic c1eft that stimulate postsynaptic dopamine receptors. 
Phasic dopamine is rapidly inactivated by removal from the synaptic c1eft 
via the dopamine transporter. (Adapted from Grace, 2016.) 
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Owing to the relatively slow response of metabotropic dopamine receptors, 
which involves voltage-gated ion channels, dopamine earns the title of neuromodulator, 
alongside serotonin, noradrenaline and histamine, to name a few. Neuromodulators are 
characterized by their capacity to regulate diverse populations of neurons, in contrast to 
other neurotransmitters binding fast-acting ionotropic receptors on more explicitly 
determined postsynaptic targets. As such, dopamine mainly acts by modulating 
the excitability of receptive postsynaptic elements to afferent inputs instead of 
directly affecting their conductance (O'Donnell, 2003). In addition, 60-70% of 
neurotransmission events occur ectopically, outside the synaptic cleft, implying 
significant delays in receptor activation, extension of spatial domains to somatodendritic 
and presynaptic targets, and diluted mediation (Descarries et al., 1996; Sesack et al., 
2003; Venton et al., 2003). 
Aside from synaptic overflow, negative feedback onto presynaptic D2 
autoreceptors and presynaptic influences from other neurotransmitters, dopaminergic 
neurotransmission is principally regulated by reuptake or catabolism (Figure 1.3). 
In particular, phasic bursts of dopamine are largely cleared via the Na+-CI- - dependent 
dopamine transporter (DAT) on presynaptic elements (McElvain and Schenk, 1992; 
Schroeter et al., 2000). Tonic dopamine, on the other hand, occurs mainly outside of 
synapses and is therefore predominantly metabolized by catechol-O-methyltransferases. 
Once in the cytosol, dopamine is rapidly catabolized by monoamine oxidase and 
aldehyde dehydrogenase into 3,4-dihydroxyphenylacetic acid that is further excreted and 
transformed extracellularly by catechol-O-methyltransferase into homovanillic acid 
(Eisenhofer et al. , 2004). Noteworthy, two isoforms of the key degradation enzyme 
exist: monoamine oxidase A, expressed in CNS neuronal and glial cells but also in 
peripheral adrenergic neurons, predominantly metabolizes serotonin and catecholamines, 
whereas monoamine oxidase B, which makes up 80% of this class of enzymes in 
dopaminergic loci, metabolizes catecholamines with a preference for dopamines. 
5 Preferential midbrain and striatal expression renders monoamine oxidase B favoured targets in the 
elaboration oftreatments for Parkinson's disease (Youdim and Weinstock, 2004). 
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Both ofthem were found to generate reactive oxygen species (ROS), which contribute to 
oxidative stress in dopaminergic neurons6 (Andersen et al., 1994; Graham, 1984). 
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Figure 1.3 Dopamine reuptake and catabolism. 
Postsynaptic 
element 
Besides presynaptic reuptake and metabolism described in the text, 
dopamine can also be absorbed by astrocytes via a transporter whose 
identity remains unknown. There, it undergoes degradation mediated by 
catechol-O-methyltransferase before it is transformed by monoamine 
oxidase and aldehyde dehydrogenase into homovanillic acid (Dahlin 
et al., 2007; Hansson and Sellstrom, 1983; Takeda et al., 2002). 3-MT, 
3-methoxytyramine; AADC, aromatic amino acid decarboxylase; 
AD, aldehyde dehydrogenase; COMT, catechol-O-methyltransferase; 
Dl/D2 DA-R, Dl-like/D2-1ike dopamine receptors; DA, dopamine; 
DAQ, dopamine quinones; DA T, dopamine transporter; DOPA, L-3 ,4-
dihydroxyphenylalanine; DOPAC, 3,4-dihydroxyphenylacetic acid; 
DOPAL, 3,4-dihydroxyphenylacetaldehyde; HV A, homovanillic acid; 
MAO, monoamine oxidase; TH, tyrosine hydroxylase; VMA T2, vesicular 
monoamine transporter 2. 
6 Oxidative stress is later described in section 1.2.4. 
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1.1.2 Central dopaminergic systems 
As previously mentioned, dopaminergic neurons are divided into groups 
concurring to cytoarchitectonic and chemoarchitectonic stains, best described in the 
mouse (Fu et al., 2012) and rat (Ikemoto, 2007). Most of these neuronal clusters are 
found in midbrain structures. Explicitly, groups A8-AlO correspond neuroanatomically 
to the retrorubral field, the substantia nigra and the ventral tegmental area, respectively. 
On the other hand, group AlI is rather located in the hypothalamic arcuate nucleus and 
projects to the median eminence where it releases dopamine in the circulation via the 
hypophyseal portal system to influence the secretion of pituitary hormones, notably 
prolactin (see for review Grattan, 2015). Neurons of the AlI group that constitute this 
dopaminergic system, termed the tuberoinfundibular pathway, will not be discussed here 
as its endocrinological role dwells outside of the scope of our present work. 
Midbrain dopaminergic neurons receive afferents from the striatum, the brainstem 
pedunculopontine nucleus, and the lateral habenula via the globus pallidus, the superior 
colliculus and the rostromedial tegmental nucleus. In tum, they extend their projections 
to various subcortical and cortical targets, principally the striatum, thalamus, amygdala, 
globus pallidus and hippocampus (see for reviews Haber, 2014; Lanciego et al., 2012). 
As such, the midbrain participates in basal ganglia circuitry, principally by providing a 
dopaminergic input to gamma-aminobutyric acid (GABA)-producing medium spiny 
neurons of the striatum (Figure lA). The latter receive incoming goal-directed messages 
from various cortical areas, acting as a gateway to basal ganglia that process and manage 
the information before it is transmitted to the thalamus for action 7 (Schultz, 2002). 
Basal ganglia allow action selection by exerting a modulatory foothold on cortical 
information via the stimulatory direct and inhibitory indirect pathways, which oppose 
each other to activate or silence the thalamus. Midbrain dopamine serves to modulate 
7 There are currently two opposing models to explain action selection by dopaminergic inputs to basal 
ganglia. One of these is the Go-NoGo model, which stipulates that direct and indirect pathways act in 
opposition to, respectively, allow actions (Go) or inhibit them (NoGo) (Frank et al., 2004; Shen et al., 
2008). Contrarily, the prepare-and-select model grants basal ganglia dopamine more complicated 
functions , wherein initial direct pathway activation in reaction to stimuli allows the preparation of a set 
of appropriate responses, and subsequent indirect pathway activity permits the selection of one action 
among these choices (Keeler et al., 2014). 
10 
this tight control and to allow more activation of the thalamus by phasically activating 
direct pathway medium spiny neurons that harbour stimulatory Dl , and by tonically 
inhibiting indirect pathway medium spiny neurons that harbour inhibitory D2 receptors. 
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Basal ganglia circuitry in decision-ma king. 
Top: Basal ganglia comprise the caudate-putamen, and the internaI and 
externa1 globus pallidus. The subthalamic nucleus, substantia nigra pars 
compacta and ventral tegmental area are sometimes considered as 
secondary basal ganglia. Bottom: At rest, the thalamus, central activator 
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of actions, is kept in check by the substantia nigra pars reticulata and 
internai globus pallidus. This hold can be lifted through the direct 
pathway when the cerebral cortex activates medium spiny neurons of the 
striaturn, which in turn lifts the inhibition on the thalamus exerted by the 
internai globus pallidus and substantia nigra pars reticulata, thereby 
allowing the achievement of the goal. Conversely, a tighter control of 
the thalamus via the indirect pathway requires the activation of medium 
spiny neurons that will rather inhibit the external globus pallidus, which 
ultimately leads to the activation of the internai globus pallidus and 
substantia nigra pars reticulata responsible for silencing the thalamus and 
thus thwarting the achievement of the goal. Midbrain dopaminergic 
neurons fine-tune the sensitive equilibrium of this basal ganglia circuit 
via aforementioned mechanisms. ac, anterior commissure; CN, caudate 
nucleus; Dl , D1-like dopamine receptor-expressing medium spiny 
neurons; D2, D2-like dopamine receptor-expressing medium spiny 
neurons; DLS, dorsolateral striatum; DMS, dorsomedial striatum; 
GPe, external globus pallidus; GPi, interior globus pallidus; NAc, nucleus 
accumbens; Put, putamen; SNc, substantia nigra pars compacta; SNr, 
substantia nigra pars reticulata; STN, subthalamic nucleus; VTA, ventral 
tegmental area. (Top adapted from Lanciego et al. , 2012; bottom adapted 
from Macpherson et al. , 2014.) 
1.1.2.1 The nigrostriatal pathway 
Restricted to the ventrolateral reglOn of the midbrain, the substantia mgra 
constitutes the first dopaminergic structure to be identified in 1786 in a study addressing 
neuromelanin distribution in the human brain (Parent and Parent, 2010; Vicq D'Azyr, 
1786). However, it was only much later that its role in motor control was recognized 
following its association with Parkinson ' s disease (Bremer, 1920; Brissaud, 1895; 
Hassler, 1939). The substantia nigra harbours group A9 cells, totalling approximately 
16000 in rats (Oorschot, 1996) and 160000-232000 in macaque monkeys (German 
et al. , 1988; Percheron et al. , 1989), and is thus recognized as the most dense population 
of dopaminergic neurons (Figure 1.5). Their localization coincides with the pars 
compacta region of the substantia nigra, dorsal to the pars reticulata zone that contains 
more loosely packed GABAergic neurons. 
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Figure 1.5 A8-AIO dopaminergic neuronal c1usters in the rat brain. 
Immunohistochemical staining of dopaminergic neurons in rat 
brain coronal sections organized rostrocaudally (A-F) depict the 
neuroanatomical location of each cluster at the level of the midbrain. 
Particularly important to us, the substantia nigra pars compacta is found 
laterally to the ventral tegmental area. Scalebars: A-F, 1 mm; inset F, 
0.5 mm. aq, cerebral aqueduct; de, dorsocaudal; f, fomix; IPN, 
interpeduncular nucleus; ml, medial lemniscus; MT, mammillothalamic 
tract; P AGvl, ventrolateral periaqueductal grey; RRF, retrorubral field ; 
SNI, substantia nigra pars lateralis. (From Yetnikoff et al., 2014.) 
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The substantia nigra pars compacta provides the greatest dopaminergic input to 
the striatum, particularly - but not restricted (Yetnikoff et al. , 2014) - to the dorsal 
striatum better known in primates as the caudate nucleus and putamen or simply the 
caudate-putamen8 (Figure 1.6). Nigrostriatal dopaminergic neurons project in a fairly 
mediolateral topographical manner (Lynd-Balta and Haber, 1994) to an estimated 
2.8 million and 31 million striatal neurons in rats and macaques, respectively, each axon 
ramifying abundantly and harbouring sorne 500 000 varicosities (Andén et al., 1966). 
This affords the dorsal striatum with a near-total exposure to dopamine input, implying a 
significant divergence factor of 300-400 between nigrostriatal neurons and striatal 
targets. The importance of nigrostriatal arborizations is even better appreciated when 
taking into account that, at least in rats, one striatal neuron is innervated by an average 
of 100-200 dopaminergic neurons and that one nigrostriatal axon is estimated to interact 
with sorne 75 000 striatal neurons (Matsuda et al., 2009). Such a profuse dopaminergic 
innervation necessarily in fers critical modulatory effects on the dorsal striatum, 
which receives important glutamatergic inputs from the cerebral cortex, thalamus and 
amygdala (Donoghue and Herkenham, 1986; Graybiel, 1990; Sadikot et al., 1992). 
Striatal modulation by nigrostriatal neurons is best appraised in corticostriatal 
motor circuits. As it consists in the most important source of tonic dopamine to 
the striatum, the substantia nigra pars compacta especially inactivates indirect 
pathway medium spiny neurons expressing D2 receptors, thereby downgrading the 
inhibition on the thalamus. In Parkinson's disease, degeneration of nigrostriatal 
dopaminergic neurons disrupts tonic firing in the striatum, which allows for the 
D2 receptor-modulated indirect pathway to exert its full inhibitory effect on the 
thalamus. This pathophysiological feature dwells at the core of parkinsonian motor 
symptoms, chiefly bradkyinesia/akinesia and rigidity (Albin et al., 1989). In fact, several 
animal models employ nigrostriatal pathway les ions of ail sorts to emulate parkinsonian 
symptoms (Deumens et al., 2002; Dut Y and Jenner, 2011; Jackson-Lewis et al. , 2012; 
Nagatsu, 1997; Pinna and Morelli, 2014; Ungerstedt, 1968). 
8 Whether in rodents, primates or humans, the caudate-putamen will hereafter be termed dorsal striatum. 
14 
A mesocortical 
pathway 
B 
midbrain 
mesolimbic 
pathway 
nigrostriatal 
pathway 
# 
midbrain 
Llmbic 
Figure 1.6 Mesocorticolimbic and nigrostriatal projections. 
Both mesocorticolimbic and nigrostriatal pathways ongmate in the 
midbrain, illustrated sagittally (A) and coronally (B). The nigrostriatal 
pathway projects especially onto dorsal regions of the striatum, while 
the mesocorticolimbic pathway mainly innervates the ventral striatum 
(mesolimbic) and the prefrontal cortex (mesocortical). Midbrain 
projections onto the striatum are fairly topographic, depicted by 
colour gradients (B), and modulate specific corticostriatal circuits (C). 
Afferents supplied by sensorimotor, associative and limbic cortical are as 
are also distributed in a particular neuroanatomical manner, which bears 
implications on the behavioural programs that different midbrain 
projections can control (C). dStr, dorsal striatum; OT, olfactory tubercle. 
(Adapted from Chuhma et al., 2017.) 
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1.1.2.2 The mesocorticolimbic pathway 
In the first half of the 20th century, neuroscientists bore a rather unyielding vision 
of basal ganglia as movement processing centres, still somewhat enduring today. 
More complex functions were much later ascribed to these structures upon the 
identification of corticostriatal circuit loops that did not involve motor areas (Alexander 
et al. , 1990; Haber et al., 1985; Young et al. , 1984), and the parallel discovery of a 
particular striatal subdivision located ventrally and sUITounding the anterior commissure 
termed the nucleus accumbens (Heimer, 1978). In the meantime, a collection of studies 
were showing rats to electrically self-stimulate certain regions of their brain as positive 
reinforcement (Olds and Milner, 1954), later found to receive dopaminergic inputs 
(Crow, 1972) and to be sensitive to dopamine agonists or antagonists (Stein, 1964; 
Wise and Bozarth, 1987). Pioneering microdialysis work from the laboratory of 
Prof. Gaetano Di Chiara at the University of Cagliari, Italy, later confirmed the nucleus 
accumbens identity of this region, shown to be sensitive to dopamine agonizing drugs9 
(Di Chiara and Imperato, 1988). 
The nucleus accumbens, found in the ventral striatum, is one of the key dopamine 
terminaIs of the mesocorticolimbic pathway. This system is composed of the mesolimbic 
and mesocortical pathways, originating from groups A8 and Al 0 neurons (Figure 1.5). 
Both lodged in the midbrain, group Al 0 coïncides with the ventral tegmental area 
medial to the substantia nigra pars compacta, whereas group A8 is contained in the 
retrorubral field 10 located dorsocaudally to the substantia nigra pars compacta (Fu et al. , 
2012; Halliday et al. , 20 12a). Mesolimbic dopaminergic neurons project to the striatum, 
preferentially to ventral areas such as the nucleus accumbens and the olfactory tubercle, 
whereas the mesocortical pathway connects the ventral tegmental are a and retrorubral 
9 Di Chiara' s group also made the groundbreaking di scovery that the nucleus accumbens is in fact di vided 
into core and shell subregions, which operate very di fferently in reward valuation (Pontieri et al., 1995 ). 
10 The retrorubral field does not account for much of the dopaminergic innervation provided by the 
midbrain and therefore little attention is pa id to it in this thesi s. Likewise, the olfactory tuberc\e is a 
secondary ventral striatum structure whose functions in the mesolimbic pathway will not be granted 
much focus . 
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field to the pre frontal cortex, but these connections are mu ch less dense than striatal ones 
(Figure 1.6). 
Akin to nigrostriatal dopaminergic neurons, the ventral tegmental area 
operates via modulation of corticostriatal circuits at the level of the striatum. However, 
inasmuch as the nigrostriatal pathway is known for tonically enabling movement, 
the mesocorticolimbic pathway stands out as a reward processing system endowed with 
limbic and executive dimensions permitted by phasic bursts of dopamine (Haber et al. , 
2000). There exists today a wide array of pharmacological paradigms mimicking 
dysfunctional dopaminergic neurotransmission in the ventral striatum and prefrontal 
cortex (Espafia and Jones, 2013; Jones et al., 2011). Notably, these models bear a 
striking likeness to pathologies such as addiction and other neuropsychiatric disorders 
(Bassareo et al., 2011 ; Di Chiara et al., 1993; Grace, 2000, 2016; Tanda et al. , 1996). 
1.1.2.3 Converging and diverging functions 
While nigrostriatal and mesocorticolimbic pathways appear to operate very 
differently considering their fairly different roles in human behaviour and disease, 
they actually function in similar ways. In fact, aside from their archetypal tonic-motor 
and phasic-reward instructions, the nigrostriatal and mesocorticolimbic pathways are 
both endowed with the following characteristics: 1) they comprise dopaminergic 
neurons that can fire both phasically and tonically depending on the information 
conveyed by dopamine; 2) they project onto striatal medium spiny neuron D 1-like 
and D2-1ike receptors thereby modulating corticostriatal circuitry, and; 3) their 
neuroanatomical origins receive feedback projections from the targets they innervate 
that refine dopaminergic neurotransmission. Despite the widely acknowledged 
movement enabling functions of the nigrostriatal pathway, regulation of the striatum by 
its afferents also holds a role in many other decision-making processes, leamed 
behaviours and habits arising from outcome prediction, especially with regard to 
sensorimotor functions. These roles may have to do with time scales of dopamine 
impulses, where sensory-evoked phasic firing encodes teaching signaIs for the 
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acquisition of a behaviour, (Chaudhury et al., 2013; Redgrave and Gurney, 2006; 
Schultz et al., 2006), and where baseline tonic firing enables the proper selection of 
these pre-Iearned behaviours by the basal gang lia (Ellwood et al., 2017; Hikosaka et al., 
2000; Redgrave et al., 1999). Both firing modes are impaired in Parkinson's disease 
(Beeler, 2011; Marklund et al., 2009; Redgrave et al., 2010), although the loss of 
dopamine tone is more typically acknowledged with respect to the motor symptoms it 
produces. The same holds true for the mesocorticolimbic pathway, which is also devoted 
to tonic enabling of pre-Ieamed behaviours aimed at seeking pleasure and rewards that 
had previously required a learning period provided by phasic firing of dopamine 
(Ellwood et al., 2017). 
In a larger sense, nigrostriatal and mesocorticolimbic dopamine operates both as 
a phasic carrier of predicted outcomes and a tonic enabler of postsynaptic neurons, 
from which originates its dual informationallmodulatory role (Saddoris et al., 2013; 
Schultz, 1998). Indeed, in both pathways, fast phasic bursts encode reward, slow phasic 
changes inform on punishing/ambiguous elements, and tonic maintenance enables 
postsynaptic functions (Schultz, 2007). In this respect, an overarching the ory proposes 
CNS dopamine to mediate the basic reactivity of animaIs to their environrnent, ensuring 
their survival by permitting economic decision-making, reward recognition, monitoring 
of uncertainty and detection of punishing elements via the prediction of favourable or 
unfavourable outcomes, wherein dopamine encodes prediction errors (Schultz, 2007) 
and leaming entails progressive reduction of prediction errors. This is applicable to 
motor, social, cognitive, motivational and reward processes regulated by these pathways. 
This begs the following questions: Why are mesocorticolimbic dysfunctions 
highly associated with addiction, whereas nigrostriatal ones are linked with Parkinson's 
disease? And why is the mesocorticolimbic pathway largely spared in Parkinson's 
disease? At first glance, behavioural and pathological disparities in these pathways are 
the result of rather c1ear neuroanatomical distinctions between their origins, embedded 
in different environrnents, and between their targets, innervated by distinct cortical 
inputs and expressing differential distribution patterns of D l-like and D2-like 
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receptors (Bertran-Gonzalez et al., 2008; Centonze et al., 2003; Lanciego et al., 2012). 
As such, even if both pathways operate with a similar dopamine interface regulating 
corticostriatal circuitry, they modulate different cortical programs. Other sources of 
dopaminergic dichotomies in health and disease may rather lie in differential exposures 
to noise-to-signal (tonic-to-phasic) ratios. Indeed, the dorsal striatum is submitted to a 
greater noise-to-signal ratio than the ventral striatum, due to the marked tonicity of 
nigrostriatal neurons responsible for very high basal release of dopamine in the dorsal 
striatum (Dreyer, 2014; Zhang et al., 2009). This al10ws two implications: first, phasic 
firing do es not have the same weight in the dorsal striatum than in the ventral striatum, 
which explains the great differences in the information carried by dopamine in these 
two areas; second, high basal pacemaking activity may in itself constitute a risk factor in 
neurodegeneration, later discussed in the context ofParkinson's disease. 
In keeping with the discriminating elements that pick these pathways apart, 
the remainder of this thesis will address the apparent preferential degeneration of 
nigrostriatal dopaminergic neurons in various conditions, as in Parkinson's disease next 
addressed, and the behavioural alterations that may arise from this neurodegeneration. 
1.1.3 Parkinson 's disease 
The year 2017 marked the 200th anniversary of Dr. James Parkinson's An Essay on 
the Shaking Paisy wherein were described 6 subjects suffering from a pathological state 
that he termed at the time paralysis agitans (see for historical reviews Obeso et al. , 
2017; Parent and Parent, 2010). In this es say, Dr. Parkinson illustrated with acute 
precision several symptomatic aspects exhibited by his subjects that we know today 
were effectively attributable to Parkinson's disease. Indeed, he accurately identified 
the graduai nature of both onset and progression, as well as the expression of gait 
disturbances, forward flexion of the trunk, resting tremors, sleeping troubles and 
gastrointestinal issues in these individuals (Parkinson, 1817). Charcot later expanded on 
these observations to include bradykinesia and rigidity to the key features of the disease, 
and proposed to rename the paralysis agitans disorder Parkinson's disease upon 
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observing that the loss of motor functions was not attributable to weakness (paIsy) 
(Charcot, 1877). 
Since the publication of this pioneering report, the field of Parkinson ' s disease has 
phenomenally progressed. In this age of effervescent neuroscientific developments, 
clinical profiles are more accurately drawn, long-term patient management is improving, 
and the pursuit of etiological and pathophysiological explanations is starting to bear fruit 
(Chaudhuri and Jenner, 2017). The preferential degeneration of the dopaminergic 
nigrostriatal pathway is weIl appreciated today and additional pieces of the puzzle are 
continuously falling into place, especially with respect to non-dopaminergic affections 
(Hall et al., 2014; Qarnhawi et al. , 2015; Remy, 2005). The following section 
surnmarizes state-of-the-art knowledge on Parkinson's disease and draws particular 
attention to the apparent vulnerability of nigrostriatal dopaminergic neurons in 
this pathology. The CUITent state of the field regarding symptomatology, diagnostics, 
pathological basis, genetic and idiopathie etiopathogeneses, experimental models, 
neuroimaging, biomarkers, treatments and unmet needs is extensively reviewed 
elsewhere by preeminent researchers in a special collaborative publication underlining 
the second centenary of the shaking paIsy (Obeso et al. , 2017). 
1.1.3.1 Clinical symptomatology and treatments 
As highlighted by Dr. Parkinson's and others ' early observations, a wide array of 
motor and non-motor symptoms characterize Parkinson ' s disease, which both enable and 
complicate the process for clinicians to arrive to a diagnosis. Indeed, this disorder is 
pronouncedly heterogeneous in terms of inter-individual symptomatology, but also with 
respect to disease progression and sensitivity to treatments (Lang and Obeso, 2004) 
(Figure 1.7). For the sake of example, the age of onset can range from as early as the 
third de cade of life to very old ages (Pagano et al. , 2016); initial motor manifestations 
may affect either upper or lower limbs on either side of the body (Roberts et al. , 2017); 
deterioration rates may present benign or malignant courses (Jankovic et al., 1990), and; 
distinct subpopulations of patients may respond differently to dopamine treatments 
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(Miller et al., 2017). The clinical landscape is further convoluted by the existence of 
idiopathie and genetic forrns of the disease. As a result, the dogma according to which 
Parkinson's disease is a single uniforrn pathology is slowly ce ding to newer concepts 
handling it as a multisystem syndrome or as Parkinson 's diseases (Marras and Lang, 
2008). Clinicians are only beginning to understand how to hamess these inter-individual 
differences in order to improve treatments and clinical trials (Athauda and Foltynie, 
2016a; Marras and Chaudhuri, 2016; Nutt, 2016; Payami, 2017). 
PIGD PD 
• Poor prognosis with rapid 
progression 
• Bradykinesia and rigidity 
• Dementia 
• Depression 
• Anosmia 
• Levodopa 
• Degeneration in 
ventrolateral SN 
MlxedPO 
• DAT SPECT 
• "Egg-shaped" configuration 
on DAT SPECT 
LOPD 
Onset after age 60 y 
Sporadic 
Tremor-dominant PD 
• Good prognosis with slow 
progression 
• Essential tremor 
• Benign tremulous parkinsonism 
• Good response to levodopa 
• Wearing off 
• Increased fMRI activity in CTC 
circuitry 
• Degeneration in medial SN, 
ventral GPi, thalamic serotonin, 
and midbrain (AS) 
• "Eagle wing" configuration 
on DAT SPECT 
YOPD 
Onset between ages 
20 and 40 y 
Genetic 
Dystonia 
Figure 1.7 The various forms of Parkinson 's disease. 
Parkinson's disease is characterized by a wide spectrum of pathological 
expressions. Based on symptomatological peculiarities and disease 
evolution, this pathology can be divided into postural instability and 
gait difficulty, tremor-dominant, mixed, late-onset and young-onset 
Parkinson 's disease. CTC, cerebellothalamocortical; fMRI, functional 
magne tic resonance imaging; LOPD, late-onset Parkinson 's disease; 
PD, Parkinson's disease; PIGD, postural instability and gait difficulty; 
SN, substantia nigra; SPECT, single-photon emission computed 
tomography; YOPD, young-onset Parkinson's disease. (From Thenganatt 
and Jankovic, 2014.) 
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The most prominent feature of Parkinson's disease remams the presence of 
motor symptoms expressed in a majority of patients as a classical triad of resting 
tremors, bradykinesia and rigidity; two of them are required for diagnostic purposes 
(Parkinson Québec, 2018). Later, motor disabilities evolve to implicate gait and postural 
reflex disturbances, though nowadays they are no longer required to emit a diagnosis. 
Non-dopaminergic (extranigral) motor features also arise and consist in falls , freezing 
of gait, speech impairment and difficulty swallowing. Accompanying these motor 
symptoms are equally disabling non-motor manifestations, such as psychiatric 
disturbances, dementia and autonomic failure . Granted Parkinson ' s disease is not a fatal 
condition, patients are expected to live almost as long as healthy individuals and the 
primary cause of death appears to be pneumonia (lwasaki et al. , 1990; Pennington et al., 
2010), although manifestations of more advanced symptoms, such as falls and 
swallowing problems, may lead to premature accidentaI mortalities. 
Adequate management of the incapacitating motor symptoms in Parkinson' s 
disease was only made possible 150 years after the issuing of the shaking paIsy essay 
when George C. Cotzias and his colleagues published a trailblazing paper on L-DOPA 
(Cotzias et al., 1967) that remains, with certain modem ad just ment s, the benchmark 
therapy (Freitas et al. , 2016, Lotia and Jankovic, 2016). While its function is 
unmistakably to restore tonic dopaminergic neurotransmission (Dreyer, 2014), exactly 
how L-DOPA operates remains hazy as ofyet. Indeed, L-DOPA may not act as a simple 
precursor for dopamine allowing for its tonic replenishment in the striatum: sorne have 
advanced its possible role as a neurotransmitter itself (LeWitt and Fahn, 2016). 
Nevertheless, a slew of clinical trials, intervention studies and longitudinal observations 
ceaselessly validate L-DOPA's efficacy in alleviating motor symptoms (LeWitt and 
Fahn, 2016; Olanow, 2014; Yahr, 1969), although several collateral effects are 
manifested by acute and chronic users, the most notable being dyskinesias, impulse 
control disorders and wearing-off in longstanding administration (Aquino and Fox, 
2014; Cilia, 2012; Parkinson Study Group, 2004). In the hop es of delaying the 
apparition of these side effects, sorne patients are initially administered dopamine 
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receptor agonists or monoamine oxidase B inhibitors until these milder medicines can no 
longer manage the motor symptoms as the disease progresses (Figure 1.8). 
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Figure 1.8 
Blood-brain barrier 
Current parkinsonian drug therapies. 
On the left hand side are depicted adjuvant agents necessary for 
L-3 ,4-dihydroxyphenylalanine (L-DOPA) to reach the brain considering 
its propensity to be metabolized in the periphery, thereby dampening its 
efficacy. Other drugs are illustrated on the right, including more recent 
dopamine agonists and inhibitors of the reuptake and metabolism of 
dopamine. It is important to note that no therapy discovered to date 
achieves curative endpoints in Parkinson's disease. 3-0MD, 3-0-
methyldopa; DDC, DOPA decarboxylase. (From http: //step2.medbullets. 
com/step2-3-neurology/121704/parkinsons-disease-drugs.) 
Inter-individual irregularities not only complicate diagnosis, but also shape 
treatment efficacy in Parkinson's disease. Sorne patients, usually younger diagnostics, 
will develop a benignly progressive form presenting few non-dopaminergic symptoms 
and these usually respond weil to L-DOPA treatments. Others may suffer from a 
more malignant, rapidly progressing disease with typically early manifestations of 
non-dopaminergic motor and non-motor symptoms that resist to L-DOPA interventions 
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(Lang and Obeso, 2004). Regardless of age at onset, older individuals are more likely to 
express L-DOPA-resistant motor symptoms in conjunction with cognitive decline and 
autonomic failure (Kempster et al., 2007). In patients with severe motor fluctuations, 
other strategies may be employed, for instance deep brain stimulation of the subthalamic 
nucleus or internaI globus pallidus in basal ganglia circuitry, performed in sorne 
150 000 patients (Obeso et al., 2017) since its groundbreaking successful utilization in 
the 1990s (Pollak et al. , 1993). Akin to L-DOPA therapy, the mechanistic underpinnings 
of deep brain stimulation are ill understood (Lozano and Lipsman, 20 l3) and adverse 
effects may supervene in the likes of impaired verbal fluency, depression and ev en 
suicidaI tendencies (Benabid et al., 2005; Lang et al., 2006). To these motor symptom 
therapies are sometimes layered supplementary treatments to address psychiatric 
manifestations arising from the disease or motor symptom treatments themselves, 
for instance cholinesterase inhibitors for cognitive impairment (Emre et al., 2004) , 
antidepressants and cognitive-behavioural therapy for mood disorders (Dobkin et al., 
2011 ; Menza et al. , 2008; Richard et al. , 2012) or neuroleptics for psychoses 
(Cummings et al., 2014). 
Today, still, no therapy has been fruitful in modifying the course of Parkinson 's 
disease, ev en less so in providing hope for curative ends. This may partI y be attributable 
to the failure of clinical trials or therapeutic strategies to take into account the various 
existing subgroups of Parkinson's disease patients. Sensitive subdivision of clinical 
subtypes at the early stages of the pathology is among the most pressing research aims to 
render treatments and their development more discriminative, especially considering the 
rapid rate at which the population is aging occasioning foreseeable rises in the incidence 
of age-related neurodegenerative disorders su ch as Parkinson's disease (Olesen et al., 
2012) (Table 1.1). In order to achieve this, reliable identification of premotor phases of 
the pathology, obviously requiring robust biomarkers, will need to be accomplished first. 
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Table 1.1 
Projected prevalence of select neurological conditions in Canada 
Projection year 
2011 2016 2021 2026 2031 
Number of prevalent cases -
. 
(rate per 100,000 population ln projection year) -
Alzheimer's disease and other dementias 340,200 395,000 461,700 554,200 674,000 
(2,000) (2,200) (2,400) (2,700) (3,100) 
Brain in jury (traumatic) t 550,900 595 ,700 640,1 00 685,600 730,300 
(1,600) (1,700) (1,700) (1,800) (1,800) 
Cerebral paisy 75 ,200 79,800 84,300 89,300 94,200 
(200) (200) (200) (200) (200) 
Epilepsy 321,700 345,400 368,100 392,1 00 415,800 
(1,000) (1,000) (1,000) (1 ,000) (1 ,000) 
Multiple sclerosis 98,800 108,600 117,800 126,200 133,600 
(400) (400) (400) (400) (400) 
Parkinson 's disease/parkinsonism 84,700 99,000 116,800 138,800 163,700 
(500) (500) (600) (700) (700) 
Spinal cord in jury (traumatic) t 35,000 38,400 41,800 45,200 48,100 
(1 00) (100) (100) (100) (100) 
NOTES: 
Alzheimer's disease and other dementias and Parkinson's disease/parkinsonism projections were for a population age 40+ years. Multiple 
sclerosis projections were for a population age 20+ years. Traumatic spinal cord in jury projections were for a population age 5+ years. 
Traumatic brain in jury, cerebral paisy, and epilepsy projections were for a population age 0+ years. 
Data were rounded to the nearest hundred. 
1 Traumatic brain and spinal cord injuries were based on hospitalized cases, and excluded injuries that did not present to hospital. 
SOURCE: POHEM-Neurological (Statistics Canada and Public Health Agency of Canada)& 
& POHEM, population health mode!. 
1.1.3.2 Prodrome and biomarkers 
Abnormalities in the health of parkinsonian patients often appear years before 
a diagnosis is made during a phase termed the prodrome. These premotor or prodromal 
features are non-motor in nature, the most common manifestations being rapid 
eye movement sleep behavioural disorder, hyposmia, constipation, and psychiatrie 
disturbances such as depression or anxiety (Pont-Sunyer et al., 2015) (Table 1.2). 
Seeing as a substantial proportion of patients present one or several signs before onset, 
efforts have been deployed to elaborate specifie and reliable premotor biomarkers to 
diagnose Parkinson's disease much earlier on (Lang, 2010). A sizeable hurdle to 
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overcome remams that these symptoms are hardly specific and are often encountered 
in the general population". For the future development of prodromal biomarkers, 
the difficulty dwells in selecting individuals who will actually develop Parkinson' s 
disease, which requires setting up arduous longitudinal studies. 
Table 1.2 
Markers of prodromal Parkinson ' s disease 
Marker Level of evidence Approxlmate relative risk Lead time Testing costlburden 
O~action High 5 ?? Law 1 Moderate & 
REM Sleep Behavior Disorder& High 50 13 years Law (screens) ta High (PSG) 
Somnolence Moderate 1.8 ?? Law 
Restless legs (late onset) Law 1.5 Short Law 
Constipation High 2.5 > 15 years Law 
Orthostatic hypotension Moderate ? 2·10? 2·5 years? Law 
Urinary dysfunction Law-Moderate 2.1 ?? >5 years Law 
Erectile dysfunction Law-Moderate 1.2 mild 5·10 years Law 
3.8 severe 
Depression/anxiety High 1.8 Uncertain ?Biphasic Law, but follaw·up higher 
Color vision Law 2.5 >3 years? Moderate 
Subtle parkinsonism Moderate 10 4-5 years Moderate - High (Expert) 
Quantitative motor testing Moderate 3-4 5 years Moderate 
SN ultrasound Moderate 15 Uncertain ? risk marker? Moderate-Hlgh 
Dopaminergic PETISPECT& Law (but high 20 5 years High 
plausibility) 
PD-related pattern on SPECT/PET Law ? ? High 
Hippocampal hyperpertusion Law ? ? High 
GI synuclein palhology & Law 2? ? High 
For thls table, only markers wrth prospective evodence of predictove value are oncluded. For level of evidence, low Implies a single study, moderate ompies > 1 
high-quality study, high ompies >4 high-quality studoes. Lead time refers to the approximate tome that the marker deviates from normal values (the tome at 
which testong is reliably abnormal cannot be estimated for rnost markers). For testong cost, Iow indicates can be screened by questoonnaire (does not requira 
visit), moderate impies in-person assessment requlred but low cost (eg, research aSsistant), hlgh Implies extensive or ex pensive evaluation (>$300). 
& GI, gastrointestinal; PET, positron emission tomography; PSG, Parkinson's Study Group; REM, rapid eye movement. 
(From Obeso et al. , 201 7.) 
The crying need for prognostic biomarkers in Parkinson ' s disease arises from its 
particular pathophysiological course. lndeed, the cardinal motor symptoms permitting 
diagnosis reflect the loss of nigrostriatal dopaminergic neurons and the ensuing 
decline in tonic dopamine neurotransmission that can no longer ensure enablement of 
postsynaptic targets in the dorsal striatum interconnected with corticostriatal circuits of 
movement production. Owing to compensatory neurocircuit redundancies in the basal 
II Interestingly, considering the elevated prevalence of hyposmia in premotor patients (~75% when 
corrected for age) (Haehner et al. , 2009), Prof. Johannes Frasne lli 's group from the Uni versity of 
Québec recently demonstrated that it was possible to te ll apart individuals with Parkinson's disease from 
individuals with non-parkinsonian olfactory dysfunctions by evaluating olfactory and trigeminal 
sensiti vity. Although both cohorts of subjects displayed impaired olfaction, Parkinsonian patients did 
not show trigeminal sensitivity deficits, contrarily to hyposmic non-parkinsonian individuals (Tremblay 
et al., 2017). 
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ganglia and adjustments of dopamine receptor numbers, anywhere between 30-70% of 
nigrostriatal dopaminergic neurons and 50-80% of their striatal terminaIs have peri shed 
before the advent of clear motor symptoms (Bemheimer et al., 1973; Cheng et al., 2010; 
Feamley and Lees, 1991), dulling any hope for reversaI of the pathology. Like man y 
other neurodegenerative disorders, Parkinson's disease begins many years before 
classical symptoms arise. However, to our advantage, it is a rather special pathology in 
that neurodegeneration appears to begin in regions outside the substantia nigra pars 
compacta whose progressive dysfunction may emerge as a phenotypic non-motor 
signature that could one day be exploited for emitting diagnoses at premotor stages. 
The following section grants a closer look at the pathophysiological mechanisms 
subtending the particular course of progression in Parkinson's disease. 
1.1.3.3 Pathophysiology 
More th an a century after its identification by Félix Vicq d'Azyr (Vicq d'Azyr, 
1786), the substantia nigra was freshly emerging as the neuroanatomical substrate of 
the motor syndrome in Parkinson's disease (Blocq and Marinesco, 1892; 1893; Brissaud, 
1895). In parallel, Friedrich Heinrich Lewy was conducting histological assessments of 
parkinsonian brains, discovering the presence of cytoplasmic inclusions of aggregated 
proteins in the dorsal vagal nucleus and substantia innominata (Lewy, 1912), 
later identified in surviving nigral neurons of other patients and termed Lewy bodies in 
recognition of the former 's seminal work (Trétiakoff, 1919). In the mid 1900s, the role 
of the substantia nigra in Parkinson's disease was further bolstered by findings enlisting 
dopamine as a key contributor (Carlsson, 1958; Ehringer and Homykiewicz, 1960) and 
demonstrating the projection of nigral neurons to the dorsal striatum (Homykiewicz, 
1966). From these early discoveries were derived the two pathological requirements to 
emit a definitive post-mortem diagnosis, still standing today: first, the marked 10ss of 
pigmented dopaminergic neurons in the substantia nigra pars compacta, and second, the 
presence of Lewy bodies or their intraneuritic counterparts, Lewy neurites (Dickson 
et al. , 2009). To these findings were added, in later years, the contributions of 
Langston and colleagues describing parkinsonism in opioid addicts who had 
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accidentally consumed I-methyl-4-phenyl-l,2,3 ,6-tetrahydropyridine (MPTP) (Langston 
et al., 1983), a by-product of desmethylprodine synthesis that impedes the mitochondrial 
electron transport chain and triggers the production ofROS I2 (Greenamyre et al., 2001). 
This discovery also allowed further development of animal models of Parkinson's 
disease, complementing physical and 6-hydroxydopamine (6-0HDA) les ion paradigms 
(Ungerstedt, 1968), and coaxed investigations on environmental neurotoxins in the 
etiopathogenesis of the disease owing to MPTP's resemblance to certain known 
pesticides. 
The latest significant leap forward in the field dates back to the identification of 
the first gene mutation, explicitly a single point mutation in the SNCA gene co ding for 
a-synuclein 13, found to cause a dominant familial form of early onset Parkinson 's 
disease (Polymeropoulos et al., 1997). This event triggered a sequence of discoveries 
regarding the major constituent of Lewy bodies and neurites, a-synuclein (Spillantini 
et al., 1997), but also conceming genetic forms of the pathology. Disease-causing 
duplications (Chartier-Harlin et al., 2004) and triplications (Singleton et al., 2003) of 
the SNCA gene were quickly identified, to which were added in subsequent years several 
other genes (Table 1.3). It is important to note that idiopathie Parkinson 's disease still 
composes approximately 90-95% of diagnoses and are not always faithfully represented 
by genetic forms in terms of symptomatology and pathophysiology (see for review 
Houlden and Singleton, 2012). 
\2 The generation of ROS by the mitochondrial electron transport chain is later described in 
section 1.2.4.1. 
\3 a-Synuclein is an intrinsically unstructured protein, especially localized to presynaptic terminais 
wherein it cycles between a cytosolic natively unfolded state and a membrane-bound state. Its function 
in normal physiological conditions remains unclear to date, but it is thought to regulate synaptic activity, 
vesicular trafficking and several metabolic and transport enzymes specifie to dopaminergic neurons 
(see for review Surré, 2015). 
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Table 1.3 
List of monogenic Parkinson's disease and parkinsonism 
Designalioo and reference & 
1. Classical PO 
PARK-SNC4 
PARK-LRRK2 
PARK-VPS35 
2. Early-onset PO 
PARK -parkin 
PARK-PINK1 
PARK-OJ1 
3. Parkinsonism 
PARK-ATP1342 
PARK-FBX07 
PARK-ONAJC6 
PARK-SYNJI 
GeneReviews and OMIM& 
Reference 
GeneReviews hl1p://www.ncbi. 
nlm.nih.govlbookslNBK1 'l231 
DMIM 168601 
GeneReviews hl1p://www.ncbi. 
nlm.nih.govlbookslNBKl2081 
OMIM 607060 
GeneReviews 
hI1pJIwww.ncbi.nlm.nih.gov/ 
books/NBK1223J 
OMIM 614203 
GeneReviews 
hI1pJIwww.ncbi.nlm.nih.gov/ 
books/NBKl1551 
OMIM 600116 
GeneReviews 
httpJIwww.ncbi.nlm.nih.gov/ 
books/NBK1223J 
OMIM 605909 
GeneReviews 
hI1pJIwww.ncbi.nlm.nih.gov/ 
books/NBK1223J 
OMIM 606324 
GeneReviews 
hI1pJIwww.ncbi.nlm.nih.gov/ 
books/NBK1223J 
OMIM 606693 
GeneReviews 
hI1pJIwww.ncbi.nlm.nih.gov/ 
books/NBK1223J 
OMIM: 260300 
GeneReviews: nIa 
OMIM 615528 
GeneReviews: nIa 
OMIM 615530 
Clinical cluBs 
M issense mutations cause 
dassical par1<insonism. 
Duplication IX' triplication 
mutations in this gene 
cause early onset 
parkinsonism with pro minent 
dementia 
Clinically typical PO 
Clinically typical PO 
Often presents with dystonia, 
typically in a leg 
Often presents with psychiatrie 
leatures 
Kufor-Rakeb syndrŒne with 
parkinsonism and dystonia; 
Additional leatu res: 
Supranuclear gaze paisy, 
spastidty/pyramidal signs, 
dementia, lacial-laudal-
linger mini-myodonus, 
dysphagia, dysarthria, 
~Iactory dyslunction 
Early onset parkinsonism with 
pyramidal signs 
May present with mental 
retwdation and seizures 
May have seizures, cognitive 
decline, abnorrnal eye 
movements, and dystonia 
Inheritance& 
AD 
AD 
AD 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
Previous locus symbol 
PARK1 
PARK8 
PARK17 
PARK2 
PARK6 
PARK7 
PARK9 
PARK15 
PARK19 
PARK20 
& AD, autosomal dominant; AR, autosomal recessive; OMIM, Online Mendelian Inheritance in Man; PARK-ATPI 3A2, 
probable cation-transporting adenosine triphosphatase 13A2 gene; P ARK-DJI , oncogene OJ- I gene; P ARK-
DNAJC6, auxilin gene; PARK-FBX0 7, F-box only protein 7 gene; PARK-LRRK2, leucine-ri ch repeat kinase 2 gene; 
PARK-parlan, parkin gene; PARK-PINKl , phosphatase and tensin homologue-induced putative kinase 1 gene; 
PARK-SNCA, alpha-synuclein gene; PARK-SYNJI , synaptojanin 1 gene; PARK- VPS35, vacuolar protein sorting-
associated prote in 35 gene. 
(From Obeso et al., 20 17, adapted From Bar-Gad et al., 2003 .) 
Another hint pointing to a distinguishing pathological sequence initially surfaced 
when Kosaka and colleagues described patterns of Lewy body distribution in patients 
over the course of the disease (Kosaka et al., 1988). This was later confirmed and 
transmuted into a highly controversial staging framework by a German group 
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spearheaded by Heiko Braak and Kelly Del Tredici (Braak et al., 2003). They reported 
that in many idiopathie Parkinson's disease patients, though not all l4 (Kalaitzakis et al. , 
2008b; Milber et al., 2012; Parkkinen et al., 2005; Zaccai et al., 2008), Lewy bodies and 
neurites appear to colonize the olfactory bulb or the brainstem early in the pathology 
(stages 1 and 2), spreading sequentially through the midbrain (stages 3 and 4), 
and ultimately reaching neocortical and limbic areas (stages 5 and 6) (Braak et al., 2003) 
(Figure 1.9). Interestingly, Lewy bodies had been identified in the brainstem almost one 
century prior (Lewy, 1912). More recent hypotheses conforming with Braak staging 
(Braak et al., 2006) go as far as to suggest that the pathology may begin in the periphery 
downstream from the vagal nerve, for instance in the enteric nervous system, and spread 
to the CNS as substantiated by evidence in rodents (Holmqvist et al., 2014; Pan-Montojo 
et al., 2010, 2012; Phillips et al., 2008; Ulusoy et al., 2013), and as alluded to in human 
studies (Stokholm et al., 2016). Of particular interest, apparition of Lewy bodies in 
extranigral regions may lead to the dysfunction - but not necessarily to the demise - of 
these neurons, partly explaining the prodromal phase and later dopamine-unresponsive 
symptoms. Whether this theory holds true or not, the conjecture that Lewy bodies 
spread across interconnected neuroanatomical regions has provided a cornerstone for 
more advanced theories of trans-synaptic neuron-to-neuron propagation of misfolded 
a-synuclein, for example the discordant prion hypothesis 15, supported by experimental 
demonstrations (Desplats et al., 2009; Luk et al., 2012; Recasens et al., 2014; Volpicelli-
Daley et al., 2011) and observations of host-to-graft spreading of Lewy bodies in 
humans 10-14 years after transplants (Kordower et al., 2008; Li et al., 2008). 
14 Many parkinsonian post-mortem samples present Lewy body patterns that deviate from Braak's 
staging framework (Halliday et al., 2012b; Kalaitzakis et al. , 2008a) . In addition, neuroanatomical 
connectomics do not aid ·in predicting the apparition of Lewy bodies. Exemplarily, striatal medium 
spiny neurons, highly interconnected with Lewy body-Iaden nigrostriatal dopaminergic neurons, hardly 
ever display Lewy pathology (Halliday et al. , 20 Il ; Martin et al. , 2008). 
15 Today, no doubt remains that fibrillar a-synuclein can spread from one neuron to another upon 
experimental inoculation. However, the time course (only 50% of patients show Lewy pathology by 
13 years of onset) and infectiousness of a-synuclein in humans are significantly different than those 
observed in preclinical prion models. In fact, no direct evidence of spreading in humans is available. 
For many, the question remains whether prion-like spreading and toxicity is the primary governing 
factor in the selective vulnerability of nigrostriatal dopaminergic neurons in Parkinson 's disease 
(McCann et al. , 2015 ; Surmeier et al. , 2017). 
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Figure 1.9 
(~ dm co an me he te 
1 
2 '. 
Braak staging of the progression of Parkinson 's disease-related 
Lewy body pathology. 
According to this staging framework, spreading of Lewy body pathology 
(dm to fc at the top of the graph) begins in the dorsal IX/X motor nucleus 
(stage 1) but aiso in the anterior olfactory nucleus, sequentially spreading 
toward coeruleus regions (stage 2), the midbrain (stage 3), mesocortical 
entorhinal regions (stage 4), high order cortical areas (stage 5) and finally 
to first order cortical areas (stage 6). Colour intensity indicates the degree 
of Lewy body pathology: in the schematic representations of the brain, 
stage 6 is depicted. co, coeruleus/subcoeruleus complex ; dm, dorsal IX/X 
motor nucleus; fc, first order sensory association areas and premotor areas 
and/or primary sensory and motor fields of the neocortex; hc, high order 
sensory association are as and pre frontal areas of the neocortex; mc, 
transentorhinal region and/or ectorhinal region (anteromedial temporal 
mesocortex); sn, posterior portion of substantia nigra pars compacta. 
(Adapted from Braak et al., 2003.) 
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Connecting this constellation of breakthroughs has led to our current appreciation 
of the pathophysiology that characterizes Parkinson ' s disease, without however fully 
unscrambling its etiopathogenesis. We suspected and have confirmed that the 
degeneration of nigrostriatal dopaminergic neurons leads to the depletion of dopamine at 
the striatal interface of basal ganglia circuits, accounting for motor symptoms (Calabresi 
et al., 2014; Kravitz et al. , 2010; Tritsch and Sabatini, 2012). However, formai 
recognition that Parkinson' s disease do es not necessarily start in the substantia nigra 
pars compacta leaves us at loss as to why nigrostriatal dopaminergic neurons degenerate 
long before other Lewy body-Iaden neurons do. It is likely that various cellular and 
molecular mechanisms account for the select vulnerability of nigrostriatal dopaminergic 
neurons in Parkinson ' s disease, which only accentuates our awareness of the multiple 
dimensions that demarcate this pathology. 
1.1.3.4 Vulnerability of the nigrostriatal pathway 
Identifying exogenous and endogenous risk factors is a sensible place to start on 
the quest for c1ues to unravel one of the most important questions left unsettled in 
Parkinson ' s disease, that is, the selective early death of nigrostriatal dopaminergic 
neurons. The incidence of idiopathic Parkinson's disease is c1early linked with 
environmental factors. The discovery of MPTP as a mitochondria-targeting agent of 
parkinsonism broke new ground for the exploration of other chemicals, such as 
pesticides (Furlong et al., 2015; Priyadarshi et al. , 2000), solvents (Goldman et al. , 
2012; Pezzoli and Cereda, 2013), metals (Finkelstein and Jerrett, 2007; Gorell et al. , 
1997) and organochlorines (Steen land et al. , 2006; Weisskopf et al. , 2012), subsequently 
shown to constitute risk factors acting via bioenergetic disruption and oxidative 
mechanisms. Elements of infection were also suggested long ago to promote 
Parkinson' s disease (Charcot, 1877; Gowers, 1886), substantiated by the occurrence 
of postencephalitic parkinsonism that succeeded the great pandemic of encephalitis 
lethargica in the early 1900s (Schwab et al. , 1956; Vilensky et al., 2010). Later, studies 
found certain of these exogenous elements to represent a greater hazard in individuals 
carrying a specific genetic profile. Indeed, a host of genetic variants are known today 
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to synergistically increase the odds of developing Parkinson 's disease, in gene-
environment interactions but also as standalone risk factors (Polito et al., 2016; Wamer 
and Schapira, 2003) (Table 1.4). Monogenic forms of Parkinson's disease also provide 
supplementary clues pointing to intrinsic issues that bode unfavourable odds. 
Noteworthy, the abnormal proteic products of these genes interfere with healthy cellular 
trafficking, prote in degradation or mitochondrial function (Figure 1.10). 
Aside from these genetic and environmental factors specifie to certain individuals, 
one element of risk stands out due to its universality and that is aging (Reeve et al., 
2014). Indeed, of ail the risk factors, aging persists as the best-established player in 
idiopathie Parkinson's disease, as is the case for several other chronic and 
neurodegenerative illnesses. However, the tightness of this relationship is such that 
Parkinson's disease is viewed today as the epitome of the synergistic potentiation that 
occurs between aging and neurodegeneration (Obeso et al., 2017) (Figure 1.11). 
For example, the substantia nigra pars compacta appears to be relatively susceptible to 
aging outside of a pathological context (Buchman et al., 2012; Rudow et al., 2008), 
as cellioss occurs at an estimated rate of 4.7-9.8% per decade in humans (Feamley and 
Lees, 1991; Ma et al. , 1999). Moreover, iron contents (Bilgic et al., 2012), levels of 
iron-binding neuromelanin (Double et al., 2003), neuroinflammation (Calabrese et al. , 
2018), oxidative stress-induced mitochondrial DNA deletions (Reeve et al., 2014), 
and malfunction of the ubiquitin proteasome system and autophagy clearance pathways 
(Jana, 2012; Li and Li, 2011; Rubinsztein et al., 2011) were ail shown to mcrease 
drastically with age, especially so in the substantia nigra pars compacta (Corral-
Debrinski et al., 1992; Daugherty and Raz, 2013; Dexter et al., 1989; Fedorow et al. , 
2006; Soong et al., 1992). Coherently, in the setting of Parkinson's disease, nigrostriatal 
neurons that contain more neuromelanin are at higher risk of degenerating (Gibb and 
Lees, 1991; Hirsch et al., 1988; Kastner et al., 1992; Marsden, 1983; Zecca et al., 2001), 
microgliosis is relatively more pronounced in the substantia nigra pars compacta (Kim 
et al., 2000; Lawson et al., 1990; McGeer et al., 1988), nigral mitochondrial DNA 
deletions accurnulate (Bender et al., 2006, 2008) and clearance pathways are impaired 
(Cuervo et al., 2010; Dehay et al., 2010). 
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Table 1.4 
Overview of the 26 genetic risk variants showing consistent association with 
Parkinson 's di sease in genome-wide association studies 
SNP Location (hg38) Nearest gene& AIIeles Risk allele freq OR P value 
rs35749011 1 :155,162,810 SLC50Al (GBA) AlG 0.017 1.824 1.37 X 10- 29 
rsl14138760* 1 :154,925,709 PMVK(GBA) C/G 0.012 1.574 3.80 X 10- 7 
rs823118 1 :205,754,444 NUCKSI TIC 0.559 1.122 1.66 X 10- 16 
rsl0797576 1 :232,528,865 SIPA1L2 TIC 0.140 1.131 4.87 X 10- 10 
rs6430538 2:134,782,397 ACMSD CfT 0.570 1.143 9.13 X 10- 20 
rs1474055 2:168,253,884 STK39 TIC 0.128 1.214 1.15 X 10- 20 
rs12637471 3:183,044,649 MCCCI GIA 0.807 1.188 2.14 X 10- 21 
rs34311866 4:958,159 TMEM175 (GAI<) GIA 0.191 1.272 1.02 X 10- 43 
rs34884217* 4:950,422 TMEM175 (GAI<) AlC 0.913 1.247 1.10 X 10- 6 
rsl1724635 4:15,735,728 BSTI AlC 0.553 1.126 9.44 X 10- 18 
rs6812193 4:76,277,833 FAM47E CfT 0.636 1.103 2.95 X 10- 11 
rs356182 4:89,704,960 SNCA CfT 0.367 1.316 4.16 X 10- 73 
rs7681154* 4: 89,842,802 SNCA CfA 0.498 1.189 7.09 X 10.19 
rs9275326 6:32,698,883 HLA-DOBI CfT 0.906 1.211 1.19 X 10- 12 
rs132011 01 * 6:32,375,827 C6orfl0 TIC 0.053 1.192 3.84 X 10- 6 
rs199347 7:23,254,127 GPNMB AlG 0.590 1.110 1.18 X 10- 12 
rs117896735 7:119,777,065 INPP5F AlG 0.014 1.624 4.34 X 10- 13 
rs329648 11:133,895,472 MIR4697HG TIC 0.354 1.105 9.83 X 10- 12 
rs76904798 12: 40,220,882 LRRK2 TIC 0.143 1.155 5.24 X 10- 14 
rsll060180 12:122,819,039 CCDC62 AlG 0.558 1.105 6.02 X 10- 12 
rsll158026 14:54,882,151 GCHI CfT 0.665 1.106 5.85 X 10- 11 
rs2414739 15:61,701 ,935 VPS13C AlG 0.734 1.113 1.23 X 10- 11 
rs14235 16:31 ,110,472 BCKDK AlG 0.381 1.103 2.43 X 10- 12 
rs17649553 17:45,917,282 MAPT GIA 0.774 1.300 2.37 X 10- 48 
rs12456492 18:43,093,415 RIT2 GIA 0.307 1.106 7.74 X 10- 12 
rs8118008 20:3,187,770 . DDRGKI AlG 0.657 1.111 3.04 X 10- 11 
This table was adapted from Table 1 and Supplementary Table 3 of the original study.13 It lists the 22 most si~nificant SNPs per locus (defined in 1 Mb bound-
aries) that showed genome-wide signiflcant Ip <5 x 1 0 ~ association with Parkinson's disease (PD) status. Furthermore, it displays 4 SNPs (Iabeled with a 
star rn that showed significant association (ie, p <1 x 10- 5 following Bonferroni correction) with PD risk upon conditioning on the mest significant SNP in the 
same genetic region (ie, corresponding to the SNP listed in this table in the preceding line). Note that the nearest gene assigned to each SNP here (as deter-
mined according to RefGene as available on the UCSC genome browser (https:lIgenome.ucsc.edul)) does not necessarily represent the functional element 
undet1ying the genetic association. The genes in parentheses refer to the more commonly used gene names for the respective locus. Full names of ail official 
gene names listed here can be found in the EntrezGene database (http://www.ncbi.nlm.nih.gov/genel).Alleles = the first allele represents the risk allele. hg38, 
human genome build 38; Freq, frequency; MAPT, microtubule-associated protein tau; OR, odds ratio; SNP, single nucleotide polymorphism. 
& ACMSD, aminocarboxymuconate semialdehyde decarboxylase gene; BCKDK, branched chain ketoacid 
dehydrogenase kinase gene; BSTl , bone marrow stromal cell antigen 1 gene; C6orfl O, chromosome 6 open reading 
frame 10 gene; CCDC62, coiled-co il domain containing 62 gene; DDRGKl , DDRGK domain containing 1 gene; 
FAM47E, fa mily with sequence similari ty 47 member E gene; GAK, cyclin G associated kinase/auxilin -2; GBA, 
beta-glucocerebrosidase gene; GCR l , guanosine triphosphate cyclohydrolase 1 gene; GPNMB, glycoprote in 
neuromedin B gene; HLA-DQBl , major histocompatibili ty complex, c lass Il, DQ beta 1 gene; INPP5F, inositol 
polyphosphate-5-phosphatase F gene; MCCCl, methylcro tonoyl-coenzyme A carboxylase 1 gene; MIR4697HG, 
microribonucleic acid 4697 host gene; NUCKSl , nuclear casein kinase and cyclin dependent ki nase substrate 1 gene; 
PMVK, phosphomevalonate kinase gene; RIT2, Ras-like without CAAX 2 gene; SIPA IL2, signal induced proli fe ration 
associated 1 like 2 gene; SLC50A l , solute carrier family 50 member 1 gene; STK39, serine/threonine kinase 39 gene; 
TMEM175, transmembrane protein 175 gene; VPS13C, vacuolar protein sorting 13 homologue C gene. 
(From Obeso et al., 20 17, adapted trom Fahn and Goetz, 1987.) 
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Synaptic/endosomal vesicle/protein recycling 
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Figure 1.10 Disease mechanisms implicated in Parkinson's disease. 
This diagram, termed the Bermuda triangle by the authors, highlights 
three important cellular pathological axes affected in monogenic forms of 
Parkinson ' s disease, which may also be implicated in idiopathic forms. 
Importantly, cellular trafficking, mitochondrial homeostasis and protein 
degradation are tightly interwoven in the pathophysiology of Parkinson 's 
disease. (From Obeso et al. , 2017.) 
In considering the sum of exogenous and endogenous risk factors that come into 
play in Parkinson ' s disease, several mechanisms proposed to dwell at the core of this 
illness emerge, notably mitochondrial dysfunction, protein aggregation, iron toxicity, 
neuroinflammation and impaired cellular trafficking, among others. Despite their 
apparent disparity, they converge to cause the preferential early degeneration of 
nigrostriatal neurons in Parkinson ' s disease and possibly contribute to oxidative stress to 
which these neurons may be more vulnerable (Brichta and Greengard, 2014; Haddad and 
Nakamura, 2015; Oliveira et al. , 2017; Surmeier, 2007; Surrneier et al., 2017). 
This concept dates back to the 1980s (G6tz et al., 1990; Jenner, 1991; Lenzi et al., 1979; 
y oudim et al., 1989), but its popularity has waxed and waned at the rhythm of 
discoveries such as the sequential spreading of Lewy bodies (Braak et al. , 2003 ). 
Nevertheless, the ide a that metabolic oxidative insults may underlie the specific 
vulnerability of nigrostriatal neurons has lately gained momentum as the pro minent 
philosophies of the 1900s and beginning of the 2000s are failing to satisfy questions 
35 
regarding the course of progressIOn of Parkinson ' s disease (Obeso et al. , 2017). 
Oxidative stress and the propagation of Lewy bodies are not mutually exclusive theories 
either: oxidative stress is a known facilitator of a-synuclein aggregation and Lewy 
bodies contribute to oxidative stress (Gupta et al. , 2009). As such, they likely engage in 
an intimate relationship in the etiopathogenesis of Parkinson's disease. 
Substantla nigra toxins 1-----------, 
Figure 1.11 Crosstalk between aging and Parkinson 's disease. 
Aging leads to several pathological events in neurons that are conducive 
to the development of Parkinson's disease. In particular, oxidative 
stress emerges as a pivotai factor. A TP, adenosine triphosphate; 
PTP, penneability transition pore; UPS, ubiquitin-proteasome system. 
(From Schapira, 2008.) 
In order for oxidative stress to incarnate the noxious interface through which ail 
of these risk factors converge onto nigrostriatal dopaminergic neurons, the latter must 
exhibit exclusive properties discerning them from other neuronal populations and 
rendering them sensitive to each of these contributing elements. It is critical that 
nigrostriatal neurons distinguish themselves from other dopaminergic neurons, 
especially their mesocorticolimbic analogues, as they ail share the liability of employing 
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dopamine as a neurotransmitter, recognized to generate ROS upon auto-oxidation 
(Segura-Aguilar et al., 2014) and to require ROS-producing monoamine oxidases for 
their degradation (Andersen et al., 1994; Graham, 1984). In this respect, we argue that 
nigrostriatal dopaminergic neurons display the following phenotypic idiosyncrasies that 
may afford their vulnerability to oxidative stress instigated by genetic mutations, 
environrnental toxins and aging: 
1) They are embedded in a particular environrnent, the substantia nigra pars compacta, 
which stores considerable amounts of iron ions (Chinta and Andersen, 2008; Hirsch 
and Faucheux, 1998) accumulating with age (Daugherty and Raz, 2013) and known 
to participate in deleterious Fenton reactions with hydrogen peroxide to produce the 
very reactive hydroxyl radical (Youdim et al., 1989); 
2) They express lower levels of VMAT2 than most other catecholaminergic neurons, 
implying the protracted presence of dopamine in the cytosol leading to the 
inevitable formation oftoxic oxidative by-products and, ultimately, potentially toxic 
neuromelanin (Liang et al. , 2004); 
3) Constituting a very small cluster of cells (German et al., 1988; Percheron et al., 
1989), they are nonetheless required to fully innervate a very large surface, 
the dorsal striatum, which entails tremendous bran ching of axons harbouring 
numerous vesicular release sites ridden with potentially pathogenic a-synuclein 
(Matsuda et al., 2009; Parent and Parent, 2006); 
4) To enable corticostriatal circuits, the y constitute the greatest striatal input of 
uninterrupted tonic dopamine relying on autonomous pacemaking activity at the 
source of high baseline levels of calcium ions, which enhance oxidative 
phosphorylation, mitochondrial membrane hyperpolarization and superoxide anion 
production (Guzman et al., 2010; Pacelli et al., 2015); 
5) To maintain their neurotransmission activities and drawn-out axonal arbours, 
these neurons keep an army of mitochondria to fulfil their exorbitant energetic 
needs, also irnplying elevated basal rates of oxidative phosphorylation and greater 
production of electron transport chain superoxide anion by-products (Pacelli et al. , 
2015); 
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6) Last, they are endowed with a limited calcium-buffering capacity (Foehring et al., 
2009) and scanty endogenous antioxidative defences (Bharath et al. , 2002), 
consequent of their low expression of calbindin (Dopeso-Reyes et al. , 2014; 
Iacopino and Christakos, 1990; Liang et al., 1996; Yamada et al., 1990) and 
glutathione (Kang et al., 1999), respectively. 
In aU evidence, these features unite to augment the basal oxidative burden to 
which are subjected nigrostriatal neurons. Upon further exposure to environrnental or 
genetic insults, endogenous antioxidative defences are eventually overwhelmed: 
this turning point typified by the failure of neurons to cope with the added oxidative load 
constitutes the origin of oxidative stress. Sustained in time and enhanced by aging 
processes, oxidative stress may eventually lead to the death of nigrostriatal neurons in 
Parkinson' s disease. Following this premise, studies have employed primary neuron 
cultures (Pacelli et al. , 2015), acute rat brain slices (Carbone et al., 2017), 
rodents (Vidyadhara et al., 2016) and primate (Dopeso-Reyes et al. , 2014) models to 
demonstrate that nigrostriatal dopaminergic neurons are more vulnerable to parkinsonian 
neurotoxins in comparison to other neuronal populations, exemplarily dopaminergic 
neurons 10dged in the neighbouring ventral tegmental area, and that this vulnerability is 
abated by pharmacologically targeting these specific phenotypic risk features (Carbone 
etaI. , 2017; Pacelli et aI. , 2015). 
If indeed nigrostriatal neurons are relatively more susceptible to insults that 
overwhelm their endogenous coping mechanisms, other sources of oxidative stress that 
are not specific to Parkinson 's disease may yield similar results and shore up the idea 
of their selective vulnerability. Indications of this are provided by epidemiological 
evidence showing a higher occurrence of Parkinson ' s disease in patients suffering 
from other pathologies with a significant component of oxidative stress, such as 
diabetes (Cereda et al. , 2012; Santiago and Potashkin, 2013; Sun et al. , 2012), ischemic 
stroke (Huang et al. , 2013) and sleep apnea (Snyder and Cunningham, 2017). 
Interestingly, Parkinson ' s disease is significantly less frequent in patients with the 
hyperuricemic illness gout wherein the antioxidative effects of uric acid may in fact 
protect nigrostriatal neurons (Alonso and Sovell, 2010). Although evidence weighs in 
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favour of the selective vulnerability of the nigrostriatal pathway in pathological states 
that induce upwelling of systemic oxidation, for instance in a hyperglycaemic setting, 
studies are required to validate this. The present thesis aims to expound on this question. 
1.2 Hyperglycaemia in the central nervous system 
Before addressing the mechanisms by which hyperglycaemia 16 may instigate 
oxidative stress in the CNS, and before laying out the epidemiological evidence in 
favour of the particular vulnerability of nigrostriatal dopaminergic neurons in these 
conditions, it is critical that we fully grasp glucose dynamics in the brain. The transport 
kinetics and metabolism of glucose are highly complex, especially in the CNS, and bear 
significant implications in the initiation of oxidative stress in neurons. Progressing in 
this direction, a fundamental appraisal of the brain' s energy sources is first required. 
1.2.1 Glucose as a preferential fuel for the brain 
Long has functional neuroimagery exposed the importance of glucose in the 
fulfilment of the adult brain's energetic needs (Landau et al., 1955; Schmidt and Kety, 
1947; Siesjo, 1978; Sokoloff et al., 1977). In fact, the brain utilizes 25% of total body 
glucose, mostly to power oxidative metabolism (Heiss, 2016; Kety and Schmidt, 1948; 
Laughlin and Attwell, 2001; Shulman et al., 2001; Sokoloff et al., 1999). Glucose is 
indispensable to neurons and thus plays a significant role in CNS health and disease. 
In settings of extreme dietary and pathological depletion of glucose or its transport, 
the brain is forced to employ other fuels, although a minimal amount of glucose is 
always required to maintain normal cerebral functions (Casazza et al., 1984; Owen 
et al., 1967; Vanltallie and Nufert, 2003). In these specifie contexts, blood-borne ketone 
bodies can account for up to 70% of brain energy requirements through its conversion to 
acetyl coenzyme A, in contrast to fatty acids that inefficiently cross the blood-brain 
16 Normoglycaemia is defined in humans as fasting blood glucose < 5.5 mM « 100 mg/dL), postprandial 
blood glucose < 7.8 mM « 140 mg/dL) or glycated haemoglobin < 5.7%; hyperglycaemia is defined as 
fasting blood glucose ~ 7.0 mM (~ 126 mg/dL), postprandial blood glucose ~ ILl mM (~ 200 mg/dL) 
or glycated haemoglobin ~ 6.5% (American Diabetes Association, 2016). 
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barrier and are oxidized too slowly for rapid energy provIsIon (Dhopeshwarkar and 
Mead, 1973; Hamilton and Brunaldi, 2007; Hasselbalch et al. , 1994; Morris, 2005; 
Schonfeld and Reiser, 2013). Likewise, circulating lactate may substitute for glucose 
and afford basal sustenance, but it do es not allow neurons to carry out efficient 
neurotransmission (Bak et al., 2006, 2012; Ivannikov et al. , 2010). In the context of 
hyperglycaemia, the peripheral production of ketones may arise if insulin levels are too 
low to supply cells with glucose despite its overabundance (Fukao et al., 2004; Fulop 
et al. , 1999). However, since the brain does not rely on insulin for intracellular import of 
glucose, as we will see next, the latter remains the preferred substrate, especially 
considering its elevated circulating concentrations. 
1.2.2 Neuronal glucose transport 
Neurons have particular needs III terrns of glucose transport and availability, 
as they are required to react extremely rapidly to a perpetually changing intra- and 
extracellular environrnent directly ensuing from neurotransmission l7. Unlike other 
energy-greedy cells endowed with glycogen stores, like striated muscle cells, neurons 
cannot count on glycogenolysis for sustenance, as this macro mole cule is almost 
exclusively confined to astrocytes in the brain (Cataldo and Broadwell, 1986; Dienel and 
Cruz, 2006; Ibrahim, 1975; Koizumi, 1974; Sagar et al., 1987; Watanabe and 
Passonneau, 1973). Intraneuronal glucose is thus mainly provided from the extracellular 
environrnent, which itself is supplied by the circulation. This implies the need for 
glucose to cross several barriers whose transport kinetics assuredly influence its 
metabolism in neurons. 
1.2.2.1 Transporters and kinetics 
Hydrophilic glucose molecules must be transported by facilitated diffusion to 
reach the intracellular space. Glucose transporters (GLUTs) ubiquitously present at the 
17 In neurons, constant restoration of membrane potentials, clearance of intracellular calcium, synthesis of 
neurotransmitters, restructuration of synapses and maintenance of highl y solicited organelles oblige an 
uninterrupted energy flux. 
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surface of cells occupy the function of taking up glucose from the extraceIlular 
environment (Table 1.5). Excluding the myo-inositol transporter, aIl GLUTs identified 
to date mediate energy-independent facilitative transport (see for review Mueckler and 
Thorens, 2013; Wood and Trayhum, 2003). 
Table 1.5 
Glucose transporter expression sites and substrates 
Type Prolein (gene)&< 
GLUTI (SLC2A/) 
GLUTl (SLC2A2) 
GL T3 (SLC2A3) 
GL T4 (SLC2M) 
(Insulin-sensilive) 
GLUTS (SLC2A5) 
FacilitativelSodium- GLUT6 (SLC2A6) 
indcpcndent 
GLUn (SLC2A7) 
GLUn (SLC2A8) 
(Insulin-responsive?) 
GLUT9 (SLC2A9) 
GLUTIO (SLC2A IO) 
iles expressed 
Brain endothelial and epithelial-Iike brain barriers, glial cells, blood-tissue 
barriers, eye, pheripheral nerves, placenta, lactating mammary gland 
(Ubiquilous distribution in mosl mammalian cells) 
Kidney, small intestine (epithelial cells), Iiver, pancreas (islets), brain 
(astrocytes) 
Neurons, testis, placenta, brain endothelial cells? 
Brown and white adipose tissue, muscle (skeletal), fal, heart (myocardium), 
hippocampal neurons, cerebellar neurons 
Intestine (jejunum), Iddney, testi , brain microglia 
Brain, peripheral and spleen (Ieukocytes) 
Small intestine (mamly in brush border mcmbranc-cntcrocytes), colon, testis, 
prostate, liver (associated with endoplasmic reticulum) 
BlaslOCytes, testis, brain (neurons), muscle, adipocytes, mammary gland? 
Liver, kidney (proximal tubule of epithelial cells), placenta? 
Liver, pancreas, heart, lung, brain, skeletal mu cie, placenta 
Iso-form A: Heart, skeletal muscle, kidney 
GLUTII (SLC2A If) lso-form B: Placenta, adipo e ti sue, kidney 
GL Tl2 (SLC2A / 2) 
(In. ulin-sensitive?) 
HMIT (SLC2Al 3) 
(co-transporler) 
lso-form C: Adipose tissue, heart, keletal muscle, pancreas 
Heart, skeletal muscle, fat, prostrate, laetating mammary gland ?, spleen 1, 
breast cancer (Ductal cell carcinoma) tissue 
Brain (neurons mtracellular vesicles) 
ubslrale/lransports 
>>Glucose, galactose, 
mannose, gl ucosamine, 
ascorbic acid 
Mannose, galactose, 
fructose, glucose, 
glucosamme 
Glucose, galactose, 
mannose, xylose, 
dehydroascorbic acid 
Glucose, 
dehydroascorbic acid, 
glucosamine 
Fructo e 
Glucose 
>Fructose, glucose 
Gluco e 
Glucose, urate 
Glucose, galactose 
Fructose, glucose 
Glucose 
H+'myo-inositol 
& GLUT, glucose transporter; HMIT, H+/myo-inosito l transporter; SLC2A, solute carrier famil y 2 gene. 
(Adapted From Simpson et al., 2007.) 
Contrary to most peripheral cells that express GLUT4 requmng insulin for 
membrane translocation, the vast majority of CNS components employ insulin-
independent GLUTs (Huang and Czech, 2007; James et al., 1988) (Figure 1.1 2). 
GLUTI is the most widespread isoform in the body and, aside from red blood ce Ils, 
it is most abundant in the brain microvasculature, evenly distributed among the luminal 
41 
and abluminal surfaces of the endothelium (Maher et al., 1994; Simpson et al. , 2001). 
It is also the main transporter employed by glial cells, especially astrocytes (Dick et al. , 
1984; Gerhart et al. , 1989; Maher et al., 1994; Simpson et al. , 2001). Neurons, on the 
other hand, overwhelmingly employ the GLUT3 isoform densely located across the cell 
surface but more intensely so at the neuropil (Leino et al. , 1997; Mantych et al., 1992; 
Nagamatsu et al. , 1993; see for review Simpson et al. , 2008). Consequently, to access 
the brain parenchyma, circulating glucose must penetrate the endothelium and astrocytic 
endfeet of the blood-brain barrier via GLUTI. In turn, glucose diffuses through the 
extracellular space where it can be absorbed by neuronal GLUT3 . 
• GLUn 55K 8 Mcn 
• GLUT1 45K MCT2 
GLUT3 K MCT3 
* GLUT4 MCT4 
Â GLUT5 
GLUT6 
GLUT8 
GLUn 
55K 
1 
GLUT5 
Figure 1.12 Glucose and monocarboxylate transporters in the mammalian brain. 
Endothelial cells solely express GLUT1 , whereas other brain celis usually 
express multitudinous isoforms. Noteworthy, endothelial cells express 
the highly glycosylated 55-kDa isoform of GLUT1 ,while astrocytes and 
oligodendrocytes express the 45-kDa variant. Neurons mainly express 
GLUT3 , but can also express GLUTS 1, 2, 4, 6, 8 and the myo-inositol 
transporter, depending on brain regions and isoforms. The fructose 
transporter GLUT5 is almost only found at the surface of microglial cells, 
but its function remains unclear in the brain due to the virtual absence of 
its known substrate in the parenchyma (Jurcovicova, 2014; Maher et al. , 
1994). MCT, monocarboxylate transporter. (From Simpson et al., 2007, 
adapted from McKenna et al. , 2005.) 
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Although cellular constituents of the brain do not rely on insulin for glucose 
uptake, several kinetic factors come into play in limiting glucose permeation between 
compartments. Seeing as GLUTs are facilitative, bidirectional, energy-independent 
transporters, they allow not for glucose accumulation but for its equilibration between 
compartments in a manner that smoothens concentration gradients. Brain GLUTs 
possess elevated affinities for glucose, highest for neuronal GLUT3 (Km ~ 1.5 mM) 
(ColviUe et al. , 1993; Maher et al. , 1996) (Table l.6). In fact, GLUT3 also presents the 
greatest turnover for glucose, defmed as the number of transport cycles per transporter 
per second (Manolescu et al., 2007; Rumsey et al., 1997). 
Table 1.6 
Glucose transport capacities of brain ce Us 
!eeU TRANSPORTER [Transporter[ [Transporter] [Transporter] !!Vmax ~m c ubstratelligand llkcat ~redicted 
SPECIES uptake uptake Vmn in 
model 
pmol/mg membrane carriers/flm 2 pmol/mg total nmol/I06 mM per mmol/sec 
protein protein ceUs/min sec 
RBC& GLUTI 2000 2083 92 80.4 8 GI CB 1166 
Endothelium GLUTI 400 fI 000 gl8 0.21 8 CB 1166 7.8 x 10 
-IS 
------
Astrocyte GLI/TI 7.3 f l8 gO.34 4.8 8 CB 1166 h.4 x 10 
-16 
!1.9 
XIO- IS 
Neuron GLUTI 9.S [24 gO.44 hS.O 2.8 3MG/CB h868 2.3 x 10 
i34.6 4;S12 - 14 
'Cell in which tran pon i measurcd. 
bMeasured or compuled maximum rate (V maJ or affinity (K.J for transpon .. 
"Tbe substrate employed in transpon (Glucose (Glc), 3-0-methylglucose (3MG) or lactale) or ligand GLUT quanlitalion experirncnts (Cytochalasin B (CB) binding). 
dcompuled k Cal ([Vm .. ,I[GLUT]) for transpon. 
' Predicled V mu for IranSpon of glucose and lactate for use in the mode!. 
fAssumes 1 mg membrane prolein is equivalenllo a surface area of 2.4 x IOll flffi2. 
IAssurnes lhat the ratio of membrane:lotal cellular protein is 0.0462 : 1. 
hMeasured a12SoC. 
iCompuled for transpon al 37°C as uming thal GLUT3 and GLUTI hare Ihe same temperature dependence. 
JOirection basal lamina 10 astrocyte. 
kOirection inlerstilium to aSlrocyte. Glucose transpon parameters in endothelial cells, aslrocytes and neurons were computed using estimated ccII membrane GLUT 
conlents and measured k Cil paramelers. MCT concentrations are estimatcd as uming MCT k cal = GLUTI k cal and using measurcd V .... values. 
&RBC, red blood cell. 
(From Simpson el al., 2007.) 
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Since normoglycaemic settings afford much more glucose than transport kinetics 
require, one would expect brain cells like neurons to contain approximately as much 
glucose as their immediate extracellular environment. Likewise, brain glucose 
concentrations should fluctuate as a function of glycaemia, regardless of insulin levels. 
According to computational studies performed by Simpson and colleagues, neurons and 
astrocytes only contain ~0.9 mM of glucose in normoglycaemic steady-state conditions 
(Simpson et al., 2007) (Table 1.7). Similarly, extracellular concentrations of glucose 
merely reach ~ 1.4 mM. Even endothelial cells that express GLUTI and are in direct 
contact with blood-bome solutes display concentrations of ~3.8 mM. This discrepancy 
between expected compartment equilibration and markedly lower levels of glucose in 
parenchymal and endothelial cells may be explained by transport inhibition at the level 
of the blood-brain barrier. Indeed, endothelial GLUT1 undergoes allosteric inactivation 
by adenosine triphosphate (ATP) in settings of metabolic abundance (Carruthers and 
Helgerson, 1989; Levine et al., 1998; Lowe and Walmsley, 1986). Consequently, 
endothelial ce Ils uptake and provide less glucose to the brain parenchyma in 
replete, normoglycaemic settings. Conversely, when glycolytic demands increase and 
ATP runs low, GLUT 1 transport is uninhibited and glucose may efficiently be 
transferred to surrounding tissues (Carruthers, 1986; Cloherty et al., 1996). Globally, 
the parenchyma's apparent Km for glucose remains 1-3 mM, signifying that glycaemia 
must significantly drop before brain uptake deficits are perceived (Rao et al. , 2006). 
This can be interpreted as an evolutionary adaptation in favour of organisms whose 
neurons were uninterruptedly supplied with fuel. 
Table 1.7 
Computed compartment glucose levels for the core (primary) model 
or the astrocyte-neuron lactate shuttle (ANLS) 
Serum [Gle] 6 30 6 30 
EndoIhchal [GIe] 3. 174 3.1 11 .0 
B3YlI.m,na [Giel 2.1 10 2.0 10.4 
Astroc)tle 1 Gle 1 0.9 1.9 U 9.4 
IO'<r!mualIGkl 14 99 U 95 
" euro .. 1 [Gkl 1.2 Il 4 
BI1IIOIGIeI 1.2 9 12 91 
(From Simpson et al. , 2007.) 
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1.2.2.2 Physiological considerations 
Notwithstanding the progress made in elucidating how glucose gains entry to the 
brain and permeates neurons, the CUITent state of the field leaves many questions 
unanswered in physiological settings. Converging data on differential expression of 
GLUTs across brain regions, between species, in health and in disease are lacking. 
We know that GLUT3 appears to occur in high levels in grey matter, especially in 
densely populous zones known to be energetically needy; fittingly, neurons from the 
hippocampal region, cerebral cortex, cerebellum, striatum and midbrain express the 
greatest amounts in the rat brain (Bondy et al., 1992; Nagamatsu et al., 1993). 
However, we know little about the transcriptional regulation of brain GLUTs and the 
stabilization of rnRNA transcripts 18. Best studied is the upregulation of GLUTs in the 
CNS during hypoglycaemic events (Anitha et al. , 2012; Nagamatsu et al., 1994; 
Santiago et al., 2006; Simpson et al., 1999). Moreover, aside from evidence of cerebral 
GLUT mobilization in specifie regions of the brain during active firing (Ashrafi et al., 
2017; FeITeira et al., 20 Il; Weisova et al., 2009), information is scarce on the recyc1ing 
and trafficking ofthese transporters (McClory et al., 2014). Unlike GLUT4, intracellular 
pools of GLUT 1 and 3 are seemingl y small and do not require insulin to be upregulated 
at the cell surface 19. 
At any rate, hyperglycaemia, especially sustained for long periods oftime, remains 
a blind spot in the study of cerebral GLUTs and glucose uptake in the brain. 
In opposition to the hypoglycaemia-induced compensatory upregulation of brain 
GLUTs, hyperglycaemia has not been demonstrated to afford a c1ear regulatory effect in 
rodents, at least on the short term (Anitha et al. , 2012; Nagamatsu et al. , 1994; Santiago 
et al., 2006; Simpson et al., 1999). Under normal physiological circumstances, literature 
further provides that microvasculature density is mostly uniform across brain regions, 
18 There is sorne evidence in the periphery to support a role for cellular stress in the transcriptional 
upregulation of GLUn , explicitly in contexts of oxidative stress, rnitochondria inhibition and hypoxia 
(Anitha et al. , 2012; Bashan et al., 1992, 1993; Baumann et al. , 2007; Kozlovsky et al., 1997; 
McMahon and Frost, 1995; Mobasheri et al., 2005; Nagarnatsu et al., 1994; Santiago et al. , 2006). 
19 Sorne have rai sed the possibility that rnernbrane-bound brain GLUTs rnay be rapidly trafficked in and 
out of lipid rafts to respond to rnetabolic signais (Bames et al., 2004; Rauch et al. , 2006). 
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including the midbrain and the striatum (lelacqua et al., 2016; Kolinko et al., 2016). 
However, the possible effects of hyperglycaemia on cerebral blood flow are 
contradictory. On the one hand, both acute and chronic hyperglycaemic states are known 
to reduce cerebral blood flow (Duckrow et al., 1987; McCall, 1992; Nishimura et al., 
2007). On the other hand, they cause the occurrence of pathological neovascularization, 
that is, a rise in the volume of capillaries with deficient pericyte coverage (Ergul et al. , 
2015; Li et al., 2010; Prakash et al., 2013). The ensuing gain of blood-brain barrier 
permeability might grant glucose the ability to sidestep endothelial ATP-inhibited 
GLUT 1 and to infuse the entire brain more profusely (Carruthers and Helgerson, 1989; 
Levine et al., 1998; Lowe and Walmsley, 1986). 
Despite these remammg ambiguities, vanous demonstrations strengthen the 
idea that hyperglycaemia causes a substantial rise in parenchymal glucose 
concentrations. Early studies demonstrated that brain glucose levels were indeed 
sensitive to glycaemic circumstances. Indeed, they faU or rise during transient 
hypoglycaemic or hyperglycaemic challenges, respectively (Abi-Saab et al., 2002; 
Béland-Millar et al., 2017; Macauley et al., 2015; McCall et al., 1986; Osborne et al., 
1997). In rodent models of sustained diabetes-induced20 hyperglycaemia, intracerebral 
glucose concentrations are also augmented (de Vries et al., 2003; Gomez and Barros, 
2003; Jacob et al., 2002; McCrimmons et al., 2003). These experiments were performed 
on who le brain tissues and reliable intraneuronal measurements are still lacking21 . 
Nevertheless, computational renderings taking into account GLUT kinetics and their 
distribution predict greater glucose permeation in ail brain constituents under 
hyperglycaemia (Simpson et al., 2007) (Table l.7). We can therefore cautiously submit 
to the idea that hyperglycaemia causes an upwelling of intraneuronal glucose likely to 
hold implications for cellular fitness. 
20 Diabetes mellitus is described in section 1.2.5.1. 
2 \ Previous studies reporting these concentrations were recently demonstrated to be tlawed, owing to 
differing transport kinetics between glucose and the tagged analogues employed for quantifications 
(Dienel et al., 2017). 
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1.2.3 Neuronal glucose metabolism 
Before addressing the metabolic singularities that characterize neurons, a brief 
outline of glucose metabolism is warranted (see for review Stryer et al. , 2007) 
(Figure 1.13). In the cytosol, glucose is first engaged along a glycolytic fate upon 
irreversible phosphorylation by an important rate-limiting, ATP-consuming enzyme, 
hexokinase. Resulting glucose 6-phosphate (G6P) is a gateway metabolite, not only to 
the glycolytic pathway, but also to glycogenesis, relevant to astrocytes, or to the pentose 
phosphate pathway (ppp)22. In glycolysis, G6P undergoes isomerization into fructose 
6-phosphate (F6P), which is in turn transformed by phosphofructokinase-l (PFK) into 
fructose 1,6-bisphosphate. Importantly, PFK is another rate-limiting, energy-consuming 
enzyme that drives glycolysis and is allosterically inhibited by high ATP:adenosine 
monophosphate (AMP) ratios, which equally ensures activation of glycolysis in times of 
energy depletion. Continuing along the glycolytic pathway, fructose 1,6-bisphosphate is 
converted into a pair of triose intermediates, glyceraldehyde 3-phosphate (GA3P), 
further metabolized by glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
into 1,3-bisphosphoglycerate. From 1,3-bisphosphoglycerate, a series of enzymatic 
transformations yields the final glycolysis metabolite, pyruvate, through irreversible 
cleavage of the phosphate group by pyruvate kinase. At this level, pyruvate can enter 
mitochondria and undergo catalysis mediated by pyruvate dehydrogenase, yielding the 
gateway intermediate to the tricarboxylic acid cycle, acetyl coenzyme A 23 . In certain 
circumstances, it can also be metabolized in the cytosol by the bidirectional lactate 
dehydrogenase enzyme to give lactate, a process termed the Warburg effecr24 (Warburg, 
1956). Exogenous lactate may also be provided as a fuel at this level through its 
transformation to pyruvate, once again via lactate dehydrogenase. Generated along the 
course of glycolysis and tricarboxylic acid cycling are matrix-dwelling electron donors, 
22 The ppp is later discussed in section 1.2.3. 1. Of note, the ppp yields GA3P and F6P, an additional 
connection between glycolysis and the PPP. 
23 This is also the access point for alternate fue ls, like ketone bodies, provided during glucose depletion, 
which is beyond the scope of this thesis. 
24 In mammalian ce lls, the Warburg effect occurs under aerobic conditions, contrarily to the lactate-
producing anaerobic glycolytic process. Tt should not be confused with the Warburg effect that occurs 
in plants, describing decreased photosynthesis in hyperoxic conditions. 
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namely reduced nicotinamide adenine dinucleotide (NADH) and flavin adenine 
dinucleotide (F ADH2), whose electrons are funnelled through the electron transport 
chain of the inner mitochondrial membrane and are relinquished to the terminal 
electron acceptor, oxygen, to yield water. Concurrently, this electron traffic establishes 
a transmembrane proton gradient serving to power the synthase that ultimately pro duces 
ATP (30-36 per molecule of glucose). 
Although this energy production pathway is present in sorne form or other in 
aIl ceIls, it is highly ramified and shares intermediates with a plethora of other parallel 
metabolic routes. A few of these are indeed relevant in the brain and in a 
hyperglycaemic setting, but, for the sake ofbrevity, only the most salient ofthese will be 
discussed in the next subsections. 
Glucose 
(il) ppp 
-
-
-~ H' 
c ~ Glucose- 6P 
NAOf>+ X GSSG X ROOH 
NAOPH GSH ROH 
~ ... ...;;......;..---~, GPI + 
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PFK ~ 
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Figure 1.13 Schematic representation of glucose metabolism and pertinent 
connecting pathways in neurons and astrocytes. 
Continued on next page. 
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(Continued.) Glucose is processed principally via glycolysis (i) leading up 
to oxidative phosphorylation (iv) with the intent of producing ATP for 
energy. However, glucose metabolites can also be diverted into tangential 
pathways. In astrocytes, glucose 6-phosphate (G6P) can be transformed 
into glycogen by glucokinase (iii). In neurons, the pentose phosphate 
pathway (PPP) is crucially provided by G6P for the maintenance of 
a proper redox status via the regeneration of the reduced form of 
glutathione (ii). ADP, adenosine diphosphate; DHAP, dihydroxyacetone 
phosphate; GA3P, glyceraldehyde 3-phosphate; GAPDH, glyceraldehyde 
3-phosphate dehydrogenase; GPI, glucose 6-phosphate isomerase; GSH, 
glutathione; GSSG, glutathione disulphide; HK, hexokinase; NAD, 
nicotinamide adenine dinucleotide (NAD+ oxidized, NADH reduced) ; 
NADP, nicotinamide adenine dinucleotide phosphate (NADP+ oxidized, 
NADPH reduced); PFK, phosphofructokinase; ROH, alcohol; 
ROOH, hydroperoxide compound; TPI, triosephosphate isomerase; 
TA, transaldolase; TCA, tricarboxylic acid; TK, transketolase. 
(From Magistretti and Allaman, 2015.) 
1.2.3.1 Specifie metabolic Jates 
Extracellular glucose levels in the CNS are always in excess of demand due to 
favourable GLUT 1 kinetics. Yet, to ensure uninterrupted intracellular glucose 
availability, it is also crucial that the velocities of uptake and metabolism be tightly 
coupled. In neurons, the first step of glycolysis holds a particular importance in this 
regard. Indeed, hexokinase phosphorylates glucose more slowly th an it is taken up by 
GLUT3 (Lowry and Passonneau, 1964; Whitesell et al., 1995; Wilson, 2003). In other 
words, GLUT3 uptake is never limiting and free cytosolic glucose is constantly available 
(Dienel, 2012). Similarly, to secure glycolysis with a sustained flow of metabolites, 
especially during neuronal activity, engagement of glucose in the pathway must not be 
rate-limiting. In this respect, processing of glucose by hexokinase allows neurons to 
"stock" fuel in the form of G6P. However, since hexokinase is inhibited by G6P, 
its accumulation is somewhat limited. Nevertheless, A TP levels dwindle during neuronal 
activation, thereby relieving the inhibition on downstream rate-limiting PFK and 
favouring the expenditure of accrued metabolites between hexokinase and PFK. In tum, 
hexokinase is disinhibited due to the consequent reduction of G6P pools and can once 
again phosphorylate glucose to provide the glycolytic pathway with substrates. 
These gating processes allowing the accumulation of glycolytic intermediates act as a 
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buffering system to account for the short-lived gap between activity-induced ATP 
utilization and its metabolic renewal (Mangia et al., 20 Il). 
As previously stated, the brain almost fully oxidizes the glucose it takes up. 
Precisely, the oxygen-glucose index ratio (equation 1) in humans is estimated at 5.5 in 
a resting state and 5.0 during neuronal activation, where 6 represents full stoichiometric 
oxidation (equation 2) (Shulman et al., 2001; Siesjo, 1978; Sokoloff, 1999). 
cerebral metabolic rate of O2 
oxygen-glucose index = . 
cerebral metaboltc rate of glucose 
(1) 
(2) 
These observations have been interpreted as the utilization of glucose for non-oxidative 
processes, which infers bypassing oxidative phosphorylation (Shulman et al., 2001). 
The engagement of glucose in the Warburg effect25, the synthesis of amino acids, 
the glycation of macromolecules and the ppp are al! non-oxidative mechanisms 
suggested to explain the oxygen-glucose index gap. However, within the context of this 
thesis, we will only discuss the fate of glucose in the ppp (Clarke and Sokoloff, 1999; 
Dienel, 2009; Shulman et al., 2001). 
The ppp is best known for its pivotaI role in supplying ribose 5-phosphate for the 
synthesis of nuc1eic acids in mitotic cells (see for review Lehninger et al., 1995). 
However, its importance in neurons rather dwells in the recyc1ing of nicotinamide 
adenine dinuc1eotide phosphate (NADPH), a vital redox cofactor (Kletzien et al., 1994). 
The glycolysis metabolite G6P is the entrance point to the ppp via the rate-limiting 
enzyme glucose 6-phosphate dehydrogenase (Figure 1.13). A sequence of non-oxidative 
25 The Warburg effect consists in the non-oxidative transformation of 1 molecule of glucose into 
2 molecules of pyruvate through glycolysis, which yields 2 ATPs and uses up 2 NAD+ cofactors. 
Subsequent reduction of 2 pyruvates into 2 lactates via the Warburg effect restores 2 NAD+ cofactors. 
During sustained neuronal activity, ATP can be produced very rapidly from glucose without the need 
for oxidative phosphorylation via a self-renewing cycle. The lactate produced can be additionally 
converted into pyruvate to drive the tricarboxylic acid cycle and, therefore, oxidative phosphorylation. 
However, its concentrations harvested through the Warburg effect are predicted to outstrip energetic 
needs and may therefore be released unprocessed into the circulation via monocarboxylate transporters, 
accounting for part of the 0.5 oxygen-glucose index gap between resting and active states (Shulman 
et al., 2001). 
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reactions regenerates 2 molecules of NADPH from G6P and returns the intermediate 
back on the glycolytic track through the production of GA3P or F6P. Irnportantly, 
NADPH produced by the ppp is employed by glutathione reductase to restore oxidized 
glutathione to its reduced and useful form26 (Hothersall et al. , 1979; Kletzien et al., 
1994). Indeed, by virtue of glutathione's detoxifying action on ROS, studies support a 
potent antioxidative role for the ppp in neurons and astrocytes (Ben-Yoseph et al., 
1996a, 1996b; Bolafios et al., 2008; Herrero-Mendez et al., 2009; Kussmaul et al., 1999; 
Vaughn and Deshmukh, 2008). Pertaining to the oxygen-glucose index gap, attention 
must rather be drawn to the shared metabolic intermediate between glycolysis and PPP, 
F6P, since it stands upstream from any irreversible reactions in the glycolytic pathway, 
as opposed to GA3P found downstream from the unidirectional PFK enzyme and 
destined to oxidative phosphorylation. Combined with evidence for a bottleneck effect 
at the level of PFK in neurons27 (Bolafios et al., 2010; Herrero-Mendez et al., 2009), 
sorne have suggested that F6P is recycled through the PPP by catalytic revers ion to G6P 
(Bouzier-Sore and Bolafios, 2015). Therefore, any fraction ofthese metabolites that keep 
cycling through the non-oxidative PPP may weil account for a portion of the 
0.5 stoichiometric gap between glucose and oxygen use (Bouzier-Sore and Bolafios, 
2015). 
1.2.3.2 Current hypotheses in neuroenergetics 
For the most part, the metabolic processes described above have not been clearly 
ascribed to neurons or other brain cells on account of the lack of consensus per the 
proportion of glucose absorbed and metabolized by each compartment. For the past 
20 years, the field of neuroenergetics has been a battleground of ideas around this 
26 Glutathione, or y-L-glutamyl-L-cysteinylglycine, is a pseudo-tripeptide whose thiol moiety acts as a 
reducing agent. Glutathione peroxidase catalyzes the transfer of electrons between two glutathiones and 
one hydrogen peroxide molecule, yielding water and one glutathione disulphide, a condensation of 
two oxidized glutathiones. Glutathione disulphide is reverted to its useful form, reduced glutathione, 
by glutathione reductase. Glutathione transferase can also catalyze the addition of glutathione onto 
potentially toxic xenobiotics. 
27 The bottleneck effect is described in section 1.2.3 .2. 
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emgma, ansmg mainly from two groups that allot differential importance to these 
processes in neurons and astrocytes28. 
The first group, spearheaded by Pellerin and Magistretti, defends the position that 
astrocytes, and not neurons, are the principal site of glucose uptake, especially during 
neuronal activation (Pellerin and Magistretti, 1994). In tum, astrocytes pro vide energy to 
neurons in the form of lactate, a hypothetic process hence termed the astrocyte-neuron 
lactate shuttle29 (Figure 1.14). According to this the ory, astrocytes are predominantly 
glycolytic, meaning that the y utilize glucose to produce lactate through glycolysis and 
the Warburg effect. On the other hand, neurons are rather oxidative and transform 
astrocyte-derived lactate into pyruvate, which is metabolized through the tricarboxylic 
acid cycle to power oxidative phosphorylation. The authors put forward two central 
arguments: 1) astrocytes import more glucose than neurons; 2) neurons cannot 
upregulate their rate of glycolysis. The first contention hinges on evidence 
demonstrating astrocytes as importing more than 50-90% of available brain glucose 
(Barros et al., 2009; Nehlig et al., 2004; Vega et al. , 2003). The second is based 
on studies revealing that the levels of a specific enzyme, 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase 3 (Pfkfb3), are markedly downregulated in neurons 
compared to astrocytes due to constant proteasomal degradation (Bolaiios et al., 2010; 
Herrero-Mendez et al., 2009). Pfkfb3 phosphorylates F6P to produce fructose 
2,6-bisphosphate (Fru-2,6-P2) known to activate one of the key rate-limiting glycolytic 
enzymes, PFK. The authors therefore con tend that sparse expression of Pfkfb3 in 
neurons explains the bottleneck effect at the level of PFK, liable for its lirnited glycolytic 
capacities. 
28 A heated debate took place a few years ago between these two groups in the Journal of Cerebral Blood 
Flow and Metabolism. A succession of commentaries offers very interesting insight into the arguments 
hired by both parties to support their theories (Jolivet et al., 2010; Mangia et al., 20 II) . 
29 Later biophysical computations and physiological applications came in support of this model 
(Aubert and Costalat, 2005; Aubert et al., 2007; Béland-Millard et al., 2017; Machler et al., 2016). 
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The second theory, termed the core model3o, is advocated by Mangia, Simpson and 
Vannucci, and rather posits that the lactate shuttle effect is negligible (Mangia et al., 
2009; Simpson et al., 2007). Their computational model relies on the same variables 
used by the former group, with the exception that it considers experimentally measured 
transporter kinetics and distribution patterns throughout the brain. Taking into account 
these additional parameters, this group arrives at the conclusion that neurons constitute 
the main site of glucose uptake. To bolster their position, they recapitulated and 
invalidated the two main arguments in support of the former model. First, regarding the 
preferred astrocytic uptake of glucose, sorne of the studies demonstrating a greater 
glucose influx in favour of astrocytes (80-90%) were performed in cerebellar slices 
(Barros et al., 2009) and ex vivo rat vagus nerves (Vega et al., 2003), which may po orly 
represent physiological situations. Other reports in freely moving animais indeed 
moderate these numbers and rather support equal partitioning or even preferential 
neuronal uptake (50-80%) (Nehlig et al., 2004; Zielke et al., 2007). Second, while the 
former group argues that glycolytic activity is capped in neurons due to the bottleneck 
effect at PFK (Bolafios et al. , 2010; Herrero-Mendez et al., 2009), Mangia and 
colleagues contend instead that PFK may be activated by metabolites other th an 
Fru-2,6-P2, thus, that glycolysis can be enhanced31 (Ogushi et al. , 1990). In support of 
this, other neuronal monosaccharidic metabolites were found to be more potent 
activators of PFK, and Fru-2,6-P2 appears to be expendable in the amplification of 
glycolysis during neurotransmission (Ogushi et al., 1990; Pauwels and Trouet, 1984). 
Based on these arguments, the core model stipulates that neurons, and not astrocytes, 
take up more glucose and account for lactate transients during brain activity. 
In a final attempt to reach a consensus, one group gathered both models into a 
unified computational framework, which ultimately favoured the theory that astrocyte-
neuron lactate shuttling is negligible, that neurons are the principal glucose consuming 
30 This position is bolstered by physiological evidence that contradicts the studies in support of the 
astrocyte-neuron lactate shuttle (Diaz-Garcia et al. , 2017; Drulis-Faidasz et al. , 2019; Hall et al., 201 2). 
31 Simpson and colleagues further provide reports that indirectly contradict the alleged lack of glycolysis 
upregulation, showing ri ses in surface GLUT3 in response to neuronal activity a nd, by the same token, 
proving that neurons di spose of purposeful pathways for controlling internaI energy supplies, Iikely via 
glycolytic processes (Ferreira et al. , 2011 ; Weisova et al. , 2009) . 
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cells of the CNS, and that they can carry out both glycolysis and oxidative 
phosphorylation (DiNuzzo et al., 2010). Regardless of whether neurons constitute the 
preferential consumers of glucose, we can cautiously surmise that intraneuronal glucose 
levels rise during hyperglycaemia and that they fuel ATP production at least partially 
through oxidative phosphorylation. However, these models have not been specifically 
applied to different neuronal subtypes such as dopaminergic neurons or to various brain 
regions, such as the midbrain and striatum, which aU are likely to exhibit distinct 
metabolic behaviours. 
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Figure 1.14 A schematic representation of the astrocyte-neuron lactate shuttle 
theory. 
The premise of this school of thought provides that astrocytes are more 
glycolytic and neurons are more oxidative. It is proposed that the 
bottleneck effect at the level of PFK is seemingly more pronounced in 
neurons and accounts for their low glycolytic capacity. A direct corollary 
of this is that lactate must be shuttled to neurons for it to be able to 
produce ATP. Glo, glyoxalase; Ox Phos, oxidative phosphorylation; 
PDH, pyruvate dehydrogenase; Pfkfb3 , 6-phosphofructo-2-kinase/ 
fructose-2 ,6-bisphosphatase 3; PKM, pyruvate kinase lsozymes. 
(From Magistretti and AUaman, 2015.) 
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1.2.4 Neuronal oxidative stress in hyperglycaemia 
The clinical significance of hyperglycaemia emerged upon its formai identification 
as the prime culprit in comorbid diabetic complications (Diabetes Control and 
Complications Trial Research Group, 1993; Gaede et al. , 2008; Giacco and Brownlee, 
2010; UK Prospective Diabetes Study Group, 1998). The most affected collateral targets 
in diabetes mellitus are the kidneys, the cardiovascular system and the nervous system 
(Nathan, 1993). Within each ofthese tissues dwell cells that are preferentially vulnerable 
to hyperglycaemia, namely mesangial cells of renal glomeruli, endothel ial capillary 
celIs, and brain cells. Despite their many functional and phenotypic differences, 
these cells share the distinct liability of taking up glucose in a manner that is reliant on 
extracellular concentrations (Heilig et al. , 1995; Kaiser et al., 1993). Indeed, mesangial 
and endothelial cells predominantly express insulin-independent GLUT1 (Brosius and 
Heilig, 2005; Mueckler and Thorens, 2013 ; Sone et al. , 2000); likewise, brain cells 
express several insulin-independent GLUTs, chiefly GLUT1 and GLUT3 (Mantych 
et al. , 1992; Nagamatsu et al. , 1993; Simpson et al. , 2008). Although it is c1ear that 
glucose concentrations rise in these ce Ils un der conditions of hyperglycaemia, 
how exactly cellular damage occurs is not as forthright. The CUITent concensus is that 
oxidative stress explains hyperglycaemia-induced diabetic complications32 (Araki and 
Nishikawa, 2010; Brownlee, 2005; Ceriello, 2003 ; Giugliano et al. , 1996) . 
Oxidation is a ubiquitous phenomenon common to al! organisms that engage in 
aerobic respiration for energy. Indeed, ROS are mainly produced from the leakage of 
the mitochondrial electron transport chain during oxidative phosphorylation, but can also 
arise from other endogenous (e.g. , monoamine oxidase activity, dopamine auto-
oxidation, Fenton reactions in the presence of transition metals, etc.) or exogenous 
sources (e.g., exposure to pesticides, smoking, ultraviolet and ionizing radiations, 
pollution, etc.). Although required for a number of desirable physiologica1 processes, 
the excessive generation of ROS can affect almost aIl cellular components, namely 
32 Understanding the link between hyperglycae mia and diabetic complications required the discovery of 
particular markers in the blood and tissues of diabetic patients indicating a state of oxidative stress 
(Cheng and Gonzalez, 1986; Jones el al. , 1988; Matkovics et al. , 1982). 
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DNA, lipids and proteins (Barzilai and Yamamoto, 2004; Niki, 2008). To cope with 
the unavoidable production of ROS, antioxidative defences are provided endogenously, 
by superoxide dismutase (SOD), catalase, urate, ascorbate and glutathione, or 
exogenously, by vitamins, polyphenols and other nutrients found in the di et. Per se, 
oxidative stress arises from an imbalance between the generation and clearance of ROS, 
in favour of the former, and may ultimately provoke cell death. This inability to cope 
with an oxidative overload constitutes a key pathological element, not only in 
hyperglycaemia (Brownlee, 2005; Wolff et al. , 1991), but also in Parkinson ' s disease 
(Hwang, 2013; Schapira and Jenner, 2011 ; Tsang and Chung, 2009) and aging (Finkel 
and Holbrook, 2000; Pérez et al. , 2009). 
In consummg approximately 20% of total inhaled oxygen (Jain et al. , 20 lO; 
Quastel and Wheatley, 1932), the brain is doubtlessly susceptible to undergo oxidative 
stress. Indeed, processing of this oxygen implies engagement of oxidative 
phosphorylation, which inexorably entails the generation of mitochondrial ROS (Kudin 
et al. , 2004; Liu et al. , 2002). Owing to their steep demands in ATP, neurons possess a 
high basal oxidative metabolism compared to other types of cells in the brain or 
elsewhere, and are thus plausibly more vulnerable to additional sources of stress. 
Although the literature do es not provide an adequate account of the mechanisms 
underlying hyperglycaemia-induced oxidative stress in the CNS, let alone in nigrostriatal 
dopaminergic neurons, we can speculate on the events that contribute to this critical 
coping threshold based on experimental data and our knowledge of neuronal glucose 
metabolism. 
1.2.4.1 Mitochondrial mechanisms 
Following an upsurge in intraneuronal glucose, a plausible event that may occur is 
an amplified flux of electron donors toward oxidative phosphorylation. In a first 
scenario, high intraneuronal glucose concentrations may provide the glycolysis pathway 
and tricarboxylic acid cycle with more fuel , culminating in the increased production of 
electron donors and the improvement of oxidative phosphorylation. In a second scenario, 
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ta king into account the possibility of an astrocyte-neuron lactate shuttle in 
hyperglycaemia, lactate may be converted to pyruvate to power the tricarboxylic acid 
cycle in neurons. The end result remains the enhanced solicitation of the electron 
transport chain. 
Many have indeed advocated the theory elaborated by Brownlee and colleagues, 
postulating that the production of superoxide anion by the overworked electron transport 
chain constitutes the initial oxidative insult that takes place in cells vulnerable to 
hyperglycaemia, including neurons (Brownlee, 2005; Du et al. , 2001; Giacco and 
Brownlee, 2010; Nishikawa et al., 2000; Tomlinson and Gardiner, 2008). The premise 
of this theory hinges on electron transport chain overload, resulting from increased 
delivery of electrons by donors formed via the glycolytic pathway or the tricarboxylic 
acid cycle (Figure 1.15). Normally, electron transport chain leaks are estimated to occur 
at a rate of 1-3% (Boveris, 1977; Kudin et al., 2004; Liu et al., 2002), but other studies 
demonstrate that hyperglycaemia elicits an early production of superoxide anion beyond 
basal levels (Du et al. , 2001; Nishikawa et al. , 2000). Hence, superoxide anion exceeds 
antioxidative defences and reacts with mitochondrial molecules to form secondary ROS 
that are apolar, thus, free to diffuse across membranes and to damage the various 
constituents of the ceIl, including nuclear DNA. The resulting strand breaks activate the 
NAD+-dependent DNA repair enzyme, poly(adenosine diphosphate-ribose) polymerase 
(PARP), whose catalytic activity inhibits a key glycolytic enzyme, GAPDH33 (Du et al. , 
2003) (Figure 1.16). Obstruction of glycolysis at GA3P causes upstream intermediates to 
be rerouted toward deleterious tangential pathways. It is proposed that generation of 
ROS by these pathways contributes to a self-perpetuating cycle of DNA damage, P ARP 
activation and GAPDH inhibition, leading to a permanent glycolytic impasse and 
sustained oxidative stress (Brownlee, 2005). 
33 Alongside adenosine di phosphate (ADP)-ribosylation by PARP, oxidative stress also di rectly inhibits 
GAPDH. Together, these mechanisms a\low for the dynamic rerouting of glucose through the ppp with 
the aim of producing NADPH co factors for the renewal of the cofactor glutathione by glutathione 
reductase (Ralser et al., 2007). The sum result remains the impediment of glycolysis. 
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Figure 1.15 Hyperglycaemia-induced generation of superoxide anion at the level 
of the mitochondrial electron transport chain. 
Electron traffic through the complexes (I-IV) of the chain allows the 
pumping of protons into the mitochondrial intermembrane space, which 
affords an electrochemical potential difference that powers A TP synthase 
(Trumpower, 1990). Protons are usually trafficked back into the matrix by 
ATP synthase, paired to its catalytic activity, and by uncoupling protein-
1, which generates heat to alleviate overly steep gradients. However, 
when electron transport is profuse, the transmembrane potential increases 
faster than it can be dissipated by ATP synthase and uncoupling protein-
1. Above a certain potential threshold, certain complexes, especially 
complex III, of the electron transport chain undergo inhibition and begin 
to leak their electrons, which are in turn captured by oxygen to pro duce 
superoxide anion (Adam-Vizi, 2005 ; Korshunov et al., 1997; Kwong and 
Sohal, 1998; Starkov et al., 2004). Owing to its negative charge that 
prevents it from crossing phospholipid bilayers, superoxide anion remains 
trapped within mitochondria. There, it is usually deactivated by the 
mitochondrial superoxide dismutase (SQD) into peroxide, another 
reactive oxygen species (ROS) that can cross phospholipid bilayers and 
damage other components of the cell. An upsurge in oxidative 
phosphorylation as it occurs in states of high intracellular glucose 
availability will necessarily increase superoxide anion generation. 
Cyt c, cytochrome c; e-, electron; 0 2·-, superoxide anion; Pi, inorganic 
phosphate; Q, quinone; UCP, uncoupling protein. (From Brownlee, 
2005.) 
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Figure 1.16 Detrimental activation ofPARP in response to DNA damage. 
Oxidative stress leads to ROS-induced nuclear DNA damage responsible 
for activating poly(adenosine diphosphate-ribose) polyrnerase (PARP). 
Besides repairing single-stranded DNA nicks, it also operates as an 
adenosine diphosphate-ribosyl transferase (Sawa et al., 1997; Schmidtz, 
2001). One of its targets is GAPDH, known to shuttle between the cytosol 
and the nucleus. Upon ADP-ribosylation, GAPDH is inactivated, thereby 
contributing to the accrual ofupstream glycolysis rnetabolites. Moreover, 
if PARP is not inactivated, it can lead to the depletion of the NAD+ 
cofactor. ADPR, adenosine diphosphate ribosyl; NA, nicotinamide. 
(From Brownlee, 2005.) 
It is important to note that the key results in support of Brownlee's theory were 
obtained in bovine aortic endothelial cells treated with 30 mM of glucose for 7 da ys 
(Du et al., 2001; Nishikawa et al., 2000). Consequently, these conditions may not reflect 
what occurs in the brains of animais exposed to high levels of glucose. A small body of 
literature investigating these mechanisms in the CNS and the periphery of rodents does 
not clearly validate this model in neurons. In fact, whether at the level of glycolysis or 
the tricarboxylic acid cycle, the data inconsistently reports up- or downregulation of 
these pathways, both in peripheral nerves or brains of hyperglycaemic rodents (Akude 
et al., 2011; Chowdhury et al., 2010; Hinder et al., 2013; Kaur and Bhardwaj, 1998; 
Price et al., 2006; Thakran et al., 2003; Thurston et al., 1995; Zheng et al., 20 17) . 
However, with regard to oxidative phosphorylation, most studies revealed a decreased 
activity or expression of electron transport chain constituents in the brain and in 
peripheral sensory neurons (Aghanoori et al., 2017; Akude et al., 2011; Chowdhury 
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et al., 2010; Kaur and Bhardwaj, 1998; Stancié et al. , 2013). A closer look at the 
duration of hyperglycaemia affords a clearer understanding of the process. Early events 
in hyperglycaemia cause the upregulation of glycolysis and tricarboxylic acid cycling 
(Kaur and Bhardwaj, 1998; Price et al., 2006; Thakran et al. , 2003; Thurston et al., 
1995). Later, however, these pathways are impeded (Aghanoori et al., 2017; Akude 
et al., 2011; Chowdhury et al., 2010; Hinder et al., 2013; Zheng et al., 2017). At aIl time 
points, oxidative phosphorylation is impaired (Aghanoori et al., 2017; Akude et al., 
2011; Chowdhury et al., 2010; Kaur and Bhardwaj, 1998; Stancié et al., 2013). In other 
words, dysfunction of mitochondrial respiration likely occurs before glycolysis and 
tricarboxylic acid cycle hindrance. This supports the theory that hyperglycaemia induces 
an early upsurge in glucose metabolism leading to the initial insult arising from 
mitochondrial respiration (Brownlee, 2005; Du et al., 2001; Giacco and Brownlee, 2010; 
Nishikawa et al., 2000; Tomlinson and Gardiner, 2008). However, since the model 
proposed by Brownlee does not account for precise cellular effects of long-term 
hyperglycaemia, it cannot explain the global impairment of glucose metabolism 
observed at later time points. 
Among these studies, very few groups measured superoxide amon levels and 
proper mitochondrial respiration. In these reports, solely performed in peripheral sensory 
neurons of long-term hyperglycaemic rats, superoxide anion production and respiration 
rates were downscaled even when corrected for mitochondrial numbers, despite overt 
manifestations of oxidative stress (Aghanoori et al., 2017; Akude et al., 20 Il; 
Chowdhury et al., 2010). This may indicate that sustained hyperglycaemia causes the 
waning of mitochondrial respiratory functions over time, sparing superoxide anion 
production while ROS generation is maintained by non-mitochondrial sources. 
One explanation provides that the initial superoxide anion overload proposed by 
Brownlee's model may cause deleterious mutations in mitochondrial DNA, leading to 
defects in electron transport chain components that in tum generate more ROS34. 
34 Unlike nuclear DNA, mitochondrial DNA lacks protection afforded by histones and repair enzymes. 
For this reason, the rates of mutagenesis in mitochondria are relatively high. Sorne subunits of 
complexes l and IV of the electron transport chain are encoded in mitochondrial DNA and, thus, 
are highly susceptible to mutation-induced impairments (Wei , 1998). 
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In the long term, excessive oxidative damage to mitochondrial DNA may impair 
respiratory chain expression altogether, causing the observed shortfall in superoxide 
anion35 (see for reviews Guo et al., 2013; Wei, 1998). Although studies employing 
proper animal models of hyperglycaemia have not investigated very early mitochondrial 
events in neurons, a prompt increase in superoxide anion is observed following 
ischaemia-reperfusion, a paradigm similar in sorne respects to a transient nse ln 
glycaemia (Iwata et al., 2014; Muranyi and Li, 2006; Won et al. , 20 15). 
1.2.4.2 Rerouting mechanisms: polyol pathway and macromolecule glycation 
Aside from ROS generated through mitochondrial failure, hyperglycaemia may 
trigger the onset of oxidative stress via pathways that dwell upstream in glycolysis. 
As previously demonstrated, free glucose is present in the cytosol of neurons and its 
concentrations rise during hyperglycaemia. Under normal circumstances, hexokinase is 
mandated to transform available glucose into G6P. However, due to substrate-mediated 
inhibition, it can only engage a fraction of cytosolic glucose along the glycolytic 
pathway before it is saturated. Excess glucose is therefore consumed by other pathways 
and is constantly replenished by high extracellular levels. The principal compensatory 
outlets are the polyol pathway and macromolecule glycation. 
The polyol pathway is driven by aldose reductase whose affinity for glucose is 
relatively low (Gabbay et al., 1966). Under normal glycaemia, aldose reductase does not 
appoint glucose to the polyol pathway, but high intraneuronal concentrations drive its 
catalytic activity. Aldose reductase preferentially employs the NADPH cofactor, 
produced by the PPP, to reduce glucose into the polyalcohol sorbitol (Lee and Chung, 
35 Another explanation is that the increased glucose availability may provide ample supply of ATP via 
the non-respiratory Warburg effect, thereby circumventing the need for oxidative phosphorylation 
and culminating in a downward adjustment of mitochondrial functions , akin to the Crabtree effect 
(Hamberger and Hyden, 1963; Ibsen, 1961). Accounts of thi s are , however, inconsistent in 
hyperglycaemic models (Herse and Petchell, 1998; Koziel et al. , 2012 ; Padnick-Silver and Linsenmeier, 
2003). 
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1999)36. Sorbitol then undergoes enzymatic converSIOn to fructose by sorbitol 
dehydrogenase, which exploits the important co factor NAD+ (Verdin, 2015; Williamson 
et al., 1993; Wu et al., 2016) (Figure 1.17). Increased processing of glucose through the 
polyol pathway thus drains pools of cofactors required for the activity of a plethora of 
enzymes, including glutathione reductase, GAPDH and others in the glycolytic pathway 
and tricarboxylic acid cycle (Vander Jagt et al., 1995). 
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Figure 1.17 NAD in glucose metabolism. 
This schematic represents the nurnerous enzymes that require the 
NAD+ cofactor to function and highlights the hazard that its depletion 
represents for the maintenance of normal metabolism. Acetyl-CoA, acetyl 
coenzyme A. (From Wu et al., 2016.) 
36 A possible noxious effect of driving the polyol pathway was first proposed to be osmotic damage, 
seeing as cells do not export sorbitol efficiently. However, sorbitol concentrations measured in diabetic 
nerves and capillaries were too low to endorse thi s effect (Brownlee, 2001). 
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The second outlet of excess glucose is via macromolecule glycation, which may 
indirectly contribute to oxidative stress (Vicente Miranda et al., 2016). Glycation 
consists of the slow non-enzyrnatic, energy-independent, covalent addition of a 
monosaccharide to macromolecules, usually lipids or proteins termed advanced 
glycation end-products (AGEs)37 (Figure 1.18). Although glucose is a poor glycating 
agent, one of its downstream metabolites, methylglyoxal, exceeds its reactivity 
20000 times (Thomalley, 2005). Methylglyoxal is formed from the non-enzyrnatic 
degradation of triose phosphates, such as the glycolysis intermediate GA3P, and readily 
glycates proteins at the level of arginine and lysine residues (Ahmed et al., 1997; 
Oya et al., 1999; Phillips and Thomalley, 1993; Richard, 1984; Shipanova et al., 1997; 
Thomalley et al., 1999). Intracellular AGEs produced via this pathway are harmful to 
cells because of the loss or alteration of their normal prote in or lipid functions, but also 
by virtue of the mechanisms in place to ensure the prophylactic clearance of glycating 
agents (Ahmed et al. , 2003). Indeed, methylglyoxal and other agents are enzyrnatically 
degraded by glyoxalase and aldose reductase (Izaguirre et al., 1998; Monder, 1967; 
Sousa Silva et al., 20 13; Vander Jagt et al., 1992). In the setting of hyperglycaemia, 
excess glycating agents may overwhelm these pathways and lead nonetheless to AGEs, 
evidenced by the proportional rise in CNS glycation as a function of glycaemia, which 
can reach an exorbitant 34-fold increase (Uchiki et al., 2012). Most importantly, 
however, glyoxalase employs gluthathione to deactivate molecules, while we know that 
aldose reductase depletes pools of NADPH (Schieber and Chandel, 2014; Thomalley, 
1988). Therefore, methylglyoxal and other glycating agents derived from glucose or 
its metabolites indirectly worsen the oxidative status of neurons by monopolizing 
endogenous antioxidative defences or the cofactors necessary for their restoration. 
Since glycation is a non-specific and spontaneous reaction, AGEs may also occur 
extracellularly. These activate deleterious inflammatory pathways by binding their 
designated membrane receptor, RAGE (Jakus and Rietbrock, 2004; Singh et al., 2001). 
37 In diabetic patients, the gold standard in the assessment of systemic glycation, thus of the severity of 
hyperglycaemia, consists in quantification of circulating glycated haemoglobin (Kovatchev, 2017). 
In fact, on account of the graduaI nature of these reactions, this measure is insensitive to daily glycaemic 
fluctuations and rather indicates glycaemic control spanning over the previous few weeks. 
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Binding of RAGEs by AGEs or other endogenous ligands induced by hyperglycaemia is 
a known mechanism of systemic inflammation in diabetes mellitus and can trigger 
intracellular signalling cascades that lead to the activation of nuc1ear factor kappa-light-
chain-enhancer of activated B cells (NF-KB) (Bierhaus et al., 2005; Haslbeck et al., 
2007; Rong et al., 2005). In the brain parenchyma, neuroinflammation primarily 
mediated by glial cells can exert additional extraneuronal oxidative injuries38. 
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Figure 1.18 The chemistry of protein glycation. 
CH , - NH - Protein 
1 
c=o 
1 
• HO-C-H 
1 
H-C-OH 
1 
H-C-OH 
1 
CH,OH 
Ketoamine 
(Amadori Product ) 
1 
AGE - Protein - AGE 
(Protein crosslink) 
Glycation begins by the formation of a Schiff base wherein the aldehyde 
group of a glycating agent will bind the amino group of a lysine or 
arginine molecule in a protein. This is followed by the formation of an 
Amadori product, consisting in a rearrangement of the hydrogen from the 
hydroxyl group adjacent to the imine of the Schiff base onto the nitrogen, 
which yields a ketone function. The ultimate formation of an advanced 
glycation end-product (AGE) requires the oxidation of the Amadori 
product, usually catalyzed by transition metals (see for review Jakus and 
Rietbrock, 2004; Singh et al., 2001). (From Gkogkolou and B6hm, 2012.) 
Gathering ail the evidence, hyperglycaemia wields its detrimental effects on 
neurons by an assortment of conceivable mechanisms leading to oxidative stress: 
1) The initial rise in glucose metabolism enhances oxidative phosphorylation, 
which intensifies the rate of superoxide anion formation at the electron transport 
38 We have reviewed the cellular and molecular mechanisms underlying neuroinflammation 10 
Appendix A. The article was published in the French language. 
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chain. On the one hand, superoxide anion damages mitochondrial DNA, causing the 
expression of respiratory components prone to generate more ROS, which may lead 
to global mitochondrial failure in the long term. On the other hand, superoxide 
anion creates more ROS that cause nuclear DNA strand breaks, thereby activating 
PARP. 
2) Increased expenditure of NAD+ by P ARP slows the rates of glycolysis, 
tricarboxylic acid cycling and oxidative phosphorylation operating via enzymes that 
require this cofactor. PARP may also ADP-ribosylate and inhibit the glycolytic 
enzyme GAPDH, which provokes upstream accumulation of metabolites. 
3) Accrued levels of GA3P upstream of GAPDH are non-enzymatically converted into 
the glycating agent methylglyoxal whose decomposition by glyoxalase and aldose 
reductase expends antioxidative cofactors, such as glutathione and NADPH. 
4) Excess glucose can be diverted into the deleterious polyol pathway, powered once 
again by aldose reductase that further depletes stocks of NADPH required for the 
renewal of the antioxidative co factor glutathione. 
What emerges here is a number of different pathways that collectively cause a 
shortage of antioxidant defences layered with mitochondrial dysfunction, two pivotai 
factors likely responsible for pushing vulnerable cells beyond the critical coping 
threshold. The sum of these undesirable processes appears to be particularly relevant in 
neurons, in light of their relatively low glutathione levels and their reliance on the ppp 
for its rapid regeneration (Bolafios et al., 1995; Kang et al., 1999). In fact, insufficient 
provision of the ppp leads to poor regeneration of glutathione and neuronal apoptosis 
(Herrero-Mendez et al., 2009). Neurons may reach the coping threshold quicker than 
other brain cells, for instance astrocytes that display comparatively greater ppp activity 
(Garcia-Nogales et al. , 2003; Herrero-Mendez et al., 2009). 
Most importantly, the proposed molecular events leading to neuronal oxidative 
stress in hyperglycaemia, explicitly via increased superoxide anion generation (Ziegler 
et al. , 2015), mitochondrial dysfunction (see for review Patti and Corvera, 2010), 
PARP activation (Obrosova et al., 2005), impairment of the PPP (Ziegler et al., 2017), 
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glycation (Aubert et al., 2014) and glutathione system deficits (Kasznicki et al., 2012 ; 
Mendez et al., 2015), are all cogently established in diabetic patients with neuronal 
pathology. Remarkably, clinical trials employing pharmacological agents to target sorne 
of these pathways, notably aldose reductase inhibitors to diminish polyol pathway influx 
(Greene et al., 1999; Kawai et al. , 2010; Obrosova et al., 2002) or exogenous SOD to 
quench superoxide anion (Bertolotto and Massone, 2012), are demonstrated to improve 
diabetic peripheral nerve damage and oxidative status, further solidifying the importance 
of oxidative stress in neuronal affections arising from hyperglycaemia in humans. 
Unquestionably, though, glycaemic control remains the most accessible means to 
preclude oxidative stress-induced diabetic complications in the brain and in peripheral 
nerves (Van den Berghe et al., 2005). 
1.2.5 Vulnerability of the nigrostriatal pathway 
In light of their comparatively heightened basal oxidative burden39, it may be 
surmised that sustained hyperglycaemia may precipitate the death of nigrostriatal 
dopaminergic neurons. The validity of this hypothesis transpires from epidemiological 
evidence suggesting a link between the prime pathologies involving the nigrostriatal 
pathway and hyperglycaemia, explicitly Parkinson 's disease and diabetes mellitus. 
Before describing how they are pathologically interlaced, the latter disease will be 
defined in more detail for contextual purposes. Bearing in mind that a handful of other 
medical conditions also cause hyperglycaemia and may be associated with Parkinson 's 
disease, as is the case for metabolic syndrome (Saaksjarvi et al., 2015), we deliberately 
hold our focus on diabetes mellitus that offers a more tangible collection of experimental 
and clinical evidences to work with. 
1.2.5.1 Epidemiological basis: Parkinson 's disease in diabetic patients 
Diabetes mellitus is the most widespread chronic metabolic disorder estimated to 
affect over 400 million adults worldwide, its prevalence having doubled since 1980 on 
39 Refer to the list ofphenotypic liabilities in section 1.1 .3.4. 
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the likely account of the marked ri se in overweight or obese phenotypes in the 
population (World Health Organization, 2016). Today, diabetes has joined the infamous 
list of leading causes of death, responsible for 8.4% of global mortality in adulthood 
(International Diabetes Federation, 2013). Both types l and II diabetes occur from the 
progressive failure of the body to manage circulating blood glucose. However, 
the etiopathogenesis of type l diabetes (5-10% of diabetic patients) is specifically rooted 
in the auto immune destruction of insulin-producing pancreatic ~ cells and usually, 
but not always, develops before adulthood (Yoon and Jun, 2001). On the other hand, 
type II diabetes ensues from peripheral resistance to and deficient production of insulin, 
alongside other secondary metabolic elements. It is more frequently diagnosed in adults 
although youth-onset forrns are dramatically on the rise (Correia et al. , 2008; Nadeau 
et al., 2016). The perceived relative or absolute lack of insu lin control, which especially 
wields its effects on cells harbouring GLUT4 like striated muscle cells and adipocytes, 
culminates in prolonged hyperglycaemia and impaired ability to control glycaemic 
fluctuations , known as glucose intolerance (see for detailed review of their 
pathophysiology Cnop et al., 2005). Other symptoms also include polyuria, polydipsia 
and hyperphagia (increased urination, thirst and hunger, respectively). 
Granted the multiple aspects of health it impinges on, diabetes nurtures the 
development of a myriad Qf diverse comorbid conditions. As previously stated, 
a number of central (encephalopathies) and peripheral (neuropathies) complications are 
associated with diabetes, regardless of the type (Biessels et al. , 2002). Neuropathies 
remain the most prevalent neuronal affections in diabetes, as peripheral nerves are 
devoid of blood-brain barrier protection, which, as we know, serves to limit exposure 
to circulating glucose (Bansal et al. , 2006; Rajabally et al., 2017). Nonetheless, 
encephalopathies are a widely acknowledged feature of diabetes (DeJong, 1950) and 
manifest themselves in the forrn of cognitive decline (Brands et al., 2007; Brayne et al., 
2005; Hofman et al., 1997), white and grey matter atrophy (Moran et al. , 2013), altered 
cortical connectivity (Lyoo et al. , 2013; van Duinkerken et al., 2012), and 
neurodegenerative diseases, predominantly Alzheimer's and Parkinson ' s diseases 
(Armstrong et al. , 2005 ; Correia et al. , 2011; Verdile et al., 2015 ; Vicente Miranda 
et al. , 2016). 
67 
The first accounts of a possible association between diabetes and Parkinson's 
disease date back to almost 60 years ago. Studies conducted in parallel showed that 
diabetes exacerbates the progression of motor and cognitive deficits in Parkinson's 
disease (Schwab, 1960), and that non-diabetic parkinsonian patients present impaired 
glucose tolerance (Barbeau et al. , 1961) and hyperglycaemia (Boyd et al., 1971). 
Since then, these findings have been reiterated numerous times in treated individuals40 
(Cereda et al., 2012; Lipman et al., 1974; Sandyk, 1993), but also in drug-naïve patients 
who still displayed higher-than-normal levels of fasting blood glucose, within the 
prediabetic diagnostic range41 (Santiago and Potashkin, 2015). In addition, dietary habits 
featuring an elevated intake of high glycaemic indexed carbohydrates42 have more 
recently been associated with greater odds of developing Parkinson's disease (Cheng 
et al., 2009; Murakami et al. , 2010; Okubo et al., 2012; Stafstrom and Rho, 2012; Yang 
and Cheng, 2010). 
In light of accumulating reports showing a possible association between the 
two pathologies, numerous prospective cohort studies were elaborated to unravel their 
temporal relationship (see for reviews Santiago and Potashkin, 2013; Wirdefeldt et al., 
2011) (Table l.8). Most, though not all (Becker et al., 2008; Cereda et al., 2011; Driver 
et al., 2008) showed that pre-existing diabetes is a risk factor for the development of 
Parkinson's disease (Arvanitakis et al., 2007; Cereda et al., 2012; Hu et al., 2007; 
Xu et al., 20 Il). To dispel any doubt, one group addressed the question in a cohort 
10 times larger (1.8 million patients) than previously, and robustly confirmed the risk 
that diabetes represents for the future development ofParkinson's disease (Klimek et al., 
2015). Today, little doubt remains as to the hazard that a diabetic prelude represents in 
the development ofParkinson's disease. 
40 If anything, many dopaminergic drugs employed in the treatment of Parkinson's disease actually exert a 
blood glucose lowering effect (Cincotta et al., 1999; Lopez Vicchi et al. , 2016). 
4\ Prediabetes is defined in humans as fasting blood glucose 5.5-7 mM (100-126 mg/dL), postprandial 
blood glucose 7.8- 1l.! mM (140-200 mg/dL) or glycated haemoglobin 5.7-6.5% (American Diabetes 
Association, 2016). 
42 The glycaemic index of a food is defined as the rise in glycaemia that it occasions 2 hours after 
consumption in humans. Low glycaemic indexed nutrients release glucose slowly and steadily, 
in contrast to high glycaemic indexed foods that cause a rapid hyperglycaemia. 
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Table 1.8 
Recent studies investigating the association between diabetes and Parkinson's disease 
Hu er al., 2007 (5) Cohort study, Finnish population 
Moran er al., 2008 (14) Meta-analysis 
D'Amelia er a/., 2009 (122) Case-<:ontrol 
Palacios er al .. 2011 (101 ) Cohort Sludy 
Schernhammer er al., 2011 [1231 Case-<:ontrol , Danish population 
Xu er al., 2011 (4) 
Bosco er al., 2012 [181 
Menon er al., 2011 [491 
Cereda er a/., 2011 (121) 
Cereda er a/., 2012 (19) 
Cohort study 
Case-control , Italian population 
Genome-wide association study 
Meta-analysis 
Case-control 
PD: 633 Contrais: 51 552 T2DM is associated wlth an increased risk 
01 PD. 
NIA Shared blological pathwavs between PD, 
T2DM, cancer, and inllammation. 
PD: 318 Contrais: 318 Inverse association between PD and 
PD: 656 
PD. 1931 Contrais: 9651 
diabetes preeeding PD onset. 
No association. 
T2DM Is assoclated wlth an increased 
risk 01 PD, espeeially younger onset PD. 
Dlabetes: 21 611 Contrais: T2DM is associated with an increased 
267 051 risk 01 PD. 
PD~emenlia: 53 PD: 57 Insulin resistance is associated with 
an increased risk 01 dementla in PD. 
NIA Shared pathways between PD and T1 DM. 
lA Diabetes appears ta be a risk lactor lor 
PD. 
Diabetes prlor ta PD onset: Dnset 01 T2DM belore onset 01 PD is 
89 Contrais: 89 associated wlth an increased severity 01 
PD symptoms. 
Sun er al., 2012 (124) Case-<:ontrol , Chinese population Diabetes: 603413 Contrais: Diabetes is associated with an increased 
472 718 risk 01 PD onset. 
WahlqviSl er al. , 2012 (61) Case-control , Talwanese population Diabetes: 64 166 Contrais: T2DM is associated with an increased risk 
698587 in PD. Metlormin-sullonylurea therapy 
reduces the rlsk 01 PD. 
& TlDM, type l diabetes melli tus; T2DM, type Il diabetes mellitus. 
(From Santiago and Potashkin, 2013 .) 
From this point onward, the particuJar bond between diabetes and Parkinson's 
disease Joses focus . What exactly triggers nigrostriatal degeneration in Parkinson's 
disease among the multifarious metabolic changes that occur in diabetes remains 
unclear. The two predominant lines of thought grant importance to the dimensions of 
dysfunctional insulin signalling and oxidative stress. Although insulin occupies an 
increasingly acknowledged role in the human CNS, by activating neuron-bound insulin 
receptors responsible for controlling appetite, reward, cognition and memory (Anthony 
et al., 2006; Benedict et al. , 2004, 2007; Craft et al. , 1996; Hallschmid et al. , 2008; 
Khanh et al. , 2014; Reger et al. , 2008), we will address these dimensions in the 
discussion and maintain our focus on oxidative stress for now. 
1.2.5.2 Molecular and cellular bases 
Aside from the epidemiological relationship between Parkinson 's disease and 
diabetes, further clues support the possible susceptibility of nigrostriatal dopaminergic 
neurons in hyperglycaemia. As previously discussed, oxidative stress mediated 
by sustained hyperglycaemic conditions arises from 1) mitochondrial dysfunction, 
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2) activation of the polyol pathway, and 3) macromolecule glycation, which together 
accentuate ROS production and expenditure of antioxidative resources. We will briefly 
illustrate how these features manifest themselves in Parkinson ' s disease and how they 
can be traced back to the phenotypic risk factors identified in nigrostriatal dopaminergic 
neurons. 
One of the most prominent liabilities specific to nigrostriatal dopaminergic 
neurons consists in their vulnerability to mitochondrial dysfunction. Indeed, 
their characteristic pacemaking activity leads to steep intracellular calcium 
fluctuations, known to augment oxidative phosphorylation, mitochondrial membrane 
hyperpolarization and superoxide anion production (Guzman et al. , 2010; PaceUi et al. , 
2015). On top of this, nigrostriatal neurons have a limited ability to bind excess 
intracellular calcium (Dopeso-Reyes et al. , 2014; Iacopino and Christakos, 1990; 
Liang et al., 1996; Yamada et al., 1990) and comprise a relatively high number of 
mitochondria to sustain their dense arbours (Pacelli et al., 2015). It is, therefore, not 
surprising that mitochondrial dysfunction has long been associated with Parkinson 's 
disease (Perier and Vila, 2012). This pathological node first emerged upon identifying 
potent parkinsonian toxins (e.g. , MPTP and rote none) whose detrimental effects are 
principally conveyed by means of complex l inhibition in the electron transport chain 
(BeaI, 2001 , 2003; Betarbet et al. , 2000; Greenamyre et al., 2001; Langston et al. , 1983). 
The relevance of these findings was then fully recognized upon disceming complex l 
deficiencies and accumulation of mitochondrial DNA deletions in the substantia nigra 
pars compacta of parkinsonian patients (Bender et al., 2006, 2008; Schapira et al., 
1989). Later, robust support for impaired respiration was provided by the identification 
of genes that cause familial forms of Parkinson ' s disease and that are involved in 
mitochondrial homeostasis, for instance leucine-rich repeat kinase 2 (LRRK2) 
(Mortiboys et al., 2010; Wang et al. , 2012), DJ-1 (Irrcher et al. , 2010; Krebiehl et al., 
2010), and the mitochondrial duo, PTEN-induced putative kinase 1 (PINK1) and parkin 
(Ashrafi et al., 2014; Deng et al. , 2008; Exner et al. , 2007). 
Parkinson ' s disease does not directly point to a hyperactive polyol pathway, 
although one isolated study showed increased plasma levels of sorbitol in drug-naïve 
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parkinsonian patients, suggested to arise from glucose metabolism via non-oxidative 
pathways ensuing from mitochondrial dysfunction (Ahmed et al., 2009). There is sorne 
indirect evidence for a link between polyol pathway activation and neurodegeneration, 
via downregulation of nerve growth factor (NGF) as demonstrated in hyperglycaemia-
induced neuropathies (Hounsom et al., 2001 , 1998; Obrosova et al., 2001). Levels of 
brain growth factors , like NGF, that promote neuronal survival and differentiation 
indeed de cline in the substantia nigra pars compacta and dorsal striaturn of parkinsonian 
patients (Mogi et al. , 1999). More substantially, though, endogenous antioxidant 
depletion, provoked by polyol pathway activation, has been repeatedly suggested to 
partake in the pathogenesis of Parkinson's disease. Indeed, exhaustion of the reduced 
glutathione cofactor is one of the earliest events to occur in the brains of parkinsonian 
patients (Jenner, 1993; Pearce et al. , 1997; Sian et al. , 1994), markedly so in 
nigrostriatal dopaminergic neurons, which are inherently endowed with limited stocks of 
glutathione (Bharath et al. , 2002; Kang et al., 1999). 
Spontaneous methylglyoxal formation and macromolecule glycation are 
particularly salient elements linking Parkinson's disease to hyperglycaemia. The most 
obvious connection dwells in the inhibition of the ubiquitin proteasome system caused 
both by protein and ubiquitin glycation, as it occurs in the CNS (Munch et al. , 2012; 
Rabbini and Thomalley, 2012; Uchiki et al., 2012; Vicente Miranda et al., 201 6). 
In fact, the pathologically relevant a-synuclein protein is glycated in Lewy bodies 
(Auburger and Kurz, 2011 ; Cereda et al. , 2012; Kurz et al. , 2011 ; Vincent et al., 
2012). Interference with the ubiquitin proteasome system may therefore trigger a 
self-perpetuating cycle, wherein increased levels of glycated a-synuclein further obstruct 
proteasome function, consequently contributing to accumulation of the former, but also 
to its oligomerization, aggregation and purported toxicity (Chen et al., 2006; Tanaka 
et al., 2001). Additionally, RAGE polyrnorphisms have been shown to both offer 
protection against and favour the development ofParkinson ' s disease (Gao et al. , 201 4) . 
Insightful in vitro studies further demonstrate the shielding effect of ablating the 
receptor in a dopaminergic neuronal model of the disease (Sathe et al. , 2012; Teismann 
et al., 2012). Interestingly, not only can methylglyoxal glycate proteins and erode stocks 
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of NADPH VIa glyoxalase and al do se reductase activation, it participates like other 
aldehydes in deleterious reactions with dopamine to form salsolinol-like compounds 
(Deng et al. , 2012; Song et al., 2014; Szent-Gyorgi and McLaughlin, 1975), 
which resemble 6-0HDA, MPTP and endogenous dopamine derivatives already 
recognized for their toxicity (Kurnik-Lucka et al., 2018; Maruyama et al., 1999; Naoi 
et al., 2002; Su et al., 2013). Of prime significance, parkinsonian patients display 
particularly elevated levels of salsolinol-like compounds in the substantia nigra pars 
compacta and dorsal striatum (Deng et al., 2012). Since nigrostriatal neurons express 
relatively low levels of VMAT2 responsible for the vesicular uptake of lingering 
cytosolic dopamine, they may also offer ideal temporal conditions for the transformation 
of the latter into salsolinol-like compounds in a hyperglycaemic setting (Liang et al., 
2004). 
To surnmarize, hyperglycaemia represents an additional cause of superoxide anion 
production, mitochondrial dysfunction, antioxidative bankruptcy, ubiquitin proteasome 
system failure and dopamine toxicity that may well favour the early demise of 
nigrostriatal dopaminergic neurons. Although buttressed by a wealth of epidemiological, 
molecular and cellular evidence, this hypothesis has not been directly tested. In the aim 
of establishing the selective vulnerability of nigrostriatal neurons to a supplementary 
oxidative burden, proper demonstrations would require43 a) the testing of a single 
exogenous insult, for instance sustained hyperglycaemia; b) the comparison of 
neurodegeneration III each loci involved in the nigrostriatal and mesocorticolimbic 
pathways, preferably with concomitant verifications in other brain regions; c) the 
assessment of neurodegeneration at more than one time point; d) the evaluation of glial 
populations to gain insight into non-neuronal outcomes, and; e) the full appraisal of 
behavioural alterations that may arise from nigrostriatal neurodegeneration. It is 
precisely in this perspective that were elaborated a series of experiments presented 
43 The most pertinent studies in this sense have only demonstrated neurodegeneration in the substantia 
nigra pars compacta of rodent models of diabetes, without investigating the repercussions on the totality 
of central doparninergic pathways, on other populations of brain cells, or on the range of behavioural 
alterations that may arise from neuronal death (Brambilla Bagatini et al., 2014; do Nascimento et al., 
2011). Other studies have also combined various parkinsonian insults with a hyperglycaemic challenge, 
which does not address the intrinsic hazard that hyperglycaernia represents to nigrostriatal neurons in 
otherwise healthy subjects (Choi et al., 2005; Morris et al., 2010; Roterrnund et al., 2014). 
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herein to fulfil these interrogations that warrant answers, in light of the epidemiological 
risk incurred by diabetic patients with regard to the potential development of 
Parkinson's disease. 
1.3 The antioxidative polyphenol resveratrol 
The proposaI that a heightened vulnerability to oxidative stress is at the origin of 
the preferential degeneration of nigrostriatal dopaminergic neurons can be tested by 
verifying the ability of an exogenous antioxidant to prevent this death. In the present 
thesis, we hire this strategy by employing a well-known antioxidative polyphenol, 
resveratrol, ln dopaminergic neurons exposed to high glucose conditions. 
Although resveratrol and other dietary polyphenols can offer protection in various 
disease settings, the scope of our CUITent work does not encompass providing evidence 
of its already widely acknowledged neuroprotective potential44. Used here as an 
antioxidative tool, the following section thus focuses on resveratrol's ability to preclude 
oxidative stress. Before detailing its protective mechanisms in dopaminergic neurons, 
we will nonetheless provide sorne background information on resveratrol pertaining to 
its origins, its dietary sources and the chemico-structural peculiarities that shape its 
antioxidative properties. 
1.3.1 Background 
1.3.1.1 Historical context 
Centuries of traditional medicine practiced in native cultures worldwide have 
revolved around the potency of edible medicinal herbs and plants ri ch in polyphenols to 
ameliorate human health (Manyam et al., 1999; Song et al., 2012). When dietary habits 
and health status were initially associated, the role of polyphenols in human health 
44 We have already reviewed the therapeutic potential of polyphenols in Parkinson ' s disease elsewhere 
(Regl6di, Renaud et al. , 2017; Renaud et al., 2015). A critical appraisal of the employment of 
polyphenols against neurodegenerative diseases is also presented in Appendix B. Specifically regarding 
resveratrol, our group has extensively discussed its anti-inflammatory mechanisms in the CNS 
(Appendix C) and has detailed the various demonstrations of its protective properties in preclinical 
models (Renaud and Martinoli, 2014). 
73 
immediately sparked vivid scientific interest. At the root of polyphenol studies, 
a mixture of flavonoids extracted from citrus fruit was initially coined "vitamin P" 
because of its anti-scurvy, vitamin C-sparing effects (Bentsath et al. , 1936; Rusznyak 
and Szent-Gy6rgi, 1936). The term was later abandoned upon disceming that "vitamin 
P" was not truly essential , although the observed health benefits still held true. A host of 
controlled epidemiological reports have since then supported the protective role of 
polyphenols in abating numerous health issues, su ch as cardiovascular diseases (Estruch 
et al., 2013 ; Hertog et al. , 1993; Joshipura et al. , 2001 ; von Ruesten et al. , 2013), 
diabetes (Carter et al., 2010; Sargeant et al., 2001) and cancer (Lunet et al. , 2005 ; 
Masala et al., 2012; Steinmetz and Potter, 1996). As evidence amassed, intervention 
studies were warranted to bolster the significance of these findings, and most, though not 
all (Anderson et al. , 2002; Conquer et al. , 1998; Simons et al. , 2000), confirmed a 
positive function for specific dietary polyphenols in hurnan health (see for review 
Williamson and Manach, 2005). As research progressed, certain biofunctional 
polyphenols gained more attention than others by virtue of their promising protective 
competences. 
In the field of polyphenol research, resveratrol holds a special place. Indeed, 
its popularity shot through the roof in the 90s following the airing of an episode of 
"60 minutes" on the CBS network wherein Dr. Serge Renaud was interviewed on the 
topic of the "French Paradox", a term henceforth etemalized (Renaud and de Lorgeril, 
1992). The expression was employed to describe the apparently low incidence of 
coronary heart diseases in Southem France populations despite their relatively elevated 
consumption of saturated fats in comparison to other industrialized countries (Wu et al. , 
2001). A vital food staple in Southem France, red wine was thought to afford 
cardioprotection (Renaud and de Lorgeril, 1992) and resveratrol was later proposed to 
be one of the key bioactive constituents responsible for these observed health 
benefits (Fauconneau et al. , 1997; Frankel et al. , 1993; Pace-Asciak et al. , 1995). 
Robust demonstrations that resveratrol exerts antioxidative effects (Frankel et al. , 1993 ; 
Kerry and Abbey, 1997; Jang et al. , 1999) and mitigates carcinogenesis (Della Ragione 
et al. , 1998; Gehm et al., 1997; Hsieh et al. , 1999; Jang et al., 1997; Lu and Serrero, 
1999; Mgbonyebi et al. , 1998) truly launched the field from thereon (Figure 1.19). 
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Figure 1.19 Resveratrol in the scientific Iiterature. 
A 2018 PubMed search employing the term "resveratrol" yields an 
approximate total of 10000 hits since 1987. A trending rise can be 
observed as early as 1997. 
1.3.1.2 Dietary origins 
Polyphenols are usually derived from phenylpropanoid metabolism in plants 
(Parr and Bolwell, 2000). As such, polyphenols usually comprise an assembly of phenyl 
rings with variable carbon connectors and hydroxylation patterns. Several subclasses 
arise from the variable complexity of these molecules, for instance phenolic acids 
(C6-C3 and C6-C 1), flavonoids (C6-C3-C6), lignans (C6-C3-C3-C6) and stilbenes 
(C6-C2-C6) to which belongs trans-3,5,4'-trihydroxystilbene, better known as 
resveratrol (Figure 1.20). 
Polyphenols confer plants with evolutively gainful signalling and protective 
systems. Regarding resveratrol, its exact functions remain uncertain but they are 
generally recognized to act as phytoalexins (plant-synthetized antimicrobial substances) 
(Chang et al., 2011). Resveratrol is produced in high concentrations in response to 
environmental stressors such as pathogenic insults, nutrient deficiency, temperature 
fluctuations and ultraviolet radiation (Orallo, 2008; Soleas et al., 2001). As such, it is 
found in substantial quantities in grapevines (Vitis vinifera), possibly as an evolutionary 
adaptation in response to fungal infections (Chong et al., 2009; Dercks and Creasy, 
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1989). Remarkably, stilbene synthase involved in the biosynthesis of resveratrol 
promotes disease resistance when artificially expressed in plants (Hain et al., 1993). 
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Figure 1.20 Frequently encountered polyphenols. 
Found ubiquitously in fresh herbs, fruits, vegetables, nuts, grains and legumes, 
polyphenols represent on average 1 g/day of a balanced diet (Scalbert and Williamson, 
2000). However, resveratrol is one of the least encountered polyphenols in the 
human di et. Akin to most other polyphenols, stilbenes predominantly accumulate in the 
outer component of foodstuffs . In the skins of grapes, its levels can reach 50-100 mg/g 
of fresh weight. Due to the maceration process, red wines generally present greater 
concentrations of stilbenes th an whites or rosés, with resveratrol reaching levels 
of approximately 0.3-7 mg/L (Bertelli et al., 1998; Lamuela-Ravent6s and de la 
Torre-Boronat, 1999; Siemann and Creas y, 1992; Vitrac et al., 2002). Besides grapes, 
numerous other plants were shown to synthesize stilbenes, though, among the 72 plant 
76 
specles identified, mulberries and peanuts are the only other typical sources rich ln 
resveratrol in the human diet (Langcake and Pryce, 1977). 
1.3.1.3 Structure, chemistry and antioxidative functions 
Insofar as the > 8000 polyphenols known to date are structurally diverse, 
they share several hall marks that undoubtedly underlie their therapeutic potential in 
living organisms, namely phenyl rings, hydroxyl moieties and conjugated double bonds. 
These chemico-structural features grant polyphenols like resveratrol the potential to 
tackle a keystone of dopaminergic neurodegeneration, explicitly oxidative stress. 
Resveratrol wields its antioxidative effects via both direct and indirect mechanisms 
(Foresti et al., 2013; Leonard et al., 2003). Its hydroxyl groups are thought to account 
for the near totality ofits direct antioxidative actions (Fauconneau et al. , 1997; Frémont, 
2000; Kawada et al. , 1998; Stivala et al., 2001). Indeed, resveratrol scavenges free 
radical species principally by lending its most acidic hydrogen from the para-phenol 
group or other hydrogen atoms from the meta-hydroxyl groups of the resorcinol moiety 
(Stivala et al., 2001) (Figure 1.20). It may also cede a 1t bond from the resorcinol ring 
to accommodate radicals (Khanduja and Bhardwaj , 2003). The radicalized form of 
resveratrol is stabilized by its multiple conjugated double bonds that allow the 
delocalization of the unpaired electron (Figure 1.21). 
While resveratrol is appreciated for its ability to directly scavenge free radical 
species, it is not among the most efficient metal chelators. Since divalent transition 
metals like iron are toxic, cells are endowed with tight control systems to regulate their 
availability in a free form. When in excess, however, they are known to participate in 
deleterious reactions that generate ROS45 . Chelation by bidentate molecules possessing 
phenol rings is possible, but is best achieved when there are two or three hydroxyl 
45 For example, Fenton reactions occur between ferric ions and superoxide anion to yield ferrous ions and 
oxygen (Jomova et al., 2010). In turn, Haber-Weiss reactions between ferro us ions and hydrogen 
peroxide further give ferric ions and hydroxyl radicals, the most reactive kind of ROS (Valko et al. , 
2004). In the substantia nigra pars compacta endowed with appreciable levels of iron ions, 
these deleterious reactions are extremely pertinent. 
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groups next to each other (hydroxyl groups in the ortho-position), such as in galloyl or 
catechol groups (Petry et al. , 2010) (Figure 1.20). Resveratrol possesses a resorcinol 
group wherein two hydroxyl groups are far apart, and, by the same token, it is a much 
less potent monodentate chelator (Chan et al. , 2016; Hider et al., 2001 ; Purawatt et al., 
2007). 
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Figure 1.21 Resveratrol's putative direct scavenging mechanisms. 
Two examples of reaction partners were provided: superoxide anion and 
the hydroxyl radical. Superoxide anion is ubiquitous in cells, especially at 
the level of the electron transport chain. As for the hydroxyl radical, 
it is the most reactive physiological ROS. 
In contrast to direct scavenging mechanisms, the chemico-structural features 
responsible for polyphenols' indirect antioxidative actions are more difficult to pinpoint. 
These indirect effects are likely conveyed via the activation of endogenous antioxidative 
mechanisms and oblige knowledge of polyphenolic interactions. Resveratrol's stilbene 
carbon scaffold likely contributes to its capacity to interact with molecular effectors of 
endogenous antioxidative pathways, discussed later. Indeed, resveratrol is planar and 
relatively hydrophobic, which theoretically should increase its affinity and specificity for 
hydrophobic pockets found in proteic binding sites (Figure 1.20). In addition, it harbours 
polar hydroxyl moieties in a conformation that resembles certain endogenous 
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ligands, such as estrogen. These hydroxyl groups participate in hydrogen bonds with 
multiple amino acid side chains within hydrophobic pockets. A few studies have also 
demonstrated the importance of resveratrol's phenol rings, especially the one bearing 
the para-hydroxyl moiety, and its trans stereoisomery in binding certain proteins 
(Nwachukwu et al., 2014; Stivala et al., 2001). In other instances, resveratrol may not 
require its hydroxyl functions to mediate its neuroprotective effects. Studies tested this 
hypothesis by preparing a plethora of resveratrol analogs devoid of hydroxyl functions 
(Heynekamp et al., 2006; Solberg et al., 2014). Despite their inability to scavenge ROS, 
these stilbene compounds were nonetheless capable of dampening neuroinflammation in 
a NF-KB-Iuc reporter ceIl line (Heynekamp et al., 2006) and reducing ~-amyloid plaque 
density in the CNS of a mouse model of Alzheimer's disease (Solberg et al., 2014). 
Such studies highlight the importance of resveratrol 's multiple chemico-structural 
singularities in shaping both the nature and the variety of molecular interactions it can 
engage in, which undoubtedly account for its multifarious modes of action. 
1.3.2 Protection of dopaminergic neurons against oxidative stress 
Resveratrol 's ability to improve various clinical endpoints has been demonstrated 
m myriads of disease settings, including neurodegenerative diseases (Moussa et al. , 
2017), diabetes (Goh et al., 2014; Imamura et al., 2017), obesity (Xue et al., 2016) , 
polycystic ovary syndrome (Banaszewska et al., 2016) and ulcerative colitis 
(Samsamikor et al., 2016). Its antioxidative potential has been shown to contribute to its 
protective effects in preclinical models of diabetes (Jezek et al., 2014; Jiang et al., 2013 ; 
Sadi et al., 2014) and neurological disorders, such as ischemic stroke (Rodrigo et al. , 
2013; Saleh et al., 2013; Sun et al., 2010), neurodegenerative diseases (Karuppagounder 
et al., 2009; Maher et al., 2011; Varamini et al., 2014) and traumatic brain injuries 
(Gatson et al., 2013; Hall et al., 2010; Liu et al., 2011). SpecificaIly re1ated to our work, 
resveratrol improves the oxidative status of the CNS in rodent models of diabetes 
(Bagatini et al., 2017; Sadi and Konat, 2016), but this parameter has not been addressed 
in dopaminergic neurons challenged with high glucose concentrations. Nevertheless, 
its antioxidative properties have been verified numerous times in preclinical models of 
Parkinson's disease. As a basis for the employment of resveratrol in dopaminergic 
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neurons to antioxidative ends, this section will therefore briefly review the findings 
provided by these studies. 
To study Parkinson's disease, several models were developed in vitro as well as 
in vivo that depend on pro-oxidative mechanisms to induce dopaminergic neuronal 
death. Typical parkinsonian toxins include the aforementioned 6-0HDA and I-methyl-
4-phenylpyridinium (MPP+, the active metabolite of MPTP), as well as pesticides like 
rotenone and paraquat, which instigate ROS overproduction by various means (Deumens 
et al. , 2002; Dut Y and Jenner, 2011 ; Jackson-Lewis et al., 2012; Nagatsu, 1997). 
Accordingly, studies consistently show resveratrol to rescue dopaminergic neurons from 
the various oxidative assaults that typify these models (Blanchet et al. , 2008; Gélinas 
and Martinoli, 2002; Wu et al. , 2011). Neuroprotection is complemented with reduced 
levels of ROS, like the hydroxyl radical (Lu et al. , 2008), which prevents neuronal 
oxidative damages from arising, as assessed by the measurement of lipid peroxidation 
and prote in carbonyl by-products (Anandhan et al. , 2010; Khan et al. , 2010; Okawara 
et al. , 2007; Palle and Neerati, 2018). Most remarkable is the recovery of motor 
behaviour in animal models, which reflects the concrete protection afforded by 
resveratrol on dopaminergic neurons in models of Parkinson 's disease (Anandhan et al. , 
2010; Jin et al. , 2008; Lu et al. , 2008; Makhija and Jagtap, 2014; Palle and Neerati et al. , 
2018; Zhao et al. , 2017). 
A recurring the me in parkinsonian models is the apoptotic death46 of dopaminergic 
neurons. Indeed, this mode of programmed cell death is particularly relevant in 
Parkinson ' s disease (Anglade et al. , 1997; Mochizuki et al. , 1996; Toulorge et al. , 
2016), but also in diabetes (Maiese et al. , 2007; Russell et al., 1999). In this respect, 
resveratrol is weil appreciated for its ability to abrogate oxidation-induced apoptosis. 
Congruently, resveratrol favourably modulates various pro- or anti-apoptotic proteins, 
su ch as p53 , protein kinase B (Akt) and glycogen synthase kinase 3 (GSK-3) (Bournival 
et al. , 2009; Feng et al. , 2015; Lin et al. , 2014; Okawara et al. , 2007; Wu et al., 2011 ; 
Zeng et al. , 2017). As mitochondria are a nexus of apoptotic processes, studies 
46 We address apoptotic mechanisms in greater detail in section 1.5.104. 
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specifically uncovered resveratrol's aptitude to repeal the leakage of mitochondrial pro-
apoptotic factors , such as apoptosis inducing factor and cytochrome c, likely through 
modulation of proteins involved in the formation of the mitochondrial permeability 
transition pore, exemplarily B cell Iymphoma 2 (Bcl-2) and Bcl-2-associated X protein 
(Bax) (Bournival et al., 2009; Mud6 et al., 2012; Zeng et al., 2017). 
Among these studies, many have reported certain upstream events that may 
account for the antioxidative and anti-apoptotic effects afforded by resveratrol. 
On the one hand, resveratrol remarkably restores endogenous antioxidative defences, 
for instance glutathione, SOD, thioredoxin, heme oxygenase and catalase (Anandhan 
et al. , 2010; Khan et al., 2010; Lin et al. , 2014; Mud6 et al. , 2012; Okawara et al. , 2007; 
Palle and Neerati, 2018; Srivastava et al., 2012). On the other hand, resveratrol displays 
a striking ability to foster mitochondrial homeostasis, by ameliorating respiration (Palle 
and Neerati, 2018; Mud6 et al., 2012) and providing protection against ultrastructural 
changes (Jin et al., 2008; Peng et al. , 2016). Interestingly, in primary skin fibrob last 
cultures from patients with early-onset Parkinson's disease caused by different PARK2 
mutations, encoding parkin, resveratrol markedly improved mitochondrial functions, 
substantiated by increased ATP production, complex l activity, oxygen consumption, 
and decreased generation of lactate and ROS (Ferretta et al. , 2014). 
The sum of these results obtained in vanous cell lines, pnmary cultures, 
organotypic midbrain slice models and rodent paradigms leaves no doubt as to the 
capacity of resveratrol to protect dopaminergic neurons by virtue of its ability to 
counteract oxidative stress, a key contributor of apoptosis. These neuroprotective 
benefits seem to stem from the improvement of endogenous antioxidative defences 
and mitochondrial functions . Taking into consideration the mechanisms by which 
hyperglycaemia induces oxidative stress, that is, by expending endogenous antioxidants 
and causing mitochondrial dysfunction, it is reasonable to expect resveratrol to confer 
protection against high glucose conditions in dopaminergic neurons. 
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1.3.3 Direct putative targets 
Although polyphenols like resveratrol are theoretical ROS scavengers, their ability 
to do so in a physiological environment remains controversial. First, polyphenol 
scavenging dictated by the transfer of a proton or the breaking of a double bond must 
occur faster than any reaction between the free radical species and susceptible 
constituents of the cell, for instance lipids (Di Meo et al. , 2013). Second, in order to 
offer significant antioxidative support, polyphenols are theoretically required to accrue 
in similar concentrations to that of endogenous antioxidants such as ascorbate 
(30-100 !lM) and urate (140-200 !lM) (Hollman, 2014). However, tissue or plasma 
concentrations of polyphenols rarely exceed micromolar magnitudes at any given time 
(Del Rio et al., 2013). Consequently, the direct scavenging properties of polyphenols 
like resveratrol may be trivial in a physiological context (Benzie et al. , 1999; Hollman 
et al., 20 Il). In this regard, it is argued that cellular events occurring at nanomolar 
concentrations might better uphold polyphenols ' antioxidative actions. These indirect 
effects are likely conveyed via the activation of endogenous antioxidative mechanisms 
and require only very low concentrations owing to the diverging and amplifying nature 
of many cell signalling cascades. 
In an attempt to reconcile resveratrol's bioefficacy with the improbability of 
firsthand scavenging, efforts have been deployed to identify these putative direct targets 
(see for review Britton et al. , 2015) (Table 1.9). Among the multiple molecules 
identified to date, a few are directly or indirectly linked to oxidative stress, namely 
ribosyldihydronicotinamide dehydrogenase (quinone) (NQ02) (Buryanovsky et al., 
2004; Wang et al. , 2004), phosphodiesterases (PDEs) (Park et al. , 2012), and the 
mammalian target of rapamycin (mTOR) (Park et al. , 2016). In neurons, the se effectors 
are notorious for executing noxious processes and their inhibition by resveratro1 may 
explain the latter' s beneficial properties in the CNS (Cant6 and Auwerx, 2009; 
Chaturvedi and BeaI, 2013; Lee et al. , 2012; Li et al. , 2010; Sharma et al. , 2012; 
Wang et al., 2008). 
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Table 1.9 
Direct putative targets of resveratrol 
Molecular target& 
CycJooxygenase-l 
CycJooxygenase-2 
Fatty acid synthase 
NQ02 
GSTP1 
AKT-1 
HDACs 
PDE1, 3, and 4 
ATM 
SIRTl 
PKCa, [3I, and PKD1 
Aromatase 
DNA/RNA 
Lipoproteins 
DNA polymerase a and 8 
F1-ATPase 
CBR1 
LTA-tH 
PPAR-y and 8 
Various kinases 
TyrRS 
aUnder oxidizing conditions (H202). 
bDirect binding disproved. 
'Cocrystal with cis-resveratrol. 
Enz Inhib, Xray 
Chem Pro t, Enz Inhib 
Enz Inhib 
Chem Prot, Xray, Enz Inhib 
Chem Prot 
Chem Prot 
Enz Inhib 
Fluor 
Kinase assay 
Fluor 
Kinase assay 
Enz Inhib, in silico 
Spec 
HPLC 
Enz Inhib 
Xray 
Chem Prot, Enz Inhib 
Chem Prot, in silico 
Xray, Affin Chrom 
Activity assay 
Enz Inhib, Xray' 
Observation& 
IC50 = 0.535 !-LM 
IC50 = 0.996 !-LM 
IC50 = 8.5 !-LM 
Binding, KI = 35 nM 
Binding 
Binding 
pan-HDACi 
IC50 = 6, ID, and 14 !-LM 
Activationa 
Activationb 
IC50 = 2,100, and 800 !-LM 
IC50 = 12.8 !-LM 
Destabilizing 
Binding 
Ki = 3.3 and 5.0 !-LM 
Binding 
Binding, Ki = 55.8 !-LM 
Binding 
Kd = lA and 2.7 !-LM 
Moderate to no effect 
Ki = 22 !-LM 
& Affin Ch rom, affinity chromatography; AKT - l , protein kinase B; ATM, ataxia telangiectasia mutated 
serine/threonine kinase; Chem Prot, chemical proteomics; CBRI , carbonyl reductase 1; Enz lnhib, enzyme 
inhibition assay; FI-ATPase, FI portion of adenosine triphosphatase; Fluor, fluorescence assay; GSTPI , 
glutathione S-transferase P; HDAC, hi stone deacetylase; HPLC, high-performance Iiquid chromatography; IC5o, 
half maximal inhibitory concentration ; Kd, di ssoc iation constant; Ki, inhibition constant, L T A4H, leukotriene A4 
hydrolase; NQ02, ribosyldihydron icotinamide dehydrogenase (quinone); PDE, phosphodiesterases; PKC, 
protein kinase C; PKD, protein kinase D; PPAR, peroxisome proliferator-activated receptor; SIRTl, silent 
mating type information regulation 2 homologue 1; Spec, spectroscopie assay; TyrRS, tyrosine-transfer RNA 
ligase; Xray, X-ray cocrystal structure. 
(Adapted from Britton et al., 2015.) 
1.3.3.1 Ribosyldihydronicotinamide dehydrogenase (quinone) and oxidative stress 
NQ02 is a detoxifying enzyme mandated to catalyze the reduction of quinones to 
hydroquinones (Monks et al., 1992; Vella et al., 2005). At first sight, it appears to 
operate as an endogenous antioxidative enzyme, due to its role in reducing quinone 
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ROS. However, it was recently found to produce ROS by-products during quinone 
reduction in sorne settings (Gong et al. , 2008; Reybier et al. , 2011). In fact, NQ02 
appears to impart the noxious effects of certain parkinsonian toxins and of exogenous 
dopamine on dopaminergic neurons (Janda et al., 2013 , 2015 ; Wang et al. , 2008). 
Interestingly, NQ02 has emerged as a novel risk factor for Parkinson's disease. 
Indeed, genetic polymorphisms associated with the pathology were initially speculated 
to result in decreased NQ02 expression (Harada et al. , 2001). However, later findings 
showed these polymorphisms to occur in the promoter and to enhance NQ02 
expression, which was further sustained in human fibroblasts of individuals with or 
without the genetic modification (Wang et al. , 2004). In this light, it was concluded that 
amplified expression of the reductase constitutes a risk factor for the development of 
Parkinson's disease. 
Likely the most relevant target in oxidative stress, NQ02 displays the greatest 
affinity for resveratrol to date (nanomolar range) . Its interaction with the polyphenol has 
also been ascertained by no less than three methods carried out by two independent 
groups (Buryanovsky et al. , 2004; Wang et al. , 2004). It follows that resveratrol ' s 
inhibitory action on NQ02 is presumed to confer protection in this setting, but this 
remains to be confirmed in neurons. 
1.3.3.2 Phosphodiesterases and the energy sensing axis 
Many of the abovementioned studies demonstrating resveratrol's antioxidative and 
neuroprotective properties in dopaminergic neurons also expose its modulatory effect 
on a selection of interrelated bioenergetic power players, namely 5' adenosine 
monophosphate-activated prote in kinase (AMPK) , silent mating type information 
regulation 2 homologue 1 (SIR T 1) and peroxisome proliferator-activated receptor 
gamma coactivator l-alpha (PGC-l a) (Albani et al., 2009; Feng et al., 2015; Ferretta 
et al., 2014; Mudè et al., 2012; Wu et al. , 2011). The signalling axis to which they 
belong is thought to be responsible for lifespan amelioration provided by exercise and 
calorie restriction (Tennen et al. , 2012). 
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In this growingly popular axis, PGC-1 a is key effector of mitochondrial biogenesis 
and efficient respiration (Canto and Auwerx, 2009) (Figure 1.22). As upstrearn energy 
sensors, AMPK is activated when cellular ATP:AMP ratios are low and SIRTI is 
stirnulated by elevated NAD+:NADH ratios (Canto et al., 2009; Spasié et al. , 2009). 
SIRT1 and AMPK also maintain an intirnate bidirectional relationship, since SIRTI 
deacetylates liver kinase BI (LKB1) that in turn phosphorylates and activates AMPK 
(Hou et al., 2008; Lan et al., 2008), whereas AMPK increases NAD+ leve ls responsible 
for stirnulating SIRT1 (Canto et al., 2009). In concert, SIRT1 and AMPK enhance 
rnitochondrial function by deacetylating and phosphorylating PGC-l a, which is required 
for its activation (Canto and Auwerx, 2009). Although allosteric activation of SIRT1 
was at first greatly advocated to explain resveratrol's effects on this bioenergetic 
crossroads (Dai et al. , 2010; Howitz et al., 2003), methodological oversights came to 
light and direct binding was refuted (Beher et al. , 2009; Borra et al. , 2005; Kaeberlein 
et al., 2004; Pacholec et al., 2010). Later identification of PDEs as direct targets of 
resveratrol finally shed sorne light on this cell signalling puzzle (Park et al., 2012). 
PDEs play a key rnodulatory role on intracellular levels of nucleotidic secondary 
rnessengers by hydrolysing cyclic adenosine monophosphate (cAMP) and cyclic 
guanosine monophosphate (cGMP) to their respective AMP and GMP forms. 
By competing with cyclic nucleotides and inhibiting PDEs, resveratrol fosters an 
environment rich in cAMP, which triggers a series of events leading to the activation of 
AMPK responsible for the ensuing cascade of events (Park et al., 20 12) (Figure 1, 
Appendix C). The PDE-AMPK-SIRTI-PGC-la axis is indirectly yet critically involved 
in arneliorating the oxidative status of neurons. By improving mitochondrial biogenesis 
and respiration, energy can be afforded to the clearance of ROS and to damaged 
organelles through activation of autophagy (Canto and Auwerx, 2009). This axis has 
congruently triggered discussions on possible therapeutic avenues to explore in 
Parkinson's disease, in view of the vital role occupied by mitochondrial homeostasis in 
this disease (Chaturvedi and BeaI, 2013; Maiese, 2016). 
CALORIE RESTRICTION, FASTING, EXERCISE 
~ 
----t l Glucagon . 
High-fat diet Catecholamine 
!~00~ 
" , 
, 
, 
, 
, 
, 
, 
, 
, 
~ Q MPV ·, "'" 
Resveratrol 
, , 
~ "" '~ 
"tNAD+ "...  
.,' , , , '- , ~
.- '( OtherNAD+- ~~ " 
dependent enzymes ,,' '- '~ 
: ,',' ŒGC-~ 
.l.Genome~nstabilitY ~", / 
.1. Triglyceride synthesis 
.1. Glycolysis 
.1. ROS 
.1. Inflammation 1 
"t Fatty acid oxidation 
"t Gluconeogenesis 
l Mitochondrial biogenesis and respiration 
METABOLIC AND AGING-RELATED DISEASE? 
Figure 1.22 Molecular mainstays of metabolic homeostasis. 
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By sensing levels of cyclic adenosine monophosphate (cAMP) and 
NAD+, and by acting on each other, this highly ramified pathway 
promotes equilibrium in instances of metabolic deficits. Moreover, 
they protect cells against a slew of noxious molecular events and 
are thought to mediate the beneficial effects of calorie restriction. AMPK, 
adenosine monophosphate kinase; CamKK~, calcium/calmodulin-
dependent prote in kinase kinase 2 or beta; Epac l , exchange factor 
directly activated by cyclic adenosine monophosphate 1; PGC-l a, 
peroxisome proliferator-activated receptor gamma coactivator l-alpha; 
PKA, protein kinase A. (From Tennen et al., 2012.) 
1.3.3.3 Mammalian target ofrapamycin and autophagy 
Autophagy is an intricately structured cascade of events that promotes the 
equilibrium between clearance and production of organelles and proteins. Per se, 
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autophagy degrades non-essential or damaged cellular components and is therefore 
activated in settings of energy depletion and oxidative stress. Moreover, its role in 
Parkinson's disease has been evoked time and again, as it is a process required to clear 
misfolded proteins, pathogenic fibrils and full-fledged aggregates expressed in 
a-synuclein pathology (Hashimoto et al., 2003; Schapira and Gegg, 20 Il; Schneider and 
Zhang, 2010). 
Focal to autophagy is mTOR, an inhibitor of the initial stages of this process, 
which is of capital importance in tissues disposing of meagre regenerative capacities, 
like the CNS (Lee et al., 2012). Akin to AMPK and SIRT1, mTOR is an energy sensor, 
but it is activated in instances of energy and nutrient abundance, thus occupying a 
central position in bridging energy levels and autophagy (Kundu, 2011) (Figure l.23). 
mTOR phosphorylates the initial effector of autophagy, autophagy-related protein 13 
(Atg13), thereby obstructing the onset of autophagy (Chan et al., 2009). However, 
mTOR is repressed both by AMPK activation (Boister et al., 2002) and oxidative 
modifications (Dames et al., 2005), in which context autophagy is accordingly activated 
to restore cellular homeostasis. mTOR therefore collaborates narrowly with the 
PDE-AMPK-SIRT 1-PGC-l a axis to alleviate oxidative stress and restore favourable 
bioenergetic dynamics. 
Resveratrol was recently shown to bind and inhibit mTOR by competing with 
A TP, thereby promoting autophagy in proper cellular contexts (Park et al., 2016). 
Correspondingly, previous reports demonstrating resveratrol 's neuroprotective capacities 
in dopaminergic neurons challenged with rotenone concurrently found it to stimulate the 
autophagie flux (Lin et al., 2014; Wu et al., 2011). Moreover, suppression of the master 
metabolic regulator AMPK dampened these beneficial effects, which bolsters the 
pertinence of bioenergetics-autophagy crosstalk in the neuroprotection afforded by 
resveratrol against oxidative stress (Wu et al., 2011). 
Energy Starvation 
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Figure 1.23 Metabolic regulation of cell growth and autophagy dynamics. 
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A tri ad of kinases senses nutrient and energy availability, acting in 
concert to promote cellular homeostasis by modulating cell growth and 
autophagy. The central bioenergetic power player, AMPK, can have 
opposite effects in the cell depending on the ATP:adenosine 
monophosphate (AMP) ratio. ln a replete, high ATP setting, AMPK 
will activate the tuberous sclerosis complex (TSC) duo that inhibits 
mammalian target of rapamycin complex 1 (mTORCl), a complex 
constituted of mammalian target of rapamycin (mTOR) and its regulators, 
thereby promoting ceU growth and silencing autophagic pathways. 
ln circurnstances of energy depletion, AMPK will rather activate Unc-51 
like autophagy activating kinase (ULKl), which wiU stimulate autophagy 
and inhibit cell growth. This toggle is highly sensitive and meticulously 
regulated by feedback loops between the different components of 
this triad. Atg13, autophagy-related protein 13; FIP200, retinoblastoma 
l-inducible coiled-coil protein 1; LKB 1, liver kinase BI; Lst8, mTORC 
subunit lethal with SEC13 protein 8. (From Dunlop and Tee, 2013.) 
1.3.3.4 Other targets 
While focus has only been granted to three of numerous putative direct targets of 
resveratrol, other binding partners may likely play an indirect though significant role in 
conveying this polyphenol's antioxidative effects. Worthy of mention is a ho st of 
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important players in the arena of inflammation, for instance cyclooxygenases-l and 
-2 (Calamini et al., 2010; Murias et al., 2004; Zykova et al., 2008), leukotriene 4A 
hydrolase (Oi et al., 2010) and estrogen receptors (Bowers et al., 2000; Nwachukwu 
et al. , 2014), which have been reviewed elsewhere with respect to resveratrol's anti-
inflammatory potential (Appendix C). Neuroinflammation is greatly acknowledged to 
actively participate in the etiopathogenesis ofParkinson's disease and is interwoven with 
oxidative processes, as suggested by microglia-derived oxidative bursts and oxidative 
stress-induced microglial activation (Langston et al., 1999; More et al. , 2013; Russo 
et al., 2014; Zecca et al., 2008). As such, resveratrol's antioxidative effects in the CNS 
of rodents and humans may also be conveyed via impeding pro-oxidative enzymes in 
microglial cells that may injure neurons in the substantia nigra pars compacta, su ch as 
myeloperoxidase and NADPH oxidase (Chang et al., 2013). 
Ali evidence considered, its capacity to modulate a wide array of proteic activities 
affords resveratrol tangible pathway-modifying properties that converge toward the 
prevention of oxidative stress in dopaminergic neurons. Although mostly tried in 
parkinsonian paradigms or in non-neuronal diabetic models, the literature grants a 
credible role for resveratrol in protecting cultured dopaminergic neurons against high 
glucose conditions. 
1.4 Research aims and hypotheses 
Provided the pre mIse that dopaminergic neurons of the nigrostriatal pathway 
are relatively more susceptible to insults that overwhelm their endogenous coping 
mechanisms in Parkinson's disease, it is reasonable to surmise that other sources of 
stress, not specific to this pathology, may lead to their death, thereby shoring up this 
concept. As already mentioned, Parkinson's disease occurs more frequently in patients 
suffering from pathologies featuring a generalized state of oxidative stress, su ch as 
diabetes (Cereda et al., 2012; Santiago and Potashkin, 2013; Sun et al., 2012). 
Although awareness of these pathological associations has been growing, the selective 
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vulnerability of nigrostriatal dopaminergic neurons in the se settings has never been the 
object of investigations. 
In this respect, the core work of my thesis addresses the following central 
hypothesis: nigrostriatal dopaminergic neurons are more vulnerable to hyperglycaemic 
conditions compared to other neuronal populations, expressly the mesocorticolimbic 
pathway. 
Accordingly, we elaborated a senes of experiments employing dopaminergic 
neuronal cultures in high glucose conditions as well as a rat model of hyperglycaemia. 
We assessed the degeneration of dopaminergic neurons in vitro and in vivo, and 
described the ensuing behavioural alterations in rats. By offsetting the production of 
ROS using a well-known antioxidant, resveratrol, we also verified the role of high 
glucose-induced oxidative stress in the death of dopaminergic neuronal cultures. 
1.4.1 Objective 1: Evaluate the degeneration of cultured dopaminergic neuronal 
cells in high glucose conditions 
We first tested whether dopaminergic neurons in culture undergo degeneration in 
sustained high glucose conditions. We employed an in vitro model of dopaminergic 
neurons cultured in elevated though physiologically plausible concentrations of glucose. 
The production of ROS was measured and dopaminergic neuronal cell death was 
assessed. We specifically quantified the superoxide anion radical, as it is thought to 
constitute the initial toxic species overproduced in hyperglycaemia and liable for the 
cascade of oxidative events leading up to cellular injuries (Brownlee, 2005). 
Next, we investigated the mechanisms by which dopaminergic neuronal cells degenerate 
in high glucose conditions, focusing on the apoptotic cascade. Particular indices of 
apoptosis were examined, expressly the terminal events occurring at the level of the 
DNA supported by changes in the expression of various proteins involved in the process. 
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1.4.2 Objective 2: Determine the potential of the antioxidative polyphenol 
resveratrol to hamper the high glucose-induced degeneration of cultured 
dopaminergic neuronal cells 
Alongside objective 1, we employed a strategy aimed at moderating oxidative 
stress to demonstrate its role in dopaminergic neurodegeneration. In this regard, 
we selected the stilbene resveratrol whose protective competences were extensively 
studied by virtue of its antioxidative potential. In line with objective 1, we verified the 
ability of resveratrol to prevent dopaminergic neuronal cell death, diminish superoxide 
anion radical production, and impede the apoptotic cascade. 
Results for objectives 1 and 2 are reported in the article entitled "Resveratrol 
protects dopaminergic PC12 cells against high glucose-induced oxidative stress and 
apoptosis: effect on p53 and glucose-regulated protein 75 colocalization" published in 
November 2013 in the peer-reviewedjournal Neurotoxicity Research (see Chapter II). 
1.4.3 Objective 3: Characterize dopaminergic neurodegeneration in a rat model 
of long-term hyperglycaemia 
On the grounds of results acquired in vitro, the preferential degeneration of the 
nigrostriatal pathway compared to the mesocorticolimbic pathway was next assessed 
in vivo in a well-established rat model of hyperglycaemia induced by a toxin that targets 
insulin-producing pancreatic ~ cells. Neurodegeneration assessments were performed 
following long-term hyperglycaemia, allowing the graduai instatement and maintenance 
of oxidative stress required to overwhelm susceptible targets. Accordingly, we measured 
glucose concentrations at source and terminal regions of the nigrostriatal and 
mesocorticolimbic pathways to inquire whether ail areas were equally exposed to 
circulating glucose. By immunohistochemical and immunoblotting methods, 
we appraised neurodegeneration in both pathways as weil as in the hippocampus for 
comparative means. Dopamine was measured at the terminais of these neurocircuits to 
corroborate observations of neurodegeneration in the midbrain. We also assessed the 
fate of glial cells in these regions to gain a better understanding of the effects of long-
term hyperglycaemia in the substantia nigra pars compacta of rats. 
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1.4.4 Objective 4: Assess the behavioural alterations resulting from nigrostriatal 
neurodegeneration in a rat model of long-term hyperglycaemia 
Degeneration of neurocircuits involved in the regulation of behaviours, as is the 
case for the nigrostriatal and mesocorticolimbic pathways, often leads to measurable 
behavioural alterations. Although both the nigrostriatal and mesocorticolimbic pathways 
fulfil highly complex mandates that can in sorne ways overlap, it remains that the former 
specializes in regulating motor behaviours. In keeping with our hypothesis, motor 
behavioural assessments were performed in the same subjects as in objective 3 to 
determine whether observed nigrostriatal neurodegeneration may lead to discernable 
motor deficits. Rats executed motor tasks typically employed in models of Parkinson 's 
disease. To comparative ends, a cognitive novel object recognition test was performed to 
evaluate non-spatial working memory regulated by the hippocampus (Bast, 2007; 
Bast et al., 2009), but also involving the mesocorticolimbic components nucleus 
accumbens (Annett et al., 1989) and prefrontal cortex (Akirav and Maroun, 2006). 
Insights of these behavioural tests in conjunction with the results pertaining to 
objective 3 are reported in the article entitled "Dopaminergic neurodegeneration in a 
rat model of long-term hyperglycemia: preferential degeneration of the nigrostriatal 
motor pathway" published online in May 2018 and issued in September 2018 in the 
peer-reviewed journal Neurobiology of Aging (see Chapter III). 
Given the role of dopamine in social reward, social cognition and rough-and-
tumble play processes (Narvaes and Martins de Almeida, 2014; Plavén-Sigray et al., 
2014; Trezza et al., 2010), we next investigated whether nigrostriatal degeneration 
disrupts these behaviours in our rat model of long-term hyperglycaemia. In order to 
evaluate social behaviour, interactions between unacquainted conspecifics and emissions 
of ultrasonic vocalizations (USVs) were recorded simultaneously. USVs inform on the 
emotional state of rats during social contexts such as mating, play or aggression 
(Burgdorf et al., 2008) and are largely regulated by dopamine (Brudzynski, 2009). 
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Complementary to the evaluation of motor deficits, these inquiries into the social 
behaviours of our model further extend our comprehension of the various ways that 
dopaminergic neurodegeneration may manifest itself. These specific results are reported 
in the article entitled "Long-term hyperglycaemia modifies social behaviour and 
emission of ultrasonic vocalisations in rats: a possible experimental model of altered 
sociability in diabetes" (see Chapter IV). The manuscript was submitted to the peer-
reviewed journal Scientific Reports on July 9th, 2018. 
1.5 Methodology 
1.5.1 Objective 1: Evaluate the degeneration of cultured dopaminergic neuronal 
cells in high glucose conditions 
1.5.1.1 Cell culture 
To elucidate the possible neurodegenerative effects of a hyperglycaemic state 
on dopaminergic neurons in vitro, we employed the well-established model of 
dopaminergic neurons, the NGF-differentiated pheochromocytoma (PCI2) cell line. 
These cells were initially derived from a neuroendocrine turnour in the adrenal medulla 
of a rat (Greene and Tischler, 1976), and as such they can be subcultured almost 
indeterminately. PC12 cells both synthesize and store catecholamines, principally 
dopamine, in large dense-core vesicles that are released upon depolarization (Greene and 
Rein, 1977; Greene and Tischler, 1976). PCI2 cells share embryonic origins with 
neuroblastic cells. Thus, they can be differentiated into neuron-like cells with NGF 
treatments that phosphorylate and activate the tropomyosin receptor kinase A (Huang 
and Reichardt, 2003). Differentiation to a neuronal phenotype is enhanced by low serum 
concentrations (Yung et al., 2010). Ensuing signal transduction abrogates cell division 
and enhances the activity of the rate-limiting enzyme in dopamine synthesis, 
TH (Schubert et al., 1980), as weIl as the outgrowth of neurites and the expression of 
neurofilaments (Greene and Tischler, 1976; Lee et al., 1982). The PC12 cell line also 
expresses dopamine transport and metabolic machinery, such as DAT, VMATI 
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(preferentially expressed in adrenal glands, as opposed to neuronal VMAT2) and 
monoamine oxidase (Kadota et al., 1996; Liu et al., 1994; Youdim et al., 1986). 
Figure 1.24 Characterization of dopaminergic neuronal cell cultures. 
Top: From left to right are shown naïve pheochromocytoma (PCI2) cells 
and 3-, 5-, 7-day nerve growth factor (NGF)-differentiated neuronal 
PC12 cells. Bottom: Immunofluorescent assessment of the expression 
of neuronal and dopaminergic markers. From left to right: 7 -day 
differentiated neuronal PC12 cells marked for TH (green), neurofilaments 
(red) and nuclei (blue); dopaminergic N27 cells with Hoechst-stained 
nuclei marked for neurofilaments (yellow), DAT (green), and TH (red). 
In this respect, our group employs 5-1O-day NGF-differentiated neuronal PC12 
cells (50 ng/mL) cultured in low concentrations of fetal bovine serum (1%) (Achour 
et al., 2016; Bournival et al., 2012a, 2012b; Renaud et al., 2014). Figure 1.24 displays 
representative microphotographs of naïve (undifferentiated) PC12 cells and neuronal 
PC12 cells cultured in our laboratory. Pertinent to the present project, the y also express 
markers necessary for a high glucose context, expressly insulin-independent GLUT347 
(Mah~r et al., 1991). 
47 PC12 cells also express insulin-dependent GLUT4 (Hudson et al. , 1993), as weil as insulin-independent 
GLUTl and GLUT8 (Maher et al. , 1991), although the latter dwells in intracellular compartrnents and 
has not yet been found to translocate to the cell surface (Widmer et al. , 2005). Given the high affinity 
and capacity of GLUT3 compared to ail other GLUTs (Maher et al., 1996), it is the most relevant 
glucose transporter in our model in the absence of insulin. Accordingly, midbrain dopaminergic neurons 
express GLUT3 and only very little GLUT4, at least in the rat brain (El Messari et al., 1998; Maher 
et al., 1991). 
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1.5.1.2 High glucose conditions 
High glucose conditions in vitro alm to emulate the increase in extracellular 
glucose concentrations that takes place in hyperglycaemia. Depending on the culture 
medium, typical glucose concentrations range between 5.5 mM (1 g/L) to 17.5 mM 
(3.5 g/L). Taking into consideration the normal concentrations at which neurons are 
cultured, careful optimization of D-glucose concentrations and treatment times are 
required to achieve a faithful model of a physiologically hyperglycaemic state in cell 
cultures. In this respect, undiagnosed, untreated or uncontrolled diabetes can lead to a 
ri se in glycaemia reaching 25 mM (450 mg/dL), qualified as severe hyperglycaemia 
(Amblee et al., 2016; Marchese et al., 2017; Saul et al., 2016). In rats exhibiting a 
glycaemia of 30 mM48 , neurons are predicted to be exposed to ~9 mM of glucose, 
while at normoglycaemic values of 6 mM, they are exposed to 1.2 mM (Simpson et al., 
2007) (Table 1.7). This represents a 7.5-fold increase between normal and severe 
hyperglycaemic conditions. Since PC12 cells are normally cultivated in I l mM of 
glucose, we tested the following concentrations within this physiological 7.5-foid 
increase in dose-response and time course studies: 25, 50 and 75 mM (Figure 1.25). 
Seeing as we were aiming for a moderate cytotoxic effect averagmg 30-50% 
(or 50-70% viability) with the lowest dose of D-glucose, results of these kinetic 
dose-response studies allowed for the selection of a concentration of 25 mM (4.5 g/L) 
administered for a duration of 96 h in neuronal PC 12 cells. We also tested the effect of 
D-glucose on naïve PC 12 cells and irnrnortalized fetal mesencephalic dopaminergic 
N27 cells. Akin to PC12 cells, the latter secrete dopamine in addition to expressing the 
principal dopaminergic neuronal proteins, namely TH, DAT, nestin, neurofilaments and 
a neuron-specific enolate (Adams et al., 1996; Prasad et al., 1994), also characterized in 
our laboratory (Figure 1.24). These additional kinetic dose-response investigations ruled 
out the use of naïve PC12 cells, in light oftheir proliferative response, at least at 25 mM. 
These data also confirm that dopaminergic neuronal cells are vulnerable to high glucose 
48 We williater see that this glycaemia was indeed sustainable for 6 months in our rat mode\. 
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conditions, even when these are rather moderate (25 mM), strengthened by experiment 
repetitions in dopaminergic N27 cells. 
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Figure 1.25 Time-course and dose-response study of the toxicity of glucose on 
dopaminergic cells in culture. 
Cells were cultured in high glucose conditions ranging between 
25-75 mM for 0-120 h and cell viability (top A-C) or cell death (bottom 
D-F) were measured by MTT assay and lactate dehydrogenase 
quantification, respectively. Differentiated neuronal PCI2 ceIls (red lines) 
demonstrated a greater vulnerability th an naïve ceIls (blue lines). 
Dopaminergic N27 ceIls exhibited intermediate susceptibility (green line). 
There seems to be a slight proliferative effect for non-differentiated ceIls 
(B, C), likely owing to the fact that these populations were not in a 
post-mitotic state: glucose may have stimulated ceIl growth at low 
concentrations. This effect was lost at the highest dose. The chosen 
concentration, 25 mM, is portrayed as a bold !ine. 
As with any ceIl line, the PCI2 model presents limitations. In this regard, 
we performed tests in a rat model of hyperglycaemia, detailed later. Nonetheless, among 
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the vanous utilizations of the PC12 cell line, our paradigrn is advantaged by the 
differentiation of the cells to a clear neuron-like phenotype with pronounced expression 
of dopaminergic markers and cessation of division. In contrast, most other publications 
utilizing PC12 cells do not differentiate them, implying a tumoural phenotype and 
tapered dopaminergic properties, or use much higher concentrations of D-glucose that 
are not physiologically explainable (75-300 mM)49 (Aminzadeh, 2017; Fouda and 
Abdel-Rahman, 2017; Rayegan et al. , 2017; Song et al. , 2017; Wang et al. , 2017; Zhao 
et al., 2015). Additionally, naïve and NGF-treated PC12 cells are differentially 
susceptible to oxidative stress particularly caused by methylglyoxal, a by-product of 
sustained exposure to high glucose concentrations (Okouchi et al., 2005). Differences in 
cellular redox states, specifically regarding the reduced glutathione-to-oxidized 
glutathione disulphide ratio, are likely accountable for these distinct responses. 
1.5.1.3 Superoxide anion quantification 
The primary goal of this part of the thesis was to verify that oxidative stress likely 
underpins the death of dopaminergic neuronal cells cultured in high glucose conditions. 
We measured the initial oxidative event that is believed to occur early in response to a 
glucose overload, that is, the overproduction of superoxide anion (Brownlee, 2005). 
Quantification of superoxide anion at the level of mitochondria is possible using a 
modified hydroethidine superoxide anion fluorogenic probe marketed under the name 
MitoSOXTM (Robinson et al., 2006) (Figure 1.26). Hydroethidine is a reduced form of 
ethidium (3,8-diamino-5-ethyl-6-phenylphenanthridinium), shown to undergo oxidation 
by potassium superoxide into a red fluorescent molecule (Rothe and Valet, 1990). 
Since its discovery, hydroethidine has been widely used as an intracellular superoxide 
anion detector (Perticarari et al., 1994; Rothe and Valet, 1990; Tarpey et al., 2004). 
The modified hydroethidine molecule is conjugated with a triphenylphosphonium 
moiety that steers molecules toward mitochondria. The three lipophilic phenyl groups 
49 Such high concentrations of any solute, in fact, constitute a risk for noxious hypertonie effects that can 
be mistaken for the toxicity of the molecule per se. Although we remained within a reasonable 
concentration range, our work also provides D-mannitol control s, scarcely metabolized by mammalian 
cells, to rule out the possibility ofa toxic osmotic effect in our mode!. 
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facilitate movement across membranes of live cells and the positively charged 
phosphonium group further favours accumulation in the mitochondrial matrix endowed 
with a negative membrane potential. As such, MitoSOXTM almost exclusively reacts 
with mitochondrial superoxide anion (Robinson et al. , 2006) (Figure 1.27). 
H2 ~ li ~!J NH2 2-hydroxy-5-
- \ JJ=\1 (triphenylphosphonium) 
- (CH2)e- PNJ hexylethidium 
~ li 3 590 nm 
Figure 1.26 Structure and fluorescent mechanism of MitoSOXTM Red. 
Vpon reacting with superoxide anion, MitoSOXTM adopts a more 
highly conjugated structure enabling it to produce red fluorescence when 
it is excited at a wavelength of 510 nm. We can also appreciate 
the hydroethidine structure to the left and the positively charged 
triphenylphosphonium responsible for driving MitoSOXTM to 
mitochondria. 
Granted superoxide anion overproduction in response to stress is a very early event 
in cell cultures (Carange et al. , 2011; Ronson et al. , 1999), we performed time course 
studies and identified 3 h as the optimal incubation time when to perform measurements 
in high glucose conditions. We have also previously shown that levels of nitrates and 
nitrites, reactive nitrogen species arising from secondary reactions between superoxide 
anion and nitric oxide (Pacher et al. , 2007), are increased at a later time point in our 
model (Boumival et al., 2012a). In the article presented in Chapter II, the use of 
diethyldithiocarbamate, a selective inhibitor of SOD causing the accumulation of 
superoxide anion (Khazaei et al. , 2009; Puglia and Loeb, 1984), substantiated the 
specificity of MitoSOXTM in our paradigm. 
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Figure 1.27 Selectivity of MitoSOXTM Red. 
The speeifieity of two ROS probes, dihydrorhodamine 123 (white bars) 
and MitoSOXTM Red (black bars), were tested on a variety of speeies. 
While dihydrorhodamine 123 was not specifie for any partieular ROS, 
MitoSOXTM Red more readily seavenged superoxide anion, as evideneed 
by measures of fluorescence. It remains that this probe emits a weaker 
signal than dihydrorhodamine 123. The inset graph with grey bars 
displays Griess nitrite determination results, as a control for the detection 
of reactive nitrogen species. H202, hydrogen peroxide; HRP, horseradish 
peroxidase. (From the product information sheet provided by Molecular 
Probes, 2015.) 
1.5.1.4 Evaluation of ap op to tic death 
Apoptosis is a key contributor to the degeneration of neurons in Parkinson 's 
disease50 (Anglade et al., 1997; Moehizuki et al., 1996; Toulorge et al., 2016) as weB as 
in diabetes (Maiese et al., 2007; Russell et al., 1999). Alongside autophagie death, 
neeroptosis, ferroptosis, anoikis and many others, apoptosis belongs to a family of 
programmed cell death processes that occur in multicellular organisms (Ke et al., 2016) 
50 Several apoptotic hall marks were revealed in post-mortem substantia nigra pars compacta samples of 
parkinsonian patients, for instance chromatin condensation and DNA fragmentation (Tatton, 2000), 
p53 and Bax overexpression (Mogi et al. , 2007; Tatton, 2000), and elevated caspase-3 activity (Mogi 
et al. , 2000; Tatton, 2000). 
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(Figure 1.28). Cellular apoptosis is a profitable course of death for an organism owing to 
its tight regulation and to the cleanliness of the process that does not induce overt 
inflammation, as opposed to necrosis (Alberts et al., 2008). The importance of apoptosis 
becomes aIl the more apparent in cancer, wherein its pathological impairment is at the 
basis of several forms of the disease (Evan and Vousden, 2001; Green and Kroemer, 
2009). However, excessive apoptosis, due to lax cellular control or elevated death 
signais in the immediate environment, is also cause for pathology especially in tissues 
with scant regenerative potential such as the CNS (Bredesen et al. , 2006). 
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Figure 1.28 The classic intrinsic and extrinsic pathways in apoptosis. 
Continued on next page. 
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(Continued.) The intrinsic pathway is usually triggered by an endogenous 
stress, which activates p53 responsible for the initiation of the apoptotic 
cascade via transcriptional upregulation of pro-apoptotic factors. These 
will disrupt mitochondrial homeostasis at the level of the permeability 
transition pore, allowing for pro-apoptotic factors to escape into the 
cytoplasm where they will participate in the formation of the apoptosome. 
This multiproteic structure activates effector caspases, which will then 
execute the remainder of the apoptotic program. The extrinsic pathway 
is rather instigated by external death or stress, which will lead to 
the activation of terminal effector caspases via the stimulation of 
intermediary caspases. Both pathways are intimately linked. Akt, protein 
kinase B; Apaf-l , apoptotic protease activating factor 1; Ap02L/TRAIL, 
apoptosis antigen 2 ligand/tumour necrosis factor-related apoptosis-
inducing ligand; Bad, B cell lymphoma 2 (Bcl-2)-associated death 
promoter; Bak, Bcl-2 homologous antagonist/killer; Bax, Bcl-2-
associated X protein; Bcl-XL, B cell lymphoma-extra large; Bid, Bcl-2 
homology 3 interacting-domain death agonist; c-FLIP, first apoptosis 
signal receptor-associated protein with death domain-like interleukin-l-
beta converting enzyme (FLICE/caspase 8)-like inhibitory protein; DISC, 
death-inducing signalling complex; DR4/DR5, death receptor 4/5; F ADD, 
first apoptosis signal receptor-associated death domain; IAP, inhibitor of 
apoptosis proteins; Mcl-l, induced myeloid leukemia cell differentiation 
protein; Noxa, phorbol-12-myristate-13-acetate-induced prote in 1; PI3K, 
phosphatidylinositol 3-kinase; Puma, p53 upregulated modulator of 
apoptosis; Smac/DIABLO, second mitochondria-derived activator of 
caspases/direct IAP binding protein with low pl. (From Ashkenazi, 2008.) 
Numerous archetypal events occur over the course of apoptosis, for instance cell 
shrinkage, chromatin condensation, DNA fragmentation and blebbing, to name a few. 
The point of no retum in apoptosis is often regarded as the modification of chromatin 
and DNA. We verified this in our model by employing a DNA denaturation method that 
specifically detects cells whose chromatin is condensed (Frankfurt and Krishan, 2001) 
(Figure 1.29). This technique harnesses the amplified sensitivity of condensed apoptotic 
chromatin to thermal denaturation (Allera et al., 1997). Therefore, following high 
glucose treatments, we heated neuronal PC12 cells and applied formamide to induce 
denaturation of sensitive apoptotic chromatin. Using a HRP-conjugated monoclonal 
antibody that specifically targets single-stranded DNA, we were able to measure the 
proportion of terminally apoptotic neuronal cells by colorimetric detection. 
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Figure 1.29 Specificity with respect to temperature kinetics of formamide-
induced DNA denaturation. 
Formamide was applied in cells submitted to several kinds of treatments 
described in the box. DNA denaturation was quantified over the course of 
rising temperatures. Apoptotic cells begin to exhibit DNA denaturation at 
manifestly cooler temperatures compared to other non-apoptotic cells, 
which corroborates the specificity of this test, performed at 70°C. 
(From Frankfurt and Krishan, 2001.) 
To bolster our findings , we also verified other events that accompany the major 
phenotypic changes that occur during apoptosis, mainly modifications in the expression, 
subcellular localization or post-translational alterations of proteins. Activation of the 
caspase cascade, a sequence of proteic cleavage events controlled by caspase proteases, 
is a hallmark of apoptosis (Sakahira et al. , 1998). Caspase-3 is the terminal effector of 
this cascade that, upon cleavage, is responsible for the activation of a DNA 
fragmentation enzyme, caspase-activated deoxyribonuclease. Therefore, we verified 
terminal caspase activation and DNA fragmentation in our model, by employing 
immunofluorescence for cleaved caspase-3 labeling combined with the terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) method to isolate cells 
displaying DNA fragmentation. To ensure the exclusive counting of apoptotic cells, 
we only identified ones that exhibited both fluorescent signais. The specificity of our 
results was also substantiated by the use of an irreversible inhibitor of cleaved caspase-3 , 
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the fluormethy1ketone-conjugated tetrapeptide Z-DEVD-FMK, expected to yie1d cells 
with very little or no TUNEL signal. 
Next, we evaluated the expressIOn of proteins upstream or downstream from 
caspase-3 by immunoblotting. Upstream at the level of the mitochondria, one of the 
pro-apoptotic member of the Bcl-2 family, Bax, spearheads the formation of the 
mitochondrial permeability transition pore responsible for the cytosolic release of 
apoptogenic molecules, such as cytochrome c (Gollapudi et al. , 2003). Bcl-2, an anti-
apoptotic member of the Bcl-2 family, interacts with Bax to prevent permeabilization 
(Renault et al. , 2013) (Figure 1.30). It follows that an elevated Bax to Bcl-2 expression 
ratio is a faithful indicator that apoptosis is on-going (Cory and Adams, 2002). 
At the level of the nucleus, the DNA repair enzyme P ARP constitutes a downstream 
target of caspase-3 and its cleavage in 24 and 89 kDa fragments is a recognized feature 
of apoptosis (Kaufmann et al., 1993). Thus, a low ratio of full-Iength-to-cleaved PARP 
constitutes a marker of apoptosis. Farther upstream of caspase activation, the tumour 
suppressor p53 was also assessed in light of its role in evoking apoptosis and sensing 
oxidative stress. Indeed, p53 is stabilized by oxidative stress and localizes to the nucleus 
where it induces the transcription of pro-apoptotic factors (Lee et al., 2008; Macip et al., 
2003; Nair, 2006). Consequently, we studied the cytoplasmic and nuclear localization of 
p53 in neuronal PC12 cells following high glucose treatments, a high nuclear-to-
cytoplasmic ratio likely indicating its active promotion of apoptosis in our model. 
Directly linked to this, we also verified by immunoblotting and 
immunofluorescence the subcellular localization of a constitutively expressed chaperone 
of the heat shock protein family, glucose-regulated protein 75 (GRP75), known to 
sequester p53 in the cytoplasm, thereby preventing apoptosis in multiple models 
(Kaul et al., 2005). Fluorescence colocalization analyses were performed to evaluate its 
aptitude to bind p53 in the cytoplasm in conditions of oxidative stress. Normally, GRP75 
acts as a mitochondrial chaperone and guardian against oxidative stress among a 
plethora of other functions. However, its role under conditions of stress is highly 
variable (Londono et al., 2012) (Figure 1.31). One of our aims was to define its role in 
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high glucose-induced oxidative stress due to its purported implication III 
neurodegeneration. Indeed, GRP75 is depleted in the affected brain regions of 
Parkinson's disease patients (Burbulla et al. , 2010; Jin et al. , 2006) and knocking out its 
expression leads to neurodegeneration that can be rescued by the parkinsonian gene 
product parkin (Yang et al., 2011). In addition, it is a well-recognized binding partner of 
other genes mutated in Parkinson ' s disease, namely DJ-l and a-synuclein (Jin et al. , 
2006; Li et al., 2005) . 
Bcl-2 
inactive Bax 
activator 
BH30 
Bad 
Figure 1.30 Mitochondrial translocation of Bax followed by the formation of 
the mitochondrial permeability transition pore. 
Bax is usually found in an inactive state (light blue) in the cytoplasm. 
When Bcl-2 homology 3 (BH3)-only proteins such as tBid, Bcl-2-like 
protein Il (Bim) or Puma are produced in response to an apoptosis-
inducing stress, these can activate Bax, rende ring it more liable to insert 
itself in the mitochondrial membrane leading to the generation of the 
permeability transition pore. Anti-apoptotic members of the Bcl-2 family, 
on the other hand, prevent Bax from inserting itself in the membrane. 
Considering the ratio of these proteins can offer insight into events 
occurring at the level of the mitochondrial membrane during apoptosis. 
p38MAPK, p38 mitogen-activated protein kinases. (From Renault et al., 
2013.) 
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Figure 1.31 The multiple roles of GRP75. 
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Glucose-regulated prote in 75 (GRP75 or mortalin) is primarily involved 
in the mitochondria, where it fulfils chaperone, import, and oxidation-
sensing functions. In the advent of cellular stress, GRP75 is recruited to 
the cytoplasm where it can regulate several processes, including 
apoptosis. By binding p53, it abrogates this transcription factor 's 
translocation to the nucleus where it usually perforrns pro-apoptotic 
operations. Nevertheless, much remains to be elucidated pertaining to 
its functions. FGF-l , fibroblast growth factor 1; Hsp, heat shock 
protein; IL-IR, interleukin-l receptor; MVD 1, diphosphomevalonate 
decarboxylase; p66Shc, 66 kDa proto-oncogene Src homologous-collagen 
homologue adaptor protein; VDAC, voltage-dependent anion channel. 
(From Londono et al., 2012.) 
Further methodological details conceming the utilization of neuronal PC12 cells 
cultured in 25 mM of D-glucose for 96 h, the measurement of superoxide anion at 3 h, 
or the assessment of apoptosis in our model are provided in Chapter II. 
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1.5.2 Objective 2: Determine the potential of the antioxidative polyphenol 
resveratrol to hamper the high glucose-induced degeneration of cultured 
dopaminergic neuronal cells 
1.5.2.1 Resveratrol treatments 
In addition to measunng superoxide amon production in neuronal PC12 cells 
treated with high glucose conditions, we employed an antioxidative strategy to verify the 
importance of oxidative mechanisms in dopaminergic neurodegeneration in vitro . 
The polyphenol resveratrol was chosen for its potent antioxidative capacities 
demonstrated in various cellular (Karlsson et al., 2000; Savaskan et al., 2003; Wu et al. , 
2017; Zhuang et al., 2003) and animal models (Kiziltepe et al., 2004; Palle and Neerati, 
2018; Sinha et al., 2002). In neuronal paradigms, resveratrol is best known for its ability 
to enhance the activity of SOD, an enzyme that catalyzes superoxide anion 
inactivationS! , both in vitro (Bai et al., 2013; Lee et al., 2012; Yuan et al., 2013) and 
in vivo (Cheng et al. , 2014; Kesherwani et al., 2013; Nalagoni and Karnati, 2016; 
Ren et al., 2011). 
Very few studies have used resveratrol on neuronal PC12 cells, solely focusing on 
demonstrating its pro-differentiation competences (Lecomte et al., 2017; Ma et al. , 
2014; Sugino et al., 2010). These projects established resveratrol's effects at 
concentrations ranging from 0.5 )lM to 20 )lM. Most other applications of resveratrol on 
cultured neurons typically provide its use at 1-120)lM (Calabrese et al., 2010; Jardim 
et al., 2017). In our paradigm, resveratrol was administered at an optimized 
concentration of 0.1 )lM, constituting the lowest dose that reliably protects our model 
against various oxidative insults (Bournival et al., 2009; Bureau et al., 2008; Gélinas and 
Martinoli, 2002). To verify the ability of resveratrol to modulate superoxide anion 
concentrations in mitochondria, neuronal PC 12 cells were co-treated with the 
polyphenol for the duration of high glucose treatments. 
5\ In purified neuronal mitochondria, resveratrol also demonstrates direct scavenging properties for the 
superoxide anion (Zini et al., 1999, 2002). One group employed PC 12 cells challenged with high 
glucose concentrations to demonstrate its protective effects via the activation of the phosphatidylinositol 
3-kinase/ Akt/forkhead box 03 (PI3K1 Akt/Fox03a) pathway (Liu et al., 2015). However, the authors 
used undifferentiated cells, which, as previously discussed, respond differently to oxidative insults 
(Okouchi et al., 2005). 
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The differentiation of PC12 cells with NGF is important, not only to yield a clear 
neuronal phenotype, but also to prevent adverse effects from resveratrol treatments. 
Indeed, resveratrol exhibits both protective (Agrawal et al. , 20 Il; Dasgupta and 
Milbrandt, 2007; Della-Morte et al. , 2009) and toxic (Muqbil et al., 2012; Trincheri 
et al., 2007; Wenner, 2012) properties depending on cellular contexts. In naïve PC1 2 
cells, resveratrol is cytotoxic, whereas it promotes neurite outgrowth, mitochondria 
renewal and energy balance in NGF-differentiated ones (Hayakawa et al., 2013). 
For this reason, PC12 cells were differentiated for at least 5 days with NGF before high 
glucose or resveratrol treatments were employed. 
The application of polyphenols m cell cultures also reqUlres certain 
methodological adjustments. One of these is to ensure the absence of other phenolic 
substances in the cell culture medium to mIe out any effect not attributable to the 
polyphenol treatrnent. To that end, ail sera used during experiments were charcoal-
stripped to remove steroids, the principal phenolic compounds found in these ceU culture 
additives (Boumival et al., 2009; Bureau et al., 2008; Cao et al., 2009; Gélinas and 
Martinoli, 2002). 
Further methodological information concernmg the use of resveratrol ln our 
dopaminergic model is provided in Chapter II. 
1.5.3 Objective 3: Characterize dopaminergic neurodegeneration in a rat model 
of long-term hyperglycaemia 
1.5.3.1 Rat model oflong-term hyperglycaemia 
Selection of an appropriate paradigm to simulate long-term hyperglycaemia in 
rodents likely constituted the most critical aspect of the in vivo portion of this thesis. 
Attempts to model diabetes and other metabolic diseases as working platforms to 
develop treatments and elucidate pathological mechanisms have yielded today a slew of 
weU-described paradigms (see for reviews Baxter and Duckworth, 2004; Islam and 
Loots, 2009; Kim et al., 1998; Srinivasan and Ramarao, 2007; Van Belle et al., 2009). 
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Our choice was founded on accessibility, operational simplicity and hyperglycaemia 
sustainability. While the aim of this thesis is not to provide an extensive description of 
the multiple paradigms of diabetes, an overview of the most salient rodent models is 
offered next with respect to our selection criteria. 
Diabetic rodent models are conveniently separated into two categories: genetic and 
experimentally-induced (Table 1.10). Various genetic and transgenic models of diabetes 
mellitus have been developed to date, sorne of the most common being Long Evans 
Tokushima Fatty rats (cholecystokinin receptor deficiency), Zucker fatty rats (leptin 
receptor deficiency), and db/db (leptin receptor deficiency) or ob/ob (leptin deficiency) 
strains of mice, reflective of a type II diabetes-like state, as well as the non-obese 
diabetic mouse strain (polygenic cause) and BioBreeding diabetes-prone rats (polygenic 
cause), rather mimicking a type I-like pathology (Bell and Hye, 1983; Kawano et al. , 
1992; Shafrir, 2003; Verdaguer et al. , 1996). These models bear the advantage of 
developing a spontaneous pathology. However, they are costly and require meticulous 
maintenance, which diminishes their accessibility. In addition, frank hyperglycaemia is 
not observed in sorne instances, as is the case for Zucker fatty rats or ob/ob mice. 
Conversely, when hyperglycaemia is readily present, for example in db/db or non-obese 
diabetic mice, insulin treatrnent may be required to main tain the animaIs. 
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Experimentally-induced models are, on the other hand, generally inexpensive, 
flexible and require little to no special maintenance (Islam and Loots, 2009). 
This category can further be subdivided into chemical-, diet- and surgically-induced 
models. Partial or total pancreatectomies were formerly common procedures to generate, 
respectively, type II or type 1 diabetes-like phenotypes presenting prominent 
hyperglycaemia (Foglia, 1950; Pauls and Bancroft, 1950). However, their popularity 
dwindled with the recognition that much simpler chemical protocols cou Id efficiently 
deplete insulin-producing pancreatic ~ cells. By a large amount, the two most prominent 
toxins are alloxan (Goldner and Gomori, 1943) and streptozotocin (Rakieten et al. , 
1963). Both operate via oxidative mechanisms to cause the necrosis of pancreatic ~ cells 
(Rerup, 1970; Yamamoto et al. , 1981) (Figure l.32) . Owing to its greater stability and 
longer half-life, streptozotocin is sometimes preferred over alloxan in rats and mice, 
but not in rabbits who are in sensitive to the former (Rerup, 1970; Srinivasan and 
Ramarao, 2007). Depending on the intravenous (i.v.) dose52 , these molecules can yield 
either type 1- (higher dose) or type II-like (lower dose) diabetic features (Rakieten et al., 
1963). However, most agree that, regardless of the dose, i.v. alloxan and streptozocin 
induce a diabetic phenotype that closely resembles type 1 diabetes with manifestations of 
acute hypoinsulinaemia instead of insulin resistance. Intraperitoneal (i.p.) injections in 
adult or neonatal rodents were later adopted to moderate the outcomes and to enhance 
their maintainability (lto et al. , 1999, 2001 ; Kodama et al. , 1993; Portha et al. , 1974, 
2007). 
Other methods used to generate more sustainable experimentally-induced models 
consist in laye ring different treatrnents to modulate extreme phenotypes. One of the most 
widely hired strategies in this sense employs single i.p. injections of nicotinamide prior 
to streptozotocin administration (Masiello et al., 1998; Nakamura et al. , 2006). 
Nicotinamide moderates the necrosis of pancreatic ~ cells induced by streptozotocin, 
thereby generating a model that is hypoinsulinaemic and hyperglycaemic, but viable for 
52 When administered i.v., alloxan is usually given in doses ranging From 40-200 mg/kg body weight 
[b.w.] in rats or 50-200 mg/kg b.w. in mice. Streptozotocin, on the other hand, is administered i.v. 
in doses ranging From 35-65 mg/kg b.w. in rats or 40-200 mg/kg b.w. in mice. 
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several months without the need for insulin treatment53 . In recent years, mixed chemical-
diet paradigms were implemented that more faithfully emulate type II diabetes (Reed 
et al. , 2000; Srinivasan et al., 2005). Indeed, standalone specialized diets (high-fat, 
high-carbohydrate, high-fat low-carbohydrate, etc.) present the disadvantage of causing 
a very progressive form of metabolic syndrome, characterized mostly by obesity and 
insulin resistance, but rarely associated with frank hyperglycaemia or glucose 
intolerance (Houssay and Martinez, 1947; Surwit et al., 1988; Winzell and Ahren, 
2004). Combined with a low i.p. dose of streptozotocin, high-fat diets induce increased 
body weight, hyperglycaemia, hyperinsulinaemia and dyslipidaemia in rodents (Reed 
et al. , 2000; Srinivasan et al., 2005). Uniting insults in the form of diets and toxins is 
today considered a core framework for the development of long-term type II diabetic-
like models (Zhang et al. , 2003). Nevertheless, despite attempts to refine existing 
models, none described to date are fully representative of either type l or II diabetes in 
humans (Baxter and Duckworth, 2004; Islam and Loots, 2009; Van Belle et al. , 2009). 
Granted the purpose of our work dwells in evaluating the effects of a sustained 
hyperglycaemic phenotype and not in faithfully simulating a specific disease, we were 
principally interested in models displaying this key feature for a long period of time 
without the need for ectopic insulin interventions. In this spirit, moderate chemical-
induced and diet-chemical mixed paradigms constituted the simplest and most accessible 
protocols. Thus, we tested two well-documented paradigms in parallel: moderate dose 
nicotinamide-streptozotocin-treated rats and low dose streptozotocin-treated rats fed a 
high-fat diet (Reed et al., 2000; Srinivasan et al., 2005). In the first protocol, ovemight 
fasted rats were simply injected with nicotinamide (i.p. 100 mg/kg b.w.) 20 min prior to 
administration of streptozotocin (i.p. 55 mg/kg b.w.), as previously described (Badole 
et al., 2015; Masiello et al. , 1998). In the second protocol, rats were maintained on a 
60% high-fat di et adjusted for calories that began two weeks prior to a single i.p. 
injection of streptozotocin (35 mg/kg b.w., overnight fasted) (Srinivasan et al. , 2005). 
Hyperglycaemia was first assessed 72 h following injections and thereafter measured on 
53 Precise ly, nicotinamide inhibits PARP, who se exaggerated activation by streptozotocin-induced DNA 
alkylation leads to the depletion of NAD+ and ATP, liable for pancreatic P cell necrosis. Nicotinamide 
also offers protection by serving as a precursor of NAD+ (Szkudelski, 201 2). 
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a regular basis, alongside body weight and food intake. Figure 1.33 surnmarizes these 
monitored metabolic parameters in our models. 
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Figure 1.32 Mechanisms of pancreatic P cell death in chemical-induced diabetes. 
Alloxan and streptozotocin both enter pancreatic ~ cells via GLUT2, 
competing with glucose on the way. Alloxan engages in different 
mechanisms to participate in the death of pancreatic ~ cells. For instance, 
alloxan fuels a redox cycle with its reduction product, dialuric acid, 
thereby producing highly reactive ROS, such as the hydroxyl radical 
(-OH) via Fenton and Haber-Weiss reactions, and depleting antioxidative 
cofactors, like GSH and NADPH. Alloxan may also inactivate 
glucokinase, leading to hampered A TP production and insu lin secretion, 
a mechanism inhibited by the presence of glucose. Contrary to alloxan, 
streptozotocin's primary mechanism is quite straightforward and 
implicates firsthand alkylation of DNA. Exposure to either toxin leads to 
damaged DNA and the activation of the reparation enzyme PARP whose 
overstimulation will deplete stocks of the NAD+ cofactor: pancreatic 
~ cells thereby undergo necrosis. Fe2+, ferrous iron ions; Fe3+ , ferric iron 
ions; GS-, glutathione radical ; GSSH, glutathione disulphide; NO, nitric 
oxide. (Adapted from Radenkovié et al. , 2016.) 
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Figure 1.33 Metabolic follow-up of nicotinamide-streptozotocin or high fat-
streptozotocin treated rats. 
Weight (A), glycaemia (B), cumulative food intake (C) and calorie 
intake (D) per cage were measured for over two months in two different 
models of diabetes. High fat-fed rats injected with streptozotocin 
(purple tines) clearly did not develop hyperglycaemia or hyperphagia, 
while nicotinamide-streptozotocin rats (red lines) were manifestly 
hyperglycaemic and hyperphagic. CTRL, control; HF, high-fat diet. 
Protocol 1 yielded the best results regarding the maintenance of a moderate to 
elevated hyperglycaemia. Despite manifestations of a progressive hyperphagia, rats from 
protocol 1 stopped gaining weight. Conversely, protocol 2 did not render rats either 
hyperglycaemic or hyperphagic54. Indeed, rats administered the high-fat diet did not 
seem to find the food palatable. Accordingly, they did not gain weight faster than control 
rats. As the diet contained a great amount of fat (Table 1.11), it is possible that the food 
pellets became rancid quicker at room temperature upon contact with air. In fact, 
54 We suspected the amount of calories to contribute to the diminished intake of weighted food, 
but correcting for the energetic value of the diets did not provide further insight. 
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the high-fat di et did not conta in antioxidants to prevent rancidification known to give 
foods an off flavour. In addition, high-fat food pellets were much softer, which may 
have contributed to the rats' indifference or dislike toward this diet. The manufacturers 
of this diet could not provide any explanations, either. 
Table 1.11 
Ingredient lists of the rat diets provided by Harlan 
Ingredients 
Casein 
L-Cysteine 
Maltodextrin 
Sucrose 
Soybean oil 
Cellulose 
Mineral mix 
Vitamin mix 
Choline bitartrate 
TBHQ antioxidant& 
Corn starch 
Lard 
Calcium phosphate dibasic 
Blue food colour 
& TBHQ, tert-butylhydroquinone. 
AfN-93G purified diet 
(TD.94045) 
(g/kg) 
200 
3 
132 
100 
70 
50 
35 
10 
2.5 
0.014 
397 
o 
o 
o 
Adjusted calories diet (60/fat) 
(TD.064 14) 
(g/kg) 
265 
4 
160 
90 
30 
65.5 
48 
21 
3 
o 
o 
310 
3.4 
0.1 
The sum of these observations led us to adopt protocol 1 for the project at hand, 
while rats from protocol 2 were redirected toward another study. Nicotinamide-
streptozotocin55 injected rats, hereafter designated hyperglycaemic, and vehic1e-injected 
control rats fed a normal diet were employed to produce the results presented in 
Chapter III. Rats were maintained for up to 6 months without the need for insulin 
interventions. In the brains of our mode l, we studied the various regions of the 
nigrostriatal and mesocorticolimbic pathways, explicitly the substantia nigra pars 
compacta, ventral tegmental area, dorsal striatum, nucleus accumbens and prefrontal 
cortex, but also the hippocampus for comparative means. In addition, experiments were 
conducted at two time points, either at 3 or 6 months following induction of 
55 Noteworthy, peripherally administered streptozotocin does not enter the brain (Bhuyan et al., 1974). 
Other models do employ intracerebroventricular injections of streptozotocin to cause insulin resistance 
in the CNS, a model of Alzheimer's disease (Correia et al., 20 Il) . 
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hyperglycaemia, in order to gam a clearer insight regarding the time necessary for 
neurodegeneration to manifest itself in our mode!. Moreover, many experiments were 
repeated in different cohorts and in different institutions (Université du Québec à 
Trois-Rivières, and University of Cagliari, Italy) , thereby solidifying our findings. 
Chapter III offers further details pertaining to the experimental design and the various 
metabolic parameters monitored along the course of this project, including haemoglobin 
glycation measurements and a terminal oral glucose tolerance test commonly used in 
humans and in animal models to assess the severity of hyperglycaemia and glucose 
intolerance, respectively. 
1.5.3.2 Intracerebral glucose measurements 
The central hypothesis of this thesis requires firsthand observations of a rise in 
glucose concentrations in the brain regions of interest, namely the substantia nigra pars 
compacta and dorsal striatum of the nigrostriatal pathway, and the ventral tegmental 
area, nucleus accumbens and prefrontal cortex of the mesocorticolimbic pathway. 
As previously stated, precise quantifications of intraneuronal glucose are lacking in the 
literature. Extracellular levels of glucose have, however, been appraised in rodents, 
but reports usually coyer one single brain region at a time during specific tasks56. 
More pertinent to our project, several studies demonstrated that hyperglycaemic or 
hypoglycaemic challenges in otherwise healthy rodents provoke same-direction changes 
in extracellular glucose levels, as previously discussed (Abi-Saab et al., 2002; Béland-
Millar et al. , 2017; Macauley et al., 2015; Osborne et al., 1997). In diabetic paradigms, 
rises in extracellular glucose concentrations were only measured in the inferior 
colliculus of the brainstem (Jacob et al., 2002; McCrimmons et al., 2003), the striaturn 
(Gomez and Barros, 2003) and the ventromedial hypothalamus (de Vries et al., 2003). 
Several reports in humans account for cerebral glucose levels but were mostly conducted 
in pathological states, for instance in partial seizures (Abi-Saab et al. , 2002), following 
56 Many experiments have been conducted during various tasks or in response to several stimuli, such as 
anaesthetics, tail pinching or hypo/hyperoxia. The brain regions targeted during the se studies are the 
striatum (Osborne et al. , 1997; Fellows and Boutelle, 1993; Lowry et al., 1998a, 1998b, 1 998c), 
hippocampus (Macauley et al. , 2015; McNay et al. , 2000, 2001a, 2001b, 2004; Rex et al., 2009; 
Su et al., 2015) and motor cortex (Béland-Millar et al. , 2017). 
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a cardiac arrest (Hifumi et al. , 2017) and especially in traumatic brain injuries (Jalloh 
et al. , 2013 ; Rostami, 2014). 
Despite these reports indicating a nse In extracellular glucose levels in 
hyperglycaemic or diabetic states, no adequate account exists to support the supposition 
that concentrations increase evenly throughout several neuroanatomical locations. 
We therefore performed glucose measurements in the multiple regions of interest in our 
hyperglycaemic model by two different methods allowing us to estimate both 
intracellular and extracellular concentrations. For intracellular glucose assessments, 
brain homogenates were prepared from the striatal, midbrain, prefrontal cortex and 
hippocampal regions, the latter serving for comparative means. We used a standard 
glucose measurement kit that employs a mutarotase enzyme to transform a-D-glucose to 
~-D-glucose, further oxidized by glucose oxidase. This generates hydrogen peroxide that 
can be colorimetrically quantified upon its reaction with a chromogenic agent (Crystal 
Chem, Downers Grove, IL, USA). Since rats were perfused upon sacrifice with ice-cold 
phosphate-buffered saline, it is possible that the results obtained may provide an 
underestimation of intracellular glucose concentrations. 
For extracellular assessments, the intracerebral microdialysis technique in freely 
moving and awake rats was employed, later described in greater detail. Seeing as 
separation of the different subregions of the striatum and midbrain was not possible in 
the previous method, intracerebral microdialysis advantageously allowed us to 
specifically target the ventral tegmental area, substantia nigra pars compacta, nucleus 
accumbens and dorsal striatum by stereotactic vertical insertion of dialysis probes that 
coUect interstitial fluid solutes in real time. Given the various glycaemic and feeding 
profiles of our rats, especiaUy between control and hyperglycaemic individuals, 
our protocol required to standardize these parameters. We therefore fasted aU rats 
ovemight and administered a specific amount of food diluted in water by intragastric 
gavage precisely 30 min before the beginning of microdialysis experiments. To obtain a 
reliable baseline measurement, samples were collected over a I-hour lapse of time and 
glucose was quantified using the same kit employed for brain homogenates. 
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Combining these methods ensured a robust confirmation of the increase in 
intracerebral glucose levels in our model. It also allowed us to verify that glucose 
concentrations rise evenly across the brain regions of interest. 
1.5.3.3 Assessment ofneurodegeneration 
Objective 3 aimed to characterize the effects of long-term hyperglycaemia on the 
nigrostriatal and mesocorticolimbic pathways with a keen focus on neurodegeneration. 
We combined immunoblotting and immunohistochemical techniques to strengthen any 
findings of neurodegeneration upon which hinges this part of the project. TH and DAT 
were employed as dopaminergic markers expressed in the whole length of dopaminergic 
neurons of either the nigrostriatal or mesocorticolimbic pathways. NeuN served as a 
general neuronal marker, as it is expressed in ail neuron ceil bodies, but not in processes, 
regardless of their type. Harvesting one brain hemisphere for immunoblotting and the 
other for immunohistochemistry maximized the use of animaIs. 
Immunoblotting assays allowed for a semi-quantitative measurement of the 
expression levels of dopaminergic and neuronal markers in the midbrain, striatum, 
prefrontal cortex and hippocampus of our model, 3 and 6 months following induction of 
hyperglycaemia. Altered TH and DA T expression levels in our model provided hints of 
dopaminergic modifications, perhaps indicative of neurodegeneration, whereas NeuN 
measurements served to support these results. We exercised caution when analysing 
NeuN expression in the striatum, since dopaminergic neuronal cell bodies are not found 
in this region but rather in the midbrain. 
The immunohistochemical method served to confirm whether changes in 
expression were attributable to a proper loss of dopaminergic neurons. It also permitted 
the precise neuroanatomical identification of these changes. Since expression levels of 
TH, DAT and NeuN were altered only at 6 months in the striatum and midbrain of our 
hyperglycaemic model, we performed immunohistochemical analyses at this time point. 
Post-fixed frozen hemispheres were sliced rostrocaudally in coronal sections and 
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neuronal markers were revealed immunohistochemicaIly. In the substantia mgra 
pars compacta and ventral tegmental area, TH-positive dopaminergic neurons or 
NeuN-positive overall neurons were counted. In the various regions of the striatum, 
the density of TH-positive dopaminergic fibres originating from the midbrain was 
measured by optical densitometry. As such, we were able to verify proper 
neurodegeneration of either neuronal cell bodies or terminal arbours in both pathways. 
NeuN-positive neurons were also counted in the striatum, prefrontal cortex and 
hippocampus to make sure that other non-dopaminergic populations remained 
unchanged. TH-positive dopaminergic fibre staining was not seen In the prefrontal 
cortex, as it is only lightly innervated by the ventral tegmental area. Likewise, the 
hippocampus, which receives minor dopaminergic input from the ventral tegmental 
area57 (Lisman and Grace 2005), did not display any staining. 
1.5.3.4 Assessment of glial profiles 
In an attempt to gain better insight into the changes that take place in the CNS of . 
our hyperglycaemic rat model, the fate of glial populations was studied alongside that of 
neurons. Astrocyte proliferation, or astrogliosis, is a well-appreciated feature of the 
diabetic nervous system, both in humans (Araszkiewicz and Zozulinska-Ziolkiewicz, 
2016; DeJong, 1977; Lu et al., 2014) and in models (Alomar et al., 2016; Baydas et al., 
2003; Duarte et al., 2009; Nagayach et al., 2014; Rostami et al., 2017; Saravia et al. , 
2002). However, studies have not addressed astrogliosis in multiple regions at a time nor 
have they tackled this feature in long-term hyperglycaemia. Likewise, microgliosis is an 
appreciated feature of retinal and peripheral nerve pathologies in models of diabetes 
(Gaucher et al., 2007; Krady et al., 2005; Mazzeo et al., 2017; Zeng et al., 2000) as weIl 
as in patients (Altmann and Schmidt, 2018; Zeng et al., 2008), but many gaps remain 
pertaining to the CNS (Oliveira et al., 2016; Nagayach et al., 2014). Conversely, the loss 
of microglial cells or astrocytes may also be indicative of the general distress expressed 
57 The hippocampus and ventral tegmental area form a functional loop. When the hippocampus detects 
new information that is not stored in long-term memory, it sends a novelty signal through the nucleus 
accumbens and ventral pallidum to the ventral tegmental area. Then, the ventral tegmental are a releases 
dopamine in the hippocampus, thereby enhancing long-term potentiation and leaming. (Lisman and 
Grace, 2005). 
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by resident cells of the CNS. Although under-acknowledged, degeneration of glial cells 
may in fact occur in the context of sustained oxidative stress (Streit et al. , 2008). 
The importance of addressing glial populations in our models lies in their 
purported role with regard to neurodegeneration, especially in the context ofParkinson 's 
disease (McGeer et al., 1988; More et al., 2013; Russo et al., 2014). Indeed, glial 
alterations may imply a neuroinflammatory state likely connected to the death of 
dopaminergic neurons (Cabezas et al., 2014; Hirsch et al., 2003), as micro glial cells 
were shown to be more abundant in the substantia nigra pars compacta of post-mortem 
brains of parkinsonian patients (Kim et al., 2000; Lawson et al., 1990). 
The knowledge gaps highlighted above alongside the relevance of glial 
populations in neurodegeneration stress the pertinence of addressing the fate of glial 
populations as an indicator of the severity of the hyperglycaemic insult in our model. 
To that end, microglial cells and astrocytes were immunohistochemically detected using 
antibodies raised against ionized calcium-binding adapter molecule 1 (Iba1) or glial 
fibrillary acidic protein (GF AP), respectively. Cells were counted in all of the 
aforementioned brain regions using the method previously described. 
1.5.3.5 Intracerebral dopamine measurements 
ldeally, observed losses of neurons or their terminaIs should be supported by 
further neurochemical investigations. To that end, we measured extracellular dopamine 
in the terminal regions of the nigrostriatal and mesocorticolimbic pathways, that is, 
the dorsal striatum, the nucleus accumbens and the prefrontal cortex. The microdialysis 
technique, also used to measure extracellular brain glucose, allows for the accurate 
assessment of these regions. However, it entails complicated surgical procedures that 
could not be performed in our model at the 6-month time point. Instead, we conducted 
experiments at 3 months to evaluate the possibility that a functional loss of 
dopaminergic neurotransmission could emerge before the neurodegeneration observed at 
6 months. Information provided at this time point was nonetheless relevant to our 
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interpretation of several behavioural manifestations observed at 3 months in our model, 
presented next in objective 4. 
Ever since its design was optimized (Ungerstedt and Pycock, 1974; Un gers te dt 
et al., 1982), intracerebral microdialysis has been extensively used to measure small 
solutes in the interstitial fluid of the brain (see for review Chefer et al., 2009) 
(Figure 1.34). This technique employs a minute probe composed of a metal cannula that 
contains in its centre a tubular dialysis membrane permitting free transport of solutes 
smaller than the molecular weight cut-off, typically of 20 000 Da. The probe is equipped 
with an inlet, to transport the perfusate, and an outlet, to collect the microdialysate. 
Referring to an atlas of neuroanatomical coordinates, the probe is vertically inserted in 
the brain region of choice with the assistance of a stereotactic apparatus. A defined 
portion of the semipermeable dialysis membrane at the very tip of the probe is directly 
exposed to the parenchyma; only this surface participates in molecular exchanges and 
can be modified to accommodate the dorsoventral thickness of the region of interest. 
Perfusion begins as soon as the probe is inserted and the automatic syringe dispenser is 
activated. Typical perfusion rates range between 0.3-3 ~Llmin and have a direct 
incidence on the recovery rate, that is, the fraction of solute collected by the probe found 
to be inversely proportional to the speed of its production, diffusion and replacement in 
the interstitial fluid (Wages et al., 1986; Zetterstrom et al., 1988). Aiso depending on the 
perfusion rate as well as on the sensitivity of the analytical apparatus, sample collection 
times range from 1-20 min. The perfusate c1i1ssically consists of a solution that most 
faithfully represents the extracellular environrnent in which the probe is inserted, except 
that it is completely depleted in the solute meant to be sampled. Indeed, it is usually 
accepted that uptake occurs by diffusion along a concentration gradient58 . In our 
experiments, we prepared the probes according to the widely employed protocol 
established in Prof. Gaetano Di Chiara's laboratory (Bassareo et al., 2011; Di Chiara 
et al., 1993; Tanda et al., 1996). This protocol presents the advantage of employing a 
dialysis membrane mounted on a tungsten fibre and covered in an impermeable silicone 
58 This also means that retrodialysis is possible if a certain solute is included in the perfusate, but found 
in lower concentrations in the brain parenchyma (Khan-Dawood et al., 1994; Wei et al., 1997). 
Such strategies allow for the delivery of drugs to very precise neuroanatomical loci. 
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sheath. As they are rigid and do not reqmre a cannula to guide them, the brain 
parenchyma is not in direct contact with metal. 
.yringo pump (aCSF, 1 !JI/min) 
signai ttansduetlon 
fradion colledor (10·20 min) 
ventriculaf space 
CSF 
Figure 1.34 Schematic representation of solute exchanges during microdialysis 
experiments. 
Not only do microdialysis probes uptake neurotransmitters, they can also 
sample most any molecule present in the environment that is smaller than 
the molecular weight cut-off. These can come from glial cells and blood 
capillaries, in addition to neurons. Likewise, solutes can be infused in 
discrete brain regions employing a retrodialysis paradigm, wherein a 
greater concentration of the substance is supplied in the perfusate (H6cht 
et al., 2007). aCSF, artificial cerebrospinal fluid; CSF cerebrospinal fluid. 
(From Bossers et al., 2013.) 
Our protocol did not involve behavioural assessments or pharmacological 
interventions sensitive to the state of the animal that, in these circumstances, must 
recover for several days. As such, baseline dopamine was measured on the day 
following acute cannulations in well-rested, awake and healthy rats. An intermediate 
perfusate rate of 1 ilL/min was employed and 9 samples were collected over 20-min 
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periods for a total of 3 h. Microdialysates were collected and analyzed by high-
perfonnance liquid chromatography. This technique separates the various molecules 
present in a liquid according to their affinity for a stationary (solid column) phase that is 
usually polar, for instance silica. However, microdialysates usually conta in rather 
hydrophilic solutes whose retention times on the column are too long, hence the use of 
a reverse-phase high-performance liquid chromatography wherein the stationary phase is 
non-polar to allow the movement of these molecules (Irnperato and Di Chiara, 1984). 
Solutes are electrochemically detected and their identity is confinned by appraisal of 
their signature elution time. 
Although microdialysis offers great neuroanatomical precision, it does not offer 
very good temporal resolution. The sensitivity of the analytical apparatus usually 
requires samples to be at least a few microlitres, which, at best, implies collection times 
of 1 min. Consequently, phasic bursts are difficult to quantify by microdialysis as they 
occur below the l-second threshold and require voltammetric or electrophysiological 
methods that are sensitive to infrasecond fluctuations caused by behaviour or stimuli 
(Hauber, 2010; Schultz, 2010; Segovia et al., 2011 ; Wightman and Robinson, 2002). 
Tonic release, however, is feasibly quantified by intracerebral microdialysis experiments 
that measure events dependent on time constants greater than 1 min (Di Chiara, 1990). 
Extracellular concentrations of dopamine measured in our experiments therefore 
represent dopaminergic tonic firing59 at baseline and hold important implications for 
behavioural interpretations that we will address in the discussion. 
To fulfil objective 3, the joint evaluation of neurodegeneration, glial disturbances 
and dopamine release in the various brain regions of the nigrostriatal and 
mesocorticolimbic pathways offered a broad appreciation of the dopaminergic neuronal 
alterations present in our hyperglycaemic model. Supplementary information, especially 
pertaining to probe insertion locations in microdialysis experiments, can be found in the 
article presented in Chapter III. 
59 We must bear in mind that a loss of tonie firing in the dorsal striatum is most eonspieuously observed 
in Parkinson's disease and leads to bradyki nesia and rigidity. 
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1.5.4 Objective 4: Assess the behavioural alterations resulting from nigrostriatal 
neurodegeneration in a rat model of long-term hyperglycaemia 
Video samples of the behavioural experiments described below can be viewed 
at the following address: goo.gl/9HF6ux. Copy and paste this shortened URL in your 
browser to access the Dropbox file. 
1.5.4.1 Assessment ofmotor deficits 
In consonance with the three previous objectives, we wanted to achieve a broad 
perception of the effects of long-term exposure to high concentrations of glucose on 
dopaminergic neurons. Working with a rodent model allowed us to appreciate 
behavioural consequences arising from dopaminergic neurodegeneration. lndeed, several 
well-established tests exist to evaluate nigrostriatal or mesocorticolimbic functions. 
As previously mentioned, the nigrostriatal pathway is prominently involved in the 
production of movement owing to its important pacemaker activity that provides the 
striatum, especially the dorsal region, with tonic dopamine (Lanciego et al., 2012) . 
Rat models ofParkinson's disease are commonly subjected to specifically designed tests 
to uncover motor symptoms that may arise from the degeneration of the nigrostriatal 
pathway (see for reviews Dunnett and Lelos, 2010; Meredith and Kang, 2006; Pinna and 
Morelli, 2014; Plowman and Kleim, 2011). They are also used to develop treatments to 
alleviate motor symptoms that are thought to arise from loss of dopamine tonicity 
(Bergstrom and Garris, 2003; Bergstrom et al., 2011). 
Among the great many experimental tools developed to assess motor deficits in 
rodents, only a few were applicable to our model. Indeed, many tests are designed for 
asymmetrically lesioned animais induced, for instance, by a unilateral injection of 
6-0HDA into the ascending nigrostriatal bundle of rats (Schwarting and Huston, 1996; 
Ungerstedt and Arbuthnott, 1970; Vellucci et al., 1993). These tests are usually based on 
the evaluation of tuming behaviour in response to stimuli that is due to the enhanced 
sensitivity of postsynaptic receptors following striatal denervation rather th an the proper 
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loss of dopamine tonicity (Creese et al., 1977). Unilateral utilization of limbs in tasks is 
another behaviour that can be scored in hemiparkinsonian rodents. However, the CNS 
of our model is evidently subjected to a wide bilateral exposure to high glucose 
concentrations and therefore asymmetric neurodegeneration is unlikely. In light of this, 
we chose tests typically employed in bilateral models ofParkinson's disease or ones that 
could be adapted to our needs. We did not expect our rats to express overt motor 
symptoms and, as such, we performed the most sensitive tests possible to uncover 
bradykinesia or akinesia, as weil as gait disturbances and sensorimotor deficits (Pinna 
and Morelli, 2014). We also selected tests that could be performed at multiple time 
points, expressly before the induction of hyperglycaemia, then at 3 and 6 months 
following that mark so as to link results with our neurobiological evaluations. 
The stepping test, a form of beam traversai task, is used in rats to assess three 
different parameters: time of initiation, time to cross and numbers of steps made 
. (Meredith and Kang, 2006; Olsson et al., 1995; Pinna et al., 2007, 2010). The test 
employs a 20 cm-wide beam inclined at 15 degrees leading to the home cage. 
Briefly, rats are trained to depart from the hands of the experimenter with one forelimb 
placed at the beginning of the beam. Protracted initiation of movement toward the home 
cage and time to cross the beam both uncover bradykinesia or akinesia. The numbers of 
steps made, usually greater in parkinsonian rodents, inform on the gait. The stepping test 
therefore reliably picks up subtle basal ganglia alterations and has been used in genetic 
models and aged animais that present little nigrostriatal damage (Drucker-Colin and 
Garcia-Hemandez, 1991). In our model based on a bilateral hyperglycaemic insult to the 
CNS, differences between starting forelimbs were not found and results were pooled. 
We also employed the horizontal bar test typically used to measure 
pharmacologically-induced catalepsy in rodents (Alvarez-Cervera et al., 2005; Ciucci 
and Connor, 2009; Kuschinsky and Homykiewicz, 1972; Sanberg et al. , 1981 , 1988). 
In our model, however, this test rather served to identify bradykinetic or akinetic 
individuals. In this task, the experimenter places untrained rats habituated to the test 
cage in an unusual posture by placing both its front limbs on a cylindrical bar placed at a 
1 
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convenient height. Normal rodents naturally seek to correct imposed postures and will 
quickly remove both limbs. Latency to disengage from the bar is thought to expose basal 
ganglia dysfunction (Duvoisin, 1976; Sanberg, 1980), although it is less sensitive than 
the previous method, at least in certain genetic models (Kelm-Nelson et al. , 2015). 
This test is however criticized for its sensitivity to recurring trials (Costall and Olley, 
1971 ; Stanley and Click, 1976) likely ensuing from repeated handling that may cause 
tonic immobility (Sanberg et al., 1980). Since we performed tests at wide intervals, 
at 0, 3 and 6 months, these confounding events were unlikely. Nevertheless, overt 
manifestations of proper catalepsy in otherwise active control or hyperglycaemic rats 
were extremely rare and were omitted from data, as they could have been the result of 
tonic immobility. 
We conducted a third test to evaluate limb gait and bradykinesia, termed the 
forelimb adjusting step test (Chang et al., 1999; Meredith and Kang, 2006; Pinna et al., 
2007, 2010). Briefly, trained rats are held by the torso with only one forelimb placed on 
a surface and bearing weight. During trials, rats are laterally moved back and forth 
across the surface at a fixed speed, and forehand (forelimb adjusts toward the torso) or 
backhand (forelimb adjusts away from the torso) steps are counted (Chang et al., 2003 ; 
Kirik et al., 2000, 2002; Olsson et al. , 1995; Schallert et al. , 2003; Tillerson and Miller, 
2002). Akin to the stepping test, the forelimb adjusting step test is performed unilaterally 
but results were combined upon confirmation that both limbs responded similarly in all 
animaIs . 
Many other tests were considered for their application in our model but either 
failed to expose any deficits or were impractical. This was the case for the vibrissae-
elicited forelimb placement test wherein a rat's whiskers are brushed upon a surface, 
which normally .evokes a paw placement response (Meredith and Kang, 2006; Pinna 
et al., 2007, 2010). Sensorimotor integrative deficits are identified when rats fail to 
respond to brushing of their vibrissae. Our hyperglycaemic model did not perform 
differently compared to control rats at any time point. We also attempted to perform an 
adapted pole test for rats, which evaluates coordination and motor skills (Chompoopong 
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et al., 2016; Zaitone et al., 2012), as weil as an adhesive removal task, highly sensitive 
for uncovering sensorimotor deficits and fine motor impairment in minimally dopamine-
deficient animais (SchaUert et al., 1982), but rats failed to perform the tasks correctly for 
vanous reasons. 
Nonetheless, results obtained with the three abovementioned tests were 
sufficient to draw up a picture of the key motor deficits displayed by our long-term 
hyperglycaemic model, especiaUy with respect to bradykinesia/akinesia and gait 
disturbances. Detailed experimental designs foUowed to fulfil this part of the objective 
are provided in Chapter III. 
1.5.4.2 Evaluation of social behaviour 
Although best appreciated in the regulation of motor processes, nigrostriatal 
dopamine also partakes in the modulation of many other behaviours. Owing to its role in 
goal-directed conducts and habit leaming (Bromberg-Martin et al. , 2011 ; Faure et al., 
2005; Gunaydin et al. , 2014; Haber et al. , 2000; Redgrave et al. , 2010; Saddoris et al., 
2013; Schultz, 2002; Seger and Spiering, 2011 ; Wang et al. , 2011), nigrostriatal 
dopamine has recently emerged as a regulator of social interactions and affective-based 
decisions, which were hitherto exc1usively lent to the mesocorticolimbic pathway (Burke 
et al. , 2010; King-Casas et al. , 2005; Lamichhane et al. , 2014; Narvaes and Martins 
de Almeida, 2014; Ong et al. , 2011 ; Palmeri et al., 2017; Plavén-Sigray et al., 2014; 
Stoeckel et al. , 2014; Trezza et al. , 2010). Although a proper correlation with 
nigrostriatal degeneration has not been drawn, Parkinson ' s disease patients do 
experience an altered quality of social life very early in the pathology. In particular, 
social interactions, communication and emotion recognition are impaired to variable 
extents in these individuals (PeU et al. , 2006; Schrag et al. , 2000; Y oshimura et al. , 
2005). 
For this reason, we designed experiments wherein social behaviours were scored 
concomitantly to the measurement of an outwardly accessible indicator of dopaminergic 
1 
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functions modulated in social encounters, namely USV caUs (Figure 1.35). In social 
behaviour research, US Vs constitute a growingly valuable instrument in the assessment 
of the valence of encounters, as they convey information on the affective state of rodents 
during courtship, rough-and-tumble play, cooperation and aggression (Brudzynski, 
20l3 ; Burgdorf et al., 2008; Knutson et al., 1998; Lopuch and Popik, 2011 ; Wëhr and 
Schwarting, 2013). Most importantly, however, they provide information on the 
activation of midbrain dopaminergic pathways involved in their production. The two 
principal neurotransmitters involved in the emission of ultrasonic calls are dopamine and 
acetylcholine, which function together as a switch that can quickly activate positive or 
negative affective states, respectively (Brudzynski, 2007; Cragg, 2006; Rakovska et al., 
2003). Dopamine and acetylcholine are sensitively released in response to salient and 
novel environmental stimuli, inc1uding social encounters, and cooperate at the striatal 
interface to select the appropriate affective state. This is accompanied by the emission of 
USVs at different ranges of frequency6o. Dopamine is principally associated with the 
emission of 50-kHz caUs, which are positively valenced and produced during social 
interactions, su ch as tickling (Panksepp and Burgdorf, 2000), playing (BruneUi et al. , 
2006) or mating (Bialy et al., 2000). Acetylcholine is rather linked to 22-kHz USVs 
reflecting negative affective states in various contexts, for instance social isolation 
(Francis, 1977) and aggression (Kaltwasser, 1990). Sorne suggest that 22-kHz caUs are 
also emitted in paradigms of chronic pain (Calvino et al. , 1996; Jourdan et al. , 1995), 
but this association was disproven in the streptozotocin-treated rat model of neuropathic 
pain (Jourdan et al. , 2002). 
Affiliative/exploratory and aggression-related behaviours were scored in our rats 
and associated with the emissions of 50- and 22-kHZ USVs. Rats interacted in a novel 
and neutral arena, and not in resident-intruder paradigms (Hilakivi-Clarke et al., 1990; 
Meehan et al. , 1986), to obtain insight into the reactions driven by socialization, which 
more faithfuUy represent encounters between humans in day-to-day life. Behaviours and 
USVs were related to the degree of striatal dopaminergic denervation and to insulin 
levels and function. This allowed us to draw up the socioaffective profiles of our rat 
60 Examples ofUSV audiograms are presented in Figure 4.7 of Chapter IV. 
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model of hyperglycaemia and to identify neurobiological or hormonal influences on 
social behaviours and associated USV caUs. These results also constitute the first report 
of USV emissions in a rodent paradigm of hyperglycaemia and are found in Chapter IV 
alongside precise details on the experimental design. 
Figure 1.35 Experimental setup of social behaviour assessments. 
Pairs of unacquainted rats were placed in a neutral and novel environment 
for the duration of the tests. A !id with a microphone was placed on top of 
the cy!indrical arena and two cameras were positioned on opposite sides 
to record ultrasonic vocalizations (USVs) emitted during the encounters. 
To briefly summarize the introduction of this thesis, we have laid the foundations 
for the purpose of our investigations, by discussing the selective vulnerability of the 
nigrostriatal pathway in Parkinson's disease and by offering robust arguments in support 
of the hazard that hyperglycaemia may represent to this population of neurons. 
Precisely, we have committed to demonstrating how nigrostriatal dopaminergic neurons 
are more vulnerable to oxidative stress and how hyperglycaemia may contribute to 
oxidative injury in neurons. Both these suppositions are supported by epidemiological 
evidence. Based on CUITent knowledge, we designed a series of in vitro and in vivo 
experiments exploring multiple dimensions of dopaminergic neurodegeneration and 
128 
have also used a strategy employing an antioxidant, resveratrol, to offer further 
validation of the pertinence of oxidative stress in high glucose-induced neuronal death. 
The results of these experiments are presented in Chapters II, III and IV, and offer 
molecular, cellular, neurochemical, neuroanatomical and behavioural evidence in 
support of our central hypothesis that nigrostriatal dopaminergic neurons are more 
vulnerable to hyperglycaemic conditions compared to other neuronal populations, 
expressly the mesocorticolimbic pathway. 
CHAPTERII 
RESVERATROL PROTECTS DOPAMINERGIC PC12 CELLS FROM HIGH 
GLUCOSE-INDUCED OXIDATIVE STRESS AND APOPTOSIS: EFFECT ON 
P53 AND GLUCOSE-REGULATED PROTEIN 75 LOCALIZATION 
Renaud, J., Bournival, J., Zottig, X., Martinoli, M. G. (2014). 
Neurotox. Res. 14, 110-23. 
The content of this chapter was published online in November 2013 and issued in 
January 2014 in the peer-reviewedjournal Neurotoxicity Research. 
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the manuscript. 
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2.2 Résumé 
Le resvératrol est un composé polyphénolique dont les propriétés 
cardioprotectrices et anti-inflammatoires sont déjà bien connues. Il détient également 
des capacités antioxydantes permettant de protéger des neurones dopaminergiques 
contre l'apoptose engendrée par le stress oxydant dans des paradigmes de la maladie de 
Parkinson. De récentes études ont démontré qu'une hyperglycémie soutenue peut causer 
un stress oxydant pouvant être nocif pour le système nerveux central. À la lumière de ce 
qui précède, notre étude avait pour but a) d'évaluer le potentiel antioxydant du 
resvératrol contre des concentrations physiologiquement élevées de glucose dans des 
neurones dopaminergiques en culture, b) d'étudier les capacités anti -apoptotiques du 
resvératrol dans ce contexte, et c) d'analyser la relation particulière entre le facteur de 
transcription pro-apoptotique p53 et son séquestreur cytoplasmique GRP75 dont les 
niveaux sont faibles dans le cerveau de patients parkinsoniens. Nos résultats démontrent 
que le resvératrol protège les neurones dopaminergiques en culture contre un stress 
oxydant induit par de fortes concentrations de glucose, précisément en diminuant les 
niveaux d'anion superoxyde. De plus, les neurones dopaminergiques en culture traités 
avec le resvératrol ne succombaient pas à l'apoptose qu'engendrait le glucose à des 
doses élevées. En particulier, le resvératrol prévenait la fragmentation de l'ADN et 
l'altération des profils d'expression de plusieurs marqueurs de l'apoptose. De fortes 
concentrations de glucose causaient une translocation de p53 vers le noyau, et une forte 
augmentation des niveaux de GRP75 dans le cytoplasme qui répondait à un besoin d'y 
séquestrer le facteur de transcription pro-apoptotique. En effet, une augmentation du 
taux de colocalisation entre GRP75 et p53 était observée. À cet égard, le resvératrol était 
en mesure de prévenir la translocation nucléaire de p53. Ces résultats appuient les études 
épidémiologiques soulignant que les patients diabétiques courent un plus grand risque de 
développer la maladie de Parkinson que la population générale. Notre étude suggère 
également que le resvératrol détient un rôle neuroprotecteur pouvant se prêter au 
développement de thérapies préventives ou complémentaires contre le développement de 
complications neuronales dans le diabète. 
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2.3 Full article in English: Resveratrol protects dopaminergic pe12 cells from 
high glucose-induced oxidative stress and apoptosis: effect on p53 and 
glucose-regulated protein 75 localization 
Abstract 
Resveratrol (RESV), a polyphenolic natural compound, has long been 
acknowledged to have cardioprotective and anti-inflammatory actions. Evidence 
suggests that RESV has antioxidant properties that reduce the formation of reactive 
oxygen species leading to oxidative stress and apoptotic death of dopaminergic 
(DAergic) neurons in Parkinson's disease (PD). Recent literature has recognized 
hyperglycemia as a cause of oxidative stress reported to be harmful for the nervous 
system. In this context, our study aimed a) to evaluate the effect of RESV against high 
glucose (HG)-induced oxidative stress in DAergic neurons, b) to study the anti-apoptotic 
properties of RESV in HG condition, and c) to analyze RESV's ability to modulate p53 
and GRP75, a p53 inactivator found to be under-expressed in post-mortem PD brains. 
Our results suggest that RESV protects DAergic neurons against HG-induced oxidative 
stress by diminishing cellular levels of superoxide anion. Moreover, RESV significantly 
reduces HG-induced apoptosis in DAergic cells by modulating DNA fragmentation and 
the expression of several genes implicated in the apoptotic cascade, such as Bax, Bcl-2, 
cleaved caspase-3, and cleaved PARP-I. RESV also prevents the pro-apoptotic increase 
of p53 in the nucleus induced by HG. Such data strengthens the correlation between 
hyperglycemia and neurodegeneration while providing new insight into the high 
occurrence of PD in patients with diabetes. This study enlightens potent neuroprotective 
roles for RESV that should be considered as a nutritional recommendation for 
preventive and/or complementary therapies ln controlling neurodegenerative 
complications in diabetes. 
Introduction 
Glucose is the essential energy substrate of the central nervous system and large 
amounts of it are required to fill the high energetic needs of neurons. Unlike muscle cells 
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or adipocytes that depend on insulin, glucose uptake in neurons depends mainly on 
its extracellular concentration (Tom lins on and Gardiner, 2008). Persistent episodes of 
long-term glucose exposure may induce oxidative stress that results in cellular damage 
(Giaccari et al. , 2009), such as neuropathic complications resulting from hyperglycemia 
in uncontrolled diabetes (Rajabally, 2011). Accumulating evidence has enlightened the 
relationship between diabetes and neurodegenerative disorders, including Alzheimer's 
disease (AD) (Vignini et al. , 2013) and Parkinson ' s disease (PD) (Jagota et al. , 201 2) . 
Recent literature has reported an increased risk of developing PD in patients with type 2 
diabetes mellitus (Hu et al., 2007; Sun et al., 2012) . 
PD is a neurodegenerative disorder characterized by the progressive loss of 
nigrostriatal dopaminergic (DAergic) neurons in the substantia nigra pars compacta 
(SNpc). DAergic neurons in this region are selectively lost due to the high activity of 
monoamine oxidase and elevated levels of iron which both lead to increased generation 
of reactive oxygen species (ROS) (Cui et al., 2012; Pearce et al. , 1997). At the cellular 
level, mechanisms of high glucose (HG)-induced toxicity are similarly sustained by 
oxidative stress in vitro (Boumival et al., 2012; Cao et al. , 2012) as weIl as in vivo 
(Styskal et al. , 2012). By increasing aerobic respiration, raised sugar metabolism 
promotes excessive formation of ROS that, jointly with insufficient antioxidant 
defences, may damage cells (Apel and Hirt, 2004). Indeed, generation of mitochondrial 
superoxide is increased and is thought to be at the origin of several HG-induced 
complications (Brownlee, 2001). Currently, it is weIl known that oxidative stress may 
lead to apoptosis (Circu and Aw, 2010) and increased production of ROS in HG 
conditions may account for glucose neurotoxicity duly observed. 
In addition, several genes are known to be implicated in the pathogenesis of 
PD, such as PINK 1 and DJ-l. Glucose-regulated protein 75 (GRP75, also called 
mortalinimtHSP70/mot-2), a member of the cytoprotective Hsp70 family of chaperon es, 
interacts with both PINKI (Jin et al., 2006, 2007; Li et al. , 2005; Rakovic et al., 2011 ) 
and DJ-l (Jin et al. , 2005; Li et al. , 2005). GRP75 is mainly localized within the 
mitochondria matrix of neurons where it accomplishes several functions such as 
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mitochondrial import and oxidative stress management (Yaguchi et al., 2007). 
Overexpression of GRP75 leads to the extension of life span in nematodes and human 
cells. On the other hand, it serves as a major target for oxidation and it was shown to be 
involved in aging of nerve cells and in particular in the degeneration of DAergic neurons 
(Burbulla et al., 2010). In mitotic ceIls, GRP75 localized in the cytoplasm sequestrates 
and inactivates p53 preventing its nuclear translocation and apoptosis (Kaul et al. , 2001 , 
2005; Wadhwa et al., 2002). Indeed, p53 is a tumor suppressor protein known to play an 
important role in evoking apoptosis when located in the nucleus by encouraging the 
transcription of several pro-apoptotic genes such as Bax (Macip et al. , 2003). 
p53 activity is stabilized in response to oxidative stress through posttranslational 
modifications disrupting interactions with negative regulators (Neilson et al., 2008). 
It is also a recurrent target in PD given the involvement of oxidative stress in p53 
activation (Nair, 2006) and the evidence of DNA fragmentation and chromatin 
condensation in DAergic neurons of the SNpc in PD patients (Hartmann and Hirsch, 
2001; Tatton, 2000). 
Prevention of neuronal loss in PD has not yet been addressed by existing 
syrnptomatic treatments. Neuroprotection by dietary polyphenols may be an interesting 
avenue in CUITent attempts to overcome oxidative stress induced by hyperglycemia. 
We have recently shown that quercetin and sesamin, antioxidant polyphenols, exert 
neuroprotective effects in neurons exposed to HG (Bournival et al. , 2012). The stilbene 
resveratrol (RESV) is another polyphenol, primarily found in red wine, known for its 
potent cardioprotective, anti-inflammatory and anticarcinogenic actions (Aluyen et al. , 
2012; Rosa et al., 2012). Our group, as weIl as others, have highlighted its potential in 
defending neurons against oxidative assaults induced by a spectrum of treatments, 
including neurotoxins (Blanchet et al. , 2008; Boumival et al. , 2009; Gélinas and 
Martinoli, 2002; Peritore et al., 2013) or cerebral ischemic injury (MOITis et al. , 2011; 
Simào et al. , 2012). Abundant literature suggests that RESV plays a protective role in 
several neurodegenerative diseases including PD, AD and Huntington's disease (Albani 
et al. , 2010; Hung et al., 2010) as weIl as against neuroinflammation (Foti Cuzzola 
et al. , 2011). 
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Although the beneficial properties of RESV in neurodegenerative diseases are 
extensively depicted in the literature, its role in defending neurons against HG-induced 
damage has yet to be elucidated. The present study was designed to examine the 
neuroprotective effects of the polyphenol RESV in differentiated DAergic PC12 cells 
maintained in HG condition. NGF-differentiated PC12 cells are a reliable model for the 
investigation of oxidative stress and neuroprotection of DAergic neurons. They express 
tyrosine hydroxylase (TH), high-affinity dopamine transporter, estrogen receptor-a and 
-~ , neurofilaments and secrete high levels of dopamine (Gélinas and Martinoli, 2002; 
Kadota et al. , 1996; Nilsen et al. , 1998). In this comprehensive investigation, we outline 
the roles of RESV in preventing neural parameters of cellular oxidative stress and 
apoptosis induced by HG exposure in a cellular DAergic system. Our results 
demonstrate that RESV can modulate the expression and localization of GPR75 and thus 
might mediate mitochondria pathways of ce Il stress. 
Materials and methods 
Drugs and chemicals 
All reagents and chemicals were purchased from Sigma (St. Louis, MO) unless 
noted otherwise. Mouse anti-GRP75 (raised against amino acids 525-679 of GRP75 of 
human origin), rabbit anti-p53 (raised against full length p53 of human origin, 
for immunofluorescence), rabbit anti-Bcl-2 (raised against a peptide mapping at the 
N-terminus of Bcl-2 of human origin), rabbit anti-Bax (raised against a peptide mapping 
near the N-terminus of Bax of mouse origin), mouse anti-cleaved PARP-l (poly(ADP-
ribose) polymerase, raised against C-terminal purified thymus PARP-l of calf origin), 
goat anti-HDAC 1 (histone deacetylase 1, raised against amino acids 450 to 
C-terminus of human HDACl), and mouse anti-GAPDH (glyceraldehyde 3-phosphate 
dehydrogenase, raised against recombinant GAPDH of human origin) antibodies were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse anti-p53 (raised 
against amino acids surrounding Ser20 of hum an p53 , for Western blotting) and rabbit 
anti-cleaved caspase-3 (raised against amino-terminal residues surrounding Asp 175 in 
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human caspase-3) antibodies were purchased from Cell Signaling (Boston, MA). 
Rabbit anti-VDAC (voltage-dependent anion channel , raised against amino acids 
152-169 of VDAC of human origin), mouse anti-TH (raised against rat TH) primary 
antibodies, and anti-mouse and -rabbit horseradish peroxidase-conjugated secondary 
antibodies were purchased from Sigma. Anti-mouse Cy3 (cyanine 3)-conjugated 
secondary antibody was purchased from Medicorp (Montreal, QC, Canada). Goat anti-
rabbit FITC (fluorescein isothiocyanate)-conjugated secondary antibody was purchased 
from Millipore (Temecula, CA). 
Cell culture and treatments 
PC 12 cells, obtained from American Type Culture Collection (ATCC, Rockville, 
MD), were maintained in a humidified environment at 37°C and 5% C02 atmosphere. 
Cells were grown in Roswell Park Memorial Institute medium 1640 (RPMI 1640) 
supplemented with 10% (v/v) heat-inactivated horse serum, 5% (v/v) heat-inactivated 
fetal bovine serum (FBS) and gentamicin (50 Jlg/mL). PC 12 cell neuronal differentiation 
was evoked by administration of nerve growth factor-7S (NGF, 50 ng/mL) in 
Dulbecco's Modified Eagle medium (DMEM) supplemented with 1 % FBS for 7 days, as 
already described (Bournival et al., 2009, 2012). The DMEM containing 1.0 g/L of 
D-glucose (Sigma D5523) is further called control (CTRL) medium, whereas HG 
DMEM containing 4.5 g/L of D-glucose (Sigma D7777) is named HG medium. DAergic 
PC12 cells were incubated with CTRL or HG medium for 96 h, unless stated otherwise. 
We previously performed lactate dehydrogenase-based cytotoxicity assays to determine 
the appropriate time of treatment in order to study the apoptotic process in the remaining 
live cells (Bournival et al., 2012). For the last 24 h of treatment, DAergic PC12 cells 
were incubated with or without RESV (0.1 JlM). RESV concentration was selected after 
dose-response and kinetic studies (Boumival et al. , 2009; Bureau et al. , 2008). 
An osmotic control consisting of CTRL medium supplemented with 3.5 g/L of 
D-mannitol (MANN) was used to rule out a hypertonic effect of HG medium on PC12 
ceUs. Charcoal-stripped serum was used in aU experiments to ensure that media were 
free from steroids. For each experiment, initial seeding density was 30 000 ceUs/cm2. 
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Detection of mitochondrial superoxide radical 
DAergic PC12 cells were grown and treated on collagen-coated circular glass 
coverslips (Fisher Scientific, Ottawa, ON, Canada). Intracellular superoxide anion ("02-) 
production was measured with MitoSOX™ Red (Invitrogen, Burlington, ON, Canada), 
a fluorogenic dye used for the selective detection of superoxide in the mitochondria of 
live cells. After treating cells with CTRL or HG medium for 3 h with or without RESV, 
the cells were incubated with MitoSOX™ Red (5 mM) for 10 min at 37°C. MitoSOX™ 
Red is rapidly and selectively targeted to the mitochondria. Once in the mitochondria, 
it is oxidized by superoxide and exhibits red fluorescence. Cells were washed with 
Hank's balanced salt solution (HBSS, Invitrogen), and Hoechst 33342 counterstained 
all nuclei. Cells were fixed in 4% paraformaldehyde for 6 min at 37°C. Coverslips were 
mounted with Molecular Probes ' ProLong® Antifade Kit (Invitrogen). Images were 
acquired by a Leica SD AF confocal microscope, and analyzed with Leica Application 
Suite 3.l.3 software (Leica Microsystems, Concord, ON, Canada). To demonstrate 
MitoSOX™ Red selectivity, a positive control was performed using sodium 
diethyldithiocarbamate (DDC), a superoxide dismutase (SOD) inhibitor, in CTRL 
medium. 
Immunojluorescence and terminal deoxynucleotidyl transferase dUTP nick end 
labeling assay 
Apoptotic cells were also detected by both terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL) assay (Roche Diagnostics, Laval, QC, Canada) and 
activated caspase-3 immunofluorescence. DAergic PC12 cells were grown and 
treated on collagen-coated circular glass coverslips. Cells were then fixed in 4% 
paraforma1dehyde for 15 min at 37°C, washed with phosphate-buffered saline (PBS) and 
further incubated in a blocking and permeabilizing solution (1 % bovine serum albumin 
[BSA], 0.18% fish skin gelatin, 0.1% Triton-X and 0.02% sodium azide) for 30 min 
at RT. Fixed cells were incubated with polyclonal anti-cleaved caspase-3 antibody 1:500 
in PBS overnight. The slides were washed and treated with Cy3-conjugated secondary 
antibody diluted 1 :500 in PBS for 4 h and then incubated with the TUNEL enzyme and 
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fluorescent dUTP mixture for 1 h at 37°C. Nuclei were counterstained 4',6-diamidino-2-
phenylindole (DAPI). Coverslips were mounted with ProLong® Antifade Kit. 
Images were acquired by a Leica SD AF confocal microscope. DAergic PC 12 cells were 
considered to be apoptotic when they were positive for cleaved caspase-3 and their 
nuclei were stained with TUNEL. The number of apoptotic DAergic PC12 ce ll s among 
300 randomly chosen neuronal was counted on 10 different optical fie lds from three 
slides per group, as already reported (Bournival et al. , 2009, 2012), with Leica 
Application Suite 3.1.3 software. In each experiment 50 !lM of fluormethylketone-
conjugated tetrapeptide Z-DEVD-FMK (Bachem, Torrance, CA), a cell-permeable 
caspase-3 inhibitor, was used on DAergic PC12 cells in HG and HG RESV conditions as 
internai control for caspase-3 activation (Bournival et al., 2009, 2012). 
Specifie apoptotic DNA denaturation analysis 
Specific DNA denaturation in apoptotic cells was assessed with a single-stranded 
DNA (ssDNA) apoptosis ELISA kit (Chemicon International, Temecula, CA). 
This procedure is based on the selective denaturation ofDNA by formamide in apoptotic 
cells but not in necrotic cells (Frankfurt and Krishan, 2001). After treatment with CTRL 
or HG medium with or without RESV, denatured DNA was detected with a monoclonal 
antibody highly specific to ssDNA and a peroxidase-Iabeled secondary antibody. 
The reaction was then stopped with a hydrochloric acid solution and ssDNA 
fragmentation was quantified by measuring absorbance at 405 nm with a Multiscan 
Ascent microplate reader (Thermolab System, Franklin, MA). ssDNA was quantified 
with reference to CTRL conditions. Absorbance of positive (wells coated with ssDNA) 
and negative controls (wells treated with SI nuclease) served as quality control for the 
ELISA. 
Protein extraction 
DAergic PC12 cells were grown and treated in collagen-coated 6-well plates. 
Total proteins were extracted using a nuclear extraction kit (Active Motif, Carlsbad, 
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CA). Briefly, cells were washed with a mixture of ice-cold PBS and phosphatase 
inhibitors, and then harvested in centrifuge tubes. Cell lysis was performed using the 
supplied buffer and samples were centrifuged to obtain membrane-free supernatants 
containing total proteins. 
Cytoplasmic-nuclear fractionation was achieved using the nuclear extraction kit. 
Briefly, cells were washed with a mixture of ice-cold PBS and phosphatase inhibitors, 
and then harvested in centrifuge tubes. Cytoplasmic membranes were ruptured by 
treatment with a hypotonic buffer and detergent. Samples were centrifuged to pellet the 
intact nuclei, and soluble material was preserved as the cytoplasmic fraction. Nuclei 
were then lysed and conserved in the provided lysis buffer. 
Mitochondrial-cytoplasmic fractionation was achieved usmg a mitochondrial 
extraction kit (Active Motif, Carlsbad, CA). Cells were washed with a mixture of 
ice-cold PBS and phosphatase inhibitors, and then harvested in centrifuge tubes. 
Cells were incubated on ice with isotonic cytosol buffer for 15 min. Cell membranes 
were ruptured with a pestle homogenizer. Intact cells and nuclei were pelleted after two 
centrifugations and discarded. Supernatants containing cytoplasm and mitochondria 
were centrifuged twice to obtain a pellet of mitochondria. The resulting supernatant was 
preserved as the cytoplasmic fraction. Mitochondria were washed with cytosol buffer 
and lysed with detergent. 
Electrophoresis and Western blotting analysis 
Protein dosage was performed with a bicinchoninic acid-based sodium dodecyl 
sulfate (SDS)-compatible Protein Assay Kit (Pierce, Rockfort, IL) for each fraction of 
every sample. Equal amounts of protein were loaded onto 12% SDS polyacrylamide 
gels. After electrophoretic separation, the gels were transferred to polyvinylidene 
difluoride membranes (0 .22)lm pore size, BioRad, Hercules, CA). The blots were 
blocked for 1 h at RT in Blotto B (1 % non-fat powdered milk, 1 % BSA, 0.05% Tween 
20, 0.5 mg/mL sodium azide, in Tris buffered saline). Dilution of primary anti-GRP75, 
139 
anti-p53 , anti-Bax, anti-Bcl-2, anti-cleaved PARP-1 , anti-GAPDH, anti-HDAC1 , 
anti-VDAC and anti-TH (1 :200, 1:200, 1 :50, 1 :50, 1: 1000, 1:50, 1 :50, 1 :500 and 
1: 10000 respectively) antibodies was prepared in Blotto B. The blots were then 
incubated with peroxidase-conjugated secondary antibody (l : 10 000) in Blotto B for 2 h 
at RT and finally developed with an enhanced chemiluminescence substrate solution 
(Haan and Behrmann, 2007). 
Glucose-regulated protein 75-p53 colocalization 
DAergic PC12 cells were grown and treated on collagen-coated circular glass 
coverslips. Then, the y were fixed in 4% paraformaldehyde for 15 min at 37°C, washed 
with PBS and further incubated in a blocking and permeabilizing solution for 30 min 
at RT. Fixed cells were incubated with both rabbit anti-p53 antibody 1: 100 and mouse 
anti-GRP75 1: 100 in PBS ovemight. The slides were washed with and subsequently 
treated with anti-rabbit Cy3-conjugated and anti-rabbit FITC-conjugated secondary 
antibodies both diluted 1 :500 in PBS for 4 h. Nuclei were counterstained with DAPI. 
Coverslips were mounted with Molecular Probes ' ProLong® Antifade Kit. Images were 
acquired by a Leica SD AF confocal microscope. Colocalization was assessed for 
100 randomly chosen PC12 cells on 6 different optical fields from three slides per group 
with Leica Application Suite 3.1.3 software. 
Statistical analysis 
Significant differences between groups were ascertained by one-way analysis of 
variance (ANOVA), followed by Tukey's post-hoc analysis with the GraphPad Instat 
program, version 3.06 for Windows (San Diego, CA; www.graphpad.com). Ail data, 
analyzed at the 95% confidence interval, are expressed as means ± standard error of 
the mean (SEM) from at least 3 independent experiments. Asterisks indicate statistical 
differences between the treatrnent and CTRL condition (***p < 0.001 , **p < 0.01 and 
*p < 0.05); plus signs show statistical differences between the treatment and HG 
condition (+++p < 0.001 , ++p < 0.01 and +p < 0.05). 
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Results 
Resveratrol rescues high glucose-induced production of superoxide 
To study the mechanisms underlying the neuroprotective effects of RESV against 
HG, we measured the production of superoxide with a derivative of ethidium bromide, 
MitoSOX™ Red, after administration of HG with or without RESV for 3 h. This time 
period was considered since free radical generation and eventually oxidative stress 
are early events in the causative process of cellular death (Carange et al. , 2011; 
Pérez-De La Cruz et al. , 2010; Zhou et al. , 2008). Figure 2.1A disc10ses low 
fluorescence levels in CTRL and MANN conditions as well as in cells treated with 
RESV in CTRL medium after 24 h, whereas a marked signal was detected in HG- and 
DDC-treated cells. When RESV was added to HG medium, fluorescence was strongly 
reduced. Figure 2.1B also reports the semi-quantitative analysis of mitochondrial 
superoxide anion presented in Figure 2.1 A, revealing high fluorescence levels with HG 
and positive control DDC as well as a very significant reduction (p < 0.001) when 
DAergic PC12 ce Ils in HG medium were treated with RESV. In the DDC condition, 
inhibition of SOD supports the specific detection of superoxide anion. AlI nuc1ei are 
stained blue by Hoechst 33342 (Figure 2.1A). 
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RESV reduces HG-induced superoxide anion production in DAergic 
PC12 cells. 
Resveratrol (RESV) reduces high glucose (HG)-induced superoxide anion 
production in dopaminergic (DAergic) PC12 cells. (A) Fluorescence 
microphotographs. Blue: DAergic PC12 nuclei counterstained with 
Hoechst 33342. Red: MitoSOX™ Red superoxide indicator signal. 
A marked red signal is evident in DAergic PC12 cells treated with 
HG or diethyldithiocarbamate (DDC) (control [CTRL] + DDC). 
Red fluorescence was less intense in cells treated with CTRL medium, 
RESV alone or when RESV was added in HG medium (HG RESV). (B) 
Semi-quantitative image analysis. ***p < 0.001 compared with CTRL, 
+++p < 0.001 compared with HG, as determined by one-way one-way 
analysis of variance (ANOV A), followed by Tukey's multiple-
comparison test. Fluorescence units (F.U). 
Resveratrol reduces high glucose-induced apoptosis 
We measured DNA denaturation induced by formamide, a specific hallmark 
of apoptosis (Frankfurt and Krishan, 2001), using a ssDNA specific antibody 
(Figure 2.2A). Specific apoptotic DNA denaturation is observed in early as well as 
in late apoptotic cells. HG condition showed a 43% increase in apoptotic cells in 
comparison to CTRL wells. This increment was fully reversed by RESV treatment in 
HG medium (Figure 2.2A). MANN medium did not yield significant apoptosis. 
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We then examined the effect of HG and RESV on later events of the apoptotic 
cascade leading to DNA fragmentation. Detection of cleaved caspase-3, the terminal 
effector caspase responsible for late apoptosis-mediated DNA fragmentation (Fan et al., 
2005), was conducted by immunofluorescence alongside a TUNEL assay measuring 
DNA degradation (Figure 2.2B and C). In the HG condition, immunofluorescence 
revealed the presence of cleaved caspase-3 positive cells (Figure 2.2C, red signal), 
while TUNEL assay stained numerous nuclei undergoing DNA fragmentation 
(Figure 2.2C, green signal). Total nuclei were stained with DAPI (Figure 2.2C, blue 
signal). DAergic PCI2 cells were considered to be in late apoptosis when they hosted 
both caspase-3 activation and DNA fragmentation events (Figure 2.2C, cells pointed by 
white arrows). Treatment with RESV for 24 h clearly reduced the presence of apoptotic 
nuclei as implied by the lower number ofDAergic PCI2 cells exhibiting both green and 
red fluorescence . The number of apoptotic cells was also counted (Figure 2.2B), 
as described in the Materials and Methods section. Administration of RESV decreased 
the number of apoptotic cells compared to the HG condition. MANN medium did not 
yield a significant rise in apoptotic cells compared to CTRL. To show that caspase-3 
activation is a key step in the HG-induced apoptotic pathway, DAergic PCI2 cells were 
pretreated with 50 ).lM Z-DEVD-FMK, a cell-permeable selective caspase-3 inhibitor, 
followed by treatment with HG with or without RESV (Figure 2.2B and C). 
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RESV reduces HG-induced apoptosis in DAergic PC12 cells. 
Continued on next page. 
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(Continued.) (A) Histogram of specific apoptotic DNA denaturation by 
formamide in DAergic PC12 cells as detected with a monoclonal 
antibody against single-stranded DNA (ssDNA). CTRL, MANN and 
RESV alone do not affect specific apoptotic DNA denaturation. 
HG increases apoptotic DNA denaturation. Treatment of HG-exposed 
cells with RESV elicits a significant decrease in specific apoptotic DNA 
denaturation (HG RESV). (B) The number of apoptotic DAergic cells 
among 300 randomly chosen DAergic cells was counted on 10 different 
optical fields from 3 slides per group, as illustrated in panel C on a 
subsequent page. (C) Microphotographs of immunofluorescence detection 
of apoptotic DAergic PC12 cells. Blue: DAergic PC12 nuclei 
counterstained with 4',6-diamidino-2-phenylindole (DAPI). Red: anti-
cleaved caspase-3 signal. Green: Terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL) staining of nuclei exhibiting DNA 
fragmentation. Triple-staining (cells points by white arrows) clearly 
reveals several apoptotic cells on si ides treated with HG and fewer 
apoptotic cells when DAergic PC12 cells are treated with CTRL medium, 
RESV alone or wh en RESV is administered in HG conditions 
(HG RESV). To show that caspase-3 activation is a key step in the 
HG-induced apoptotic pathway, DAergic PC12 cells were pretreated with 
50)lM of fluormethylketone-conjugated tetrapeptide Z-DEVD-FMK, 
a cell-permeable caspase-3 inhibitor, followed by treatment with HG, 
with or without RESV (HG- Z-DEVD-FMK and HG RESV- Z-DEVD-
FMK, respectively). MANN condition is similar to CTRL cells. Enlarged 
microphotographs: HG and HG RESV merge microphotographs, to show 
apoptotic nuclei in these key conditions. **p < 0.01 and ***p < 0.001 
compared with CTRL, +p < 0.05, ++p < 0.01 and +++p < 0.001 
compared with HG, as determined by one-way ANOVA, followed by 
Tukey's multiple-comparison test. 
In order to further support these findings, we analyzed the expression of several 
proteins acting in the apoptotic cascade. Western blotting was performed on total 
proteins extracted from DAergic PC 12 cells treated with HG or CTRL medium, with or 
without RESV (Figure 2.3). We analyzed the pro-apoptotic Bax and anti-apoptotic Bcl-2 
protein ratio (Figure 2.3A) reported to be correlated with apoptosis (Cory and Adams, 
2002). A high BaxlBcl-2 ratio favors the release of mitochondrial factors leading to the 
activation of effector caspases in the apoptotic cascade (Kang and Reynolds , 2009). 
Our results demonstrate that the administration of HG medium for 96 h increases the 
Bax/Bcl-2 ratio two-fold compareq to CTRL medium, supporting that HG-induced 
apoptosis in DAergic PC12 cells is mediated, at least in part, by the mitochondrial 
pathway (Figure 2.3A, histogram full grey line). The HG-induced raise of the Bax/Bcl-2 
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ratio was fully reversed in DAergic PCl2 cells treated with RESV. Explicitly, 
HG medium increases Bax expression (Figure 2.3A, histogram white bars, Bax Western 
bands) but does not modulate Bcl-2 (Figure 2.3A, histogram black bars, Bcl-2 Western 
bands). RESV reverses the HG-induced increase in Bax expression and increases Bcl-2 
expression. We also examined the ratio of full-Iength PARP-l on inactivated cleaved 
PARP-l (Figure 2.3B). As Chaitanya et al. (2010) have demonstrated, PARP-l is a 
major player in the prevention of programmed cell death and its cleavage by activated 
caspase-3 is a hallmark of apoptosis. HG treatment markedly reduced full-length/cleaved 
ratio, which was fully reversed by RESV administered in HG medium (Figure 2.3B, 
histogram full grey line) . MANN medium did not have a substantial effect on either the 
Bax/Bcl-2 ratio or the P ARP-l full-lengthlcleaved ratio. HG increased PARP-l cleavage 
while RESV prevented this rise (Figure 2.3B, histogram black bars, cleaved P ARP-l 
Western bands). Full-length PARP- Iexpression was not affected in any condition 
(Figure 2.3B, histogram white bars, full-length PARP-l Western bands). 
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RESV modulates the expression of apoptotic protein markers. 
(A) Effect of RESV on the B cell lymphoma 2 (Bcl-2)-associated X 
protein (Bax)/Bcl-2 ratio in DAergic PC12 cells (full grey line). 
CTRL, MANN and RESV al one do not modulate the Bax/Bcl-2 ratio. 
HG increases the Bax/Bcl-2 ratio significantly and the addition of RESV 
to HG medium strongly prevents this increment (HG RESV). Bottom: 
Bax and Bcl-2 bands, as revealed by Western blotting. (B) Analysis of 
poly(ADP-ribose) polymerase (PARP-l) protein expression. These results 
are presented as the ratio of full-length (white bars)/cleaved (black bars) 
PARP-l. CTRL, MANN and RESV alone do not modulate the PARP-l 
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ratio in DAergic PC12 cells (full grey line). A decrease ofPARP-l ratio 
is apparent in HG condition. When RESV is delivered in HG condition, 
a significant increase of full-Iength/cleaved P ARP-l was evident 
(HG RESV). Bottom: Western blot bands of full-Iength and cleaved 
PARP-l. **p < 0.01, ***p < 0.001 compared with CTRL and +p < 0.05, 
+++p < 0.001 compared with HG, as determined by one-way ANDV A, 
followed by Tukey's multiple-comparison test. 
Resveratrol modulates p53 and glucose-regulated protein 75 subcellular localization 
and colocalization 
We studied the expression levels ofp53, a tumor suppressor, and GRP75, a stress 
response protein (Figure 2.4). In several models, GRP75 binds and inactivates pro-
apoptotic p53 in the cytosol, therefore helping to prevent apoptosis. In order to elucidate 
this alleged relationship between both markers, protein levels were measured in the 
cytoplasm and the nucleus (p53) or in the cytoplasm and the mitochondria (GRP75) 
(Figure 2.4A and B). Treatment of DAergic PC12 ce lis with HG medium for 96 h 
noticeably decreased p53 cytoplasmic/nuclear ratio (Figure 2.4A, histogram full grey 
line). This was prevented by administration with RESV. Expressly, HG increased p53 
expression in the nucleus (Figure 2.4A, histogram black bars, p53 nuclear Western 
bands) while it did not seem to affect cytoplasmic levels (Figure 2.4A, histogram white 
bars, p53 cytoplasmic Western bands). RESV in HG medium preserved p53 levels 
at CTRL range in both compartments. HG administration for 96 h increased GRP75 
expression both in the cytoplasm and in the mitochondria (Figure 2.4B, histogram white 
and black bars, GRP75 mitochondrial and cytoplasmic Western bands). Treatment with 
RESV in HG medium prevented GRP75 levels from rising in the cytoplasmic 
fraction only. The result is a small but significant decrease m the GRP75 
cytoplasmic/mitochondrial ratio (Figure 2.4B, histogram full grey line). MANN medium 
did not affect the expression of either GRP75 or p53. 
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Effeet of RESV on the subeellular loealization of p53 and GRP75. 
(A) HG medium significantly increases nuclear localization of p53 
(black bars) and administration of RESV in HG medium prevents this 
increase (HG RESV). RESV and MANN alone do not modulate p53 
cellular localization. Cytoplasmic p53 (white bars) is not affected in any 
condition. Ratio of cytoplasmic/nuclear p53 is decreased in HG condition, 
which is prevented by RESV administration (HG RESV, full grey line). 
Bortom: p53 , cytoplasmic fraction (C) purity marker tyrosine hydroxylase 
(TH) and nuclear fraction (N) purity marker histone deacetylase 1 
(HDAC1) bands as revealed by Western blorting. (B) Effect of RESV on 
the cellular localization of glucose-regulated protein 75 (GRP75) in 
DAergic PC12 cells. HG treatment increases both cytoplasmic and 
mitochondrial content of GRP75 . Administration of RESV in HG 
medium (HG RESV) significantly reduces cytoplasmic levels of GRP75 
(white bars) while it does not amend mitochondrial levels (black bars). 
Ratio of cytoplasmic/mitochondria GRP75 is decreased in HG condition, 
which is prevented by RESV administration (HG RESV, full grey line). 
Bottom: GRP75, cytoplasmic fraction purity marker glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) and mitochondrial fraction (M) 
purity marker voltage-dependent anion channel (VDAC) bands, 
as revealed by Western blotting. **p < 0.01 , ***p < 0.001 compared with 
CTRL and +p < 0.05, ++p < 0.01 compared with HG, as determined by 
one-way ANOV A, followed by Tukey' s multiple-comparison test. 
Finally, to evaluate the potential for GRP75 and p53 to interact in the cytoplasm, 
immunofluorescence colocalization measurements were performed following treatment 
ofDAergic PCI2 cells with HG medium with or without RESV. Scatter plots show that 
p53 (Figure 2.5A, green signal distribution) and GRP75 (Figure 2.5A, red signal 
distribution) signaIs are mainly independent from one another except for slight 
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colocalization (Figure 2.5A, plots and micrographs, Figure 2.5B). However, treatment 
with HG medium still appears to yield more colocalization on the scatter plot 
(Figure 2.5A, plots), which is also supported by the colocalization rate histogram 
(Figure 2.5B). Overlaid pictures ofp53 and GRP75 staining (Figure 2.5A, micrographs) 
in CTRL, MANN, and RESV condition show dispersed punctual staining (white signal) 
in the cytoplasm, while in the HG condition a perinuclear dense staining is clearly 
visible. Administration of RESV in HG medium reveals a more scattered staining than 
in HG condition alone. 
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Figure 2.5 RESV modulates p53 and GRP75 colocalization. 
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(Continued.) (A) Scatter plots and corresponding overlaid micrographs of 
p53 and GRP75 . Scatter plots show signal intensity for p53 (green signal) 
on the y axis and GRP75 (red signal) on the x axis. Each dot represents 
one event of fluorescent signal. Thresholds for green and red signal are 
optimized at 85% (two white lines) and mean background at 10% (arched 
delimitation), in each condition. Signal is colocalized when signais in 
scatter plots are located between the threshold lines on the outside of the 
background delimitation. White signal in microphotographs indicates 
high probability of colocalization. CTRL, RESV and MANN conditions 
are similar in that p53 and GRP75 colocalization is scarce and scattered in 
the cell cytoplasm. HG increases the white signal around the perinuclear 
area as well as the nurnber of dots in the region of interest on the plot. 
Treatment with RESV yields a scatter plot and overlaid white signal 
(HG RESV) similar to the CTRL condition, suggesting its potential to 
diminish colocalization between GRP75 and p53. (B) Histogram 
depicting the colocalization rate of GRP75 and p53 observed in panel A. 
HG increases the colocalization rate significantly. RESV administration 
in HG medium reverses this increase in colocalization rate (HG RESV). 
Ail other conditions are similar to CTRL. ***p < 0.001 compared with 
CTRL and ++p < 0.001 compared with HG, as determined by one-way 
ANOVA, followed by Tukey' s multiple-comparison test. 
We previously reported that several natural polyphenols, including the stilbene 
RESV, exert powerful neuroprotective activity in DAergic PC12 cells against the 
oxidative burden triggered by the administration of the potent parkinsonian toxin 
1-methyl-4-phenyl-1 ,2,3,6-tetrahydropyridine (MPTP) in vivo (Blanchet et al. , 2008) or 
its active metabolite I-methyl-4-phenylpyridinium (MPP+) in vitro (Bournival et al. , 
2009; Gagné et al. , 2003 ; Lahaie-Collins et al. , 2008). Since hyperglycemia has also 
been listed as a growing risk factor for PD (Hu et al. , 2007; Jagota et al., 2012; 
Sun et al. , 2012), we focused our study on the neuroprotective effect of RESV on 
HG-induced oxidative stress and apoptosis in DAergic PC12 cells with regard to GRP75 
and p53 localization. 
The Diabetes Control and Complications Trial (1993) together with the u.K. 
Prospective Diabetes Study (1998) have determined that hyperglycemia is the culprit to 
blame for tissue damage in type l and type II diabetes. Currently, we know that 
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overproduction of superoxide is the single upstream event leading to the following 
pathways involved in glucose toxicity (Giacco and Brownlee, 2010): 1) increased flux 
of glucose and other sugars through the polyol pathway; 2) increased intracellular 
formation of advanced glycation end-products (AGEs); 3) increased expression of the 
receptor for AGEs and its activating ligands; 4) activation of protein kinase C (PKC) 
isoforms; 5) overreactivity of the hexosamine pathway. The formation of AGEs and 
activation of AGE receptors (Shaikh and Nicholson, 2008), the activation of PKC (Aoki 
and Li, 20 Il) and the dysfunction of the polyol pathway (Ahrned et al., 2009) have been 
identified as contributors in the development of PD. These mechanisms suggest a strong 
link between neuronal apoptosis observed in PD and hyperglycemic damage in diabetes 
(Klein et al., 2004; Li et al., 2002; Li et al., 2008) . 
In this study, we demonstrated the defensive role of RESV in counteracting 
cellular distress parameters evoked by HG in DAergic PC12 cells. We tested 
NGF-differentiated PC 12 cells, a known, reliable and efficient model for the 
investigation of oxidative stress, apoptosis and neuroprotection of DAergic neurons 
(Bournival et al., 2012; Gélinas and Martinoli, 2002; Lahaie-Collins et al., 2008). 
Since oxidative stress is an essential factor in glucose toxicity and in the pathogenesis of 
PD, we investigated whether RESV protects DAergic PC12 cells by reducing levels of 
mitochondrial superoxide in HG condition. Our results show that RESV effectively 
diminishes superoxide production after as early as 3 h. In PD, superoxide reacts with 
iron cations to form hydroxyl radical (Ramas arma, 2012), known to exert very 
deleterious effects on DNA, lipids and proteins. This ROS can also react with nitric 
oxide, an important signaling molecule in the brain, to form peroxynitrite, a powerful 
oxidant shown to play a significant role in protein aggregation pertinent to PD 
(Danielson and Andersen, 2008). 
It is currently weil known that oxidative stress may cause apoptosis through 
several pathways: 1) ROS-induced expression or activation of nuclear factor-kappa B 
(NF-KB) (Gloire et al. , 2006); 2) mitochondria-mediated cell apoptosis (Circu and Aw, 
2010); 3) ROS-mediated DNA damage and p53 activation (Liu and Xu, 2011); 
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4) stress-activated protein kinases pathway to apoptosis (Johnson and Nakamura, 2007). 
We performed a set of experiments to investigate the apoptotic cascade in DAergic 
PC 12 cells ensuing oxidative stress to further demonstrate the preventive role of RESV. 
A specific apoptotic DNA denaturation assay demonstrated that RESV significantly 
prevents apoptosis in cells exposed to HG. We further examined markers of late 
apoptosis to determine whether the prote in cascade leads to terminal events such as the 
irreversible fragmentation of DNA. RESV in HG clearly reduced the number of 
apoptotic PC12 cells in comparison to the HG condition alone as shown by the decline 
in TUNEL and cleaved caspase-3 double-positive cells. Another target of activated 
caspase-3 is PARP-l , a protein known to participate in the repair of damaged DNA 
(Wang et al. , 2012). Our findings reveal that the PARP-l protein ratio, full-Iength versus 
cleaved, was decreased after HG treatment and was then improved by RESV 
administration, hence supporting once more the neuroprotective anti-apoptotic role of 
RESV in a HG paradigm. In addition, the Bax and Bcl-2 expression was studied to 
determine the apoptotic events surrounding the mitochondria. Bax contributes to the 
leakiness of the outer mitochondrial membrane, while Bcl-2 blocks the permeability 
transition pore, thus inhibiting mitochondria-mediated programmed cell death (Smith 
et al., 2008). The rise in the Bax to Bcl-2 ratio is a characteristic feature in apoptosis 
(Cory and Adams, 2002) equally observed in glucose toxicity (Allen et al. , 2005) and in 
several models of PD including hum an post-mortem brains (Vila and Perier, 2008). 
Our data reveal that the Bax/Bcl-2 protein ratio is increased after HG administration, and 
is decreased by RESV treatment in the HG condition, strongly suggestive of a role for 
mitochondrial dysfunction in the mechanisms underiying the apoptosis of DAergic 
neurons in our cellular paradigm of hyperglycemia. 
GRP75 has often been linked to PD pathogenesis as reported in studies showing 
binding properties to PD-associated proteins in the mitochondria (Jin et al., 2005 , 2006, 
2007; Li et al. , 2005; Rakovic et al., 2011) and reduced levels of the protein in 
post-mortem PD brain samples (Burbulla et al. , 2010; Jin et al. , 2005; Shi et al. , 2008). 
While GRP75 is mainly confined to the outer membrane of mitochondria, several studies 
have shown that it may bind and sequestrate pro-apoptotic p53 in the cytosol thereby 
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preventing its entry ln the nucleus, impeding apoptosis and ultimately promoting 
p53 degradation by the MDM2 proteasome degradation pathway (Kaul et al., 2001, 
2005; Wadhwa et al., 2002). Such studies were mainly conducted in cancer cells (Kaul 
et al., 2001 , 2005; Wadhwa et al., 2002) or in naïve, mitotic PC12 cells (Guo et al. , 
2009; Li et al., 2011). Our results obtained in post-mitotic PC12 cells, show that 
HG treatment increases GRP75 expression in the cytoplasm as weIl as in mitochondria 
thus suggesting that GRP75 is induced by HG cellular stress. While RESV reduced 
GRP75 levels in the cytoplasm, it did not ensure a significant effect in diminishing 
mitochondria GRP75 localization. Apparently, in our cellular paradigm, RESV 
modulates the subcellular distribution of GRP75 by preventing cytoplasmic levels from 
rising. RESV may be responsible for quenching HG-induced stress signais that promote 
the induction of GRP75 in the cytoplasm. Moreover, p53 localization is increased in the 
nucleus, which points toward a pro-apoptotic effect of HG on DAergic PC12 cells. 
RESV in HG medium maintains the cellular distribution of p53 , which partially accounts 
for its anti-apoptotic properties. Altogether, these results show an increase of GRP75 in 
the cytoplasm while p53 levels rise significantly in the nucleus in HG condition, 
suggesting relatively weak interaction between both markers in post-mitotic cells. 
Colocalization studies deepened our understanding of the relationship between GRP75 
and p53 in our cellular model. We show that GRP75 and p53 have a potential to bind in 
the cytoplasm but to a limited extent. Binding in HG condition is significantly enhanced, 
perhaps due to increased expression of both pro teins in the cytoplasm, but still remains 
limited. We show for the first time that post-mitotic DAergic PC12 cells exert weak 
binding of GRP75 and p53, which contrasts with findings in non-differentiated mitotic 
PC12 cells (Guo et al. , 2009; Li et al. , 2011). Moreover, GRP75 levels are decreased in 
post-mortem PD brains (Burbulla et al., 2010; Jin et al., 2005; Shi et al. , 2008) while we 
see an increase of expression in HG condition. Perhaps long-term mitochondrial 
dysfunction is responsible for the depletion of stress markers such as GRP75 in PD. 
Altogether, our results demonstrate that HG-induced oxidative stress and apoptosis 
of DAergic PC12 cells can be improved by RESV, sustaining an important role for this 
naturally occurring polyphenol in diabetes treatment. RESV has been the object of 
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several diabetes studies because of its ability to improve insulin sensitivity, protect 
pancreatic ~ cells and control glycaemia (Lee et al., 2012; Milne et al., 2007; Szkudelski 
and Szkudelska, 2011). lndeed, RESV protects against retinopathy in rats with diabetes 
(Soufi et al., 2012) and prevents nephropathy in db/db mice by inhibiting lipotoxicity-
related apoptosis and oxidative stress in the kidney (Kim et al., 2013). Additional 
beneficial effects of the stilbene RESV may contribute to alleviate obesity-induced 
metabolic complications (Rosenow et al., 2012) often related with diabetes. A recent 
clinical study has found oral administration of RESV to be effective in improving 
glycaemia in type 2 diabetes mellitus (Bhatt et al. , 2012). 
Even though RESV is principally metabolized into its glucoronide and sulfate 
conjugates, recent data show that these metabolites may possess beneficial properties 
(Delmas et al. , 20 Il). lncreased bioavailability due to a synergistic effect with other 
polyphenols or compounds, such as curcumin or the glycemic control drug metformin, 
must also be taken into account (Bruckbauer and Zernel, 2013 ; Du et al. , 2013). Besides, 
recent pharmacological advances have improved bioavailability of RESV (for details see 
Amiot et al. , 2013; Neves et al., 2013). Finally, the potential beneficial properties of 
RESV on hurnan health are broadly displayed in the literature and justify the need to 
further unravel the powerful cellular role of this dietary polyphenol. 
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3.2 Résumé 
De nombreuses études épidémiologiques soutiennent une corrélation entre le 
diabète et les maladies neurodégénératives liées à l'âge, telles les maladies d'Alzheimer 
et de Parkinson. En effet, l'hyperglycémie engendre un stress oxydant auquel est 
vulnérable le système nerveux central. Nous avons récemment démontré que des 
concentrations physiologiquement élevées de glucose causent un stress oxydant menant 
à la mort de neurones dopaminergiques en culture. Les altérations dopaminergiques 
survenant avec l'âge dans le diabète demeurent méconnues. Dans cette optique, le but de 
notre étude était de caractériser l'état des deux voies dopaminergiques principales du 
système nerveux central dans l 'hyperglycémie chronique. Nous avons donc employé un 
modèle modéré de rat diabétique, soit le paradigme nicotinamide-streptozotocine 
permettant le maintien d' une hyperglycémie à long terme. Spécifiquement, nous nous 
sommes attardés à la voie nigrostriée, bien connue pour son rôle dans le contrôle de 
la motricité et dans la maladie de Parkinson, ainsi qu'à la voie mésocorticolimbique, 
un circuit voisin davantage associé au système de la récompense. Les neurones et 
les cellules gliales ont fait l'objet d'analyses 3 et 6 mois suivant l'induction de 
l'hyperglycémie. Nos résultats démontrent une neurodégénérescence préférentielle de 
la voie nigrostriée, celle-ci étant accompagnée d'une prolifération marquée des 
astrocytes et de la mort des cellules micro gliales à 6 mois. Des tests comportementaux 
ont confirmé l'existence de déficits moteurs évoquant les symptômes de la maladie 
de Parkinson, survenant de cette neurodégénérescence. La somme de ces résultats 
démontre une relation entre l'hyperglycémie et la mort préférentielle des neurones 
dopaminergiques de la VOle nigrostriée, appuyant de surcroît les études 
épidémiologiques soulignant le risque que comporte un diabète préexistant pour le 
développement de la maladie de Parkinson. 
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3.3 Full article in English: Dopaminergic neurodegeneration in a rat model of 
long-term hyperglycemia: preferential degeneration of the nigrostriatal 
motor pathway 
Abstract 
Epidemiological evidence suggests a correlation between diabetes and 
age-related neurodegenerative disorders, including Alzheimer's and Parkinson ' s 
diseases. Hyperglycemia causes oxidative stress in vulnerable tissues such as the brain. 
We recently demonstrated that elevated levels of glucose lead to the death of 
dopaminergic neurons in culture through oxidative mechanisms. Considering the lack of 
literature addressing dopaminergic alterations in diabetes with age, the goal of this study 
was to characterize the state of two critical dopaminergic pathways in the nicotinamide-
streptozotocin rat model of long-term hyperglycemia, specifically the nigrostriatal motor 
pathway and the reward-associated mesocorticolimbic pathway. Neuronal and glial 
alterations were evaluated 3 and 6 months after hyperglycemia induction, demonstrating 
preferential degeneration of the nigrostriatal pathway complemented by a noticeable 
astrogliosis and loss of microglial cells throughout aging. Behavioral tests confirmed the 
existence of motor impairments in hyperglycemic rats that resemble early parkinsonian 
syrnptomatology in rats, ensuing from nigrostriatal alterations. These results solidify the 
relation between hyperglycemia and nigrostriatal dopaminergic neurodegeneration, 
providing new insight on the higher occurrence of Parkinson's disease in diabetic 
patients. 
Introduction 
Glucose is the obligate energy substrate of adult neurons. Owing to the 
preponderant expression of glucose transporter 1 (GLUTl) at the blood-brain 
barrier (Anraku et al. , 2017) and GLUT3 at the neuron plasma membrane (Patching 
et al. , 2017, Simpson et al. , 2007), uptake overwhelmingly occurs in an insulin-
independent fashion. Thus, intraneuronal glucose concentrations directly depend on 
extracellular concentrations, i.e. , on plasma glucose concentrations (Jacob et al., 2002) . 
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Indeed, neurons belong to the most severely hit targets in hyperglycemia, along 
with mesangial and capillary endothelial ceUs (for review see Brownlee, 2005). 
Well appreciated is the fact that persistent hyperglycemia induces oxidative stress 
occasioning damage in the peripheral nervous system, as is the case in comorbid 
neuropathies of uncorttrolled diabetes (Rajabally, 2017). Fewer studies have focused 
their attention on hyperglycemia in the human central nervous system (Moulton et al., 
2015) but go as far as to draw relationships between diabetes and age-related 
neurodegenerative disorders, including Alzheimer's and Parkinson's diseases (Jagota 
et al., 2012, Vicente Miranda et al., 2016, Vieira et al., 2017, Vignini et al., 2013). 
Notwithstanding the wealth of evidence supporting a toxic role for glucose ln 
neurons of the central nervous system (see for review Tomlinson and Gardiner 2008, 
Vicente Miranda et al., 2016), details are lacking in the bigger picture. Most studies 
have addressed neurodegeneration in discrete brain regions on a short-term scale 
(Do Nascimento et al., 2011, Kamboj and Sandhir, 2011), which do not represent 
temporal or spatial breadths of hyperglycemic distress in aging diabetic patients. 
Moreover, literature describing dopaminergic neurodegeneration in hyperglycemic 
models remains modest. Our group demonstrated a role for chronic glucose exposure in 
apoptotic death of dopaminergic neurons through oxidative mechanisms (Bournival 
et al., 2012, Renaud et al., 2014) and several studies report dopaminergic alterations in 
diabetes or acute hyperglycemia (Lozovsky et al., 1981 , Murzi et al. , 1996, Sevak et al. , 
2007). Nevertheless, the state of entire dopaminergic pathways in the long-term has not 
been inquired. 
In order to improve our understanding of central dopaminergic neurodegeneration 
in hyperglycemia, we focused on two critical central dopaminergic systems, namely 
the nigrostriatal and mesocorticolimbic pathways (for review see Haber, 2014). 
The nigrostriatal pathway is primarily involved in the generation of movement. 
Cell bodies of nigrostriatal neurons are found in the substantia nigra pars compacta 
(SNe), lodged in the ventral midbrain, and extend their dopaminergic fiber terminaIs to 
the dorsal striatum (DS). The mesocorticolimbic pathway is often termed the reward 
system. Cell bodies of mesocorticolimbic neurons are also found in the ventral midbrain, 
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though in a neighboring subregion named the ventral tegmental area (VT A). 
This pathway innervates both the ventral striatum (VS, mesolimbic pathway), 
which contains the nucleus accumbens (NAcc) and the olfactory tubercle (ûT), as weil 
as the prefrontal cortex (PFC, mesocortical pathway) (Squire et al. , 2008). We thus 
evaluated neurodegeneration and analyzed glial populations in these regions to obtain a 
better appreciation of the global state of the dopaminergic pathways in long-term 
hyperglycemia. Finally, behavioral assessments were carried out to uncover motor and 
cognitive alterations possibly expressed as a consequence of neurodegeneration. 
Research design and methods 
Subjects 
A total of 91 rats were used ln this study. For immunoblotting, 
immunohistochemical and behavioral studies, two different cohorts totaling 61 male 
Sprague-Dawley rats (Charles River, St-Constant, Canada) weighing 175-200 g and 
aged 5-6 weeks were housed under standard laboratory conditions (12 h light/dark 
cycle). In Italy, motor and cognitive behavior analyses were repeated and 
complementary microdialysis studies were carried out in 30 male Sprague-Dawley rats 
(Harlan Italy, Udine, Italy) of the same weight and age, also housed under standard 
laboratory conditions. In all experiments, standard food and water were available 
ad libitum. Rats were acclimated for 2 weeks and were therefore 7 -8 weeks of age upon 
induction of hyperglycemia described below. 
AH experiments were conducted in accordance with the guidelines for animal 
experimentation of the EU directives (2010/63/EU; L.276; 22/09/2010), of the Ethical 
Committee of the University of Cagliari , of the AnimaIs for Research Act and following 
the legislation and policies of the Canadian Council on Animal Care, as well as with the 
guidelines established by the Animal Care Committee of the Université du Québec 
(Trois-Rivières) (2014-M.G.M.5) . Maximal efforts were made to minimize discomfort 
and numbers of animaIs used. 
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Induction of long-term hyperglycemia 
Rats were randomly divided Ïnto two groups; control (CTRL) and hyperglycemic 
(HG). Long-term hyperglycemia was induced in fasted rats (overnight, 12-16 h) by a 
single i.p. injection of freshly dissolved streptozotocin (STZ, 0.1 M cold citrate buffer, 
pH 4.5, 55 mg/kg b.w.). Nicotinamide (NA, 100 mg/kg b.w.) dissolved in physiological 
saline was administered i.p. exactly 20 min prior to the STZ injection to minimize the 
destruction of insulin-producing pancreatic beta cells, yielding HG rats that would 
survive for 6 months without the need for glycemia-Iowering treatments (Badole et al., 
2015, Masiello et al., 1998). CTRL rats received i.p. injections ofvehicles. All rats were 
injected on mornings within a time frame of 3 h. Hyperglycemia was confirmed 72 h 
after NA-STZ injections using a digital glucose meter (UltraMini with One Touch Ultra 
strips) to analyze blood collected from the tail vein. Only rats with a glycemia steadily 
above 10 mM were used in this study. Exhaustive metabolic follow-ups were conducted 
regularly throughout experiments (Supplementary Figure SI). 
Motor behavior assessments 
We investigated the possibility that the degeneration of neurons and neuronal 
fibers may be accompanied by alterations in motor behavior. Rats were submitted to 
motor behavior assessments, beginning with baseline evaluations prior to hyperglycemia 
induction, followed by trials 3 and 6 months later. 
Stepping test and forepaw adjusting step test: Both tests were adapted for 
non-parkinsonian models, implying bilateral rende ring of results, and conducted as 
previously described (Pinna et al., 2007). The stepping test measures the rapidity of rats 
to initiate movement and cross a beam. Briefly, rats were held with one forelimb placed 
at the beginning of a beam leading to the home cage. The initiation time was measured 
from the moment the free forelimb was placed on the beam until the rat started to step 
using the same forelimb. Time to reach the home cage and nurnbers of strides were 
also recorded. The adjusting step test measures akinesialbradykinesia (Chang et al., 
1999) in rats by dragging their forepaw sideways on a surface at a constant speed. 
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Briefly, rats were moved s10wly sideways along the table surface by an experimenter, 
first in a forehand and then in a backhand direction. Adjusting steps made in forward 
and backward directions were counted. 
Horizontal bar test: Healthy rats typically correct their position quickly when 
placed in an awkward posture. To evaluate the ability of rats to correct an extemally 
imposed posture, we performed a horizontal bar test (Sanberg et al. , 1981). Following a 
10-min habituation phase to the test cage, rats were tested by gently placing both 
forepaws on a horizontal bar (0.8 cm diameter, 3 cm from floor). Descent latency was 
measured as the time span from placing the animal on the bar until both paws were 
removed. The test cage was washed after each animal. 
Cognitive behavior 
Novel object recognition task: Evaluation of novel object recognition (NOR) 
performance is widely used for assessing non-spatial working memory in rodents 
(Ennaceur, 2010), a function regulated by limbic and cortical areas such as the 
hippocampus (HPC), NAcc and PFC. NOR experiments were performed as previously 
described (Simola et al., 2008). The experimental procedure consisted of habituation, 
acquisition and testing phases. Habituation to the test cage took place on the day before 
tests during a single 5-min trial. The following day, the acquisition phase was performed 
by placing the rat in the test cage together with two identical copies of an object 
(familiar objects). Rats were left to freely explore the objects for 3 min. The testing 
phase took place 60 min after acquisition and consisted in exposing the rat to one copy 
of the objects presented previously and a novel object. Results were obtained 3 months 
after injections but not after 6 months since HG rats develop cataracts and their sight is 
likely to be impaired. 
Sacrifices and tissue harvest 
At 3 or 6 months, rats were intracardially perfused with ice-cold PBS containing 
protease and phosphatase inhibitors. The brain was sectioned into hemispheres. One was 
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irnmediately used to sequester the striatum, the midbrain and the PFC, which were 
frozen in dry ice-cooled isopentane and stored at -80°C for later irnmunoblotting 
analyses or intraceUular glucose quantification in tissues. The HPC was also harvested 
for comparison purposes, as it constitutes a secondary DA hub receiving dopaminergic 
input from the VT A through the hippocampal-VT A loop (Lisman and Grace, 2005). 
The other hemisphere was post-fixed in 4% paraformaldehyde, cryoprotected through 
gradients of sucrose, and conserved at -80°C for immunohistochemical analyses. 
The Paxinos and Watson rat brain atlas (1998) served as a reference for aU tissue 
harvests. 
Immunohistochemistry 
Frozen post-fixed brain hemispheres were cut into 20 I-lm-thick coronal free-
floating seriaI sections. By systematic random sampling (West, 2012), one out of every 
six sections was immunoreacted with antibodies raised against either the specific 
dopaminergic neuron marker anti-tyrosine hydroxylase (anti-TH), the general neuronal 
marker anti-NeuN, the astrocyte marker anti-glial fibriUary acidic protein (anti-GFAP), 
or the microglial ceU marker anti-ionized calcium-binding adapter molecule l (anti-
Thal) (for list of antibodies, concentrations and manufacturers see Supplementary 
Table SI). Then, sections were incubated with a HRP-conjugated secondary antibody, 
revealed with 3,3' -diaminobenzidine, mounted on microscope slides, dehydrated, and 
analyzed under a microscope in brightfield mode (MBF Bioscience, WiUiston, VT, 
USA). Neuroanatomical loci were determined according to the atlas of Paxinos and 
Watson (1998) and were identicaUy delimited in aU sections of the same anteriority 
between animaIs. Because of the systematic random sampling method, the same 
numbers of sections at the same anteriorities per region were consistently analyzed in 
each animal, foUowing guidelines already established for stereology (West, 2012). 
Total counts of overaU neurons (NeuN+), dopaminergic neurons (TH+), astrocytes 
(GFAP+) and microglial ceUs (Tha1+) were performed in the SNc and in the VTA 
(bregma -4.80 to -6.30 mm) using the manual ceU counting marker function provided by 
the NIH ImageJ software version 1.49. In the DS (lateral and media l, bregma 2.2 to 
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-1.0 mm), the VS (NAcc and OT, bregma 2.7 to 0.5 mm), the PFC (bregma 4.0 to 
2.0 mm) and the HPC (bregma -2.3 to -6.0 mm), we counted total numbers of NeuN+, 
GF AP+ and Iba+ cells. Density of TH+ dopaminergic terminais in the striatum (Iateral, 
medial, NAcc and OT, refer to aforementioned bregmas) was evaluated by densitometric 
assays using ImageJ. These were systematically performed on non-overlapping spherical 
regions of interest (3 x 1 mm2 for lateral or medial DS; 5 x 0.5 mm2 for NAcc or OT). 
Immunoblotting 
Frozen tissues were homogenized by steel bail milling in RIPA buffer and proteins 
were quantified by the bicinchoninic acid method before running them in a SDS-PAGE. 
Proteins were transferred cnte polyvinylidene difluoride membranes, which in tum 
were incubated with primary antibodies raised against the dopaminergic markers TH 
or dopamine transporter (DAT), or against the general neuronal marker NeuN. 
Following incubation with HRP-conjugated secondary antibodies, blots were finally 
developed with an enhanced chemiluminescence substrate solution and immunopositive 
chemiluminescent signaIs were visualized using the AlphaEase FC imaging system and 
software (San Leandro, CA, USA). Densitometric blot analyses were performed using 
ImageJ. ~-tubulin blots served as a loading comparative standard and ail immunoblotting 
results have been accordingly normalized to ~-tubulin levels. 
Intracerebral microdialysis in freely moving rats 
Two microdialysis trials in separate experiment-naïve groups of rats were 
conducted to verify extracellular glucose or DA concentrations in discrete brain regions 
in order to support and complete data obtained by the other techniques in this study. 
Probe preparation: Vertical microdialysis probes were prepared with AN69 
membranes (Hospal Dasco, Bologna, Ital y) according to the method described by 
Di Chiara et al. (1993) further modified by Tanda et al. (1996). Probes had a dialyzing 
portion of 1.5 mm for the NAce, the SNe and the VT A, and of 3 mm for the DS and 
the PFC. 
172 
Surgery: Three months after hyperglycemia induction, rats underwent stereotaxic 
acute probe-insertion surgery as previously described by Bassareo et al. (2011). 
Briefly, the probes were inserted vertically under the following coordinates: 
NAcc (A: 1.9, L: 1.1 from bregma; V: -7.6 from dura), DS (A: 0.7, L: 2.8 from bregma; 
V: -6.5 from dura), PFC (A: 3.8, L: 0.9 from bregma; V: -5.0 from dura), SNc (A: -5.8, 
L: 1.7 from bregma; V: -8.3 from dura) and VTA (A: -6.0, L: 0.5 from bregma; V: -8.2 
from dura) according to the atlas of Paxinos and Watson (1998). A maximum of 
two regions on opposite hemispheres were targeted in each rat (for glucose: VTA and 
NAcc, VTA and DS, SNc and NAcc, or SNc and DS; DA: DS and NAcc, NAcc and 
PFC, or PFC and DS), and each subject was tested only once during the experimental 
session. We collected data in 3-month HG rats for glucose and DA microdialysis 
experiments. Rats did not undergo surgery at 6 months due to their delicate health. 
Methods specific to microdialysis experiments dedicated to glucose 
measurements: Prior to analytical procedures, rats were fasted overnight to normalize 
the contribution of feeding on glycemia. Thirty minutes before the start of experiments, 
each rat was fed with normal chow diluted in water (1.5 g/kg b.w. by intragastric 
gavage). Glycemia was monitored before, during and after microdialysis experiments 
to ensure its stability. 
Microdiaysis experiments: On the day following surgery, microdialysis 
experiments were conducted in freely moving and awake rats, as previously described 
(Bassareo et al., 2011). Briefly, dialysate samples (20 ~L) were taken every 20 min, 
for a total of 9 samples (180 min) for DA quantification and 3 samples (60 min) 
for glucose measurements. For DA quantification, 20 ~L samples were immediately 
injected into a high-performance liquid chromatography, whereas, for glucose 
measurements, samples were pooled and immediately frozen for later quantification. 
Basal dialysate DA was calculated as the area under the curve of the 9 consecutive 
samples collected during the 180-min session, varying by no more than 10% (for time 
course see Supplementary Figure S2). 
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Histology: At the end of experiments, rats were sacrificed and transcardially 
perfused with 50 mL of saline and 50 mL of a 4% forrnaldehydell % calcium 
acetatellOO mM NaCI solution. Sections were cut with a vibratome and probe location 
was ensured as reported by Bassareo et al. (2011) (Supplementary Figure S3). 
Brain tissue and microdialysate glucose concentrations 
In order to investigate whether glucose concentrations may be altered differentially 
in the various brain regions of interest following long-terrn hyperglycemia, glucose 
concentrations in homogenized brain tissue and intracerebral microdialysis samples were 
measured according to the manufacturer' s protocol using a Rat Glucose Assay kit 
(Crystal Chem, Downers Grove, IL, USA). For homogenized brain tissue, frozen 
striatum, midbrain, PFC or HPC tissues were homogenized by steel baIl milling in 
volume/weight equivalents of RIPA buffer and immediately deproteinized by 
trichloroacetic acid precipitation before glucose quantification. 
Statistical analyses 
Statistical analyses were carried out using GraphPad Prism 7 software (San Diego, 
CA, USA; http: //www.graphpad.com). Significant differences between groups were 
ascertained by Student's unpaired two-tailed t-test, or by two-way ANOV A followed 
by Sidak's post-hoc analysis. Ali data, analyzed at the 95% confidence interval, 
are expressed as means ± SEM. T and F statistics for each figure are described in 
Supplementary Table S2. 
Results 
Glucose concentrations increase in ail brain regions of interest 
At 3 (Figure 3.1 A) and 6 months (Figure 3.1 B), glucose concentrations in HG rats 
(black bars) were increased compared to CTRL rats (white bars) in homogenized tissues 
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of midbrain, striatum, PFC and HPC. Microdialysis experiments confirmed these results 
at 3 months in discrete brain regions, namely the SNc and VTA of the midbrain and the 
DS and NAcc of the striatum (Figure 3.1C). 
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Figure 3.1 Brain glucose concentrations in HG rats compared to CTRL rats. 
(A, B) Frozen striatum, midbrain, prefrontal cortex (PFC) and 
hippocampus (HPC) brain tissues were homogenized by steel ball 
milling and deproteinized before glucose quantification. Three (A) and 
six (B) months after hyperglycemia-inducing nicotinamide-streptozotocin 
(NA-STZ) injections, hyperglycemic (HG) rats displayed increased 
intracellular glucose concentrations in all brain regions analyzed 
compared to the control (CTRL) group. (C) Three months after injections, 
microdialysis samples were obtained from acute probes inserted in the 
nucleus accumbens (NAcc), the dorsal striatum (DS), the substantia nigra 
pars compacta (SNc), and the ventral tegmental area (VTA). 
Thirty minutes before the start of experiments, ovemight fasted rats were 
fed with normal chow diluted in water (1.5 g/kg body weight [b.w.] by 
intragastric gavage). Glucose was measured in the samples, confirming 
higher extracellular concentrations in ail the brain regions of HG rats 
compared to CTRL rats . Data presented as means ± SEM. Asterisks 
indicate statistical differences between the HG group and CTRL group 
(***p < 0.001, **p < 0.01 and *p < 0.05). 
Long-term hyperglycemia causes preferential degeneration of dopaminergic neurons 
in the substantia nigra pars compacta 
By immunoblotting (Figure 3.2A and B), we observed no difference in the 
expression levels of TH (Figure 3.2A and C), DAT (Figure 3.2A and D) or NeuN 
(Figure 3.2A and E) in the midbrain of 3-month HG rats compared to CTRL rats . 
At 6 months, all three markers were decreased (Figure 3.2B, C, D and E), suggesting 
dopaminergic degeneration. We confirmed these results by immunohistochemical 
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analyses, focusing on discrete dopaminergic subregions within the ventral midbrain, 
namely the SNc and the YTA (Figure 3.2F). Six months after hyperglycemia induction, 
HG rats displayed a significant loss of dopaminergic neurons in the SNc but not in the 
VTA, as ascertained by reduced TH+ (Figure 3.2G) and NeuN+ (Figure 3.2H) neuron 
counts. 
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Figure 3.2 Analyses of midbrain markers of neurodegeneration in HG rats 
compared to CTRL rats. 
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(Continued.) (A-E) Immunoblotting analyses of midbrain homogenates. 
A SDS-PAGE was performed on steel baIl milled frozen midbrain 
homogenates. The midbrain contains the SNc and the VT A. (A, B) 
Representative immunoblots of dopaminergic markers TH and dopamine 
transporter (DAT), and the general neuronal marker NeuN 3 (A) and 
6 (B) months following hyperglycemia-inducing NA-STZ injections. 
(C-E) TH (C), DAT (D) and NeuN (E) expression levels are lower in HG 
rats 6 months, but not 3 months, after injections compared to CTRL rats. 
Expression levels are normalized to ~-tubulin. Blots were independently 
repeated at least 3 times each. (F-H) Immunohistochemical analyses of 
the midbrain region. Six months after hyperglycemia-inducing NA-STZ 
injections, frozen post-fixed brain hemispheres were cut into 20 )..lm-thick 
coronal seriai sections and stained for the dopaminergic neuronal marker 
TH or the general neuronal marker NeuN. (F) Representative midbrain 
microphotographs of TH staining at 2 different anteriorities and of NeuN 
staining. The midbrain subregions include the SNc and the VTA, isolated 
by dotted lines in the NeuN microphotograph. Scalebar 1 mm. (G, H) Cell 
counts in the SNc and VTA demonstrated lower numbers of both TH+ 
(G) and NeuN+ (H) cells in the SNc of HG rats compared to CTRL rats. 
No differences were found in the VT A. AlI data presented as means ± 
SEM. Asterisk indicates statistical differences between the HG group and 
CTRL group (*p < 0.05). 
Long-term hyperglycemia causes preferential degeneration of dopaminergic fiber 
terminais in the dorsal striatum 
By immunoblotting (Figure 3.3A and B), we observed no difference in the 
expression levels of TH (Figure 3.3A and C), DAT (Figure 3.3A and D) or NeuN 
(Figure 3.3A and E) in the striatum of 3-month HG rats compared to CTRL rats. 
At 6 months, HG rats expressed lower levels of the dopaminergic markers TH 
(Figure 3.3B and C) and DAT (Figure 3.3A and D), indicative of dopaminergic fiber 
terminal degeneration in the striatum. NeuN, mainly expressed in the ceIl bodies of 
neurons, remained unchanged in HG rats at 6 months (Figure 3.3B and E), suggesting 
that no neurons were lost in the striatum. Irnmunohistochemical assays in the various 
subregions of the striatum (Figure 3.3F) confirmed a significant loss of dopaminergic 
fiber terminaIs in 6-month HG rats, especiaIly in the DS, both in the DMS and DLS 
subregions, as ascertained by quantification of the density of TH+ fibers (Figure 3.3G). 
No distinctions between 6-month HG and CTRL rats were detected in the ventral 
regions of the striatum, namely the NAcc and the OT (Figure 3.3G). NeuN+ ceIl counts 
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did not differ between CTRL and HG groups in any of the reglOns investigated 
(Figure 3.3H), corroborating previous immunoblotting observations of unchanged 
striatal NeuN expression levels. 
Degeneration of dopaminergic fiber terminaIs may be accompanied by alterations 
in regional DA release (G6rska et al., 2017). To address this possibility, microdialysis 
samples were collected at 3 months in the main central DA terminaIs, namely the DS, 
the N Acc and the PFC. We noticed that, even in the absence of TH loss made apparent 
at 3 months by immunoblotting (Figure 3.3A and C), HG rats displayed impaired basal 
DA release in the DS, but not in the other brain regions (Figure 3.31). Together, these 
data suggest early (3 months) dopaminergic fiber terminal dysfunction, and later 
(6 months) degeneration in the DS coinciding with loss of neurons in the SNc where the 
fibers originate. It is also possible that a moderate amount of neurodegeneration was 
present at 3 months that we failed to detect by immunoblotting, due to the fewer 
numbers of rats employed at this time point. If this were the case, dampened dopamine 
release at' 3 months wou Id coincide with this loss of dopaminergic neurons or fibers. 
Immunohistochemical analyses of brains at 3 months are required to confirm either of 
these hypotheses. The main finding remains that neurodegeneration was observed in 
6-month HG rats, as corroborated by 2 different techniques. 
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Analyses of striatal markers of neurodegeneration in HG rats 
compared to CTRL rats. 
(A-E) Immunoblotting analyses of striatum homogenates. A SDS-PAGE 
was performed on steel ball milled frozen striatum homogenates. 
The striatum contains the DS and the NAcc. (A, B) Representative 
immunoblots of dopaminergic markers TH and DAT, and the genera1 
neuronal marker NeuN 3 (A) and 6 (B) months following hyperglycemia-
inducing NA-STZ injections. (C-E) TH (C) and DAT (D) expression 
levels are lower in HG rats 6 months, but not 3 months, after injections 
compared to CTRL rats. No differences in NeuN (E) expression levels 
were observed at either 3 or 6 months. Expression levels are normalized 
to ~-tubu1in. B10ts were independently repeated at least 3 times each. 
(F-H) Immunohistochemical analyses of the striatal region. Six months 
after hyperglycemia-inducing NA-STZ injections, frozen post-fixed brain 
hemispheres were cut into 20 Ilm-thick coronal seriaI sections and stained 
for the dopaminergic terminal fiber marker TH or the general neuronal 
marker NeuN. (F) Representative microphotographs of TH and NeuN 
staining in the striatum. The striatal subregions include the DS (including 
the dorsomedial striatum [DMS] and dorsolateral striatum [DLS]), 
the NAcc and the olfactory tubercle (OT), iso1ated by dotted lines in the 
far right panel. Scalebars 1 mm. (G) Density of TH+ fibers was assessed 
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by densitometric assays in the DMS, DLS, NAcc and the OT, showing 
less dense dopaminergic terminal fibers in the DMS and DLS, but not in 
the NAcc or the OT, of HG rats compared to CTRL rats. (H) Cell counts 
in the DMS, DLS, NAcc and OT demonstrated no differences between 
HG and CTRL rats. (1) Three months after injections, microdialysis 
samples were obtained from the NAcc, the DS and the PFC. 
Measurements of DA in the samples were performed by high-
performance liquid chromatography and revealed lower extracellular 
concentrations in the DS, but not in the NAcc or the PFC, in HG rats 
compared to CTRL rats. Ali data presented as means ± SEM. Asterisk 
indicates statistical differences between the HG group and CTRL group 
(*p < 0.05, **p < 0.01). ac, anterior commissure; AUC, area under curve; 
DA, dopamine. 
Long-term hyperglycemia does not cause substantial neurodegeneration in the 
prefrontal cortex or in the hippocampus 
In the PFC and the HPC, we report no sensible changes of TH or DAT expression 
at either 3 (Figure 3.4A, C and D; Figure 3.5A, C and D) or 6 months (Figure 3.4B, C 
and D; Figure 3.5B, C and D) as revealed by immunoblotting assays (Figure 3.4A 
and B; Figure 3.5A and B). In addition, hyperglycemia sustained for 6 months did not 
modulate NeuN expression (Figure 3.4A, Band E; Figure 3.5A, Band E), suggesting no 
visible degeneration in neuronal cell bodies housed in the PFC or the HPC. 
Immunohistochemical analyses confirmed these findings since no changes in NeuN+ 
cell counts were observed in HG rats at 6 months compared to the CTRL group 
(Figure 3.4F and G; Figure 3.5F and G). Lack of neuronal degeneration in the HPC is 
corroborated by another study in long-term diabetic mice (Duarte et al. , 2012). 
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Analyses of prefrontal markers of neurodegeneration in HG rats 
compared to CTRL rats. 
(A-E) Irnmunoblotting analyses of PFC homogenates. A SDS-PAGE 
was perfonned on steel baIl milled frozen PFC homogenates. (A, B) 
Representative immunoblots of dopaminergic markers TH and DAT, 
and the general neuronal marker NeuN 3 (A) and 6 (B) months following 
hyperglycemia-inducing NA-STZ injections. ~-tubulin blots served as a 
loading standard. (C-E) No differences in TH (C), DAT (D) or NeuN (E) 
expression levels were observed at either 3 or 6 months. Expression levels 
are nonnalized to ~-tubulin . Blots were independently repeated at least 
3 times each. (F, G) Irnmunohistochemical analyses of the PFC region. 
Six months after hyperglycemia-inducing NA-STZ injections, frozen 
post-fixed brain hemispheres were cut into 20 Ilm-thick coronal 
seriaI sections and stained for the general neuronal marker NeuN. 
(F) Representative microphotographs of NeuN staining. Prelimbic (PL) 
and infralimbic (IL) subregions of the medial PFC are isolated by dotted 
lines. Scalebar 1 mm. (G) No differences in NeuN+ cell counts in the 
PFC of HG rats compared to CTRL rats. Ali data presented as means ± 
SEM. cc, corpus callosum. 
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Analyses of hippocampal markers of neurodegeneration in HG rats 
compared to CTRL rats. 
(A-E) Immunoblotting analyses ofHPC. A SDS-PAGE was performed on 
steel bail milled frozen HPC homogenates. (A, B) Representative 
immunoblots of dopaminergic markers TH and DAT, and the general 
neuronal marker NeuN 3 (A) and 6 (B) months following hyperglycemia-
inducing NA-STZ injections. B-tubulin blots served as a loading standard. 
(C-E) No differences in TH (C), DAT (D) or NeuN (E) expression levels 
were observed at either 3 or 6 months. Expression levels are normalized 
to B-tubulin. Blots were independently repeated at least 3 times each. 
(F, G) Immunohistochemical analyses of the HPC region. Six months 
after hyperglycemia-inducing NA-STZ injections, frozen post-fixed brain 
hemispheres were cut into 20 J..lm-thick coronal seriai sections and 
stained for the general neuronal marker NeuN. (F) Representative 
microphotographs of NeuN staining in the dentage gyms (DG), Cornu 
ammonis (CA) 1 and 3 regions of the HPC. Scalebars 0.5 mm. 
(G) No differences in NeuN+ cell counts in the HPC of HG rats compared 
to CTRL rats. Ali data presented as means ± SEM. 
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Long-term hyperglycemic rats display astrogliosis and loss of microglial cells 
in degenerated dopaminergic regions 
Six months following hyperglycemia induction, HG rats exhibitedgreater GF AP+ 
staining revealed by immunohistochemistry in the SNc and DS (Figure 3.6A), 
both regions displaying dopaminergic degeneration. Interestingly, these same regions 
also showed a significant decrease of Tha+ staining (Figure 3.6A). In 6-month HG rats, 
this apparent astrogliosis and 10ss of microglial cells was confirmed by GF AP+ 
(Figure 3.6B) and Thal + (Figure 3.6C) cell counts. Although we could not demonstrate 
neurodegeneration in the NAcc (Figure 3.3F, Gand H), we detected an increase in 
numbers of astroglial cells (Figure 3.6A and B) together with a 10ss of microglial cells 
(Figure 3.6A and C) in HG rats compared to CTRL rats. The PFC, on the other hand, 
displayed signs of astrogliosis (Figure 3.6A and B) without a decrease in Thal + cells 
(Figure 3.6A and C). No effects were identified in the HPC, the VTA (Figure 3.6A, B 
and C) or the OT (Figure 3.6B and C). 
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Immunohistochemical analyses of astrocytes and microglial cells in 
the brains of HG rats compared to CTRL rats. 
Six months after hyperglycemia-inducing NA-STZ injections, frozen 
post-fixed brain hemispheres were cut into 20 f.lm-thick coronal seriai 
sections and stained for the astrocytic marker glial fibrillary acidic protein 
(GFAP) or the microglial marker ionized ca1cium-binding adapter 
molecule 1 (Tha 1). (A) Representative microphotographs of GF AP or 
Thal staining in the different brain regions analyzed in this article 
with neuroanatomical landmarks isolated by dotted lines. The HPC 
microphotographs are taken from the CAl region and the PFC 
microphotographs are taken from the PL region. Not shown: OT and 
subregions of the DS (DMS and DLS). Scalebar 100 f.lm. (B) Cell counts 
in the various regions demonstrated higher numbers of GF AP+ cells in 
the SNc, DMS, DLS, NAcc and PFC of HG rats compared to CTRL rats. 
No differences were observed in other regions. (C) Cell counts in the 
various regions demonstrated lower numbers of Thal + cells in the SNc, 
DMS, DLS and NAcc of HG rats compared to CTRL rats. No differences 
were observed in other regions. Ail data presented as means ± SEM. 
Asterisk indicates statistical differences between the HG group and CTRL 
group (* **p < O.OOI , **p < O.OI and *p < 0.05) . SNr, substantia nigra 
pars reticulata. 
Long-term hyperglycemic rats show altered motor behaviour 
In the stepping test, HG rats took longer to cross the beam (Figure 3.7B) and made 
more strides (Figure 3.7C) at 3 and 6 months compared to the CTRL group. Time to 
initiate movement was not different between CTRL and HG groups at any time point 
(Figure 3.7A). While no changes were detected at the 3-month mark in the horizontal 
bar test, 6-month HG rats exhibited an increase in the latency to remove paws compared 
to their baseline results and in relation to the CTRL group (Figure 3.7D). In the adjusting 
step test, HG rats performed lower numbers of adjustments with either forepaw, in both 
forehand (white bars for CTRL or black bars for HG) and backhand (horizontally lined 
184 
white bars for CTRL or checkered bars for HG) directions, compared to CTRL rats at 
both time points (Figure 3.7E). In the NOR test, we did not find any difference in the 
am ou nt of time HG rats spent exploring novel objects compared to the CTRL group 
(Figure 3.7F). This was confirmed by expressing novel object exploration times in 
relation to old object exploration times, yielding a discrimination index that did not 
significantly contrast between CTRL and HG rats (Figure 3.7G). 
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Figure 3.7 Behavioral assessments of HG rats compared to CTRL rats. 
Three or six months after hyperglycemia-inducing NA-STZ injections, 
rats were subjected to behavioral tests to evaluate the presence of motor 
(A-E) or memory impairments (F, G). (A-C) A stepping test was 
conducted, consisting in a beam-crossing task. Both groups improved 
their time to initiate movement at 3 and 6 months compared to baseline, 
although no differences were observed between CTRL and HG rats (A). 
At 3 and 6 months, however, HG rats took longer than CTRL rats to cross 
the beam, and their results at 6 months grew significantly different from 
baseline (B). HG rats also made more strides to cross the beam than 
Discussion 
185 
CTRL rats at 3 and 6 months, and only the latter performed better than 
baseline tests at both 3 and 6 months (C). (D) For the horizontal bar test, 
descent latency was measured as the time taken for rats to remove both 
forepaws from a horizontal bar. At 6 months, but not 3 months, HG rats 
took longer to remove both paws compared to CTRL rats and their own 
baseline. (E) During the forepaw adjusting step test, the rat was moved 
slowly sideways along the table surface by an experimenter, first in a 
forehand and then in a backhand direction. Numbers of adjusting steps 
made were fewer in HG rats at 3 and 6 months compared to CTRL rats 
and their own baseline. (F, G) A novel object recognition task, based on 
exploratory behavior of newly introduced elements in an environment, 
was used to assess non-spatial working memory in rats at 3 months. 
Rats were not tested at 6 months due to loss of eyesight (cataracts) of HG 
rats. Both CTRL and HG groups explored the nover object for a longer 
period of time than the old object (F). No differences were seen between 
groups in their capacity to discriminate old and nover objects (G). 
AU data presented as means ± SEM. Asterisk indicates statistical 
differences between the HG group and CTRL group (***p < 0.001 and 
*p < 0.05). Plus signs indicate statistical differences between results at the 
3- or 6-month time point and the baseline evaluation (+++p < 0.001 , 
++p < 0.01 and +p < 0.05). For the novel object recognition (NOR) task, 
circles indicate statistical differences between exploration time of the 
novel object and the old object (OOp < 0.01 and Op < 0.05). 
The CUITent study sheds a new light on neuronal degeneration in long-term 
hyperglycemia, innovative in that the condition was extended to a penultimate length of 
6 months in the NA-STZ rat model without the need for glycemia-Iowering treatments. 
The noxious effects of long-term hyperglycemia were evaluated in the nigrostriatal 
and mesocorticolimbic pathways. Our findings are relevant to elucidate the interplay 
between hyperglycemia and age-related neurodegenerative conditions, such as 
Parkinson' s disease. 
To the best of our knowledge, this is the first time that hyperglycemia-induced 
neuropathological manifestations have been related to glucose measurements in brain 
tissue homogenates and extracellular intracerebral microdialysates. Since glucose 
overload is one of the major contributors to diabetic complications (Brownlee, 2005 , 
Tomlinson and Gardiner, 2008), the sole observation that glucose levels are significantly 
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increased indiscriminately in all brain regions studied herein raises the question as to 
why sorne structures degenerate preferentially over time. It is now well appreciated that 
oxidative stress is a key player in the nigrostriatal degeneration observed in Parkinson ' s 
disease (Schapira and Jenner, 20 Il), a relative susceptibility attributable to various 
factors: 1) All dopaminergic neurons are submitted to oxidative insults from dopamine 
auto-oxidation and the elevated activity of mono amine oxidase (Goldstein et al., 2014); 
2) Specifically, the SNc holds high levels of iron ions that generate highly reactive 
hydroxyl radicals, but also possesses low levels of the ubiquitous antioxidant molecule 
glutathione (Chinta and Andersen, 2008); 3) Dopaminergic nigrostriatal neurons are 
endowed with an exceptionally dense dendritic arborization, rich in mitochondria and 
constantly requiring costly metabolic sustenance (Surmeier et al., 2017). On the basis of 
these physiological peculiarities, we argue that the relative vulnerability of the 
nigrostriatal pathway, as compared here to the mesocorticolimbic pathway, stems from 
its elevated basal oxidative burden paired with its scanty survival mechanisms faced to 
sustained hyperglycemia over the course of aging. 
In our long-term model of hyperglycemia, other pathological indices manifested 
themselves concurrently to dopaminergic neurodegeneration, expressly a prominent 
astrogliosis and loss of micro glial cells both in the SNc and the DS. Astrogliosis has 
been observed in several animal models of diabetes (Nagayach et al., 2014, Rostami 
et al., 2017), with implications for dopaminergic neuron death (Cabezas et al., 2014). 
However, our present study constitutes an original report of the fate of glial cells 
following long-term hyperglycemia, moreover demonstrating astrogliosis in the SNc of 
STZ-treated rats for the first time. Microgliosis is well appreciated in retinas and 
peripheral nerves of diabetic models (Mazzeo et al., 2017) though less well known in the 
central nervous system (Nagayach et al., 2014, Oliveira et al., 2016). Yet, microglial cell 
degeneration is an under-recognized feature in diabetes as well as in neuropathologies. 
In our model, it is likely that microglial cells are lost due to the sustained oxidative 
burden, supported by observations that this population is susceptible to oxidative stress 
in health and in disease (Streit et al. , 2008). In fact, iron accumulation in the aging 
human brain promotes oxidative stress and may lead to microglial degeneration 
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(Streit et al., 2008). lnterestingly, in patients deceased from septic shock, microglial 
apoptosis was correlated to hyperglycemia, possibly due to lack of GLUT5 
downregulation (Polito et al. , 2011). Other studies have found that advanced-glycation 
end-products (AGEs), abundant in diabetic and aging brains, cause microglial apoptosis 
in a dose-dependent manner (Khazaei et al., 2008, Sabokdast et al., 2015). Microglial-
derived AGEs were further shown to promote dopaminergic neuron death (Bayarsaikhan 
et al. , 2016). lnasmuch as previous reports reveal microgliosis in rodent models of 
diabetes within 2 months (Nagayach et al., 2014, Oliveira et al. , 2016), we suggest that 
microglial cells are activated early in hyperglycemia, in turn causing the activation and 
proliferation of astrocytes (Liddelow et al. , 2017). The latter persist in high numbers at 
6 months while microglial ce Ils degenerate over time due to the overwhelming oxidative 
load of sustained hyperglycemia. Although confirmation of this tentative timeline is 
required, it remains interesting that this astrogliosis paired to microglial cell loss 
preferentially targets dopaminergic regions. 
Motor deficits possibly ansmg from this nigrostriatal neurodegeneration 
expressed themselves in tests employed to characterize motor impairment in rat models 
of Parkinson's disease (Pinna and Morelli , 2014). ln particular, HG rats showed 
bradykinesia and made greater numbers of sm ail steps, bearing likeness to motor 
symptoms found in parkinsonian patients (Pinna and Morelli , 2014). Together with 
immunohistochemical, immunoblotting and microdialysis studies, these data provide 
new insight on the higher occurrence of Parkinson's disease in aging diabetic patients 
(Cereda et al. , 2011 , Santiago and Potashkin, 2013, Sun et al. , 2012). One study 
investigating blood biomarkers in 99 de nova patients of Parkinson ' s disease even found 
their average fasting glycemia (5.64 mM) comparable to that of pre-diabetic individuals 
(5.55 mM) (Santiago and Potashkin, 2015). Of high interest, recent clinical trials (Barker 
et al. , 2013) are employing drug-repurposing strategies in Parkinson ' s disease patients 
using anti-diabetic treatments such as exenatide (Aviles-Olmos et al., 2013) and 
thiazolidinediones (NET-PD FS-ZONE, 2015). Whereas the link between Parkinson 's 
disease and diabetes remains foggy, sorne have suggested shared dysfunctional cellular 
pathways (Santiago and Potashkin, 2013) or neurochemical hypotheses (Deng et al., 
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2012). Indeed, high reactivity between the glycation metabolite methylglyoxal and DA 
was recently shown to yield a salsolinol-like toxin specifie to dopaminergic neurons 
(Song et al., 2014). Interestingly, this toxin can be found in brains of parkinsonian 
patients (Deng et al. , 2012). 
In summary, our results mend our appreciation of the relationship that may exist 
between diabetes and Parkinson's disease, by demonstrating the preferential nigrostriatal 
dopaminergic neurodegeneration that occurs in long-term hyperglycemia. As it is 
expressed in uncontrolled diabetes, hyperglycemia may cause premature aging of the 
central nervous system, fostering the development of age-related neurodegenerative 
disease. 
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Supplementary data 
Metabolic follow-up and disease progression 
Each individual rat's weight (Supplementary Figure SlA), food and water intake 
(Supplementary Figure SlB), glycemia (Supplementary Figure SIC), and general health 
were monitored on a regular basis. Glycemia was estimated twice a week and weight 
was measured weekly. Food and water intake was assessed for group-paired cages, 
since rats were not housed individually. 
Oral glucose tolerance test: On the moming of their sacrifice, 6 months after 
NA-STZ injections, we performed an oral glucose tolerance test (OGTT; Supplementary 
Figure SIE and F) on 6 CTRL rats and 16 HG rats. Fasted rats (12-16 h) were 
administered 2 glkg of a D-glucose solution by intragastric gavage. Approximately 
0.5 mL of blood was collected by the jugular vein right before the OGTT (0 min) and 
at 30, 60 and 120 min after administration of the bolus. Samples were kept on ice and 
plasma glucose and insulin were quantified immediately after. Rats were lightly 
anesthetized by isoflurane inhalation prior to blood sampling. Plasma glucose 
concentrations following the terminal OGTT were measured using the Rat Glucose 
Assay kit provided by Crystal Chem (Downers Grove, IL, USA), whereas plasma insulin 
was quantified using a Milliplex Adipokine Magnetic Bead Multiplex Assay (Millipore; 
Etobicoke, ON, Canada). 
Glycated hemoglobin: In a different group of rats, plasma hemoglobin A1c 
(HbA1c) levels (Supplementary Figure SlD) were assessed terminally at 3 or 6 months 
following NA-STZ injections. On the moming of their sacrifice, intracardiac blood 
samples from CTRL (3 months n = 4; 6 months n = 10) and HG (3 months n = 5; 
6 months n = 16) rats were drawn when under deep anesthesia by isoflurane inhalation. 
Glycated Hb was measured immediately using a rat HbAlc assay kit (Crystal Chem; 
Downers Grove, IL, USA). 
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Table 81 
Antibodies used for immunohistochemical (IRC) or immunoblotting (WB) experiments 
Antibody Antigen Host/Isotype/ Class Manufacturer Catalog Dilution 
number 
Rat ~-tubulin mouselIgG2a K light Santa Cruz sc-80005 1:2000 
chain/monoclonal Biotechnology 
Dopamine rabbit/IgG/ Santa Cruz 
sc-14002 1:100 
transporter polyclonal Biotechnology 
Glial fibrillary rabbit/IgG/ Abcam ab7260 1:5000 
acidic protein polyclonal (IHC) 
Ionized calcium- 1 :2500 binding adapter rabbit/ polyclonal Wako 019-19741 (IHC) Primary molecule 1 
NeuN mouse/IgG 11 Millipore MAB377 1:1000 
monoclonal Sigma (IBC) 
NeuN rabbit/IgG/ Cell Signaling 24307 1:1000 polyclonal Technology (WB) 
1:4000 
Tyrosine mouse/IgG 11 Millipore Tl299 (IBC) hydroxylase monoclonal Sigma 1 :4000 
(WB) 
mouse/IgG/ 1:5000 
Rabbit monoclonal Santa Cruz sc-2357 (IBC) 
(HRP conjugated) Biotechnology 1: 10 000 (WB) 
Secondary 
1:5000 
recombinant IgGK Santa Cruz (IBC) Mouse light chain (HRP Biotechnology sc-516102 1:10000 
conj ugated) (WB) 
Table 82 
Detailed statistics 
Figure Statistical test Factor T- or F-value P-value 
Midbrain glycemia T(7) = 3.823 p = 0.0065 
Figure 3.1A Unpaired, two-tailed 
Striatum glycemia T(7) = 2.627 p = 0.0341 
(-test PFC glycemia T(5) = 2.982 P = 0.0307 
HPC glycemia T(4) = 3.755 p = 0.0199 
Midbrain glycemia T(12) = 2.36 P = 0.0360 
Figure 3.1B Unpaired, two-tailed 
Striatum glycemia T(15) = 3.401 P = 0.0040 
(-test PFC glycemia T(22) = 2.785 p = 0.0108 
HPC glycemia T(14) = 2.181 P = 0.0467 
SNe glycemia T(6) = 3.488 p = 0.0130 
Figure 3.1C Unpaired, two-tailed 
VTA glycemia T(7)= 5.515 p = 0.0009 
(-test DS glycemia T(6) = 4.03 P = 0.0069 
NAcc glycemia T(8) = 3.461 P = 0.0086 
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Figure Statistical test Factor T- or F-value P-value 
Figure 3.2C Unpaired, two-tailed 
3 months glyeemia T(7) = 0.9727 P = 0.3631 
(-test 6 months glyeemia T(43) = 2.589 p = 0.013 
Figure 3.2D Unpaired, two-tailed 
3 months glyeemia T(6) = 0.6376 P = 0.5473 
(-test 6 months glyeemia T(17) = 2.274 P = 0.036 
Figure 3.2E Unpaired, two-tailed 
3 months glycemia T(7) = 0.2629 p = 0.8002 
(-test 6 months glyeemia T(43) = 2.462 p = 0.018 
Figure 3.2G Unpaired, two-tailed 
SNe glyeemia T(7)= 3.471 p = 0.0104 
(-test YT A glyeemia T(7) = 0.4764 P = 0.6483 
Figure 3.2H Unpaired, two-tailed 
SNe glyeemia T(7) = 2.439 p = 0.0448 
(-test YTA glyeemia T(7) = 0.1207 P = 0.9073 
Figure 3.3C Unpaired, two-tailed 
3 months glyeemia T(7) = 0.5223 p = 0.6176 
(-test 6 months glyeemia T(43) = 2.432 P = 0.019 
Figure 3.3D Unpaired, two-tailed 
3 months glyeemia T(7) = 0.9898 p = 0.3552 
(-test 6 months glyeemia T(lo) = 2.256 P = 0.048 
Figure 3.3E Unpaired, two-tailed 
3 months glyeemia T(7) = 0.4726 p = 0.6509 
(-test 6 months glyeemia T(42) = 0.5358 P = 0.595 
DMS glyeemia T(7) = 2.443 P = 0.0446 
Figure 3.3G Unpaired, two-tailed 
DLS glyeemia T(7) = 2.628 P = 0.0340 
(-test NAee glyeemia T(7) = 1.495 p = 0.1785 
OT glyeemia T(7) = 1.462 p = 0.1871 
DMS glyeemia T(7) = 0.7135 P = 0.4986 
Figure 3.3H Unpaired, two-tailed 
DLS glyeemia T(7) = 0.1507 P = 0.8845 
(-test NAee glyeemia T(7) = 1.134 P = 0.2942 
OT glyeemia T(7) = 0.0886 p = 0.9319 
Region x glyeemia F(2 ,14) = 3.60 P = 0.0546 
Figure 3.31 Two-way ANOY A Region F(2, 14) = 34.3 P < 0.0001 
G1yeemia F(I ,14) = 7.59 P = 0.0155 
Figure 3.4C Unpaired, two-tailed 
3 months glyeemia T(7) = 0.4794 P = 0.6463 
(-test 6 months glyeemia T(44) = 0.9042 P = 0.3708 
Figure 3.4D Unpaired, two-tailed 
3 months glyeemia T(7) = 0.30 13 p = 0.7719 
(-test 6 months glyeemia T(l5) = 0.7387 P = 0.472 
Figure 3.4E Unpaired, two-tailed 
3 months glyeemia T(7) = 1.705 p = 0.1319 
(-test 6 months glyeemia T(44) = 0.8821 P = 0.3825 
Figure 3.4G Unpaired, two-tailed PFC glyeemia T(7) = 1.168 p = 0.2810 (-test 
Figure 3.5C Unpaired, two-tailed 
3 months glycemia T(5) = 0.6179 P = 0.5637 
(-test 6 months glyeemia T(45) = 0.6687 P = 0.5071 
Figure 3.5D Unpaired, two-tailed 
3 months glyeemia T(5) = 0.8448 P = 0.4368 
(-test 6 months glyeemia T(25) = 1.272 p = 0.215 
Figure 3.5E Unpaired, two-tailed 
3 months glyeemia T(5) = 1.365 P = 0.2303 
(-test 6 months glyeemia T(47) = 0.4349 P = 0.6656 
Figure 3.5G Unpaired, two-tailed HPC glyeemia T(7) = 0.9185 P = 0.3889 (-test 
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Figure Statistical test Factor T- or F-value P-value 
SNc glycemia T(7) = 2.546 P = 0.0383 
YT A glycemia T(7) = 0.4241 P = 0.6842 
DMS glycemia T(7) = 2.637 P = 0.0336 
Figure 3.6B Unpaired, two-tailed DLS glycemia T(7) = 3.100 p = 0.0173 (-test NAcc glycemia T(7) = 3.432 p = O.OllO 
OT glycemia T(7) = 1.038 p = 0.3340 
PFC glycemia T(7) = 3.292 p = 0.0133 
HPC glycemia T(7) = 0.7282 p = 0.4901 
SNc glycemia T(7) = 2.564 P = 0.0373 
YTA glycemia T(7) = 1.295 p = 0.2363 
DMS glycemia T(7) = 5.882 p = 0.0006 
Figure 3.6C Unpaired, two-tailed 
DLS glycemia T(7) = 3.885 p = 0.0060 
(-test NAcc glycemia T(7) = 3.077 P = 0.0179 
OT glycemia T(7) = 0.2407 p = 0.8167 
PFC glycemia T(7) = 0.2923 P = 0.7785 
HPC glycemia T(7) = 1.282 P = 0.2405 
Time x glycemia F (2,60) = 0.28 P = 0.7554 
Figure 3.7A Two-way ANOY A Time F (2 ,60) = 13.7 P < 0.0001 
Glycemia F(I ,30) = 0.18 P = 0.6742 
Time x glycemia F (2 ,60) = 2.61 p = 0.0816 
Figure 3.7B Two-way ANOY A Time F (2,60) = 1.66 p = 0.1972 
Glycemia F (I ,30) = 24.2 p < O.OOOI 
Time x glycemia F (2 ,60) = 7.20 p = 0.0016 
Figure 3.7C Two-way ANOY A Time F (2 ,60) = 11 .1 P < 0.0001 
Glycemia F(I ,30) = 10.5 P = 0.0029 
Time x glycemia F (2 ,60) = 3.23 P = 0.0463 
Figure 3.7D Two-way ANOY A Time F (2 ,60) = 7.51 p = 0.0012 
Glycemia F(I ,30) = 2.96 P = 0.0952 
Time x glycemia F (2 ,60) = 8.95 P = 0.0004 
Figure 3.7E Two-way ANOY A Time F (2 ,60) = 23 .6 p < O.OOO I forehand 
Glycemia F(I ,30) = 13 .3 p = O.OOIO 
Time x glycemia F (2,60) = 9.99 p = 0.0002 
Figure 3.7E Two-way ANOY A Time F (2 ,60) = 18.3 P < 0.0001 backhand 
Glycemia F(I ,30) = 10.5 P = 0.0028 
Object x glycemia F (I ,60) = 0.13 P = 0.7102 
Figure 3.7F Two-way ANOY A Object F(I ,60) = 18.4 P < 0.0001 
Glycemia F(I ,60) = 4.17 P = 0.0455 
Figure 3.7G Unpaired, two-tailed Glycemia T(3o) = 0.0628 p = 0.9503 [-test 
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Metabolic follow-up. 
(A) Mean weight of CTRL and HG rats from the beginning to the end 
of experiments. (B) Mean total cumulative intake of water (left y-axis) 
and food (right y-axis) over time. In blue, mean cumulative intake of 
cages containing solely CTRL animais . In red, mean cumulative intake of 
cages containing solely HG animais. In purple, me an cumulative intake of 
cages containing both CTRL and HG animaIs. (C) Mean glycemia of 
CTRL and HG rats from the beginning to the end of experiments. 
(D) Percentage of glycated hemoglobin (Hb) of CTRL and HG animais 
3 and 6 months after NA-STZ injections. CTRL 3 months: 6.6% 
200 
(49 mmol/mol). CTRL 6 months: 6.0% or (42 mmol/mol). HG 3 months: 
22.3% or (220 mmol/mol). HG 6 months: 21.9% or (215 mmol/mol). 
(E) Oral glucose tolerance test (OGTT) of fasted CTRL and HG rats 
6 months after injections. (F) Ratio of AUC of insulin on glucose from 
the OGTT. Asterisks indicate statistical differences between the HG and 
the CTRL groups (***p < 0.001 and **p < 0.01). 
Glycated Hb: In a different group of rats, plasma HbAlc levels (Supplementary 
Figure SlD) were assessed terminally at 3 or 6 months following NA-STZ injections. 
On the moming of their sacrifice, intracardiac blood samples from CTRL (3 months 
n = 4; 6 months n = 10) and HG (3 months n = 5; 6 months n = 16) rats were drawn 
wh en under deep anesthesia by isoflurane inhalation. Glycated Hb was measured 
immediately using a rat HbAlc assay kit (Crystal Chem; Downers Grove, IL, USA). 
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Time course of microdialysis experiments performed to measure 
basal DA. 
Three months after injections, microdialysis samples were obtained from 
the NAcc, the DS and the PFC. Measurements of DA in the sampi es were 
performed by high-performance liquid chromatography and revealed 
lower extracellular concentrations in the DS, but not in the NAcc or 
the PFC, in HG rats compared to CTRL rats. Data presented as 
means ± SEM. Statistical analysis was carried out by Statistica for 
Windows. Basal dialysate DA values, expressed as femtomoles per 20-j.!L 
dialysate, were compared between groups by two-way ANOV A. 
Results showing significant differences between CTRL and HG groups 
were subjected to Tukey's post-hoc test with p < 0.05 (*) as statistically 
significant. 
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Localization of dialysis probes (dialyzing portion) in microdialysis 
experiments performed to measure basal DA or extracellular glucose. 
Three months after NA-STZ injections, microdialysis samples were 
obtained from acute probes inserted in (A) the NAcc, the DS, the VTA 
and the SNc, for glucose measurements or in the NAcc, the DS, and the 
PFC for DA measurements (B). At the end of experimental procedures, 
rats were deeply anesthetized and transcardially perfused with 50 mL of 
saline and 50 mL of a 4% formaldehydell % calcium acetatell 00 mM 
NaCI solution. Sections were cut with a vibratome and probe location was 
reconstructed by referring to the Paxinos and Watson atlas (1998). 
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LONG-TERM HYPERGL YCAEMIA MODIFIES SOCIAL BEHA VIOUR AND 
EMISSION OF ULTRASONIC VOCALISATIONS IN RATS : A POSSIBLE 
EXPERIMENT AL M O DEL OF AL TERED SOCIABILITY IN DIABETES 
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4.2 Résumé 
Il ne fait plus de doute que le diabète soit un facteur de risque contribuant au 
déclin cognitif et aux troubles de l 'humeur se manifestant avec l'âge. Néanmoins, 
des études adressant les effets de l'hyperglycémie chronique sur les comportements 
sociaux, tels que le jeu et l'agressivité, se font toujours attendre. Dans cette étude, 
nous avions pour but d'évaluer les comportements sociaux manifesté par des rats 
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chroniquement hyperglycémiques. Dans cette optique, nous avons examiné les 
interactions de type affiliation/exploration et agression entre des paires de rats dans une 
enceinte neutre, et ce, 5 mois suivant l'induction de l'hyperglycémie dans le paradigme 
nicotinamide-streptozotocine. Simultanément, les vocalisations ultrasoniques, porteuses 
de l'état affectif des sujets, étaient enregistrées. Nos résultats démontrent que les rats 
chroniquement hyperglycémiques sont manifestement agressifs et hyper-sociables dans 
des contextes de nouveauté sociale. Ceux-ci émettent également beaucoup plus de 
vocalisations ultrasoniques régulées en partie par le neurotransmetteur dopamine. 
En fait, ces comportements corrélaient avec le degré de perte d'innervation 
dopaminergique du striatum, mais pas avec des paramètres liés aux concentrations ou 
aux fonctions de l' insul ine. En somme, nos résultats suggèrent un lien entre 
l'hyperréactivité sociale causée par l'hyperglycémie chronique et la neurotransmission 
dopaminergique dans le striatum, déjà reconnu pour son rôle modulateur sur les 
comportements sociaux. Cette étude jette une nouvelle lumière sur de possibles substrats 
neurobiologiques, soit la dopamine, pouvant sous-tendre les difficultés psychiatriques et 
socioaffectives auxquelles font face les patients diabétiques. 
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4.3 Full article in English: Altered social behaviour in long-term hyperglycemic 
rats displaying dopaminergic striatal denervation: an ultrasonic vocalisation 
study 
Abstract 
Diabetes is a well-known risk factor of cognitive decline and mood disorders . 
However, there is no adequate account of the effects of long-term hyperglycaemia on the 
various dimensions of social behaviours, such as play and aggression. In this study, 
we evaluated the social behaviour presented by the nicotinamide-streptozotocin 
rat model of long-term hyperglycaemia. Five months following induction of 
hyperglycaemia, we scored affiliative/exploratory or aggressive social interactions 
between pairs of unacquainted rats in a neutral arena. Concurrently, we recorded 
ultrasonic vocalisations (USVs), envisaged as behavioural markers of emotional states in 
rats. Our results demonstrate alterations in the behaviour of long-term hyperglycaemic 
rats faced with social novelty. Specifically, hyperglycaemic rats engaged in hyper-
sociable and hyper-aggressive encounters, while emitting greater numbers of USVs. 
The magnitude of social interactivity and vocalisations was associated with the degree of 
striatal denervation observed in the brains of long-term hyperglycaemic rats, but not 
with insulin levels or functions . Altogether, our data suggest a lack of social 
appropriateness in long-term hyperglycaemic rats, which may be parti y linked to 
changes in striatal dopamine known to regulate social behaviour. This study exposes 
additional dopaminergic neural substrates that may underlie the social dimensions of the 
psychiatric challenges faced by diabetic patients. 
Introduction 
The ability to suitably engage in social encounters occupies a significant role in 
the lives of individuals, epitomized by the debilitating nature of the behavioural 
inappropriateness manifested in neuropsychiatric disorders like autism, schizophrenia 
and attention deficit hyperactivity disorder [1-4]. Although less acknowledged, altered 
social behaviours are also a feature of diabetes. lndeed, recent studies link diabetes with 
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increased aggression and agitation in patients [5-7]. In addition, both hypoglycaemic 
« 70 mg/dL or 3.88 mM) and hyperglycaemic (> 120 mg/dL or 6.66 mM) states are 
known to foster hostility and aggression [8-11]. To date, very few studies have sought to 
investigate social interactions in diabetic-like rodents and these have yielded highly 
inconsistent results [12-14] . Moreover, none have employed long-term paradigms of 
hyperglycaemia that could better represent the chronicity of diabetes in humans. 
Perhaps for this reason, the possible neural substrates of inappropriate behaviours in 
diabetes remain iU defined. 
Ultrasonic vocalisations (USVs) are a valuable tool in social behavioural research, 
carrying information on the affective state of rats during aggressive and playful 
interactions [15-18]. USV scan be categorized based on average frequency and 
frequency modulation in the two large families of 22-kHz caUs and 50-kHz caUs, which 
are thought to have different behavioural significance [19]. USVs of 22-kHz are 
considered markers of negative affective states, since rats emit these calls in aversive 
situations, for example, during aggressive social interactions with conspecifics or upon 
exposure to predators [20]. On the other hand, rats mainly emit 50-kHz USVs in 
pleasurable situations such as mating and playful interactions with conspecifics or 
familiar humans [15]. Moreover, 50-kHz US Vs can be further classified in the 
two subcategories of frequency modulated (FM) and fiat caUs based on the modulation 
of sound frequency [16]. FM caUs have a sound frequency that varies substantially, 
whereas fiat caUs present a sound frequency that remains nearly unchanged within 
individual caUs [16]. Moreover, FM 50-kHz USVs are thought to be tightly linked to 
positive emotional states, and to function as affiliative calls to elicit approach behaviour 
and to maintain playful interactions [21, 22]. Flat 50-kHz caUs, on the other hand, are 
unclear in the exact functions they serve [23 , 24], but appear to bear a role in pacing 
social behaviour, supposedly acting as ambivalent contact caUs [25,26]. 
In addition to conveymg information on the affective state of rats, USVs are 
intimately linked with the activation of specific neuronal circuits [15]. In particular, 
activation of the ascending mesolimbic dopaminergic system produces 50-kHz US Vs 
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[27, 28], whereas activation of the ascending mesolimbic cholinergie system produces 
22-kHz caBs [15]. Notably, dopamine and acetylcholine extensively interact at the 
striatal interface to dynamically regulate the affective state of rodents [15]. As such, 
dopamine and acetylcholine antagonize each other in a cooperative system wherein one 
or the other prevails in a context-dependent manner, allowing for the rapid and 
appropriate activation of one of two states: positive or negative [29]. These states are 
thus mutually exclusive and are rendered specifically in rats by the categories of USVs 
emitted [15, 30]. From this perspective, it is reasonable to believe that alterations in 
mesostriatal dopaminergic neurotransmission may be reflected at the behavioural level 
by modifications in social interactions and USV emission. 
A recent study by our group demonstrated the occurrence of mesostriatal 
dopaminergic neurodegeneration in a rat model of long-term hyperglycaemia [31]. 
In light of these results, we evaluated herein the presence of social behavioural 
abnormalities that may arise from hyperglycaemia-induced dopaminergic denervation 
III the striatum. In particular, we measured the occurrences of specifie 
affiliative/exploratory as weIl as aggressive behaviours in pairs of unacquainted rats in 
a neutral, novel environment. Since no other studies have investigated USVs in 
hyperglycaemic rats in a social context, we quantified the numbers of 22-kHz, 
FM 50-kHz and flat 50-kHz calls emitted during these encounters. Lastly, we evaluated 
the impact of the degree of striatal denervation on the magnitude of social interactivity 
and USV emissions. 
Results 
Occurrences of social behaviours and ultrasonic vocalisations 
The occurrences of affiliative/exploratory (dorsal contacts, allogrooming, 
anogenital sniffmg and crawl-overs) and aggression-related (freezing, nose-offs, boxing, 
pins) behaviours were scored during 10-min encounters between pairs of unacquainted 
rats of the same group, namely control (CTRL) or hyperglycaemic (HG). Noticeably, 
many behaviours occurred more often between pairs of HG rats compared to duos of 
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the CTRL group, whether affiliative/exploratory (Figure 4.1A) or aggression-related 
(Figure 4.1B). In particular, among the affiliative/exploratory behaviours scored, 
anogenital sniffing and crawl-overs were markedly recurrent. Moreover, aggression 
events were more numerous between HG rats, as evidenced by significantly greater 
occurrences of freezing (***p < 0.001), boxing (**p < 0.01) and pmnmg events 
(*p < 0.05). USVs were also recorded and analysed for the entire duration of the 
encounters. Figures 4. 1 C, D and E show that subjects of the HG group emitted greater 
numbers of distinct USVs than CTRL rats during these encounters. In particular, HG rats 
emitted a greater number of negatively valenced 22-kHz (*p < 0.05, Figure 4.1 C). 
In addition, caUs of the 50-kHz group were significantly more numerous in pairs of 
HG rats (**p < 0.01 for FM 50-kHz caUs and ***p < 0.001 for fiat 50-kHz caUs, 
Figure 4.1D and E). Altogether, these data demonstrate the hyper-sociable and 
hyper-aggressive nature of social encounters between pairs of HG rats in relation to 
the CTRL group. 
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(Continued.) The number of occurrences of affiliative/exploratory (A) 
and aggression-related (B) behaviours were scored during 10-min 
encounters between pairs of rats of the same group (control [CTRL] or 
hyperglycaemic [HG]). Negatively valenced (22-kHz) (C), positively 
valenced (frequency modulated [FM] 50-kHz) (D) and supposed 
ambivalent (flat 50-kHz) (E) Ultrasonic vocalisations (USVs) emirted by 
pairs of rats during these confrontations were also scored. AIl data 
presented as means ± SEM. Asterisks indicate statistical differences 
between the HG group and CTRL group, ascertained by a multiple t-test 
for A and B, or by Mann-Whitney's U test for C, D and E (*p < 0.05, 
**p < 0.01, ***p < 0.001). 
Behavioural covariance profile 
Pearson correlation coefficients were calculated for each pair of behavioural 
variables measured during encounters between two rats of the same group, and rendered 
in a covariance matrix wherein values of + l, 0 and -1 signify the tendency for 
two variables to covary similarly (positive covariance), differently (no covariance) or 
oppositely (negative covariance), respectively. The CTRL group matrix (Figure 4.2A) 
revealed tendencies for most behaviours of the affiliative/exploratory type to positively 
covary together within the same 10-min encounter (upper-Ieft quadrant). In particular, 
dorsal contacts most positively covaried with crawl-overs. More significantly, 
aggression-related behaviours positively covaried together within the same encounter 
between pairs of CTRL rats (lower-right quadrants, *p < 0.05 or ***p < 0.001). Boxing 
and pins were the strongest associated behaviours of the aggression type (***p < 0.001). 
This is indeed expected in an escalating sequence of rough-and-turnble play where 
upright boxing between rats usuaIly leads to pinning of one of the animaIs in a 
supine position. In addition, bortom-left and upper-right quadrants iIlustrate that 
affiliative/exploratory behaviours and aggression behaviours negatively covaried within 
the same 10-min encounter. This was most significant for allogrooming behaviours 
(*p < 0.05). These data reflect coherence in the interactions between healthy CTRL rats. 
Compared to the CTRL group, HG rats displayed a visibly altered behavioural 
profile (Figure 4.2B). Although there were strong associations between most behaviours 
of the same nature, whether affiliative/exploratory (upper-left quadrant) or aggression-
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related (lower-right quadrant), other behaviours not shown to similarly covary in 
CTRL rats within the same encounter were markedly positively associated in HG rats. 
Specifically, the affiliative/exploratory anogenital sniffing behaviour tended to 
positively covary with aggressive behaviours such as boxing and nose-offs, but was 
most tightly associated to pins (***p < 0.001). Relatedly, we found a strong positive 
covariance between pins and dorsal contacts (**p < 0.01). Despite their higher rate of 
occurrence (Figure 4.2B), freezing events did not consistently positively covary with any 
other behaviour during encounters between pairs of HG rats. With respect to the pattern 
of association displayed by the CTRL group, rats of the HG group seem to engage in 
incoherent social interactions characterized by episodes of play and fight intertwining 
within the same encounter. 
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Affiliative/exploratory and aggression behavioural covariance 
matrices. 
Matrices show strength of association, expressed as Pearson correlation 
coefficients, for each combination of behaviour laid out on the x- and 
y-axes as measured during 10-min encounters between two rats of 
the same group. Values of 1 (deep red), 0 (white) and -1 (deep blue) 
signify the tendency for two variables to covary similarly (positive 
covariance), di fferentl y (no covariance) or oppositely (negative 
covariance), respectively. Affiliative/exploratory behaviours are dorsal 
contacts, allogrooming, anogenital sniffing and crawl-overs. Aggression 
behaviours are freezing, nose-offs, boxing and pins. Behavioural profiles 
are provided for the CTRL (A) and HG (B) groups. Asterisks indicate 
statistical significance of the positive or negative covariance of two 
variables (*p < 0.05, **p < 0.01, ***p < 0.001). 
211 
Behaviour-vocalisation covariance profile 
A similar strategy was employed to evaluate whether the emlSSlOn of certain 
categories of USVs covaried with distinct types of behaviours within the same 10-min 
encounter between pairs of same-group rats (Figure 4.3). Between pairs of CTRL rats 
(left quadrants), the emission of negatively valenced 22-kHz caUs and aggression 
behaviours of aU types positively covaried (***p < 0.001). ln addition, FM 50-kHz 
USVs positively covaried with one of the most positively valenced behaviours, that is, 
aUogrooming [32] (*p < 0.05). Accordingly, 22-kHz US Vs negatively covaried with this 
behaviour (*p < 0.05). Flat 50-kHz caUs, on the other hand, were more often emitted 
during encounters wherein anogenital sniffing activities were nurnerous (**p < 0.01), 
but also slightly positively covaried with aUogrooming and pins. This is in line with 
the proposed ambivalent nature of flat calls, which may have served here to pace 
intrusive exploratory behaviours, su ch as anogenital sniffing and allogrooming, or to 
signal discomfort or uncertainty during pinning events. 
With respect to the CTRL group, HG rats (Figure 4.3, right quadrants) presented 
pronounced distortions in the covariance relationships between the USVs they emitted 
and the behaviours they exhibited during the same 10-min encounter. Most striking is 
the lack of a c1ear positive covariance between 22-kHz calls and behaviours likely to 
induce these USV s, such as nose-offs, boxing and pins. ln addition, FM 50-kHz and 
affiliative/exploratory behaviours did not positively covary. The most coherent pattern 
of positive covariance remained the significantly nurnerous emissions of 22-kHz calls 
during encounters that also featured numerous freezing events between HG rats 
(***p < 0.001). 
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Figure 4.3 
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Behaviour-vocalisation covariance matrix. 
Matrices show strength of association, expressed as Pearson correlation 
coefficients, for each combination of USV category (x-axis) and type of 
behaviour (y-axis) as measured during 10-min encounters between 
two rats of the same group. Values of 1 (deep red), 0 (white) and -1 
(deep blue) signify the tendency for two variables to covary similarly 
(positive covariance), differently (no covariance) or oppositely 
(negative covariance), respectively. Affiliative/exploratory behaviours are 
dorsal contacts, aUogrooming, anogenital sniffing and crawl-overs. 
Aggression behaviours consist in freezing, nose-offs, boxing and pins. 
Twenty-two-kHz USVs are negatively valenced, FM 50-kHz US Vs 
are positively valenced, and flat 50-kHz USVs are supposed ambivalent 
caUs. Behaviour-vocalisation profiles are provided for the CTRL 
(left quadrants) and HG (right quadrants) groups. Asterisks indicate 
statistical significance of the positive or negative covariance of two 
variables (*p < 0.05, **p < 0.01, ***p < 0.001). 
Magnitude of social interactivity and ultrasonic vocalisations in relation to the degree 
of striatal denervation, hypoinsulinaemia and glucose intolerance 
We performed densitometric immunohistochemical analyses of striatal tyrosine 
hydroxylase (TH)-positive terminal fibres in the brains of certain CTRL (n = 3) and 
HG rats (n = 6) utilized in the experiments described above. This allowed for the 
division of these HG subjects into two distinct subgroups: low denervation and high 
denervation (Figure 4.4A). Figure 4.4B displays representative microphotographs of the 
striatal denervation observed in HG brains compared to healthy CTRL rats. The baseline 
insulinaemia and glucose tolerance of certain CTRL (n = 5-6) and HG (n = 17-20) rats 
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utilized in the experiments described abovewere also obtained on the day of their 
sacrifice following an oral glucose tolerance test. This allowed for the division of 
HG subjects based on the severity of their hypoinsulinaemia (Figure 4.4C, low and 
high hypoinsulinaemia) or glucose intolerance (Figure 4.4D, low and high glucose 
intolerance ). 
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(Continued.) (A, B) Irnmunohistochemical analyses of the striatal region 
of CTRL and HG rat brains. At the end of behavioral experiments, frozen 
post-fixed brain hemispheres were cut into 20 Ilm-thick coron al seriai 
sections and stained for the dopaminergic terminal fiber marker, tyrosine 
hydroxylase. A. Densitometric analyses allowed for the distinction of 
two subgroups, LOW (> 50% of CTRL) or HIGH « 50% of CTRL), 
within the HG group concurring to the degree of striatal dopaminergic 
denervation. B. Representative microphotographs of tyrosine hydroxylase 
staining in the striatum (Bregma ~ 1 mm, scalebar 1 mm). C: Baseline 
insulinemia measurements upon sacrifices allowed for the separation of 
HG rats between LOW hypoinsulinemia (> 200 pg!mL) and HIGH 
hypoinsulinemia « 200 pg/mL). D: Following an oral glucose tolerance 
test performed on the moming of their sacrifice, are as under the curve of 
glycemias on areas under the curve of insulinemias yielded indices of 
glucose intolerance. Rats were separated on this basis between LOW 
(> 0) and HIGH (0) glucose intolerance. AlI data presented as 
means ± SEM. Asterisks indicate statistical differences between the 
HG group and CTRL group (**p < 0.01). 
The mean rate of occurrence of specific affiliativelexploratory and aggression-
related behaviours was obtained for each abovementioned subgroup ranked by degree 
of striatal denervation, hypoinsulinaemia and glucose intolerance (Figure 4.5). 
In particular, HG rats exhibiting the highest levels of striatal denervation engaged in 
more numerous affiliativelexploratory (Figure 4.5A) and aggression-like (Figure 4.5B) 
behaviours than rats from the other two subgroups, significantly for dorsal contacts 
(***p < 0.001 compared to CTRL and +p < 0.05 compared to the low denervation 
subgroup), anogenital sniffing (***p < 0.001 compared to CTRL and ++p < 0.01 
compared to the low denervation subgroup), boxing (***p < 0.001 compared to CTRL 
and +++p < 0.001 compared to the low denervation subgroup) and pinning 
(***p < 0.001 compared to CTRL and ++p < 0.01 compared to the low denervation 
subgroup). No c1ear trend for increased affiliativelexploratory or aggression behaviour in 
relation to the degree of hypoinsulinaemia (Figure 4.5C and D) or glucose intolerance 
(Figure 4.5E and F) was revealed. In fact, dorsal contacts were less frequent in the high 
hypoinsulinaemia subgroup than in the low insulinaemia subgroup (+p < 0.05). 
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Figure 4.5 Occurrences of social behaviours in relation to the degree of striatal 
denervation, hypoinsulinaemia or glucose intolerance. 
Occurrences of affiliative/exploratory (A, C, E) or aggression-related 
(B, D, F) behaviours performed by pairs ofCTRL rats or pairs of HG rats 
belonging to the low or high striatal denervation (A, B), hypoinsulinaemia 
(C, D) or glucose intolerance (E, F) groups were plotted. AH data 
presented as means ± SEM. Asterisks indicate statistical differences 
between groups and the CTRL group, ascertained by two-way ANOVA 
followed by Tukey's post-hoc analysis (*p < 0.05, **p < 0.01 , 
***p < 0.001). Plus signs indicate statistical differences between high and 
low groups, ascertained by two-way ANOVA followed by Tukey' s 
post-hoc analysis (+p < 0.05, ++p < 0.01 , +++p < 0.001). 
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Next, the mean rate of occurrence of USVs emitted was obtained for the same 
defined subgroups (Figure 4.6). In particular, HG rats exhibiting the highest levels of 
striatal denervation emitted more numerous FM 50-kHz USVs compared to the CTRL 
subgroup (*p < 0.05), which was not the case for the low denervation subgroup 
(Figure 4.6A). In addition, nonoticeable link was found between the degree of 
hypoinsulinaemia (Figure 4.6D, E and F) or glucose intolerance (Figure 4.6G, H and 1) 
and emissions of USVs of any category. Together with the previous data, Figure 4.6 
supports previous observations of a hyper-sociable and hyper-aggressive behavioural 
phenotype in long-term HG rats that appears to be partly dictated by the degree of 
striatal denervation exhibited by individual subjects. 
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Figure 4.6 Numbers of social behaviours in relation to the degree of striatal 
denervation, hypoinsulinaemia or glucose intolerance. 
Continued on next page. 
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(Continued.) Numbers of US Vs emitted by CTRL rats or HG rats 
belonging to the low or high striatal denervation (A-C), insulinaemia 
(D-F) or glucose intolerance (G-I) groups were plotted. (A, D, G) 
Negatively valenced 22-kHz USVs. (B, E, H) Positively valenced FM 
50-kHz USVs. (C, F, 1) Supposed ambivalent flat 50-kHz USVs. Ali data 
presented as means ± SEM. Asterisks indicate statistical differences 
between groups and the CTRL condition, ascertained by Kruskal-Wallis 
ANOVA followed by Dunn's post-hoc analysis (*p < 0.05). 
Although awareness of behavioural alterations in diabetic patients has been on the 
rise lately, research offers limited insight on the physiological factors that may impinge 
on these issues. While acute hypo or hyperglycaemic states are acknowledged to foster 
more aggressive states in humans [8-11], little is known about the effects of long-terrn 
dysglycaemia. Prior studies have employed acutely hyperglycaemic mice (duration of 
hyperglycaemia < 1 month) in resident-intruder paradigms [13 , 14] or hyperglycaemic 
rats in mating paradigms [12] , but have yielded inconsistent findings on the social 
effects of hyperglycaemia in paradigms that, further, poorly reflect the chronicity of 
the diabetic condition. 
To the best of our knowledge, the present report constitutes the fIfst detailed 
account of alterations in social behaviour and USV communications in a rat model of 
long-terrn hyperglycaemia. In aIl evidence, rats of the HG group were hyper-sociable 
and hyper-aggressive, as supported by marked increases in the occurrences of both 
affiliative/exploratory and aggression-related behaviours. Accordingly, compared to 
CTRL rats, they emitted many more USVs thought to operate both as social contact caIls 
[21 , 33] and expressions of affective states [15]. In addition to the rise in occurrences of 
social behavioural or vocalisation events, the covariance profiles of these variables were 
radically different between CTRL and HG groups. Coherent associations between 
behaviours of the same kind or between behaviours and USVs that supposedly have the 
same valence were aimost completely lost in HG rats. 
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ln an attempt to better understand the neurobiological underpinnings of impaired 
social behaviour and disjointed USV communications in our mode l, results were related 
to the degree of TH-positive fibres in the striaturn. lndeed, focal to social behaviour 
are a variety of neurotransmitters acting via circuits that can be modulated by 
pharmacological interventions [34, 35]. One such neurotransmitter is dopamine, 
exemplarily targeted by dopaminergic antagonists to treat abnormal aggresslve 
behaviours in autism, schizophrenia and excessive stress [36-40]. By releasing dopamine 
in the striatum, midbrain neurons partake in the regulation of social behaviours but also 
of other goal-directed operations ranging from movement production to reward-seeking 
processes [41-44]. ln agreement with the purported role of mesostriatal dopamine in 
social conduct, we found the altered social behaviours between pairs of unacquainted 
rats to be predicted by the degree of striatal TH-positive fibre loss. This is supported by 
the differences in 50-kHz USV emissions between CTRL and HG rats, also importantly 
modulated by mesostriatal dopamine [15]. Nevertheless, we cannot exclude that our 
results may have been partly influenced by toxic and/or adaptive modifications induced 
by long-term hyperglycaemia in non-dopaminergic neurotransmitter systems, which also 
critically regulate social behaviour and emission of USVs [35, 45-50]. For example, 
based on the loss of striatal TH-positive fibres, it could be hypothesized that 
hyperglycaemic damage of the noradrenergic system may have participated in the 
behavioural abnormalities observed here. Further studies will be necessary to precisely 
determine the interplay between social and vocal behaviour and neurotransmitter 
systems in HG rats. 
The role for increased mesostriatal dopamine neurotransmission in the promotion 
of impulsive, social and reward-related behaviours as weIl as in the emission of 50-kHz 
USVs seems to challenge our results showing an apparent correlation between striatal 
denervation and increased sociability, aggression and vocalisation. Nevertheless, our 
findings on the emission of 50-kHz USVs by HG rats are consistent with results from a 
previous study in male rats bearing a unilateral terminal denervation of the dopaminergic 
nigrostriatal system [51] . lndeed, the latter study showed that dopamine-denervated rats 
showed a trend towards an increase in the numbersof 50-kHz USVs emitted during 
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mating, compared with neurologically intact rats. It is possible that the occurrence of 
dopamine receptor supersensitivity due to deafferentiation and/or an imbalance in tonic 
and phasic firing may account for the increased reactivity to social novelty in our model 
[52]. Indeed, we have previously shown a decrease in tonic dopaminergic transmission 
in the striatum oflong-term HG rats [31]. Tonic firing consists in the slow and irregular 
single-spike release of dopamine produced by the baseline pacemaker activity of 
mesostriatal dopaminergic neurons, which main tains a certain level of striatal dopamine 
"noise" [53]. Tonic dopamine is required to enable striatal postsynaptic targets 
embedded in corticostriatal circuits involved in the selection of pre-Ieamed programs 
[54-56] . Phasic firing, on the other hand, involves a stimulus-mediated discharge of 
spikes in a short amount of time [57] . These bursts raise the levels of striatal dopamine 
above the noisy tonicity, acting as a "signal" that directs attention to a salient stimulus. 
When striatal tonicity is low, phasic dopamine becomes much more relevant over the 
reduced noisy background; thus, when produced in response to salient stimuli like 
exposure to a novel social context or emission of 50-kHz USVs [58], phasic firing might 
cause inappropriately intense reactions as observed in our mode!. Notably, transcending 
neurodegeneration, receptor supersensitivity, altered dopamine concentrations or 
imbalances in tonic-to-phasic (noise-to-signal)firing have aIl been proposed to explain 
various psychiatric disorders such as schizophrenia [59, 60] and attention deficit 
hyperactivity disorder [61 , 62]. Importantly, hyper-sociable and hyper-aggressive traits 
are typical of the latter and very similar to those present in our model [63-65]. 
The overt hyper-sociable and hyper-aggressive behaviours exhibited by HG rats 
are also reminiscent of impulsive traits found in the streptozotocin model, albeit in 
other contexts. Indeed, drugs that modulate mesostriatal dopamine are more rewarding 
in streptozotocin-treated rats than in untreated conspecifics [66-68]. In addition, 
hyperphagia, a hallmark of the model, is at least partly regulated by mesostriatal 
dopamine [69, 70]. To aIl appearances, the streptozotocin model increases the rewarding 
properties of several environmental stimuli. We show here that this could include social 
interactions as supported by the concomitant increase in the emission of 50-kHz USVs, 
which are a marker of positive affective states [15]. While metabolic hormonal 
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imbalances may be implicated to sorne extent in the hyper-reactive phenotype of 
streptozotocin-treated rats, as suggested by sorne [66, 69], it remains that the extent of 
behavioural alterations was tightly associated with striatal denervation and not with 
insu lin concentrations or functions in long-term hyperglycaemia. Given its implication 
in modulating behaviour in short- and medium-term [71-73], a role for the 
hypothalamic-pituitary-adrenal axis cannot be ruled out in the behavioural abnormalities 
observed here in streptozotocin-treated rats and should be addressed in future works 
[14, 74] . 
In summary, the present results demonstrate explicit manifestations of hyper-
sociable and hyper-aggressive traits in our model of long-term hyperglycaemia. 
The striking overall increases in positively and negatively valenced events, either 
behavioural or vocal, combined with the loss of coherence between the affective states 
represented by USVs and the social behaviour displayed may arise from neurobiological 
alterations. This is supported by the tight association between striatal denervation as 
opposed to the lack of a clear link between insulin and hyper-reactivity. These findings 
may ultimately lead to the formaI identification of dopaminergic neural substrates that 
may be targetable by pharmacological treatments, both to prevent striatal denervation 
and to palliate neurochemical imbalances in diabetic patients faced with psychiatric 
challenges. 
Methods 
Subjects 
Fort y male Sprague-Dawley rats (Charles River, St-Constant, Canada) weighing 
175-200 g were housed under standard laboratory conditions (12 h light/dark cycle). 
In all experiments, standard food and water were available ad libitum. Rats were housed 
two per cage to rule out any effect of social isolation on their subsequently measured 
behaviours [75]. Experiments were conducted in accordance with legislation and 
policies of the Canadian Council on Animal Care, as weIl as with the guidelines 
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established by the Animal Care Committee of the Université du Québec (Trois-Rivières) 
(2014-M.G.M.5). 
Induction of hyperglycaemia 
Rats were randomly assigned to the control or hyperglycaemic group (CTRL 
n = 18; HG n = 22). Hyperglycaemia was induced as previously described [31]. 
Briefly, fasted rats of the HG group were intraperitoneally injected with nicotinamide 
(100 mg/kg b.w.) followed by the beta cell toxin streptozotocin (55 mg/kg b.w., 
Enzo Life Sciences, Farmingdale, NY, USA). Pre-injections with nicotinamide restrain 
the death of insulin-producing pancreatic beta cells and yield long-term HG rats that 
do not require glycaemia-Iowering treatments [31 , 76]. CTRL rats received vehicle 
injections. Throughout experiments, glycaemia was estimated using an UltraMini digital 
glucose meter and matching strips (One Touch Ultra) both purchased at a local Brunet 
pharmacy (Trois-Rivières, QC, Canada). Hyperglycaemia was confirmed 3 days after 
nicotinamide-streptozotocin injections and rats from the HG group that did not display a 
glycaemia steadily above 10 mM were discarded from this study. Importantly, rats from 
both groups were matched for age and experience, meaning that they were handled in 
the same manner and at the same frequency, in light of studies showing the role of age 
and experience on the emission ofUSVs [26]. 
Oral glucose intolerance test and baseline insulinemia 
On the morning of their sacrifice, we performed an oral glucose tolerance test 
(OGTT) on fasted rats, as previously described [31] . Briefly, rats were intragastrically 
administered 2 glkg of a D-glucose solution. Glycaemia and insulinaemia were measured 
right before the OGTT (0 min, baseline) and at 30, 60 and 120 min after administration 
of D-glucose using the Rat Glucose Assay kit provided by Crystal Chem (Downers 
Grove, IL, USA) and the Milliplex Adipokine Magnetic Bead Multiplex Assay 
(Millipore; Etobicoke, ON, Canada), respectively. The ratio of the area under the curve 
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of plasma insulin concentrations on the area under the curve of plasma glucose 
concentrations yielded indices of glucose intolerance. 
Ultrasonic vocalisations and social behaviour 
We began experiments 5 months following the induction of hyperglycaemia, at the 
time when rats were fit to engage in social interactions. Experiments consisted in 3 trials 
separated by 7 days each in order to prevent the behavioural habituation of rats to 
multiple encounters in a short amount of time [77]. Experiments were performed in 
3 different quiet rooms to rule out any environmental effects on the behaviour of the 
rats. USV recordings were performed as previously described [78]. Two group-paired 
unacquainted rats (CTRL 9 pairs times 3 trials; RG Il pairs times 3 trials) were placed 
in a Plexiglas cylinder (diameter, 25 cm; height, 30 cm) with fresh bedding, surrounded 
by walls to enhance the feeling of security, and topped with a sound-insulating lido 
An ultrasonic microphone (CM16/CMPA, Avisoft) was placed through a tight-fitting 
hole in the lid and was connected to an ultrasound-recording device (UltraSoundGate 
116 Rb, Avisoft). During USV recordings, constant gain was maintained. Figure 4.7 
shows examples of 22- and 50-kHz USVs recorded during this study. Two video 
cameras were positioned on opposite sides of the cylinder to record the encounters. 
USVs and images were recorded for 10 min, starting immediately after both rats were 
simultaneously placed in the cylinder. Rence, neither rat was an intruder in this context. 
Recording time was selected based on previous studies that evaluated the emission of 
US Vs by rats that engaged in social contacts [49, 71]. A blinded experimenter scored 
eight types of interactions provided by the video recordings. Affiliative/exploratory 
behaviours consisted in dorsal contacts (with both paws), allogrooming, anogenital 
sniffing, and crawl-overs (one rat crawls over the other rat) [79-81]. Aggression-related 
behaviours consisted in freezing (a submissive rat remains 5 consecutive seconds or 
more without movement except sniffing), nose-offs (both rats are immobile, facing each 
other, four paws on the ground or front paws raised, but do not box), boxing (one or both 
rats stand on their hind legs and push or paw their opponent), pins (one rat tops another 
one that is in supine position) [16, 82]. Occurrences of any of these behaviours were 
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counted for both rats, regardless of the amount of time the y lasted. Rats were never 
opposed to the same partner twice, thus social novelty was preserved throughout trials. 
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Examples of sonograms of ultrasonic vocalisations. 
Representative sonograms of 22-kHz (A) and 50-kHz (B) USVs. 
FM 50-kHz USVs (B, right) differ from flat ones (A and B left) in that 
there is a change in frequency within the cali. Ultrasonic vocalisations 
reported are examples of independent calls emitted by different rats. 
Immunohistochemistry 
At the end of the 3 trials, isoflurane anesthetized rats were intracardially perfused 
with cold PBS supplemented with protease and phosphatase inhibitors. Brains were 
harvested and post-fixed in 4% paraformaldehyde, cryoprotected through gradients of 
sucrose and conserved at -80oe for immunohistochemical analyses [15]. Frozen post-
fixed tissues were cut into 20 )..lm-thick coronal free-floating seriaI sections and 
immunoreactions were performed with a primary antibody raised against the rate-
limiting enzyme of dopamine synthesis, TH. Sections were then incubated with 
a horseradish peroxidase-conjugated secondary antibody, exposed with 3,3'-
diaminobenzidine, mounted on microscope slides, dehydrated and coverslipped. 
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Using a microscope ln brightfield mode (MBF Bioscience, Williston, VT, USA), 
the density of striatal terminais positive for TH was quantified densitometricaUy using 
the NIH ImageJ software version 1.49, and averaged in 4 slices per animal. A total of 
3 brains from the CTRL group and 6 brains from the HG group were randomly selected 
and analysed. Due to normal interindividual variability, degrees of denervation differed 
across the 6 HG rats, allowing for the separation of these individuals into high (n = 3) or 
low (n = 3) denervation subgroups. 
Statistical analyses 
USV recordings were converted into spectrograms using the software SASLab 
Pro 4.52 (Avisoft) with the foUowing settings: 512 FFT-Iength, Hamming window and 
75% overlap frame set-up [83]. A ski lied experimenter visually inspected and manuaUy 
cleaned aU signaIs that could not be univocaUy classified as vocalisations. Nurnbers of 
22-kHz and 50-kHz USVs were then counted using the SASLab Pro 4.52 software. 
Moreover, an experienced experimenter unaware of treatments manually counted 
numbers of FM and fiat 50-kHz USVs. USVs of 22-kHz were defined as caUs with 
sound frequency maintained between 20- and 35-kHz and long duration, higher than 
300 ms for a single caU [19]. In the present study, no 22-kHz USVs of duration shorter 
than 300 ms were observed [84]. USVs of 50-kHz were defmed as caUs with sound 
frequency maintained between 35- and 80-kHz and short duration, usually 10-15 ms for 
a single caU [19]. USV s of 50-kHz were further divided in fiat and FM USV s, based on 
the modulation of their sound frequency. Thus, fiat calls have the sound frequency 
within 35-50-kHz that remains nearly unchanged over the duration of the individual 
USVs [26]. Conversely, FM 50-kHz caUs have the sound frequency within 40-80-kHz 
that shows substantial changes within individual USVs [16]. 
Ail data were submitted to statistical analyses performed using GraphPad Prism 7 
software (San Diego, CA, USA; http://www.graphpad.com). Data were tested for 
normality and homoscedasticity, and were analysed accordingly. Behaviour-behaviour 
and behaviour-USV covariation matrices (Figure 4.2 and Figure 4.3) were derived from 
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Pearson correlation coefficients calculated for each pair of variables, where + 1, 0, and 
-1 respectively indicate the tendency for two variables to covary similarly (positive 
covariance), differently (no covariance) or oppositely (negative covariance) [85]. 
Occurrences of social behaviours, relative density of TH fibres , and measures of 
insulinaemia and glucose intolerance were parametrically distributed. Thus, significant 
differences between groups shown in Figure 4.lA and B were ascertained by multiple 
t-tests , ones in Figure 4.4A, C and D were ascertained by one-way ANOV A followed by 
Tukey's post-hoc analysis, and those shown in Figure 4.5 were determined by two-way 
ANOVA followed by Tukey's post-hoc analysis. On the other hand, emissions of VSVs 
were non-parametrically distributed. Therefore, significant differences between groups 
shown in Figure 4.1C, D and E were ascertained by Mann-Whitney's U test, 
while significant differences between groups shown in Figure 4.6 were ascertained by 
the Kruskal-Wallis ANOVA, followed by Dunn' s post-hoc analysis. All data were 
analysed at the 95% confidence interval and are expressed as means ± SEM. 
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CHAPTERV 
DISCUSSION 
Based on evidence of a unique phenotypic liability, and supported by the greater 
prevalence of Parkinson ' s disease in diabetic patients, the work presented in this thesis 
aimed to verify the hypothesis that nigrostriatal dopaminergic neurons are more 
vulnerable to hyperglycaemic conditions compared to other neuronal populations, 
expressly the mesocorticolimbic pathway. In the process, we attempted to coyer as 
man y dimensions of dopaminergic functioning as possible, harvesting evidence on a 
molecular, cellular, neurochemical, neuroanatomical and behavioural level to render a 
comprehensive picture of hyperglycaemia-induced neurodegeneration. To that end, four 
objectives were fulfilled and will be examined in light of elements brought to the table in 
the introduction. l will conclude these discussions by translating the significance of our 
results to the realities of diabetic and parkinsonian patients. 
5.1 Objectives 1 and 2: In vitro, high glucose-induced oxidative stress leads to the 
death of dopaminergic neurons avertible by 'resveratrol treatments 
In Chapter II, we successfully demonstrated that dopaminergic neurons degenerate 
when cultured in high glucose conditions. Using neuronal PC12 ceUs treated with the 
antioxidant resveratrol, we confirmed the implication of oxidative stress in high glucose-
induced apoptosis. This first step of the project provided a crucial comerstone upon 
which we built subsequent in vivo work. 
5.1.1 Drawing parallels with Brownlee's theory 
Brownlee's theory proposes that superoxide anion production is the earliest event 
leading up to oxidative stress in a hyperglycaemic setting (Brownlee, 2005; Du et al., 
2001; Giacco and Brownlee, 2010; Nishikawa et al., 2000). As previously stated, 
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early superoxide amon generation has not been investigated in animal models of 
hyperglycaemia. Our group was the first to verify the production of this specifie ROS 
in cultured neurons exposed to high concentrations of glucose (Boumival et al. , 2012a). 
In the present work, we further confirmed that this event occurs as early as 3 h following 
high glucose treatments, thereby supporting Brownlee's hypothesis. 
5.1.1.1 From oxidative stress to apoptosis 
Trailing this theory's mechanistic progression, superoxide anion should lead to the 
formation of other ROS that can damage nuclear DNA. In high glucose conditions, 
p53 was indeed markedly upregulated61 (Figure 5.1A and B) and it strongly localized to 
the nucleus at 96 h, indicating its probable transcriptional activation, stabilization and 
recruitment to damaged DNA, ail ensuing from oxidative insults (Lee et al. , 2008; Liu 
and Xu, 2011 ; Macip et al. , 2003; Norbury and Zhivotovsky, 2004; Sun et al. , 1995). 
Following its nuclear localization, p53 can either induce DNA reparation or prompt the 
activation of apoptosis when injuries are too substantial (Liu and Kulesz-Martin, 2000). 
Accordingly, our results show that neuronal PC12 cells undergo apoptosis in high 
glucose conditions, as evidenced by chromatin modifications, caspase-3-induced DNA 
fragmentation, PARP cleavage and a rise in Bax-to-Bcl-2 expression ratios. 
Supplementary evidence that oxidative stress is ongoing in our model is the rise in 
GRP75 expression under high glucose conditions (Figure 5.1 C and D), which confirms 
other reports of its induction during cellular stress (Londono et al. , 2012). Furthermore, 
we observe an increase in GRP75 and p53 colocalization in the cytoplasm62 , which 
likely occurs as a result of oxidative stress (Lee et al., 2007). Indeed, in response to 
oxidative insults, p53 is phosphorylated, which enables its interaction with GRP75 in 
the cytoplasm (Figure 5.2). Bound by GRP75 , p53 cannot enter the nucleus and induce 
61 Other groups also found the induction of p53 in response to DNA damage to consti tute a key event in 
the provocation of apoptosis. Indeed, p53 upregulation in dopaminergic neurons challenged with 
parkinsonian toxins seems to occur before any other apoptotic event (Li et al. , 2016; Nair, 2006). 
62 During cytoplasmic sequestration, GRP75-p53 colocalization is noticeably peri nuclear in our model, 
which corroborates the findings of others (Taurin et al., 2002) . 
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apoptosis ln otherwise lethal conditions. However, when p53 is steeply expressed, 
as in our model, it may partially evade GRP75 sequestration in the cytoplasm and enter 
the nucleus to induce apoptosis. 
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Total levels of p53 and GRP75 in neuronal pe12 cells treated with 
high glucose concentrations. 
Previously, we showed subcellular modulation of p53 and GRP75 levels. 
Here, total cellular levels are addressed. Neuronal PCl2 cells were treated 
with 25 mM of glucose for 96 h, with or without 0.1 !lM of resveratrol. 
Isotonie mannitol served as an osmotic control. (A, C) Relative total 
p53 or GRP75 immunofluorescence levels. (B, D) Relative total p53 or 
GRP75 expression measured by immunoblotting. High glucose 
concentrations increased total p53 expression levels, which was rescued 
by resveratrol treatments. In response to the glucose-induced rise in 
p53 levels, GRP75 expression is accordingly enhanced, with or without 
resveratrol treatments. *p < 0.05 , ***p < 0.001 compared with CTRL and 
+p < 0.05, +++p < 0.001 compared with HG, as determined by one-way 
analysis of variance (ANOVA), followed by Tukey' s multiple-
comparison test. Refer to Chapter II for methodological details. 
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Role of GRP75 in oxidative stress-induced apoptosis. 
As a sensor of oxidative stress and protein chaperone, GRP75 (mortalin) 
fulfils numerous functions in cells that are dependent on context. 
Under normal circumstances, GRP75 is thought to promote homeostasis 
in the subcellular localizations it occupies, expressly mitochondria. 
In conditions of stress, GRP75 is upregulated and translocates to the 
cytoplasm where it can also convey protection by preventing apoptosis 
(1). In particular, GRP75 can bind the phosphorylated form of the pro-
apoptotic effector p53. Under sustained amounts of stress, GRP75 can 
undergo deleterious alterations, which impede its protective functions (2). 
When the cell is only mildly stressed, GRP75 is poorly recruited to the 
cytoplasm, likely owing to a lack of significant p53 activation (3). 
OS, oxidative stress; P, phosphate group. (From Londono et al., 2012.) 
5.1.1.2 Paradoxical poly(adenosine di phosphate-ribose) polymerase inactivation 
Brownlee's model provides that the activity of the DNA repair enzyme PARP is 
augmented early in hyperglycaemic conditions, in response to ROS-induced DNA 
damage. This leads to the ADP-ribosylation of GAPDH and its consequent inhibition, 
inducing an accumulation of upstream glycolysis metabolites responsible for the 
rerouting of glucose into deleterious pathways. However, we observe that activated 
caspase-3 cleaves P ARP in its 24 and 89 kDa fragments, thereby preventing its 
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ADP-ribosylation function (Kaufmann et al., 1993). In fact, PARP cleavage is required 
in order to carry out apoptosis (Boulares, 1999). Irreversible binding of the 24 kDa 
portion to damaged DNA inhibits DNA repair and conserves energy pools in 
anticipation of apoptosis (D'Amours, 2001). Indeed, in its activated form, PARP is a 
heavy user of NAD+ whose exhaustion can lead to energy depletion-induced necrosis 
(Boulares, 1999). Since the full-Iength-to-cleaved ratio was measured in our model after 
96 h of exposure to high glucose conditions, it is probable that P ARP inactivation occurs 
late in the apoptotic cascade, which does not contradict a possible transient early 
increase in its activity. 
5.1.1.3 Validating Brownlee's model 
Although our results corroborate the implication of oxidative stress in the high 
glucose-induced apoptosis of dopaminergic neurons in culture, a deeper mechanistic 
insight is warranted to verify the neuronal suitability of Brownlee's theory, originally 
elaborated in bovine aortic endothelial cells. In this view, a step-by-step analysis of 
the events leading up to the death of dopaminergic neurons in culture is presently 
under way. 
The strategy we envision calls upon the inhibition of the most salient checkpoints 
in glucose metabolism dysfunction in the neuronal PC12 and N27 dopaminergic models. 
First, we will characterize by immunofluorescence the regulation of GLUT localization 
at the surface of neuronal cultures in response to glucose in a series of kinetic 
dose-response studies. In parallel, we will appraise the effect of varying glucose 
concentrations on its uptake at various time points, keeping in mind that accurate 
quantifications are not possible with CUITent fluorescent glucose analogues (Dienel et al., 
2017). Next, we will ver if y if GLUT inhibitors, such as cytochalasin B63 , can fully 
abrogate high glucose-induced neuronal death. Early events of mitochondrial 
63 Cytochalasin B is a competitive inhibitor of ail GLUT isoforms. In fact, this inhibitor is used to estimate 
absolute concentrations of GLUT proteins at the surface of cells, by measuring its equilibrium binding 
(Kalaria et al. , 1988; Maher and Simpson, 1994; Maher et al. , 1994). Such measurements were utilized 
in computing glucose and lactate transport capacities of brain cells in the core model (Simpson et al., 
2007) (Table 1.6). 
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dysfunction will be investigated as per the strategy hired by Brownlee and colleagues, 
which employed inhibitors of the electron transport chain, like rotenone (complex l 
inhibitor) and antimycin A (complex III inhibitor), to confirm the site of superoxide 
anion generation (Du et al., 2001; Nishikawa et al., 2000). Ideally, application of 
a mitochondrial uncoupler or upregulation of mitochondrial SOD should also be 
performed to verify, respectively, that dissipating the elevated transmembrane potential 
induced by the overworked electron transport chain and that quenching superoxide anion 
at the site of production are individually sufficient to prevent the death of neurons 
(Du et al., 2001; Nishikawa et al., 2000). We also plan to employ PJ34 and INO-I00l, 
specific P ARP inhibitors, to uncover the importance of enhanced P ARP activity in the 
death of neurons, especially in view of our current results demonstrating its cleavage in 
late apoptosis. Correspondingly, we will assess the level of GAPDH ADP-ribosylation 
and measure this enzyme's activity in conditions of high glucose. It would also be 
interesting to verify whether the inhibition of GAPDH by koningic acid is sufficient to 
elicit the death of neurons in a way that emulates high glucose conditions. Last, the 
polyol pathway will be investigated, on the one hand, by weighing the benefits of 
inhibiting aldose reductase with sorbinil in high glucose conditions, and on the other, by 
measuring the state of reduced glutathione-to-oxidized glutathione in our mode\. 
Considering the lack of evidence pertaining to the chain of early events that lead to 
neuronal degeneration in high glucose or hyperglycaemic conditions, it would be highly 
pertinent to determine whether neuronal apoptosis occurs before a tangible loss of 
mitochondrial respiration. For the moment, the literature only reports a drop in the 
respiratory rate of cultured peripheral nerves from diabetic rodents at later time points 
(Aghanoori et al. , 2017; Akude et al., 2011; Chowdhury et al. , 2010). This question 
should be investigated both in vitro and in vivo in order to determine whether cultured 
neurons are faithful mechanistic models of what occurs in the CNS. The elaboration of 
proper in vitro frameworks provided with a valid precinct of applicability would 
therefore allow for more cautious and robust conclusions to be drawn from cultured 
neurons. In our case, we simply aimed to verify the death of cultured dopaminergic 
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neurons in high glucose conditions, permitting a careful inference of their probable 
demise in a rodent model ofhyperglycaemia. 
5.1.2 Resveratrol: partial antioxidative effects, but full neuroprotection 
In addition to demonstrating that high glucose concentrations trigger the oxidative 
stress-induced apoptosis of dopaminergic neurons, Chapter II also provides evidence for 
the protection conferred by the antioxidant resveratrol in these conditions. These results 
constitute the first report of the protective effect of resveratrol on neurons challenged 
with high glucose concentrations or hyperglycaemia. Studies performed in the CNS of 
diabetic rodents were issued later and support our results (Bagatini et al. , 2017; Sadi and 
Konat, 2016). 
Although we did not aim to unravel the mechanistic underpinnings of resveratrol 's 
effects, it is possible to surmise that direct scavenging of ROS occurred in our model, 
as it was shown to be possible in vitro (Fauconneau et al. , 1997; Frémont, 2000; Kawada 
et al. , 1998; Stivala et al., 2001). Additional antioxidative mechanisms may have been 
mediated indirectly through inhibition of PDE, mTOR or NQ02, respectively leading to 
activation of the AMPK-SIRTI-PGC-la axis, stimulation of autophagy, and reduced 
production of cytoplasmic ROS. Ali of these events may have contributed to mitigate 
oxidative stress and to prevent the apoptotic death of neuronal PC 12 cells in high 
glucose conditions. 
It remains that sorne of the protective effects exerted by resveratrol treatments 
were admittedly limited. This was the case for the inhibition of superoxide anion 
generation and the reversai of GRP75 , s compensatory overexpression. Our results show 
that resveratrol did not completely prevent the formation of superoxide anion at 3 h. 
However, we did not verify this effect at later time points, and the antioxidant may weil 
have exerted its full effect by 96 h. More plausible is that resveratrol's antioxidative 
effect was indeed partial, but sufficient to confer total neuroprotection, as evidenced by 
the complete abrogation of apoptosis. The lack of mitochondrial GRP75 downregulation 
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in neuronal PC12 cells treated with high glucose concentrations and resveratrol indicates 
a likely need for the chaperone to wield a protective response in this organelle still 
displaying higher-than-norrnal levels of superoxide anion. However, in the cytoplasm, 
resveratrol treatments successfully prevented the overexpression of GRP75. This could 
be attributable to the fact that DNA damage was no longer critical, that p53 was not 
upregulated, and that GRP75 was not required to impound this apoptotic factor in the 
cytoplasm. It follows that resveratrol may have exerted just enough protection to 
preclude apoptosis by diminishing superoxide anion production to sublethallevels. 
Polyphenols often exert partial effects in biological systems that can only partially 
be optimized by increasing doses. One theory provides that a biphasic dose-response 
relationship, for instance horrnesis, may explain the limited though significant 
bioefficacy of this class of molecules (Figure 5.3). We have discussed this topic in 
greater detail elsewhere (Appendix B). 
Figure 5.3 
Maximum response 
(averages 130-160% of control) 
/ 
Hormetic Zone 
(averages 10- to 20-fold) 
Increasing Dose 
Distance to NOEL 
(averages 5-fold) 
NOEL (No Observed Effect Level) 
Control 
Dose-response curve depicting the quantitative features of hormesis. 
Horrnesis is most commonly expressed as a J or inverted U dose-response 
curve, which either dips below or rises above a threshold of efficacy, 
depending on the observed endpoint. In this horrnetic zone, effects are 
consistently predicted to be moderate, ranging between 30-60%. 
(From Calabrese et al. , 2013.) 
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5.1.3 The relevance of glucose-regulated protein 75 in Parkinson 's disease 
Reports showed the depletion of GRP75 in post-mortem substantia nigra pars 
compacta samples of patients before our paper was published (Burbulla et al. , 2010; 
Jin et al., 2006). Gaining momentum as a possible novel genetic risk factor, reports 
today are rather equivocal regarding its association with the disease. Indeed, one group 
found two point mutations, albeit rare, in the GRP75 gene of parkinsonian patients 
(Wadhwa et al. , 2015), whereas another study concluded that this chaperone was not 
genetically associated to Parkinson ' s disease (Chung et al. , 2017). Nevertheless, 
evidence converges toward the reduced expression of GRP75 in specific affected brain 
regions, expressly the substantia nigra pars compacta, both in patients and in rodent 
models of Parkinson ' s disease (Cook et al. , 2016; Koo et al. , 2017; Liu et al., 2015). 
In this view, our results rather show a rise in GRP75 expression levels in response 
to a cellular stress. What occurs in our in vitro model challenged with high 
concentrations of glucose is likely not representative of these physiological observations 
harvested in brain samples having sustained months, in rodents, or years, in humans, 
of Parkinson's disease-related stress. It is nevertheless interesting to see how GRP75 is 
systematically downregulated in the substantia nigra pars compacta and invites the 
question of whether this protective chaperone may be a supplementary phenotypic 
liability specific to the neurons harboured in this structure. 
5.2 Objectives 3 and 4: In vivo, long-term hyperglycaemia causes preferential 
nigrostriatal dopaminergique neurodegeneration and consequential 
behavioural alterations 
Upon validating that dopaminergic neurons cultured in high glucose conditions 
undergo cell death, we elaborated a rodent paradigm wherein neurodegeneration 
could be assessed following long-term hyperglycaemia. Through immunoblotting, 
immunohistochemical, neurochemical and behavioural analyses, we obtained data 
presented in Chapter III demonstrating a decrease in dopamine neurotransmission in the 
dorsal striatum, the degeneration of nigrostriatal neurons, motor impairments and glial 
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alterations in long-term hyperglycaemic rodents. Chapter IV provided further 
information on the behavioural manifestations displayed by hyperglycaemic rats In a 
social context, correlated to the level of striatal denervation. 
5.2.1 Intracerebral glucose concentrations 
The first element discussed in Chapter III was the nse ln CNS glucose 
concentrations in hyperglycaemic rats. This firsthand demonstration was required to 
solidify the argument that sustainably elevated intracerebral glucose concentrations may 
induce neurodegeneration. Precisely, providing proof that glucose concentrations were 
not altered differentially in the various brain regions of interest was crucial. 
As previously stressed, aIl studies reporting intracerebral glucose measurements to date 
have provided quantifications in, at best, two brain regions at a time (Abi-Saab et al., 
2002; Béland-Millar et al., 2017; de Vries et al., 2003; Gomez and Barros, 2003; Jacob 
et al., 2002; Macauley et al., 2015; McCrimmons et al., 2003; Osborne et al., 1997). 
Granted inter- and intra-individual variability ainong hyperglycaemic models, we thus 
sought to rely on our own measurements to confirm - instead of presuming, like others 
have - a uniform rise in glucose concentrations throughout various brain regions at a 
time64. 
In this Vlew, we aimed to verify the rise in brain glucose by more than one 
single method. Using the microdialysis technique, we were able to obtain estimations of 
extracellular glucose concentrations in uniformly-fed rats. This technique also allowed 
us to distinguish midbrain and striatal subareas, owing to the spatial precision afforded 
by the probes. By homogenizing brain tissues, we also appraised intracellular glucose 
concentrations, although we were fully aware that terminal perfusion of the animaIs 
constituted a cause for underestimations due to efflux through bidirectional GLUTs 
driven by concentration gradients. Nevertheless, the purpose of these procedures was to 
assess if there was a significant rise in glucose concentrations throughout the brain, 
64 Speculative computations performed by Simpson and colleagues (2007) sti ll provided a theoretical basis 
for an initial assumption that glucose concentrations may rise in the brain in hyperglycaemic conditions 
and for justifying the purpose of our in vivo investigations (Table l .7). 
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and if there were substantial differences between neuroanatomical loci. We also aimed 
to verify that intra- and extracellular observations coincided. For these reasons, 
ail results were reported in relative and not absolute values. 
Our results provided a firm validation that intracerebral glucose concentrations 
increase significantly and uniformly throughout the midbrain, striatum, prefrontal cortex 
and hippocampus of hyperglycaemic rats. Elevated concentrations were also sustained 
over the course of 6 months. These results were important to unravel several remaining 
interrogations with respect to a possible downregulation of glucose uptake in long-term 
hyperglycaemia. Indeed, there is no adequate account of the regulation of GLUTs over 
long periods of hyperglycaemia (Anitha et al. , 2012; Nagamatsu et al., 1994; Santiago 
et al. , 2006; Simpson et al. , 1999), nor is there evidence to sustain reduced glucose 
uptake due to reductions in cerebral blood flow arising from abnormal vascular features 
in this chronic setting (Carruthers and Helgerson, 1989; Duckrow et al., 1987; Levine 
et al. , 1998; Lowe and Walmsley, 1986; McCall, 1992; Nishimura et al. , 2007). We are 
currently quantifying GLUT expression in brain slices from our model in the aim of 
filling these knowledge gaps. There is, nevertheless, reason to believe that intracellular 
glucose concentrations remain significantly elevated after 6 months of sustained 
hyperglycaemia in our rat mode\. 
5.2.2 Altered glial profiles as an indicator of oxidative stress 
On the quest to coyer as many aspects of CNS dysfunction III our paradigm, 
we reported the effects of long-term hyperglycaemia not only in neurons, but also in 
glial populations. These glial alterations are discussed first on account of the information 
they can convey with respect to the oxidative status of the CNS, directly linked to our 
in vitro work. 
By immunohistochemical staining, we discovered a marked proliferation of 
astrocytes in the substantia nigra pars compacta, the dorsal striatum, the nucleus 
accumbens and the prefrontal cortex. Conversely, there was a noticeable loss of 
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microglial ceIls in the substantia nigra pars compacta, the dorsal striatum, and the 
nucleus accumbens. A first appraisal of these results aIlowed us to conclude that both 
pathological features are present in the substantia nigra pars compacta, but not in the 
ventral tegmental area, further underlining a regional vulnerability to pathological 
alterations ensuing from hyperglycaemia. They also manifested themselves throughout 
the striatum. 
In Chapter III, we discussed the well-appreciated association between astrogliosis 
and diabetes. We also proposed a role for oxidative stress in causing the death of 
microglial ceIls, an under-recognized feature in CNS affections. We can further 
elaborate on the tentative timeline proposed in this article, which stipulated that an initial 
microglial ceIl activation in turn conduces to astroglial activation, foIlowed by the death 
of the former, which are not equipped to cope with sustained oxidative stress. lndeed, 
CNS microgliosis occurs early in hyperglycaemic rodent models (Nagayach et al. , 2014; 
Oliveira et al., 2016). Importantly, microgliosis can be triggered by oxidative stress, as 
demonstrated in various paradigms (Bordt and Poister, 2014; Kang et al., 2001; Mander 
et al., 2006; Rojo et al., 2010). This event th en directly contributes to the activation of 
astrocytes (Liddelow et al., 2017) whose elevated levels can be appraised in our model 
6 months following hyperglycaemia induction. One question that dweIls here is the 
physiological pertinence of upregulating astrocyte proliferation by oxidative stress-
activated microglial cells. Recalling the importance of the ppp in protecting against 
oxidative stress offers one clue. With neurons, astrocytes constitute the main ceIl type to 
process important amounts of G6P through the ppp for the recovery ofNADPH serving 
to regenerate the antioxidative co factor glutathione. In fact, the ppp is 4-5 times more 
active in astrocytes th an in neurons and is upregulated in high glucose conditions65 
(Ben-Yoseph et al., 1996a, 1996b; Garcia-Nogales et al., 2003; Takahashi et al., 2012) 
(Figure 5.4). Remarkably, microglial cells can also mediate the increase in astroglial 
ppp activity, independently of its influence on the proliferation of these cells (Iizurni 
et al., 2016). It is therefore reasonable to surmise that microglial activation serves to 
65 Similarly, the ppp is downregulated when glucose levels are reduced, thereby dulling the antioxidative 
potential of neural cells (Takahashi et al., 2012). Sorne have suggested this phenornenon to explain the 
risks that sharp glycaernic variations represent in diabetic patients. 
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promote the proliferation of astrocytes, alongside their ppp flux , in order to respond to 
oxidative insults. Interestingly, the ppp also serves to generate ribose 5-phosphate for 
the synthesis of nucleic acids required for mitosis, such as in proliferating astrocytes, 
constituting yet another way by which this compensatory effect is coupled with 
purposeful cellular functions (Lehninger et al. , 1995). 
Figure 5.4 
A B c 
Metabolic activities of astrocytes and neurons. 
In primary neuronal (black) and astroglial (white) cultures, the rate of 
ppp activity (C) was obtained by measuring the difference between 
radio-carbon dioxide ('4C02) production ensuing from the ppp and the 
tricarboxylic acid cycle (A) or the tricarboxylic acid cycle alone (B) by 
employing glucose isotopes labelled at the Cl or C6 positions. Focusing 
on the graph on the right, astroglial cultures display ppp activities 
4-5-fold times greater than neuronal cultures. Means ± standard 
deviation. *p < 0.05 ; ***p < 0.001 between groups, according to t-test. 
(From Takahashi et al., 2012 .) 
The functional relationship between oxidative stress-induced microglial activation 
and astrogliosis clearly emerges upon disceming the near-perfect correspondence 
between loci displaying high levels of astrocytes and those harbouring significantly 
fewer micro glial cells. If indeed microglial cells perish due to sustained oxidative stress, 
as granted by several lines of evidence (Khazaei et al., 2008; Sabokdast et al. , 2015 ; 
Streit et al. , 2008), it follows that these identified loci were prone to oxidative events in 
our mode!. It is therefore likely that, before their demise, microglial cells were indeed 
activated by this oxidative stress, as supported by previous demonstrations (Bordt and 
Poister, 2014; Kang et al., 2001 ; Mander et al., 2006; Rojo et al. , 2010). In these 
J 
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reglOns, we can infer that activated microglial cells may have initiated a reactive 
astrogliosis, still perceptible 6 months foilowing hyperglycaemia. In other words, 
regions displaying high levels of oxidative stress led to consequent changes in glial 
profiles to promo te ROS clearance via the purposeful activation of the ppp and the 
generation of antioxidative cofactors. Several supplementary firsthand verifications 
would be required to support this proposed timeline of events occurring in glial 
populations. Nonetheless, we can say without a doubt that this possible coping 
mechanism provided by a reactive astrogliosis did not afford sufficient protection to 
dopaminergic neurons of the nigrostriatal pathway nor to micro glial cells in oxidation-
prone areas, which ail visibly degenerated in our model 6 months following 
hyperglycaemia induction. 
What remains unclear is why the substantia nigra pars compacta and the striaturn 
were auspicious to oxidative stress-related events, precisely astrogliosis and microglial 
death, whereas the hippocampus was relatively spared. One explanation might be that 
these regions share the liability of processing large amounts of dopamine66 , known to 
react with hyperglycaemia-induced methylglyoxal to form oxidative salsolinol-like 
compounds (Deng et al., 2012; Song et al., 2014; Szent-Gyorgi and McLaughlin, 1975). 
Another option is that the substantia nigra pars compacta is rich in iron (Chinta and 
Andersen, 2008; Hirsch and Faucheux, 1998), whereas the entire striatum is rich in 
midbrain dopaminergic fibres that harbour a wealth of mitochondria (Pacelli et al. , 
2015), two independent elements conducive to ROS generation. These lines of thought 
in fact boil down to the risk phenotypes characteristic of nigrostriatal neurons. We are 
currently in the process of measuring advanced glycation end-products in these various 
regions employing antibodies raised against glycated arginine and lysine residues. 
By these means, we aim to identify differential levels of glycation throughout the CNS, 
an indirect marker of oxidative stress, and to determine vulnerable cell types between 
neurons, astrocytes or micro glial ceils. 
66 In fact, the prefrontal cortex contains smaller amounts of dopamine than these two regions, 
as evidenced by our own microdialysis studies (Figure 3.31), and was also partially spared as it did not 
display signs of microglial cell death (Figure 3.6A and C); perhaps the proliferation of PPP-utilizing 
astrocytes in this region was sufficient to partially protect microglial cells against oxidative stress. 
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5.2.3 Nigrostriatal dopaminergic neuronal death: beyond the validation of 
our hypothesis 
The work presented ln Chapter III was pivotaI to this project, as it provided 
a direct confirmation of the core hypothesis. Indeed, our results show that the 
nigrostriatal pathway is preferentially targeted in a hyperglycaemic setting, compared to 
mesocorticolimbic neurons. Bridging these findings with observed motor deficits and 
tracing the sequence of events offer further insight into how nigrostriatal dopaminergic 
neurodegeneration may have operated in our rat model of long-term hyperglycaemia. 
5.2.3.1 Subtle neurodegeneration and motor deficits 
Upon inspecting the results presented in Chapter III, it is possible to observe 
that most changes occurring because of long-term hyperglycaemia are subtle. Indeed, 
the reduction in the expression of dopaminergic markers in the midbrain and striaturn, 
the relative loss of dopaminergic nigrostriatal neurons, and the dampened tonic 
dopamine release in the dorsal striatum do not exceed 50% of age-matched controls. 
Other groups also observed these modest effects in a similar rodent paradigm 
(Brambilla Bagatini et al., 2014; do Nascimento et al., 2011). Both groups found small 
amounts of neurodegeneration in the substantia nigra pars compacta in streptozotocin-
treated animais. However, these results were obtained 60 (Brambilla Bagatini et al., 
2014) or 90 days (do Nascimento et al., 2011) following streptozotocin injections, while 
we did not observe neurodegeneration at the 3-month mark, at least wh en considering 
expression levels of dopaminergic and neuronal markers67• This could be explained by 
the fact that these studies employed considerably harsher chemical-induced rodent 
paradigms of diabetes, thereby accelerating the neurodegenerative process. It is unclear 
whether these models would exhibit more dopaminergic neuronal death at 6 months or 
67 Brambilla Bagatini and colleagues employed i.p. injections of 65 mg/kg b.w. of streptozotocin 
without nicotinamide, a fairly high concentration in rats affording complete insulin depletion 
(Brambilla Bagatini et al. , 2014). In an even harsher paradigm, the other group administered rats with 
streptozotocin at a dose of 50 mg/kg b.w. i.v. , once again without nicotinamide (do Nascimento et al., 
2011). 
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whether neurodegeneration would slow down to reach a stable degree of modest 
denervation that could resemble the levels found in our paradigm. However, granted the 
severity of the hyperglycaemic phenotype, it is unlikely that such models could survive 
to the 6-month time point. 
Other findings corroborating our work contrast with studies performed 
ln paradigms combining parkinsonian and diabetic insults in which overt 
neurodegeneration can be observed (Choi et al., 2005; Morris et al., 2010; Rotermund 
et al., 2014). For example, after one week on a high-fat diet following MPTP treatments, 
mice display almost complete nigrostriatal neurodegeneration (Choi et al., 2005). 
Although such studies provide information suggesting that metabolic alterations 
exacerbate the deleterious effects of parkinsonian toxins, they do not provide insight into 
the natural processes that may underlie neurodegeneration in a longstanding metabolic 
syndrome. Our model thus presents the advantage of mimicking the dopaminergic 
neurodegeneration that occurs in a hyperglycaemic setting over the course of aging 
without other exogenous effects: this neuronal loss is realistically modest. 
Most importantly, our findings support the moderate motor deficits observed in 
our rat model of hyperglycaemia, recalling bradykinesia and gait disturbances in 
parkinsonian patients. In fact, as already mentioned, sorne tests did not reveal any 
differences between control and hyperglycaemic rats, such as in the vibrissae-elicited 
forelimb placement test used to assess sensorimotor integrative deficits. 
These observations evoke the compensatory neurocircuit redundancies in the basal 
ganglia of parkinsonian patients that account for the fact that 30-70% of nigrostriatal 
dopaminergic neurons and 50-80% of their striatal projections have usually perished 
before the initiation of gross motor symptoms (Bernheimer et al., 1973; Cheng et al. , 
2010; Feamley and Lees, 1991). Accordingly, we found approximately 30% of neuronal 
loss in the substantia nigra pars compacta and 50% of denervation in the striatum of 
long-term hyperglycaemic rats. This level of neurodegeneration stands at the threshold 
of symptomatic detection and likely explains why we observe modest, yet significant, 
indices ofbradykinesia and gait disturbances. 
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5.2.3.2 Time course of neurodegeneration 
In Chapter III, we investigated dopaminergic and motor alterations at 3 and 
6 months in our model of hyperglycaemic rats. At 6 months, hyperglycaemic rats 
displayed clear neurodegeneration of the nigrostriatal pathway, as substantiated by 
immunoblotting and immunohistochemical assays. However, sorne indications of 
dopaminergic dysfunction were already apparent at the 3-month mark before 
immunoblotting measurements could attest of any neurodegeneration. 
Specifically, tonic dopamine release in the dorsal striatum was already dampened 
at 3 months. We cannot exclude the possibility that the immunoblotting method 
may not have allowed for the detection of inconspicuous neurodegeneration in 
striatal dopaminergic fibres, which could have been picked up by more sensitive 
immunohistochemical analyses at 3 months. Nevertheless, the literature consistently 
shows a dulling of dopamine neurotransmission occurring without visible 
neurodegeneration. Indeed, our observations bolster other reports showing that neither 
TH activity or expression are reduced in the striatum of streptozotocin rats, despite 
visible downregulation of dopamine neurotransmission as early as 2 weeks following the 
induction of hyperglycaemia (Bitar et al. , 1986; Lim et al., 1994). Depreciation of 
striatal dopamine neurotransmission despite undetectable neurodegeneration is also 
typical of sorne transgenic models of Parkinson ' s disease (Abeliovich et al. , 2000; 
Li et al. , 2009). 
Although neurodegeneration was unnoticeable at 3 months, several motor deficits 
were already apparent, as highlighted by the stepping and forepaw adjusting step tests. 
In support of our observations, others have reported modest impairments of motor 
functions in rodent models of Parkinson's disease despite the absence of nigrostriatal 
neurodegeneration (Abeliovich et al. , 2000; Li et al. , 2009). Yet, the horizontal bar test 
did not uncover any motor abnormalities in our model at 3 months. As previously 
mentioned, it is the least sensitive of the 3 tests, which may explain why modest 
dopaminergic dysfunctions at 3 months may not have manifested themselves in this 
specific task (Kelm-Nelson et al., 2015). Another group reported horizontal bar deficits 
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in a similar model 60 days following the induction of hyperglycaemia. However, these 
rats were submitted to a harsher streptozotocin regimen and also displayed substantial 
immobility in the open field test (Brambi lla Bagatini et al. , 2014). In contrast, although 
we did not perform this specific test, our rats did not manifest signs of hypolocomotion, 
on the contrary68 . 
Ail evidence considered, it appears that dopaminergic neurotransmission 
dysfunctions occur before a detectable loss of nigrostriatal neuron bodies or their 
projections in our hyperglycaemic rat mode!. Dampened tonic dopamine release and 
manifestations of motor deficits preceding neurodegeneration sustain this proposed time 
course. Nevertheless, a proper immunohistochemical appraisal of the density of striatal 
dopaminergic fibres at 3 months is warranted to confirm this. It would also be interesting 
to measure dopamine release at 6 months to assess the extent of neurotransmission 
deterioration once neurodegeneration is perceptible. However, the surgical procedures 
inherent to the microdialysis method are risky in our model at that time point, explaining 
why we didn ' t perform these analyses. 
5.2.4 Hyper-aggressive and hyper-sociable manifestations 
In addition to motor deficits highlighted in Chapter III, we discovered hyper-
aggressive and hyper-sociable traits in our model of long-term hyperglycaemia. In fact, 
these results presented in Chapter IV constitute the first adequate account of social 
behaviour in hyperglycaemic rats obtained in neutral circumstances69. In addition, 
we report the first USV recordings ever performed in a diabetic model, whether 
chemical-induced, diet-induced or genetic. 
68 Observations of hyperactivity in our hyperglycaemic model were partly responsible for sparking our 
interest in their atypical social behaviour, related in Chapter IV. 
69 Ali other behavioural investigations in similar models relied on resident-intruder paradigms that may 
uncover submissive or dominant traits, but the y do not report normal interspecies interactions (File and 
Seth, 2003 ; Hilakivi-Clarke et al. , 1990; Meehan et al. , 1986). 
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5.2.4.1 A possible relationship with nigrostriatal dopaminergic neurodegeneration 
A rapid analysis of our results reveals much more frequent emissions of all types 
of USVs and manifestations of affiliation/exploration or aggression-related behaviours 
made by long-term hyperglycaemic rats. Covariance profiles between kinds of 
behaviours or between behaviours and USVs are also noticeably altered. Our results 
converge toward the conclusion that long-term hyperglycaemic rats are hyper-aggressive 
and hyper-sociable, displaying behaviours that do not coincide with the affective valence 
of their communications. Importantly, we found a correlation between the degree of 
striatal denervation and the severity of these phenotypes. Because the article presented in 
Chapter IV did not precisely address nigrostriatal neurodegeneration, we separated our 
rats into groups according to overall striatal denervation. However, as we know from 
Chapter III, this denervation is greatest in the dorsal area; separating the animaIs on the 
basis of dorsostriatal denervation still yields the same 3 groups (Figure 5.5). Therefore, 
although not within the scope of the article presented in Chapter IV, we can still say in 
the context of this thesis that hyper-aggressive and hyper-sociable manifestations 
alongside USV emissions were specifically associated with the degree of nigrostriatal 
dopaminergic neurodegeneration. 
Figure 5.5 
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Classification of long-term hyperglycaemic rats based on the degree 
of striatal denervation in multiple regions. 
In Figure 4.4, hyperglycaemic rats were already divided in groups 
according to total striatal denervation. Using the same animaIs in identical 
groups, we show here that dorsomedial and dorsolateral denervation are 
responsible for this total observed striatal denervation reported in 
Chapter IV. Ali data presented as means ± SEM. Asterisks indicate 
statistical differences between the HG group and CTRL group 
(**p < 0.01). Refer to Chapters III and IV for methodological details. 
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5.2.4.2 A possible relationship with phasie and tonie dopaminergie 
neurotransmission 
Our findings raise the legitimate question of how dampened dorsostriatal 
dopaminergic neurotransmission can account both for a rise in motor deficits and for 
abnormal social reward-related behaviours. The link between insufficient tonic firing in 
the dorsal striatum and manifestations of motor deficiencies reported in our model and 
manifested in parkinsonian patients in the form of bradykinesia and rigidity is weil 
appreciated (Dreyer, 2014). However, the association between a loss of dopamine tone 
and increased reactivity to novel or rewarding elements in the environment is much less 
obvious. In fact, parkinsonian patients usually exhibit apathy or motivational deficits, 
which starkly contrast with the hyper-sociable and hyper-aggressive traits found in our 
model (Drui et al., 2014; Magnard et al., 2016). A challenge therefore emerges upon 
attempting to reconcile these two seemingly divergent behavioural manifestations in 
light of evidence of depleted dorsostriatal dopamine in our model of long-term 
hyperglycaemia. 
Identifying neuropathologies bearing similar social abnormalities is a sensible 
place to start in the aim of unravelling this daunting question. Our model quite 
noticeably exhibits archetypal behavioural features of attention-deficit hyperactivity 
disorder70 . This neuropathology is strongly associated with hyper-reactivity to novel 
elements in the environment, whether social or not, which can manifest itself in the form 
of inappropriate impulsivity, curiosity and aggression, both in animal models and 
in humans (Hopkins et al., 2009; Jhang et al., 2017; King et al., 2003; Ko et al., 2013 ; 
Rosa-Neto et al., 2005). Like Parkinson's disease, its pathophysiological underpinnings 
are tightly linked to dopaminergic dysfunction7 \ (Levy, 1991; 2004; Sikstrom and 
Soderlund, 2007). Recent studies have slowly begun to extricate the neuroanatomical 
loci implicated in this disease, and the dorsal striatum and substantia nigra pars 
compacta have emerged among the most important regions. Indeed, patients with 
70 The highly complex epidemiological relationship between Parkinson ' s disease and attention-deficit 
hyperactivity disorder is discussed in a short commentary provided in Appendix D. 
71 In fact, the dopamine reuptake inhibitor methylphenidate remains the benchmark treatment. 
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attention-deficit hyperactivity disorder present an altered nigral morphology (deI Campo 
et al., 2013; Romanos et al., 2010). In addition, others have reported diminished tonic 
and enhanced phasic dopaminergic neurotransmission in the dorsal striatum of these 
subjects (Badgaiyan et al., 2015; Sikstrom and Soderlund, 2007). 
This last piece of evidence provides important insight into what may occur in our 
modei of long-term hyperglycaemia. There is cause to believe that low dopamine 
tonicity, or background noise, favours the saliency of phasic signaIs. As previously 
stated, the dorsal striaturn is normally submitted to higher noise-to-signal ratios than the 
ventral striatum 72, owing to the marked pacemaking activity of nigrostriatal neurons 
(Dreyer, 2014; Zhang et al., 2009). In a context of partial tonic depletion, signais 
provided by phasic dopamine are overstated when apposed to a diminished background 
of tonic noise, and also by means of a compensatory upregulation of postsynaptic 
dopamine receptors 73. However, when dopaminergic denervation is substantial, as m 
Parkinson's disease, neither phasic nor tonic dopaminergic neurotransmission IS 
properly fulfilled, giving rise to motor symptoms and loss of hyper-reactivity, or even to 
the apparition of apathy (Dreyer, 2014). On this basis, we can carefully submit to the 
idea that our hyperglycaemic paradigm yields a model that is sufficiently denervated to 
allow the timely overlap between a moderately hypotonic phenotype responsible for 
subtle motor deficits and a relative hyperphasicity accounting for social hyper-reactivity. 
We could suppose that if the nigrostriatal pathway had undergone greater levels of 
degeneration, our model would have more closely resembled the apathetic, motor-
deficient parkinsonian phenotype. Noteworthy, proper demonstrations of enhanced 
dorsostriatal phasic signalling are warranted to confirm this, and would require the 
employment of methods allowing the infrasecond detection of dopamine transients, 
72 In fact, the low noise-to-signal ratio in the ventral striatum is conducive to proper phasic signalling by 
ventral tegmental area neurons, which underlies the mesocorticolimbic pathway's prominent role in 
encoding reward saliency and value. 
73 Recently emerged complementary evidence in humans and rodents supports a role for nigrostriatal 
hyperphasicity in behavioural alterations. In particular, self-driven curiosity, motivation, and 
aggression-related behaviours, ail applicable to social settings, are enhanced by phasic nigrostriatal 
dopaminergic neurotransmission (Di Domenico and Ryan, 2017; Rossi et al., 2013; Skibsted et al., 
2017). 
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for instance fast-scan cyc1ic voltarnrnetry or electrophysiological techniques (Hauber, 
2010; Schultz, 2010; Segovia et al., 2011; Wightman and Robinson, 2002). 
5.2.5 Effects attributable to hypoinsulinaemia 
To obtain a long-term hyperglycaemic phenotype, rats were rendered permanently 
hypoinsulinaemic. Given insulin's highly complex roles in the healthy and diseased 
CNS, extensively reviewed elsewhere (Blazquez et al. , 2014; Ghasemi et al., 2013 ; 
Gray et al., 2014; Porte et al., 2005), our challenge arises upon attempting to pick apart 
the effects attributable to hypoinsulinaemia or hyperglycaemia in the multiple neuronal 
and behavioural alterations observed in our mode!. 
5.2.5.1 Insulin in neurodegeneration 
As described in section 1.2.2, insulin is not required for glucose transport in the 
brain parenchyma or in most resident cells. Nevertheless, this hormone is ubiquitous in 
the CNS where it mediates developmental, differentiation, plasticity and survival 
signaIs. In a normal setting, insulin 's concentrations are highest in the pons, medulla and 
hypothalamus, and lowest in the occipital cortex and thalamus (Banks et al., 1998), 
our brain regions of interest falling within the average. As well, the insulin receptor is 
also widely expressed throughout the CNS, especially so at the neuronal surface 
(Havrankova et al. , 1978a; Hill et al. , 1986; Schulirigkamp et al., 2000; Unger et al., 
1991), and possesses similar kinetic properties to its peripheral counterpart (LeRoith 
et al. , 1988; Zahniser et al., 1984). Insulin signalling in neurons is quite similar to that in 
peripheral cells and leads to the activation of PI3K1Akt and RAS-extracellular signal-
related kinase (ERK) pathways responsible for the stimulation of synaptic plasticity and 
gene transcription, among many other effects (Figure 5.6). By modulating these 
pathways, it is generally accepted that insulin acts as a neurotrophic factor, 
promoting the survival of neurons. Accordingly, several demonstrations of insulin 's 
neuroprotective competences have been carried out in vitro, for instance in settings of 
excitotoxicity or oxidative stress (Duarte et al., 2006; Kim and Han, 2005; Ribeiro et al., 
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2014; Sun et al., 2010). In vivo, near-direct application of insulin on the CNS, 
via intranasal or interacerebroventricular treatments, are highly effective in promoting 
various aspects of neuronal health, as demonstrated in a rat model of Parkinson's disease 
(Haas et al., 2016; Pang et al., 2016) . 
Figure 5.6 
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Overview of insulin and insulin-Iike peptide signalling in the brain. 
In the periphery as in the brain, insulin and insulin-like peptides bind 
3 kinds of receptors: the insulin receptor (IR), insulin-like growth factor 
receptors (IGFIR and IGF2R), and hybrid receptors. Insulin preferentially 
binds the IR but can also bind IGFIR or hybrids. In the central nervous 
system (CNS), insulin and insulin-like peptides are produced locally or 
provided by the circulation. Insulin transport across the blood-brain 
barrier is not weil understood. Focusing on insulin, its action on receptors 
triggers canonical pathways via the insulin receptor substrate that lead to 
a plethora of cellular changes favouring plasticity and differentiation. 
4 EBP l , eIF 4 E-binding protein 1; ELK l , ETS-like transcription factor; 
ERKs, extracellular signal-related kinases; FOXO, forkhead box 0 ; 
GS3K, glycogen synthase kinase 3; IGF, insulin-like growth factor; 
IGFBF and IGFBP, insulin-like growth factor binding proteins; IRS, 
insulin receptor substrate; LRP1, low-density lipoprotein receptor-related 
protein 1; PLC, phospholipase C. (From Benarroch, 2012.) 
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Although the neuroprotective competences of in situ insulin treatment are 
undeniable, the abovementioned reports do not directly address the possible harmful 
effects of hypoinsulinaemia pertinent to our project. Other studies attempting to 
demonstrate that neuronal death directly ensues from hypoinsulinaemia employ 
peripheral insulin administration to reverse cellular or structural damage induced by 
streptozotocin treatments in the CNS of rodents 74 (Hung et al., 2014; Moreira et al., 
2005, 2006; Ramanathan et al., 1999). However, they do not take into account the 
various peripheral benefits exerted by this hormone replacement therapy, for instance on 
glycaemic control. Such strategies exploiting organism-wide paradigms to establish 
causality between hypoinsulinaemia and CNS neuronal death are based on the 
misconception that Intracerebral insulin is solely provided from the circulation, 
itself supplied by the pancreas. As a matter of fact, insulin concentrations are 
considerably greater in the brain parenchyma than in the plasma, and are unexpectedly 
upregulated in hypoinsulinaemic, hyperglycaemic streptozotocin-treated rats (Banks 
et al., 1997b; Gupta et al., 1992; Havrankova et al., 1978a, 1978b, 1979) (Figure 5.7). 
In support of this, insulin receptors are modulated in the periphery but not in the brain 
of streptozotocin models (Pacold and Blackard, 1979; Pezzino et al. , 1996). 
These preliminary findings led to the discovery that, besides being taken up through the 
blood-brain barrier (Banks et al., 1997 a; Margol is and Altszuler, 1967; Woods and 
Porte, 1977), insulin is synthesized by neurons within the mammalian brain (Birch et al. , 
1984; Deltour et al., 1993; Devaskar et al., 1994; Dom et al., 1983; Frolich et al., 1998; 
Mehran et al., 2012; Molnar et al. , 2014; Schechter et al., 1994; Young, 1986). 
Importantly, one group demonstrated that high glucose conditions enhance insulin 
production by cortical neurons (Molnar et al., 2014), which may be a mechanism to 
maintain appropriate Intracerebral concentrations of insu lin when pancreatic supplies 
plunge (Banks et al., 1997b; Gupta et al., 1992; Havrankova et al., 1979). As the 
aforementioned studies have not quantified insulin in the injured regions of the 
74 One group did c1aim to show that streptozotocin-induced hypoinsulinaemia to cause CNS injuries, 
albeit without cell loss, and to further uncover the protective effects of intranasal insulin treatments 
(Francis et al. , 2008). However, this article, along with 7 others from the same group on the sa me 
subject, was retracted in 2014. 
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CNS following its peripheral depletion, there is no way to assertively avow a direct 
negative influence of hypoinsulinaemia on neurons. 
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Insulin content and binding in the brain of streptozotocin-treated 
rats. 
Left, top: Brain insulin levels (black bars) are not diminished one month 
after the induction of hyperglycaemia by streptozotocin compared to 
control conditions (hatched bars), although serum insulin is clearly 
reduced (white bars). Left, bottom: Pancreatic insulin levels are depleted 
in the pancreas of streptozocin-treated rats. Right: Insulin binding does 
not differ between control (C, hatched bars) and streptozotocin-treated 
(S, black bars) rats across various brain regions. Hepatic insu lin binding, 
on the other hand, is greatly increased in hyperglycaemic rats, owing to 
an enhanced sensitivity of receptors. White bars indicate non-specific 
binding. (From Havrankova et al. , 1979.) 
Regarding our studies, we did not measure insulin concentrations in the brain 
regions of interest in our long-terrn hyperglycaemic mode!. However, faced with the 
unverified possibility that hypoinsulinaemia can trigger neuronal death, we re-exarnined 
our data in a similar manner to Chapter IV by factoring in our rats' insulin profiles. 
In our model, hypoinsulinaemia and glucose intolerance clearly do not correlate with 
the loss of nigrostriatal neurons (Figure 5.8). Yet, we strongly agree that future 
investigations would require quantifications of insulin and its receptor in targeted brain 
reglOns to corroborate hypoinsulinaemia' s apparent lack of influence on 
neurodegeneration in our mode!. 
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Nigrostriatal dopaminergic neurodegeneration in relation to the 
degree of hypoinsulinaemia or glucose intolerance. 
Streptozotocin-treated 6-month hyperglycaemic rats were classified 
according to the degree of hypinsulinaemia (A, B) or glucose intolerance 
(C, D). Numbers of TH-positive neurons in the substantia nigra pars 
compacta were related to the degree of hypoinsulinaemia (A) or glucose 
intolerance (C): no correlation is observed between both variables in these 
circumstances. Similarly, the density of TH-positive fibres in the various 
regions of the striatum were related to the degree ofhypoinsulinaemia (B) 
or glucose intolerance (D), and no association is found. All data presented 
as means ± SEM. Asterisks indicate statistical differences between the 
LOW or HIGH subgroups within the HG group and the CTRL group 
(*p < 0.05, **p < 0.01 , ***p < 0.001). Refer to Chapters III and IV for 
methodological details . 
5.2.5.2 Insulin in behaviour 
Not only is insulin endowed with neurotrophic competences, it is a potent 
regulator of behaviours such as feeding, reward valuation, cognition and memory 
(Anthony et al., 2006; Benedict et al., 2004, 2007; Craft et al., 1996; Hallschmid et al., 
2008; Khanh et al., 2014; Reger et al. , 2008). Indeed, intracerebroventricular or 
intranasal administration of insu lin reduces food intake, Improves memory, 
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and ameliorates cognitive performances in humans and rodents (Babri et al. , 2007; 
Benedict et al., 2004; Haj-ali et al. , 2009; Park et al., 2000; Stockhorst et al. , 2004). 
Under physiological circumstances, postprandial peripheral insulin most significantly 
regulates the hypothalamus, directly at the level of the median eminence devoid of 
blood-brain barrier protection, where it normally conveys satiety signais. Ail of these 
regulatory effects, wh ether physiological or exogenous, are mediated by insulin ' s ability 
to promote neuronal plasticity, but also by its modulatory role on neurotransmission 
itself (Gupta et al. , 1992; Ohtani et al., 1997). An emerging and important 
neurotransmitter on which insulin exercises its control is striatal dopamine. Granted the 
central position it holds in our project, we will focus here on the relationship between 
insulin75 and mesostriatal (nigrostriatal and mesolimbic) dopaminergic signalling, 
especially pertaining to ensuing effects on food intake behaviours, which are overtly 
altered in streptozotocin-treated models. This will allow us to draw parallels with the 
abnormal behaviours we uncovered in our hypoinsulinaemic, hyperglycaemic rat mode!. 
lnsulin ' s effect on the midbrain is primarily indirect. By inhibiting neuropeptide Y 
/GABA/agouti-related protein (NPY/GABA/AgRP or NGA) neurons and by activating 
pro-opiomelanocortinlcocaine and amphetamine regulated transcript (POMC/CART) 
neurons, both located in the arcuate hypothalamus, insulin allows for the stimulation of 
anorexigenic neurons and the silencing of orexigenic neurons (Abizaid et al. , 2006; 
Cone et al. , 2005; Morton et al. , 2006) (Figure 5.9). The sum of these effects converges 
toward decreased food intake and increased catabolism. Pertinent to our project, 
orexigenic neurons in the lateral hypothalamus innervate many targets including 
midbrain dopaminergic neurons in the ventral tegrnental area and the substantia nigra 
pars compacta (Sakurai et al., 1998). lmpeding orexigenic signaIs onto midbrain neurons 
leads to decreased dopaminergic neurotransmission in the striatum and diminished food-
seeking behaviours. Although insulin ' s effects are broadly conveyed to mesostriatal 
circuits, dopaminergic neurotransmission in the dorsal striatum appears to be essential 
for feeding, whereas signalling to the nucleus accumbens plays only a secondary role in 
75 In an attempt to simplify this part of the di scussion, we will disregard other hormonal changes that occur 
in our model, namely the depletion of leptin and the rise in ghrelin, which more or less mimic the effects 
of insulin on behaviour (see for review Palmiter, 2007). 
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modulating food anticipation behaviours (Baldo and Kelley, 2007; Cannon et al., 2004; 
Drago et al. , 1994; Salamone and Correa, 2002; Ungerstedt, 1971). 
Figure 5.9 
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Insulin 's action on the hypothalamus. 
The arcuate nucleus is directly exposed to blood-bome hormones, 
as it is located at the level of the median eminence devoid of the 
blood-brain barrier. As such, insulin has a direct effect on the two 
principal populations that dwell therein. Neuropeptide Y (NPY)/gamma-
aminobutyric acid (GABA)/agouti-related protein (AgRP) neurons 
(NGA) neurons innervate the paraventricular nucleus (PVN) and 
inhibit anorexigenic neurons. Its projections onto orexigenic neurons 
of the lateral hypothalamic area (LHA) rather activates them. 
Pro-opiomelanocortin/cocaine and amphetamine regulated transcript 
(POMC/CART) neurons innervate the same targets but have opposite 
effects than NGA neurons. Orexigenic and anorexigenic neurons project 
to the nucleus of the solitary tract (NTS), thereby regulating food intake. 
Since insulin inhibits NGA neurons and stimulates POMC/CART ones, 
its sum effect is to inhibit food intake and promote energy expenditure. 
Not shown here are the LHA's projections to the midbrain. GSHR, 
growth hormone secretagogue receptor or ghrelin receptor; INSR, insulin 
receptor; LepR, leptin receptor; MC4R, melanocortin 4 receptor; a-MSH, 
alpha-melanocyte-stimulating hormone; YIR, neuropeptide Y receptor 
y 1. (From http: //www.cellbiol.net/ste/alpobesity2.php.) 
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In this vlew, one wou Id expect a hypoinsulinaemic setting, resulting from 
fasting or streptozotocin treatments for instance, to lead to the disinhibition of orexigenic 
neurons and the enhancement of midbrain dopaminergic neurotransmission; 
the consequential rise in striatal dopamine, encoding the subjective reward value of 
food, would compel the organism to feed itself, as it is a goal-directed behaviour. In fact, 
hyperphagia is archetypal in the spectrurn of abnormal behaviours displayed by 
streptozotocin-treated rodents, confirmed by our own findings (Figure 1.33). However, 
what actually occurs at the level of striatal dopamine is highly inconsistent with these 
theoretical extrapolations. 1ndeed, almost ail studies 76 performed in genetic or chemical-
induced hypoinsulinaemic models, including ours (Figure 3.31), report low basal levels 
of striatal dopamine (Bradberry et al. , 1989; Chen and Yang, 1991 ; Crandall and 
Femstrom, 1983; Kono and Takada, 1994; Kowk and Jurio, 1986; Kwok et al. , 1985; 
Lim et al., 1994; O'Dell et al. , 2014; Saller, 1984; Samandari et al. , 2013; Trulson and 
Himmel, 1983). Once again, we are faced with ostensibly irreconcilable and opposite 
outcomes evoked by - what appears to be - one factor. 
To date, no adequate explanation has accounted for this dualism. However, we and 
others propose that, since striatal dopamine transients have ne ver been measured in 
hypoinsulinaemic models by techniques sensitive enough to detect infrasecond events, 
it is probable that we are missing very important pieces of the puzzle pertaining to 
phasic neurotransmission77 (Palmiter, 2007, 2008). Sorne indications of a role for phasic 
firing that could explain overt feeding behaviours in hypoinsulinaemic subjects despite 
low levels of dopamine are provided by experiments employing psychostimulants. 
Indeed, streptozotocin-treated rodents manifest a greater sensitivity to addictive 
substances like nicotine78 (O 'Dell et al. , 2014; Samandari et al. , 2013). In addition, 
76 Sorne reports have shown enhanced dopamine levels in the brains of streptozotocin-treated rodents, 
but today the consensus remains that concentrations are in fact lower in the striatum (S itar et al., 1986; 
Gupta et al., 1992; Lackovié et al. , 1990). 
77 One study did measure phasic dopamine in striatal neurons by fast-scan cyclic voltammetry, but data 
were obtained in organotypic slices to which insulin was applied (Stouffer et al. , 2015). As we know, 
it is not clearly known whether peripheral insulin may have a direct effect on regions protected by the 
blood-brain barri er. 
78 In fact, smoking rates in diabeti c pati ents are higher than in the general population (Bishop et al. , 2009). 
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amphetamine and apomorphine, which flood the striatum with dopamine thereby raising 
the noise-to-signal ratio, exert a hypophagic effect on fasted, hypoinsulinaemic rats that 
would normally engage in feeding (Cannon et al., 2004; Sotak et al., 2005). Moreover, 
knocking out DAT, especially important in clearing phasic dopamine transients from the 
extracellular space, enhances motivation for food rewards and yields a hyperphagic 
phenotype (Cagniard et al., 2006; Pecifia et al., 2003). Without providing a clear answer, 
these data do converge toward a heightened production of or sensitivity to phasic 
dopamine bursts in streptozotocin-treated models like ours. 
This proposai bears significant implications for other behaviours mediated by 
mesostriatal dopaminergic neurotransmission. We observed marked hyper-sociable and 
hyper-aggressive behaviours in our long-term hypoinsulinaemic, hyperglycaemic rats, 
which we explained by a possible drop in the noise-to-signal ratio. Admittedly, it is 
unlikely that the sole decrease in tonic firing in the dorsal striatum arising from 
hyperglycaemia-induced nigrostriatal neurodegeneration could have accounted for a 
low-enough noise-to-signal ratio conducive to these hyper-reactive behaviours. 
Chronic hypoinsulinaemia favouring enhanced mesostriatal dopamine phasicity may 
well have participated in reducing this ratio. However, our data presented in Chapter IV 
evokes a lack of correlation between the degree of hypoinsulinaemia or glucose 
intolerance and the intensity of behavioural abnormalities (Figure 4.5 and Figure 4.6). 
This can either signify that long-term hypoinsulinaemia do es not hold a role in 
heightening phasicity and hyper-reactivity, or that the low and high subgroups were not 
different enough to yield a perceptible gradation of behaviour. We reiterate here the 
need for experiments addressing phasic dopamine transients in hypoinsulinaemic rats. 
At any rate, substantial gaps remam m our understanding of the role held by 
insulin, or lack thereof, on the CNS. Investigations are warranted to explain low 
dopamine levels in hypoinsulinaemic rats, apparent even after a few days of treatment 
and, in our model, observed before nigrostriatal neurons had perished at 3 months. 
It would be imprudent not to contemplate the prospect of a plethora of peripheral and 
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central substances modulating the effects of insulin on the brain, likely exerting a 
compensatory effect in times of induced depletion. 
5.2.6 Improving the model 
The nicotinamide-streptozotocin rat model of long-term hyperglycaemia has 
allowed us to verify our main hypothesis, but still leaves certain questions pending. 
Uncertainties remain over the influence that a systemic defect can have on the CNS, 
a caveat shared by ail experimental strategies employing complex peripheral disease 
models and attempting to ascribe noxious effects on the brain to a single pathological 
component. In our model , much more than a single variable is tampered with; 
thus, while it is tempting to attribute selective nigrostriatal dopaminergic 
neurodegeneration solely to a hyperglycaemic state, we can truly only interpret that the 
sum of physiological disruptions arising from nicotinamide-streptozotocin injections in 
our rats maintained over 6 months leads to the preferential death of this subpopulation of 
neurons. It remains that this multilayered physiological condition constitutes a stress 
conducive to CNS oxidative stress to which nigrostriatal neurons were manifestly more 
susceptible. Demonstrations achieved in the introduction section firmly support the 
legitimacy of this basis upon which hinges our conclusion. 
The literature offers a collection of astutely constructed experiments aiming to 
circurnvent this problem. Ideally, the need for tampering with peripheral hormones 
should be avoided in creating a high glucose environment. In addition, concentrations of 
glucose should be controlled between individuals. In this view, it is reasonable to 
propose verifying the selective degeneration of certain populations of neurons 
throughout the brain by chronic infusions of glucose via the intracerebroventricular route 
(Park et al. , 2009). Worthy of mention, glucose infusion in the brain al one can have 
peripheral effects by modulating central homeostasis hubs, thus pilot studies would be 
required to identify these outcomes (Carey et al., 2013 ; Park et al., 2009). In the same 
vein, retrodialysis, described earlier, could address certain issues with widespread effects 
of high or low circulating levels of glucose or insulin on behavioural endpoints 
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(see for review H6cht et al., 2007). Although this has never been attempted before, 
glucose could easily be administered directly in the brain regions of interest following 
a chronic daily regimen. Behaviour or neurotransmission responses could then be 
measured in acute or chronic paradigms. This would dissipate any doubt regarding the 
neuroanatomical loci responsible for the behavioural effects observed. Advantageously, 
in situ measurement of oxidative stress could also be conducted in parallel using the 
salicylate trapping method, which implies administering salicylic acid through the 
microdialysis cannula and measuring stable oxidized adducts by high-performance 
liquid chromatography (Mertens et al. , 20 Il) . 
These kinds of experiments are appealing on the account that they specifically 
target the CNS or precise regions therein, allowing for the identification of clear-cut 
causal relationships between high glucose levels, oxidative stress, neuronal death and 
behavioural outcomes. However, since such experiments imply maintaining a chronic 
cannula in the CNS of rodents, they cannot be performed for more than a couple of 
months on end. A methodological compromise would dwell in the employment of 
a more moderate peripheral phenotype via the maintenance of appreciable levels of 
circulating insu lin without sacrificing the hyperglycaemic condition. To that end, 
Femyhough ' s group designed a strategy utilizing streptozotocin-treated rodents injected 
with subcutaneous insu lin implants into the nape of the neck that can be renewed 
monthly (Aghanoori et al. , 2017; Akude et al. , 2011). Using a small implant limits the 
amount of insulin dispensed and yields a low-maintenance model of long-term 
hyperglycaemia that do es not display overt hypoinsulinaemia. Peripheral alterations are 
accordingly less pronounced than in the classic streptozotocin model, reducing the risk 
of inferring inaccurate associations between hyperglycaemia and CNS affections. 
5.3 Therapeutic perspectives 
This thesis addressed the selective vulnerability of dopaminergic neurons to 
hyperglycaemia-induced oxidative stress. In the process, we touched upon Parkinson 's 
disease and diabetes whose pathophysiological facets and epidemiological relationship 
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are directly linked to the core question. We can extend the significance of our findings 
to these pathologies. 
5.3.1 Implications for diabetic patients 
Diabetic patients present highly heterogeneous clinical profiles, on account of high 
inter-individual variations in lifestyle, in disease management and in the presence of 
additional pathological conditions. However, whether they suffer from type 1 or type II 
diabetes mellitus, medical authorities have reached the consensus that glycaemic control 
constitutes the topmost priority for the prevention of severe comorbidities. Our data 
provide further support for this approach by demonstrating that uncontrolled 
hyperglycaemia can, in the long term, lead to dopaminergic neurodegeneration. 
Importantly, hyperglycaemia on its own was sufficient to cause this modest neuronal 
death. 
The importance of glycaemic control emerged from large trials that marked a 
milestone in diabetes research by demonstrating that tight blood glucose management 
could delay the ons et of complications (Diabetes Control and Complications Trial 
Research Group, 1993; Holman et al., 2008; Nathan et al. , 2005; UK Prospective 
Diabetes Study Group, 1998). Most striking was the discovery that these benefits 
persisted long after efforts of glycaemic control had been abandoned with respect to a 
cohort of patients who had never undergone tight blood glucose management. 
This phenomenon is termed "glycaemic memory" and is thought to at least partially 
arise from oxidative damage to mitochondrial DNA that is vulnerable to permanent 
mutations leading to irreversible respiratory defects (Giacco and Brownlee, 2010). 
Seeing as certain neuronal subtypes are intrinsically susceptible to oxidative stress, 
as we have demonstrated here, there is an imperative need to stress the importance of 
early blood glucose control in diabetic patients: the mindfulness of practitioners has 
accordingly evolved in this direction. Because the existence of a glycaemic memory 
implies that damage appearing at any moment of the disease is irretrievable and 
accumulative, the current state of the field is more actively striving for the development 
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of therapies that could reverse cellular defects thought to underlie this phenomenon 
(Giacco and Brownlee, 2010; Lovre and Fonseca, 2015; Misra and Bloombarden, 2018). 
One legitimate question remams concernmg the relative risk that constitutes 
pre-existing diabetes for the development of Parkinson's disease. As previously stated, 
certain epidemiological studies did not find diabetic patients to present an increased 
chance of developing this neurodegenerative disease (Becker et al., 2008; Cereda et al., 
20 Il; Driver et al., 2008). However, the sum of the other positive reports converges 
toward a mode st two-fold increase in this risk (Arvanitakis et al., 2007; Cereda et al., 
2012; Hu et al., 2007; Klimek et al., 2015; Xu et al., 2011). It is possible to surmise that 
the life expectancies of patients with type 1 or II diabetes, respectively shortened by as 
much as 15 or 5-10 years (Canadian Diabetes Association, 2009), may account for these 
moderate findings 79. If diabetic patients lived longer, one could expect the incidence of 
age-related neurodegenerative disorders like Parkinson's disease to be substantially 
superior than in the general population. Bearing in mind the idiopathic and multifaceted 
nature of Parkinson's disease, uncontrolled glycaemia may interact with other risk 
factors besides aging to additively or synergistically hasten the ons et of oxidative stress-
induced neurodegeneration; this is plausibly what is picked up by epidemiological 
studies. 
5.3.2 Implications for parkinsonian patients 
The keynote finding of our studies provides that hyperglycaemia can lead to the 
selective degeneration of the nigrostriatal pathway. On the one hand, these results 
support the hypothesis that nigrostriatal dopaminergic neurons present a characteristic 
phenotype that rend ers them susceptible to what we suspect is oxidative stress. On the 
other, they warn of a possible additional risk factor, especially present in diabetic 
patients, which could contribute to the development of Parkinson's disease. 
These results are important in light of persisting doubts regarding the significance of 
79 0ther explanations for the heterogeneity of these data could be variations in the type of studies 
employed (case control vs. cohort), the diagnosis of Parkinson's disease and diabetes (medical 
examination vs. self-reported) and, as previously stated, the sizes of the populations evaluated. 
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reports stating that parkinsonian patients display elevated glycaemias (Boyd et al. , 1971 ; 
Cereda et al. , 2012; Lipman et al., 1974; Sandyk, 1993; Santiago and Potashkin, 2015). 
It is unclear whether hyperglycaemia appears after the onset of the disease or if it 
manifests itself upstream; a direct corollary of the latter would be that hyperglycaemia 
may contribute to the development of Parkinson's disease. Our work offers strong 
support in favour of this second option, without however refuting a possible 
bidirectional relationship between parkinsonian neurodegeneration and blood glucose 
control (Brunerova et al. , 2013). 
For parkinsonian patients who already suffer from this disease, war must be waged 
on further nigrostriatal dopaminergic neurodegeneration; sorne rather prioritize tackling 
the deterioration of their syrnptoms, which is not always directly linked to further 
neurodegeneration. Our findings, though not obtained in a parkinsonian model (Choi 
et al. , 2005; Morris et al. , 2010; Rotermund et al., 2014), clearly expose the hazard that 
uncontrolled hyperglycaemia represents for the survival of nigrostriatal dopaminergic 
neurons. Moreover, other studies provide evidence supporting a possible link between 
diabetes and the severity of the syrnptoms in Parkinson's disease (Cereda et al., 2012; 
Schwab, 1960). Likewise, in older persons without Parkinson's disease, parkinsonian 
syrnptoms like gait disturbances are more intimately correlated to existing diabetes 
(Arvanitakis et al., 2007). Considering the elevated rates of hyperglycaemia in 
parkinsonian patients (Barbeau et al., 1961 ; Boyd et al., 1971; Cereda et al., 2012 ; 
Lipman et al. , 1974; Sandyk, 1993), exercising a tighter glycaemic control constitutes an 
achievable target to prevent the exacerbation of both neurodegeneration and worsening 
of syrnptoms. 
Among the most recent clinical advances, anti-diabetic drugs have emerged as 
strong candidates for the development of disease-modifying therapies. A sharp interest 
in these substances surfaced following reports evoking a decreased risk of 
developing Parkinson 's disease in diabetic patients employing such drugs. Specifically, 
the incidence of Parkinson's disease was found to be lower in diabetic patients treated 
with metformin or thiozolidinediones, two glucose-lowering medications (Brauer et al., 
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2015; Wahlqvist et al. , 2012). For example, CUITent clinical trials are investigating the 
anti-diabetic and glucose-Iowering drug exenatide, a glucagon-like peptide 1 (GLP-l) 
receptor agonist that largely mimi cs insulin's action (see for review Athauda and 
Foltynie, 2017). An initial open label trial carried out in 44 medicated parkinsonian 
patients showed that twice-daily injections of exenatide for 12 months improved 
ovemight off-medication motor symptoms and dementia, rated according to the unified 
Parkinson's disease rating scale and the Mattis dementia rating scale, respectively 
(Aviles-Olmos et al. , 2013). This trial employed a washout design wherein exenatide 
treatments were ceased at 12 months and patients were re-evaluated at later time points. 
Remarkably, the benefits observed at 12 months still held at 14 (Aviles-Olmos et al., 
2013) and 24 months (Aviles-Olmos et al. , 2014). This encouraged the elaboration of 
subsequent double-blinded, placebo-controlled trials once aga in designed to include a 
washout period and to measure symptoms in off-medication patients. The benefits of 
exenatide were reiterated and supplementary DaTscan neuroimaging results, which 
conveyed information on the amount of presynaptic DAT left in the striatum of patients, 
confirmed a significant positive difference between treated and control parkinsonian 
patients (Athauda et al., 2017). 
These results are very encouragmg and are pavmg the way for further 
investigations that will perhaps address the mechanistic underpinnings of exenatide's 
efficacy. In this regard, it is surprising that glycaemic profiles were not drawn 
throughout these clinical trials . We can nonetheless suppose that glycaemic control was 
improved in parkinsonian patients based on robust evidence provided by trials in 
diabetic patients (Bergenstal et al., 2010; Buse et al. , 2009). However, a link between 
improved glycaemia and symptomatic amelioration in these investigations cannot be 
presumed. Indeed, GLP-l and exenatide are neurotrophic factors, akin to insulin 
(Athauda and Foltynie, 2016b; Perry et al., 2002). Exenatide may therefore wield its 
disease-modifying effects independently of glycaemic ameliorations. It remains that our 
data grant indirect evidence of the benefits of reducing hyperglycaemia, which we 
believe is a contributing factor in the efficacy of exenatide treatments in Parkinson 's 
disease. 
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5.3.3 Employing resveratrol to therapeutic ends 
There is compelling evidence to suggest that oxidative stress occuples a 
central position in both diabetic complications and nigrostriatal dopaminergic 
neurodegeneration in Parkinson's disease. Accordingly, antioxidants like the polyphenol 
resveratrol have been the object of much scientific and public interest for their 
therapeutic potential, either as complementary or preventive treatments. Although not 
the aim of this thesis, we previously introduced the idea of utilizing resveratrol as a 
neuroprotective strategy. The many sensitive elements that impinge on the employment 
of polyphenols in the CNS are reviewed in Appendix B. 
5.4 Concluding remarks 
The etiopathogenesis of Parkinson 's disease remains largely enigmatic, in part 
due to our lack of comprehension regarding the seemingly selective vulnerability of 
the nigrostriatal pathway to undergo degeneration, despite the neuroanatomical breadth 
of neuropathological manifestations in this illness. Ascending hypotheses grant a 
preeminent role to the existence of a particular phenotypic liability that characterizes 
neurons of the substantia nigra pars compacta and that may render them more sensitive 
to oxidative stress. In the aim of verifying the preferred susceptibility of nigrostriatal 
dopaminergic neurons to oxidative stress, we hired a strategy that employed high 
glucose conditions to induce the graduaI death of neurons in vitro and in vivo. For the 
first time, we provided robust evidence for the selective demise of the nigrostriatal 
pathway compared to mesocorticolimbic neurons over the course of 6 months of 
sustained hyperglycaemia, attended by alterations in glial profiles that indirectly 
supported a role for oxidative stress as a key conspirator in this neuronal death, further 
evinced by in vitro groundwork. Despite mode st neurodegeneration, hyperglycaemia 
evoked motor deficits strikingly reminiscent of parkinsonian motor symptoms. We also 
reported noticeably abnormal social behaviours in a hyperglycaemic mode l, which 
further informed us on a possible imbalance between phasic and tonic dopaminergic 
signalling arising from nigrostriatal neurodegeneration and, perhaps, hypoinsulinaemia. 
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These findings also direct our attention toward a rising need to better understand how 
diabetes may alter the quality of patients' social encounters. 
Across the se experiments, we demonstrated the various advantages that a long-
term hyperglycaemic model presents, especial1y regarding the physiological significance 
of inducing a graduaI and moderate neuronal death without layering additional 
parkinsonian insults. Indeed, by revealing that hyperglycaemia is sufficient to induce 
nigrostriatal dopaminergic neurodegeneration, we lend vigorous support to rather 
modest epidemiological accounts of the relationship between pre-existing diabetes and 
the development of Parkinson's disease in later years. According to our findings, it is 
critical that the efforts recently deployed to tighten glycaemic control in diabetic patients 
be firmly maintained. We further wish to express the tangible risk that an inappropriate 
glycaemic health may represent for the survival of remaining nigrostriatal dopaminergic 
neurons in the CNS of parkinsonian patients. 
From this wealth of information, we can also fully appreciate the complexity of 
several dimensions specifie to the CNS that, in remaining unsettled, dwell at the core of 
numerous longstanding debates. There is a profound lack of clarity pertaining to the 
bond shared between the brain and the periphery, especially in pathological settings. 
In our project, this was apparent upon attempting to identify the elements responsible for 
neurodegeneration in a model presenting multifaceted peripheral alterations. 
Dopaminergic systems also exposed their intricate nature that emerged on our daunting 
venture to draw connections between neurodegeneration, dopamine functions and 
behaviour. Most evidently, our understanding of the se pending issues is at its infancy, 
but formaI identification of these chasms in our knowledge draws us closer to their 
unravelling. 
REFERENCES 
Abeliovich, A. , Schmitz, Y. , Farifias, L, Choi-Lundberg, D. , Ho, W. H. , Castillo, P. E. , 
Shinsky, N., Verdugo, J. M., Annanini, M. , Ryan, A., Hynes, M. , Phillips, H. , 
Sulzer, D. , Rosenthal, A. (2000) . Mice lacking alpha-synuclein display functional 
deficits in the nigrostriatal dopamine system. Neuron, 25, 239-252. 
Abi-Saab, W. M. , Maggs, D. G. , Jones, T. , Jacob, R., Srihari, v., Thompson, 1. , 
Kerr, D., Leone, P. , Krystal , J. H. , Spencer, D. D. , During, M. 1. , Sherwin, R. S. 
(2002). Striking differences in glucose and lactate levels between brain 
extracellular fluid and plasma in conscious human subjects: effects of 
hyperglycemia and hypoglycemia. J Cereb. Blood Flow Metab., 22, 271-279. 
Abizaid, A. , Gao, Q. , Horvath, T. L. (2006). Thoughts for food: brain mechanisms and 
peripheral energy balance. Neuron, 51, 691-702. 
Achour, L, Arel-Dubeau, A. M., Renaud, J., Legrand, M., Attard, E. , Germain, M. , 
Martinoli, M. G. (2016). Oleuropein prevents neurodegeneration, mitigates 
mitochondrial superoxide production and modulates autophagy in a dopaminergic 
cellular model. Int. J Mol. Sei. , 17, pii:E1293 . 
Adam-Vizi, V. (2005). Production of reactive oxygen species in brain mitochondria: 
contribution by electron transport chain and non-electron transport chain sources. 
Antioxid. Redox Signal., 7, 1140-1149. 
Adams, F. S. , La Rosa, F. G. , Kumar, S. , Edwards-Prasad, J. , Kentroti, S. , Vernadakis, 
A., Freed, C. R. , Prasad, K. N. (1996). Characterization and transplantation of two 
neuronal celilines with dopaminergic properties. Neurochem. Res., 21, 619-627. 
Aghanoori, M. R., Smith, D. R. , Roy Chowdhury, S., Sabbir, M. G. , Calcutt, N. A. , 
Fernyhough, P. (2017). Insulin pre vents aberrant mitochondrial phenotype in 
sensory neurons of type 1 diabetic rats . Exp. Neurol., 29 7, 148-157. 
Agrawal, M. , Kumar, V. , Kashyap, M. P. , Khanna, V. K. , Randhawa, G. S., Pant, A. B. 
(2011) . Ischemic insult induced apoptotic changes in PC12 cells: protection by 
trans resveratrol. Eur. J Pharmacol. , 666, 5-11 . 
Ahmed, M. u., Brinkmann Frye, E. , Degenhardt, T. P. , Thorpe, S. R. , Baynes, 1. W. 
(1997). N-epsilon-( carboxyethyl)lysine, a product of the chemical modification of 
proteins by methylglyoxa1, increases with age in human lens proteins. Biochem. J , 
324, 565-570. 
274 
Ahrned, S. S. , Santosh, W. , Kumar, S., Christlet, H. T. (2009). Metabolic profiling of 
Parkinson's disease: evidence of biomarker from gene expression analysis and 
rapid neural network detection. J Biomed. Sei. 16, 63. 
Ahrned, N., Thomalley, P. J. , Dawczynski, 1. , Franke, S. , Strobel, J., Stein, G., 
Haik, G. M. (2003). Methylglyoxal-derived hydroimidazolone advanced glycation 
end-products ofhuman lens proteins. Invest Ophthalmol. Vis. Sei., 44, 5287-5292. 
Akirav, L, Maroun, M. (2006). Ventromedial prefrontal cortex is obligatory for 
consolidation and reconsolidation of object recognition memory. Cerebral Cortex, 
16, 1759-1765. 
Akude, E., Zherebitskaya, E. , Chowdhury, S. K. , Smith, D. R., Dobrowsky, R. T., 
Femyhough, P. (2011). Diminished superoxide generation is associated with 
respiratory chain dysfunction and changes in the mitochondrial proteome of 
sensory neurons from diabetic rats. Diabetes, 60, 288-297. 
Albani, D. , Polito, L. , Batelli, S. , De Mauro, S., Fracasso, C., Martelli, G., Colombo, L., 
Manzoni, C. , Salmona, M. , Caccia, S. , Negro, A., Forloni, G. (2009). The SIRT 1 
activator resveratrol protects SK-N-BE cells from oxidative stress and against 
toxicity caused by alpha-synuc1ein or amyloid-beta (1-42) peptide. J Neurochem., 
110, 1445-1456. 
Alberts, B. , Johnson, A., Lewis, J., Raff, M., Roberts, K., Walter, P. (2008). Chapter 18 
Apoptosis: Programmed Cell Death Eliminates Unwanted Cells. In: Molecular 
Biology of the Cel! (textbook), (5 th ed.). Garland Science. p. 1115. 
Albin, R. L. , Young, A. B. , Penney, J. B. (1989). The functional anatomy of basal 
ganglia disorders. Trends Neurosci., 12, 366-375. 
Alexander, G. E., Crutcher, M. D. , DeLong, M. R. (1990). Basal ganglia-thalamocortical 
circuits: parallel substrates for motor, oculomotor, "prefrontal" and " limbic" 
functions. Prog. Brain Res., 85, 119-146. 
Allaman, L, Magistretti, P. J. , (2013). Brain energy metabo1ism. In Squire, L. R. , 
Berg, D. , Bloom, F. E., du Lac, S., Ghosh, A. , Spitzer, N. C. (eds), Fundamental 
Neuroscience, Academic Press, San Diego, pp. 261-284. 
Allera, C., Lazzarini, G. , Patrone, E. , Alberti, L, Barboro, P., Sanna, P. , Melchiori, A. , 
Parodi, S., Balbi, C. (1997). The condensation of chromatin in apoptotic 
thyrnocytes shows a specific structural change. J Biol. Chem. , 272, 10817-10822. 
275 
Alliot, F., Godin, I. , Pessac, B. (1999). Microglia derive from progenitors, originating 
from the yolk sac, and which proliferate in the brain. Brain Res. Dev. Brain Res. , 
11 7, 145-152. 
Alomar, F., Singh, J., Jang, H. S., Rozanzki, G. 1. , Shao, C. H. , Padanilam, B. 1., 
Mayhan, W . G., Bidasee, K. R. (2016). Smooth muscle-generated methylglyoxal 
impairs endothelial cell-mediated vasodilatation of cerebral microvessels in type 1 
diabetic rats. Br. J Pharmacol. , 1 73, 3307-3326. 
Alonso, A. , Sovell, K. A. (2010). Gout, hyperuricemia, and Parkinson's disease: 
a protective effect? Curr. Rheumatol. Rep. , 12, 149-155. 
Altmann, C. , Schmidt, M. H. H. (2018). The Role of Microglia in Diabetic Retinopathy: 
Inflammation, Microvasculature Defects and Neurodegeneration. Int. J Mol. Sei. , 
19, pii: E110. 
Alvarez, E. , Martinez, M. D. , Roncero, I. , Chowen, J. A. , Garcia-Cuartero, B. , 
Gispert, J. D. , Sanz, C., Vazquez, P. , Maldonado, A. , de Caceres, 1., Desco, M ., 
Pozo, M. A. , Blazquez, E. (2005). The expression of GLP-I receptor rnRNA and 
protein allows the effect of GLP-1 on glucose metabolism in the human 
hypothalamus and brainstem. J Neurochem., 92, 798-806. 
Alvarez-Cervera, F. 1. , Villanueva-Toledo, J., Moo-Puc, R. E. , Heredia-Lopez, F. J., 
Alvarez-Cervera, M. , Pineda, J. C. , Gongora-Alfaro, 1. L. (2005). A novel 
automated rat catalepsy bar test system based on a RISC microcontroller. 
J Neurosci. Methods, 146, 7683 . 
Amblee, A. , Lious, D., Fogelfeld, L. (2016). Combination of Saxagliptin and Metformin 
Is Effective as Initial Therapy in New-Onset Type 2 Diabetes Mellitus With 
Severe Hyperglycemia. J Clin. Endocrinol. Metab., 101, 2528-2535 . 
American Diabetes Association. (2016). Diagnosing Diabetes and Learning About 
Prediabetes. http://www . diabetes. org/ diabetes-bas ics/ diagnosis/ 
Aminzadeh, A. (2017). Protective effect of tropisetron on high glucose induced 
apoptosis and oxidative stress in PC12cells: roles of JNK, P38 MAPKs, and 
mitochondria pathway. Metab. Brain Dis., 32, 819-826. 
Amiot, M. J., Romier, B. , Anh Dao, T. M. , Fanciullino, R. , Ciccolini, 1. , Burcelin, R. , 
Pechere, L. , Emond, C., Savouret, J . F., Seree, E. (2013). Optimization of 
trans-resveratrol bioavailability for human therapy. Biochimie, pü: S0300-9084, 
00011-4. 
276 
Anandhan, A., Tamilselvam, K. , Vijayraja, D., Ashokkumar, N., Rajasankar, S., 
Manivasagam, T. (2010). Resveratrol attenuates oxidative stress and improves 
behaviour in l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) challenged 
mice. Ann. Neurosci., 17, 113-119. 
Andén, N. E. , Dahlstr6m, A., Fuxe, K., OIson, L., Ungerstedt, U. (1966). Ascending 
noradrenaline neurons from the pons and the medulla oblongata. Exp erien tia, 
22,44-45. 
Anderson, J. J., Chen, X. , Boass, A., Symons, M., Kohlmeier, M., Renner, J. B., 
Garner, S. C. (2002). Soy isoflavones: no effects on bone minerai content and 
bone mineraI density in healthy, menstruating young adult women after one year. 
J Am. Coll. Nutr., 21, 388-393 . 
Andersen, J. K., Frim, D. M., Isacson, O., Beai, M. F. , Breakefield, X.O. (1994). 
Elevation of neuronal MAO-B activity in a transgenic mouse model 
does not increase sensitivity to the neurotoxin 1-methyl-4-phenyl-1 ,2,3,6-
tetrahydropyridine (MPTP). Brain Res., 656, 108-114. 
Andres-Lacueva, c., Shukitt-Hale, B., Galli, R. L., Jauregui, O., Lamuela-Raventos, 
R. M., Joseph, J. A. (2005). Anthocyanins in aged blueberry-fed rats are found 
centrally and may enhance memory. Nutr. Neurosci. , 8, 111-120. 
Anglade, P., Vyas, S., Javoy-agid, F. , Herrero, M. T., Marquez, J. , Mouatt-Prigent, A., 
Ruberg, M., Hirsch, E. c., Agid, y. (1997) . Apoptosis and autophagy in nigral 
neurons of patients with Parkinson's disease. Histol. Histopathol., 12, 25-31. 
Anitha, M. , Abraham, P. M. , Paulose, C. S. (2012). Striatal dopamine receptors 
modulate the expression of insu lin receptor, IGF-1 and GLUT-3 in diabetic rats: 
effect of pyridoxine treatment. Eur. J Pharmacol. , 696, 54-61. 
Annett, L. E., McGregor, A., Robbins, T. W. (1989). The effects ofibotenic acid lesions 
of the nucleus accumbens on spatial learning and extinction in the rat. Behavioural 
Brain Research, 31, 231-242. 
Anthony, K. , Reed, L. J., Dunn, J. T. , Bingham, E., Hopkins, D., Marsden, P.K, Amiel, 
S. A. (2006). Attenuation of insulin-evoked responses in brain networks 
controlling appetite and reward in insulin resistance: the cerebral basis for 
impaired control of food intake in metabolic syndrome? Diabetes, 55,2986-2992. 
Aquino, C. C., Fox, S. H. (2014). Clinical spectrum of levodopa-induced complications. 
Mov. Disord. , 30, 80-89. 
277 
Araki, E., Nishikawa, T. (2010) . Oxidative stress: A cause and therapeutic target of 
diabetic complications. J Diabetes Investig. , 1, 90-96. 
Araszkiewicz, A., Zozulinska-Ziolkiewicz, D . (2016) . Retinal Neurodegeneration 
in the Course of Diabetes-Pathogenesis and Clinical Perspective. Curr. 
Neuropharmacol., 14, 805-809. 
Arenas, E. , Denham, M., Villaescusa, J. C. (2015). How to make a midbrain 
dopaminergic neuron. Development, 142, 1918-1936. 
Arluison, M ., Quignon, M., Nguyen, P. , Thorens, B. , Leloup, C. , Penicaud, L. (2004). 
Distribution and anatomical localization of the glucose transporter 2 (GLUT2) 
in the adult rat brain - an immunohistochemical study. J Chem. Neuroanat. , 
28, Il 7 -13 6. 
Armstrong, R. A. , Lantos, P. L. , Cairns, N. J. (2005). Overlap between 
neurodegenerative disorders. Neuropathology, 25, 111-124. 
Arvanitakis, Z. , Wilson, R. S. , Bienias, J. L. , Bennet, D. A. (2007). Diabetes and 
parkinsonian signs in older persons. Alzheimer Dis. Assoc. Disord. , 21, 144-149. 
Ashkenazi, A. (2008). Directing cancer cells to self-destruct with pro-apoptotic receptor 
agonists. Nat. Rev. Drug Discov., 7, 1001-1012. 
Ashrafi , G. , Schlehe, 1. S. , LaVoie, M. J. , Schwarz, T. L. (2014). Mitophagy of damaged 
mitochondria occurs locally in distal neuronal axons and requires PINK1 and 
Parkin. J Cel!. Biol., 206, 655-670. 
Ashrafi, G., Wu, Z., Farrell, R. J. , Ryan, T. A. (2017). GLUT4 Mobilization Supports 
Energetic Demands of Active Synapses. Neuron. , 93, 606-615. 
Athauda, D., Foltynie, T. (2016a). Challenges in detecting disease modification In 
Parkinson's disease clinical trials. Parkinsonism Relat. Disord. , 32, 1-11. 
Athauda, D., Foltynie, T . (2016b). The glucagon-like peptide 1 (GLP) receptor as a 
therapeutic target in Parkinson ' s disease: mechanisms of action. Drug Discov. 
Today, 21, 802-818. 
Athauda, D. , Foltynie, T. (2017). Protective effects of the GLP-l mimetic exendin-4 in 
Parkinson's disease. Neuropharmacology, pii: S0028-3908(17)30440-9. 
278 
Athauda, D., Maclagan, K. , Skene, S. S. , Bajwa-Joseph, M. , Letchford, D., 
Chowdhury, K. , Hibbert, S. , Budnik, N., Zampedri, L. , Dickson, J., Li, Y., 
Aviles-Olmos, I. , Wamer, T. T. , Limousin, P., Lees, A. J., Greig, N . H., Tebbs, S., 
Foltynie, T. (2017). Exenatide once weekly versus placebo in Parkinson's disease: 
a randomised, double-blind, placebo-controlled trial. Lancet, 390, 1664-1675. 
Aubert, A., Costalat, R. (2005). Interaction between astrocytes and neurons studied 
using a mathematical model of compartmentalized energy metabolism. J Cereb. 
Blood Flow Metab., 25, 1476-1490. 
Aubert, A. , Pellerin, L. , Magistretti, P. J., Costalat, R. (2007). A coherent 
neurobiological framework for functional neuroimaging provided by a model 
integrating compartmentalized energy metabolism. Proc. Nat/. Acad. Sei. USA, 
104,4188-4193. 
Aubert, C. E., Michel, P. L. , Gillery, P., Jaisson, S., Fonfrede, M ., Morel, F., 
Hartemann, A. , Bourron, O. (2014). Association of peripheral neuropathy with 
circulating advanced glycation end products, soluble receptor for advanced 
glycation end products and other risk factors in patients with type 2 diabetes. 
Diabetes Metab. Res. Rev., 30, 679-685. 
Auburger, G., Kurz, A. (2011) . The role of glyoxalases for sugar stress and aging, 
with relevance for dyskinesia, anxiety and Parkinson's disease. Aging, 3, 5-9. 
Aviles-Olmos, I., Dickson, J. , Kefalopoulou, Z. , Djamshidian, A. , Ell, P., Soderlund, T., 
Whitton, P., Wyse, R, Isaacs, T., Lees, A., Limousin, P. , Foltynie, T. (2013). 
Exanatide and the treatment of patients with Parkinson 's disease. J Clin. In vest. , 
123, 2730-2736. 
A viles-Olmos, I. , Dickson, J. , Kefalopoulou, Z., Djamshidian, A., Kahan, 1. , 
Fmedsci, P. E. , Whitton, P. , Wyse, R, Isaacs, T. , Lees, A., Limousin, P., 
Foltynie, T. (2014). Motor and cognitive advantages persist 12 months after 
exenatide exposure in Parkinson 's disease. J Parkinsons Dis. , 4, 337-344. 
Babri, S. , Badie, H. G. , Khamenei, ~. , Ordikhani-Seyedlar, M. (2007). Intrahippocampal 
insulin improves memory in a passive-avoidance task in male wistar rats. 
Brain Cogn. , 64, 86-91. 
Badgaiyan, RD., Sinha, S., Sajjad, M., Wack, D. S. (2015) . Attenuated Tonic and 
Enhanced Phasic Release of Dopamine in Attention Deficit Hyperactivity 
Disorder. PLoS One, 10, e0137326. 
279 
Badole, S. L. , Chaudhari, S. M. , Jangam, G. B., Kandhare, A. D., Bodhankar, S. L. 
(2015). Cardioprotective Activity of Pongamia pinnata in Streptozotocin-
Nicotinamide Induced Diabetic Rats. Biomed. Res. Int., 2015, 403291. 
Bagatini, P. B. , Xavier, L. L. , Bertoldi, K. , Moysés, F., Lovatel, G., Neves, L. T. , 
Barbosa, S. , Saur, L. , de Senna, P. N. , Souto. A. A., Siqueira, 1. R., Achaval, M. 
(2017). An evaluation of avers ive memory and hippocampal oxidative status in 
streptozotocin-induced diabetic rats treated with resveratrol. Neurosci. Leu., 
636, 184-189. 
Bai , T., Dong, D. S. , Pei, L. (2013). Resveratrol mltlgates isoflurane-induced 
neuroapoptosis by inhibiting the activation of the Akt-regulated mitochondrial 
apoptotic signaling pathway. Int. J Mol. Med., 32, 819-826. 
Bak, L. K. , Obel, L. F. , Walls, A. B. , Schousboe, A. , Faek, S. A. , Jajo, F. S., 
Waagepetersen, H. S. (2012). Novel model of neuronal bioenergetics: Postsynaptic 
utilization of glucose but not lactate correlates positively with Ca2+ signalling in 
cultured mouse glutamatergic neurons. ASN Neuro., 4, pii: e00083. 
Bak, L. K. , Schousboe, A. , Sonnewald, U., Waagepetersen, H. S. (2006). Glucose is 
necessary to maintain neurotransmitter homeostasis during synaptic activity in 
cultured glutamatergic neurons. J Cereb. Blood Flow Metab. , 26, 1285-1297. 
Baldo, B. A. , Kelley, A. E . (2007). Discrete neurochemical coding of distinguishable 
motivational processes: insights from nucleus accumbens control of feeding. 
Psychopharmacol. (Berl), 191, 439-459. 
Baldessarini, R. 1. (1985). Principles and practice. In: Chemotherapy in psychiatry. 
Harvard University Press. 
Banaszewska, B. , Wrotynska-Barczyilska, J. , Spaczynski, R . Z., Pawelczyk, L. , 
Duleba, A. J. (2016). Effects of Resveratrol on Polycystic Ovary Syndrome: 
A Double-blind, Randomized, Placebo-controlled Trial. J Clin. Endocrinol. 
Metab. , 101, 4322-4328. 
Banks, W. A. , Jaspan, 1. B., Huang, W. , Kastin, A. J. (1997a) . Transport of insulin 
across the blood-brain barrier: saturability at euglycemic doses of insulin. 
Peptides, 18, .1423-1429. 
Banks, W. A. , Jaspan, J. B. , Kastin, A. J. (1997b) . Effect of diabetes mellitus on the 
permeability of the blood-brain barrier to insulin. Peptides, 18, 1577-1584. 
Banks, W. A. , Kastin, A. J. (1998) . DifferentiaI permeability of the blood-brain barrier 
to two pancreatic peptides: insulin and amylin. Peptides, 19, 883-889. 
280 
Bansal, V., Kalita, J., Misra, U. K. (2006). Diabetic neuropathy. Postgrad. Med. J , 
82, 95-100. 
Bar-Gad, L, Heimer, G., Ritov, Y., Bergman, H. (2003). Functional correlations between 
neighboring neurons in the primate globus pallidus are weak or nonexistent. 
J Neurosci. 23,4012-4016. 
Barbeau, A., Giguere, R., Hardy, J. (1961). Clinical experience with tolbutamide in 
Parkinson ' s disease. Union Med. Can. , 90, 147 -15l. 
Bames, K. , Ingram, J. C. , Bennett, M. D., Stewart, G. W., Baldwin, S.A. (2004). 
Methyl-beta-cyclodextrin stimulates glucose uptake in Clone 9 cells: a possible 
role for lipid rafts. Biochem. J, 378, 343-351. 
Barros, L. F., Courjaret, R., Jakoby, P. , Loaiza, A., Lohr, C. , Deitmer, J. W. (2009) . 
Preferential transport and metabolism of glucose in Bergmann glia over Purkinje 
cells: a multiphoton study of cerebellar slices. Glia, 5 7, 962-970. 
Barzilai , A. , Yamamoto K. (2004). DNA damage responses to oxidative stress. 
DNA Repair (Amst), 3, 1109-1115. 
Bashan, N., Burdett, E., Gumà, A. , Sargeant, R., Tumiati, L., Liu, Z. , Klip, A. (1993). 
Mechanisms of adaptation of glucose transporters to changes in the oxidative 
chain of muscle and fat cells. Am. J Physiol. , 264, 430-440. 
Bashan, N., Burdett, E., Hundal, H. S., Klip, A. (1992). Regulation of glucose transport 
and GLUT 1 glucose transporter expression by 02 in muscle cells in culture. 
Am. J Physiol., 262, 682-690. 
Bassareo, V., Musio, P., Di Chiara, G. (2011). Reciprocal responsiveness of nucleus 
accumbens shell and core dopamine to food- and drug conditioned stimuli. 
Psychopharmacol. , 214, 687-697. 
Bast, T. (2007). Toward an integrative perspective on hippocampal function: from the 
rapid encoding of experience to adaptive behavior. Rev Neurosci., 18, 253-281. 
Bast, T., Wilson, 1. A., Witter, M. P., Morris, R. G. (2009). From rapid place leaming to 
behavioral performance: a key role for the intermediate hippocampus. PLoS Bio!. , 
7, elO00089. 
Batandier, C., Fontaine, E., Kériel , c., Leverve, X. M. (2002). Determination of 
mitochondrial reactive oxygen species: methodological aspects. J Cel!. Mol. Med., 
6, 175-187. 
281 
Baumann, M. u., Zamudio, S. , Illsley, N. P. (2007). Hypoxic upregu1ation of glucose 
transporters in BeWo choriocarcinoma cells is mediated by hypoxiainducible 
factor-1. Am. J Physiol. Cel!. Physiol., 293, 477-485. 
Baxter, A. G., Duckworth, R. C. (2004). Models of type 1 (auto immune) diabetes. 
Drug Discov. Today Dis. Models, 1, 451-455. 
Baydas, G. , Nedzvetskii, V. S. , Tuzcu, M. , Yasar, A. , Kirichenko, S. V. (2003). Increase 
of glial fibrillary acidic protein and S-100B in hippocampus and cortex of diabetic 
rats: effects ofvitamin E. Eur. J Pharmacol. , 462, 67-71. 
Bazelton, M., Fenichel, G M., Randall, J. (1967). Studies on neuromelanin. 1. a melanin 
system in the adult human brainstem. Neurology, 17, 512-519. 
Beai, M. F. (2001). Experimental models of Parkinson's disease. Nat. Rev. Neurosci. 2, 
325-334. 
Beai, M. F. (2003). Mitochondria, oxidative damage, and inflammation in Parkinson 's 
disease. Ann. NY Acad. Sei., 991, 120-131. 
Becker, C. , Brobert, G. P., Johansson, S. , Jick, S. S., Meier, C. R. (2008). Diabetes in 
patients with idiopathic Parkinson's disease. Diabetes Care, 31, 1808-1812. 
Beeler, J. A. (2011). Preservation of function in Parkinson's disease: what's leaming got 
to do with it? Brain Res., 1423, 96-113. 
Beher, D. , Wu, J., Cumine, S. , Kim, K. W., Lu, S. C., Atangan, L., Wang, M. (2009). 
Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem. Biol. 
Drug Des., 74,619-624. 
Béland-Millar, A. , Larcher, J., Courtemanche, J. , Yuan, T. , Messier, C. (2017). 
Effects of Systemic Metabolic Fuels on Glucose and Lactate Levels in the Brain 
Extracellular Compartment of the Mouse. Front. Neurosci., Il, 7. 
Bell, R. H. , Hye, R. J. (1983). Animal models of diabetes mellitus: physiology and 
pathology. J Surg. Res. , 35, 433-460. 
Belluzzi, E., Bisaglia, M. , Lazzarini, E., Tabares, L. C., Beltramini, M., Bubacco, L. 
(2012). Human SOD2 modification by dopamine quinones affects enzymatic 
activity by promoting its aggregation: possible implications for Parkinson 's 
disease. PLoS One, 7, e38026. 
282 
Ben-Yoseph, O. , Boxer, P. A., Ross, B. D. (1 996a). Assessment of the role of the 
glutathione and pentose phosphate pathways in the protection of primary 
cerebrocortical cultures from oxidative stress. J Neurochem., 66, 2329-2337. 
Ben-Yoseph, O., Boxer, P. A., Ross, B. D. (1996b). Noninvasive assessment of the 
relative roles of cerebral antioxidant enzymes by quantitation of pentose phosphate 
pathway activity. Neurochem. Res., 21, 1005-1012. 
Benabid, A. L., Chabardès, S. , Seigneuret, E . (2005). Deep-brain stimulation in 
Parkinson's disease: long-term efficacy and safety - What happened this year? 
Curr. Opin. Neurol., 18, 623-630. 
Benarroch, E. E. (2012). Insulin-like growth factors in the brain and their potential 
clinical implications. Neurology, 79, 2148-2153. 
Bender, A., Krishnan, K. 1., Morris, C. M., Taylor, G. A., Reeve, A. K., Perry, R. H., 
Jaros, E., Hersheson, J. S., Betts, 1., Klopstock, T., Taylor, R. W., Turnbull, D. M. 
(2006). High levels of mitochondrial DNA deletions in substantia nigra neurons in 
aging and Parkinson disease. Nat. Genet., 38, 515-517. 
Bender, A., Schwarzkopf, R. M. , McMillan, A., Krishnan, K. J. , Rieder, G. , 
Neumann, M. , Eistner, M., Turnbull , D. M., Klopstock, T. (2008). Dopaminergic 
midbrain neurons are the prime target for mitochondrial DNA deletions. 
J Neurol., 255, 1231-1235. 
Benedict, C., Hallschmid, M., Hatke, A., Schultes, B., Fehm, H. L., Born, J., Kern, W. 
(2004) . lntranasal insulin improves memory in humans. Psychoneuroendocrinol. , 
29, 1326-1334. 
Benedict, C., Hallschmid, M. Schmitz, K. , Schultes, B., Ratter, F., Fehm, H. L., Born, J. , 
Kern, W. (2007). Intranasal insulin improves memory in humans: superiority of 
insulin aspart. Neuropsychopharmacology, 32, 239-243 . 
Benes, F. M. (2001). Carlsson and the discovery of dopamine. Trends in 
Pharmacological Sciences, 22, 46-47. 
Bentsath, A., Rusznyak, S.T. , Szent-Gyorgyi, A. (1936). Vitamin nature of flavones . 
Nature (London), 138, 798. 
Benzie,1. F., Szeto, Y. T. , Strain, J. J., Tomlinson, B. (1999). Consumption of green tea 
causes rapid increase in plasma antioxidant power in humans. Nutr. Cancer., 
34,83-87. 
283 
Bernheimer, H. , Birkmayer, W ., Hornykiewicz, O. , Jellinger, K. , Seitelberger, F. (1973). 
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, 
morphological and neurochemical correlations. J Neurol. Sei., 20, 415-455 . 
Bergenstal, R. M. , Wysham, c., Macconell, L. , Malloy, J ., Walsh, B. , Yan, P., 
Wilhelm, K., Malone, J ., Porter, L. E. (2010). Efficacy and safety of exenatide 
once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for 
treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet, 376, 
431-439. 
Bergstrom, B. P. , Garris, P. A. (2003). "Passive stabilization" of striatal extracellular 
dopamine across the les ion spectrum encompassing the presymptomatic phase 
of Parkinson's disease: a voltammetric study in the 6-0HDA-Iesioned rat. 
J Neurochem., 87, 1224-1236. 
Bergstrom, B. P., Sanberg, S. G. , Andersson, M., Mithyantha, J., Carroll, F. L, 
Garris, P . A. (2011). Functional reorganization of the presynaptic dopaminergic 
terminal in parkinsonism. Neuroseience, 193, 310-322. 
Bertelli, A. , Bertelli, A. A. E ., Gozzini, A., Giovannini, L. (1998). Plasma and tissue 
resveratrol concentrations and pharmacological activity. Drugs Exp . Clin. Res. , 24, 
133-138. 
Bertolotto, F., Massone, A. (2012) . Combination of alpha lipoic acid and superoxide 
dismutase leads to physiological and symptomatic improvements in diabetic 
neuropathy. Drugs R. D., 12, 29-34. 
Bertran-Gonzalez, 1. , Bosch, C. , Maroteaux, M. , Matamales, M., Hervé, D. , Valjent, E., 
Girault, J. A. (2008). Opposing patterns of signaling activation in dopamine Dl 
and D2 receptor-expressing striatal neurons in response to cocaine and 
haloperidol. J Neurosei. 28, 5671-5685. 
Betarbet, R. , Sherer, T. B. , MacKenzie, G., Garcia-Osuna, M. , Panov, A. V., 
Greenamyre, 1. T. (2000). Chronic systemic pesticide exposure reproduces 
features ofParkinson ' s disease. Nat. Neurosei. , 3, 1301-1306. 
Bharath, S. , Hsu, M. , Kaur, D., Rajagopalan, S. , Andersen, J. K. (2002). Glutathione, 
iron and Parkinson's disease. Biochem. Pharmacol., 64, 1037-1048. 
Bhuyan, B. K. , Kuentzel, S. L. , Gray, L. G. , Fraser, T. J., Wallach, D. , Neil, G. L. 
(1974) . Tissue distribution of streptozotocin (NSC-85998). Cancer Chemother. 
Rep ., 58, 157-165. 
284 
Bialy, M., Rydz, M., Kaczmarek, L. (2000). Precontact 50-kHz vocalizations in male 
rats during acquisition of sexual experience. Behav. NeurosCÎ., 114, 983-990. 
Bierhaus, A., Hurnpert, P. M., Morcos, M., Wendt, T., Chavakis, T., Arnold, B., 
Stern, D. M., Nawroth, P. P. (2005). Understanding RAGE, the receptor for 
advanced glycation end-products. J Mol. Med., 83, 876-886. 
Biessel, G. J., van der Heide, L. P. , Kamal, A., Bleys, R. L., Gispen, W. H. (2002). 
Ageing and diabetes: implications for brain function. Eur. J Pharmacol. , 
441,1-14. 
Bilgic, B., Pfefferbaum, A., Rohlfing, T., Sullivan, E. V., Adalsteinsson, E. (2012). 
MRI estimates of brain iron concentration in normal aging using quantitative 
susceptibility mapping. Neuroimage, 59, 2625-2635. 
Birch, N. P., Christie, D. L., Renwick, A. G. C. (1984). Proinsulin-like material ln 
mouse foetal brain cell cultures. FEBS LeU., 168, 299-302. 
Bishop, F. K., Maahs, D. M., Snell-Bergeon, J. K., Ogden, L. G., Kinney, G. L., 
Rewers, M. (2009). Lifestyle risk factors for atherosc1erosis in adults with type 1 
diabetes. Diab. Vasco Dis. Res. , 6, 269-275. 
Bitar, M., Koulu, M., Rapoport, S. L, Linnoila, M. (1986). Diabetes-induced alteration in 
brain monoamine metabolism in rats. J Pharmacol. Exp. Ther., 236, 432-437. 
Bjorklund, A., Dunnett, S. (2007). Dopamine neuron systems in the brain: an update. 
Trends NeurosCÎ. , 30, 194-202. 
Blanchet, J. , Longpré, F., Bureau, G., Morissette, M., DiPaolo, T., Bronchti, G., 
Martinoli, M. G. (2008). Resveratrol, a red wine polyphenol, protects 
dopaminergic neurons in MPTP-treated mice. Prog. Neuropsychopharmacol. 
Biol. Psychiatry, 32, 1243-1250. 
Blâzquez, E., Velâzquez, E. , Hurtado-Carneiro, V., Ruiz-Albusac, J. M. (2014). 
Insulin in the brain: its pathophysiological implications for States related 
with central insulinresistance, type 2 diabetes and Alzheimer's disease. 
Front. Endocrinol. (Lausanne), 5, 161 . 
Blocq, P., Marinesco, G. (1892). Sur les lésions de la pathogénie de l'épilepsie 
essentielle. Sem. Med. , 12, 445-446. 
Blocq, P., Marinesco, G. (1893). Sur un cas de tremblement parkinsonien hémiplégique 
symptomatique d 'une tumeur du pédoncule cérébral. C. R. Soc. Biol. , 5, 105-111. 
285 
Boissy, A., Manteuffel, G. , Jensen, M. B. , Moe, R. O., Spruijt, B. , Keeling, L. 1., 
Winckler, C., Forkman, B., Dimitrov, L, Langbein, J. , Bakken, M., Veissier, L, 
Aubert, A. (2007). Assessment of positive emotions in animais to improve their 
welfare. Physiol. Behav., 92, 375-397. 
Bolafios, J. P., Almeida, A. , Moncada, S. (2010). Glycolysis: a bioenergetic or a survival 
pathway? Trends Biochem. Sei., 35, 145-149. 
Bolafios, J . P., Delgado-Esteban, M. , Herrero-Mendez, A. , Femandez-Femandez, S., 
Almeida, A. (2008). Regulation of glycolysis and pentose-phosphate pathway by 
nitric oxide: impact on neuronal survival. Biochim. Biophys. Acta. , 1777, 789-793. 
Bolster, D. R., Crozier, S. J ., Kimball , S. R. , Jefferson, L. S. (2002). AMP-activated 
protein kinase suppresses protein synthesis in rat skeletal muscle through 
downregulated mTOR signaling. J Biol. Chem., 2 77, 23977-23980. 
Bondy, C. A. , Lee, W. H. , Zhou, J. (1992). Ontogeny and cellular distribution of brain 
glucose transporter gene expression. Mol. Cel!. Neurosci. , 3, 305-314. 
Bordt, E. A. , Polster, B. M. (2014). NADPH oxidase- and mitochondria-derived reactive 
oxygen species in proinflammatory microglial activation: a bipartisan affair? 
Free Radic. Biol. Med. , 76, 34-46. 
Borra, M. T. , Smith, B. C., Denu, 1. M. (2005). Mechanism of human SIRTI activation 
by resveratrol. J Biol. Chem., 280, 17187-17195. 
Borroto-Escuela, D. O., Carlsson, 1. , Ambrogini, P. , Narvaez, M. , Wydra, K. , 
Tarakanov, A. O., Li, X., Mi1l6n, C., Ferraro, L., Cuppini, R., Tanganelli, S. , 
Liu, F. , Filip, M., Diaz-Cabiale, Z., Fuxe, K. (2017). Understanding the Role of 
GPCR Heteroreceptor Complexes in Modulating the Brain Networks in Health and 
Disease. Front Cel!. Neurosci., Il, 37. 
Bossers, S. M., de Boer, R. D., Boer, C., Peerdeman, S. M. (2013). The diagnostic 
accuracy of brain microdialysis during surgery: a qualitative systematic review. 
Acta Neurochir. (Wien). , 155, 345-353. 
Boulares, A. H. , Yakovlev, A. G. , Ivanova, V. , Stoica, B. A. , Wang, G., Iyer, S. , 
Smulson, M. (1999). Role of poly(ADP-ribose) polymerase (PARP) cleavage in 
apoptosis. Caspase 3-resistant P ARP mutant increases rates of apoptosis in 
transfected ceUs. J Biol. Chem., 2 74, 22932-22940. 
Boumival, J. , Francoeur, M. A. , Renaud, J. , Martinoli, M. G. (2012a). Quercetin and 
sesamin protect neuronal PC12 ceUs from high-glucose-induced oxidation, 
nitrosative stress and apoptosis. Rejuvenation Res., 15, 322-333. 
286 
Boumival, J., Plouffe, M., Renaud, J. , Provencher, C., Martinoli, M. G. (2012b). 
Quercetin and sesamin protect dopaminergic cells from MPP+-induced 
neuroinflammation in a micro glial (N9)-neuronal (PC 12) coculture system. 
Oxid. Med. Cel! Longev., 2012, 921941. 
Boumival, J., Quessy, P., Martinoli, M. G. (2009). Protective effects of resveratrol and 
quercetin against MPP+-induced oxidative stress act by modulating markers of 
apoptotic death in dopaminergic neurons. Cel!. Mol. Neurobiol., 29, 1169-1180. 
Bouzier-Sore, A. K., Bolafios, J. P. (2015). Uncertainties in pentose-phosphate pathway 
flux assessment underestimate its contribution to neuronal glucose consumption: 
relevance for neurodegeneration and aging. Front. Aging Neurosci., 7, 89. 
Boveris, A. (1977) . Mitochondrial production of superoxide radical and hydrogen 
peroxide. Adv. Exp. Med. Biol., 78, 67-82. 
Bowers, J. L., Tyulmenkov, V. V., Jemigan, S. C., Klinge, C. M. (2000). Resveratrol 
acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. 
Endocrinology, 141, 3657-3667. 
Boyd, A. E. 3rd , Lebovitz, H. E., Feldman, J. M. (1971). Endocrine function and glucose 
metabolism in patients with Parkinson 's disease and their altemation by L-dopa. 
J Clin. Endocrinol. Metab., 33, 829-837. 
Braak, H. , de Vos, R. A. I. , Bohl, J. , Del Tredici , K. (2006). Gastric a-synuclein 
immunoreactive inclusions in Meissner's and Auerbach 's plexuses in cases staged 
for Parkinson 's disease-related brain pathology. Neurosci. LeU., 396, 67-72. 
Braak, H., Tredici, K. D., Rüb, u., de Vos, R. A. I., Jansen Steur, E. N. H., Braak, E. 
(2003). Staging of brain pathology related to sporadic Parkinson's disease. 
Neurobiol. Aging, 24, 197-211 . 
Bradberry, C. W. , Karasic, D. H. , Deutch, A. Y., Roth, R. H. (1989). Regionally-specific 
alterations in mesotelencephalic dopamine synthesis in diabetic rats: association 
with precursor tyrosine . J Neural Transm. Gen. Sect., 78, 221-229. 
Brambilla Bagatini, P., Xavier, L. L. , Neves, L. , Saur, L. , Barbosa, S., Baptista, P. P. , 
Augustin, O. A., Nunes de Senna, P. , Mestriner, R. G., Souto, A. A., Achaval, M. 
(2014). Resveratrol pre vents akinesia and restores neuronal tyrosine hydroxylase 
immunoreactivity in the substantia nigra pars compacta of diabetic rats. 
Brain Res., 1592, 101-112. 
287 
Brands, A. M. , Biessels, G. J. , Kappelle, L. J., de Haan, E. H. , de Valk, H. W. , Algra, A. , 
Kessels, R. P. , Utrecht Diabetic Encephalopathy Study Group. (2007). Cognitive 
functioning and brain MRI in patients with type 1 and type 2 diabetes mellitus: 
a comparative study. Dement. Geriatr. Cogn. Disord. , 23, 343-350. 
Brayne, c., Gao, L., Matthews, F., MRC Cognitive Function and Ageing Study. (2005). 
Challenges in the epidemiological investigation of the relationships between 
physical activity, obesity, diabetes, dementia and depression. Neurobiol. Aging, 1, 
6-10. 
Brauer, R. , Bhaskaran, K. , Chaturvedi, N. , Dexter, D . T., Smeeth, L. , Douglas, 1. (2015). 
Glitazone treatment and incidence of Parkinson's disease among people with 
diabetes: a retrospective cohort study. PLoS Med. , 12, p.e1001854. 
Bredesen, D. E. , Rao, R. V. , Mehlen, P . (2006). Cell death in the nervous system. 
Nature, 443, 796-802. 
Bremer, T. (1920). Encephalite lethargique avec syndrome parkinsonien et catatonie. 
Rev. Neurol., 27, 772-770. 
Brichta, L. , Greengard, P. (2014). Molecular determinants of selective dopaminergic 
vulnerability in Parkinson's disease: an update. Front. Neuroanat., 8, 152. 
Brightman, M. W. , Reese, T.S. (1969). Junctions between intimately apposed cell 
membranes in the vertebrate brain. J Cel!. Bio!. , 40, 648-677. 
Brissaud, E. (1895). Nature et pathogénie de la maladie de Parkinson. In Meige, H. (ed), 
Leçon sur les maladies nerveuses (Salpêtrière, 1893-1894), Vol. 1, leçon 23. 
Paris: Masson. p. 488-501 . 
Britton, R. G. , Kovoor, C., Brown, K. (2015). Direct molecular targets of resveratrol: 
identifying key interactions to unlock complex mechanisms. Ann. N. Y Acad. Sei., 
1348, 124-133. 
Bromberg-Martin, E. S. , Matsumoto, M ., Hikosaka, O. (2010). Dopamine III 
motivational control: rewarding, aversive, and alerting. Neuron, 68, 815-834. 
Brosius, F. C. , Heilig, C. W. (2005). Glucose transporters in diabetic nephropathy. 
Pediatr Nephrol, 20, 447-451. 
Brown, K. A. (2001). Factors modifying the migration of lymphocytes across the blood-
brain barrier. Int. Immunopharmacol., 1, 2043-2062. 
288 
Brownlee, M. (2001). Biochemistry and molecular cell biology of diabetic 
complications. Nature, 414, 813-820. 
Brownlee, M. (2005). The pathobiology of diabetic complications: a unifying 
mechanism. Diabetes, 54, 1615-1625. 
Brudzynski, S. M. (2007). Ultrasonic calls of rats as indicator variables of negative 
or positive states: acetylcholine-dopamine interaction and acoustic coding. 
Behav. Brain Res., 182,261-273. 
Brudzynski, S. M. (2009) . Communication of adult rats by ultrasonic vocalization: 
biological, sociobiological, and neuroscience approaches. ILAR J,50, 43-50. 
Brudzynski, S. M. (2013). Ethotransmission: communication of emotional states through 
ultrasonic vocalization in rats. Curr. Opin. Neurobiol. , 23,310-317. 
Brunelli, S. A. , Nie, R. , Whipple, C., Winiger, V., Hofer, M. A., Zimmerberg, B. (2006). 
The effects of selective breeding for infant ultrasonic vocalizations on play 
behavior in juvenile rats. Physiol. Behav., 87, 527-536. 
Brunerova, L. , Potockova, J. , Horacek, J., Suchy, J., Andel, M. (2013). 
Central dopaminergic activity influences metabolic parameters in healthy men. 
Neuroendocrinology, 97, 132-138. 
Buchman, A. S. , Shulman, J. M., Nag, S., Leurgans, S. E., Arnold, S. E., Morris, M. C. , 
Schneider, J . A., Bennett, D. A. (2012). Nigral pathology and Parkinsonian signs 
in eiders without Parkinson disease. Ann. Neurol. , 71, 258-266. 
Burbulla, L. F., Schelling, C., Kato, H., Rapaport, D., Woitalla, D. , Schiesling, C., 
Schulte, C. , Sharma, M., Illig, T. , Bauer, P., Jung, S. , Nordheim, A., Schols, L. , 
Riess, O., Krüger, R. (2010). Dissecting the role of the mitochondrial chaperone 
mortalin in Parkinson 's disease: Functional impact of disease-related variants on 
mitochondrial homeostasis . Hum. Mol. Genet., 19, 4437-4452. 
Bureau, G. , Longpré, F., Martinoli, M. G. (2008). Resveratrol and quercetin, two natural 
polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. 
J Neurosci. Res., 86, 403-410. 
Burgdorf, J. , Kroes, R. A., Moskal, J. R., Pfaus, J. G., Brudzynski, S. M. , Panksepp, J. 
Ultrasonic vocalizations of rats (Rattus norvegicus) during mating, play, 
and aggression: Behavioral concomitants, relationship to reward, and 
self-administration ofplayback. (2008). J Comp. Psycho!., 122,357-367 . 
289 
Burke, C. J. , Kisko, T. M. , Pellis, S. M., Euston, D. R. (2017). Avoiding escalation 
from play to aggression in adult male rats: The role of ultrasonic calls. 
Behav. Processes., 144, 72-81. 
Burke, C. J., Tobler, P. N., Schultz, W. , Baddeley, M. (2010). Striatal BOLD response 
reflects the impact of he rd information on financial decisions. Front. Hum. 
Neurosci., 4, 48 . 
Burré, J. (2015). The Synaptic Function of a-Synuclein. J Parkinsons Dis., 5, 699-713. 
Buryanovskyy, L. , Fu, Y. , Boyd, M., Ma, Y. , Hsieh, T. C., Wu, J. M. , Zhang, Z. (2004). 
Crystal structure of quinone reductase 2 in complex with resveratrol. Bioehemistry, 
43, 11417-11426. 
Buse, J. B. , Rosenstock, J., Sesti, G. , Schmidt, W. E., Montanya, E. , Brett, J. H., 
Zychma, M. (2009). Liraglutide once a day versus exenatide twice a day for type 2 
diabetes: a 26-week randomised, parallel-group, multinational, open-label trial 
(LEAD-6). Lancer (London, England), 374, 39-47. 
Cabezas, R, Avila, M., Gonzalez, J. , EI-Bacha, R S. , Baez, E. , Garcia-Segura, L. M. , 
Jurado Coronel, J. C., Capani, F., Cardona-Gomez, G. P. , Barreto, G. E. (2014). 
Astrocytic modulation of blood brain barrier: perspectives on Parkinson's disease. 
Front. Cell. Neurosci. 8, 211. 
Cagniard, B. , Balsam, P. D., Brunner, D. , Zhuang, X. (2006). Mice with chronically 
elevated dopamine exhibit enhanced motivation, but not leaming, for a food 
reward. Neuropsyehopharmaeology, 31, 1362-1370. 
Canadian Diabetes Association. (2009) . An Economic Tsunami: The Co st of 
Diabetes in Canada. http://www.diabetes.ca/publications-newsletters/advocacy-
reports/ economic-tsunami-the-cost-of-diabetes-in-canada. 
Calabrese, E. J. (2013). Biphasic dose responses in biology, toxicology and medicine: 
accounting for their generalizability and quantitative features. Environ. Po llut., 
182, 452-460. 
Calabrese, E. J. , Mattson, M. P., Calabrese, V. (2010). Resveratrol commonly displays 
hormesis: occurrence and biomedical significance. Hum. Exp. Toxieol., 29, 
980-1015. 
Calabrese, V. , Santoro, A., Monti, D., Crupi, R , Di Paola, R. , Latteri, S. , Cuzzocrea, S. , 
Zappia, M. , Giordano, J. , Calabrese, E. J. , Franceschi, C. (2018). Aging and 
Parkinson's Disease: Inflammaging, neuroinflammation and biological remodeling 
as key factors in pathogenesis. Free Radie. Biol. Med., 115, 80-91. 
290 
Calabresi, P., Picconi, B. , Tozzi A. , Ghiglieri, V., Di Filippo, M. (2014). Direct and 
indirect pathways of basal ganglia: a critical reappraisal. Nat. Neurosci., 17, 
1022-1030. 
Calamini, B. , Ratia, K., Malkowski, M. G., Cuendet, M., Pezzuto, J. M., Santarsiero, 
B. D. , Mesecar, A. D. (2010). Pleiotropic mechanisms facilitated by resveratrol 
and its metabolites. Biochem. J , 429, 273-282. 
Calvino, B. , Besson, J. M. , Boehrer, A. , Depaulis, A. (1996). Ultrasonic vocalization 
(22-28 kHz) in a model of chronic pain, the arthritic rat: effects of analgesic drugs. 
Neuroreport, 7,581 -584. 
Cannon, C. M., Abdallah, L., Tecott, L. H., During, M. J., Palmiter, R. D. (2004). 
Dysregulation of striatal dopamine signaling by amphetamine inhibits feeding by 
hungry mice. Neuron, 28, 509-520. 
Canto, C., Auwerx, J. (2009). PGC-1alpha, SIRT1 and AMPK, an energy sensing 
network that controls energy expenditure. Curr. Opin. Lipidol. , 20, 98-105. 
Canto, c., Gerhart-Hines, Z., Feige, J. N., Lagouge, M., Noriega, L., Milne, J. C., Elliott, 
P. J. , Puigserver, P., Auwerx, J. (2009). AMPK regulates energy expenditure by 
modulating NAD+ metabolism and SIRT1 activity. Nature, 458, 1056-1060. 
Cao, Z. , West, C., Norton-Wenzel, C. S., Rej , R., Davis, F. B., Davis, P. J., Rej , R. 
(2009). Effects of resin or charcoal treatment on fetal bovine serum and bovine 
calf serum. Endocr. Res. , 34, 101-108. 
Carange, J. , Longpré, F., Daoust, B. , Martinoli, M. G. (2011). 24-Epibrassinolide, 
a Phytosterol from the Brassinosteroid Family, Protects Dopaminergic Cells 
against MPP-Induced Oxidative Stress and Apoptosis. J Toxicol. , 2011, 392859. 
Carbone, C., Costa, A. , Provensi, G., Mannaioni, G. , Masi, A. (2017). 
The Hyperpolarization-Activated CUITent Determines Synaptic Excitability, 
Calcium Activity and Specific Viability of Substantia Nigra Dopaminergic 
Neurons. Front. Cel!. Neurosci. , 11, 187. 
Carey, M., Kehlenbrink, S., Hawkins, M. (2013). Evidence for central regulation of 
glucose metabolism. J Biol. Chem., 288, 34981-34988. 
Carlsson, A., Lindqvist, M. , Magnusson, T., Waldeck, B. (1958). On the presence of 
3- hydroxytyramine in brain. Science, 127, 471. 
Carruthers, A. (1986). A TP regulation of the hum an red cell sugar transporter. J Biol. 
Chem., 261, 11028-11037. 
291 
Carruthers, A. , Helgerson, A. L. (1989). The human erythrocyte sugar transporter is also 
a nucleotide binding protein. Biochemistry. 28, 8337-8346. 
Carter, P ., Gray, L. J ., Troughton, J. , Khunti , K. , Davies, M. J. (2010). Fruit and 
vegetable intake and incidence of type 2 diabetes mellitus: systematic review and 
meta-analysis. BMJ, 341, c4229. 
Cartier, E. A. , Parra, L. A. , Baust, T. B. , Quiroz, M., Salazar, G. , Faundez, V., 
Egafia, L. , Torres, G. E . (2010) . A biochemical and functional protein complex 
involving dopamine synthesis and transport into synaptic vesicles . J Biol. Chem., 
285, 1957-1966. 
Casazza, 1. P. , Felver, M. E. , Veech, R. L. (1984) . The metabolism of acetone in rat. 
J Biol. Chem. , 259, 231-236. 
Castro, M. A., Pozo, M ., Cortes, C., Garcia, M. de L. , Concha, II. , Nualart, F. (2007). 
Intracellular ascorbic acid inhibits transport of glucose by neurons, but not by 
astrocytes. J Neurochem., 102, 773-782. 
Cataldo, A. M ., Broadwell, R. D. (1986). Cytochemical identification of cerebral 
glycogen and glucose-6-phosphate activity under normal and experimental 
conditions. 1. Neurons and glia. J Electron Microsc. Techn. 3, 413-437. 
Cereda, E., Barichella, M. , Cassani, E. , Caccialanza, R. , Pezzoli, G. (2012). Clinical 
features of Parkinson disease when onset of diabetes came first: A case-control 
study. Neurology, 78, 1507-1511. 
Cereda, E. , Barichella, M., Pedrolli, C. , Klersy, c., Cassani, E. , Caccialanza, R. , 
Pezzoli, G. (2011). Diabetes and risk of Parkinson's disease: a systematic review 
and meta-analysis. Diabetes Care, 34, 2614-2623 . 
Ceriello, A. (2003). New insights on oxidative stress and diabetic complications may 
lead to a "causal" antioxidant therapy. Diabetes Care, 26, 1589-1596. 
Centonze, D. , Grande, C. , Usiello, A. , Gubellini, P. , Erbs, E. , Martin, A. B ., Pisani, A. , 
Tognazzi, N., Bernardi, G., Moratalla, R. , Borrelli, E. , Calabresi, P. (2003). 
Receptor subtypes involved in the presynaptic and postsynaptic actions of 
dopamine on striatal interneurons. J Neurosci. , 23, 6245-6254. 
Chan, E . Y. , Longatti , A. , McKnight, N. C., Tooze, S. A. (2009). Kinase-inactivated 
ULK proteins inhibit autophagy via their conserved C-terminal domains using an 
Atgl3-independent mechanism. Mol. Cel!. Biol. , 29, 157-171. 
292 
Chan, S., Kantham, S., Rao, V. M. , Palanivelu, M. K., Pham, H. L. , Shaw, P. N., 
McGeary, R. P., Ross, B. P. (2016). Metal chelation, radical scavenging and 
inhibition of AB42 fibrillation by food constituents in relation to Alzheimer's 
disease. Food Chem. , 199, 185-194. 
Chang, C. Y., Choi, D. K., Lee, D. K., Hong, Y. J., Park, E. J. (2013). Resveratrol 
confers protection against rotenone-induced neurotoxicity by modulating 
myeloperoxidase levels in glial cells. PLoS One, 8, e60654. 
Chang, J. W., Wachtel, S. R., Young, D., Kang, U. 1. (1999). Biochemical and 
anatomical characterization of forepaw adjusting steps in rat models of Parkinson's 
disease: studies on medial forebrain bundle and striatal lesions. Neuroscience, 
88, 617-628. 
Chang, J. Y. , Shi, L. H. , Luo, F., Woodward, D. J. (2003). High frequency stimulation 
of the subthalamic nucleus improves treadmill locomotion in unilateral 
6-hydroxydopamine lesioned rats. Brain Res., 983, 174-184. 
Chang, X., Heene, E., Qiao, F., Nick, P. (2011). The phytoalexin resveratrol regulates 
the initiation of hypersensitive cell death in Vitis cell. PLoS One, 6, e26405 . 
Charcot, J. M. (1877). Lectures on the Diseases of the Nervous System, Delivered at 
La Salpêtrière. London: The New Sydenham Society. 
Chartier-Harlin, M. c., Kachergus, J., Roumier, c., Mouroux, V., Douay, X. , 
Lincoln, S., Levecque, c., Larvor, L., Andrieux, J., Hulihan, M. , Waucquier, N., 
Defebvre, L., Amouyel, P., Farrer, M., Destée, A. (2004). Alpha-synuclein locus 
duplication as a cause of familial Parkinson's disease. Lancet, 364, 1167-1169. 
Chaturvedi, R. K. , Beai, M. F. (2013). Mitochondria targeted therapeutic approaches in 
Parkinson's and Huntington's diseases. Mol. Cell. Neurosci., 55, 101-114. 
Chaudhuri, K. R., Jenner, P. (2017). 200 years since James Parkinson ' s essay on 
"The Shaking PaIsy" Have we made progress? Mov. Disord. , 32, 1311-1315. 
Chaudhury, D., Walsh, J. J., Friedman, A. K., Juarez, B., Ku, S. M. , Koo, J. W., 
Ferguson, D., Tsai, H. C., Pomeranz, L., Christoffel, D. J., Nectow, A. R., 
Ekstrand, M., Domingos, A. , Mazei-Robison, M. S., Mouzon, E., Lobo, M. K. , 
Neve, R. L. , Friedman, J. M. , Russo, S. J., Deisseroth, K., Nestier, E. J. , 
Han, M. H. (2013). Rapid regulation of depression-related behaviours by control 
ofmidbrain dopamine neurons. Nature, 493, 532-536. 
Chefer, V. L, Thompson, A. C., Zapata, A., Shippenberg, T. S. (2009). Overview of 
brain microdialysis. Curr. Protoc. Neurosci., 7. 
293 
Chen, C. c., Yang, 1. C. (1991). Effects of short and long-lasting diabetes mellitus on 
mouse brain monoamines. Brain Res. , 552, 175-179. 
Chen, L., Thiruchelvam, M. J., Madura, K ., Richfield, E. K. (2006). Proteasome 
dysfunction in aged human alpha-synuclein transgenic mice. Neurobiol. Dis., 23, 
120-126. 
Cheng, B. , Yang, X. , An, L. , Gao, B. , Liu, X. , Liu, S. (2009) . Ketogenic diet protects 
dopaminergic neurons against 6-0HDA neurotoxicity via up-regulating 
glutathione in a rat mode) ofParkinson's disease. Brain Res., 1286, 25-31. 
Cheng, H. C., Ulane, C. M. , Burke, R. E. (2010). Clinical progression in Parkinson 
disease and the neurobiology of axons. Ann. Neurol., 67, 715-725 . 
Cheng, H. M ., Gonzalez, R. G. (1986). The effect of high glucose and oxidative stress 
on lens metabolism, al do se reductase, and senile cataractogenesis. Metabolism, 
35, 10-14. 
Cheng, P. W. , Ho, W. Y, Su, Y T. , Lu, P. J. , Chen, B. Z. , Cheng, W. H. , Lu, W. H., 
Sun, G. C., Yeg, T. C. , Hsiao, M. , Tseng, C. 1. (2014). Resveratrol decreases 
fructose-induced oxidative stress, mediated by NADPH oxidase via an AMPK-
dependent mechanism. Br. J Pharmacol. , 171, 2739-2750. 
Chinta, S. J., Andersen, 1. K. (2008). Redox imbalance in Parkinson's disease. Biochim. 
Biophys. Acta. , 1780, 1362-1367. 
Choi, J. Y , Jang, E. H. , Park, C. S. , Kang, J. H. (2005). Enhanced susceptibility 
to I-methyl-4-phenyl-l ,2,3,6-tetrahydropyridine neurotoxicity in high-fat diet-
induced obesity. Free Radie. Biol. Med. , 38, 806-816. 
Chong, J. , Poutaraud, A. , Hugueney, P. (2009). Metabolism and roles of stilbenes in 
plants. Plant Sei. , 177, 143-155. 
Chompoopong, S. , Jarungjitaree, S., Punbanlaem, R. , Rungruang, T. , Chongthammakun, 
S., Kertawan, A. , Taechowisan, T. (2016). Neuroprotective Effects of Germinated 
Brown Rice in Rotenone-Induced Parkinson's-Like Disease Rats. Neuromolecular 
Med. , 18, 334-346. 
Chow, H. S. , Cai, Y , Hakim, 1. A., Crowell, 1. A. , Shahi, F. , Brooks, C. A. , DOIT, R. T., 
Hara, Y ., Alberts, D. S. (2009). Pharmacokinetics and safety of green tea 
polyphenols after multiple-dose administration of epigallocatechin gallate and 
polyphenon E in healthy individuals. Clin. Cancer Res., 9, 3312-3319. 
294 
Chow, 1. c., Young, D. W., Golenbock, D. T. , Christ, W. J., Gusovsky, F. (1999). 
Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. 
J Biol. Chem., 274, 10689-10692. 
Chowdhury, S. K., Zherebitskaya, E., Smith, D. R. , Akude, E., Chattopadhyay, S., 
Jolivalt, C. G., Calcutt, N. A., Femyhough, P. (2010). Mitochondrial respiratory 
chain dysfunction in dorsal root ganglia of streptozotocin-induced diabetic rats and 
its correction by insulin treatment. Diabetes, 59, 1082-1091. 
Chuhrna, N., Mingote, S., Kalmbach, A., Yetnikoff, L., Rayport, S. (2017). 
Heterogeneity in Dopamine Neuron Synaptic Actions Across the Striatum and 
Its Relevance for Schizophrenia. Biol. Psychiatry. 81, 43-51. 
Chung, S. 1. , Kim, M. J. , Ryu, H. S., Kim, 1. , Kim, Y. J., Kim, K., You, S., Kim, S. Y., 
Lee, J. H. (2017). Lack of association of mortalin (HSPA9) and other 
mitochondria-related genes with risk of Parkinson's and Alzheimer's diseases. 
Neurobiol. Aging, 49, 215:e9-215.elO 
Cilia, R. (2012). How neurodegeneration, dopamine and maladaptive behavioral 
leaming interact to produce impulse control disorders in Parkinson's disease. 
Basal Ganglia, 2, 195-199. 
Cincotta, A. H., Meier, A. H., Cincotta, M. Jr. (1999). Bromocriptine improves 
glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new 
approach in the treatment ofdiabetes. Expert Opin. Investig. Drugs, 8,1683-1707. 
Ciucci, M. R. , Connor, N. P. (2009). Dopaminergic influence on rat tongue function and 
limb movement initiation. Exp. Brain Re., 194, 587-596. 
Clarke, D. D. , Sokoloff, L. (1999). Circulation and energy metabolism of the 
brain. In Siegel, G., Agranoff, B. , Albers, R. W., Fisher, S. (eds), Basic 
Neurochemistry: Molecular, Cellular, and Medical Aspects. (6th ed), Lippincott-
Raven, Philadelphia, pp. 637-669. 
Clayton, D. F., George, 1. M. (1998). The synucleins: a family of proteins involved in 
synaptic function, plasticity, neurodegeneration and disease. Trends Neurosei. , 
21, 249-254. 
Clifford, M. N. (2000). Anthocyanins-nature, occurrence and dietary burden. J Food 
Sei. Agric., 80, 1063-1072. 
Clifford, M. N., Scalbert, A. (2000). Ellagitannins-occurrence in food, bioavailability 
and cancer prevention. J Food. Sci. Agric., 80, 1118-1125. 
295 
Cloherty, E. K. , Heard, K. S. , Carruthers, A. (1996). Human erythrocyte sugar transport 
is incompatible with available carrier models. Biochemistry, 35, 10411-10421. 
Cnop, M. , Welsh, N. , Jonas, J. C. , J6rns, A. , Lenzen, S. , Eizirik, D. L. (2005). 
Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many 
differences, few similarities. Diabetes, 54, 97-107. 
Colville, C. A. , Seatter, M. J., Jess, T. J. , Gould, G. W. , Thomas, H. M. (1993). 
Kinetic analysis of the liver-type (GLUT2) and brain-type (GLUT3) glucose 
transporters in Xenopus oocytes: substrate specificities and effects of transport 
inhibitors. Biochem. J , 290, 701-706. 
Cone, R. D. (2005). Anatomy and regulation of the central melanocortin system 
Nat. Neurosci. , 8, 571-578. 
Conquer, J. A., Mainai, G. , Azzini, E. , Raguzzini, A. , Holub, B. 1. (1998). 
Supplementation with quercetin markedly increases plasma quercetin 
concentration without effect on selected risk factors for he art disease in healthy 
subjects. J Nutr., 128, 593-597. 
Cook, T. J., Hoekstra, J . G., Eaton, D. L. , Zhang, J. (2016). Mortalin is Expressed by 
Astrocytes and Decreased in the Midbrain of Parkinson's Disease Patients. 
Brain Pathol., 26, 75-81. 
Corral-Debrinski, M. , Horton, T. , Lott, M. T., Shoffner, J. M. , Beai, M. F. , 
Wallace, D. C. (1992) . Mitochondrial DNA deletions in human brain: regional 
variability and increase with advanced age. Nat. Genet. , 2, 324-329. 
Correia, S. C. , Santos, R. X. , Perry, G. , Zhu, X. , Moreira, P. I., Smith, M. A. (2011) . 
Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease? 
Ageing Res. Rev., 10, 264-273. 
Correia, S. , Carvalho, c., Santos, M. S., Seiça, R. , Oliveira, C. R. , Moreira, P. I. (2008). 
Mechanisms of action of metformin in type 2 diabetes and associated 
complications: an overview. Mini Rev. Med. Chem., 8, 1343-1354. 
Cory, S. , Adams, J. M. (2002) . The Bc12 Family: Regulators of the Cellular Life-or-
Death Switch. Nat. Rev. Cancer, 2, 647-656. 
Cossette, L. J. , Gaumond, I., Martinoli, M. G. (2002). Combined effect of xenoestrogens 
and growth factors in two estrogen-responsive celllines. Endocrine, 18, 303-308. 
296 
Costall, B., Olley, 1. E. (1971). Cholinergic- and neurolepticinduced catalepsy: 
Modificationtoy les ions in the caudate-putamen. Neuropharmacol., la, 297-306. 
Cotzias, G. C. , Van Woert, M. H., Schiffer, L. M. (1967). Aromatic amine acids and 
modification ofparkinsonism. N. Engl. J. Med., 276,374-379. 
Craft, S., Newcomer, 1., Kanne, S., Dagogo-Jack, S., Cryer, P., Sheline, Y., Luby, J., 
Dagogo- Jack, A. , and Alderson, A. (1996). Memory improvement following 
induced hyperinsulinemia in Alzheimer's disease. Neurobiol. Aging, 1 7, 123-130. 
Cragg, S. 1. (2006). Meaningful silences: how dopamine listens to the ACh pause. 
Trends Neurosci., 29,125-131. 
Crandall, E. A., Femstrom, 1. D. (1983). Effect of experimental diabetes on the levels of 
aromatic and branched-chain amino acids in rat blood and brain. Diabetes, 32, 
222-230. 
Creese, L, Burt, D. R. , Snyder, S. H. (1977). Dopamine receptor binding enhancement 
accompanies lesion-induced behavioral supersensitivity. Science, 197, 596-598. 
Crow, T. J. (1972). Catecholamine-containing neurones and electrical self-stimulation. 
1. A review ofsome data. Psychol. Med. , 2, 414-421. 
Cuervo, A. M., Wong, E. S. , Martinez-Vicente, M. (2010). Prote in degradation, 
aggregation, and misfolding. Mov. Disord. , 25, 49-54. 
Cummings, 1., Isaacson, S. , Mills, R. , Williams, H. , Chi-Burris, K., Corbett, A., 
Dhall, R., Ballard, C. (2014). Pimavanserin for patients with Parkinson's disease 
psychosis: a randomised, placebo-controlled phase 3 trial. Lancet, 383, 533-540. 
D'Amours, D., Sallmann, F. R. , Dixit, V. M., Poirier, G. G. (2001). Gain-of-function 
of poly(ADP-ribose) polymerase-l upon c1eavage by apoptotic proteases: 
implications for apoptosis. J. Cell. Sci. , 114, 3771-3778. 
da Rocha Lindner, G. , Bonfanti Santos, D., Colle, D., Gasnhar Moreira, E. L., 
Daniel Prediger, R., Farina, M., Khalil, N. M. , Mara Mainardes, R. (2015). 
Improved neuroprotective effects of resveratrol-Ioaded polysorbate 80-coated 
poly(lactide) nanopartic1es in MPTP-induced Parkinsonism. Nanomedicine 
(Lond.), la, 1127-1138. 
Dahlin, A. , Xia, L. , Kong, W., Hevner, R. , Wang, J. (2007). Expression and 
immunolocalization of the plasma membrane mono amine transporter in the brain. 
Neuroscience, 146, 1193-1211. 
297 
Dahlstrôm, A., Fuxe, K. (1964). Localization of monoamines in the lower brain stem. 
Experientia, 20, 398-399. 
Dai, H ., Kustigian, L., Camey, D., Case, A., Considine, T ., Hubbard, B. P., 
Pemi, R. B. , Riera, T. V., Szczepankiewicz, B., Vlasuk, G. P ., Stein, R. L. (2010). 
SIRT1 activation by small molecules: Kinetic and biophysical evidence for direct 
interaction of enzyme and activator. J Biol. Chem., 285, 32695-32703. 
Dames, S. A. , Mulet, 1. M., Rathgeb-Szabo, K., Hall, M. N., Grzesiek, S. (2005). 
The solution structure of the FA TC domain of the protein kinase target of 
rapamycin suggests a role for redox-dependent structural and cellular stability. 
J Biol. Chem., 280, 20558-20564. 
Dantzer, F. , Amé, 1. C., Schreiber, V. , Nakamura, 1. , Ménissier-de-Murcia, 1., 
de Murcia, G. (2006). Poly(ADP-ribose) polymerase-1 activation during DNA 
damage and repair. Methods Enzymol., 409, 493-510. 
Dasgupta, B., Milbrandt, 1. (2007). Resveratrol stimulates AMP kinase activity ln 
neurons Proc. Nat!. Acad. Sei. U.S.A., 104, 7217-7222. 
Daubner, S. c., Le, T. , Wang, S. (2011). Tyrosine hydroxylase and regulation of 
dopamine synthesis. Arch. Biochem. Biophys., 508, 1-12. 
Daugherty, A., Raz, N. (2013). Age-related differences in iron content of subcortical 
nuclei observed in vivo: a meta-analysis. Neuroimage, 70, 113-121. 
de Vries, M. G., Arseneau, L. M., Lawson, M. E., Beverly, J. L. (2003) . Extracellular 
glucose in rat ventromedial hypothalamus during acute and recurrent 
hypoglycemia. Diabetes, 52, 2767-2773. 
Dehay, B. , Bové, 1. , Rodriguez-Muela, N. , Perier, C., Recasens, A., Boya, P. , Vila, M. 
(2010). Pathogenic lysosomal depletion in Parkinson's disease. J Neurosei., 30, 
12535-12544. 
DeJong, R. N. (1950). The nervous system complications in diabetes mellitus with 
special reference to cerebrovascular changes. J Nerv. Ment. Dis. , 111, 181-206. 
dei Campo, N. , Fryer, T. D. , Hong, Y. T. , Smith, R., Brichard, L. , Acosta-Cabronero, J., 
Chamberlain, S. R. , Tait, R. , Izquierdo, D. , Regenthal, R. , Dowson, J. , 
Suckling, 1. , Baron, J. C., Aigbirhio, F. I. , Robbins, T. W ., Sahakian, B. 1. , 
Müller, u., (2013). A positron emission tomography study of nigrostriatal 
dopaminergic mechanisms underlying attention: implications for ADHD and its 
treatment. Brain, 136, 3252-3270. 
298 
Del Rio, D., Rodriguez-Mateos, A., Spencer, J. P., Tognolini, M., Borges, G., 
Crozier, A. (2013). Dietary (poly)phenolics in human health: structures, 
bioavailability, and evidence of protective effects against chronic diseases. 
Antioxid. Redox Signal., 18,1818-1892. 
Della-Morte, D. , Dave, K. R, DeFazio, RA., Bao, Y. C., Raval, A. P., 
Perez-Pinzon, M. A. (2009). Resveratrol pretreatment protects rat brain from 
cerebral ischemic damage via a sirtuin l-uncoupling protein 2 pathway. 
Neuroseience, 159, 993-1002. 
Della Ragione, F. , Cucciola, V., Borriello, A., Della Pietra, V., Racioppi , L. , Soldati, G., 
Manna, C., Galletti, P., Zappia, V. (1998). Resveratrol arrests the cell division 
cycle at S/G2 phase transition. Biochem. Biophys. Res. Commun., 250, 53-58 . 
Deltour, L., Leduque, P., Blume, N., Madsen, O., Dubois, P., Jami, 1., Bucchini, D. 
(1993). Differentiai expression of the two nonallelic proinsulin genes in the 
developing mouse embryo. Proc. Natl. Acad. Sei. U.S.A., 90, 527-531. 
Deng, H., Le, W., Shahed, 1., Xie, W., Jankovic, J. (2008). Mutation analysis of the 
parkin and PINKI genes in American Caucasian early-onset Parkinson disease 
families. Neurosei. LeU., 430, 18-22. 
Deng, Y., Zhang, Y. , Li, Y., Xiao, S., Song, D., Qing, H., Li, Q. , Rajput, A. H. 
(2012). Occurrence and distribution of a salsolinol-like compound, l-acetyl-6.7-
dihydroxy-l,2,3,4-tetrahydroisoquinoline (ADTIQ) in Parkinsonian brains. 
J Neural. Transm. (Vienna), 119,435-441. 
Dercks, W., Creasy, L. L. (1989). The significance of stilbene phytoalexins in 
the Plasmopara viticola-grapevine interaction. Physiol. Mol. Plant Pathol., 34, 
189-202. 
Descarries, L. , Watkins, K. C., Garcia, S., Bosler, O., Doucet, G. (1996). Dual character, 
asynaptic and synaptic, of the dopamine innervation in adult rat neostriatum: 
a quantitative autoradiographie and immunocytochemical analysis. J Comp. 
Neurol., 375, 167-186. 
Desplats, P., Lee, H. J., Bae, E. J., Patrick, C., Rockenstein, E., Crews, L., Spencer, B., 
Masliah, E., Lee, S. J., (2009). Inclusion formation and neuronal cell death through 
neuron-to-neuron transmission of alpha-synuclein. Proc. Nat!. Acad. Sei. U.S.A., 
106, 13010-13015. 
Deumens, R, Blokland, A., Prickaerts, J. (2002) . Modeling Parkinson's disease in rats : 
an evaluation of 6-0HDA lesions of the nigrostriatal pathway. Exp. Neurol., 175, 
303-317. 
299 
Devaskar, S. D., Giddings, S. J., Rajakumar, P. A. , Camaghi, L. R. , Menon, R K. , 
Zahm, D. S. (1994). Insulin gene expression and insulin synthesis in mammalian 
neuronal cells. J Biol. Chem. , 269, 8445-8454. 
Dexter, D. T. , Wells, F. R, Lees, A. J., Agid, F. , Agid, Y. , Jenner, P., Marsden, C. D. 
(1989). Increased nigral iron content and alterations in other metal ions occurring 
in brain in Parkinson's disease. J Neurochem. , 52, 1830-1836. 
Dhopeshwarkar, G. A. , Mead, J. F. (1973). Dptake and transport of fatty acids into the 
brain and the role of the blood-brain barrier system. Adv. Lipid Res., Il, 109-142. 
Di Chiara, G. (1990). In-vivo brain dialysis of neurotransmitters. Trends Pharmacol. 
Sei. , 11, 116-121. 
Di Chiara, G., Imperato, A. (1988). Drugs abused by humans preferentially increase 
synaptic dopamine concentrations in the mesolimbic system of freely moving rats. 
Proc. Natl. Acad. Sei. U.S. A., 85, 5274-5278. 
Di Chiara, G., Tanda, G., Frau, R. , Carboni, E. (1993). On the preferential release 
of dopamine in the nucleus accumbens by amphetamine: further evidence 
obtained by vertically implanted concentric dialysis probes. Psychopharmacology, 
112, 398-402. 
Di Domenico, S. L, Ryan, R. M. (2017). The Emerging Neuroscience of Intrinsic 
Motivation: A New Frontier in Self-Determination Research. Front. Hum. 
Neurosci., Il, 145. 
Di Meo, F., Lemaur, V. , Cornil, J. , Lazzaroni, R , Duroux, J. L. , Olivier, Y. , Trouillas, P. 
(2013). Free radical scavenging by natural polyphenols: atom versus electron 
transfer. J Phys. Chem. A., 11 7, 2082-2092. 
Diabetes Control and Complications Trial Research Group, Nathan, D. M. , Genuth, S., 
Lachin, 1. , Cleary, P. , Crofford, O. , Davis, M. , Rand, L. , Siebert, C. (1993). 
The effect of intensive treatment of diabetes on the development and progression 
of long-term complications in insulin-dependent diabetes mellitus. N Engl. 
J Med. , 329, 977-986. 
Diaz-Garcia, C. M., Mongeon, R , Lahmann, C., Koveal, D., Zucker, H., Yellen, G. 
(2017) . Neuronal Stimulation Triggers Neuronal Glycolysis and Not Lactate 
Dptake. Cel!. Metab. , 26, 361-374. 
300 
Dick, A. P. , Harik, S. L, Klip, A. , Walker, D. M. (1984). Identification and 
characterization of the glucose transporter of the blood-brain barrier by 
cytochalasin B binding and irnrnunological reactivity. Proc. Natl. Acad. Sei U. S.A., 
81, 7233-7237. 
Dickinson, A., Balleine, B. (1994) . Motivational control of goal-directed action. 
Anim. Learn. Behav., 22, 1-18. 
Dickson, D. W. , Braak, H. , Duda, J. E., Duyckaerts, c., Gasser, T., Halliday, G. M., 
Hardy, J. , Leverenz, 1. B. , Del Tredici, K. , Wszolek, Z. K. , Litvan, 1. (2009). 
Neuropathological assessment of Parkinson 's disease: refining the diagnostic 
criteria. Lancet Neurol. , 8, 1150-1157. 
Dienel, G. A. (2009). Energy metabolism in the brain. In Byrne, J. H. , Roberts, J. L. 
(eds), From Molecules to Networks: an Introduction to Cellular and Molecular 
Neuroseience, (2nd ed), Academic Press, London, pp. 49-110. 
Dienel, G. A. (2012). Brain lactate metabolism: the discoveries and the controversies. 
J Cereb. Blood Flow Metab., 32, 1107-1138. 
Dienel, G. A., Cruz, N. F. (2006). Astrocyte activation in working brain: energy supplied 
by minor substrates. Neurochem. Int. , 48, 586-595 . 
Dienel, G. A., Cruz, N. F. , Sokoloff, L. , Driscoll, B. F. (2017). Determination 
of Glucose Utilization Rates in Cultured Astrocytes and Neurons with 
[14C]deoxyglucose: Progress, Pitfalls, and Discovery of Intracellular Glucose 
Compartmentation. Neurochem. Res., 42,50-63 . 
DiNuzzo, M., Giove, F., Maraviglia, B., Mangia, S. (2013). Glucose metabolism down-
regulates the uptake of 6-(N-(7 -nitrobenz-2-oxa-l ,3-diazol-4-yl)amino )-2-
deoxyglucose (6-NBDG) mediated by glucose transporter 1 isoform (GLUT1 ): 
the ory and simulations using the symmetric four-state carrier mode!. 
J Neurochem. 125, 236-246. 
DiNuzzo, M. , Mangia, S., Maraviglia, B., Giove, F. (2010) . Changes in glucose uptake 
rather than lactate shuttle take center stage in subserving neuroenergetics: evidence 
from mathematical modeling. J Cereb. Blood Flow Metab., 30, 586-602. 
Do Nascimento, P. S. , Lovatel , G. A. , Barbosa, S., Ilha, J. , Centenaro, L. A. , Malysz, T., 
Xavier, L. L. , Schaan, B. D. , Achaval, M. (2011). Treadmill training improves 
motor skills and increases tyrosine hydroxylase irnrnunoreactivity in the substantia 
nigra pars compacta in diabetic rats. Brain Res., 1382, 173-180. 
301 
Dobkin RD, Menza M, Allen LA, Gara, M. A. , Mark, M. H. , Tiu, J. , Bienfait, K. L. , 
Friedman, J. (2011). Cognitive-behavioral therapy for depression in Parkinson ' s 
disease: a randomized, controlled trial. Am. J Psychiatry, 168, 1066-1074. 
Donoghue, J. P. , Herkenham, M. (1986). Neostriatal projections from individual cortical 
fields conform to histochemically distinct striatal compartments in the rat. 
Brain Res. , 365, 397-403. 
Dopeso-Reyes, 1. G. , Rico, A.1. , Roda, E ., Sierra, S., Pignataro, D. , Lanz, M., 
Sucunza, D. , Chang-Azancot, L. , Lanciego, 1. L. (2014). Calbindin content and 
differential vulnerability of midbrain efferent dopaminergic neurons in macaques. 
Front. Neuroanat., 8, 146. 
Dom, A., Bernstein, H. G., Rinne, A. , Ziegler, M., Hahn, H. J., Ansorge, S. (1983). 
Insulin and glucagonlike peptides in the brain. Anat. Rec. , 207, 69-77. 
Double, K. L. , Gerlach, M. , Schunemann, V. , Trautwein, A. X. , Zecca, L. , Gallorini, M. , 
Youdim, M. B. , Riederer, P ., Ben-Shachar, D. (2003). Iron-binding characteristics 
of neuromelanin of the human substantia nigra. Biochem. Pharmacol., 
66, 489-494. 
Drago, J. , Gerfen, C. R. , Lachowicz, J. E. , Steiner, H. , Hollon, T. R. , Love, P. E. , 
Ooi, G. T. , Grinberg, A. , Lee, E. 1. , Huang, S. P. (1994). Altered striatal function 
in a mutant mouse lacking DIA dopamine receptors. Proc. Natl. Acad. Sei. U S. A., 
91, 12564-12568. 
Dreyer, J. K. (2014). Three mechanisms by which striatal denervation causes breakdown 
of dopamine signaling. J Neurosei., 34, 12444-12456. 
Dreyer, J. K. , Herrik, K. F. , Berg, R. W. , Hounsgaard, J. D. (2010). Influence of phasic 
and tonic dopamine release on receptor activation. J Neurosei., 30, 14273-14283. 
Driver, J. A. , Smith, A., Buring, J. E., Gaziano, J. M., Kurth, T. , Logroscino, G. (2008). 
Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease. 
Diabetes Care, 31, 2003-2005 . 
Drucker-Colin, R. , Garcia-Hernandez, F. (1991). A new motor test sensitive to aging 
and dopaminergic function. J Neurosci. Methods, 39, 153-161. 
Drui, G. , Carnicella, S., Carcenac, C., Favier, M. , Bertrand, A. , Boulet, S., Savasta, M. 
(2014) . Loss of dopaminergic nigrostriatal neurons accounts for the motivational 
and affective deficits in Parkinson's disease. Mol. Psychiatry, 19, 358-367. 
302 
Drulis-Fajdasz, D., Gizak, A., W6jtowicz, T., Wisniewski, J. R., Rakus, D. (2018). 
Aging-associated changes in hippocampal glycogen metabolism in mice. 
Evidence for an against astrocyte-to-neuron lactate shuttle. Glia, 66, 1481-1495. 
Du, X. L., Edelstein, D. , Dimme1er, S., Ju, Q., Sui, C., Brownlee, M. (2001). 
Hyperglycemia inhibits endothelial mtnc oxide synthase actlvlty by 
posttranslational modification at the Akt site. J Clin. Invest., 108, 1341-1348. 
Du, X., Matsumura, T., Edelstein, D., Rossetti, L., Zsengeller, Z. , Szabo, C., 
Brownlee, M. (2003). Inhibition of GAPDH activity by poly(ADP-ribose) 
polymerase activates three major pathways of hyperglycemic damage in 
endothelial cells. J Clin. Invest., 112, 1049-1057. 
Duarte, A. L, Proenca, T., Oliveira, C. R., Santos, M. S., Rego, A. C. (2006). lnsulin 
restores metabolic function in cultured cortical neurons subjected to oxidative 
stress. Diabetes, 55, 2863-2870. 
Duarte, J. M. N., Carvalho, R. A., Cunha, R. A., Gruetter, R. (2009). Caffeine 
consumption attenuates neurochemical modifications in the hippocampus of 
streptozotocin-induced diabetic rats. J Neurochem. , 111,368-379. 
Ducat, L., Rubenstein, A., Philipson, L. H., Anderson, BJ. (2015). A review of the 
mental health issues of diabetes conference. Diabetes Care, 38, 333-338. 
Duckrow, R. B. , Beard, D. C., Brennan, R. W. (1987). Regional cerebral blood flow 
decreases during chronic and acute hyperglycemia. Stroke, 18, 52-58. 
DueUi, R., Enerson, B.E., Gerhart, D.Z., Drewes, L.R. (2000). Expression of 
large neutral amine acid transporter LAT 1 in rat brain endothelium. J Cereb. 
Blood Flow Metab. , 20, 1557-1562. 
Dunlop, E. A., Tee, A. R. (2013). The kinase triad, AMPK, mTORCI and ULK1 , 
maintains en erg y and nutrient homeostasis. Biochem. Soc. Trans. , 939-943 . 
Dunnett, S. B., Lelos, M. (2010). Behavioral analysis ofmotor and non-motor symptoms 
in rodent models ofParkinson's disease. Prog. Brain Res. , 184, 35-5l. 
Dut y, S., Jenner, P. (2011). Animal models of Parkinson's disease: a source of 
novel treatments and cIues to the cause of the disease. Br. J Pharmacol., 164, 
1357-139l. 
Duvoisin, R. C. (1976). Parkinsonism: Animal analogues of human movement disorder. 
In Yahr, M. D. (ed), The basal ganglia, New York: Raven Press, pp. 293-303. 
303 
Ehringer, H. , Homykiewicz, O. (1960). Veteilung von Noradrenalin und Dopamine 
(3-hydroxytyramin) im Gehim des Menschen und ihr Verhalten bei Erkankungen 
des Extrapyramidalen Systems. KUn. Wochenschr, 38, 1236-1239. 
Eiden, L. E. , Schafer, M. K. , Weihe, E., Schutz, B. (2004). The vesicular amine 
transporter family (SLCI8): amine/proton antiporters required for vesicular 
accumulation and regulated exocytotic secretion of monoamines and 
acetylcholine. Pfliigers Arch., 447, 636-640. 
Eisenhofer, G. , Kopin, 1. J. , Goldstein, D. S. (2004). Catecholamine metabolism: 
a contemporary view with implications for physiology and medicine. 
Pharmacological Reviews, 56, 331-349. 
Ekman, P., Davidson, R. J. , Friesen, V. W. (1990). The Duchenne smile: emotional 
expression and brain physiology II. J Pers. Soc. Psychol. , 58, 342-353 . 
El Messari, S., Leloup, C. , Quignon, M. , Brisorgueil, M. 1., Penicaud, L. , Arluison, M. 
(1998). Immunocytochemical localization of the insulin-responsive glucose 
transporter 4 (Glut4) in the rat central nervous system. J Comp. Neurol. , 
399, 492-512. 
Ellwood, 1. T., Patel, T., Wadia, v., Lee, A. T. , Liptak, A. T. , Bender, K. J., Sohal, V. S. 
(2017). Tonic or Phasic Stimulation of Dopaminergic Projections to Prefrontal 
Cortex Causes Mice to Maintain or Deviate from Previously Leamed Behavioral 
Strategies. J Neurosci. , 3 7, 8315-8329. 
Emre M, Aarsland D, Albanese A, Byme, E. J. , Deuschl, G., De Deyn, P. P. , Durif, F. , 
Kulisevsky, J., van Laar, T. , Lees, A. , Poewe, W. , Robillard, A. , Rosa, M. M., 
Wolters, E., Quarg, P. , Tekin, S. , Lane, R. (2004). Rivastigmine for dementia 
associated with Parkinson ' s disease. N. Engl. J Med. , 351, 2509-2518. 
Engelhardt, B., Vajkoczy, P. , WeIler, R. O. (2017). The movers and shapers in immune 
privilege of the CNS. Nat. lmmunol. , 18, 123-131. 
Ergul, A. , Abdelsaid, M. , Fouda, A. Y. , Fagan, S. C. (2014) . Cerebral neovascularization 
in diabetes: implications for stroke recovery and beyond. J Cereb. Blood Flow 
Metab. , 34, 553-583. 
Ergul, A. , Valenzuela, J. P. , Fouda, A. Y. , Fagan, S. C. (2015). Cellular connections, 
microenvironment and brain angiogenesis in diabetes: Lost communication signais 
in the post-stroke period. Brain Res., 623, 81-96. 
Espafia, R. A. , Jones, S. R. (2013) . Presynaptic dopamine modulation by stimulant self-
administration. In: Front. Biosci. (Schol Ed), 5, 261-276. 
304 
Espin, J. C. , Gonzalez-Sarrias, A., Tomas-Barberan, F. A. (2017). The gut microbiota: 
A key factor in the therapeutic effects of (poly)phenols. Bioehem. Pharmaeol. , 
139, 82-93 . 
Estrela, J. M., Ortega, A. , Mena, S., Rodriguez, M. L. , Asensi, M. (2013). Pterostilbene: 
biomedical applications. Crit. Rev. Clin. Lab. Sei. , 50, 65-78. 
Estruch, R., Ros, E. , Salas-Salvad6, J. , Covas, M. L, Corella, D. , Ar6s, F. , G6mez-
Gracia, E. , Ruiz-Gutiérrez, V., Fiol, M. , Lapetra, 1. , Lamuela-Raventos, R. M., 
Serra-Majem, L. , Pint6, X. , Basora, 1. , Muiloz, M. A. , Sorli, J. V. , Martfnez, J. A., 
Martinez-Gonzalez, M. A. , PREDIMED Study Investigators. (2013). Primary 
prevention of cardiovascular disease with a Mediterranean diet. N. Engl. J Med., 
368, 1279-1290. 
Evan, G. L, Vousden, K. H. (2001). Proliferation, cell cycle and apoptosis in cancer. 
Nature, 411, 342-348. 
Exner, N. , Treske, B. , Paquet, D., Holmstrôm, K. , Schiesling, C. , Gispert, S. , Carballo-
Carbajal, L, Berg, D., Hoepken, H. H., Gasser, T., Krüger, R., Winklhofer, K. F., 
Vogel, F. , Reichert, A. S., Auburger, G. , Kahle, P. J., Schmid, B. , Haass, C. 
Loss-of-function of human PINKI results in mitochondrial pathology and can be 
rescued by parkin. J Neurosei. , 27, 12413-12418. 
Fahn, S. (2008). The history of dopamine and levodopa in the treatment of Parkinson's 
disease. Movement Disorders, 23, 497-508. 
Fahn, S., Goetz, C. G. ( 1987). Charcot, the clinician: the Tuesday lessons: excerpts from 
nine case presentations on general neurology delivered at the Salpêtrière Hospital 
in 1887-88 by Jean-Martin Charcot. Mov. Disord. 4, 123-140. 
Fauconneau, B. , Waffo-Teguo, P. , Huguet, F. , Barrier, L. , Decendit, A., Merillon, 1. M. 
(1997) . Comparative study of radical scavenger and antioxidant properties of 
phenolic compounds from Vitis vinifera cell cultures using in vitro tests. Life Sei., 
61, 2103-2110. 
Faure, A. , Haberland, u., Conde, F. , El Massioui, N. (2005). Lesion to the nigrostriatal 
dopamine system disrupts stimulus-response habit formation. J Neurosei., 25, 
2771-2780. 
Fearnley, J. M. , Lees, A. J. (1991) . Ageing and Parkinson's disease: substantia nigra 
regional selectivity. Brain, 114, 2283-2301 . 
305 
Fedorow, H., Halliday, G. M. , Rickert, C. H., Gerlach, M ., Riederer, P. , Double, K. L. 
(2006). Evidence for specific phases in the development of human neuromelanin. 
Neurobiol. Aging. , 27, 506-512. 
Fellows, L. K. , Boutelle, M. G. (1993). Rapid changes in extracellular glucose levels and 
blood flow in the striatum of the freely moving rat. Brain Res., 604, 225-231 . 
Fellows, L. K. , Boutelle, M. G. , Fillenz, M. (1993). ATP-sensitive potassium 
channels and local energy demands in the rat hippocampus: an in vivo study. 
J Neurochem. , 61, 949-954. 
Feng, Y., Liu, T. , Dong, S. Y. , Guo, Y. 1., Jankovic, 1., Xu, H., Wu, Y. C. (2015). 
Rotenone affects p53 transcriptional activity and apoptosis via targeting SIRT1 
and H3K9 acetylation in SH-SY5Y cells. J Neurochem., 134, 668-676. 
Femândez-Moncada, L, Ruminot, L, Robles-Maldonado, D., Alegria, K. , Deitmer, J . W., 
Barros, L. F. (2018). Neuronal control ofastrocytic respiration through a variant of 
the Crabtree effect. Proc. Natl. Acad. Sci. US.A ., 115, 1623-1628. 
Ferre ira, J. M., Bumett, A. L. , Rameau, G. A. (20 Il). Activity-dependent regulation of 
surface glucose transporter-3 . J Neurosci. , 31, 1991-1999. 
Ferretta, A., Gaballo, A., Tanzarella, P., Piccoli, c., Capitanio, N. , Nico, B., Annese, T., 
Di Paola, M., Dell'aquila, C., De Mari, M., Ferranini, E. , Bonifati, V. , Pacelli, C., 
Cocco, T. (2014). Effect of resveratrol on mitochondrial function: implications 
in parkin-associated familiar Parkinson's disease. Biochim. Biophys. Acta, 
1842,902-915. 
Figlewicz, D. P. , Evans, S. B. , Murphy, 1. , Hoen, M. , Baskin, D. G. (2003). Expression 
of receptors for insulin and leptin in the ventral tegmental arealsubstantia nigra 
(VT A/SN) of the rat. Brain Res. , 964, 107-115. 
File, S. E. , Seth, P. (2003). A review of 25 years of the social interaction test. 
Eur. J Pharmacol., 463, 35-53. 
Finkel, T., Holbrook, N . J. (2000) Oxidants, oxidative stress and the biology of ageing. 
Nature, 408, 239-247. 
Finkelstein, M. M. , Jerrett, M. (2007). A study of the relationships between Parkinson's 
disease and markers of traffic-derived and environmental manganese air pollution 
in two Canadian cities. Environmental Research, 104, 420-432. 
306 
Foehring, R. C. , Zhang, X. F. , Lee, J . c., Callaway, J. C. (2009). Endogenous calcium 
buffering capacity of substantia nigral dopamine neurons. J Neurophysiol., 
102,2326-2333 . 
Foglia, V. G. (1950). Experimental diabetes. Rev. Asoc. Med. Argent., 64, 124-127. 
Folbergrova, J. , Jesina, P. , Kubova, H., Otahal, J. (2018). Effect of Resveratrol on 
Oxidative Stress and Mitochondrial Dysfunction in Immature Brain during 
Epileptogenesis. Mol. Neurobiol., 55, 7512-7522. 
Foresti, R. , Bains, S. K. , Pitchurnony, T. S., de, L. E., Drago, F., Dubois-Randé, 1. L. , 
Bucolo, c., Motterlini, R. (2013). Small molecule activators of the Nrf2-HO- l 
antioxidant axis modulate heme metabolism and inflammation in BV2 microglia 
cells. Pharmacol. Res., 76, 132-148. 
Fouda, M. A. , Abdel-Rahman, A. A. (2017). Endothelin Confers Protection against 
High Glucose-Induced Neurotoxicity via Alleviation of Oxidative Stress. 
J Pharmacol. Exp . Ther., 361, 130-139. 
Francis, R. L. (1977). 22-kHz calls by isolated rats. Nature, 265, 236-238. 
Francis, G. 1., Martinez, J. A. , Liu, W. Q. , XU, K. , Ayer, A. , Fine, J ., Tuor, U, L, 
Glazner, G. , Hanson, L. R. , Frey, W. H. 2nd, Toth, C. (2008). Intranasal insulin 
prevents cognitive decline, cerebral atrophy and white matter changes in murine 
type l diabetic encephalopathy. Brain, 131, 3311-3334. 
Frank, M. J. , Seeberger, L.C. , O 'Reilly, R. C. (2004). By carrot or by stick: cognitive 
reinforcement learning in Parkinsonism. Science, 306, 1940-1943, 
Frankel, D ., Schipper, H. M. (1999). Cysteamine pretreatment of the astroglial 
substratum (mitochondrial iron sequestration) enhances PC12 cell vulnerability to 
oxidative injury. Exp. Neurol., 160, 376-385. 
Frankel, E. N. , Waterhouse, A. L. , Kinsella, J. E. (1993) . Inhibition of human 
LDL oxidation by resveratrol. Lancet, 341, 1103-1104. 
Frankfurt, O. S. , Krishan, A. (2001). Identification of apoptotic cells by formamide-
induced DNA denaturation in condensed chromatin. J Histochem. Cytochem., 
49, 369-378. 
Fray, A. E. , Boutelle, M. , Fillenz, M. (1997). Extracellular glucose turnover in 
the striatum of unanaesthetized rats measured by quantitative microdialysis. 
J Physiol. , 504, 721-726. 
307 
Freitas, M. E. , Ruiz-Lopez, M. , Fox, S. H. (2016). Novel levodopa formulations for 
Parkinson ' s disease. CNS Drug, 30, 1079-1095 . 
Frémont, L. (2000). Biological effects ofresveratrol. Life Sci., 66, 663-673 . 
Frolich, L. , Blum-Degen, D., Bernstein, H. G., Engelsberger, S., Hurnrich, J., Laufer, S., 
Muschner, D. , Thalheimer, A. , Türk, A. , Hoyer, S. (1998). Brain insulin and 
insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm. , 
105, 423-438 . 
Fu, Y. , Yuan, Y. , Halliday, G. , Rusznak, Z. , Watson, c., Paxinos, G. (2012). 
A cytoarchitectonic and chemoarchitectonic analysis of the dopamine cell groups 
in the substantia nigra, ventral tegmental area, and retrorubral field in the mouse. 
Brain Struct. Funct. , 21 7, 591-612. 
Fukao, T. , Lopaschuk, G. D. , Mitchell , G. A. (2004). Pathways and control of ketone 
body metabolism: on the fringe of lipid biochemistry. Prostaglandins Leukot. 
Essent. Fatty Acids. 70, 243-251. 
Fulop, M., Murthy, V. , Michilli, A. , Nalamati, J. , Qian, Q. , Saitowitz, A. (1999). 
Serum betahydroxybutyrate measurement in patients with uncontrolled diabetes 
mellitus. Arch. Intern. Med. , 159, 381-384. 
Furlong, M. , Tanner, C. M ., Goldman, S. M. , Bhudhikanok, G. S. , Blair, A. , Chade, A. , 
Comyns, K. , Hoppin, J . A. , Kasten, M. , Korell , M. , Langston, 1. W. , Marras, C. , 
Meng, C. , Richards, M. , Ross, G. W. , Umbach, D. M. , Sandler, D. P. , Kamel, F. 
(2015). Protective glove use and hygiene habits modify the associations of specific 
pesticides with Parkinson's disease. Environ. Int. , 75, 144-150. 
Gabbay, K. H. , Merola, L. O. , Field, R. A. (1966). Sorbitol pathway: presence in nerve 
and cord with substrate accumulation in diabetes. Science, 151, 209-210. 
Gaede, P., Lund-Andersen, H. , Parving, H. H., Pedersen, O. (2008). Effect of a 
multifactorial intervention on mortality in type 2 diabetes. N. Engl. J Med. , 
358, 580-591. 
Gagné, B. , Gélinas, S. , Bureau, G. , Lagacé, B. , Ramassamy, c., Chiasson, K. , 
Valastro, B. , Martinoli, M. G. (2003) . Effects of estradiol, phytoestrogens, and 
Ginkgo biloba extracts against I-methyl-4-phenyl-pyridine-induced oxidative 
stress. Endocrine, 21, 89-95. 
Gao, J., Teng, J. , Liu, H., Han, X., Chen, B. , Xie, A. (2014). Association of RAGE gene 
polymorphisms with sporadic Parkinson's disease in Chine se Han population. 
Neurosci. LeU., 559, 158-162. 
308 
Garcia-Nogales, P., Almeida, A. , Bolafios, J . P. (2003). Peroxynitrite protects neurons 
against nitric oxide-mediated apoptosis. A key role for glucose-6-phosphate 
dehydrogenase activity in neuroprotection. J Biol. Chem., 278, 864-874. 
Gatson, J. W., Liu, M. M., Abdelfattah, K., Wigginton, J. G., Smith, S. , Wolf, S., 
Minei, 1. P. (2013). Resveratrol decreases inflammation in the brain of mice with 
mild traumatic brain injury. J Trauma Acute Care Surg., 74, 470-474. 
Gaucher, D. , Chiappore, J. A., Pâques, M., Simonutti, M., Boitard, C., Sahel, J . A., 
Massin, P., Picaud, S. (2007). Microglial changes occur without neural cell death 
in diabetic retinopathy. Vision Res., 47, 612-623. 
Gauuan, P. 1., Trova, M. P., Gregor-Boros, L., Bocckino, S. B., Crapo, J. D. , Day, B. 1. 
(2002). Superoxide dismutase mimetics: synthesis and structure-activity 
relationship study of MnTBAP analogues. Bioorg. Med. Chem., JO, 3013-3021. 
Gehm, B. D., McAndrews, J. M., Chien, P. Y., Jameson, J. L. (1997). Resveratrol, 
a polyphenolic compound found in grapes and wine, is an agonist for the estrogen 
receptor. Proc. Nat!. Acad. Sei. U.S.A., 94, 14138-14143. 
Gélinas, S. , Bureau, G., Valastro, B. , Massicotte, G., Cicchetti, F., Chiasson, K., 
Gagne, B. , Blanchet, J., Martinoli, M. G. (2004). Alpha and beta estradiol protect 
neuronal but not native PC12 cells from paraquat-induced oxidative stress. 
Neurotox. Res., 6, 141-148. 
Gélinas, S. , Martinoli, M. G. (2002). Neuroprotective effect of estradiol and 
phytoestrogens on MPP+-induced cytotoxicity in neuronal PC12 cells. 
J Neurosci. Res., 70, 90-96. 
Gerhart, D. Z., LeVasseur, R. 1., Broderius, M. A. , Drewes, L. R. (1989). Glucose 
transporter localization in brain using light and electron immunocytochemistry. 
J Neurosei. Res. , 22, 464-472. 
German, D. C. , Dubach, M., Askari, S. , Speciale, S. G., Bowdon, D. M. (1988). 
1-methyl-4-phenyl- l ,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonian 
syndrome in macaca fascicularis: which midbrain dopaminergic neurons are [ost? 
Neuroscience, 24, 161-174. 
Ghasemi, R. , Haeri, A., Dargahi, L., Mohamed, Z., Ahmadiani, A. (2013). Insulin in the 
brain: sources, localization and functions. Mol. Neurobiol. , 47, 145-171. 
Giacco, F., Brownlee, M. (2010) . Oxidative stress and diabetic complications. 
Circ. Res. , 107, 1058-1070. 
309 
Gibb, W. R., Lees, A. J. (1991). Anatomy, pigmentation, ventral and dorsal 
subpopulations of the substantia nigra, and differential cell death in Parkinson's 
disease. J Neurol. Neurosurg. Psychiatry, 54, 388-396. 
Giovannini, C., Masella, R. (2012). Role of polyphenols III cell death control. 
Nutr. Neurosci., 15, 134-149. 
Giovinazzo, G., Ingrosso, 1. , Paradiso, A. , Gara, L., Santino, A. (2012). Resveratrol 
biosynthesis: Plant metabolic engineering for nutritional improvement of food. 
Plant Foods Hum. Nutr., 67, 191-199. 
Giugliano, D., Ceriello, A., Paolisso, G. (1996). Oxidative stress and diabetic vascular 
complications. Diabetes Care, 19, 257-267. 
Gkogkolou, P. , B6hm, M. (2012). Advanced glycation end products: Key players in skin 
aging? Dermatoendocrinol. , 4, 259-270. 
Goh, K. P., Lee, H. Y, Lau, D. P. , Supaat, W. , Chan, Y H., Koh, A. F. (2014). Effects 
of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRTI 
expression and energy expenditure. Int. J Sport Nutr. Exerc. Metab., 24, 2-13. 
Goldberg, D. M. , Yan, J., Soleas, G. J. (2003). Absorption of three wine-related 
polyphenols in three different matrices by healthy subjects. Clin. Biochem., 36, 
79-87. 
Goldman, S. M. , Quinlan, P. J., Ross, G. W. , Marras, C., Meng, C., Bhudhikanok, G. S., 
Comyns, K., Korell, M. , Chade, A. R , Kasten, M. , Priestley, B. , Chou, K. L. , 
Femandez, H. H. , Cambi, F., Langston, J. W., Tanner, C. M. (2012). Solvent 
exposures and Parkinson disease risk in twins. Ann. Neurol., 71, 776-784. 
Goldner, M. G., Gomori, G. (1943). Alloxan diabetes in the dog. Endocrinology, 33, 
297-308. 
Gollapudi, S., McCormick, M. J. , Gupta, S. (2003). Changes in Mitochondrial 
Membrane Potential and Mitochondrial Mass Occur Independent of the Activation 
of Caspase-8 and Caspase-3 during CD95-Mediated Apoptosis in Peripheral Blood 
T Cells. International Journal of On co logy, 22, 597-600. 
Gomez, R, Barros, H. M. (2003). Clonazepam increases in vivo striatal extracellular 
glucose in diabetic rats after glucose overload. Pharmacol. Biochem. Behav., 76, 
443-450. 
Gong, X., Gutala, R, Jaiswal, A. K. (2008). Quinone oxidoreductases and vitamin K 
metabolism. Vitam. Horm. , 78,85-101. 
310 
Gorell , J. M. , Johnson, C. c., Rybicki, B. A. , Peterson, E. L. , Kortsha, G. X., 
Brown, G. G., Richardson, R. J. (1997). Occupational exposures to metals as risk 
factors for Parkinson's disease. Neurology, 48, 650-658 . 
Gotz, M. E. , Freyberger, A. , Riederer, P. (1990). Oxidative stress: a role in the 
pathogenesis ofParkinson's disease. J. Neural Transm. Suppl., 29, 241-249. 
Gowers, W. R. (1886). A Manual of Diseases of the Nervous System. London: 1. & A. 
Churchill. 
Grace, A. A. (2000). The tonic/phasic model of dopamine system regulation and its 
implications for understanding alcohol and psychostimulant craving. Addiction, 
95, 119-128. 
Grace, A. A. (2016). Dysregulation of the dopamine system in the pathophysiology of 
schizophrenia and depression. Nat. Rev. Neurosci., 1 7, 524-532. 
Grace, A. A. , Bunney, B. S. (1984a). The control of firing pattern in nigral dopamine 
neurons: burst firing. J. Neurosci., 4, 2877-2890. 
Grace, A. A. , Bunney, B. S. (1984b). The control of firing pattern in nigral dopamine 
neurons: single spike firing. J. Neurosci. , 4, 2866-2876. 
Graham, D.G. (1984). Catecholamine toxicity: a proposaI for the molecular pathogenesis 
ofmanganese neurotoxicity and Parkinson's disease. Neurotoxicology, 5, 83-95. 
Grattan, D. R. (2015). 60 Years of neuroendocrinology: The hypothalamo-prolactin axis. 
J. Endocrinol. , 226, 101-122. 
Gray, S. M. , Meijer, R. I. , Barrett, E. J. (2014). Insulin regulates brain function, but how 
does it get there? Diabetes, 63, 3992-3997. 
Graybiel, A. M. (1990). Neurotransmitters and neuromodulators in the basal ganglia. 
Trends Neurosci., 13, 244-254. 
Green, D. R. , Kroemer, G. (2009). Cytoplasmic functions of the tumour suppressor p53. 
Nature, 458, 11 27-1130. 
Greenamyre, J. T. , Sherer, T. B. , Betarbet, R., Panov, A. V. (2001 ). Complex l and 
Parkinson ' s disease. IUBMB Life, 52, 135-141. 
311 
Greene, D. A., Arezzo, 1. C., Brown, M. B. (1999). Effect of aldose reductase inhibition 
on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study 
Group. Neurology, 53, 580-591. 
Greene, L. A. , Rein, G. (1977). Release, storage and uptake of catecholamines by a 
clonai cell line of nerve growth factor (NGF) responsive pheo-chromocytoma 
cells. Brain Res., 129, 247-263. 
Greene, L. A., Tischler, A. S. (1976) . Establishment of a noradrenergic clonai line of 
rat adrenal pheochromocytoma cells which respond to nerve growth factor. 
Proc. Natl. Acad. Sei. U.S.A. , 73, 2424-2428. 
Grundy, S. M. , Benjamin, 1. 1., Burke, G. L., Chait, A. , Eckel, R. H. , Howard, B. V., 
Mitch, W. , Smith, S. C. Jr., Sowers, J. R. (1999). Diabetes and cardiovascular 
disease: a statement for healthcare professionals from the American Heart 
Association. Circulation, 100, 1134-1146. 
Gunaydin, L. A., Grosenick, L. , Finkelstein, 1. C. , Kauvar, 1. V., Fenno, L. E. , 
Adhikari, A. , Lammel, S. , Mirzabekov, J. 1. , Airan, R. D. , Zalocusky, K. A., 
Tye, K. M. , Anikeeva, P., Malenka, R. C., Deisseroth, K. (2014). Natural neural 
projection dynamics underlying social behavior. CeU, 15 7, 1535-155l. 
Guillot, T. S., Miller, G. W. (2009). Protective actions of the vesicular monoamine 
transporter 2 (VMAT2) in monoaminergic neurons. Mol. Neurobiol. , 39, 149-170. 
Guo, C. , Sun, L., Chen, x., Zhang, D. (2013) . Oxidative stress, mitochondrial damage 
and neurodegenerative diseases. Neural Regen. Res., 8, 2003-2014. 
Gupta, G. , Azam, M. , Baquer, N. Z. (1992). Effect of experimental diabetes on the 
catecholamine metabolism in rat brain. J Neurochem. , 58, 95-100. 
Gupta, A. , Dawson, V.L. , Dawson, T.M. (2009). What causes cell death in Parkinson's 
disease? Ann. Neurol. , 64, 3-15. 
Guzman, J. N., Sanchez-Padilla, J. , Wokosin, D., Kondapalli, J. , Ilijic, E. , 
Schumacker, P. T. , Surmeier, D. 1. (2010). Oxidant stress evoked by pacemaking 
in dopaminergic neurons is attenuated by DJ-l. Nature, 468, 696-700. 
Haas, C. B. , Kalinine, E., Zimmer, E. R. , Hansel, G. , Brochier, A. W. , Oses, J. P. , 
Portela, L. v., Muller, A. P. (2016). Brain Insulin Administration Triggers Distinct 
Cognitive and Neurotrophic Responses in Young and Aged Rats. Mol. Neurobiol. , 
53, 5807-5817. 
312 
Haber, S. N. (2014). The place of dopamine In the cortico-basal ganglia circuit. 
Neuroscience, 282,248-257. 
Haber, S. N., Fudge, J. L., McFariand, N. R. (2000). Striatonigrostriatal pathways in 
primates form an ascending spiral from the shell to the dorsolateral striatum. 
J. Neurosci., 20, 2369-2382. 
Haber, S. N. , Groenewegen, H. J. , Grove, E. A., Nauta, W. J. (1985). Efferent 
connections of the ventral pallidum: evidence of a dual striato pallidofugal 
pathway. J. Comp. Neurol., 235, 322-335 . 
Habemy, S. L., Carr, K. D. (2005). Food restriction increases NMDA receptor-mediated 
calcium-calmodulin kinase II and NMDA receptor/extracellular signal-regulated 
kinase 1/2-mediated cyclic AMP response element-binding protein 
phosphorylation in nucleus accumbens upon D-l dopamine receptor stimulation. 
Neuroscience, 132, 1035-1043. 
Haddad, D., Nakamura, K. (2015). Understanding the susceptibility of 
dopamine neurons to mitochondrial stressors in Parkinson's disease. FEES LeU. , 
589, 3702-3713. 
Haehner, A. , Boesveldt, S., Berendse, H. W. , Mackay-Sim, A., Fleischmann, J., 
Silbum, P. A., Johnston, A. N., Mellick, G. D., Herting, B. , Reichmann, H., 
Hummel, T. (2009). Prevalence of smell loss in Parkinson's disease-a multicenter 
study. Parkinsonism Relat. Disord. , 15, 490-494. 
Hain, R. , Reif, H. J., Krause, E., Langebartels, R., Kindl, H., Vomam, B., Wiese, W. , 
Schmelzer, E., Schreier, P. H., Stocker, R. H. , Stenzel, K. (1 993). Disease 
resistance results from foreign phytoalexin expression in a novel plant. Nature, 
361, 153-156. 
Haj-ali, V. , Mohaddes, G., Babri, S. (2009) Intracerebroventricular insulin improves 
spatialleaming and memory in male Wistar rats. Behav. Neurosci. , 123, 1309. 
Hall, C. N., Klein-Flügge, M. C., Howarth, C., Attwell, D. (2012). Oxidative 
phosphorylation, not glycolysis, powers presynaptic and postsynaptic mechanisms 
underlying brain information processing. J. Neurosci. , 32, 8940-8951 . 
Hall, E. D. , Vaishnav, R., Mustafa, A. G. (2010). Antioxidant therapies for traumatic 
brain injury. Neurotherapeutics, 7, 51-61. 
313 
Hall, H., Reyes, S., Landeck, N., Landeck, N ., Bye, C., Leanza, G., Double, K. , 
Thompson, L. , Halliday, G. , Kirik, D. (2014). Hippocampal Lewy pathology and 
cholinergic dysfunction are associated with de menti a in Parkinson's disease. 
Brain, 137, 2493-2508. 
Halliday, G. , McCann, H., Shepherd, C. (2012b). Evaluation of the Braak hypothesis : 
how far can it explain the pathogenesis of Parkinson's disease? Expert Rev. 
Neurother., 12, 673-686. 
Halliday, G., Reyes, S., Double, K. (2012a). Chapter 13 - Substantia Nigra, Ventral 
Tegmental Area, and Retrorubral Fields. In: The Human Nervous System (3rd ed), 
pp. 439-455. 
Halliday, G. M., Holton, J. L. , Revesz, T. , Dickson, D. W. (2011). Neuropathology 
underlying clinical variability in patients with synucleinopathies. Acta 
Neuropathol., 122, 187-204. 
Hallschrnid, M., Benedict, C., Schultes, B., Born, J. , Kern, W. (2008) . Obese men 
respond to cognitive but not to catabolic brain insulin signaling. Int. J Obes. 
(Lond.), 32, 275-282. 
Hamberger, A., Hyden, H. (1963). Inverse enzymatic changes in neuros and glia during 
increased function and hypoxia. J Cel!. Bio., 16, 521-525. 
Hamilton, J. A., Brunaldi, K. (2007). A model for fatty acid transport into the brain. 
J Mol. Neurosci., 33, 12-17. 
Han, c., Rice, M. W. , Cai, D. (2016). Neuroinflammatory and autonomic mechanisms in 
diabetes and hypertension. Am. J Physiol. Endocrinol. Metab. , 311, 32-41. 
Hansson, E., Sellstrom, A. (1983). MAO, COMT and GABA-T activities in primary 
astroglial cultures. J Neurochem., 40, 220-225. 
Harada, S., Fujii, C., Hayashi, A., Ohkoshi, N. (2001). An association between 
idiopathic Parkinson's disease and polymorphisms of phase II detoxification 
enzymes: glutathione S-transferase Ml and quinone oxidoreductases 1 and 2. 
Biochem. Biophys. Res. Commun., 288, 887-892. 
Haroon, S. , Vermulst, M. (2016). Linking mitochondrial dynamics to mitochondrial 
protein quality control. Curr. Opin. Genet. Dev., 38, 68-74. 
Hashimoto, M., Rockenstein, E., Crews, L., Masliah, E. (2003). Role of protein 
aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's 
and Parkinson's diseases. Neuromolecular Med., 4, 21-36. 
314 
Haslbeck, K. M., Neundorfer, B. , Sch16tzer-Schrehardtt, o., Bierhaus, A., Schleicher, 
E., Pauli, E., Haslbeck, M., Hecht, M., Nawroth, P ., Heuss, D. (2007). Activation 
of the RAGE pathway: a general mechanism in the pathogenesis of 
polyneuropathies? Neurol. Res., 29, 103-110. 
Hasselbalch, S. G. , Knudsen, G. M., Jakobsen, J., Hageman, L. P. , Holm, S., 
Paulson, O. B. (1994). Brain metabolism during short-term starvation in humans. 
J Cereb. Blood Flow Metab., 14, 125-131. 
Hassler, R. (1939). Zur pathologischen anatomie des senilen und des parkinsonistischen 
tremor. Journal fitr psychologie und neurologie, 13-15. 
Hauber, W. (2010). Dopamine Release in the Prefrontal Cortex and Striatum: Temporal 
and Behavioural Aspects. Pharmacopsychiatry, 43, 32-41. 
Havrankova, J ., Roth, J. , Brownstein, M. (1978a). Insulin receptors are widely 
distributed in the central nervous system of the rat. Nature, 272, 827-829. 
Havrankova, J. , Schmechel, D., Roth, J., Brownstein, M. (1978b). Identification of 
insulin in rat brain. Proc. Nat!. Acad. Sei. U.S.A., 75, 5737-5741. 
Havrankova, J. , Roth, J., Brownstein, M. J. (1979). Concentrations of insulin and insulin 
receptors in the brain are independent of peripheral insulin levels: studies of obese 
and streptozotocin-treated rodents. J Clin. Invest., 64, 636-642. 
Hayakawa, N. , Shiozaki, M., Shibata, M., Koike, M., Uchiyama, Y., Matsuura, N., 
Gotow, T. (2013). Resveratrol affects undifferentiated and differentiated PC1 2 
ceUs differently, particularly with respect to possible differences in mitochondrial 
and autophagic functions. Eur. J Cel!. Biol. , 92, 30-43 . 
Heilig, C. W., Concepcion, L. A. , Riser, B. L. , Freytag, S. O., Zhu, M., Cortes, P. 
(1995). Overexpression of glucose transporters in rat mesangial ceUs cultured 
in a normal glucose milieu mimics the diabetic phenotype. J Clin. In vest. , 96, 
1802-1814. 
Heimer, L. (1978). The olfactory cortex and the ventral striatum. In Livingston, K. E. , 
Homykiewicz, O. (eds), Limbic Mechanisms. New York: Plenum Press, 
pp. 95-187. 
Heiss, W. D. (2016). Cerebral Glucose Metabolism. In Dierckx, R. A. J. O. , Otte, A. , 
de Vries, E. F. J., van Waarde, A., Luiten, P. G. M. (eds), PET and SPECT of 
neurobiological systems. Springer-Verlag, Berlin An. 
315 
Hendrich, S. (2002). Bioavailability of isoflavones. J Ch rom a togr. BAnal. Technol. 
Biomed. Life. Sei. , 777, 203-210. 
Hemandez-Munive, A. K. , Rebolledo-Solleiro, D., Ventura-Aquino, E., Femandez-
Guasti, A. (2018). Reduced Lordosis and Enhanced Aggression in Paced and 
Non-Paced Mating in Diabetic Female Rats. J Sex. Med. , 15, 124-135. 
Herraiz, T., Guillén, H. (2011). Inhibition of the bioactivation of the neurotoxin MPTP 
by antioxidants, redox agents and monoamine oxidase inhibitors. Food Chem. 
Toxicol. , 49, 1773-1781. 
Herrero-Mendez, A. , Almeida, A. , Femandez, E. , Maestre, C. , Moncada, S. , 
Bolanos, J. P. (2009). The bioenergetic and antioxidant status of neurons is 
controlled by continuous degradation of a key glycolytic enzyme by 
APC/ C-Cdhl. Nat. Cell. Biol. , Il, 747-752. 
Herse, P. , Petchell, M. (1998). Oxygen consumption and A TPase activity in the comeal 
epitheliurn of rabbits with alloxan induced hyperglycemia. Acta. Ophthalmol. 
Scand., 76, 528-532. 
Hertog, M. G. , Feskens, E. J. , Hollman, P. C. , Katan, M. B., Krornhout, D. (1993). 
Dietary antioxidant flavonoids and risk of coronary heart disease: The Zutphen 
Elderly Study. Lancet, 342, 1007-101l. 
Hertog, M. G. L. , Hollman, P. C. H. , Katan, M. B. (1992). Content of potentially 
anticarcinogenic flavonoids of 28 vegetables and 9 fruits cornmonly consumed in 
the Netherlands. J Agric. Food Chem. , 40, 2379-2383 . 
Heynekamp, J.1., Weber, W. M. , Hunsaker, L. A. , Gonzales, A. M. , Orlando, R. A., 
Deck, L. M., Jagt, D. L. (2006). Substituted trans-stilbenes, including analogues of 
the natural product resveratrol, inhibit the human tumor necrosis factor alpha-
induced activation of transcription factor nuclear factor kappaB. J Med. Chem., 
49, 7182-7189. 
Hider, R. C., Liu, Z. D., Khodr, H. H. (2001) .. Metal chelation of polyphenols. Methods 
Enzymol. , 335, 190-203. 
Hifumi, T. , Kawakita, K. , Yoda, T. , Okazaki , T. , Kuroda, Y. (2017). Association of 
brain metabolites with blood lactate and glucose levels with respect to 
neurological outcomes after out-of-hospital cardiac arrest: A preliminary 
microdialysis study. Resuscitation, 110, 26-3l. 
Hikosaka, O. , Takikawa, Y. , Kawagoe, R. (2000). Role of the basal ganglia in the 
control ofpurposive saccadic eye movements. Physiol. Rev., 80, 953-978. 
316 
Hilakivi-Clarke, L. A. , Wozniak, K. M., Durcan, M. J. , Linnoila, M. (1990). Behavior of 
streptozotocin-diabetic mice in tests of exploration, locomotion, anxiety, 
depression and aggression. Physiol. Behav. , 48, 429-433. 
Hill, J. , Lesniak, M. , Pert, C., Roth, J. (1986). Autoradiographic localization of insulin 
receptors in rat brain: prominence in olfactory and limbic areas. Neuroseience, 17, 
1127-1138. 
Hinder, L. M., Vivekanandan-Giri, A., McLean, L. L. , Pennathur, S., Feldman, E. L. 
(2013). Decreased glycolytic and tricarboxylic acid cycle intermediates coincide 
with peripheral nervous system oxidative stress in a murine model of type 2 
diabetes. J Endocrinol., 216, 1-1 1. 
Hirsch, E. C., Breidert, T., Rousselet, E., Hunot, S., Hartmann, A., Michel, P. P. (2003). 
The role of glial reaction and inflammation in Parkinson's disease. Ann. N Y 
Acad. Sei. , 991,214-228. 
Hirsch, E. c., Faucheux, B. A. (1998). Iron metabolism and Parkinson's disease. 
Mov. Disord., 1, 39-45. 
Hirsch, E., Graybiel, A. M. , Agid, Y. A. (1988). Melanized dopaminergic neurons 
are differentially susceptible to degeneration in Parkinson 's disease. Nature, 334, 
345-348. 
H6cht, C., Opezzo, J. A., Taira, C. A. (2007). Applicability of reverse microdialysis 
in pharmacological and toxicological studies. J Pharmacol. Toxicol. Methods., 55, 
3-15. 
Hofman, A. , Ott, A. , Breteler, M. M. , Bots, M. L. , Slooter, A. J. , van Harskamp, F. , 
van Duijn, C. N., Van Broeckhoven, C. , Grobbee, D. E. (1997). Atherosclerosis, 
apolipoprotein E, and prevalence of dementia and Alzheimer' s disease in the 
Rotterdam Study. Lancet., 349, 151-154. . 
H6kfelt, T. , Martensson, R., Bj6rklund, A. , Kleinau, S. , Goldstein, M. (1984). 
Distribution maps of tyrosine-hydroxylase-immunoreactive neurons in the rat 
brain. In Bj6rklund, A. , H6kfelt, T. , (eds), Classical Transmitters in the CNS. 
Handbook of Chemical Neuroanatomy. Vol. 2, Part 1. Amsterdam, Netherlands: 
Elsevier Press, pp. 277-379. 
Hollman, P. C. (2014). Unravelling of the health effects of polyphenols is a complex 
puzzle complicated by metabolism. Arch. Biochem. Biophys., 559, 100-105. 
317 
Hollman, P. c., Cassidy, A. , Comte, B. , Heinonen, M. , Richelle, M., Richling, E. , 
Serafini, M., Scalbert, A. , Sies, H. , Vidry, S. (2011). The biological relevance of 
direct antioxidant effects of polyphenols for cardiovascular health in humans is not 
established. J Nutr., 141 , 989S-1 009S. 
Holman, R. R. , Paul, S. K. , Bethel, M. A. , Matthews, D. R., Neil, H. A. (2008). 10-year 
follow-up of intensive glucose control in type 2 diabetes. N. Engl. J Med. , 359, 
1577-1589. 
Holmqvist, S., Chutna, O. , Bousset, L. , Aldrin-Kirk, P. L. W. , Bj6rklund, T. , 
Wang, Z.-Y. , Roybon, L. , Melki, R. , Li, J.-Y. (2014) . Direct evidence of Parkinson 
pathology spread from the gastrointestinal tract to the brain in rats. Acta 
Neuropa th 01. , 128, 805-820. 
Hopkins, M. E. , Sharma, M., Evans, G. C., Bucci, D. J. (2009). Voluntary physical 
exercise alters attentional orienting and social behavior in a rat model of attention-
deficit/hyperactivity disorder. Behav. Neurosci. , 123, 599-606. 
Hom, T., Klein, J. (2010). Lactate levels in the brain are elevated upon exposure to 
volatile anesthetics: a microdialysisstudy. Neurochem. Int. , 5 7, 940-947. 
Hornykiewicz, O. (1966). Metabolism of brain dopamine in human Parkinsonism: 
Neurochemical and c1inical aspects. In Costa, E. , et al. , (eds), Biochemistry and 
pharmacology of the basal ganglia. Hewlett, N. Y: Raven Press, pp. 171-185. 
Hothersall, J. S. , Baquer, N . Z., Greenbaum, A. L. , McLean, P. (1979). Alternative 
pathways of glucose utilization in brain. Changes in the pattern of glucose 
utilization in brain during development and the effect of phenazine methosulphate 
on the integration ofmetabolic routes. Arch. Biochem. Biophys. 198, 478-492. 
Hou, X. , Xu, S., Maitland-Toolan, K. A. , Sato, K., Jiang, B. , Ido, Y. , Lan, F. , Walsh, K. , 
Wierzbicki, M., Verbeuren, T. J., Cohen, R. A. , Zang, M. (2008) . SIRTI regulates 
hepatocyte lipid metabolism through activating AMP-activated protein kinase. 
J Biol. Chem., 283, 20015-20026. 
Houlden, H. , Singleton, A. B. (2012).The genetics and neuropathology of Parkinson ' s 
disease. Acta Neuropathol., 124, 325-338. 
Hounsom, L. , Corder, R., Patel, J., Tomlinson, D. R. (2001). Oxidative stress 
participates in the breakdown of neuronal phenotype in experimental diabetic 
neuropathy. Diabetologia, 44, 424-428. 
31 8 
Hounsom, L. , Horrobin, D. F. , Tritschler, H. , Corder, R. , Tomlinson, D. R. (1998). 
A lipoic acid-gamma linolenic acid congugate is effective against multiple indices 
of experimental diabetic neuropathy. Diabetologia, 41, 839-843. 
Houssay, B.A. , Martinez, C. (1947). Experimental diabetes and diet. Science, 
105, 548-549. 
Howitz, K. T., Bitterman, K. J., Cohen, H. Y. , Lamming, D. W., Lavu, S., Wood, 1. G., 
Zipkin, R. E. , Chung, P. , Kisielewski, A., Zhang, L. L., Scherer, B., Sinclair, D. A. 
(2003). Small molecule activators of sirtuins extend Saccharomyces cerevisiae 
lifespan. Nature, 425, 191-196. 
Hsieh, T. C., Burfeind, P. , Laud, K. , Backer, J. M. , Traganos, F. , Darzynkiewicz, Z. , 
Wu, J. M. (1999). Cell cycle effects and control of gene expression by resveratrol 
in human breast carcinoma cell lines with different metastatic potentials. 
Int. J Oncol. , 15, 245-252. 
Hu, W., Yang, E., Ye, 1. , Han, W. , Du, Z. L. (2018) . Resveratrol protects neuronal 
cells from isoflurane-induced inflammation and oxidative stress-associated death 
by attenuating apoptosis via Akt/p38 MAPK signaling. Exp. Ther. Med. , 15, 
1568-1573. 
Huang, E. J., Reichardt, L. F. (2003). Trk receptors : roles In neuronal signal 
transduction. Annu. Rev. Biochem. , 72, 609-642. 
Huang, S. , Czech, M. P. (2007) . The GLUT4 glucose transporter. Cel!. Metab., 5, 
237-252. 
Huang, T. J. , Priee, S. A., Chilton, L. , Calcutt, N . A. , Tomlinson, D. R. , Verkhratsky, A., 
Femyhough, P. (2003). Insulin prevents depolarization of the mitochondrial inner 
membrane in sensory neurons of type 1 diabetic rats in the presence of sustained 
hyperglycemia. Diabetes, 52, 2129-2136. 
Huang, Y. P., Chen, L. S. , Yen, M. F. , Fann, C. Y. , Chiu, y. H. , Chen, H. H., Pan, S. L. 
(2013). Parkinson's disease is related to an increased risk of ischemic stroke-a 
population-based propensity score-matched follow-up study. PLoS One, 8, 
e68314. 
Hudson, A. W., Fingar, D. C. , Seidner, G. A. , Griffiths, G., Burke, B. , Birnhaum, M. J. 
(1993). Targeting of the "insulin-responsive" glucose transporter (GLUT4) to the 
regulated secretory pathway in PC12 cells. J Cel!. Biol. , 122, 579-588. 
319 
Huhn, S., Kharabian Masouleh, S., Stumvoll, M., Villringer, A. , Witte, A. V. (2015). 
Components of a Mediterranean diet and their impact on cognitive functions in 
aging. Front. Aging. Neurosei., 7, 132. 
Hung, L. M. , Huang, 1. P. , Liao, J. M., Yang, M. H. , Li, D. E. , Day, Y. J. , Huang, S. S. 
(2014). Insulin renders diabetic rats resistant to acute ischemic stroke by arresting 
nitric oxide reaction with superoxide to form peroxynitrite. J Biomed. Sei., 21, 92. 
Hwang, O. (2013). Role of oxidative stress in Parkinson's disease. Exp. Neurobiol., 22, 
11-17. 
Iacopino, A. M. , Christakos, S. (1990). Specific reduction of calcium-binding protein 
(28-kilodalton calbindin-D) gene expression in aging and neurodegenerative 
diseases. Proe. Natl. Aead. Sei. U.S.A. , 8 7, 4078-4082. 
Ibrahim, M. Z. M. (1975). Glycogen and its related enzymes of metabolism in the 
central nervous system. Adv. Anat. Embryol. Cel!. Biol., 52, 1-85. 
Ibsen, H. K. (1961). The Crabtree effect: a review. Cancer Res., 21, 829-841. 
Ielacqua, G. D., Schlegel, F., Füchtemeier, M., Xandry, J. , Rudin, M., Klohs, J. (2016). 
Magnetic Resonance Q Mapping Reveals a Decrease in Microvessel Density in the 
arcA~ Mouse Model of Cerebral Amyloidosis. Front. Aging Neurosci., 7, 241. 
Iizumi, T. , Takahashi, S. , Mashima, K. , Minami, K. , Izawa, Y. , Abe, T., Hishiki, T. , 
Suematsu, M. , Kajimura, M. , Suzuki, N. (2016). A possible role of microglia-
derived nitric oxide by lipopolysaccharide in activation of astroglialpentose-
phosphate pathway via the Keapl/Nrf2 system. J Neuroinjlammation, 13, 99. 
Ikemoto, S. Dopamine reward circuitry: two projection systems from the ventral 
midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Res. 
Rev., 56, 27-78. 
Imamura, H. , Yamaguchi, T. , Nagayama, D., Saiki, A. , Shirai, K. , Tatsuno, 1. (2017). 
Resveratrol Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular 
Index in Patients with Type 2 Diabetes Mellitus. Int. Heart J , 58, 577-583. 
Imperato, A., Di Chiara, G. (1984). Trans-striatal dialysis coupled to reverse-phase high 
performance liquid chromatography with electrochemical detection: A new 
method for study of the in vivo release of endogenous dopamine and metabolites. 
J Pharmaeol. Exp. Ther., 4, 966-977. 
320 
International Diabetes Federation, (2013). In: Diabetes Atlas. 6th ed. Brussels, Belgium: 
International Diabetes Federation. 
Irrcher, L, Aleyasin, H., Seifert, E. L., Hewitt, S. 1., Chhabra, S. , Phillips, M., 
Lutz, A. K., Rousseaux, M. W., Bevilacqua, L., Jahani-AsI, A., Callaghan, S., 
MacLaurin, J. G., Winklhofer, K. F., Rizzu, P., Rippstein, P. , Kim, R. H., 
Chen, C. X., Fon, E. A., Slack, R. S., Harper, M. E., McBride, H. M. , Mak, T. W. , 
Park, D. S. (2010). Loss of the Parkinson's disease-linked gene DJ-1 perturbs 
mitochondrial dynamics. Hum. Mol. Genet., 19,3734-3746. 
Islam, M. S., Loots du, T. (2009). Experimental rodent models of type 2 diabetes: 
a review. Methods Find. Exp. Clin. Pharmacol., 31, 249-261. 
Ito, M. , Kondo, Y, Nakatani, A., Hayashi, K., Naruse, A. (2001) . Characterization of 
low dose streptozotocin-induced progressive diabetes in mice. Environment 
Toxicol. Pharmacol. , 9, 71-78. 
Ito, M., Kondo, Y, Nakatani, A., Naruse, A. (1999). New model of progressive 
noninsu1in- dependent diabetes mellitus in mice induced by streptozotocin. 
Biol. Pharm. Bull. , 22, 988-989. 
Ivannikov, M. V., Sugimori, M. , Llinas, R. R. (2010). Calcium clearance and its energy 
requirements in cerebellar neurons. Cell Calcium, 47, 507-513. 
Iwasaki, S. , Narabayashi, Y , Hamaguchi, K., Iwasaki, A., Takakusagi, M. (1990) . 
Cause of death among patients with Parkinson's disease: a rare mortality due to 
cerebral haemorrhage. J Neurol. , 237, 77-79. 
Iwata, N., Okazaki, M., Xuan, M., Kamiuchi, S., Matsuzaki, H. , Hibino, Y (2014). 
Orally administrated ascorbic acid suppresses neuronal damage and modifies 
expression of SVCT2 and GLUT1 in the brain of diabetic rats with cerebral 
ischemia-reperfusion. Nutrients, 6, 1554-1577. 
Izaguirre, G., Kikonyogo, A., Pietruszko, R. (1998). Methylglyoxal as substrate and 
inhibitor of human aldehyde dehydrogenase: comparison of kinetic properties 
among the three isozymes. Comp. Biochem. Physiol. B. Biochem. Mol. Biol., 119, 
747-754. 
Jackson-Lewis, V., Blesa, J., Przedborski, S. (2012). Animal models of Parkinson's 
disease. Parkinsonism Relat. Disord., 18, 183-185. 
Jacob, R. J., Fan, x., Evans, M. L., Dziura, J., Sherwin, R. S. (2002). Brain glucose 
levels are elevated in chronically hyperglycemic diabetic rats: no evidence for 
protective adaptation by the blood brain barrier. Metabolism, 51, 1522-1524. 
321 
Jain, V., Langham, M. C. , Wehrli, F. W. (2010). MRI estimation of global brain oxygen 
consumption rate. J Cereb. Blood Flow Metab. , 30, 1598-1607 . 
Jakus, V. , Rietbrock, N. (2004) . Advanced glycation end products and the progress of 
diabetic vascular complications. Physiol. Rev., 53, 131-142. 
Jalloh, L, Helmy, A. , Shannon, R. 1., Gallagher, C. N., Menon, D. K. , Carpenter, K. L. , 
Hutchinson, P. 1. (20l3). Lactate uptake by the injured human brain: evidence 
from an arteriovenous gradient and cerebral microdialysis study. J Neurotrauma, 
30, 2031-2037. 
James, D. E. , Brown, R. , Navarro, 1., Pi1ch, P. F. (1988). Insulin-regulatable tissues 
express a unique insulin-sensitive glucose transport protein. Nature, 333, 183-185. 
Jomova, K. , Vondrakova, D. , Lawson, M. , Valko, M. (2010) . Metals, oxidative stress 
and neurodegenerative disorders. Mol. Cel!. Biochem., 345, 91-104. 
Jana, N. R. (2012). Prote in homeostasis and aging: role of ubiquitin protein ligases. 
Neurochem.lnt. 60, 443-447. 
Janda, E. , Lascala, A. , Carresi, C. , Parafati, M., Aprigliano, S., Russo, V., Savoia, C. , 
Ziviani, E. , Musolino, V., Morani, F. , Isidoro, C. , Mollace, V. (2015). 
Parkinsonian toxin-induced oxidative stress inhibits basal autophagy in 
astrocytes via NQ02/quinone oxidoreductase 2: Implications for neuroprotection. 
Autophagy, 11, 1063-1080. 
Janda, E. , Parafati, M. , Aprigliano, S. , Carresi , C. , Visalli , V. , Sacco, L, Ventrice, D. , 
Mega, T. , Vadala, N. , Rinaldi , S. , Musolino, V. , Palma, E., Gratteri, S. , 
Rotiroti , D. , Mollace, V. (20l3). The antidote effect of quinone oxidoreductase 2 
inhibitor against paraquat-induced toxicity in vitro and in vivo. Br. J Pharmacol, 
168,46-59. 
Jang, D. S. , Kang, B. S. , Ryu, S. Y. , Chang, 1. M., Min, K. R. , Kim, Y. (1999) . 
Inhibitory effects of resveratrol analogs on unopsonized zymosan-induced oxygen 
radical production. Biochem. Pharmacol. , 5 7, 705-712. 
Jang, M. , Cai, L. , Udeani, G. O., Slowing, K. V. , Thomas, C. F. , Beecher, C. W. , 
Fong, H. H. , Famsworth, N. R. , Kinghom, A. D., Mehta, R. G., Moon, R. C., 
Pezzuto, J. M. (1997). Cancer chemopreventive activity of resveratrol, a natural 
product derived from grapes. Science, 2 75, 218-220. 
322 
Jankovic, J. , McDennott, M., Carter, J., Gauthier, S., Goetz, c., Golbe, L. , Huber, S., 
Koller, W., Olanow, c., Shoulson, I., et al.' (1990). Variable expression of 
Parkinson's disease: a base-line analysis of the DA TATOP cohort. The Parkinson 
Study Group. Neurology, 40, 1529-1534. 
Jardim, F. R. , de Rossi , F. T ., Nascimento, M. X., da Silva Barros, R. G., Borgesm P. A., 
Prescilio, I. C. , de Oliveira, M. R. (2018). Resveratrol and Brain Mitochondria: 
a Review. Mol. Neurobiol. , 55, 2085-2101. 
Jenner, P. (1991). Oxidative stress as a cause of Parkinson's disease. Acta Neurol. Scand. 
Suppl. , 136,6-15. 
Jenner, P. (1993). Altered mitochondrial function, iron metabolism and glutathione 
levels in Parkinson's disease. Acta Neurol. Scand. Suppl. 146, 3-13. 
Jezek, P., Olejâr, T. , Smolkovâ, K. , Jezek, 1., Dlaskovâ, A., Plecitâ-Hlavatâ, L., 
Zelenka, 1., Spacek, T., Engstovâ, H., Pajuelo Reguera, D. , Jabürek, M. (2014). 
Antioxidant and regulatory role of mitochondrial uncoupling protein UCP2 in 
pancreatic beta-cells, Physiol. Res., 63, 73-91. 
Jhang, C. L. , Huang, T. N. , Hsueh, Y. P. , Liao, W. (2017). Mice lacking cyc1in-
dependent kinase-like 5 manifest autistic and ADHD-like behaviors. Hum. 
Mol. Genet., 26, 3922-3934. 
Jiang, B. Guo, L. , Li, B. Y. , Zhen, J. H., Song, 1., Peng, T. , Yang, X. D. , Hu, Z., 
Gao, H. Q. (2013). Resveratrol attenuates early diabetic nephropathy by 
down-regulating glutathione s-transferases Mu in diabetic rats. J Med. Food, 
16, 481-486. 
Jin, F., Wu, Q., Lu, Y. F. , Gong, Q. H., Shi, 1. S. (2008). Neuroprotective effect of 
resveratrol on 6-0HDA-induced Parkinson's disease in rats. Eur. J Pharmacol., 
600, 78-82. 
Jin, J. , Hulette, C. , Wang, Y. , Zhang, T., Pan, C., Wadhwa, R. , Zhang, J. (2006). 
Proteomic identification of a stress protein, mortalinlmthsp70/GRP75: relevance to 
Parkinson disease. Mol. Cel!. Proteomics, 5, 1193-1204. 
Jolivet, R. , Allaman, I. Pellerin, L., Magistretti, P. J. , Weber, B. (2010). Comment on 
recent modeling studies of astrocyte-neuron metabolic interactions. J Cereb. 
Blood Flow Metab., 30, 1982-1986. 
Jones, A. F., Winkles, J. W., Jennings, P. E., Florkowski, C. M., Lunec. J. , 
Barnett, A. H. (1988) . Serum antioxidant activity in diabetes mellitus. Diabetes 
Res., 7, 89-92. 
323 
Jones, C. A., Watson, D. J., Fone, K. C. (2011). Animal models of schizophrenia. Br. 
J Pharmacol., 164, 1162-1194. 
Jones, H. M., Pilowski , L. S. (2002). Dopamine and antipsychotic drug action revisited. 
Br. J Psychiatry, 181, 271-275. 
Joshipura, K. J. , Hu, F. B. , Manson, J. E. , Stampfer, M. J. , Rimm, E. B. , Speizer, F. E., 
Colditz, G. , Ascherio, A., Rosner, B., Spiegelman, D. , Willett, W. C. (2001). 
The effect of fruit and vegetable intake on risk for coronary heart disease. Ann. 
Intern. Med., 134, 1106-1114. 
Jourdan, D. , Ardid, D. , Chapuy, E., Eschalier, A., Le Bars, D. (1995). Audible and 
ultrasonic vocalization elicited by single electrical nociceptive stimuli to the tail 
in the rat. Pain, 63, 237-249. 
Jourdan, D., Ardid, D. , Eschalier, A. (2002). Analysis of ultrasonic vocalisation do es not 
allow chronic pain to be evaluated in rats. Pain, 95, 165-173. 
Jurcovicova, J. (2014). Glucose transport in brain - effect of intlammation. Endocr. 
Regul., 48, 35-48. 
Justesen, o., Knuthsen, P., Leth, T. (1998). Quantitative analysis of tlavonols, flavones, 
and tlavanones in fruits , vegetables and beverages by highperforrnance liquid 
chromatography with photo-diode array and mass spectrometric detection. 
J Chromatogr. A., 799, 101-110. 
Kadota, T. , Yamaai, T. , Saito, Y. , Akita, Y. , Kawashima, S., Moroi, K. , Inagaki, N. , 
Kadota, K. (1996). Expression of dopamine transporter at the tips of growing 
neurites ofPC12 cells. J Histochem. Cytochem., 44, 989-996. 
Kaeberlein, M. , Kirkland, K. T., Fields, S., Kennedy, B. K. (2004). Sir2- independent 
life span extension by calorie restriction in yeast. PLoS Biol., 2, E296. 
Kaiser, N., Sasson, S., Feener, E. P., Boukobza-Vardi, N. , Higashi, S., Moller, D. E., 
Davidheiser, S. , Przybylski, R. J. , King, G. L. (1993). Differentiai regulation of 
glucose transport and transporters by glucose in vascular endothelial and smooth 
muscle ceUs. Diabetes, 42, 80-89. 
Kalaitzakis, M. E., Graeber, M. B., Gentleman, S. M. , Pearce, R. K. (2008a) . 
Controversies over the staging of alpha-synuclein pathology in Parkinson's 
disease. Acta Neuropathol., 116, 125-128. 
324 
Kalaitzakis, M. E., Graeber, M. B., Gentleman, S. M., Pearce, R. K. (2008b). The dorsal 
motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: 
a critical analysis of a-synuclein staging. Neuropathol. Appl. Neurobiol., 34, 
284-295. 
Kalaria, R. N., Gravina, S. A. , Schmidley, J. W., Perry, G., Harik, S. 1. (1988). 
The glucose transporter of the human brain and blood-brain barrier. Annals of 
Neurology, 24, 757-764. 
Kaltwasser, M. T. (1990). Acoustic signaling in the black rat (Rattus rattus). J Comp. 
Psychol., 104,227-232. 
Kang, J., Park, E. J. , Jou, L, Kim, J. H., Joe, E. H. (2001). Reactive oxygen species 
mediate A beta(25-35)-induced activation of BV -2 microglia. Neuroreport, 12, 
1449-1452. 
Kang, Y., Viswanath, V., Jha, N. , Qiao, x., Mo, J. Q. , Andersen, J. K. (1999). Brain 
gamma-glutamyl cysteine synthetase (GCS) rnRNA expression patterns correlate 
with regional-specific enzyme activities and glutathione levels J. Neurosci. Res., 
58, 436-441. 
Kar, P., Chawla, H., Saha, S., Tandon, N. , Goswami, R. (2016). Identification of 
reference housekeeping-genes for mRNA expression studies in patients . with 
type 1 diabetes. Mol. Cell. Biochem., 417, 46-56. 
Karlsson, J., Emgard, M., Brundin, P. , Burkitt, M. J. (2000) . trans-resveratrol protects 
embryonic mesencephalic cells from tert-butyl hydroperoxide: electron 
paramagnetic resonance spin trapping evidence for a radical scavenging 
mechanism. J Neurochem., 75, 141-150. 
Karuppagounder, S. S., Pinto, J. T., Xu, H., Chen, H. L., BeaI, M. F., Gibson, G. E. 
(2009) . Dietary supplementation with resveratrol reduces plaque pathology in a 
transgenic model of Alzheimer's disease. Neurochem. Int. , 54, 111-118. 
Kastner, A. , Hirsch, E. C., Lejeune, O., Javoy-Agid, F., Rascol, O. , Agid, Y. (1992). 
Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's 
disease related to their neuromelanin content? J Neurochem., 59, 1080-1089. 
Kasznicki, J., Kosmalski, M., Sliwinska, A., Mrowicka, M., Stanczyk, M. , Majsterek, L, 
Drzewoski, J. (2012). Evaluation of oxidative stress markers in pathogenesis of 
diabetic neuropathy. Mol. Biol. Rep., 39, 8669-8678. 
325 
Kaufmann, S. H., Desnoyers, S. , Ottaviano, Y. , Davidson, N . E. , Poirier, G. G. (1993). 
Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of 
chemotherapy-induced apoptosis. Cancer Res., 53, 3976-3985. 
Kaul, S. c., Aida, S. , Yaguchi, T. , Kaur, K. , Wadhwa, R. (2005). Activation ofwild type 
p53 function by its mortalin-binding, cytoplasmicaUy localizing carboxyl terminus 
peptides. J Biol. Chem. , 280, 39373-39379. 
Kaur, G., Bhardwaj, S. K. (1998). The impact of diabetes on CNS. Role of bioenergetic 
defects. Mol. Chem. Neuropathol. , 35, 119-31. 
Kawada, N. , Seki, S. , Inoue, M. , Kuroki , T. (1998). Effect of antioxidants, resveratrol, 
quercetin, and N-acetylcysteine, on the functions of cultured rat hepatic steUate 
ceUs and Kupffer ceUs. Hepatology, 2 7, 1265-1274. 
Kawai, T. , Takei, L, Tokui, M. , Funae, O. , Miyamoto, K., Tabata, M. , Hirata, T. , 
Saruta, T. , Shimada, A., Itoh, H. (2010). Effects of epalrestat, an aldose reductase 
inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in 
relation to suppression of N(c)-carboxymethyl lysine. J Diabetes Complications, 
24, 424-432. 
Kawano, K. , Hirashima, T. , Mori, S. , Saitoh, Y. , Kurosumi, M. , Natori, T. (1992). 
Spontaneous long-term hyperglycemic rat with diabetic complications, Otsuka 
Long-Evans Tokushima Fatty (OLE TF) strain. Diabetes, 41, 1422-1428. 
Ke, B. , Tian, M. , Li, J. , Liu, B. , He, G. (2016). Targeting Programmed CeU Death Using 
Small-Molecule Compounds to Irnprove Potential Cancer Therapy. Med. Res. 
Rev., 36, 983-1035. 
Keeler, J . F., Pretsell, D. O. , Robbins, T. W. (2014). Functional implications of 
dopamine Dl vs. D2 receptors: A ' prepare and select' model of the striatal direct 
vs. indirect pathways. Neuroscience, 282, 156-175. 
Ke1m-Nelson, C. A. , Yang, K. M. , Ciucci, M. R . (2015) . Exercise Effects on Early 
Vocal Ultrasonic Communication Dysfunction in a PINKI Knockout Model of 
Parkinson's Disease. J Parkinsons Dis., 5, 749-763 . 
Kempster, P. A. , Williams, D. R. , Selikhova, M. , HoIton, J., Revesz, T. , Lees, A. J. 
(2007). Patterns of levodopa response in Parkinson ' s disease: a clinico-
pathological study. Brain, 130, 2123-2128. 
Kerry, N. L. , Abbey, M. (1997). Red wine and fractionated phenolic compounds 
prepared from red wine inhibit low density lipoprotein oxidation in vitro. 
Atherosclerosis, 135, 93-102. 
326 
Kesherwani, V., Atif, F. , Yousuf, S., Agrawal, S. K. (2013). Resveratrol protects spinal 
cord dorsal colurnn from hypoxic injury by activating Nrf-2. Neuroscience, 
241, 80-88. 
Kety, S. S. , Schmidt, C. F. (1948) . The nitrous oxide method for the quantitative 
determination of cerebral blood flow in man: theory, procedure and normal values. 
J Clin. Invest. , 27, 476-483. 
Khan, M. M., Ahmad, A. , Ishrat, T. , Khan, M. B., Hoda, M. N., Khuwaja, G., 
Raza, S. S. , Khan, A. , Javed, H., Vaibhav, K. , Islam, F. (2010). Resveratrol 
attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion 
in rat model of Parkinson's disease. Brain Res., 1328, 139-151 . 
Khan-Dawood, F. S. , Gargiulo, A. R. , Dawood, M. Y. (1994). Baboon corpus lutem: 
Autonomous pulsatile progesterone secretion and evidence for an intraluteal 
oscillator demonstrated by in vitro microretrodialysis. J Clin. Endocrinol. Metab., 
79, 1790-1796. 
Khanduja, K. L. , Bhardwaj , A. (2003). Stable free radical scavengmg and 
antiperoxidative properties of resveratrol compared in vitro with sorne other 
bioflavonoids.lndian J Biochem. Biophys., 40, 416-422 . 
Khanh, D.V., Choi, y. H. , Moh, S. H., Kinyua, A. W., Kim, K. W. (2014). Leptin and 
insulin signaling in dopaminergic neurons: relationship between energy balance 
and reward system. Front. Psychol. , 5, 846. 
Khayat, Z. A. , McCaIl, A. L. , Klip, A. (1998). Unique mechanism of GLUT3 glucose 
transporter regulation by prolonged energy demand: increased protein half-life. 
Biochem. J , 333, 713-718. 
Khazaei, M., Moien-Afshari, F. , Elmi, S. , Mirdamadi, A. , Laher, 1. (2009). The effects 
of diethyldithiocarbamate, a SOD inhibitor, on endothelial function in sedentary 
and exercised db/db mice. Pathophysiology, 16, 15-18. 
Khazaei, M. R. , Habibi-Rezaei , M., Karimzadeh, F., Moosavi-Movahedi, A. A., 
Sarrafnejhad, A. A. , Sabouni, F. , Bakhti, M. (2008). Microglial ceIl death induced 
by glycated bovine serum albumin: nitric oxide involvement. J Biochem., 144, 
197-206. 
Kim, J. H., Nishina, P. M. , Naggert, J. K. (1998). Genetic models for non insulin 
dependent diabetes mellitus in rodents. J Basic Clin. Physiol. Pharmacol. , 9, 
325-345 . 
327 
Kim, S. J., Han, Y. (2005). Insulin inhibits AMPA-induced neuronal damage via 
stimulation of protein kinase B (Akt) . J Neural Transm. (Vien na), 112, 179-191 . 
Kim, W., Mohney, R. P., Wilson, B., Jeohn, G., Liu, B., Hong, J. (2000). Regional 
difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat 
brain: role of microglia. J Neurosci., 20, 6309-6316. 
King, J. A., Tenney, J. , Rossi, V., Colamussi, L. , Burdick, S. (2003). Neural substrates 
underlying impulsivity. Ann. N Y. Acad. Sci., J008, 160-169. 
King-Casas, B., Tomlin, D., Anen, C., Camerer, C. F., Quartz, S. R., Montague, P. R. 
(2005). Getting to know you: reputation and trust in a two-person economic 
exchange. Science, 308, 78-83. 
Kirik, D., Georgievska, B. , Burger, c., Winkler, C., Muzyczka, N., Mandel, R. J. , 
Bjorklund, A. (2002). Reversai of motor impairments in parkinsonian rats by 
continuous intrastriatal delivery of L-dopa using rAA V -mediated gene transfer. 
Proc. Natl. Acad. Sci. US.A., 99, 4708-4713. 
Kirik, D., Rosenblad, c., Bjorklund, A. (2000). Preservation of a functional nigrostriatal 
dopamine pathway by GDNF in the intrastriatal 6-0HDA les ion model de pends on 
the site of administration of the trophic factor. Eur. J Neurosci., 12,3871-3882. 
Kiziltepe, U., Turan, N. N., Han, U ., Ulus, A. T., Akar, F. (2004). Resveratrol , a red 
wine polyphenol, protects spinal cord from ischemia-reperfusion injury. J Vasco 
Surg., 40, 138-145. 
Kletzien, R.F., Harris, P.K.W., Foellmi, L.A. (1994). Glucose-6-phosphate 
dehydrogenase: a housekeeping enzyme subject to tissue-specific regulation by 
hormones, nutrients, and oxidant stress, F ASEB J, 8, 174-181. 
Klimek, P., Kautzky-Willer, A., Chmiel, A., Schiller-Frühwirth, I., Thumer, S. (2015). 
Quantification of diabetes comorbidity risks across life using nation-wide big 
c\aims data. PLoS Comput. Bio!. , 11, el004125. 
Knutson, B. , Burgdorf, J. , Panksepp, J. (1998). Anticipation of play elicits high-
frequency ultrasonic vocalizations in young rats. J Camp. Psycho!. , 112, 65-73. 
Ko, I. G., Kim, S. E., Kim, T. W., Ji, E. S. , Shin, M. S., Kim, C. 1., Hong, M. H., 
Bahn, G. H. (2013). Swimming exercise alleviates the symptoms of attention-
deficit hyperactivity disorder in spontaneous hypertensive rats. Mol. Med. Rep., 
8, 393-400. 
328 
Kodama, T., Iwase, M. , Nunoi, K. , Maki, Y., Yoshinari, M., Fujishima, M. (1993). 
A new diabetes model induced by neonatal alloxan treatment in rats. Diabetes Res. 
Clin. Pract. , 20, 183-189. 
Koizumi, J. (1974). Glycogen in the central nervous system. Prog Histochem, 6, 1-35. 
Kolinko, Y. , Cendelin, J. , Kralickova, M. , Tonar, Z. (2016). Smaller absolute quantities 
but greater relative densities of microvessels are associated with cerebellar 
degeneration in lurcher mice. Front. Neuroanat., 10, 35. 
Kono, T., Takada, M. (1994). Dopamine depletion in nigrostriatal neurons 111 the 
genetically diabetic rat. Brain Res., 634, 155-158. 
Koo, J. H., Cho, J. Y. , Lee, U. B. (2017). Treadmill exercise alleviates motor deficits 
and improves mitochondrial import machinery in an MPTP-induced mouse model 
ofParkinson's disease. Exp. Gerontol. , 89, 20-29. 
Koranyi, L. , Bourey, R. E., James, D. , Mueckler, M., Fiedorek, F. T. Jr., Permutt, M. A 
(1991). Glucose transporter gene expression in rat brain: Pretranslational changes 
associated with chronic insulin-induced hypoglycemia, fasting, and diabetes. 
Mol. CeU. Neurosci., 2, 244-252. 
Kordower,1. H., Chu, Y., Hauser, R . A , Freeman, T. B., Olanow, C. W. (2008). Lewy 
body-like pathology in long-term embryonic nigral transplants in Parkinson 's 
disease. Nat. Med., 14, 504-506. 
Korshunov, S. S., Skulachev, V. P. , Starkov, A A (1997). High protonic potential 
actuates a mechanism of production of reactive oxygen species in mitochondria. 
FEBS Lett., 416, 15-18. 
Kosaka, K. , Tsuchiya, K. , Y oshimura, M. (1988). Lewy body disease with and without 
dementia: a clinicopathological study of 35 cases. Clin. Neuropathol., 7, 299-305. 
Kovatchev, B. P. (20l7). Metrics for glycaemic control - from HbAlc to continuous 
glucose monitoring. Nat. Rev. Endocrinol., 13, 425-436. 
Koziel, A , Woyda-Ploszczyca, A , Kicinska, A , Jarmuszkiewicz, W. (2012) . 
The influence of high glucose on the aerobic metabolism of endothelial 
EA.hy926 cells. Pflugers Arch., 464, 657-669. 
Kozlovsky, N. , Rudich, A., Potashnik, R., Ebina, Y. , Murakami, T. , Bashan, N. (1997). 
Transcriptional activation of the Glut1 gene in response to oxidative stress 111 
L6 myotubes. J Biol. Chem., 272, 33367-33372. 
329 
Krady, 1. K. , Basu, A. , Allen, C. M., Xu, Y. , LaNoue, K. F. , Gardner, T. W., 
Levison, S. W. (2005). Minocycline reduces proinflammatory cytokine expression, 
microglial activation, and caspase-3 activation in a rodent model of diabetic 
retinopathy. Diabetes, 54, 1559-1565 . 
Kravitz, A. V., Freeze, B. S. , Parker, P. R. , Kay, K. , Thwin, M. T. , Deisseroth, K. , 
Kreitzer, A. C. (2010). Regulation of parkinsonian motor behaviours by 
optogenetic control of basal ganglia circuitry. Nature, 466, 622-626. 
Krebiehl, G. , Ruckerbauer, S., Burbulla, L. F. , Kieper, N. , Maurer, B. , Waak, J., 
Wolburg, H., Gizatullina, Z., Gellerich, F. N. , Woitalla, D. , Riess, O. , Kahle, P. 1., 
Proikas-Cezanne, T. , Krüger, R. (2010). Reduced basal autophagy and impaired 
mitochondrial dynamics due to loss of Parkinson's disease-associated protein DJ-l. 
PLoS One, 5, e9367. 
Kudin, A. P. , Bimpong-Buta, N. Y. , Vielhaber, S. , Eiger, C. E. , Kunz, W. S. (2004). 
Characterization of superoxide-producing sites in isolated brain mitochondria. 
J Bio. Chem. , 279, 4127-4135 . 
Kumawat, K. L. , Kaushik, D.K. , Goswami, P ., Basu, A. (2014). Acute exposure to lead 
acetate activates microglia and induces subsequent bystander neuronal death via 
caspase-3 activation. Neurotoxicology, 41, 143-153. 
Kundu, M. (2011). ULK1 , mammalian target of rapamycin, and mitochondria: linking 
nutrient availability and autophagy. Antioxid. Redox. Signa!. , 14, 1953-1958. 
Kumik-Lucka, M., Panula, P. , Bugajski , A. , Gil, K. (2018). Salsolinol: an Unintelligible 
and Double-Faced Molecule-Lessons Leamed from In Vivo and In Vitro 
Experiments. Neurotox. Res., 33, 485-514. 
Kurz, A. , Rabbani, N. , Walter, M. , Bonin, M. , Thomalley, P. , Auburger, G., Gispert, S. 
(2011). a-Synuclein deficiency leads to increased glyoxalase 1 expression and 
glycation stress. Cel!. Mol. Life Sci., 68, 721-733 . 
Kuschinsky, K. , Homykiewicz, O. (1972). Morphine catalepsy in the rat. Relation to 
striatal dopamine metabolism. Eur. J Pharmaco!. , 19, 119-122. 
Kussmaul, L. , Hamprecht, B. , Dringen, R. (1999). The detoxification of 
cumene hydroperoxide by the glutathione system of cultured astroglial cells hinges 
on hexose availability for the regeneration of NADPH. J Neurochem., 73, 
1246-1253. 
330 
Kwok, R. P., Juorio, A. V. (1986). Concentration of striatal tyramine and dopamine 
metabolism in diabetic rats and effect of insulin administration. 
Neuroendocrinology, 43, 590-596. 
Kwok, R. P., Walls, E. K., Juorio, A. V. (1985). The concentration of dopamine, 
5-hydroxytryptamine, and sorne of their acid metabolites in the brain of genetically 
diabetic rats. Neurochem. Res., 10, 611-616. 
Kwong, L. K. , Sohal, R. S. (1998). Substrate and site specificity of hydrogen peroxide 
generation in mouse mitochondria. Arch. Biochem. Biophys., 350, 118-126. 
Lackovié, Z., Salkovié, M., Kuci, Z. , Relja, M. (1990). Effect of long-lasting diabetes 
mellitus on rat and hum an brain monoamines. J Neurochem. , 54, 143-147. 
Lamichhane, B., Adhikari, B. M., Brosnan, S. F., Dhamala, M. (2014). The neural basis 
ofperceived unfaimess in economic exchanges. Brain Connect., 4, 619-630. 
Lamuela-Ravent6s, R. M., de la Torre-Boronat, M. C. (1999). BeneficiaI effects of white 
wines. Drugs Exp. Clin. Res., 25, 121-124. 
Lan, F., Cacicedo, J. M., Ruderman, N., Ido, Y. (2008). SIRT1 modulation of the 
acetylation status, cytosolic localization, and activity of LKBl. Possible role in 
AMP activated prote in kinase activation. J Biol. Chem. , 283, 27628-27635. 
Lanciego, J. L., Luquin, N. , Obeso, J. A. (2012). Functionai neuroanatomy of the basal 
ganglia. Cold Spring Harb. Perspect. Med., 2, a009621. 
Landau, W. M. , Freygang, W. H. Jr., Roland, L. P., Sokoloff, L., Kety, S. S. (1955). 
The local circulation of the living brain; values in the unanesthetized and 
anesthetized cat. Trans. Am. Neurol. Assoc., 80th Meeting, 125-129. 
Lang, A. E. (2010). Clinical trials of disease-modifying therapies for neurodegenerative 
diseases: the challenges and the future. Nat. Med., 16, 1223-1226. 
Lang, A. E., Houeto, J. L., Krack, P. , Kubu, C., Lyons, K. E. , Moro, E. , Ondo, W., 
Pahwa, R., Poewe, W., Troster, A. L, Uitti, R., Voon, V. (2006). Deep brain 
stimulation: preoperative issues. Mov. Disord., 21, 171-196. 
Lang, A. E., Obeso, J. A. (2004). Time to move beyond nigrostriatal dopamine 
deficiency in Parkinson's disease. Ann. Neurol., 55, 761-765. 
Langcake, P., Pryce, R. (1977). A new c1ass of phytoalexins from grapevmes. 
Experentia, 33, 1151-1152. 
331 
Langston, J. W., Ballard, P. , Tetrud, 1. , Irwin, 1. (1983). Chronic Parkinsonism in 
humans due to a product of meperidine-analog synthesis. Science, 219, 979-980. 
Langston, J. W. , Forno, L. S., Tetrud, J. , Reeves, A. G. , Kaplan, 1. A. , Karluk, D. 
(1999). Evidence of active nerve cell degeneration in the substantia nigra of 
humans years after I-methyl-4-phenyl-l,2,3,6-tetrahydropyridine exposure. 
Ann. Neurol. , 46, 598-605. 
Lau, C. G. , Tang, W. K. , Liu, X. x., Liang, H.1. , Liang, Y., Wong, A. , Mok, V., 
Ungvari, G. S. , Wong, K. S. , Kim, J. S., Paradiso, S. (2017) . Poststroke agitation 
and aggression and social quality of life: a case control study. Top. Stroke 
Rehabil. , 24, 126-133. 
Laughlin, S. B. , Attwell, D. (2001). The metabolic cost of neural information: from 
fly eye to marnrnalian cortex. In Frackowiak, R. S. J. , Magistretti, P. J. , 
Shulman, R. G., Altman, J. S. , Adams, M. (eds), Neuroenergetics: relevance for 
functional brain imaging. HFSP - Worshop XI, Strasbourg, pp. 54-64. 
Lawson, L. J. , Perry, V. H., Dri, P., Gordon, S. (1990). Heterogeneity in the distribution 
and morphology of microglia in the normal adult mouse brain. Neuroscience. , 39, 
151-170. 
Lecomte, S., Lelong, M. , Bourgine, G. , Efstathiou, T., Saligaut, C., Pakdel, F. (2017). 
Assessment of the potential activity of major dietary compounds as selective 
estrogen receptormodulators in two distinct cell models for proliferation and 
differentiation. Toxicol. Appl. Pharmacol. , 325, 61-70. 
Lee, A. Y. , Chung, S. S. (1999). Contributions of polyol pathway to oxidative stress in 
diabetic cataract. FASEB J , 13, 23-30. 
Lee, J. G. , Yon, 1. M. , Lin, c., Jung, A. Y. , Jung, K. Y. , Nam, S. y. (2012). Combined 
treatment with capsaicin and resveratrol enhances neuroprotection against 
glutamate-induced toxicity in mouse cerebral cortical neurons. Food Chem. 
Toxicol., 50, 3877-3885. 
Lee, J., Giordano, S. , Zhang, 1. (2012). Autophagy, mitochondria and oxidative stress: 
cross-talk and redox signalling. Biochem. J , 441, 523-540. 
Lee, 1. H. , Jeong, M. W. , Kim, W. , Choi , Y. H. , Kim, K. T. (2008). Cooperative roles of 
c-Abl and Cdk5 in regulation of p53 in response to oxidative stress. J Biol. Chem., 
283, 19826-19835. 
332 
Lee, J. H., Kim, H. S., Lee, S. 1., Kim, K. T. (2007). Stabilization and activation of 
p53 induced by Cdk5 contributes to neuronal cell death. J Cell. Sci, 120, 
2259-2271. 
Lee, V., Trojanowski, J. Q., Schlaepfer, W. W. (1982). Induction ofneurofilament triplet 
proteins in PC12 cells by nerve growth factor. Brain Res., 238, 169-180. 
Lehninger, A. L., Nelson, D. L., Cox, M. M. (1995). Principles of Biochemistry. 
Worth Publishers Inc., New York. 
Leino, R. L., Gerhart, D. Z., van Bueren, A. M., McCall, A. L., Drewes, L. R. (1997). 
Ultrastructural localization of GLUT 1 and GLUT 3 glucose transporters in rat 
brain. J Neurosci. Res., 49, 617-626. 
Lenzi, G. L., Jones, T., Reid, J. L., Moss, S. (1979). Regional impairment of cerebral 
oxidative metabolism in Parkinson's disease. J Neurol. Neurosurg. Psychiatry, 42, 
59-62. 
Leonard, S. S., Xia. C., Jiang, B. H., Stinefelt, B., Klandorf, H., Harris, G. K., Shi, X. 
(2003). Resveratrol scavenges reactive oxygen species and effects radical-induced 
cellular responses. Biochem. Biophys. Res. Commun., 309, 1017-1026. 
LeRoith, D., Lowe, W. L. Jr, Shemer, 1., Raizada, M. K., Ota, A. (1988). Development 
ofbrain insulin receptors. Int. J Biochem., 20, 225-230. 
Levine, K. B., Cloherty, E. K., Fidyk, N. J., Carruthers, A. (1998). Structural and 
physiologic determinants of human erythrocyte sugar transport regulation by 
adenosine triphosphate. Biochemistry, 37, 12221-12232. 
Levy, F. (1991). The dopamine theory of attention deficit hyperactivity disorder 
(ADHD). Aust. NZ J Psychiatry, 25, 277-283. 
Levy, F. (2004). Synaptic gating and ADHD: a biological theory of comorbidity of 
ADHD and anxiety. Neuropsychopharmacology, 29, 1589-1596. 
LeWitt, P. A., Fahn, S. (2016). Levodopa therapy for Parkinson disease: a look 
backward and forward. Neurology, 86, 3-12. 
Lewy, F. H. (1912). Paralysis agitans. 1. Pathologische Anatomy. In Lewandowsky, M., 
(ed), Handbuch der Neurologie, Vol. III, spez Neurol II. Berlin: Springer; 
pp. 920-933. 
333 
Li, D. W., Li, G. R., Zhang, B. L. , Feng, J. 1. , Zhao, H. (2016) . Damage to dopaminergic 
neurons is mediated by proliferating cel! nuclear antigen through the p53 pathway 
under conditions of oxidative stress in a cel! model of Parkinson's disease. Int. J 
Mol. Med. , 3 7, 429-435 . 
Li , H. M. , Niki , T. , Taira, T. , 19uchi-Ariga, S. M. , Ariga, H. (2005) . Association of 
DJ-l with chaperones and enhanced association and colocalization with 
mitochondrial Hsp70 by oxidative stress. Free Radic. Res., 39, 1091-1099. 
Li, J.-Y., Englund, E., Holton, J . L. , Soulet, D. , Hagel!, P. , Lees, A. J. , Lashley, T. , 
Quinn, N. P. , Rehncrona, S., Bj6rklund, A., Widner, H. , Revesz, T. , Lindvall, O. , 
Brundin, P. (2008). Lewy bodies in grafted neurons in subjects with Parkinson ' s 
disease suggest host-to-graft disease propagation. Nat. Med. , 14, 501-503 . 
Li, R. , Jen, N ., Yu, F. , Hsiai, T. K. (2011). Assessing Mitochondrial Redox Status by 
Flow Cytometric Methods: Vascular Response to Fluid Shear Stress. Curr. Protoc. 
Cytom., Chapter 9: Unit 9.3 7. 
Li, W. , Prakash, R. , Kelly-Cobbs, A. L, Ogbi, S. , Kozak, A. , EI-Remessy, A. B. , 
Schreihofer, D. A. , Fagan, S. C., Ergul, A. (2010). Adaptive cerebral 
neovascularization in a model of Type 2 diabetes : Relevance to focal cerebral 
ischemia. Diabetes, 59, 228-235. 
Li, W. , Wu, S. , Ahmad, M. , Jiang, J. , Liu, H. , Nagayama, T. , Rose, M. E. , Tyurin, V. A., 
Tyurina, Y. Y. , Borisenko, G. G., Belikova, N. , Chen, J. , Kagan, V. E. , 
Graham, S. H. (2010) . The cyclooxygenase site, but not the peroxidase site of 
cyclooxygenase-2 is required for neurotoxicity in hypoxic and ischemic injury. 
J Neurochem., 113, 965-977. 
Li, X. J., Li, S. (2011). Proteasomal dysfunction ln aging and Huntington disease. 
Neurobiol. Dis., 43, 4-8. 
Li, Y. , Liu, W. , 00, T. F., Wang, L. , Tang, Y. , Jackson-Lewis, V., Zhou, C., 
Geghman, L. , Bogdanov, M. , przedborski, S. , BeaI, M . F., Burke, R. E. , Li, C. 
(2009) . Mutant LRRK2(RI441G) BAC transgenic mice recapitulate cardinal 
features ofParkinson's disease. Nat. Neurosci. , 12, 826-828. 
Li, Z. S. , Pham, T. D. , Tamir, H. , Chen, J. 1. , Gershon, M . D. (2004). Enteric 
dopaminergic neurons: definition, developmental lineage, and effects of extrinsic 
denervation. J Neurosci., 24, 1330-1339. 
334 
Li, Z. S. , Schmauss, c., Cuenca, A., Ratcliffe, E., Gershon, M. D. (2006). Physiological 
modulation of intestinal motility by enteric dopaminergic neurons and the 
D2receptor: analysis of dopamine receptor expression, location, development, and 
function in wild-type and knock-out mice. J Neurosei., 26, 2798-2807. 
Liang, C. L. , Nelson, O., Yazdani, U., Pasbakhsh, P. , German, D. C. (2004) . Inverse 
relationship between the contents of neuromelanin pigment and the vesicular 
mono amine transporter-2: human midbrain dopamine neurons. J Comp. Neurol., 
473, 97-106. 
Liang, C. L., Sinton, C. M., Sonsalla, P. K, German, D. C. (1996). Midbrain 
dopaminergic neurons in the mouse that contain calbindin-D28k exhibit 
reduced vulnerability to MPTP-induced neurodegeneration. Neurodegeneration, 5, 
313-318. 
Liddelow, S. A. , Guttenplan, K A., Clarke, L. E., Bennett, F. C., Bohlen, C. 1., 
Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W. S., Peterson, T. C., Wilton, 
D. K , Frouin, A., Napier, B. A., Panicker, N., Kumar, M., Buckwalter, M. S., 
Rowitch, D. H. , Dawson, V. L. , Dawson, T. M., Stevens, B., Barres, B. A. (2017). 
Neurotoxic reactive astrocytes are induced by activated microglia. Nature, 541, 
481-487. 
Lim, D. K, Lee, K M., Ho, 1. K (1994). Changes in the central dopaminergic systems 
in the streptozotocin-induced diabetic rats. Arch. Pharm. Res., 17, 398-404. 
Lin, T. K, Chen, S. D., Chuang, y. C., Lin, H. Y., Huang, C. R., Chuang, J. H., 
Wang, P . W., Huang, S. T., Tiao, M. M. , Chen. 1. B., Liou. C. W. (2014). 
Resveratrol partially prevents rotenone-induced neurotoxicity in dopaminergic 
SH-SY5Y cells through induction of he me oxygenase-1 dependent autophagy. 
Int. J Mol. Sci., 15, 1625-1646. 
Linnane. A. W., Kovalenko, S., Gingold, E. B. (1998). The universality of bioenergetic 
disease. Age-associated cellular bioenergetic de gradation and amelioration 
therapy. Ann. N Y Acad. Sei., 854, 202-213. 
Lipman, 1. J. , Boykin, M. E., Flora, R. E. (1974). Glucose intolerance in Parkinson 's 
disease. J Chronic. Dis., 27, 573-579. 
Lisman, J. E., Grace, A. A. (2005). The hippocampal-VTA loop: controlling the entry of 
information into long-term memory. Neuron, 46, 703-713. 
Liu, C., Shi, Z. , Fan, L., Zhang, C., Wang, K, Wang, B. (2011). Resveratrol improves 
neuron protection and functional recovery in rat model of spinal cord injury. 
Brain Res. , 1374, 100-109. 
335 
Liu, D. , Xu, Y. (2011) . p53 , oxidative stress, and aging. Antioxid. Redox Signa!. , 15, 
1669-1678. 
Liu, F. T., Chen, Y , Yang, Y. 1. , Yang, L. , Yu, M. , Zhao, J. , Wu, J. 1., Huang, F. , 
Liu, W. , Ding, Z. T. , Wang, J. (2015). Involvement ofmortalin/GRP75/mthsp70 in 
the mitochondrial impairments induced by A53T mutant a-synuc1ein. Brain Res., 
1604, 52-61. 
Liu, M. H., Yuan, C., He, J. , Tan, T. P., Wu, S. J. , Fu, H. Y , Liu, J. , Yu, S., Chen, Y D., 
Le Q. F. , Tian, W. , Hu, H. J. , Zhang, Y., Lin, X. L. (2015) . Resveratrol protects 
PC12 cells from high glucose-induced neurotoxicity via PI3KJAkt/Fox03a 
pathway. Cel!. Mo!. Neurobiol., 35, 513-522. 
Liu, X. , Xie, J. , Liu, Z., Gong, Q., Tian, R., Su, G. (2016). Identification and validation 
of reference genes for quantitative RT -PCR analysis of retinal pigment epithelium 
cells under hypoxia and/or hyperglycemia. Gene, 580, 41-46. 
Liu, Y. , Fiskum, G. , Schubert, D . (2002). Generation of reactive oxygen species by the 
mitochondrial electron transport chain. J Neurochem., 80, 780-787 . 
Liu, Y , Kulesz-Martin, M. (2000). P53 regulation and function in normal cells and 
turnors. Medicina (B Aires), 60, 9-11 . 
Liu, Y. , Schweitzer, E. S., Nirenberg, M. 1. , Pickel, V. M. , Evans, C. 1., Edwards, R. H. 
(1994). Preferential localization of a vesicular monoamine transporter to dense 
core vesic1es in PC12cells. J Cell. Biol., 12 7, 1419-1433. 
Lofrumento, D. D. , Nicolardi, G., Cianciulli, A., De Nuccio, F., La Pesa, V. , 
Carofiglio, V ., Dragone, T. , Calvello, R., Panaro, M. A. (2014). Neuroprotective 
effects of resveratrol in an MPTP mouse model of Parkinson 's-like disease: 
possible role of SOCS-l in reducing proinflammatory responses. Innate Immun. , 
20, 249-260. 
Londono, C. , Osorio, C., Gama, v., Alzate, O. (2012). Mortalin, apoptosis, and 
neurodegeneration. Biomolecules, 2, 143-164. 
Lopez Vicchi, F. , Luque, G. M. , Brie, B. , Nogueira, J. P. , Garcia Tornadu, L, 
Becu-Villalobos, D. (2016). Dopaminergic drugs in type 2 diabetes and glucose 
homeostasis. Pharmacol. Res., 109, 74-80. 
Lopuch, S., Popik, P. (2011). Cooperative behavior of laboratory rats (Rattus 
norvegicus) in an instrumental task. J Comp. Psychol., 125, 250-253 . 
336 
Lotia, M., Jankovic, J. (2016). New and emerging medical therapies in Parkinson 's 
disease. Expert Opin. Pharmacother. , 1 7, 895-909. 
Lovre, D., Fonseca, V. (2015). Benefits of timely basal insulin control in patients with 
type 2 diabetes. J Diabetes Complications, 29, 295-301 . 
Lowe, A. G., Walmsley, A. R. (1986). The kinetics of glucose transport in human red 
blood cells. Biochim Biophys. Acta, 85 7, 146-54. 
Lowry, J. P. , Demestre, M., Fillenz, M. (1998c). Relation between cerebral blood flow 
and extracellular glucose in rat striatum during mild hypoxia and hyperoxia. 
Dev. Neurosci., 20, 52-58. 
Lowry, J. P. , Miele, M. , O'Neill, R. D. , Boutelle, M. G., Fillenz, M. (l998b). 
An amperometric glucose-oxidase/poly( o-phenylenediamine) biosensor for 
monitoring brain extracellular glucose: in vivo characterisation in the striatum 
offreely-moving rats. J Neurosci. Methods, 79,65-74. 
Lowry, J. P., O'Neill, R. D., Boutelle, M. G. , Fillenz, M. (l998a) . Continuous 
monitoring of extracellular glucose concentrations in the striatum of freely moving 
rats with an implanted glucose biosensor. J Neurochem., 70, 391-396. 
Lowry, O. H., Passonneau, J. V. (1964). The relationship between substrates and 
enzymes of glycolysis in brain. J Biol. Chem., 239, 31-42. 
Lozano, A. M., Lipsman, N. (2013). Probing and regulating dysfunctional circuits using 
deep brain stimulation. Neuron, 77, 406-424. 
Lu, K. T., Ko, M. C. , Chen, B. Y , Huang, J. C., Hsieh, C. W., Lee, M. C., Chiou, R. Y , 
Wing, B. S. , Peng, C. H. , Yang, Y L. (2008). Neuroprotective effects of 
resveratrol on MPTP-induced neuron loss mediated by free radical scavenging. 
J Agric. Food Chem., 56, 6910-6913. 
Lu, Q. , Ma, Y., Xu, Y S., Jiang, Y R. (2014). Apelin in epiretinal membranes of 
patients with proliferative diabetic retinopathy. Mol. Vis., 20, 1122-113l. 
Lu, R. , Serrero, G. (1999). Resveratrol, a natural product derived from grape, exhibits 
antiestrogenic activity and inhibits the growth of hum an breast cancer cells. 
J Cel!. Physiol., 179, 297-304. 
Lu, x., Xu, H. , Sun, B., Zhu, Z. , Zheng, D., Li, X. (2013). Enhanced neuroprotective 
effects of resveratrol delivered by nanoparticles on hydrogen peroxide-induced 
oxidative stress in rat cortical ceIl culture. Mol. Pharm., 10, 2045-2053. 
337 
Luk, K. C. , Kehm, V. , Carroll, J. , Zhang, B. , O'Brien, P., Trojanowski, J. Q., Lee, V. M. 
(2012). Pathological alpha-synuc1ein transmission initiates parkinson-like 
neurodegeneration in nontransgenic mice. Science, 338, 949-953. 
Lunet, N. , Lacerda-Vieira, A. , Barros, H. (2005). Fruit and vegetables consumption and 
gastric cancer: a systematic review and meta-analysis of cohort studies. 
Nutr. Cancer, 53, 1-10. 
Lynd-Balta, E. , Haber, S. N. (1994). The organization of midbrain projections to the 
striatum in the primate: Sensorimotor-related striatum versus ventral striatum. 
Neuroscience, 59, 625-640. 
Lyoo, 1. K. , Yoon, S., Renshaw, P. F., Hwang, J., Bae, S., Musen, G. , Kim, J. E., 
Bolo, N. , Jeong, H. S. , Simonson, D. C. , Lee, S. H. , Weinger, K. , Jung, J. 1., 
Ryan, C. M. , Choi, Y. , Jacobson, A. M. (2013). Network-level structural 
abnormalities of cerebral cortex in type 1 diabetes mellitus. PLoS One, 8, e7l304. 
Ma, C. Y. , Yao, M. J., Zhai, Q. W., Jiao, J. W., Yuan, X. B. , Poo, M. M. (2014). SIRTI 
suppresses self-renewal of adult hippocampal neural stem cells. Development, 141, 
4697-4709. 
Ma, S. Y. , Roytt, M. , Collan, Y. , Rinne, 1. O. (1999). Unbiased morphometrical 
measurements show loss of pigmented nigral neurones with ageing. Neuropathol. 
Appl. Neurobiol. , 25, 394-399. 
Macauley, S. L., Stanley, M., Caesar, E. E. , Yamada, S. A. , Raichle M. E., Perez, R. , 
Mahan, T. E. , Sutphen, C. L. , Holtzman, D. M. (2015). Hyperglycemia modulates 
extracellular amyloid-~ concentrations and neuronal activity in vivo. J Clin. 
In vest., 125, 2463-2467. 
Machler, P. , Wyss, M. T., Elsayed, M. , Stobart, 1. , Gutierrez, R. , von Faber-Castell, A. , 
Kaelin, V., Zuend, M. , San Martin, A. , Romero-Gomez, L, Baeza-Lehnert, F. , 
Lengacher, S. , Schneider, B. L. , Aebischer, P., Magistretti, P. J. , Barros, L. F., 
Weber, B. (2016). In Vivo Evidence for a Lactate Gradient from Astrocytes to 
Neurons. CeU. Metab., 23, 94-102. 
Macip, S. , Igarashi, M., Berggren, P. , Yu, J. , Lee, S. W. , Aaronson, S. A. (2003). 
Influence of Induced Reactive Oxygen Species in p53-Mediated Cell Fate 
Decision. Mol. CeU. Biol. , 23, 8576-8585. 
Macpherson, T., Morita, M. , Hikida, T. (2014) . Striatal direct and indirect pathways 
control decision-making behavior. Front. Psycho/. 5, 1301. 
338 
Madsen-Bouterse, S., Mohammad, G., Kowluru, R. A. (2010) . Glyceraldehyde-3-
phosphate dehydrogenase in retinal microvasculature: implications for the 
development and progression of diabetic retinopathy. In vest. Ophthalmol. Vis. 
Sei., 51, 1765-1772. 
Magistretti, P. 1., Allaman, 1. (2015) . A cellular perspective on brain energy metabolism 
and functional imaging. Neuron, 86, 883-901. 
Magnard, R., Vachez, Y., Carcenac, C., Krack, P. , David, O. , Savasta, M. , Boulet, S., 
Camicella, S. (2016). What can rodent models tell us about apathy and associated 
neuropsychiatric symptoms in Parkinson's disease? Transi. Psychiatry, 6:e753. 
Maher, F., Davies-Hill, T. M., Lysko, P. G., Henneberry, R. C. , Simpson, 1. A. (1991) . 
Expression of two glucose transporters, GLUTI and GLUT3, in cultured 
cerebellar neurons: Evidence for neuron-specific expression of GLUT3. Mol. Cell. 
Neurosco. , 2, 351-360. 
Maher, F., Davies-Hill, T. M., Simpson, 1. A. (1996). Substrate specificity and kinetic 
parameters of GLUT3 in rat cerebellar granule neurons. Biochem. J, 315, 
827-831. 
Maher, F., Simpson, 1. A. (1994). Modulation of expression of glucose transporters 
GLUT3 and GLUT1 . by potassium and N-methyl-D-aspartate in cultured 
cerebellar granule neurons . Mol. CeU. Neurosei. , 5, 369-375. 
Maher, F., Vannucci, S. J., Simpson, 1. A. (1994). Glucose transporter proteins in brain. 
FASEB J, 8, 1003-1011. 
Maher, F., Vannucci, S., Takeda, J., Simpson, 1. A. (1992). Expression of 
mouse-GLUT3 and human-GLUT3 glucose transporter proteins in brain. Biochem. 
Biophys. Res. Commun., 182, 703-711. 
Maher, P., Dargusch, R., Bodai, L., Gerard, P. E., Purcell, J. M., Marsh, J. L. (2011). 
ERK activation by the polyphenols fisetin and resveratrol provides 
neuroprotection in multiple models of Huntington's disease. Hum. Mol. Genet. , 
20,261 -270. 
Maiese, K. (2016). Targeting molecules to medicine with mTOR, autophagy and 
neurodegenerative disorders. Br. J Clin. Pharmacol., 82, 1245-1266. 
Maiese, K., Morhan, S. D., Chong, Z. Z. (2007). Oxidative stress biology and cell injury 
during type 1 and type 2 diabetes mellitus. Curr. Neurovasc. Res., 4, 63-71. 
339 
Makhija, D. T., Jagtap, A. G. Studies on sensitivity of zebrafish as a model organism for 
Parkinson's disease: Comparison with rat model. J Pharmacol. Pharmacother. , 
5,39-46. 
Mammucari, C., Rizzuto, R. (2010). Signaling pathways in mitochondrial dysfunction 
and aging. Mech. Ageing. Dev., 131, 536-543. 
Mander, P. K. , Jekabsone, A. , Brown, G. C. (2006). Microglia proliferation is regulated 
by hydrogen peroxide from NADPH oxidase. J lmmunol., 176, 1046-1052. 
Mangia, S. , DiNuzzo, M. , Giove, F., Carruthers, A. , Simpson, 1. A. , Vannucci, S. J. 
(2011). Response to 'comment on recent modeling studies of astrocyte-neuron 
metabolic interactions': much ado about nothing. J Cereb. Blood Flow Metab., 31, 
1346-1353. 
Mangia, S. , Simpson, 1. A., Vannucci, S. J. , Carruthers, A. (2009). The in vivo neuron-
to-astrocyte lactate shuttle in human brain: evidence from modeling of measured 
lactate levels during visual stimulation. J Neurochem., 109, 55-62. 
Manolescu, A. R., Augustin, R. , Moley, K. , Cheeseman, C. (2007) . A highly conserved 
hydrophobic motif in the exofacial vestibule of fructose transporting SLC2A 
proteins acts as a critical determinant of their substrate selectivity. Mol. Membr. 
Biol. , 24, 455-463. 
Manolopoulos, K. N., Klotz, L. O., Korsten, P. , Bornstein, S. R., Barthel, A. (2010). 
Linking Alzheimer's disease to insu lin resistance: the FoxO response to oxidative 
stress, Mol. Psychiatry, 15, 1046-1052. 
Mantych, G. J. , James, D. E. , Chung, H. D. , Devaskar, S. U. (1992). Cellular 
localization and characterization of Glut 3 glucose transporter isoform in human 
brain. Endocrinology, 131, 1270-1278. 
Manyam, B. V., Sanchez-Ramos, J. R. (1999). Traditional and complementary therapies 
in Parkinson ' s disease. Adv. Neurol. , 80, 565-574. 
Marchese, M. , Leinung, M., Shawa, H. (2017) . Drug-induced hypersensitivity reaction: 
A case of simultaneous thyroiditis and fulminant type 1 diabetes. Avicenna J 
Med. , 7, 67-70. 
Margolis, R. U., Altszuler, N. (1967). Insulin m the cerebrospinal fluid. Nature, 
215, 1375-1376. 
340 
Marklund, P., Larsson, A., Elgh, E., Linder, 1., Riklund, K. A., Forsgren, L., Nyberg, L. 
(2009). Temporal dynamics of basal ganglia under-recruitment in Parkinson's 
disease: transient caudate abnormalities during updating of working memory. 
Brain, 132, 336-346. 
Marras, C. , Chaudhuri, K. R. (2016). Nonmotor features of Parkinson's disease 
subtypes. Mov. Disord., 31, 1095-1102. 
Marras, C., Lang, A. (2008). Invited Article: Changing concepts in Parkinson disease-
moving beyond the decade of the brain. Neurology, 70, 1996-2003. 
Marsden, C. D. (1983). Neuromelanin and Parkinson's disease. J Neural Transm. 
Suppl. , 19, 121-141. 
Martin, W. R. W., Wieler, M. , Gee, M. (2008). Midbrain iron content in early Parkinson 
disease: A potential biomarker of disease status. Neurology, 70, 1411-1417. 
Maruyama, W. , Abe, T., Tohgi, H., Naoi, M. (1999) . An endogenous MPTP-like 
dopaminergic neurotoxin, N-methyl(R)salsolinol, in the cerebrospinal fluid 
decreases with progression of Parkinson's disease. Neurosci. LeU., 262, 13-16. 
Masala, G. , Assedi, M., Bendinelli, B. , Ermini, L, Sieri, S., Grioni, S., Sacerdote, C., 
Ricceri, F., Panico, S. , Mattiello, A., Tumino, R. , Giurdanella, M. C., Berrino, F., 
Saieva, C. , Palli, D. (2012). Fruit and vegetables consumption and breast cancer 
risk: the EPIC Italy study. Breast Cancer Res. Treat., 132, 1127-1136. 
Masiello, P. , Broca, c., Gross, R. , Roye, M., Manteghetti, M. , Hillaire-Buys, D., 
Novelli, M. , Ribes, G. (1998). Experimental NIDDM: development of a new 
model in adult rats administered streptozotocin and nicotinamide. Diabetes, 
147, 224-229. 
Mathiisen, T. M., Lehre, K. P. , Danbolt, N. C. , Ottersen, O. P. (2010). The perivascular 
astroglial sheath provides a complete covering of the brain microvessels: 
an electron microscopie 3D reconstruction. Glia, 58, 1094-1103. 
Matkovics, B. , Varga, S. L, Szab6, L. , Witas, H. (1982). The effect of diabetes on the 
activities of the peroxide metabolism enzymes. Horm. Metab. Res., 14, 77-79. 
Matsuda, W., Furuta, T., Nakamura, K. C. , Hioki, H., Fujiyama, F., Arai, R. , Kaneko, T. 
(2009) . Single nigrostriatal dopaminergic neurons form widely spread and highly 
dense axonal arborizations in the neostriatum. J Neurosci., 29, 444-453. 
341 
Mazzeo, A., Arroba, A. L, Beltramo, E., Valverde, A. M., Porta, M. (2017). 
Somatostatin protects human retinal pericytes from inflammation mediated by 
microglia. Exp. Eye Res., 164, 46-54. 
McCall, A. L. (1992). The impact of diabetes on the CNS. Diabetes, 41, 557-570. 
McCall, A. L. , Fixman, L. B. , Fleming, N. , Tornheim, K., Chick, W. , Ruderman, N. B. 
(1986). Chronic hypoglycemia increases brain glucose transport. Am. J Physiol. , 
251, 442-447. 
McCann, H. , Cartwright, H. , Halliday, G. M. (2015). Neuropathology of a-synuc1ein 
propagation and braak hypothesis. Mov. Disord. , 31, 152-160. 
McClory, H. , Williams, D. , Sapp, E. , Gatune, L. W., Wang, P. , DiFiglia, M. , Li, X. 
(2014). Glucose transporter 3 is a rab II-dependent trafficking cargo and its 
transport to the cell surface is reduced in neurons of CAG 140 Huntington's disease 
mice. Acta Neuropathol. Commun. , 2, 179. 
McCrimmon, R. J. , Jacob, R. J., Fan, x., McNay, E. C. , Sherwin, R. S. (2003). Effects 
of recurrent antecedent hypoglycaemia and chronic hyperglycaemia on brainstem 
extra-cellular glucose concentrations during acute hypoglycaemia in conscious 
diabetic BB rats. Diabetologia, 46, 1658-1661. 
McElvain, J. S. , Schenk, J. O. (1992) . A multisubstrate mechanism of striatal dopamine 
uptake and its inhibition by cocaine. Bioehem. Pharmaeol., 43, 2189-2199. 
McGeer, P. L. , Itagaki, S. , Boyes, B. E. , McGeer, E. (1988). Reactive microglia are 
positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's 
disease brains. Neurology, 38, 1285-1291. 
McMahon, R. J. , Frost, S. C. (1995). Nutrient control of GLUTI processmg and 
turnover in 3T3-Ll adipocytes. J Biol. Chem., 270, 12094-12099. 
McNay, E. C. , Fries, T. M. , Gold, P. E. (2000). Decreases in rat extracellular 
hippocampal glucose concentration associated with cognitive demand during a 
spatial task. Proe. Natl. Aead. Sei. U.S. A., 9 7, 2881-2885. . 
McNay, E. C. , Gold, P. E. (2001a). Age-related differences in hippocampal extracellular 
fluid glucose concentration during behavioral testing and following systemic 
glucose administration. J Gerontol. A Biol. Sei. Med. Sei., 56, 66-71. 
342 
McNay, E. C. , McCarty, R. C., Gold, P. E. (2001b) Fluctuations in brain glucose 
concentration during behavioral testing: dissociations between brain areas and 
between brain and blood. Neurobiol. of Learn. Mem., 75, 325-437. 
McNay, E. c., Sherwin, R. S. (2004). Effect of recurrent hypoglycemia on spatial 
cognition and cognitive metabolism in normal and diabetic rats. Diabetes, 
53, 418-425. 
McNay, E. C., Williamson, A. , McCrimmon, R. J., Sherwin, R. S. (2006). Cognitive and 
neural hippocampal effects of long-term moderate recurrent hypoglycemia. 
Diabetes, 55, 1088-1095. 
Meehan, W. P., Leedom, L. J. , Nagayama, T. , Zeidler, A. (1986). Agonistic behavior 
patterns in mice with streptozotocin-induced diabetes mellitus. Physiol. Behav., 
38, 301-306. 
Mehran, A. E ., Templeman, N . M., Brigidi, G. S., Lim, G. E., Chu, K. Y , Hu, x., 
Botezelli, 1. D., Asadi, A., Hoffman, B. G., Kieffer, T. 1. , Bamji, S. x., 
Clee, S. M., Johnson, J. D. (2012). Hyperinsulinemia drives diet-induced obesity 
independently of brain insulin production. Cell. Metab. , 16, 723-737. 
Membrez, M., Hummler, E., Beermann, F., Haefliger, J. A., Savioz, R. , Pedrazzini, T., 
Thorens, B. (2006). GLUT8 is dispensable for embryonic development but 
influences hippocampal neurogenesis and heart function. Mol. Cell. Biol., 
26, 4268-4276. 
Mendez, M. M., Folgado, J., Tormo, C., Artero, A. , Ascaso, M. , Martinez-Hervas, S. , 
Chaves, F. J. , Ascaso, J. F., Real, J. T. (2015) . Altered glutathione system is 
associated with the presence of distal symmetric peripheral polyneuropathy in 
type 2 diabetic subjects . J Diabetes Complications, 29, 923-927. 
Meng, X. L. , Yang, 1. Y, Chen, G. L., Wang, L. H., Zhang, L. J. , Wang, S. , Li, J ., 
Wu, C. F. (2008). Effects of resveratrol and its derivatives on lipopolysaccharide-
induced microglial activation and their structure-activity relationships. Chem. Biol. 
Interact. , 174, 51-59. 
Menza, M. , Dobkin, R. D., Marin, H. , Mark, M. H., Gara, M., Buyske, S., Bienfait, K. , 
Dicke, A. (2008). A controlled trial of antidepressants in patients with Parkinson 
disease and depression. Neurology, 72, 886-892. 
Meredith, G. E., Kang, U. J. (2006). Behavioral models of Parkinson's disease In 
rodents : a new look at an oid problem. Mov. Disord. , 21, 1595-1606. 
343 
Mertens, B. , Varcin, M., Michotte, Y. , Sarre, S. (2011). The neuroprotective action of 
candesartan is related to interference with the early stages of 6-hydroxydopamine-
induced dopaminergic ceil death. Eur. J Neurosci., 34, 1141-1148. 
Mgbonyebi, O. P. , Russo, J. , Russo, 1. H. (1998). Antiproliferative effect of synthe tic 
resveratrol on human breast epithelial cells. [nt. J Oncol. , 12, 865-869. 
Milber, J. M., Noorigian, J. V. , Morley, J. F. , Petrovitch, H., White, L. , Ross, G. W. , 
Duda, 1. E. (2012). Lewy pathology is not the first sign of degeneration m 
vulnerable neurons in Parkinson disease. Neurology, 79, 2307-2314. 
Miller, N . S., Chou, K. L., Bohnen, N. L, Müller, M. L. T. M., Seidler, R. D. (2017). 
Dopaminergic polymorphisms associated with medication responsiveness of gait 
in Parkinson's disease. Parkinsonism Relat. Disord., pii: S 1353-8020(17)30836-2. 
Misra, A., Bloomgarden, Z. (2018). Metabolic memory: Evolving concepts. J Diabetes, 
10, 186-187. 
Missale, C. , Nash, S. R., Robinson, S. W. , Jaber, M. , Caron, M. G. (1998). Dopamine 
receptors: from structure to function. Physiol. Rev., 78, 189-225 . 
Mittal, R. , Debs, L. H. , Patel, A. P. , Nguyen, D., Pate l, K. , O'Cormor, G., Grati, M. , 
Mittal, J., Yan, D. , Eshraghi, A. A. , Deo, S. K. , Daunert, S., Liu, X. Z. (2017) . 
Neurotransmitters: The Critical Modulators Regulating Gut-Brain Axis. J Cell. 
Physiol. , 232, 2359-2372. 
Mobasheri, A. , Richardson, S. , Mobasheri, R. , Shakibaei, M. , Hoyland, J. A. (2005). 
Hypoxia inducible factor-l and facilitative glucose transporters GLUTI and 
GLUT3: putative molecular components of the oxygen and glucose sens mg 
apparatus in articular chondrocytes. Histol. Histopathol. , 20, 1327-1338. 
Mochizuki, H. , Goto, K. , Mori, H. , Mizuno, Y. (1996). Histochemical detection of 
apoptosis in Parkinson's disease. J Neurol. Sei. , 120-123. 
Mogenson, G. 1. , Jones, D. L. , Yim, C. y. (1980) . From motivation to action: functional 
interface between the limbic system and the motor system. Prog. Neurobiol. , 14, 
69-97. 
Mogi, M ., Kondo, T. , Mizuno, Y. , Nagatsu, T. (2007). p53 protein, interferon-gamma, 
and NF-kappaB levels are elevated in the parkinsonian brain. Neurosci. LeU., 414, 
94-97. 
344 
Mogi, M., Togari, A., Kondo, 1., Mizuno, Y., Komure, O., Kuno, S., Ichinose, H., 
Nagatsu, T. (1999). Brain-derived growth factor and nerve growth factor 
concentrations are decreased in the substantia nigra in Parkinson's disease. 
Neurosci. LeU., 270, 45-48. 
Mogi, M., Togari, A. , Kondo, T., Mizuno, Y., Komure, O., Kuno, S. , Ichinose, H., 
Nagatsu, T. (2000). Caspase activities and tumor necrosis factor receptor RI (P55) 
level are elevated in the substantia nigra from parkinsonian brain. J Neural 
Transm. (Vienna), 107, 335-341. 
Molnar, G., Farag6, N., Kocsis, Â. K, R6zsa, M., Lovas, S., Boldog, E. , Baldi, R. , 
Csajb6k, É., Gardi, J. , Puskas, L. G., Tamas, G. (2014). GABAergic neurogliaform 
cells represent local sources of insulin in the cerebral cortex. J Neurosci., 34, 
1133-1137. 
Monder, C. (1967). Alpha-keto aldehyde dehydrogenase, an enzyme that catalyzes the 
enzymic oxidation ofmethylglyoxal to pyruvate. J Biol. Chem., 242, 4603-4609. 
Monks, T. 1., Hanzlik, R. P., Cohen, G. M., Ross, D., Graham, D. G. (1992). Quinone 
chemistry and toxicity. Toxicol. Appl. Pharmacol., 112, 2-16. 
Montagu, K A. (1957). Catechol compounds in rat tissues and in brains of different 
animais. Nature, 180, 244-245. 
Moran, c., Phan, T. G., Chen, J., Blizzard, L. , Beare, R., Venn, A. , Münch, G. , 
Wood, A. G., Forbes, J., Greenaway, T. M. , Pearson, S., Srikanth, V. (2013). 
Brain atrophy in type 2 diabetes: regional distribution and influence on cognition. 
Diabetes Care, 36, 4036-4042. 
More, S. V., Kumar, H. , Kim, 1. S., Song, S. Y., Choi, D. K (2013). Cellular and 
molecular mediators of neuroinflammation in the pathogenesis of Parkinson's 
disease. Mediators Inflamm. 2013,952375. 
Moreira, P. 1., Rolo, A. P. , Sena, C. , Seiça, R., Oliveira, C. R., Santos, M. S. (2006). 
Insulin attenuates diabetes-related mitochondrial alterations: a comparative study. 
Med. Chem. , 2, 299-308. 
Moreira, P. 1., Santos, M. S., Sena, C., Seiça, R., Oliveira, C. R. (2005). Insulin protects 
against amyloid beta-peptide toxicity in brain mitochondria of diabetic rats. 
Neurobiol. Dis., 18, 628-637. 
Morris, A. A. (2005). Cerebral ketone body metabolism. J lnherit. Metab. Dis., 
28, 109-121. 
345 
Morris, J. K. , Bomhoff, G. L. , Stanford, J. A. , Geiger, P. C. (2010). Neurodegeneration 
in an animal model of Parkinson ' s disease is exacerbated by a high-fat diet. 
Am. J Physiol. Regul. Integr. Comp. Physiol., 299, 1082-1090. 
Mortiboys, H. , Johansen, K. K. , Aasly, 1. O. , Bandmann, O. (2010). Mitochondrial 
impairment in patients with Parkinson disease with the G2019S mutation in 
LRRK2. Neurology, 75, 2017-2020. 
Morton, G. J. , Cummings, D. E. , Baskin, D. G. , Barsh, G. S. , Schwartz, M. W. (2006). 
Central nervous system control of food intake and body weight. Nature, 443, 
289-295. 
Moussa, C., Hebron, M., Huang, X. , Ahn, J ., Rissman, R. A., Aisen, P . S., Turner, R. S. 
(2017). Resveratrol regulates neuro-inflammation and induces adaptive immunity 
in Alzheimer's disease. J Neuroinflammation, 14, 1. 
Mudà, G. , Miikelii, 1. , Di Liberto, V. , Tselykh, T. V. , Olivieri, M. , Piepponen, P. , 
Eriksson, O., Miilkiii, A. , Bonomo, A. , Kairisalo, M. , Aguirre, J. A. , Korhonen, L. , 
Belluardo, N. , Lindholm, D. (2012) Transgenic expression and activation of 
PGC-l a protect dopaminergic neurons in the MPTP mouse model of Parkinson's 
disease. Cell. Mol. Life Sei. , 69, 1153-1165. 
Mueckler, M., Thorens, B. (2013) . The SLC2 (GLUT) family of membrane transporters. 
Mol. Aspects Med. , 34, 121-138. 
Munch, G., Westcott, B. , Menini, T., Gugliucci, A. (2012). Advanced glycation end 
products and their pathogenic roles in neurological disorders. Amino Acids, 42, 
1221-1226. 
Muqbil, 1. , Beck, F. W. , Bao, B. , Sarkar, F. H., Mohammad, R. M., Hadi, S. M. , Azmi , 
A. S. (2012). Old wine in a new bottle: the Warburg effect and anticancer 
mechanisms of resveratrol Curr. Pharm. Des., 18, 1645-1654. 
Murakami , K. , Miyake, Y. , Sasaki, S. , Tanaka, K. , Fukushima, W. , Kiyohara, C., 
Tsuboi, Y. , Yamada, T. , Oeda, T. , Miki, T. , Kawamura, N. , Sakae, N., 
Fukuyama, H. , Hirota, Y. , Nagai, M., Fukuoka Kinki Parkinson's Disease Study 
Group. (2010). Dietary glycemic index is inversely associated with the risk of 
Parkinson's disease: a case-control study in Japan. Nutrition, 26, 515-52l. 
Muranyi, M. , Li, P. A. (2006). Hyperglycemia increases superoxide production in 
the CAl pyramidal neurons after global cerebral ischemia. Neurosei. LeU. , 393, 
119-12l. 
346 
Murias, M., Handler, N., Erker, T., Pleban, K., Ecker, G. , Saiko, P. , Szekeres, T., 
Jager, W. (2004). Resveratrol analogues as selective cyclooxygenase-2 inhibitors: 
synthesis and structure-activity relationship. Bioorg. Med. Chem., 12, 5571-5578. 
Nadeau, K. 1., Anderson, B. J., Berg, E. G., Chiang, J. L., Chou, H., Copeland, K. C., 
Hannon, T. S., Huang, T. T., Lynch, J. L., Powell, J., Sellers, E., Tamborlane, W. 
V. , Zeitler, P. (2016). Youth-Onset Type 2 Diabetes Consensus Report: CUITent 
Status, Challenges, and Priorities. Diabetes Care, 29, 1635-1642. 
Nagamatsu, S. , Sawa, H., Inoue, N., Nakamichi, Y, Takeshima, H. , Hoshino, T. (1994). 
Gene expression of GLUT3 glucose transporter regulated by glucose in vivo in 
mouse brain and in vitro in neuronal cell cultures from rat embryos. Biochem. 
J,300, 125-131. 
Nagamatsu, S., Sawa, H., Kamada, K., Nakamichi, Y , Yoshimoto, K., Hoshino, T. 
(1993). Neuron-specific glucose transporter (NSGT): CNS distribution of GLUT3 
rat glucose transporter (RGT3) in rat central neurons. FEBS LeU., 334, 289-295. 
Nagata, T. , Nakajima, S., Shinagawa, S. , Plitrnan, E. , Nakayama, K. , Graff-GueITero, A., 
Mimura, M. (2017). Baseline Predictors of Antipsychotic Treatrnent Continuation 
and Response at Week 8 in Patients with Alzheimer's Disease with Psychosis or 
Aggressive Symptoms: An Analysis of the CATIE-AD Study. J Alzheimers Dis., 
60, 263-272. 
Nagatsu, T. (1997). Isoquinoline neurotoxins m the brain and Parkinson's disease. 
Neurosci. Res., 29, 99-111. 
Nagayach, A. , Patro, N., Patro, 1. (2014). Astrocytic and microglial response m 
experimentally induced diabetic rat brain. Metab. Brain Dis., 29, 747-61. 
Nair, V. D. (2006). Activation of p53 signaling initiates apoptotic death in a cellular 
model ofParkinson's disease. Apoptosis, 11, 955-966. 
Nakamura, T., Terajima, T., Ogata, T. , Ueno, K., Hashimoto, N., Ono, K., Yano, S. 
(2006). Establishment and pathophysiological characterization of type 2 diabetic 
mouse model produced by streptozotocin and nicotinamide. Biol. Pharm. Bull. , 
29, 1 167 -1 1 74. 
Nalagoni, C. S. R., Kamati, P. R. (2016). Protective effect of resveratrol against 
neuronal damage through oxidative stress in cerebral hemisphere of aluminum and 
fluoride treated rats. Interdiscip. Toxicol., 9, 78-82. 
347 
Naoi, M. , Maruyama, W., Akao, Y. , Yi, H. (2002) . Dopamine-derived endogenous 
N-methyl-(R)-salsolinol: its role in Parkinson's disease. Neurotoxicol. Teratol. , 
24, 579-591. 
Narvaes, R. , Martins de Almeida, R. M. (2014). Aggressive behavior and three 
neurotransmitters: dopamine, GABA, and serotonin- A review of the last 10 years. 
Psychology & Neuroscience, 7, 601-607. 
Nathan, D. M. (1993). Long-term complications of diabetes mellitus. N. Engl. J Med. , 
328, 1676-1685. 
Nathan, D. M. , Cleary, P. A. , Backlund, J. Y., Genuth, S. M. , Lachin, 1. M. , 
Orchard, T. J. , Raskin, P. , Zinrnan, B. Diabetes Control and Complications 
TriallEpidemiology of Diabetes Interventions and Complications (DCCTIEDIC) 
Study Research Group. (2005). Intensive diabetes treatment and cardiovascular 
disease in patients with type 1 diabetes. N. Engl. J Med. , 353, 2643-2653 . 
Nehlig, A. , Wittendorp-Rechenmann, E. , Lam, C. D. (2004). Selective uptake of [14C]2-
deoxyglucose by neurons and astrocytes: high-resolution microautoradiographic 
imaging by cellular 14C-trajectography combined with immunohistochemistry. 
J Cereb. Blood Flow Metab., 24, 1004-1014. 
Neves, A. R. , Lucio, M. , Martins, S. , Lima, 1. L. , Reis, S. (2013) . Novel resveratrol 
nanodelivery systems based on lipid nanopartic1es to enhance its oral 
bioavailability. Int. J Nanomedicine, 8, 177-187. 
Niki, E. (2008). Lipid peroxidation products as oxidative stress biomarkers. Biofactors, 
34, 171-180. 
Nishimura, N., Schaffer, C. B. , Friedman, B. , Lyden, P. D ., Kleinfeld, D. (2007). 
Penetrating arterioles are a bottleneck in the perfusion of neocortex. Proc. Natl. 
Acad. Sci. U.S. A., 104, 365-370. 
Nishikawa, T. , Edelstein, D. , Du, X. L. , Yamagishi, S., Matsurnura, T. , Kaneda, Y. , 
Yorek, M. A. , Beebe, D. , Oates, P. J. , Hammes, H. P ., Giardino, L, Brownlee, M. 
(2000). Normalizing mitochondrial superoxide production blocks three pathways 
ofhyperglycaemic damage. Nature, 404, 787-790. 
Norbury, C. J., Zhivotovsky, B. (2004). DNA damage-induced apoptosis. Oncogene, 23, 
2797-2808. 
Nutt, J. G. (2016). Motor subtype in Parkinson's disease: different disorders or different 
stages ofdisease? Mov. Disord. , 31, 957-961. 
348 
Nwachukwu, J. C., Srinivasan, S., Bruno, N. E., Parent, A. A., Hughes, T. S., 
Pollock, J. A., Gjyshi, O. , Cavett, V., Nowak, 1., Garcia-Ordonez, R. D., 
Houtman, R., Griffin, P. R. , Kojetin, D. J. , Katzenellenbogen, J. A. , Conkright, 
M. D. , Nettles, K W. (2014). Resveratrol modulates the inflammatory response 
via an estrogen receptor-signal integration network. Elife. 3, :e02057. 
O'Dell, L. E., Natividad, L. A., Pipkin, J. A., Roman, F. , Torres, L, Jurado, J., 
Torres, O. V., Friedman, T. C. , Tenayuca, J. M. , Nazarian, A. (2014). Enhanced 
nicotine self-administration and suppressed dopaminergic systems in a rat model 
of diabetes. Addict. Biol. , 19, 1006-1019. 
O 'Donnell, P. (2003). Dopamine gating offorebrain neural ensembles. Eur. J Neurosci. , 
17, 429-435. 
Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E. , Weintraub, D., 
Bum, D., Halliday, G. M., Bezard, E., Przedborski, S., Lehericy, S., Brooks, D. 1., 
Rothwell, J. C., Hallett, M., DeLong, M. R., Marras, C. , Tanner, C. M., 
Ross, G. W., Langston, 1. W., Klein, C., Bonifati, v., Jankovic, J. , Lozano, A. M., 
Deuschl, G., Bergman, H., Tolosa, E., Rodriguez-Violante, M., Fahn, S., Postuma, 
R. B., Berg, D., Marek, K, Standaert, D. G., Surmeier, D. J. , Olanow, C. W., 
Kordower, J. H., Calabresi, P., Schapira, A. H. V., Stoessl, A. J. (2017). 
Past, present, and future of Parkinson's disease: A special essay on the 
200th Anniversary of the Shaking PaIsy. Mov. Disord., 32,1264-1310. 
Obrosova, 1. G., Drel, V. R. , Pacher, P., Ilnytska, O., Wang, Z. Q., Stevens, M. J. , 
Yorek, M. A. (2005). Oxidative-nitrosative stress and poly(ADP-ribose) 
polymerase (P ARP) activation in experimental diabetic neuropathy: the relation is 
revisited. Diabetes, 54, 3435-3441. 
Obrosova, 1. G. , Fathallah, L. , Stevens, M. 1. (2001). Taurine counteracts oxidative 
stress and nerve growth factor deficit in early experimental diabetic neuropathy. 
Exp. Neurol., 172,211-219. 
Obrosova,1. G., Van Huysen, C., Fathallah, L., Cao, X. C., Greene, D. A. , Stevens, M. J. 
(2002). An aldose reductase inhibitor reverses early diabetes-induced changes in 
peripheral nerve function, metabolism, and antioxidative defense. F ASEB J, 16, 
123-125. 
Ogushi, S. , Lawson, J. W. R., Dobson, G. P. , Veech, R. L. , Uyeda, K (1990) . A new 
transient activator of phosphofructokinase during Initiation of rapid glycolysis in 
brain. J Biol. Chem., 265, 10943-10949. 
349 
Ohtani, N. , Ohta, M., Sugano, T. (1997). Microdialysis study of modification of 
hypothalamic neurotransmitters in streptozotocin diabetic rats. J Neurochem., 69, 
1622-1628. 
~i, N., Jeong, C. H. , Nadas, J. , Cho, y. Y., Pugliese, A. , Bode, A. M., Dong, Z. (2010). 
Resveratrol, a red wine polyphenol, suppresses pancreatic cancer by inhibiting 
leukotriene A(4) hydrolase. Cancer Res., 70, 9755-9764. 
Okawara, M., Katsuki, H. , Kurimoto, E. , Shibata, H. , Kume, T., Akaike, A. (2007). 
Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple 
insults. Biochem. Pharmacol. , 73, 550-560. 
Okouchi, M. , Okayama, N. , Aw, T. Y. (2005). DifferentiaI susceptibility of naive and 
differentiated PC-12 cells to methylglyoxal-induced apoptosis : influence of 
cellular redox. Curr. Neurovasc. Res., 2, 13-22. 
Okubo, H. , Miyake, Y. , Sasaki, S. , Murakami, K. , Tanaka, K. , Fukushima, W., 
Kiyohara, C. , Tsuboi, Y. , Yamada, T. , Oeda, T. , Shimada, H., Kawamura, N. , 
Sakae, N., Fukuyama, H. , Hirota, Y. , Nagai, M. , Fukuoka Kinki Parkinson 's 
Disease Study Group. (2012). Dietary patterns and risk of Parkinson's disease: 
a case-control study in Japan. Eur. J Neurol. , 19, 681-688. 
Olanow, C. W. (2014) . Levodopa: effect on cell death and the natural history of 
Parkinson's disease. Mov. Disord. 30, 37-44. 
Olanow, C. W., Brundin, P. (2013). Parkinson's disease and alpha synuclein: 
is Parkinson's disease a prion-like disorder? Mov. Disord. , 28, 31-40. 
Olds, J. , Milner, P. (1954). Positive reinforcement produced by electrical stimulation of 
septal area and other regions of rat brain. J Comp. Physiol. Psychol. , 4 7, 419-427. 
Olesen, J. , Gustavsson, A. , Svensson, M. , Wittchen, H. u., Jonsson, B. (2012) . 
The economic co st of brain disorders in Europe. Eur. J Neurol., 19, 155-162. 
Oliveira, M. A. P., Balling, R., Smidt, M. P. , Fleming, R. M. T. (2017). Embryonic 
.development of selectively vulnerable neurons in Parkinson's disease. 
NP J Parkinson 's Dis. , 3, 21. 
Oliveira, W. H., Nunes, A. K. , França, M. E., Santos, L. A. , L6s, D. B. , Rocha, S. W., 
Barbosa, K. P. , Rodrigues, G. B. , Peixoto, C. A. (2016). Effects of metformin on 
inflammation and short-term memory in streptozotocin-induced diabetic mice. 
Brain Res., 1644, 149-160. 
350 
Olsson, M. , Nikkhah, G., Bentlage, C., Bjorklund, A. (1995). Forelimb akinesia in 
the rat Parkinson model: differential effects of dopamine agonists and nigral 
transplants as assessed by a new stepping test. J. Neurosci., 15, 3863-3875. 
Ong, L. K., Bobrovskaya, L. , Walker, F. R., Day, T. A., Dickson, P. W., Dunkley, P. R. 
(20 Il). The effect of social defeat on tyrosine hydroxylase phosphorylation in the 
rat brain and adrenal gland. Neurochem. Res. , 36, 27-33 . 
Oorschot, D. E. (1996) . Total number of neurons in the neostriatal, pallidal, subthalamic, 
and substantia nigral nuclei of the rat basal ganglia: a stereological study using the 
Cavalieri and optical disector methods. J. Comp. Neurol. 366, 580-599. 
Orallo, F. (2008). Trans-resveratrol: a magical elixir of eternal youth? Curr. Med. 
Chem., 15, 1887-1898. 
Osborne, P. G. , Niwa, O. , Kato, T. , Yamamoto, K. (1997) . On-line, continuous 
measurement of extracellular striatal glucose using microdialysis sampling and 
electrochemical detection. J. Neurosci. Methods, 77, 143-150. 
Owen, O. E., Morgan, A. P., Kemp, H. G., Sullivan, J. M. , Herrera, M. G., 
Cahill, G. F. Jr. (1967). Brain metabolism during fasting. J. Clin. Invest., 46, 
1589-1595. 
Oya, T., Hattori, N. , Mizuno, Y., Miyata, S. , Maeda, S., Osawa, T., 
Uchida, K. (1999). Methylglyoxal modification of protein. Chemical and 
immunochemical characterization of methylglyoxal-arginine adducts. J. Biol. 
Chem, 274, 18492-18502. 
Pace-Asciak, C. R., Hahn, S. , Diamandis, E. P., Soleas, G., Goldberg, D. M. (1995). 
The red wine phenolics trans-resveratrol and quercetin block human platelet 
aggregation and eicosanoid synthesis: implications for protection against coronary 
heart disease. Clin. Chim. Acta., 235, 207-219. 
Pacelli, C. , Gi guère , N., Bourque, M. J. , Lévesque, M., Slack, R. S. , Trudeau, L. É. 
(2015) . Elevated Mitochondrial Bioenergetics and Axonal Arborization Size Are 
Key Contributors to the Vulnerability of Dopamine Neurons. Curr. Biol., 25, 
2349-2360. 
Pacher, P., Beckman, J. S., Liaudet, L. (2007). Nitric oxide and peroxynitrite in health 
and disease. Physiol. Rev., 87, 315-424. 
351 
Pacholec, M., Bleasdale, J. E., Chrunyk, B. , Cunningham, D. , Flynn, D. , Garofalo, R. S. 
Griffith, D., Griffor, M. , Loulakis, P., Pabst, B. , Qiu, X., Stockman, B. , 
Thanabal, V., Varghese, A. , Ward, J. , Withka, J. , Ahn, K. (2010). SRTl720, 
SRT2183 , SRT1460, and resveratrol are not direct activators of SIRT1. J Biol. 
Chem., 285, 8340-8351. 
Pacold, S. T. , Blackard, W. G. (1979). Central nervous system insulin receptors ln 
normal and diabetic rats. Endocrinology, 105, 1452-1457. 
Padnick-Silver, L. , Linsenmeier, R. A. (2003). Effect of acute hyperglycemia on oxygen 
and oxidative metabolism in the intact cat retina. Invest. Ophthalmol. Vis. Sei., 44, 
745-750. 
Palmiter, R. D. (2007). Is dopamine a physiologically relevant mediator of feeding 
behavior? Trends Neurosei. , 30, 375-81. 
Palmiter, R. D . (2008). Dopamine signaling in the dorsal striatum is essential for 
motivated behaviors: lessons from dopamine-deficient mice. Ann. N Y Acad. Sei. , 
1129, 35-46. 
Palle, S., Neerati, P. (2018). Improved neuroprotective effect of resveratrol nanoparticles 
as evinced by abrogation of rotenone-induced behavioral deficits and oxidative 
and mitochondrial dysfunctions in rat model of Parkinson's disease. Naunyn 
Schmiedebergs Arch Pharmacol. , 391, 445-453. 
Palmeri, R. , Lo Buono, V. , Corallo, F. , Foti, M. , Di Lorenzo, G. , Bramanti, P., 
Marino, S. (2017). Nonmotor Symptoms in Parkinson Disease: A Descriptive 
Review on Social Cognition Ability. J Geriatr. Psychiatry Neurol. , 30, 109-121. 
Pan-Montojo, F., Anichtchik, O., Dening, Y. , Knels, L. , Pursche, S., Jung, R. , 
Jackson, S., Gille, G., Spillantini, M. G. , Reichmann, H. , Funk, R. H. (2010). 
Progression of Parkinson ' s disease pathology is reproduced by intragastric 
administration of rotenone in mice. PLoS One, 5, e8762 . 
Pan-Montojo, F. , Schwarz, M. , Winkler, c., Arnhold, M. , O'Sullivan, G. A. , Pal, A. , 
Said, J., Marisco, V. , Verbavatz, 1. M., Rodrigo-Angulo, M., Gille, G., 
Funk, R. H., Reichmann, H. (2012). Environmental toxins trigger PD-like 
progression via increased alpha-synuclein release from enteric neurons in mice. 
Sei Rep, 2, 898. 
Pagano, G. , Ferrara, N. , Brooks, D. J. , Pavese, N. (2016). Age at onset and Parkinson 
disease phenotype. Neurology, 86, 1400-1407. 
352 
Palle, S. , Neerati, P. (2018). Improved neuroprotective effect ofresveratrol nanoparticles 
as evinced by abrogation of rotenone-induced behavioral deficits and oxidative 
and mitochondrial dysfunctions in rat model of Parkinson's disease. Naunyn 
Schmiedebergs Arch. Pharmacol., 391, 445-453 . 
Pang, Y., Lin, S., Wright, C., Shen, 1., Carter, K. , Bhatt, A., Fan, L. W. (2016). 
Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and 
alleviates motor deficits induced by 6-0HDA in rats. Neuroseience, 318, 157-165. 
Panksepp, J., Burgdorf, J. (2000). 50-kHz chirping (laughter?) in response to 
conditioned and unconditioned tickle-induced reward in rats: effects of social 
housing and genetic variables. Behav. Brain Res. , 115, 25-38. 
Parent, M., Parent, A. (2006). Relationship between axonal collateralization and 
neuronal degeneration in basal ganglia. J Neural Transm. Suppl. , 2006, 85-88. 
Parent, M., Parent, A. (2010). Substantia nigra and Parkinson's disease: a briefhistory of 
their long and intimate relationship. Cano J Neurol. Sei., 37, 313-319. 
Park, C. R., Seeley, R. J., Craft, S., Woods, S. C. (2000). Intracerebroventricular insulin 
enhances memory in a passive-avoidance task. Physiol. Behav., 68, 509-514. 
Park, D. , Jeong, H., Lee, M. N., Koh, A., Kwon, O., Yang, Y. R., Noh, 1., Suh, P. G. , 
Park, H., Ryu, S. H. (2016). Resveratrol induces autophagy by directly inhibiting 
mTOR through ATP competition. Sei. Rep., 6, 21772. 
Park, S., Hong, S. M. , Ahn, 1. S. (2009). Long-term intracerebroventricular infusion of 
insulin, but not glucose, modulates body weight and hepatic insu lin sensitivity by 
modifying the hypothalamic insulin signaling pathway in type 2 diabetic rats. 
Neuroendocrinology, 89, 387-399. 
Park, S. J., Ahmad, F., Philp, A., Baar, K. , Williams, T., Luo, H., Ke, H. , Rehmann, H ., 
Taussig, R., Brown, A. L., Kim, M. K., Beaven, M. A., Burgin, A. B. , 
Manganiello, V. , Chung, J. H. (2012). Resveratrol ameliorates aging-related 
metabolic phenotypes by inhibiting cAMP phosphodiesterases. Celt, 148,421-433. 
Parkinson, 1. (1817). An Essay on the Shaking Paisy. London: Whittingham and 
Rowland Sherwood, Neely and Jones. 
Parkinson Québec, 2018. Symptômes moteurs. http://parkinsonquebec.ca/maladie/ 
symptomes-moteurs/ 
353 
Parkinson Study Group. (2004). Levodopa and the progression of Parkinson's disease. 
N. Engl. J. Med. , 351, 2498-2508. 
Parkkinen, L. , Kauppinen, T. , Pirttila, T. , Autere, 1. M. , Alafuzoff, 1. (2005) . Alpha-
synuclein pathology does not predict extrapyramidal symptoms or dementia. 
Ann. Neurol. , 5 7, 82-91. 
Parr, A. J., Bolwell, G. P. (2000) . Phenols in the Plant and in Man. The Potential for 
Possible Nutritional Enhancement of the Diet by Modifying the Phenols Content 
or Profile. J. Sei. Food Agrie., 80, 985-1012. 
Patel, 1. R ., Brewer, G. J. (2003). Age-related changes in neuronal glucose uptake in 
response to glutamate and beta-amyloid. J. Neurosei. Res., 72, 527-536. 
Patti, M. E. , Corvera, S. (2010) . The role of mitochondria in the pathogenesis of type 2 
diabetes. Endoer. Rev., 31, 364-395. 
Pauls, F. , Bancroft, R. W. (1950) . Production of diabetes In the mouse by partial 
pancreatectomy. Am. J. Physiol. , 160, 103-106. 
Pauwels, P. J. , Trouet, A. (1984). Role of fructose 2,6-bisphosphate in the regulation of 
glycolysis in various types of cultivated brain cell. Neurosei. LeU., 46, 173-177. 
Payami, H. (2017). The emerging science of precision medicine and pharmacogenomics 
for Parkinson's disease. Mov. Disord. , 32, 1139-1146. 
Paxinos, G., Watson, C. (1998). The Rat Brain in Stereotaxie Coordinates. (4th ed). 
Academic Press. 
Pearce, R. K. , Owen, A., Daniel, S., Jenner, P. , Marsden, C. D. (1997). Alterations in the 
distribution of glutathione in the substantia nigra in Parkinson's disease. J. Neural. 
Transm. (Vien na), 104, 661-677. 
Peciiia, S., Cagniard, B., Berridge, K. c., Aldridge, J. W., Zhuang, X. (2003) . 
Hyperdopaminergic mutant mice have higher "wanting" but not "liking" for sweet 
rewards. J. Neurosei., 23, 9395-9402. 
Pell, M. D. , Cheang, H. S., Leonard, C. L. (2006) . The impact of Parkinson's disease on 
vocal-prosodic communication from the perspective of listeners. Brain Lang., 9 7, 
123-134. 
354 
Pellegrini, C., Antonioli, L., Colucci, R., Ballabeni, V ., Barocelli, E., Bernardini, N., 
Blandizzi, C., Fornai, M. (2015) . Gastric motor dysfunctions in Parkinson's 
disease: Current pre-clinical evidence. Parkinsonism Re/al. Disord. , 21, 
1407-1414. 
Pellerin, L., Magistretti, P. J. (1994). Glutamate uptake into astrocytes stimulates aerobic 
glycolysis: a mechanism coupling neuronal activity to glucose utilization. 
Proc. Nat!. Acad. Sei. U.S.A., 91, 10625-10629. 
Pelton, E. W. 2nd, Kimelberg, H. K. , Shipherd, S. V., Bourke, R. S. (1981). Dopamine 
and norepinephrine uptake and metabolism by astroglial ceUs in culture. Life Sei, 
28, 1655-1663. 
Peng, K., Tao, Y., Zhang, J., Wang, K ., Ye, F., Dan, G. , Zhao, Y., Cai, Y., Zhao, J., 
Wu, Q., Zou, Z., Cao, 1. Sai, Y. (2016). Resveratrol Regulates Mitochondrial 
Biogenesis and Fission/Fusion to Attenuate Rotenone-1nduced Neurotoxicity. 
Oxid. Med. Cel!. Longev. , 2016, 6705621. 
Pennington, S. , Snell, K. , Lee, M., Walker, R . (2010). The cause of death in idiopathie 
Parkinson's disease. Parkinsonism Re/at. Disord. , 16,434-437. 
Percheron, G., François, C., Yelnik, J., Fenelon, G. (1989). The primate nigro-striato-
pallido-nigral system. Not a mere loop. In Crossman, A. R. , and Sambrook, M. A. 
(eds), Neura/ Mechanisms in Disorders of Movement. London: John Libbey, 
pp. 103-109. 
Pérez, V. L, Bokov, A., Van Rernrnen, H., Mele, J., Ran, Q. , Ikeno, Y., Richardson, A. 
(2009) . Is the oxidative stress theory of aging dead? Biochim. Biophys. Acta, 
1790, 1005-1014. 
Perier, C., Vila, M. (2012). Mitochondrial biology and Parkinson's disease. Cold Spring 
Harb. Perspect. Med., 2, a009332. 
Perron, N. R., Hodges, J. N., Jenkins, M., Brumaghim, 1. L. (2008). Predicting how 
polyphenol antioxidants prevent DNA damage by binding to iron. Inorg. Chem. , 
47,6153-6161. 
Perry, T. , Lahiri, D. K., Chen, D. , Zhou, J., Shaw, K. T. Y. , Egan, J. M., Greig, N. H. 
(2002). A novel neurotrophic property of glucagon-like peptide 1: a promoter 
of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol. 
Exp. Ther., 300, 958-966. 
355 
Perticarari, S., Presani, G., Banfi, E. (1994). A new flow cytometric assay for the 
evaluation of phagocytosis and the oxidative burst in whole blood. J lmmunol. 
Methods, 170, 117-124. 
Petry, N., Egli, L, Zeder, c., Wa1czyk, T., Hurrel, R. (2010). Polyphenols and phytic 
acid contribute to the low iron bioavailability from common beans in young 
women. J Nutr., 140, 1977-1982. 
Pezzino, V., Costantino, A., Russo, P., Gullo, D., Papa, V. (1996). Insulin receptor 
content in tissues of normal and diabetic rats measured by radioimmunoassay. 
J Endocrinol. lnvest., 19, 593-597. 
Pezzoli, G., Cereda, E. (2013). Exposure to pesticides or solvents and risk of Parkinson 
disease. Neurology, 80, 2035-2041. 
Phillips, R. J., Walter, G. C., Wilder, S. L., Baronowsky, E. A., Powley, T. L. (2008). 
Alpha-synuc1ein-immunopositive myenteric neurons and vagal preganglionic 
terminais: Autonomic pathway implicated in Parkinson's disease? Neuroscience, 
153, 733-750. 
Phillips, S. A., Thomalley, P. J. (1993). The formation of methylglyoxal from triose 
phosphates. Investigation using a specific assay for methylglyoxal. Eur. J 
Biochem.212, 101-105. 
Pinna, A. , Morelli, M. (2014). A critical evaluation of behavioral rodent models of 
motor impairment used for screening of antiparkinsonian activity: The case of 
adenosine A(2A) receptor antagonists. Neurotox. Res. , 25, 392-401 . 
Pinna, A., Pontis, S., Borsini, F. , Morelli, M. (2007). Adenosine A(2A) receptor 
antagonists improve deficits in initiation of movement and sensory motor 
integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease. 
Synapse, 61, 606-614. 
Pinna, A., Tronci, E. , Schintu, N., Simola, N., Volpini, R., Pontis, S. , Cristalli, G., 
Moreilli, M. (2010). A new ethyladenine antagonist of adenosine A(2A) receptors : 
behavioral and biochemical characterization as an antiparkinsonian drug. 
Neuropharmacol., 58, 613-623. 
Plavén-Sigray, P., Gustavsson, P., Farde, L. , Borg, J., Stenkrona, P., Nyberg, L. , 
Biickman, L., Cervenka, S. (2014). Dopamine Dl receptor availability is related 
to social behavior: a positron emission tomography study. Neuroimage, 102, 
590-595. 
356 
Plowman, E. K., Kleim, J. A. (2011). Behavioral and neurophysiological correlates of 
striatal dopamine depletion: a rodent model of Parkinson's disease. J Commun. 
Disord. , 44, 549-556. 
Polito, L. , Greco, A., Seripa, D. (2016). Genetic Profile, Environmental Exposure, 
and Their Interaction in Parkinson's Disease. Parkinsons Dis., 2016, 6465793. 
Pollak, P. , Benabid, A. L. , Gross, c., Gao, D. M. , Laurent, A. , Benazzouz, A., 
Hoffmann, D., Gentil, M. , Perret, J. (1993). Effects of the stimulation of the 
subthalamic nucleus in Parkinson disease. Rev. Neurol. (Paris), 149, 175-176. 
Polymeropoulos, M. H. , Lavedan, C., Leroy, E., Ide, S. E. , Dehej ia, A. , Dutra, A., 
Pike, B., Root, H. , Rubenstein, 1. , Boyer, R. , Stenroos, E. S., Chandrasekharappa, 
S., Athanassiadou, A., Papapetropoulos, T., Johnson, W. G. , Lazzarini, A. M., 
Duvoisin, R. C. , Di lori 0 , G. , Golbe, L. L, Nussbaum, R. L. (1997). Mutation in 
the alpha-synuclein gene identified in families with Parkinson's disease. Science, 
2 76, 2045-2047. 
Pont-Sunyer, C. , Hotter, A. , Gaig, C, Seppi, K. , Compta, Y., Katzenschlager, R., 
Mas, N. , Hofeneder, D. , Brücke, T. , Bayés, A., Wenzel, K. , Infante, J., Zach, H., 
Pirker, W. , Posada, 1. J. , Alvarez, R. , Ispierto, L. , De Fàbregues, O. , Callén, A., 
Palasi , A. , Aguilar, M. , Marti, M. J. , Valldeoriola, F., Salamero, M., Poewe, W. , 
Tolosa, E. (2015). The onset of nonmotor symptoms in Parkinson's disease 
(the ONSET PD Study). Mov. Disord. , 30, 229-237 . 
Pontieri, F. E. , Tanda, G. , Di Chiara, G. (1995). Intravenous cocaine, morphine, and 
amphetamine preferentially increase extracellular dopamine in the "shell" as 
compared with the "core" of the rat nucleus accumbens. Proc. Nat/. Acad. Sei. 
U. S.A. , 92, 12304-12308. 
Porras, O. H. , Loaiza, A., Barros, L. F. (2004). Glutamate mediates acute glucose 
transport inhibition in hippocampal neurons. J Neurosci. , 24, 9669-9673 . 
Porte, D. Jr, Baskin, D. G. , Schwartz, M. W. (2005). Insulin signaling in the central 
nervous system: a critical role in metabolic homeostasis and disease from 
C. elegans to humans. Diabetes, 54, 1264-1276. 
Portha, B. , Levacher, C., Picon, L. , Rosselin, G. (1974). Diabetogenic effect of 
streptozotocin in the rat during the perinatal period. Diabetes, 23, 889-895. 
Portha, B. , Movassat, J. , Bailbe, D., Dolz, M., Kergoat, M. , Giroix, M. H. , Serradas, P. 
(2007). The neonatally streptozotocin-induced (n-STZ) rat model of type 2 
diabetes. Several variants with multiple and complementary talents. Animal 
Models of Diabetes. Taylor and Francis Group, LLC: London, pp. 223-250. 
357 
Portha, B., Picon, L. , Rosselin, G. (1979). Chemical diabetes in the adult rat as the 
spontaneous evolution ofneonatal diabetes. Diabetologia, 17, 371-377. 
Postuma, R. B. , Lang, A. E. , Gagnon, 1. F., Pelletier, A. , Montplaisir, 1. Y. (2012). 
How does parkinsonism start? Prodromal parkinsonism motor changes in 
idiopathic REM sleep behaviour disorder. Brain, 135, 1860-1870. 
Potter-Baker, K. A. , Stewart, W. G. , Tomaszewski, W. H. , Wong, C. T. , Meador, W. D., 
Ziats, N. P ., Capadona, J. R. (2015). Implications of chronic daily anti-oxidant 
administration on the inflammatory response to intracortical microelectrodes. 
J Neural. Eng., 12, 046002. 
Prakash, R. , Johnson, M. , Fagan, S. c., Ergul, A. (2013). Cerebral Neovascularization 
and Remodeling Patterns in Two Different Models of Type 2 Diabetes. PloS One, 
8, e56264. 
Prasad, K. N. , Carvalho, E. , Kentroti , S. , Edwards-Prasad, J. , Freedm C. , Vernadakis, A. 
(1994). Establishment and characterization of immortalized clonaI ceIl lines from 
fetal rat mesencephalic tissue. In Vitro CeU. Dev. Biol. Anim., 30A, 596-603. 
Piotrowska, H. , Kucinska, M ., Murias, M. (2012). Biological activity of piceatannol: 
Leaving the shadow of resveratrol. Mu ta t. Res., 750, 60-82 . 
Price, S. A. , Gardiner, N . J., Duran-Jimenez, B. , Zeef, L. A., Obrosova, I. G. , 
Tomlinson, D. R. (2006) . Thioredoxin interacting protein is increased in sensory 
neurons in experimental diabetes. Brain Res., 1116, 206-214. 
Priyadarshi, A. , Khuder, S. A. , Schaub, E. A. , Shrivastava, S. (2000) . A meta-analysis of 
Parkinson's disease and exposure to pesticides. Neurotoxicology, 21, 435-440. 
Prydz, A., Stahl, K. , Puchades, M ., Davarpaneh, N., Nadeem, M., Ottersen, O. P. , 
Gundersen, V. , Amiry-Moghaddam, M. (2017). SubceIlular expression of 
aquaporin-4 in substantia nigra of normal and MPTP-treated mice. Neuroscience, 
359, 258-266. 
Puglia, C. D. , Loeb, G. A. (1984). Influence of rat brain superoxide dismutase inhibition 
by diethyldithiocarbamate upon the rate of development of central nervous system 
oxygen toxicity. Toxicol. Appl. Pharmacol. , 75, 258-264. 
Purawatt, S. , Siripinyanond, A. , Shiowatana, 1. (2007). Flow field-flow fractionation-
inductively coupled optical emission spectrometric investigation of the size-based 
distribution of iron complexed to phytic and tannic acids in food suspension: 
implications for iron availability. Anal. Bioanal. Chem., 289, 733-742. 
358 
Qarnhawi Z, Towey D, Shah B, Pagano, G. , Seibyl , J ., Marek, K. , Borghammer, P., 
Brooks, D. J ., Pavese, N. (2015) . Clinical cOITelates of raphe serotonergic 
dysfunction in early Parkinson 's disease. Brain, 138, 2964-2973. 
Quastel, 1. H. , Wheatley, A. H. (1932). Oxidations by the brain. Biochem. J, 26, 
725-744. 
Rabbini, N., Thomalley, P. J. (2012). Methylglyoxal, glyoxalase-1 and the dicarbonyl 
proteome. Amino Acids, 42, 1133-1142. 
Radenkovié, M., Stojanovié, M., Prostran, M. (2016). Experimental diabetes induced by 
alloxan and streptozotocin: The CUITent state of the art. J Pharmacol. Toxicol. 
Methods., 78, 13-31. 
Rajabally, Y. A., Stettner, M., Kieseier, B. c., Hartung, H. P. , Malik, R. A. (2017). 
CIDP and other inflarnrnatory neuropathies in diabetes - diagnosis and 
management. Nat. Rev. Neurol. , 13, 599-611. 
Rakieten, N ., Rakieten, M. L. , Nadkami, M . V. (1963) . Studies on the diabetogenic 
action ofstreptozotocin (NSC-37917). Cancer Chemother. Rep., 29, 91-98. 
Rakovska, A., Javitt, D ., Raichev, P., Ang, R., Balla, A. , Aspromonte, 1., Vizi, S. (2003) . 
Physiological release of striatal acetylcholine (in vivo): effect of somatostatin on 
dopaminergic-cholinergic interaction. Brain Res. Bull., 61, 529-536. 
Ralser, M., Wamelink, M. M. , Kowald, A. , Gerisch, B. , Heeren, G. , Struys, E. A ., 
Klipp, E., Jakobs, c., Breitenbach, M., Lehrach, H., Krobitsch, S. (2007). 
Dynamic rerouting of the carbohydrate flux is key to counteracting oxidative 
stress. Journal ofBiology, 6, 10. 
Ramanathan, M., Jaiswal , A., K., Bhattacharya, S. K. (1999). Superoxide dismutase, 
catalase and glutathione peroxidase activities in the brain of streptozotocin induced 
diabetic rats. lndian J Exp. Biol., 37, 182-183. 
Ransohoff, R. M . (2016). How neuroinflarnrnation contributes to neurodegeneration. 
Science, 353, 777-783 . 
Rao, J. , Oz, G., Seaquist, E. R. (2006). Regulation of cerebral glucose metabolism. 
Minerva Endocrinol., 31, 149-158. 
359 
Rauch, M. C. , Ocampo, M. E. , Bohle, 1., Amthauer, R. , Yanez, A. J. , Rodriguez-Gil, 
1. E., Slebe, J. C., Reyes, J. G., Concha, II. (2006). Hexose transporters GLUT 1 
and GLUT3 are colocalized with hexokinase l in caveolae microdomains of rat 
spermatogenic ceUs. J Cel!. Physiol., 207, 397-406. 
Rayegan, S., Dehpour, A. R., Sharifi, A. M. (2017). Studying neuroprotective effect 
of Atorvastatin as a smaU molecule drug on high glucose-induced neurotoxicity 
in undifferentiated PC12 ceUs: role of NADPH oxidase. Metab. Brain Dis. , 32, 
41-49. 
Recasens, A., Dehay, B., Bové, 1., Carballo-Carbajal, L, Dovero, S., Pérez-ViUalba, A., 
Femagut, P. O., Blesa, J., Parent, A., Perier, C., Farinas, L, Obeso, J. A. , 
Bezard, E., Vila, M. (2014). Lewy body extracts from Parkinson disease brains 
trigger a-synuclein pathology and neurodegeneration in mi ce and monkeys. 
Ann. Neurol., 75, 351-362. 
Redgrave, P., Gumey, K. (2006). The short-Iatency dopamine signal: a role In 
discovering novel actions? Nat. Rev. Neurosci., 7, 967-975. 
Redgrave, P., Prescott, T. , Gumey, K. N. (1999). The basal ganglia: a vertebrate solution 
to the selection problem? Neuroscience, 89, 1009-1023. 
Redgrave, P., Rodriguez, M. , Smith, Y., Rodriguez-Oroz, M. C. , Lehericy, S. , 
Bergman, H. , Agid, Y. , DeLong, M. R. , Obeso, 1. A. (2010). Goal-directed and 
habituai control in the basal ganglia: implications for Parkinson's disease. 
Nat. Rev. Neurosci., Il, 760-772. 
Reed, M. J., Meszaros, K., Entes, L. J., Claypool, M. D., Pinkett, J. G., Gadbois, T. M., 
Reaven, G. M. (2000). A new rat model of type 2 diabetes: the fat-fed, 
streptozotocin-treated rat. Metabolism, 49, 1390-1394. 
Reeve, A., Sirncox, E., Tumbul1, D. (2014). Ageing and Parkinson's disease: why is 
advancing age the biggest risk factor? Ageing Res. Rev., 14, 19-30. 
Reger, M. A., Watson, G. S., Green, P. S., Wilkinson, C. W. , Baker, L. D. , 
Cholerton, B., Fishel, M. A., Plymate, S. R., Breitner, 1. C. S. , DeGroodt, W ., 
Mehta, P., Craft, S. (2008). Intranasal insulin improves cognition and modulates 
beta-amyloid in early AD. Neurology, 70, 440-448 . 
Regl6di, D., Renaud, J., Tamas, A., Tizabi, Y. , Socias, S. B., Del-Bel, E., 
Raisman-Vozari, R. (2017). Novel tactics for neuroprotection in Parkinson's 
disease: Role of antibiotics, polyphenols and neuropeptides. Prog. Neurobiol., 
155, 120-148. 
360 
Remy, P. (2005). Depression in Parkinson's disease: loss of dopamine and noradrenaline 
innervation in the limbic system. Brain, 128, 1314-1322. 
Ren, J., Fan, C., Chen, N., Huang, J., Yang, Q. (2011). Resveratrol pretreatment 
attenuates cerebral ischemic injury by upregulating expression of transcription 
factor Nrf2 and HO-l in rats. Neuroehem. Res. , 36, 2352-2362. 
Renaud, 1., Chiasson, K., Boumival, J., Rouillard, C., Martinoli, M. G. (2014). 
17~-estradiol delays 6-0HDA-induced apoptosis by acting on Nur77 translocation 
from the nucleus to the cytoplasm. Neurotox. Res., 25, 124-134. 
Renaud, 1., Martinoli, M. G. (2014). Resveratrol as a protective molecule 
for neuroinflammation: a review of mechanisms. Curr. Pharm. Bioteehnol. 15, 
318-329. 
Renaud, J. , Nabavi, S. F., Daglia, M., Nabavi, S. M., Martinoli, M. G. (2015). 
Epigallocatechin-3-Gallate, a Promising Molecule for Parkinson's Disease? 
Rejuvenation Res. 18,257-269. 
Renaud, S., De Lorgeril, M. (1992). Wine, alcohol, platelets, and the French paradox for 
coronary heart-disease. Lancet, 339, 1523-1526. 
Renault, T. T., Teijido, O., Antonsson, B., Dejean, L. M., Manon, S. (2013). Regulation 
of Bax mitochondrial localization by Bcl-2 and Bcl-x(L): keep your friends close 
but your enemies closer. Int. J Bioehem. Cel!. Biol., 45, 64-67. 
Rerup, C.c. (1970). Drugs producing diabetes through damage of the insulin secreting 
cells. Pharmaeol. Rev., 22, 485-518. 
Rex, A., Bert, B., Fink, H., Voigt, J. P. (2009). Stimulus-dependent changes of 
extracellular glucose in the rat hippocampus determined by in vivo microdialysis. 
Physiol. Behav. , 98, 467-473. 
Reybier, K., Perio, P. , Ferry, G., Bouajila, J., Delagrange, P. , Boutin, J. A. , Nepveu, F. 
(2011). Insights into the redox cycle of human quinone reductase 2. Free Radie. 
Res., 45, 1184-1195. 
Ribeiro, M., Rosenstock, T. R., Oliveira, A. M., Oliveira, C. R., Rego, A. C. (2014). 
Insulin and IGF-l improve mitochondrial function in a PI-3K1Akt-dependent 
manner and reduce mitochondrial generation of reactive oxygen species in 
Huntington's disease knock-in striatal cells. Free Radie. Biol. Med. , 74, 129-144. 
361 
Rice, M. E. , Patel, J. c., Cragg, S. J. (2011) . Dopamine release in the basal ganglia. 
Neuroscience, 198, 112-137. 
Richard, L, McDermott, M. , Kurlan, R. , Lyness, J. M. , Como, P. G. , Pearson, N., 
Factor, S. A. , Juncos, 1. , Serrano Ramos, C. , Brodsky, M., Manning, C. , 
Marsh, L. , Shulman, L. , Femandez, H. H., Black, K. 1. , Panisset, M., 
Christine, C. W., Jiang, W., Singer, C., Hom, S., Pfeiffer, R., Rottenberg, D., 
Slevin, J. , Elmer, L., Press, D., Hyson, H. c., McDonald, W. , SAD-PD Study 
Group. (2012). A randomized, double-blind, placebo-controlled trial of 
antidepressants in Parkinson ' s disease. Neurology, 78, 1229-1236. 
Richard, 1. P. (1984). Acid-base catalysis of the elimination and isomerization reactions 
of triose phosphates. J Am. Chem. Soc., 106, 4926-4936. 
Ristow, M. (2004). Neurodegenerative disorders associated with diabetes mellitus. 
J Mol. Med. (Berl), 82, 520-529. 
Roberts, A. , Nguyen, P., Orange, 1. B. , Jog, M ., Nisbet, K. A., McRae, K. (2017). 
Differentiai impairments of upper and lower limb movements influence action 
verb processing in Parkinson disease. Cortex, 9 7, 49-59. 
Roberts, D. C., Koob, G. F., Klonoff, P. , Fibiger, H. C. (1980). Extinction and recovery 
of cocaine self-administration following 6-hydroxydopamine lesions of the 
nucleus accumbens. Pharmacol. Biochem. Behav., 12, 781-787. 
Robinson, K. M. , Janes, M. S., Pehar, M., Monette, 1. S. , Ross, M. F. , Hagen, T. M. , 
Murphy, M. P., Beckman, 1. S. (2006). Selective fluorescent imaging of 
superoxide in vivo using ethidium-based probes. Proc. Natl. Acad. Sci. US. A., 
103, 15038-15043. 
Rodrigo, R., Femandez-Gajardo, R. , Gutiérrez, R. , Matamala, J. M. , Carrasco, R. , 
Miranda-Merchak, A. , Feuerhake, W. (2013). Oxidative stress and 
pathophysiology of ischemic stroke: Novel therapeutic opportunities. CNS Neurol. 
Disord. Drug Targets, 12, 698-714. 
Rojo, A. L, Innamorato, N. G. , Martin-Moreno, A. M. , De Ceballos, M. L. , 
Yamamoto, M. , Cuadrado, A. (2010) . Nrf2 regulates microglial dynamics and 
neuroinflammation in experimental Parkinson's disease. GUa, 58, 588-598. 
Romanos, M., Weise, D. , Schliesser, M. , Schecklmann, M. , L6ffler, 1. , Warnke, A., 
Gerlach, M. , Classem, J ., Mehler-Wex, C. (2010). Structural abnormality of 
the substantia nigra in children with attention-deficit hyperactivity disorder. 
J Psychiatry Neurosci., 35, 55-58. 
362 
Rong, L. L. , Gooch, C., Szabolcs, M., Herold, K.C., Lalla, E., Hays, A. P. , Yan, S. F., 
Yan, S. S., Schmidt, A. M. (2005) . RAGE: a joumey from the complications of 
diabetes to disorders of the nervous system-striking a fine balance between injury 
and repair. Restor. Neurol. Neurosci., 23, 355-365. 
Ronson, R. S. , Nakamura, M. , Vinten-Johansen, J. (1999). The cardiovascular effects 
and implications ofperoxynitrite. Cardiovasc. Res., 44, 47-59. 
Rosa-Neto, P. , Lou, H. C., Cumming, P. , Pryds, O. , Karrebaek, H. , Lunding, 1., 
Gjedde, A. (2005). Methylphenidate-evoked changes in striatal dopamine correlate 
with inattention and impulsivity in adolescents with attention deficit hyperactivity 
disorder. Neuroimage, 25, 868-876. 
Rossi, M. A. , Fan, D. , Barter, J. W. , Yin, H. H. (2013). Bidirectional modulation of 
substantia nigra activity by motivational state. PLoS One, 8, e71598. 
Rostami, E. (2014). Glucose and the injured brain-monitored in the neurointensive care 
unit. Front. Neurol. , 5, 91. 
Rostami, F. , Javan, M., Moghimi, A. , Haddad-Mashadrizeh, A., Fereidoni, M. (2017). 
Streptozotocin-induced hippocampal astrogliosis and insulin signaling malfunction 
as experimental scales for subclinical sporadic Alzheimer mode!. Life Sei., 188, 
172-185. 
Rotermund, C., Truckenmüller, F. M., Schell, H., Kahle, P. 1. (2014) . Diet-induced 
obesity accelerates the onset of terminal phenotypes in alpha-synuclein transgenic 
mice. J Neurochem. 131, 848-858 . 
Rothe, G., Valet, G. (1990). Flow cytometric analysis of respiratory burst activity in 
phagocytes with hydroethidine and 2',7'-dichlorofluorescin. J Leukoc. Biol., 47, 
440-448. 
Rowland, N. C. , Sammartino, F. , Lozano, A. M. (2016). Advances m surgery for 
movement disorders. Mov. Disord. , 32, 5-10. 
Rubinsztein, D. C. , Marino, G., Kroemer, G. (2011). Autophagy and agmg. Cel/., 
146, 682-695. 
Rudow, G. , O'Brien, R. , Savonenko, A. V., Resnick, S. M. , Zonderman, A. B., 
Pletnikova, O., Marsh, L. , Dawson, T. M. , Crain, B. 1. , West, M. J. , Troncoso, 
J. C. (2008). Morphometry of the human substantia nigra in ageing and 
Parkinson's disease. Acta Neuropathol., 115, 461-470. 
363 
Rumsey, S. C., Kwon, O. , XU, G. W., Burant, C. F., Simpson, L, Levine, M. (1997) . 
Glucose transporter isoforms GLUT1 and GLUT3 transport dehydroascorbic acid. 
J Biol. Chem., 272, 18982-18989. 
Russell, J. W., Sullivan, K. A , Windebank, A J., Herrman, D. N., Feldman, E. L. 
(1999). Neurons undergo apoptosis in animal and cell culture models of diabetes. 
Neurobiol. Dis. 6, 347-363. 
Russo, L, Bubacco, L. , Greggio, E. (2014). LRRK2 and neuroinflammation: partners in 
crime in Parkinson's disease? J Neuroinflammation, Il, 52. 
Rusznyak, S., Szent-Gyorgyi, A (1936) . Vitamin P: Flavonals as vitamins. Nature 
(London), 138, 27. 
Saaksjarvi, K. , Knekt, P. , Mannisto, S. , Lyytinen, J. , Heliovaara, M. (2015). Prospective 
study on the components of metabolic syndrome and the incidence of Parkinson's 
disease. Parkinsonism Relat. Disord. , 21, 1148-1155. 
Sabokdast, M., Habibi-Rezaei, M. , Moosavi-Movahedi, A. A , Ferdousi, M. , 
Azimzadeh-Irani, E. , Poursasan, N. (2015). Protection by beta-Hydroxybutyric 
acid against insulin glycation, lipid peroxidation and microglial cell apoptosis. 
Daru, 23, 42. 
Saddoris, M. P., Sugam, J. A , Cacciapaglia, F., Carelli , R M. (2013). Rapid dopamine 
dynamics in the accumbens core and shell: leaming and action. Front. Biosci. 
(Elite Ed), 5, 273-288. 
Sadi, G. , Bozan, D. , Yildiz, H. B. (2014). Redox regulation of antioxidant enzymes: 
post-translational modulation of catalase and glutathione peroxidase activity by 
resveratrol in diabetic rat liver. Mol. Cell. Biochem. , 393, 111-122. 
Sadi, G. , Konat, D. (2016) . Resveratrol regulates oxidative biomarkers and antioxidant 
enzymes in the brain of streptozotocin-induced diabetic rats. Pharm. Biol. , 54, 
1156-1163 . 
Sadikot, A F. , Parent, A., Smith, Y. , Bolam, J. P. (1992) . Efferent connections of the 
centromedian and parafascicular thalamic nuclei in the squirrel monkey: A light 
and electron microscopic study of the thalamostriatal projection in relation to 
striatal heterogeneity. J Comp. Neurol. , 320, 228-242 . 
Sagar, S. M. , Sharp, F. R , Swanson, RA. (1987). The regional distribution of glycogen 
in rat brain fixed by microwave irradiation. Brain Res. 41 7, 172-174. 
364 
Sakahira, H. , Enari, M., Nagata, S. (1998). Cleavage of CAD inhibitor ln CAD 
activation and DNA degradation during apoptosis. Nature, 391, 96-99. 
Sakurai, T. , Amemiya, A. , Ishii, M., Matsuzaki, L, Chemelli, R. M., Tanaka, H., 
Williams, S. C., Richarson, J. A. , Kozlowski, G. P. , Wilson, S. , Arch, J. R., 
Buckingham, R. E. , Haynes, A. c., Carr, S. A. , Annan, R. S., McNulty, D. E., 
Liu, W. S. , Terrett, J . A., Elshourbagy, N. A., Bergsma, D. J. , Yanagisawa, M. 
(1998). Orexins and orexin receptors: a family of hypothalamic neuropeptides and 
G-protein coupled receptors that regulate feeding behavior. Cel!, 92, 573-585. 
Salamone, J. D., Correa, M. (2002). Motivational views of reinforcement: implications 
for understanding the behavioral functions of nucleus accumbens dopamine. 
Behav. Brain Res., 13 7, 3-25. 
Saleh, M. C., Connell, B. 1. , Saleh, T. M. (2013). Resveratrol induced neuroprotection is 
mediated via both estrogen receptor subtypes, ER(a) and ERW). Neurosci. 
LeU., 548, 217-221. 
Saller, C. F. (1984) . Dopaminergic activity IS reduced In diabetic rats. Neurosci. 
LeU. , 49, 301-306. 
Samandari, R ., Chizari, A. , Hassanpour, R. , Mousavi, Z. , Haghparast, A. (201 3). 
Streptozotocin-induced diabetes affects the development and maintenance of 
morphine reward in rats. Neurosci. LeU. , 543, 90-94. 
Samsamikor, M. , Daryani, N. E. , AsI, P. R ., Hekmatdoost. A. (2016). Resveratrol 
Supplementation and Oxidativel Anti-Oxidative Status in Patients with Ulcerative 
Colitis: A Randomized, Double-Blind, Placebo-controlled Pilot Study. Arch. Med. 
Res., 4 7, 304-309. 
Sanberg, P. R. (1980). Haloperidol-induced catalepsy IS mediated by postsynaptic 
dopamme receptors. Nature, 284, 472-473. 
Sanberg, P. R., Bunsey, M. D. , Giordano, M. , Norman, A. B. (1988). The catalepsy test: 
its ups and downs. Behav. Neurosci., 102, 748-759. 
Sanberg, P. R. , Faulks, 1. J., Fibiger, H. C. (1980). Experiential influences on catalepsy. 
Psychopharmacol. , 69, 225-226. 
Sanberg, P. R. , Pisa, M. , Fibiger, H. C. (1981). Kainic acid injections in the striatum 
alter the cataleptic and locomotor effects of drugs influencing dopaminergic and 
cholinergic systems. Eur. J Pharmacol. , 74, 347-357. 
365 
Sandyk, R (1993). The relationship between diabetes mellitus and Parkinson's disease. 
Int. J Neurosci., 69, 125-130. 
Santiago, 1. F. , Carvalho, F . F ., Perosa, S. R., Siliano, M. R. , Cruz, J . W., 
Fernandes, M. J., Cavalheiro, E. A., Amado, D. , da Graça Naffah-Mazzacoratti, 
M. (2006). Effect of glycemic state in rats submitted to status epilepticus during 
development. Arq Neuropsiquiatr. , 64, 233-239. 
Santiago, J. A. , Potashkin, 1. A. (2013). Shared dysregulated pathways lead to 
Parkinson's disease and diabetes. Trends Mol. Med. , 19, 176-186. 
Santiago, J. A. , Potashkin, J. A. (2015) . Blood Biomarkers Associated with Cognitive 
Decline in Early Stage and Drug-Naive Parkinson's Disease Patients. PLoS One, 
10, e0142582 . 
Saravia, F. E., Revsin, Y. , Gonzalez Deniselle, M. C., Gonzalez, S. L. , Roig, P., 
Lima, A. , Homo-Delarche, F. , De Nicola, A. F. (2002). Increased astrocyte 
reactivity in the hippocampus of murine models of type 1 diabetes: the nonobese 
diabetic (NOD) and streptozotocin-treated mice. Brain Res., 95 7, 345-353. 
Sargeant, L.A. , Khaw, K.T. , Bingham, S., Day, N. E. , Luben, RN., Oakes, S. , 
Welch, A. , Wareham, N . J. (2001). Fruit and vegetable intake and population 
glycosylated haemoglobin levels: the EPIC-Norfolk Study. Eur. J Clin. Nutr., 55, 
342-348. 
Sathe, K. , Maetzler, W., Laang, J. D., Mounsey, RB. , Fleckenstein, C. , Martin, H. L. , 
Schulte, C. , Mustafa, S. , Synofzik, M., Vukovic, Z. , Itohara, S., Berg, D., 
Teismann, P. (2012). SlOO is increased in Parkinson ' s disease and ablation 
protects against MPTP-induced toxicity through RAGE and TNF-alpha pathway. 
Brain, 135, 3336-3347. 
Saul, S. R , Aleksic, S. , Magnotti, M. (2016) . A Patient with Newly Diagnosed Diabetes 
Presenting with Sino-Orbital Mucormycosis. AACE Clinical Case Reports, 2, 
41-45. 
Savaskan, E., Olivieri, G., Meier, F. , Seifritz, E. , Wirz-Justice, A. , Müller-Spahn, F. 
(2003). Red wine ingredient resveratrol protects from beta-amyloid neurotoxicity. 
Gerontology, 49, 380-383 . 
Sawa, A. , Khan, A. A. , Hester, L. D., Snyder, S. H. (1997). Glyceraldehyde-3-phosphate 
dehydrogenase: nuclear translocation participates in neuronal and nonneuronal cell 
death. Proc. Nat!. Acad. Sci. U.S.A ., 94, 11669-11674. 
366 
Scalbert, A., Williamson, G. (2000). Dietary intake and bioavailability of polyphenols. 
J Nutr., 130, 2073S-85S. 
Scardochio, T., Trujillo-Pisanty, 1., Conover, K., Shizgal, P., Clarke, P. B. (2015). 
The Effects of Electrical and Optical Stimulation of Midbrain Dopaminergic 
Neurons on Rat 50-kHzUltrasonic Vocalizations. Front. Behav. Neurosci., 9, 33l. 
Schallert, T., Fleming, S. M., Woodlee, M. T. (2003). Should the injured and intact 
hemispheres be treated differently during the early phases of physical restorative 
therapy in experimental stroke or Parkinsonism? Phys. Med. Rehabil. Clin. N. Am., 
14,27-46. 
Schallert, T., Upchurch, M., Lobaugh, N., Farrar, S. B. , Spirduso, W. W. , Gilliam, P., 
Vaughn, D., Wilcox, R. E. (1982). Tactile extinction: distinguishing between 
sensorimotor and motor asymmetries in rats with unilateral nigrostriatal damage. 
Pharmaco!. Biochem. Behav. , 16, 455-462. 
Schapira, A. H. (2008). Mitochondria in the aetiology and pathogenesis of Parkinson's 
disease. Lancet Neural., 7,97-109. 
Schapira, A. H., Gegg, M. (2011). Mitochondrial contribution to Parkinson's disease 
pathogenesis. Parkinsons Dis., 2011, 159160. 
Schechter, R., Whitmire, J., Wheet, G. S., Beju, D., Jackson, K. W., Harlow, R., 
Gavin, J. R. III (1994) . Immunohistochemical and in situ hybridization study of 
an insulin-like substance in fetal neuron cell cultures. Brain Res., 636, 9-27. 
Schieber, M., Chandel, N. S. (2014). ROS function in redox signaling and oxidative 
stress. Curr. Bio!. , 24, 453-462. 
Schmidt, C. F. , Kety, S. S. (1947). Recent studies of cerebral blood flow and cerebral 
metabolism in man. Trans. Assac. Am. Physicians, 60, 52-58. 
Schmidtz, H. D. (2001). Reversible nuclear translocation of glyceraldehyde-3-phosphate 
dehydrogenase upon serum depletion. Eur. J Cell. Bio!., 80, 419-427. 
Schneider, L., Zhang, J. (2010). Lysosomal function in macromolecular homeostasis and 
bioenergetics in Parkinson's disease. Mol. Neurodegener., 5, 14. 
Sch6nfeld, P., Reiser, G. (2013) . Why does brain metabolism not favor buming of fatty 
acids to provide energy? Reflections on disadvantages of the use of free fatty acids 
as fuel for brain. J Cereb. Blood Flow Metab., 33, 1493-1499. 
367 
Schrag, A. , Jahanshahi, M. , Quinn, N. (2000). How does Parkinson's disease affect 
quality of life? A comparison with quality of life in the general population. 
Mov. Disord. , 15, 1112-1118. 
Schroeter, S. , Apparsundaram, S., Wiley, R. G. , Miner, L. H. , Sesack, S. R. , 
Blakely, R . D. (2000) . Immunocolocalization of the cocaine- and antidepressant-
sensitive l-norepinephrine transporter. J Comp. Neurol. , 420, 211-232. 
Schubert, D. , LaCorbiere, M. , Klier, F. G. , Steinbach, J. H. (1980). The modulation 
of neurotransmitter synthesis by steroid hormones and insulin. Brain Res., J 90, 
67-79. 
Schulingkamp, R., Pagano, T. , Hung, D. , Raffa, R. (2000). Insulin receptors and insulin 
action in the brain: review and clinical implications. Neurosci. Biobehav. Rev., 24, 
855-872. 
Schultz, W. (1998). Predictive reward signal of dopamine neurons. J Neurophysiol. , 80, 
1-27. 
Schultz, W. (2002). Getting formaI with dopamine and reward. Neuron, 36, 241-263 . 
Schultz, W. (2006). Behavioral theories and the neurophysiology of reward. Annu. Rev. 
Psychol. , 5 7, 87-115 . 
Schultz, W. (2007). Multiple dopamine functions at different time courses. Annu. Rev. 
Neurosci., 30, 259-288. 
Schultz, W. (2010). Dopamine signaIs for reward value and risk: basic and recent data. 
Behav. Brain Funct. , 6, 24. 
Schwab, R. S. (1960). Progression and prognosis in Parkinson's disease. J Nerv. Ment. 
Dis., 130, 556-566. 
Schwab, R. S. , Doshay, L. J. , Garland, H. , Bradshaw, P. , Garvey, E., Crawford, B. 
(1956). Shift to older age distribution in parkinsonism: a report on 1,000 patients 
covering the past decade from three centers. Neurology, 6, 783-790. 
Schwarting, R. K. , Huston, 1. P. (1996). The unilateral 6-hydroxydopamine les ion model 
in behavioral brain research. Analysis of functional deficits, recovery and 
treatments. Prog. Neurobiol. , 50, 275-331. 
Seger, C. A., Spiering, B. 1. (20 Il). A critical review of habit leaming and the basal 
ganglia. Front. Syst. Neurosci., 5, 66. 
368 
Segovia, K. N., Correa, M., Salamone, J. D. (2011). Slow phasic changes in nucleus 
accumbens dopamine release during fixed ratio acquisition: a microdialysis study. 
Neuroscience, 24, 178-188. 
Segura-Aguilar, 1., Paris, L, Munoz, P., Ferrari, E., Zecca, L., Zucca, F. A. (2014). 
Protective and toxic roles of dopamine in Parkinson's disease. J Neurochem. 129, 
898-915. 
Sesack, S. R, Carr, D. B., Omelchenko, N., Pinto, A. (2003). Anatomical substrates for 
glutamate-dopamine interactions: evidence for specificity of connections and 
extrasynaptic actions. Ann. N. Y Acad. Sci. , 1003, 36-52. 
Shafrir, E. (2003). Diabetes in animais: Contribution to the understanding of diabetes by 
study of its etiopathology in animal models. In Porte, D., Sherwin, R. S., Baron, A. 
(eds), Diabetes Mellitus. New York: McGraw-Hill. pp. 231-55. 
Sharma, M., Petersen, L, Nazareth, L, Coton, S. 1. (2016). An algorithm for 
identification and classification of individuals with type 1 and type 2 diabetes 
mellitus in a large primary care database. Clin. Epidemiol., 8, 373-380. 
Sharma, V., Baia, A., Deshmukh, R, Bedi, K. L., Sharma, P. L. (2012). Neuroprotective 
effect of RO-20-1724-a phosphodiesterase4 inhibitor against intracerebro-
ventricular streptozotocin induced cognitive deficit and oxidative stress in rats. 
Pharmacol. Biochem. Behav. , 101, 239-245. 
Shen, W., Flajolet, M., Greengard, P., Surmeier, D. 1. (2008). Dichotomous 
dopaminergic control of striatal synaptic plasticity. Science, 321, 848-85l. 
Shipanova, 1. N., Glomb, M. A., Nagaraj, R H. (1997) . Prote in modification by 
methylglyoxal: chemical nature and synthetic mechanism of a major fluorescent 
adduct. Arch. Biochem. Biophys., 344, 29-36. 
Shulman, R., Hyder, F., Rothman, D. (2001). Lactate efflux and the neuroenergetic basis 
ofbrain function. NMR Biomed. 14, 389-396. 
Sian, J., Dexter, D. T., Lees, A. J. , Daniel, S., Agid, Y., Javoy-Agid, F., Jenner, P., 
Marsden, C. D. (1994). Alterations in glutathione levels in Parkinson's disease 
and other neurodegenerative disorders affecting basal ganglia. Ann. Neu ro 1. , 36, 
348-355. 
Siemann, E. H. Creas y, L. L. (1992). Concentration of the phytoalexin resveratrol in 
wine. American Journal of En 0 logy and Viticulture, 43, 49-52. 
369 
Siesj6, B. K. (1978). Brain Energy Metabolism. New York: John Wiley & Sons. 
Sikstr6m, S., S6derlund, G. (2007). Stimulus-dependent dopamine release in attention-
deficit/hyperactivity disorder. Psycho!. Rev. , 114, 1047-1075. 
Simonetti, P., Pietta, P. , Testolin, G. (1997). Polyphenol content and total antioxidant 
potential of selected ltalian wines. J Agric. Food Chem., 45, 1152-1155. 
Simons, L. A., von Konigsmark, M. , Simons, J. , Celermajer, D. S. (2000). 
Phytoestrogens do not influence lipoprotein levels or endothelial function in 
healthy, postmenopausal women. Am. J Cardiol., 85, 1297-1301. 
Simpson, 1. A., Appel, N. M., Hokari, M., Oki, J., Holman, G. D., Maher, F., Koehler-
Stec, E. M. , Vannucci, S. J., Smith, Q. R. (1999). Blood-brain barrier 
glucose transporter: effects of hypo- and hyperglycemia revisited. J Neurochem., 
72, 238-247. 
Simpson, 1. A., Carruthers, A., Vannucci, S. J. (2007). Supply and demand in cerebral 
energy metabolism: the role of nutrient transporters. J Cereb. Blood Flow Metab., 
27, 1766-1791. 
Simpson, 1. A., Dwyer, D., Malide, D., Moley, K. H., Travis, A., Vannucci, S. J. (2008). 
The facilitative glucose transporter GLUT3: 20 years of distinction. Am. J 
Physiol. Endocrinol. Metab., 295, 242-53. 
Simpson, 1. A. , Vannucci, S. J. , DeJoseph, M. R., Hawkins, R. A. (2001). Glucose 
transporter asyrnmetries in the bovine blood-brain barrier. J Biol. Chem., 276, 
12725-12729. 
Simpson, 1. A. , Vannucci, S. J., Maher, F. (1994). Glucose transporters in marnrnalian 
brain. Biochem. Soc. Trans., 22, 671-675 . 
Singh, R., Barden, A., Mori, T. , Beilin, L. (2001) Advanced glycation end-products: 
a review. Diabetologia, 44, 129-146. 
Singleton, A. B., Farrer, M. , Johnson, J., Singleton, A., Hague, S. , Kachergus, J., 
Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., Lincoln, S., Crawley, A., 
Hanson, M., Maraganore, D., Adler, C., Cookson, M. R. , Muenter, M., Baptista, 
M., Miller, D., Blancato, J. , Hardy, J., Gwinn-Hardy, K. (2003). alpha-Synuclein 
locus triplication causes Parkinson's disease. Science, 302, 841. 
370 
Sinha, K., Chaudhary, G., Gupta, Y. K. (2002). Protective effect of resveratrol against 
oxidative stress in middle cerebral artery occlusion model of stroke in rats. 
Life Sei., 71, 655-665 . 
Skibsted, A. P. , Cunha-Bang, S. D., Carré, J. M., Hansen, A. E. , Beliveau, V., Knudsen, 
G. M. , Fisher, P . M . (2017) . Aggression-related brain function assessed with the 
Point Subtraction Aggression Paradigm in fMRI. Aggress. Behav., 43, 601-610. 
Smeets, W. 1., Gonzalez, A. (2000). Catecholamine systems in the brain of vertebrates: 
new perspectives through a comparative approach. Brain Res. Brain Res. Rev., 33, 
308-379. 
Snyder, B. , Cunningham, R. L. (2017). Sex differences in sleep apnea and comorbid 
neurodegenerative diseases. Steroids, pii: S0039-128X, 30232-5. 
Sokoloff, L. (1999). Energetics of functional activation in neural tissues. Neurochem. 
Res., 24, 321-329. 
Sokoloff, L., Reivich M. , Kennedy, C. , Des Rosiers, M. H. , Patlak, C. S. , Pettigrew, 
K. D. , Sakurada, O. , Shinohara, M. (1977). The [14C]deoxyglucose method for the 
measurement of local cerebral glucose utilization: the ory, procedure, and normal 
values in the conscious and anesthetized albino rat. J Neurochem., 28, 897-916. 
Solberg, N. O., Chamberlin, R., Vigil , J. R., Deck, L. M. , Heidrich, J. E. , Brown, D. C., 
Brady, C. 1. , Vander, T. A. , Garwood, M. , Bisoffi, M. , Sevems, V. , Vander 
Jagt, D. L. , Sillerud, L. O. (2014). Optical and SPION-Enhanced MR Irnaging 
Shows that trans-Stilbene Inhibitors of NF-KB Concomitantly Lower Alzheimer's 
Disease Plaque Formation and Microglial Activation in A~PPIPS-l Transgenic 
Mouse Brain. J Alzheimers Dis., 40, 191-212. 
Soleas, G. 1., Diamandis, E. P. , Goldberg, D. M. (2001). The world of resveratrol. 
Adv. Exp . Med. Biol. , 492, 159-182. 
Sone, H ., Deo, B. K. , Kumagai, A. K. (2000). Enhancement of glucose transport by 
vascular endothelial growth factor in retinal endothelial cells. Invest. Ophthalmol. 
Vis. Sei. , 41, 1876-1884. 
Song, D . W. , Xin, N. , Xie, B. J. , Li, Y. J., Meng, L. Y. , Li, H. M ., SchHippi, M. , 
Deng, Y. L. (2014). Formation of a salsolinol-like compound, the neurotoxin, 
l-acetyl-6,7-dihydroxy-l ,2,3,4-tetrahydroisoquinoline, in a cellular model of 
hyperglycemia and a rat model of diabetes. Int. J Mol. Med. , 33, 736-742. 
371 
Song, 1. X. , Sze, S. c., Ng, T. B. , Lee, C. K., Leung, G. P., Shaw, P. C. , Tong, Y. , 
Zhang, y. B. (2012). Anti-Parkinsonian drug discovery from herbaI medicines: 
what have we got from neurotoxic models ? J Ethnopharmaeol., 139, 698-711. 
Song, T. Y., Yang, N. C., Chen, C. L., Thi, T. L. V. (2017). Protective Effects and 
Possible Mechanisms of Ergothioneine and Hispidin against Methylglyoxal-
Induced Injuries in Rat Pheochromocytoma Cells. Oxid. Med. Cel!. Longev., 2017, 
4824371. 
Soong, N. W. , Hinton, D. R. , Cortopassi, G. , Arnheim, N. (1992). Mosaicism for 
a specifie somatic mitochondrial DNA mutation in adult human brain. Nat. Genet., 
2,318-323. 
Sotak, B. N., Hnasko, T. S. , Robinson, S., Kremer, E. J. , Palmiter, R. D. (2005). 
Dysregulation of dopamine signaling in the dorsal striatum inhibits feeding. 
Brain Res., 1061, 88-96. 
Sousa Silva, M., Gomes, R. A., Ferreira, A. E., Ponces Freire, A. , Cordeiro, C. (2013). 
The glyoxalase pathway: the first hundred years ... and beyond. Bioehem. J , 
453, 1-15. 
Spasié, M. R., Callaerts, P., Norga, K. K. (2009). AMP-activated prote in kinase 
(AMPK) molecular crossroad for metabolic control and survival of neurons. 
Neuroscientist, 15, 309-316. 
Spillantini, M. G. , Schmidt, M. L. , Lee, V. M. Y. , Trojanowski, J. Q. , Jakes, R., 
Goedert, M. (1997). Alpha-synuclein in Lewy bodies. Nature, 388, 839-840. 
Srinivasan, K., Ramarao, P. (2007). Animal models in type 2 diabetes research: 
an overview. lndian J Med. Res., 125, 451-472. 
Srinivasan, K., Viswanad, B. , Asrat, L. , Kaul, C. L. , Ramarao, P. (2005). Combination 
of high-fat diet-fed and low-dose streptozotocin-treated rat: A model for type 2 
diabetes and pharmacological screening. Pharmaeol. Res., 52, 313-320. 
Srivastava, G. , Dixit, A. , Yadav, S. , Patel , D. K., Prakash, O., Singh, M. P. (2012). 
Resveratrol potentiates cytochrome P450 2 d22-mediated neuroprotection in 
maneb- and paraquat-induced parkinsonism in the mouse. Free Radie. Biol. Med., 
52, 1294-1306. 
Stafstrom, C. E., Rho, J. M. (2012). The ketogenic diet as a treatment paradigm for 
diverse neurological disorders. Front. Pharmaeol. , 3, 59. 
372 
StanCié, A., Otasevié, V., Jankovié, A., Vucetié, M., Ivanovié-Burmazovié, I., 
Filipovié, M. R., Koraé, A., Markelié, M., Velickovié, K., Golié, I., Buzadzié, B., 
Koraé, B. (2013). Molecular basis of hippocampal energy metabolism in diabetic 
rats: the effects of SOD mimic. Brain Res. Bull., 99, 27-33. 
Stanley, M. E., Click, S. D. (1976). Interaction of drug effects with testing procedures in 
the measurement of catalepsy. Neuropharmacol., 15, 393-394. 
Stark, A. K. , Pakkenberg, B. (2004). Histological changes of the dopaminergic 
nigrostriatal system in aging. Cel!. Tissue Res., 318, 81-92. 
Starkov, A. A., Fiskum, G., Chinopoulos, C., Lorenzo, B. J., Browne, S. E., Patel, M. S., 
Beai, M. F. (2004). Mitochondrial alpha-ketoglutarate dehydrogenase complex 
generates reactive oxygen species. J Neurosci., 24, 7779-7788. 
Steenland, K., Hein, M. J., Cassinelli, R. T. 2nd, Prince, M. M., Nilsen, N. B., Whelan, 
E. A., Waters, M. A., Ruder, A. M., SchnOIT, T. M. (2006). Polychlorinated 
biphenyls and neurodegenerative disease mortality in an occupational cohort. 
Epidemiology, 17, 8-13. 
Stein, L. (1964). Self-stimulation of the brain and the central stimulant action of 
amphetamine. Fed Proc, 23, 836-850. 
Steinmetz, K. A., Potter, 1. D. (1996). Vegetables, fruit, and cancer prevention: a review. 
J Am. Diet. Assoc., 96, 1027-1039. 
Stivala, L. A., Savio, M., Carafoli, F., Perucca, P., Bianchi, L., Maga, G. , Forti, L., 
Pagnoni, U. M., Albini, A., Prosperi, E., Vannini, V. (2001). Specific structural 
determinants are responsible for the antioxidant activity and the cell cycle effects 
ofresveratrol. J Biol. Chem., 276,22586-22594. 
Stockhorst, U., de Fries, D ., Steingrueber, H. 1., Scherbaum, W. A. (2004). Insulin and 
the CNS: effects on food intake, memory, and endocrine parameters and the role 
of intranasal insulin administration in humans. Physiol. Behav., 83, 47-54. 
Stoeckel, L. E., Palley, L. S., Gollub, R . L., Niemi, S. M., Evins, A. E. (2014). Patterns 
of brain activation when mothers view their own child and dog: an fMRI study. 
PLoS One, 9, el07205. 
Stokholm, M. G., Danielsen, E. H., Hamilton-Dutoit, S. J. , Borghammer, P. (2016). 
Pathological a-synuclein in gastrointestinal tissues from prodromal Parkinson 
disease patients. Ann. Neurol., 79, 940-949. 
373 
Stouffer, M. A. , Woods, C. A. , Patel, J. c., Lee, C. R. , Witkovsky, P. , Bao, L. , 
Machold, R. P., Jones, K. T. , de Vaca, S. C. , Reith, M. E., Carr, K. D. , Rice, M. E. 
(2015). Insulin enhances striatal dopamine release by activating cholinergie 
intemeurons and thereby signaIs reward. Nat. Commun. , 6, 8543. 
Streit, W. J. , Miller, K. R. , Lopes, K. O. , Njie, E. (2008). Microglial degeneration in 
the aging brain--bad news for neurons? Front. Biosei. , 13, 3423-3438. 
Stryer, L. , Berg, J. M. , Tymoczko, J. L. (2007). In: Biochemistry (6th ed.). 
San Francisco: W. H. Freeman. 
Su, C. K. , Chen, C. Y. , Tseng, P. J., Sun, Y. C. (2015) . Using copper ions to amplify 
ROS-mediated fluorescence for continuous online monitoring of extracellular 
glucose in living rat brain. Biosens. Bioelectron. , 64, 535-541. 
Su, Y. , Duan, J., Ying, Z. , Hou, Y. , Zhang, Y. , Wang, R. , Deng, Y. (2013). Increased 
vulnerability of parkin knock down PC 12 cells to hydrogen peroxide toxicity: 
the role of salsolinol and NM-salsolinol. Neuroseience, 233, 72-85. 
Sugino, T. , Maruyama, M., Tanno, M. , Kuno, A., Houkin, K., Horio, Y. (2010) . 
Protein deacetylase SIRTl in the cytoplasm promotes nerve growth factor-induced 
neurite outgrowth in PCl2 cells. FEBS LeU., 584, 2821-2826. 
Sulzer, D., Bogulavsky, J., Larsen, K. E., Behr, G., Karatekin, E.? Kleinman, M. H., 
Turro, N. , Krantz, D. , Edwards, R. H. , Greene, L. A. , Zee ca, L. (2000). 
Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not 
accumulated by synaptic vesicles. Proc. Nat!. Acad. Sei. U. S.A., 9 7, 11869-11874. 
Sun, A. Y. , Wang, Q. , Simonyi, A. , Sun, G. Y. (2010). Resveratrol as a therapeutic agent 
for neurodegenerative diseases. Mol. Neurobiol. , 41, 375-383. 
Sun, x., Shimizu, H. , Yamamoto, K. (1995). Identification of a novel p53 promoter 
element involved in genotoxic stress-inducible p53 gene expression. Mol. Cell. 
Biol., 15, 4489-4496. 
Sun, x., Yao, H. , Douglas, R. M. , Gu, X. Q. , Wang, J. , Haddad, G. G. (2010). 
InsulinJPI3K signaling protects dentate neurons from oxygen-glucose deprivation 
in organotypic slice cultures. J. Neurochem., 112, 377-388. 
Sun, Y. , Chang, Y. H. , Chen, H. F. , Su, Y. H., Su, H. F., Li, C. y. (2012). Risk of 
Parkinson disease onset in patients with diabetes: a 9-year population-based cohort 
study with age and sex stratifications. Diabetes Care, 35, 1047-1049. 
374 
Surmeier, D. J. (2007) . Calcium, ageing, and neuronal vulnerability ln Parkinson's 
disease. Lancet Neurol., 6, 933-938. 
Surmeier, D. 1., Obeso, J. A., Halliday, G. M. (2017). Selective neuronal vulnerability in 
Parkinson disease. Nat. Rev. Neurosci., 18, 101-113. 
Surmeier, D. 1., Schumacker, P. T. (2013). Calcium, bioenergetics, and neuronal 
vulnerability in Parkinson's disease. J Biol. Chem., 288, 10736-10741. 
Surwit, R. S. , Kuhn, C. M., Cochrane, C., McCubbin, 1. A. , Feinglos, M. N. (1988). 
Diet-induced type II diabetes in C57BL/6J mice. Diabetes, 37, 1163-1167. 
Szkudelski, T. (2012). Streptozotocin-nicotinamide-induced diabetes in the rat. 
Characteristics of the experimental model. Exp. Biol. Med. (Maywood), 237, 
481-490. 
Tadaiesky, M. T., Dombrowski, P. A., Figueiredo, C. P. , Cargnin-Ferreira, E., 
Da Cunha, C., Takahashi, R. N. (2008). Emotional, cognitive and neurochemical 
alterations in a premotor stage model of Parkinson's disease. Neuroscience, 
156, 830-840. 
Takahashi, S., lzawa, Y , Suziki, N. (2012) . Astroglial pentose phosphate pathway rates 
in response to high-glucose environments. ASN Neuro, 4, pii:e00078. 
Takeda, H., Inazu, M. , Matsumiya, T. (2002). Astroglial dopamine transport is mediated 
by norepinephrine transporter. Naunyn Schmiedebergs Arch. Pharmacol., 
366, 620-623. 
Tanaka, Y, Engelender, S., 19arashi, S., Rao, R. K. , Wanner, T., Tanzi, R. E., 
Sawa, A. , L. Dawson, V. , Dawson, T. M., Ross, C. A. (2001). lnducible 
expression of mutant alpha-synuclein decreases proteasome activity and increases 
sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet., 10, 919-926. 
Tanda, G., Bassareo, v., Di Chiara, G. (1996). Mianserin markedly and selectively 
increases extracellular dopamine in the prefrontal cortex as compared to the 
nucleus accumbens of the rat. Psychopharmacol. , 123, 127-130. 
Tarpey, M. M. , Wink, D. A., Grisham, M. B. (2004). Methods for detection of reactive 
metabolites of oxygen and nitrogen: in vitro and in vivo considerations. Am. J 
Physiol. R egu 1. Integr. Comp. Physiol. , 286, 431-444. 
Tatton, N. A. (2000) . lncreased caspase 3 and Bax immunoreactivity accompany nuclear 
GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp. Neurol., 
166, 29-43. 
375 
Taurin, S. , Seyrantepe, V. , Orlov, S. N. , Tremblay, T. L. , Thibault, P. , Bennett, M. R., 
Hamet, P. , Pshezhetsky, A. V. (2002). Proteome analysis and functional 
expression identify mortalin as an antiapoptotic gene induced by elevation of 
[Na+]iI[K+]i ratio in cultured vascular smooth muscle cells. Circ. Res., 91, 915-922. 
Tay, T. L. , Savage, 1. c., Hui , C. W. , Bisht, K. , Tremblay, M . È. (2017). Microglia 
across the lifespan: from origin to function in brain development, plasticity and 
cognition. J Physiol. , 595, 1929-1945. 
Teismann, P., Sathe, K. , Bierhaus, A. , Leng, L. , Martin, H . L. , Bucala, R ., Weigle, B. , 
Nawroth, P. P. , Schulz, J. B. (2012). Receptor for advanced glycation end 
products (RAGE) deficiency protects against MPTP toxicity. Neurobiol Aging, 33, 
2478-2490. 
Tennen, R. I., Michishita-Kioi, E. , Chua, K. F. (2012). Finding a target for resveratrol. 
Cel!, 148, 387-389. . 
Thakran, S. , Salimuddin, Baquer, N. Z. (2003). Oral administration of orthovanadate and 
Trigonella foenum graecum seed power restore the activities of mitochondrial 
enzymes in tissues of alloxan-induced diabetic rats. Mol. Cel! Biochem., 247, 
45-53. 
Thenganatt, M. A. , Jankovic, J. (2014). Parkinson disease subtypes. JAMA Neurol. 71, 
499-504. 
Thomalley, P. J. (1988). Modification of the glyoxalase system in human red blood cells 
by glucose in vitro. Biochem. J , 254, 751-755. 
Thomalley, P. J. (2005). Dicarbonyl intermediates in the maillard reaction. Ann. N Y 
Acad. Sei. , 1043, 111-117 . 
Thomalley, P. 1. , Langborg, A. , Minhas, H. S. (1999). Formation of glyoxal, 
methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. 
Biochem. J , 344, 109-116. 
Thurston, J. H., McDougal, D. B. Jr, Hauhart, R. E., Schulz, D . W. (1995). Effects of 
acute, subacute, and chronic diabetes on carbohydrate and energy metabolism in 
rat sciatic nerve. Relation to mechanisms of peripheral neuropathy. Diabetes, 44, 
190-195. 
Tilov, B. , Semerdzhieva, M. , Bakova, D. , Tomyova, B. , Stoyanov, D. (2016). Study of 
the relationship between aggression and chronic diseases (diabetes and 
hypertension). J Eval. Clin. Pract., 22, 421-424. 
376 
Tillerson, J. L., Cohen, A. D., Philhower, J. , Miller, G. W., Zigmond, M. J., Schallert, T. 
(2001). Forced limb-use effects on the behavioral and neurochemical effects of 
6-hydroxydopamine. J Neurosei., 21, 4427-4435 . 
Tillerson, J. L. , Miller, G. W. (2002). Forced limb-use and recovery following brain 
injury. Neuroseientist, 8, 574-585. 
Tomlinson, D. R., Gardiner, N. 1. (2008). Glucose neurotoxicity. Nat. Rev. Neurosei., 9, 
36-45. 
Toulorge, D., Schapira, A. H., Hajj, R. (2016). Molecular changes in the postmortem 
parkinsonian brain. J Neurochem., 139, 27-58. 
Tremblay, C., Durand Martel, P., Frasnelli, 1. (2017). Trigeminal system in Parkinson's 
disease: A potential avenue to detect Parkinson-specific olfactory dysfunction. 
Parkinsonism Re/at. Disord., 44, 85-90. 
Trétiakoff, C. (1919). Contribution à l'étude de l'anatomie pathologique du locus niger 
de Soemmering avec quelques déductions relatives à la pathogénie des troubles du 
tonus musculaire et de la maladie de Parkinson. Paris: Jouve. 
Trezza, V., Baarendse, P. J. , Vanderschuren, L. J. (2010). The pleasures of play: 
pharmacological insights into social reward mechanisms. Trends Pharmacol. Sei., 
31, 463-469. 
Trincheri, N. F. , Nicotra, G. , FolIo, c., Castino, R. , Isidoro, C. (2007). Resveratrol 
induces cell death in colorectal cancer cells by a novel pathway involving 
lysosomal cathepsin D. Carcinogenesis, 28, 922-931. 
Tritsch, N. X. , Sabatini, B. L. (2012). Dopaminergic modulation of synaptic 
transmission in cortex and striaturn. Neuron., 76, 33-50. 
Trulson, M. E., Himmel, C. D. (1983). Decreased brain dopamine synthesis rate and 
increased [3H]spiroperidol binding in streptozotocin-diabetic rats. J Neurochem. , 
40, 1456-1459. 
Trumpower, B. L. (1990). The proton motive Q cycle. J Biol. Chem., 265, 
11409-11412. 
Tsang, A. H. , Chung, K. K. (2009) . Oxidative and nitrosative stress in Parkinson's 
disease. Biochim. Biophys. Acta, 1792,643-650. 
377 
Uchiki, T., Weikel, K. A., Jiao, W. , Shang, F., Caceres, A., Pawlak, D., Handa, 1. T. , 
Brownlee, M., Nagaraj , R., Taylor, A. (2012). Glycation-altered proteolysis as a 
pathobiologic mechanism that links dietary glycemic index, aging, and age-related 
disease (in nondiabetics). Aging Cel!, Il, 1-13. 
UK Prospective Diabetes Study (UKPDS) Group. (1998). Intensive blood-glucose 
control with sulphonylureas or insulin compared with conventional treatment and 
risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352, 
837-853. 
Uldry, M., Steiner, P., Zurich, M. G., Béguin, P., Hirling, H., Dolci, W., Thorens, B. 
(2004). Regulated exocytosis of an H+/myo-inositol symporter at synapses and 
growth cones. EMBO J , 23, 531-540. 
Uldry, M., Thorens, B. (2004). The SLC2 family of facilitated hexose and polyol 
transporters. Pflugers Arch., 447, 480-489. 
Ulusoy, A. , Rusconi, R., Pérez-Revuelta, B. L, Musgrove, R. E., Helwig, M. , Winzen-
Reichert, B. , Di Monte, D. A. (2013). Caudo-rostral brain spreading of a-synuc1ein 
through vagal connections. EMBO Mol. Med. , 5, 1051-1059. 
Unger, J. W. , Moss, A. M. , Livingston, J. N. (1991). Immunohistochemicallocalization 
of insulin receptors and phosphotyrosine in the brainstem of the adult rat. 
Neuroscience, 42, 853-861. 
Ungerstedt, U. (1968). 6-hydroxy-dopamine induced degeneration of central monoamine 
neurons. Eur. J Pharmacol., 5, 107-110. 
Ungerstedt, U. (1971). Adipsia and aphagia after 6-hydroxy dopamine induced 
degeneration of the nigrostriatal dopamine system. Acta Physiol. Scan ., 367, 
95-122. 
Ungerstedt, U., Arbuthnott, G. W. (1970). Quantitative recording ofrotational behaviour 
in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. 
Brain Research, 24, 485-493 . 
Ungerstedt, U., Herrera-Marchitz, M., Jungnelius, u., Stahle, L. , Tossman, u., 
Zetterstrom, T. (1982). Dopamine synaptic mechanisms reflected in studies 
combining behavioral recordings and braindialysis. In Kotisaka, M. , (ed), 
Advances in Dopamine Research. Pergamon Press, Elmsford, N.Y. pp. 219-231. 
Un gers te dt, u., Pycock, C. (1974). Functional correlates of dopamine 
neurotransmission. Bull. Schweitz. Akad. Med. Wiss., 30, 44-55. 
378 
Vaishnavi, S. N., Vlassenko, A. G. , Rundle, M. M., Snyder, A. Z. , Mintun, M. A., 
Raichle, M. E. (2010). Regional aerobic glycolysis in the human brain. Proc. Natl. 
Acad. Sci. U.S.A., 107, 17757-17762. 
Valko, M., Izakovic, M. , Mazur, M. , Rhodes, C. J., Telser, J. (2004). Role of oxygen 
radicals in DNA damage and cancer incidence. Mol. Cel/. Biochem., 266,37-56. 
Van Belle, T. L., Taylor, P., von Herrath, M. G. (2009). Mouse Models for Type 1 
Diabetes. Drug Discov. Today Dis. Models, 6, 41-45. 
Van den Berghe, G., Schoonheydt, K. , Becx, P., Bruyninckx, F. , Wouters, P. J. (2005) . 
Insulin therapy protects the central and peripheral nervous system of intensive care 
patients. Neurology, 64, 1348-1353. 
van Duinkerken, E. , Schoonheim, M. M., Sanz-Arigita, E. J. , IJzerman, R. G., 
Moll, A. C., Snoek, F. J., Ryan, C. M., Klein, M., Diamant, M., Barkhof, F. 
(2012). Resting-state brain networks in type 1 diabetic patients with and without 
microangiopathy and their relation to cognitive functions and disease variables. 
Diabetes, 61, 1814-1821. 
Vander Jagt, D. L., Kolb, N. S., Vander Jagt, T. J., Chino, J., Martinez, F. J. , Hunsaker, 
L. A. , Royer, R. E. (1995). Substrate specificity of human aldose reductase: 
identification of 4-hydroxynonenal as an endogenous substrate. Biochim. Biophys. 
Acta, 1249, 117-126. 
Vander Jagt, D. L., Robinson, B. , Taylor, K. K. , Hunsaker, L. A. (1992). Reduction of 
trioses by ' NADPH-dependent aldo-keto reductases. Aldose reductase, 
methylglyoxal, and diabetic complications. J Biol. Chem., 267, 4364-4369. 
VanItallie, T. B., Nufert, T. H. (2003). Ketones: metabolism's ugly duckling. Nutr. Rev., 
61, 327-341. 
Varamini, B., Sikalidis, A. K., Bradford, K. L. (2014). Resveratrol increases cerebral 
glycogen synthase kinase phosphorylation as weIl as prote in levels of drebrin and 
transthyretin in mice: an exploratory study. Int. J Food. Sei. Nutr., 65, 89-96. 
Vaughn, A. E., Deshmukh, M. (2008). Glucose metabolism inhibits apoptosis in neurons 
and cancer cells by redox inactivation of cytochrome c. Nature Cell. Biol. , 10, 
1477-1483. 
Vega, C., Martiel, J . L. , Drouhault, D. , Burckhart, M. F., Coles, J. A. (2003). Uptake of 
locally applied deoxyglucose, glucose and lactate by axons and Schwann cells of 
rat vagus nerve. J Physiol., 546, 551-564. 
379 
Vella, F., Ferry, G., Delagrande, P., Boutin, J. A. (2005). NRH:quinone reductase 2: 
an enzyme of surprises and mysteries. Biochem. Pharmacol. , 71, 1-12. 
Vellucci, S. V., Sirinathsinghji, D. 1., Richardson, P. J. (1993) . Adenosine A2 receptor 
regulation of apomorphine-induced tuming in rats with unilateral striatal dopamine 
denervation. Psychopharmacol., 111, 383-388. 
Venton, B. J., Zhang, H., Garris, P. A. , Phillips, P. E . M., Sulzer, D., Wightman, R. M. 
(2003). Real-time decoding of dopamine concentration changes in the caudate-
putamen during tonic and phasic firing. J Neurochem., 87, 1284-1295. 
Verdaguer, 1. , Yoon, J. W., Anderson, B. , Averill, N., Utsugi, T., Park, B. J., 
Santamaria, P. (1996). Acceleration of spontaneous diabetes in TCR-btransgenic 
nonobese diabetic mice by b-cell cytotoxic CD8+ T ceUs expressing identical 
endogenous TCR-a chains. J Immunol., 15 7, 4726-4735 . 
Verdile, G. , Fuller, S. J. , Martins, R. N. (2015). The role of type 2 diabetes In 
neurodegeneration. Neurobiol. Dis., 84, 22-38. 
Vicente Miranda, H. , EI-Agnaf, O. M. , Outeiro, T. F. (2016). Glycation in Parkinson's 
disease and Alzheimer's disease. Mov. Disord. , 31, 782-790. 
Vicq D'Azyr, F. (1786). Traité d 'Anatomie et de Physiologie, Tome Premier: Anatomie 
et Physiologie du Cerveau. Paris: Didot. 
Vidyadhara, D. 1., Yarreiphang, H. , Abhilash, P. L. , Raju, T. R. , Alladi. P. A. (2016). 
Differentiai expression of calbindin in nigral dopaminergic neurons in 
two mice strains with differential susceptibility to I-methyl-4-phenyl-l ,2,3,6-
tetrahydropyridine. J Chem. Neuroanat., 76, 82-89. 
Vilensky, J. A. , Gilman, S., McCall, S. (2010) . A historical analysis of the relationship 
between encephalitis lethargica and postencephalitic parkinsonism: a complex 
rather th an a direct relationship. Mov. Disord. , 25, 1116-1123. 
Vincent, A. , Briggs, L. , Chatwin, G. F. J. , Emery, E., Vincent, A. , Briggs, L. , 
Chatwin, G. F. , Emery, E. , Tomlins, R., Oswald, M. , Middleton, C. A., 
Evans, G. J., Sweeney, S. T. , Elliott, C. 1. (2012). Parkin-induced defects in 
neurophysiology and locomotion are generated by metabolic dysfunction and not 
oxidative stress . Human Mol. Gen., 21, 1760-1769. 
Vitrac, X. , Moni, J. P. , Vercauteren, J. , Deffieux, G. , Mérillon, J. M. (2002). Direct 
liquid chromatography analysis of resveratrol derivatives and flavanonols in wines 
with absorbance and fluorescence detection. Anal. Chim. Acta, 458, 103-110. 
380 
Verdin, E. (2015). NAD in aging, metabolism, and neurodegeneration. Seience, 350, 
1208-1213. 
Volpicelli-Daley, L. A., Luk, K. C., Patel, T. P., Tanik, S. A., Riddle, D. M. , Stieber, A., 
Meaney, D. F. , Trojanowski, J. Q., Lee, V. M. (2011). Exogenous a-synuclein 
fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron 
death. Neuron, 72, 57-71. 
von Ruesten, A., Feller, S., Bergmann, M.M., Boeing, H. (2013). Diet and risk of 
chronic diseases: results from the first 8 years of follow-up in the EPIC-Potsdam 
study. Eur. J Clin. Nutr., 67,412-419. 
Wadhwa, R., Ryu, J. , Ahn, H. M., Saxena, N., Chaudhary, A., Yun, C. O. , Kaul, S. C. 
(2015). Functional significance of point mutations in stress chaperone mortalin 
and their relevance to Parkinson disease. J Biol. Chem., 290, 8447-8456. 
Wages, S. A., Church, W. H., Justice, J. B. (1986). Sampling considerations for online 
microbore liquid chromatography ofbrain dialysis. Anal. Chem., 58, 1649-1656. 
Wahlqvist, M. L., Lee, M.-S., Hsu, C.-C., Chaung, S.-Y. , Lee, J.-T., Tsai, H.-N. (2012). 
Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease 
occurring with Type 2 diabetes in a Taiwanese population cohort. Park. 
Relat. Disord., 18, 753-758. 
Wang, C., Cai, Y., Zheng, Z., Tang, B. S., Xu, Y. , Wang, T., Ma, 1. , Chen, S. D., 
Langston, J. W., Tanner, C. M., Chan, P.; Chinese Parkinson Study Group 
(CPSG). (2012). Penetrance of LRRK2 G2385R and R1628P is modified 
by common PD-associated genetic variants. Parkinsonism Relat. Disord., 18, 
958-963 . 
Wang, L. P., Li, F., Wang, D., Xie, K. , Shen, X., Tsien, J. Z. (2011) . NMDA receptors in 
dopaminergic neurons are crucial for habit learning. Neuron, 72, 1055-1066. 
Wang, M., Yan, W., Liu, Y., Hu, H. Sun, Q., Chen, X., Zang, W., Chen, L. (2017). 
Erythropoietin ameliorates diabetes-associated cognitive dysfunction in vitro and 
in vivo. Sei. Rep. , 7, 2801. 
Wang, W., Jaiswal, A. K. (2004). Sp3 repression of polymorphie human NRH:quinone 
oxydoreductase 2 gene promoter. Free Radie. Biol. Med., 37, 1231-1243. 
Wang, W., Le, W.-D., Pan, T., Stringer, J. L., Jaiswal, A. K. (2008). Association of 
NRH: quinone oxidoreductase 2 gene promoter polymorphism with higher gene 
expression and increased susceptibility to Parkinson 's disease. J Gerontol. A Biol. 
Sei. Med. Sei., 63, 127-134. 
381 
Wang, Z. H. , Zhang, 1. L. , Duan, Y. L., Zhang, Q. S., Li, G. F., Zheng, D. L. (2015). 
MicroRNA-214 participates in the neuroprotective effect of Resveratrol via 
inhibiting a-synuclein expression in MPTP-induced Parkinson's disease mouse. 
Biomed. Pharmacother., 74, 252-256. 
Wang, Z. R. , Hsieh, T. C., Zhang, Z., Ma, Y., Wu, J. M. (2004). Identification and 
purification of resveratrol targeting proteins using immobilized resveratrol affinity 
chromatography. Biochem. Biophys. Res. Commun. , 323, 743-749. 
Warburg, O. (1956). On the origin of cancer cells. Science, 123, 309-314. 
Wamer, T. T., Schapira, A. H. (2003). Genetic and environmental factors in the cause of 
Parkinson's disease. Ann. Neurol., 53, 16-23; discussion 23-25. 
Watanabe, H., Passonneau, J. V. (1973). Factors affecting the turnover of cerebral 
glycogen and limit dextrin in rive. J Neurochem., 20, 1543-1554. 
Wei, 1., Huang, N. C., Quast, M . J. (1997). Hydroxyl radical formation in hyperglycemic 
rats during middle cerebral artery occlusionlreperfusion. Free Radic. Biol. Med. , 
23, 986-995. 
Wei, Y. (1998). Oxidative stress and mitochondrial DNA mutations in human aging. 
Soc. Exp. Biol. Med., 217, 53-63 . 
Weisova, P., Concannon, C. G. , Devocelle, M. , Prehn, J. H. M., Ward, M . W. (2009). 
Regulation of glucose transporter 3 surface expression by the AMP-activated 
protein kinase mediates tolerance to glutamate excitation in neurons. J Neurosci., 
29, 2997-3008. 
Weisskopf, M. G. , Knekt, P., o 'Reilly, E. J., Lyytinen, 1., Reunanen, A. , Laden, F. , 
Altshul, L. , Ascherio, A. (2012). Polychlorinated biphenyls in prospectively 
collected serum and Parkinson's disease risk. Mov. Disord. , 27, 1659-1665. 
Wenner, C. E. (2012). Targeting mitochondria as a therapeutic target in cancer J Cell. 
Physiol. , 227, 450-456. 
Westerink, R. H., Ewing, A . G. (2008). The PC12 cell as model for neurosecretion. 
Acta Physiol. (Oxj), 192, 273-285. 
Whitesell, R. R., Ward, M., McCall, A. L., Granner, D. K. , May, J . M. (1995). Coupled 
glucose transport and metabolism in cultured neuronal cells: determination of the 
rate-limiting step. J Cereb. Blood Flow Metab. , 15, 814-826. 
382 
Wickens, J. R. , Begg, A. J. , Arbuthnott, G. W. (1996). Dopamine reverses the 
depression of rat corticostriatal synapses which normally follows high-frequency 
stimulation of cortex in vitro. Neuroscience, 70, 1-5. 
Widmer, M., Uldry, M. , Thorens, B. (2005). GLUT8 subcellular localization and 
absence of translocation to the plasma membrane in PC 12cells and hippocampal 
neurons. Endocrinology, 146, 4727-4736. 
Wightman, R. M. , Robinson, D. L. (2002). Transient changes in mesolimbic dopamine 
and their association with "reward". J Neurochem., 82, 721-735 . 
Williamson, G., Manach, C. (2005) . Bioavailability and bioefficacy of polyphenols in 
humans. II. Review of 93 intervention studies. Am. J Clin. Nutr., 81, 243S-255S. 
Williamson, J . R., Chang, K. , Frangos, M., Hasan, K. S., Ido, Y. , Kawamura, T., 
Nyengaard, 1. R., van den Enden, M. , Kilo, C., Tilton, R. G. (1993). 
Hyperglycemic pseudohypoxia and diabetic complications. Diabetes, 42, 801-8 13 . 
Wilson, J. E. (2003). Isozymes of mammalian hexokinase: structure, subcellular 
localization and metabolic function. J Exp. Biol. , 206, 2049-2057. 
Winzell , M. S. , Ahren, B. (2004). The high-fat diet-fed mouse: A model for studying 
mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. 
Diabetes, 53, 215-219. 
Wirdefeldt, K. , Adami, H. O., Cole, P., Trichopoulos, D., Mandel, J. (201 1). 
Epidemiology and etiology of Parkinson's disease: a review of the evidence. 
Eur. J Epidemiol., 26, 1-58. 
Wise, R. A. , Bozarth, M. A. (1987). A psychomotor stimulant the ory of addiction. 
Psychol. Rev., 94, 469-492. 
W6hr, M., Schwarting, R. K. W. (2013). Affective communication in rodents: ultrasonic 
vocalizations as a tool for research on emotion and motivation. Cell. Tissue Res., 
354,81-97. 
Wolff, S. P. , Jiang, Z. Y., Hunt, J . V. (1991). Protein glycation and oxidative stress in 
diabetes mellitus and ageing. Free Radic. Biol. Med., 10, 339-352. 
Won, S. J., Kim, J. E., Cittolin-Santos, G. F. , Swanson, R. A. (2015). Assessment at 
the single-cell level identifies neuronal glutathione depletion as both a cause and 
effect ofischemia-reperfusion oxidative stress. J Neurosci. , 35, 7 143-7152. 
383 
Wood, 1. S., Trayhurn, P. (2003). Glucose transporters (GLUT and SGLT): expanded 
families of sugar transport proteins. Br. J Nutr., 89, 3-9. 
Woods, S. C. , Porte, D. Jr. (1977). Relationship between plasma and cerebrospinal fluid 
insulin levels ofdogs. Am. J Physiol. , 233, 331-334. 
World Health Organization. (2016). Global report on diabetes. http://apps.who.int/ 
iris/bitstrearn/l 0665/204871/ 1/9789241565257_ eng.pdf?ua= 1 
Wu, J ., Jin, Z., Zheng, H. , Yan, L. 1. (2016). Sources and implications of 
NADHlNAD(+) redox imbalance in diabetes and its complications. Diabetes 
Metab. Syndr. Obes., 9, 145-153. 
Wu, J. M. , Wang, Z. R. , Hsieh, T. C. , Bruder, 1. L. , Zou, 1. G., Huang, Y. Z. (2001). 
Mechanism of cardioprotection by resveratrol, a phenolic antioxidant present in 
red wine (review). Inter. J Mol. Med. , 8, 3-17. 
Wu, Y. L. , Chang, J. c., Lin, W. Y. , Li , C. c., Hsieh, M. , Chen, H. W. , Wang, T. S. , 
Liu, C. S. , Liu, K. L. (2017). Treatment with Caffeic Acid and Resveratrol 
Alleviates Oxidative Stress Induced Neurotoxicity in Cell and Drosophila Models 
of Spinocerebellar Ataxia Type3. Sei. Rep ., 7, 11641. 
Wu, Y. , Li, X. , Zhu, J. X. , Xie, W. , Le, W. , Fan, Z. , Jankovic, 1. , Pan, T. (2011). 
Resveratrol-activated AMPKlSIRTl/autophagy in cellular models of Parkinson's 
disease. Neurosignals, 19, 163-174. 
Xu, Q. , Park, Y. , Huang, X., Hollenbeck, A. , Blair, A. , Schatzkin, A. , Chen, H. (2011). 
Diabetes and risk ofParkinson's disease. Diabetes Care, 34, 910-915. 
Xue, M. , Weickert, M. O. , Qureshi, S. , Kandala, N. B. , Anwar, A., Waldron, M., 
Shafie, A. , Messenger, D., Fowler, M. , Jenkins, G. , Rabbani, N. , Thornalley, P. 1. 
(2016). Improved Glycemic Control and Vascular Function in Overweight and 
Obese Subjects by Glyoxalase 1 Inducer Formulation. Diabetes, 65, 2282-2294. 
Yahr, M. D. , Duvoisin, R. C. , Schear, M. J. , Barrett, R. E., Hoehn, M. M. (1969). 
Treatrnent ofparkinsonism with levodopa. Arch. Neurol. , 21, 343-354. 
Yamada, T., Mc Geer, P. L. , Baimbridge, K. G., McGeer, E. G. (1990) . Relative sparing 
in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-
D28K. Brain Res., 526, 303-307. 
384 
Yamamoto, H., Uchigata, Y., Okamoto, H. (1981). Streptozotocin and alloxan induce 
DNA strand breaks and poly(ADP-ribose) synthatase in pancreatic islets. 
Nature, 294, 284-286. 
Yamamoto, K. , Vernier, P. (2011). The evolution of dopamine systems in chordates. 
Front. Neuroanat., 5, 1-21. 
Yang, H., Zhou, X., Liu, X., Yang, L., Chen, Q., Zhao, D., Zuo, J., Liu, W. (2011 ). 
Mitochondrial dysfunction induced by knockdown of mortalin is rescued by 
Parkin. Biochem. Biophys. Res. Commun., 410, 114-120. 
Yang, X., Cheng, B. (2010). Neuroprotective and anti-inflammatory actlvltles of 
ketogenic diet on MPTP-induced neurotoxicity. J Mol. Neurosci., 42, 145-153. 
Yapo, C., Nair, A. G., Clement, L. , Castro, L. R., Hellgren Kotaleski, J. , Vincent, P. 
(2017). Detection of phasic dopamine by Dl and D2 striatal medium spiny 
neurons. J Physiol. 595, 7451-7475 . 
Yetnikoff, L., Lavezzi, H. N. , Reichard, R. A., Zahm, D. S. (2014). An update on the 
connections of the ventral mesencephalic dopaminergic complex. Neuroscience, 
282,23-48. 
Yin, F., Sancheti, H. , Liu, Z., Cadenas, E. (2016). Mitochondrial function in ageing: 
coordination with signalling and transcriptional pathways. J Physiol., 594, 
2025-2042. 
Yoon, J. W. , Jun, H. S. (2001). Cellular and molecular pathogenic mechanisms of 
insulin-dependent diabetes mellitus. Ann. N Y Acad. Sei., 928, 200-211. 
Yoshimura, N. , Kawamura, M. , Masaoka, Y., Homma, 1. (2005) . The amygdala of 
patients with Parkinson's disease is silent in response to fearful facial expressions. 
Neuroscience, 131, 523-534. 
Youdim, M. B. , Ben-Shachar, D. , Riederer, P. (1989) . Is Parkinson's disease a 
progressive siderosis of substantia nigra resulting in iron and melanin induced 
neurodegeneration? Acta Neurol. Seand. Suppl. , 126, 47-54. 
Youdim, M. B., Heldman, E., Pollard, H. B., Fleming, P., McHugh, E. (1986). 
Contrasting monoamine oxidase activity and tyramine induced catecholamine 
release in PC 12 and chromaffin cells. Neuroscience, 19, 1311-1318. 
Youdim, M. B., Weinstock, M. (2004). Therapeutic applications of selective and 
non-selective inhibitors of monoamine oxidase A and B that do not cause 
significant tyramine potentiation. Neurotoxicology, 25, 243-250. 
385 
Young, W. S. III (1986). Periventricular hypothalamic cells in the rat brain contain 
insulin rnRNA. Neuropeptides, 8, 93-97. 
Young, W. S. III, Alheid, G. F., Heimer, L. (1984). The ventral pallidal projection to the 
mediodorsal thalamus: a study with fluorescent retro grade tracers and 
immunohistofluorescence. J Neurosci. , 4, 1626-1638. 
Yuan, H ., Zhang, W. , Li, H. , Chen, C. , Liu, H. , Li, Z. (2013). Neuroprotective effects of 
resveratrol on embryonic dorsal root ganglion neurons with neurotoxicity induced 
by ethanol. Food Chem. Toxicol., 55, 192-201. 
Yung, H. S. , Lai, K. H. , Chow, K. B., Ip, N. Y. , Tsim, K. W. , Wong, y. H. , Wu, Z. , 
Wise, H. (2010). Nerve growth factor-induced differentiation of PC12 cells is 
accompanied by elevated adenylyl cyc1ase activity. Neurosignals, 18, 32-42. 
Zaccai, J., Brayne, C., McKeith, L, Matthews, F. , Ince, P. G. (2008). Patterns and stages 
of alpha-synuc1einopathy: relevance in a populationbased cohort. Neurology, 70, 
1042-1048. 
Zahniser, N. R. , Goens, M. B. , Hanaway, P . 1. , Vinych, 1. V. (1984). Characterization 
and regulation ofinsulin receptors in rat brain. J Neurochem., 42, 1354-1362. 
Zaitone, S. A. , Abo-Elmatty, D. M. , Elshazly, S. M. (2012). Piracetam and vinpocetine 
ameliorate rotenone-induced Parkinsonism in rats. lndian J Pharmacol. , 44, 
774-779. 
Zecca, L. , Casella, L. , Albertini, A. , Bellei, C., Zucca, F. A. , Engelen, M. , Zadlo, A. , 
Szewczyk, G., Zareba, M. , Sarna, T. (2008). Neuromelanin can protect against 
iron-mediated oxidative damage in system modeling iron overload of brain aging 
and Parkinson's disease. J Neurochem., 106, 1866-1875. 
Zecca, L. , Tampellini, D. , Gerlach, M. , Riederer, P. , Fariello, R. G. , Sulzer, D. (2001). 
Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. 
Mol. Pathol., 54, 414-418. 
Zeng, H. Y. , Green, W. R., Tso, M . O. (2008) . Microglial activation in human diabetic 
retinopathy. Arch. Ophthalmol. , 126, 227-232. 
Zeng, W ., Zhang, W., Lu, F., Gao, L. , Gao, G. (2017) . Resveratrol attenuates 
MPP+-induced mitochondrial dysfunction and cell apoptosis via AKT/GSK-3~ 
pathway in SN4741 cells. Neurosci. Leu. , 63 7, 50-56. 
386 
Zeng, X. X., Ng, Y. K. , Ling, E. A. (2000). Neuronal and micro glial response in the 
retina ofstreptozotocin-induced diabetic rats. Vis. Neurosei., 17,463-471. 
Zetterstrom, T., Sharp, T. , Collin, A. K., Ungerstedt, U. (1988). in vivo measurement of 
extracellular dopamine and DOP AC in the rat striatum after various dopamine-
releasing drugs: Implications for the origin of extracellular DOP AC. Eur. J 
Pharmacol. , 148, 327-334. 
Zhang, L. , Doyon, W. M. , Clark, J. J. , Phillips, P. E. , Dani, J. A. (2009). Controls of 
tonic and phasic dopamine transmission in the dorsal and ventral striatum. 
Mol. Pharmacol., 76, 396-404. 
Zhang, F. L. , Ye, C. Z. , Li, G., Ding, W., Zhou, W., Zhu, H. , Chen, G., Luo, T., 
Guang, M. , Liu, Y., Zhang, D. , Zheng, S. , Yang, J. , Gu, Y., Xie, X., Luo, M. 
(2003). The rat model of type 2 diabetic mellitus and its glycometabolism 
characters. Exp. Anim., 52, 401-407. 
Zhao, c., Wang, L. , Li , W. (2015). Protective effect of HAMI 3379 against high 
glucose-induced PC12 cell injury. Research in Pharmaceutical Biotechnology, 6, 
1-7. 
Zhao, X., Wang, J., Hu, S., Wang, R., Mao, Y., Xie, J. (2017). Neuroprotective effect of 
resveratrol on rotenone-treated C57BL/6 mice. Neuroreport, 28, 498-505. 
Zhao, X. Z. , Jiang, T., Wang, L. , Yang, H., Zhang, S., Zhou, P. (2010). Interaction of 
curcurnin with Zn(II) and Cu(II) ions based on experiment and theoretical 
calculation. Journal of Molecular Structure, 984, 316-325. 
Zheng, H., Zheng, Y. , Zhao, L. , Chen, M., Bai, G., Hu, Y., Hu, W., Yan, Z., Gao, H. 
(2017). Cognitive dec1ine in type 2 diabetic db/db mice may be associated with 
brain region-specific metabolic disorders. Biochim. Biophys. Acta, 1863,266-273. 
Zhu, Q. Y., Zhang, A. Q. , Tsang, D. , Huang, Y., Chen, Z. Y. (1997). Stability of green 
tea catechins. J Agric. Food Chem., 45, 4624-4628. 
Zhuang, H. , Kim, Y. S., Koehler, R. C., Doré, S. (2003). Potential mechanism by which 
resveratrol, a red wine constituent, protects neurons. Ann. N. Y Acad. Sei. , 993, 
276-286. 
Ziegler, D., Buchholz, S., Sohr, C. , Nourooz-Zadeh, J. , Roden, M. (2015). Oxidative 
stress predicts progression of peripheral and cardiac autonomic nerve dysfunction 
over 6 years in diabetic patients. Acta Diabetol. , 52, 65-72. 
387 
Ziegler, D. , Schleicher, E. , Strom, A. , Knebel, B. , Fleming. T. , Nawroth, P. , 
Haring, H. U , Papanas, N. , Szendr6di, J. , Müssig, K. , AI-Hasani, H. , Roden, M., 
GDS Group. (2017). Association of transketolase polymorphisms with measures 
of polyneuropathy in patients with recently diagnosed diabetes. Diabetes Metab. 
Res. Rev. , 33. 
Zielke, H. R., Zielke, C. L. , Baab, P. J. (2007). Oxidation of (14)Clabeled compounds 
perfused by microdialysis in the brains of free-moving rats. J Neurosei. Res., 85, 
3145-3149. 
Zini, R. , Morin, C. , Bertelli, A. , Bertelli, A. A. , Tillement, J. P. (1999). Effects of 
resveratrol on the rat brain respiratory chain. Drugs Exp . Clin. Res., 25, 87-97. 
Zini, R. , Morin, C., Bertelli, A., Bertelli , A. A. , Tillement, J. P. (2002). Resveratrol-
induced limitation of dysfunction of mitochondria isolated from rat brain in an 
anoxia-reoxygenation mode!. Life Sei., 71, 3091-3108. 
Zykova, T. A. , Zhu, F. , Zhai, X. , Ma, W. Y. , Ermakova, S. P. , Lee, K. W. , Bode, A. M. , 
Dong, Z. (2008). Resveratrol directly targets COX-2 to inhibit carcinogenesis. 
Mol. Careinog., 4 7, 797-805. 
~~~~~~~~~~~--------------------------~ 
APPENDIXA 
LA NEURO-INFLAMMATION : DR JEKYLL OU MR HYDE? 
Renaud, J., Thérien, H. M. , Plouffe, M., Martinoli, M. G. (2015). 
MIS, 31, 979-988. 
The content of this appendix was published ln November 2015 ln the 
peer -reviewed journal M édecinel Sciences (Paris) . 
Author contributions 
Justine Renaud wrote 45% of the manuscript, and prepared and edited aH figures 
and tables. Hélène-Marie Thérien, from the Department of Medical Biology at the 
Université du Québec à Trois-Rivières, wrote 45% of the manuscript. Marilyn Plouffe, 
student in the laboratory of Maria-Grazia Martinoli, participated in the writing. 
Maria-Grazia Martinoli, Justine Renaud 's research supervisor, was the guarantor of the 
work and provided supervision, preparation and editing of the manuscript. 
390 
Full review article in French: La neuro-inflammation : Dr Jekyll ou Mr Hyde? 
Abstract 
Sheltered in a bony cage, populated by cells with little regenerative potential, 
the central nervous system (CNS) could likely not withstand classic inflammation 
without risking major sequelae. As a consequence, it had to develop an original way to 
provide surveillance, defence and reparation, which relies on both, the complex 
architecture of the periphery-nervous parenchyma exchange zones and the tightly 
regulated collaboration between all the cell populations that reside in or pass through 
the CNS. Despite its tight regulation, neuroinflammation is sometimes the cause of 
irreversible loss but it is also where the solution stands. The specific immune crosstalk 
that takes place in the CNS needs to be decoded in order to identify the best therapeutic 
strategies aimed at helping the CNS to restore homeostasis in problematic situations 
such as is the case in neurodegenerative disorders. This review deals with this double-
edged sword nature of neuroinflammation. 
Résumé 
Enchâssé dans une cage osseuse, peuplé de cellules qui ont peu de pouvoir de 
régénération, le système nerveux central (SNC) ne peut supporter une réaction 
inflammatoire telle qu'elle se déroule en périphérie sans en subir de graves 
conséquences. Il lui a donc fallu développer une façon originale pour assurer 
surveillance, défense et réparation, qui repose à la fois sur l'architecture complexe des 
zones d'échange entre la périphérie et le parenchyme nerveux et sur la collaboration 
hautement contrôlée de toutes les cellules du SNC. Bien que parfois source de 
problèmes comme c'est le cas dans les maladies neurodégénératives, la neuro-
inflammation est aussi porteuse de la solution. C'est de cette double nature dont il est 
ici question. 
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Introduction 
On a longtemps cru le système nerveux central (SNC) à l'abri de la majorité 
des effets dévastateurs de la réaction inflammatoire. On le disait immunoprivilégié, 
protégé qu'il était des agressions étrangères par la barrière hémato-encéphalique (BHE) 
(Figure 1) et camouflé du système immunitaire par le peu d'expression des produits du 
complexe majeur d'histocompatibilité (CMH) et l'absence de drainage lymphatique. 
Mais, au cours de la dernière décennie, l'accumulation des évidences a fait s'écrouler le 
paradigme. S'il n'y a maintenant plus de doute quant à l' existence d'une réaction 
inflammatoire dans le SNC et quant à l'utilisation du langage commun de cytokines et 
de chimiokines pour contrôler ses actions [1], force est aussi de constater que la réaction 
inflammatoire du SNC se comporte de façon suffisamment différente de son homologue 
périphérique pour se mériter l'appellation particulière de «neuro-inflammation ». 
Cette façon unique de gérer l'inflammation et les étapes premières de la réaction immune 
à travers un drainage soluble plutôt que cellulaire tient aux propriétés particulières des 
différentes composantes du parenchyme nerveux [pour revue, voir 2]. La notion de 
privilège, toujours de mise, ne concerne donc plus que le parenchyme, excluant ainsi les 
zones limitrophes que sont les espaces péri vasculaires, les méninges et les ventricules. 
Privilège bien relatif car, aussi différente soit-elle de l'inflammation, la neuro-
inflammation demeure un pari risqué pour un tissu aussi fragile que celui du SNC si on 
s'en fie aux pertes fonctionnelles auxquelles on l'associe dans les maladies 
neurodégénératives telles que l'Alzheimer, la maladie de Parkinson ou la sclérose en 
plaques [3]. 
La reconnaIssance d'une perturbation interne est un prérequis essentiel à 
l'induction de la réaction inflammatoire. Cette reconnaissance est assurée par un 
ensemble de récepteurs, baptisés PRR (pattern-recognition receptors) , dont on connaît 
pour le moment une vingtaine de membres [4]. Ces PRRs peuvent être solubles, 
membranaires ou cytosoliques et reconnaissent tout autant les signatures moléculaires de 
classes de pathogènes (PAMPs pour pathogen-associated molecular patterns) que des 
molécules générées au cours de stress cellulaires autres qu ' infectieux (DAMPs pour 
damage-associated molecular patterns) . On compte parmi les DAMPs des protéines 
392 
agrégées, modifiées ou simplement mal repliées telles l' a-synuc\éine, la protéine Tau ou 
la ~-amyloïde qui, toutes, ont été associées à des maladies neurodégénératives. 
On compte aussi parmi les DAMPs de simples molécules comme l'ATP ou le glutamate, 
abondamment libérées dans le milieu lors de nécroses cellulaires au sein du SNC [5]. 
L'interaction des PAMPs/DAMPs avec leur récepteur induit une cascade de 
signalisation qui, en recrutant protéines adaptatrices et kinases, aboutit à l'activation de 
facteurs de transcription qui modifient de façon drastique le phénotype cellulaire. 
Cette modification se manifeste tant par l'acquisition de nouveaux récepteurs que par 
l'expression d'un éventai 1 de cytokines et de chimiokines qui, par des actions à la fois 
autocrines et paracrines, guident les cellules de défense au site de l'agression, permettent 
le déploiement focalisé des mécanismes de défense (phagocytose, production de dérivés 
toxiques de l'oxygène, apoptose) et préparent les étapes de la reconstruction. 
Dans le SNC, lorsqu'il est question d'inflammation, c'est la cellule microgliale, 
la cellule résidente à vocation immune du tissu, qu'on accuse d'emblée de 
débordements. L'accusation est d'autant plus facile qu'on la retrouve toujours dans 
les zones inflammées et, qui plus est, avec sa morphologie de cellule « activée» [6]. 
Cependant, au contraire de ce qu'on observe en périphérie où l'expression constitutive 
des PRRs est un attribut plutôt spécifique des cellules de la défense innée, on constate 
que, dans le SNC, les astrocytes, les oligodendrocytes et les neurones expriment leur 
propre répertoire de PRRs par lequel ils contribuent eux aussi à toutes les étapes de la 
neuro-inflammation (Tableau 1 et Figure 2) [4]. 
Figure 1 
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Jonctions communicantes 
Lame basale 
Schématisation de la barrière hémato-encéphalique. 
La barrière hémato-encéphalique (BHE) empêche la pénétration de la 
grande majorité des agents et des cellules circulant dans le sang vers 
le système nerveux central (SNC). Elle est composée de cellules 
endothéliales, de péricytes, de la lame basale et de la glia limitans. 
Les cellules endothéliales recouvrent complètement la lumière des 
capillaires du SNC et son non-fenestrées, contrairement à la majorité 
des cellules endothéliales périphériques. Elles sont reliées entre-elles 
par des jonctions serrées constituées de protéines transmembranaires -
occludines, claudines, et JAM (junctional adhesion molecules) - ainsi que 
par des jonctions adhérentes assurées par l'interaction entre des 
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cadhérines_ Ces protéines transmembranaires sont liées au cytosquelette 
à l'aide de protéines adaptatrices, tantôt ZOI et Z02 (zonula occludens 
protéines 1 et 2), tantôt des caténines_ Quant aux péricytes, elles sont 
distribuées sur 20-30 % de la surface des cellules endothéliales et régulent 
leur différenciation et prolifération, De par les propriétés contractiles de 
leurs projections cellulaires qui entourent les cellules endothéliales, 
elles peuvent modifier le diamètre des vaisseaux sanguins en réponse à 
l'activité neuronale. De plus, la lame basale tapisse intégralement 
l'extérieur des péricytes et des cellules endothéliales. La lame basale 
assure un support physique pour l' arrimage et la migration de certaines 
cellules par l' expression d ' intégrines, mais agit également comme 
barrière contre le passage de cellules ou de macromolécules indésirables 
de par sa constitution matricielle. Finalement, la glia limitans recouvre 
> 99 % de la surface des capillaires du SNe. Les pieds astrocytaires qui la 
forment sont reliés entre eux par des jonctions communicantes et 
adhérentes. La glia limitans régule la morphologie et la perméabilité de la 
BHE en contrôlant l'expression de certaines protéines des cellules 
endothéliales, 
Tableau 1 
Rôles pro- et anti-inflammatoires des divers acteurs cellulaires du SNC dans 
la neuro-inflammation (suite à la page suivante) 
Arteur 
cellulaire 
Ctll""s Micro-
Ilia •• 
Neurones 
Promotion de 'ca ,..uro ... inftCUftmotlon 
Adlon.& Fade"",lmpllqu.& 
uprenlon de cytokines pro+mflammo+ 
toires 
Expression de protéines membranolresl 
rétepteun/PRR 
ExpreSSion de chimloltlnes 
Polarisation des Th yers Thl 
Présentation d'antieènes soutenant 
,'activation d!$ cellul!$ Th activées 
Production de monoxyde d'azote 
Production de prostollandlne$ pro-
inflammatOi res 
Induct ion de $trtU oxydont et mtrasatlf 
Facllitatton de la mllrahon d!$ c!lIule$ 
défense pérlphénques 
TNF-<l, IFN-r, Il-6, Il- Ill 
TlR, RAGE, lU- l , MAC- l, CRs, FcRjl 
CXClI , 2, 12 ; cm, s, 10, 19 
Il-12,ll- 23 
CMH classe Il, facteurs de coUlmulatlon 
iNOS 
COX-2 
ROS, RNS 
MMP 
Génération de molKules neurotollques Glu, acide quinohnique (100) 
SoutJen de l'immumté innée molécules du complément 
ProductIon de OAMP ATP, HMGa l, H5P 
Sécrétion de chlmiolcines 
Ex pression de PRR 
Génération de molécules neurotoxlqulS 
Skrétion de neurotransmetteurs pro-
inflammatoires 
Production de monoxyde d'olote 
Focilitatton de la mlJfabon des cellules 
dt défense périphériques 
CXClIO, CCl21 
TLR 
Glu 
DA, substance P 
iN05 
MHP 
Inhibition de Ica neW"O-lnfla"'ftlClt'on 
Adlon.& fod_"'" impliqu'& 
Sécrétion de cyto&clntS anti · mflommo· 
toires 
ExpreSSion de protéines membronolresl 
récepteurs· 
Polarisation des cellules Th vers Tree 
Diminution de la production de NO por 
détournement de "Ara 
Production de Pfostoe'andlnes tons t,· 
tutins 
Exprtulon de facteurs neurotrophlqufS 
Inhibition de la prolifération des cel-
lules T par détournement du Trp 
Inhibition des AAP 
Induction de l'opoptose des cellules 
défense périphériques et autoréplatlon 
Sécrétion de cytollines 
Sécrétion de chimiokines anti- inflam-
matoires 
Expreuion de protéines membranaires 
Inhibant cellules immunitaires" 
Polorisation des Th vers Tre. 
Sécrétion de neurotransmetteurs et 
neuropeptides anti- inflammatoires 
Remodela,t de la matfl te. extracellu-
laire 
1l-4, ll- IO,IFN-Il, TGF-Il 
C045, C041, CO 56 (NCA.I4), C091, 
C0200R, C0112, CX3CRI , TREM2, TSa, 
Fosl, Fos 
TGF-Il 
COX-I ou détriment de COX-2 
aONF, GONF 
100 
TIHP 
Fost, Fos 
Il-IO, TGF-p 
froctalkine soluble 
C022, COH, C056 (NCA.I4), C0200, froc-
tollune, Fosl 
TGF-p 
GABA, VIP, NE, a -MSH, somatostotlRe, 
CGRP 
Protéo&1ycones 
Acte"r 
c.n.&loJ .. 
N.urones 
Astrocytls 
Olipdtndroqtes 
Promotion cie la neuro-fnftommation 
Adlono& Fact • ..,. Impllqu4io & 
Production de DAMP 
ExpreSSion de cytolnnes pro-
Inflammatoires 
expression de prot~lnes membranairesl 
ricept.urs/PRR 
ATP, HMGBI, HSP, protéin .. mol rephées 
(protélnopothllS neurodéeénérotlvH) 
THF-a,IFN-y,ll-11I 
cxm, 2, 12; ecu, 5, 10, 19 
TLR, RAGE,ICAMI, CR 
Gin~ratlon de molécules n.urotoxlques Glu (diminution dt son intffnalisatlon) 
Présentation d'antilines soutenant 
"actrvation des c.llules Th adivNs ? 
Facilitation dl la mllrollon des cellules 
de déf .... p'''ph.''qu .. 
Production de monOlyde d'azote 
Soutien de l'immuniti InnH 
Production de DAMP 
Dédifférenciation tn rod,o/-,Ua-lilte 
ctlls 
Expression de PRR 
CMH classe Il, fad.urs d. costimulotton 
MMP 
INOS 
Molécules du comp~ment 
ATP, HMGBI, HSI' 
cm 
TlR 
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Inhibition de la neuro-Inflammation 
Adlono & FOd •• ". impllquh& 
upression de fadeurs neurotrophiques 
Induction de "opoptose des microllies 
et cellules défense périphériques 
Absence d'QcUvotion des cellules cyto-
toxiques coa' 
Inhibition des cellules HK par activation 
du KIR 
Sécrétion de cytolunes ontt-Inflamma-
toires 
uprtsSlon de prot~ntS membranaires 
Inhibant cellules Immunitaires 
Polarisation des lh nrS lItt 
Remodelact d.la matrlc, atlacellu-
laire 
upression de fad.urs neurotrophiques 
Inhibition des MMP 
InductlOll de l'apoptoH des microl'ies 
et cellules défense plnphtriques 
Oécilfférenclotlon en radlal-I"a-/d,e 
(fils 
Sécrétion de cytolcines 
Expression de protéines membranai"s 
inhibant cellules immunitaires 
HGf, BONf, NTl, GOHF, CHTF 
Fosl 
Abs.nce de HLA A, BouC (CMH cl .... 
10) 
HLA G (CMH cl .... lb) 
IH, Il- ID, IFN-II, TGF-II 
Inhibiteurs du complément, CTlA-4 
TGF-II, atm 
BONF, GONf, HGF, CTHF, FGf 
TIMP 
f.sl, PO-LI (chez coll.lu T octi .... 
.. primont PO-I) 
FGF2,IGFI, SOFl, VEGF 
TGF-II 
(0200, fractalkine 
& Arg, argmme; ATP, adénosine triphosphate; BDNF, brain-derived neurotrophic factor; CCL, chemokine 
[C-C motif] ligand; CD, cluster of difJerentiation; CD200R, cluster of difJerentiation 200 receptor; CMH, complex 
majeur d' histocompatibil ité; CNTF; ciliary neurotrophic factor; COX-2, cyclooxygénase-2; CR, complement 
receptor; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; CX3CR, chemokine [C-X3-C motif] receptor; 
CXCL, chemokine [C-X-C motif] ligand; DAMP, damage-associated molecular pattern; Fas,flrst apoptosis signal 
receptor; FasL, flrst apoptosis signal receptor ligand ou ligand Fas; FcR~, fragment crystallizable region (Fe) 
receptor beta subunit; FGF, flbrob last growth factor; GDNF, glial flbrillary acidic protein; Glu, glutamate; HLA, 
human leucocyte antigen; HMGB l, high mobility group box J; HSP, heat shock protein; ICAMl, intercellular 
adhesion molecule; IDO, indoleamine 2,3-dioxygenase; IFN, interferon; IGF, insulin-like growth factor; IL, 
interleukine; iNOS, inducible nitric oxide synthase; KIR, !..:iller-cell immunoglobulin-like receptor; LF A, lymphocyte 
fitnction-associated antigen-1; MAC-l, macrophage-J antigen; MMP, matrix metalloproteinases; NCAM, neural 
cell adhesion molecule; NGF, nerve growth factor; NK, natural killer; NO, oxyde nitrique; Nn, neurotrophin-3; 
PD- l , programmed cell death protein J; PD-LI, programmed death-ligand 1; PRR, pattern-recognition receptors, 
RAGE, receptor for advanced glycation end-products; RNS, reactive nitrogen species; ROS, reactive oxygen 
species; SDF l , stromal cell-derivedfactor 1; TGF-~, transforming growthfactor-beta; Th, T helper cell subtype; 
TIMP, tissue inhibitor of metalloproteinase; TLR, toll-like receptor; TNF-a, tumor necrosis factor-alpha; 
Treg, regulatory T cell; TREM2, triggering receptor expressed on myeloid cells 2; TSB, thrombospondin; 
VEGF, vascular endothelial growthfactor. 
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C microgliales activées 
classiquement 
• 
t 
C de défense 
C microgliale au repos 
CT cytotoxique 
légende 
~ molécules du CMH de classe 1 
.: PAMPs/DAMPs 
~ molécules du CMH de classe Il 
\" antigènes présentés 
récepteurs de C T 
~. cytokines pro-inflammatoires 
~. cytokines anti-inflammatoires 
y PRRs 
..... effet anti-inflammatoire ..... effet pro-inflammatoire 
.11 couples membranaires d'immunorégulation 
.. transformation phénotypique 
Figure 2 Dialogues entre les cellules neuronales dans un contexte de neuro-
inflammation. 
Dans un contexte de neuro-inflammation, des molécules de danger 
nommées P AMPs (pathogen-associated molecular patterns) ou 
DAMPs activent les cellules munies de récepteurs PRRs, principalement 
les cellules microgliales_ L'activation de la microglie mène à leur 
multiplication et à leur transfonnation vers le phénotype pro-
inflammatoire, caractérisé par une fonne amiboïde et l'expression accrue 
de cytokines et de molécules du CMH de classe IL Suite à leur activation 
par les P AMPs ou DAMPs, les astrocytes subissent également des 
La microglie 
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changements phénotypiques tendant vers l'expression accrue de 
cytokines, la présentation d'antigènes et la prolifération. Les cellules du 
SNC, en particulier les cellules microgliales activées classiquement, 
produisent des cytokines capables de perméabiliser la BHE et sécrètent 
des chimiokines, permettant la transvasation de cellules de défense 
périphériques - lymphocytes, granulocytes, macrophages, etc. - des 
capillaires vers le parenchyme. Ces cellules peuvent également 
reconnaître des PAMPs et des DAMPs dans le parenchyme, ce qui 
soutient leur activation et leur prolifération accompagnées de l'expression 
de cytokines pro-inflammatoires. Néanmoins, plusieurs acteurs expriment 
constitutivement des cytokines anti-inflammatoires ou des molécules 
membranaires donc la fonction immunomodulatrice permet de contenir 
la réaction inflammatoire, par la polarisation des cellules Th en types 
anti-inflammatoires et par la transformation de la microglie en un état 
réparateur. L'exposition à long terme aux cytokines pro-inflammatoires 
endommage les neurones et les oligodendrocytes, les types cellulaires les 
plus sensibles à une neuro-inflammation chronique dû à leur faible 
potentiel régénérateur. 
La microglie constitue en moyenne 10 % de l'ensemble des cellules gliales. 
Originant du sac vitellin à partir d'un précurseur érythro-myéloïde CSF1R+ (coiony 
stimuiating factor 1 receptor) commun aux macrophages résidents [7] , les cellules 
microgliales colonisent très tôt le neuroépithélium où elles poursuivent leur 
différenciation selon une voie originale dans l'environnement particulier du SNe. 
Elles conservent tout au long de la vie un certain pouvoir de régénération qui leur permet 
à la fois de maintenir leur pool et de répondre à des demandes ponctuelles [8]. Après la 
naissance, une sous-population de cellules microgliales semblerait également provenir 
de source hématopoïétique par l'infiltration de monocytes dans le parenchyme [9] . 
Toujours à explorer leur environnement à travers les mouvements rapides de leurs 
extensions cytoplasmiques qui se chevauchent très peu, dotées d 'un très vaste potentiel 
d'activités, elles se métamorphosent en réponse aux influences qu 'elles subissent. 
Essentielle à la structuration du SNC et à l' exercice des fonctions nerveuses supérieures, 
un rôle dont on commence à peine à percevoir l' importance [10] , c'est cependant pour 
son rôle en situation traumatique que la microglie est le mieux connue. Exprimant tous 
les PRRs identifiés à ce jour, les cellules microgliales sont particulièrement bien 
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équipées pour percevoir les perturbations de leur environnement, fussent-elle causées 
par la concentration anormale d'une molécule, son format inhabituel ou par l'apparition 
d'un composé inusité [11]. La reconnaissance induit le passage de l'état de veille à 
celui d'activation, l'objectif étant, dans un premier temps, d'éliminer la source de la 
perturbation et, dans un second temps, de favoriser le remodelage et la régénération. 
En présence d'un signal de danger, les cellules microgliales adoptent un profil 
amiboïde qui facilite à la fois leur division et leur déplacement. Elles sont recrutées soit 
directement par les molécules de danger elles-mêmes, soit par des chimiokines libérées 
par les autres cellules neuronales alertées du danger. Elles forment autour de la région 
lésée un bouclier protecteur qui vise à en limiter l'étendue. Les conséquences précises de 
l'activation dépendent du contexte parti cul ier dans lequel se fait la rencontre du stimulus 
initiateur, les cellules microgliales oscillant entre deux états extrêmes: un état 
d'activation classique et un état d'activation alternatif à vocation réparatrice [12]. 
Dans son état d'activation classique, la microglie exhibe un profil pro-
inflammatoire (Tableau 1) caractérisé par 1) la sécrétion d'un large éventail de cytokines 
pro-inflammatoires et de polarisation Th1 (T helper cell subtype 1); 2) l'expression de 
chimiokines; 3) l'expression d'iNOS (inducible nitric oxide synthase) et de COX-2 
(cyclooxygénase-2); 4) la production de dérivés toxiques de l'oxygène et de l'azote; 
5) l'augmentation de l'expression des molécules du CMH de classe l et II et des facteurs 
de costimulation; 6) la sécrétion de métalloprotéinases matricielles; et 7) un pouvoir 
phagocytique accru. Si dans un état pro-inflammatoire la microglie possède l'arsenal 
nécessaire pour altérer l'étanchéité de la BHE, attirer les leucocytes - principalement les 
lymphocytes, monocytes et granulocytes - , faciliter leur déplacement dans la matrice 
extracellulaire, présenter des antigènes, soutenir l'activation de l' immunité spécifique et 
mettre KO les agents perturbateurs, elle a aussi le pouvoir de causer des dommages 
collatéraux souvent irréversibles au SNC. Ce potentiel auto-destructeur de la microglie 
activée classiquement est tempéré par les propriétés immunosuppressives du milieu, en 
grande partie attribuables aux neurones. 
399 
Dans son état réparateur, dicté par le contexte du milieu, la microglie adopte plutôt 
1) un métabolisme aérobie; 2) une expression accrue des récepteurs éboueurs; 
3) la synthèse de COX-1 au détriment de COX-2; 4) la synthèse d'arginase-1 ; ainsi que 
5) la sécrétion de divers facteurs neurotrophiques et d'éléments matriciels. Ainsi, la 
microglie détient également le potentiel de participer à la réparation des tissus lésés et le 
retour à l'homéostasie (Tableau 1), favorisant l'angiogenèse et stimulant la génération 
de nouveaux oligodendrocytes, astrocytes, voire même neurones, à partir de cellules 
souches toujours présentes dans le parenchyme nerveux adulte. 
Les états d'activation classique et réparateur ne constituent que les deux pôles 
d'un continuum d'états entre lesquelles les cellules microgliales oscillent en fonction des 
particularités activatrices du milieu dans lequel elles baignent [13]. Avec l'âge, pour 
des raisons qu 'on s' explique encore mal, l'induction du profil réparateur se fait plus 
difficile, une situation à mettre en lien avec l'augmentation des maladies 
neurodégénératives associée au vieillissement [14]. 
Les neurones 
Les neurones jouent un rôle primordial dans l'établissement des privilèges 
immunitaires du SNC en agissant tant en amont qu ' en aval de la réponse [15]. 
Ils expriment quelques PRRs par lesquels ils perçoivent les signaux de danger présents 
dans leur environnement et expriment plusieurs récepteurs pour les cytokines qui leur 
permettent d'ajuster leur contribution à l' immunosuppression en situation d'agression. 
Les neurones expriment notamment le récepteur TLR3 (toll-like receptor 3) dont le 
P AMP déclencheur est l' ARN double brin. La dimérisation de TLR3 mène à la 
production d'interférons de type 1 dont le rôle est crucial dans la défense innée contre les 
virus, par exemple lors d'une infection par le virus neurotropique de la rage [16]. 
La microglie avec son imposant arsenal pro-inflammatoire est une des 
cibles préférentielles de l'attention neuronale qui se veut généralement atténuante. 
La régulation de la microglie implique à la fois des contacts cellule-cellule et des 
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facteurs solubles contribuant à freiner l'inflammation (Tableau 1). La majorité de ces 
protéines sont exprimées de façon constitutive et créent donc d'entrée de jeu un mil ieu 
immunosuppresseur capable de contenir les débordements de la microglie. Ces protéines 
membranaires agissent principalement en interférant avec les voies de signalisation, 
inhibant des kinases essentielles telle la famille des MAPK (mitogen-activated protein 
kinase) et les Pi3K (phosphoinositide 3-kinases), réduisant l'expression de facteurs de 
transcription tds c-jun ou c-myc ou inhibant leur translocation nucléaire comme c'est le 
cas pour Nrf2 (nuclear factor erythroid 2-related factor 2) ou NF-KB (nuclear factor 
kappa-light-chain-enhancer of activated B ceUs). Elles permettent, en conséquence, 
de diminuer la production de cytokines inflammatoires et de dérivés toxiques de 
l'oxygène ou de l'azote dès l'engagement des PRRs de la microglie. Les neurones 
expriment en plus et de façon constitutive le FasL (ligand Fas ou CD95L) par lequel 
ils contrôlent l'apoptose des cellules microgliales activées. Outre ces facteurs 
membranaires, les neurones libèrent nombre de facteurs solubles qui contribuent aussi à 
contraindre l'activation de la microglie. Il yale TGF-~ (transforming growth factor-
beta) et la fractalkine soluble que les neurones expriment de façon constitutive et dont la 
production peut être amplifiée en situation traumatique, tandis que l 'interleukine-l 0 
(IL-I0) est plutôt sécrétée en situation de crise. À ces facteurs immunorégulateurs 
viennent s'ajouter l'activité neuronale dont l'action anti-inflammatoire est arbitrée 
par un bon nombre de neurotransmetteurs et plusieurs neurotrophines (Tableau 1). 
Sous cette influence, les cellules microgliales produisent moins de cytokines 
inflammatoires, réduisent leur stress oxydant, diminuent leur expression des molécules 
du CMH et, ainsi, soutiennent moins efficacement l'activation des cellules de défense 
périphériques ayant gagné accès au parenchyme nerveux. Quant à leur pouvoir 
phagocytaire, il peut être selon les particularités du contexte soit amplifié, soit diminué. 
Le caractère immunosuppresseur des neurones ne contient pas que les ardeurs de 
la microglie au moment de son activation; il tempère aussi les conséquences de son 
activation en s'exerçant sur les cellules de la défense périphérique qui, répondant à 
l'appel, ont gagné ou tentent de s'introduire dans le parenchyme. Ici encore, l'effet 
s'exerce tantôt par des contacts cellule-cellule impliquant entre autres des cadhérines, 
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des molécules du CMH, et le FasL, tantôt par l' intermédiaire de facteurs solubles 
dont le TGF-~ et les sémaphorines 3 et 7. Les interactions aboutissent à l'immobilisation 
des macrophages, la neutralisation des cellules cytotoxiques NK (natural killer) et 
CD8+, la polarisation des Th vers des phénotypes plus immunorégulateurs que pro-
inflammatoires tels Th2 (T helper cell subtype 2) ou Treg (regulatory T cel!) et la mort 
par apoptose des cellules activées. 
Les astrocytes 
D'origine neuroectodermique, les astrocytes sont les cellules les plus abondantes 
du SNC, comprenant jusqu'à 70 % de la névroglie. Ce sont des cellules étoilées qui, 
avec leurs extensions cytoplasmiques, participent à la formation de la glia limitans de 
la BHE (Figure 1), enrobent les synapses, communiquent entre elles par le biais de 
jonctions communicantes et contribuent au drainage glymphatique du liquide interstitiel 
parenchymateux vers le liquide céphalo-rachidien (LCR) [17]. Ils délimitent ainsi un 
territoire sur lequel ils peuvent exercer leur influence grâce aux récepteurs, canaux 
ioniques, transporteurs et enzymes de toutes sortes dont ils sont pourvus [18, 19]. 
En plus de leur rôle clé dans l'homéostasie du SNC, le métabolisme neuronal 
et la modulation dynamique de la transmission synaptique, les astrocytes sont 
particulièrement bien outillés pour appuyer la microglie dans sa fonction de sentinelle et 
de défense [20, 21]. Ils expriment le TLR3 de façon constitutive et peuvent être induits 
à exprimer plusieurs des PRRs. Tout comme les cellules microgliales, ils sont donc aptes 
à reconnaître et à réagir à un large éventail de situations dangereuses pour le SNe. 
En réponse à l'activation, les astrocytes deviennent hypertrophiques, prolifèrent et 
altèrent leur expression génique. Ils sécrètent nombre de facteurs pro-inflammatoires 
(Tableau 1) servant à attirer les cellules de défense périphériques et faciliter leur 
migration dans le parenchyme, expriment des récepteurs éboueurs par lesquels ils 
contribuent à la phagocytose, et produisent les molécules du CMH de classe II leur 
permettant de soutenir l'activation des cellules Th activées, bien que leur capacité à 
présenter des antigènes, comme le fait la microglie, est controversée. L'activation les 
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amène même à diminuer leur internalisation de glutamate et à perturber le réseau 
astrocytaire en diminuant la production de connexine 43 , ce qui contribue de surcroît au 
caractère neurotoxique de la réaction inflammatoire. 
S'ils participent foncièrement aux processus pro-inflammatoires lorsqu'activés, 
Is répondent néanmoins à l'IL-l~ par la sécrétion de TGF-~ et par la libération de 
différents facteurs neurotrophiques (Tableau 1) qui soutiennent la réparation de la BHE, 
la remyélinisation, le remodelage de la matrice ainsi que la survie des neurones et des 
oligodendrocytes. Ils contrôlent l'activation des lymphocytes T par leur expression du 
récepteur immunorégulateur CTLA-4 (cytotoxic T-lymphocyte-associated protein 4 ou 
CD152) et peuvent déclencher l'apoptose des cellules de défense activées par 
l'expression constitutive du FasL. En situation d'inflammation chronique, leur capacité 
d'activer les Th est compensée par une interaction qui biaise la réponse en faveur des 
Th2, un profil plutôt immunorégulateur que le profil Thl pour le SNC [22]. De plus, 
certains signaux d'agression permettent aux astrocytes de se dédifférencier en « radial-
glia-like ceUs» capables d'exprimer d'autres facteurs neurotrophiques (Tableau 1) qui 
ensemble promeuvent la multiplication des cellules souches neuronales et leur migration 
vers le site de lésion [23] . Enfin, les astrocytes sont particulièrement reconnus pour leur 
rôle dans la formation de la cicatrice gliale. En effet, lorsqu'activés ils se multiplient 
abondamment, circonscrivent le site d'inflammation, occupent les espaces créés par la 
mort ou la phagocytose de cellules neuronales et produisent des éléments de la matrice 
extracellulaire tels que de l'acide hyaluronique. Cependant, cette réaction de défense qui 
a pour but d'inhiber la propagation de l'inflammation et d'offrir un effet restructurant a 
aussi comme conséquence néfaste d'inhiber la migration et la différentiation des cellules 
souches neuronales [23]. 
Les oligodendrocytes 
Les oligodendrocytes partagent la même ongme neuroectodermique que les 
astrocytes et les neurones. Derniers à entrer en scène, ils établissent avec les neurones 
une relation symbiotique. Les oligodendrocytes sont tout aussi essentiels au 
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développement et à la survie des axones que les neurones le sont à la myélinisation 
[24-26]. 
Comme les neurones, les oligodendrocytes contribuent au caractère 
Immunosuppresseur du parenchyme nerveux par leur production constitutive de 
TGF-~ et par leur expression du CD200 et de fractalkine. À l'instar des autres cellules 
du SNC, ils expriment des PRRs, notamment TLR2 et TLR3 , qui leur permettent de 
réagir à certains signaux de danger. Bien que les conséquences de l' engagement de ces 
récepteurs demeurent pour le moment mal connues, elles devraient se répercuter sur 
l'ensemble du réseau d'influence des oligodendrocytes. Ce réseau, relativement vaste, 
implique tout autant les astrocytes avec lesquels les oligodendrocytes sont en lien par le 
biais de jonctions communicantes que les neurones auxquels ils sont associés par la 
gaine de myéline, un oligodendrocyte pouvant enrober jusqu'à une cinquantaine 
d'axones distincts. 
Si les oligodendrocytes peuvent participer activement à la mise en place d'une 
immunité innée par l'intermédiaire de leurs TLRs, ils peuvent aussi être eux-mêmes 
générateurs de danger. Très sensibles au stress oxydant tout comme ils le sont à la 
toxicité du glutamate ou à celle de l'A TP, les oligodendrocytes peuvent causer des 
dommages sérieux à leur environnement et entretenir l'inflammation sans être 
nécessairement les cellules initialement visées par l'agression. 
Les cellules de défense périphériques 
Au niveau du SNC sain, rares sont les leucocytes qui arrivent à s' échapper de la 
vasculature. Leur présence, bien que limitée, permet tout de même d'assurer une 
immunosurveillance dont l'importance nous apparaît indéniable lorsqu'on mesure les 
dommages encourus par la suppression de la patrouille des cellules de défense 
périphériques [pour revue, voir 27]. Dans le cas du JC polyomavirus, un virus 
ubiquitaire chez l'humain, l'arrêt del'immunosurveillance secondaire à des thérapies 
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immunosuppressives entraîne la leucoencéphalopathie multifocale progressIve, 
une maladie du SNC généralement mortelle. 
Les leucocytes qUI parviennent à pénétrer le SNC, uniquement des 
mononucléaires, prennent avantage à la fois de leur expression de certaines protéines 
d'adhésion et de l'existence de zones plus permissives de la BHE, telles que la glande 
pituitaire, l'éminence médiane, l'aire postrema, l'aire préoptique, la paraphyse, 
la glande pinéale et l'endothélium des plexus choroïdes. Les monocytes utilisent la 
voie leptoméningée pour venir peupler les espaces de Virchow-Robin en bordure des 
artérioles et en continuité avec l'espace sous-arachnoïdien. Quant aux lymphocytes, 
et uniquement les T activés, ils s'affranchissent de la barrière sang-LCR (BSLCR) en 
empruntant la voie du plexus choroïdien qui exprime constitutivement des molécules 
nécessaires à leur admission, telles que le CCL20 (chemokine [C-C motif] ligand 20) 
indispensable au recrutement des cellules CCR6+ (C-C chemokine receptor type 6) [28] . 
Une fois traversés, ils sont entraînés par le LCR, patrouillent les espaces et quittent soit 
vers le sang par le biais des villosités arachnoïdiennes, soit vers les ganglions cervicaux 
profonds par le biais de la plaque cribriforme de l'os ethmoïde ou par le biais d'un 
système lymphatique propre au SNC récemment mis en évidence [29, 30]. On constate 
donc qu'en situation normale, des cellules de défense d'origine médullaire occupent des 
niches stratégiques du SNC sans jamais pénétrer le parenchyme, qu'elles exercent 
patrouille et immunosurveillance comme elles le font en périphérie et qu'elles possèdent 
tous les attributs qui leur permettent de réagir efficacement à l'agression [27, 31-33]. 
En réponse à l'agression, les cellules du parenchyme s'activent. Elles libèrent dans 
le milieu des cytokines pro-inflammatoires qui modifient l'étanchéité de la BHE 
ainsi que des chimiokines (Tableau 1) qui guident les cellules de défense, y compris les 
granulocytes, et les autorisent à pénétrer au sein même du parenchyme [34]. 
Les macrophages périvasculaires participent au recrutement par la production de 
facteurs de croissance (Tableau 1), la modification des cellules endothéliales et par la 
sécrétion de métalloprotéinases qui facilitent les déplacements. Bien que nécessaire à 
la résolution des problèmes, l'afflux de cellules sur le pied de guerre dans le parenchyme 
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nerveux comporte des risques importants pour un tissu aussi fragile. Pour contrer les 
risques encourus, les cellules du parenchyme limitent le temps de vie des cellules de 
défense en provenance de l'extérieur ou les réorientent vers des phénotypes plus 
immunorégulateurs, notamment par l'expression constitutive de FasL ou de TGF-~ de 
l'environnement nerveux. 
Conclusion 
La neuro-inflammation est un phénomène hautement complexe par lequel le SNC 
s'allie au système immunitaire pour assurer sa protection et maintenir son homéostasie 
[35] (Figure 2). La complexité du phénomène, qui le rend difficilement abordable 
dans le contexte fragmentaire des études in vitro ou des systèmes modèles, tient tout 
autant à la multiplicité des intervenants cellulaires qu'à l'enchevêtrement des voies de 
signalisation et aux effets tantôt synergiques, tantôt antagonistes, tantôt neurotoxiques, 
tantôt neurotrophiques des signaux émis. Les conséquences en sont difficilement 
prévisibles car elles dépendent à la fois de la nature, de l'intensité, de la durée que de 
l'historique de l'agression [36] . Il semble cependant que si elle est source du mal, 
la neuro-inflammation soit aussi source de la solution [37, 38]. Il nous faut donc 
apprendre à décoder son langage et à identifier, pour chaque problématique, le maillon 
faible du réseau afin de mettre au point des stratégies d'intervention ciblées qui 
permettent de contrer la neurodégénération [39]. 
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Full review article in English: Old molecules, new insights: therapeutic 
considerations for the use of polyphenols in neurodegenerative diseases 
Abstract 
Over the last two decades, neurodegenerative diseases have received increasing 
attention due to the rapid rate at which the population is aging and the consequent rise 
in the incidence of such illnesses, itself entailing a major social and economic 
burden. Today, an increasingly large body of literature lends functional foods and 
their biofunctional molecules potential neuroprotective capacities. Among the most 
prominently studied dietary molecules, polyphenols stand in a class of their own on 
account of their multiple and often overlapping modes of action. However, ambiguity 
exists as to the significance of their influence on human health. This review discusses 
the many characteristics and functions of polyphenols that shape their possible 
therapeutic applications in neurodegenerative diseases. Knowledge gaps that remain 
under-explored will be highlighted. 
1. Introduction 
It has long been acknowledged that dietary habits play a key role in the occurrence 
and progression of non-communicable diseases . A hoard of epidemiological evidence 
shows that a diet rich in fruit and vegetables reduces the incidence of cardiovascular 
diseases [1-4], type 2 diabetes [5,6] , stroke [7,8] and nurnerous cancers [9-11]. 
Others find inverse associations between the consurnption of green tea and cognitive 
decline [12, 13]. These observed health benefits are thought to be at least partly 
attributable to a class of non-essential nutrients named polyphenols, abundantly found in 
fruit, vegetables and other edible plants [14, 15]. 
Alongside cancer and cardiovascular diseases, neurodegenerative disorders 
constitute a popular field of application for the benefits of polyphenols [see for review 
refs 16, 17] . This is the case for Parkinson's and Alzheimer's diseases, conditions that 
are often ill defined and lack a clear etiopathogenetic origin besides that they seem to 
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anse from the interaction between agmg, the environment and genetic risk factors. 
The etiology of these diseases is further convoluted by a number of proposed causative 
mechanisms, such as oxidative stress, neuroinflammation, protein aggregation, 
iron toxicity and mitochondrial dysfunction. As such, the number of proposed actions of 
polyphenols, both in terms of the numerous disease states they appear to improve and 
the manifold cellular mechanisms the y are reported to modulate, makes their use in 
complex neurodegenerative disorders compelling. In this review, the factors that 
impinge on the biofunctionality and bioavailability of dietary polyphenols in the central 
nervous system (eNS) are discussed with a particular focus on therapeutic applications 
and limitations. 
2. Chemico-structural characteristics 
2.1 Classification 
Plant polyphenols were originally c1assified in early literature as "vegetable 
tannins" owing to their tanning action on animal skins [18]. The first comprehensive 
description, referred to as the WBSSH definition, recommended that the term 
polyphenol be exclusively ascribed to water-soluble phenolic compounds having a 
molecular mass ranging between 500 to 4000 Da, possessing at least 12 phenolic 
hydroxyl groups, and 5 to 7 aromatic rings per 1000 Da [19]. A less restrictive 
interpretation was proposed by Quideau, offering a broader view of the WBSSH 
definition - that was hitherto limited to the structural characteristics common to aIl 
phenolics endowed with tanning properties (vegetable tannins) - to include simpler 
phenolic compounds with potential biological activities others than tanning [20]: 
The term "polyphenol" should be used ta define compounds exclusively 
derived from the shikimate/phenylpropanoid and/or the polyketide pathway, 
featuring more than one phenolic unit and deprived of nitrogen-based 
fitnctions . This definition lets out ail monophenolic structures as weil as ail 
their naturally occurring derivatives such as phenyl esters, methyl phenyl 
ethers and O-phenyl glycosides. 
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A majority of plant polyphenols originate from phenylalanine that is deaminated to 
cinnamic acid, which then enters the phenylpropanoid pathway [21]. Plant metabolism 
utilizes the phenylpropanoid unit C6-C3, a phenol ring with a 3-carbon side chain, 
as a building block to construct polyphenols. Classification of the resulting molecules is 
dictated by the number of phenol rings (C6) they contain and the structural elements 
binding these rings to one another. The main subclasses, varying in complexity, are 
phenolic acids (C6-C3 and C6-Cl), flavonoids (C6-C3-C6), stilbenes (C6-C2-C6) and 
lignans (C6-C3-C3-C6). Within these subclasses, hydroxylations and O-glycosylations 
at various positions as weIl as cis-trans isomerization give rise to the thousands of 
polyphenols (estimated to > 8000) known to date, offering a tremendously intricate bank 
of molecules with prospective pharmacological value to explore. These polyphenols 
alongside their content in various food products are available on databases such as 
Phenol-Explorer managed by the Institut National de la Recherche Agronomique 
(www.phenol-explorer.eu). 
2.2 Structure versus biofunctionality in neuroprotection 
The particular chemico-structural properties shared by polyphenols are pertinent 
to their therapeutic application, especially in the field of neuroprotection. Indeed, the 
presence of phenol rings, variable hydroxylation patterns and conjugated double bonds 
grants polyphenols metal-chelating, fibril-destabilizing, estrogen-like, enzyme-binding 
and antioxidative properties. These numerous modes of action afford polyphenols the 
ability to tackle the multifarious pathophysiological aspects of several neurodegenerative 
diseases, namely oxidative stress, neuroinflammation, protein aggregation, Iron toxicity 
and mitochondrial dysfunction. 
The redox properties of divalent metals, such as copper, zinc and iron, are essential 
for cellular homeostasis. When in excess, however, these metals contribute to generate 
surplus reactive oxygen species. Polyphenols that comprise at least one gallo yi or 
catechol group (hydroxyl groups in the ortho-position) are powerful bidentate chelators 
of divalent metals [22] , whereas ones having only a phenol substitution (one hydroxyl 
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function) or possessing a resorcinol group (meta-position hydroxyl pair) are less potent 
monodentate chelators [23 , 24]. For chelation to occur, a deprotonation step of the 
phenolic group is necessary and has been shown to be possible at physiological pH [23]. 
Self-assembly of amyloidogenic fibrils involves interactions between aromatic 
residues [25], as in neuropathologically relevant proteins including tau, beta amyloid 
(AB) and a-synuclein, for example. Using the same kind of aromatic interactions, phenol 
moieties in polyphenols can Interfere with fibril assembly [26], possibly by weakening 
cross-B structures. This Interference seerns to arise from hydrophobic and 7r stacking 
interactions [27], although the formation of covalent bonds through Schiff base reactions 
has also been proposed for the green tea polyphenol epigallocatechin-3-gallate (EGCG) 
[28, 29]. Upon analyzing binding energies between polyphenols and prote in fibrils , 
favorable entropic and enthalpic dynamics were discovered that also suggest the 
stabilization of H-bonds [30]. 
Sorne polyphenols, also referred to as phytoestrogens, have the ability to bind 
estrogen receptors (ERs), usually with a greater affinity for ERB [31, 32]. Depending on 
structure, dose, cell type and estrogen response element (ERE) sequence, sorne 
polyphenols have a weak or strong antagonistic or agonistic effect on ERs, affording a 
very wide spectrum of activities in cells [33-36]. As a requirement to bind ERs, 
the structure should be composed of a phenolic ring with a configuration resernbling that 
of estradiol, as found in flavonoid isoflavones or the stilbene resveratrol, for instance. 
Indeed, a specific hydroxylation pattern and an adequate distance between substituted 
hydroxyl groups are necessary to bind ERs. 
Sorne polyphenols also share structural similarities with endogenous ligands, such 
as cyclic AMP (cAMP) or nucleoside triphosphates, endowing thern with the aptitude to 
activate or inhibit key enzymes [37, 38]. To date, modulatory effects on enzymes have 
been confirmed in cellular or animal models for several polyphenols, su ch as resveratrol 
on cAMP phosphodiesterases [39] , theaflavins on the ATP synthase and respiratory 
chain [40], and curcumin on gl yoxalase 1 [ 41], to name a few. The presence of 
appropriately spaced ketone and hydroxyl groups in a planar configuration, bestowing 
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sorne polyphenols su ch as curcurnin with the ability to mimic an enediolate intennediate 
in physiological conditions [42], is a remarkable example of structural elernents that 
make enzyme binding possible. 
Notwithstanding the aforementioned functions emergmg from their umque 
chernical structures, the most vastly studied characteristic of polyphenols is their 
antioxidative action. Polyphenols are thought to exert their antioxidative action directly, 
by scavenging free radical species firsthand, and/or indirectly, by activating endogenous 
antioxidative pathways. Direct antioxidative effects usually occur through H-atom 
transfer from polyphenols' (ArOH) hydroxyl (OH) groups to the free radicals (R-): 
ArOH + R- ~ ArO- + RH (1) 
The existence of multiple conjugated double bonds in polyphenols allows for the 
unpaired electron to be delocalized over the aromatic ring, yielding a much more stable, 
hence mu ch less reactive, polyphenolic radical (ArO-) (Eq. 1). Sorne polyphenols 
also exert indirect antioxidative effects through the Kelch-like ECH-associated 
protein lInuclear factor erythroid 2-related factor 2/antioxidant response elements 
(Keap l/Nrf2/ ARE) regulatory pathway made possible by the presence of electrophilic 
functions (a,~-unsaturated carbonyl group, 1,2- and l,4-quinones, or other groups) that 
alkylate thiol sensors in the cysteine pocket of Keap 1 [43, 44]. Others, like stilbenes, 
engage their resorcinol hydroxyl functions in hydrogen bonds with the Kelch pocket of 
Keap 1 [45]. Both these events lead to the disruption of the Keap l/Nrf2 complex, 
allowing Nrf2 to translocate to the nucleus where it can trigger the expression of 
antioxidant proteins like herne oxygenase-l via binding of AREs. This cysteine-
modifying function of polyphenols may also bear other implications in various enzymes 
[44]. 
3. Factors influencing pharmacokinetics and bioavailability 
To be effective in the prevention or amelioration of neurodegenerative diseases, 
polyphenols must be bioavailable in the CNS. Extensive reports on the bioavailability of 
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the most common dietary polyphenols can be found elsewhere [46-48]. Within the scope 
of this review, we will first discuss the principal obstacles that hinder polyphenol 
bioavailability and later address CNS permeability. 
3.1 Food matrix or vehicle 
Oral administration is by far the most practical of pharmacological routes, 
but often raises daunting challenges in terms of bioavailability. Particular factors to 
consider wh en developing an oral drug are the molecule's interaction with the vehicle, 
the transformations it undergoes by digestive and microbial enzymes, and its absorption 
in the gastrointestinal tract [49] . 
Acting as the vehicle of administration, food matrices are central to the bioefficacy 
of polyphenols [50]. Of the few studies conducted, inconsistent results have been 
obtained, demonstrating either a negligible [51 , 52] or a significant [53-56] contribution 
of the food matrix in polyphenol absorption. For instance, bioavailability differs for 
quercetin among dietary sources, largely depending on the glycoside form they exist in. 
Indeed, onions, which contain quercetin conjugated to glucosyl functions, are better 
sources of bioavailable quercetin th an are apples and tea, which contain different 
quercetin glycosides [57, 58] . It is also unclear whether ethanol bears a role in 
polyphenol absorption in light of studies showing improved bioavailability of quercetin 
in rats when administered in a 30% solution of ethanol, an alcohol content that is 
physiologically improbable in an every day diet [59]. In fact, confounding results were 
obtained in humans administered red wine or dealcoholized red wine that showed no 
differences in catechin plasma levels and also demonstrated increased catechin excretion 
likely due to a diuretic effect [60]. 
3.2 Gastrointestinal transformations and absorption 
Once in transit, sorne polyphenols remain stable though most are converted with 
galloyl [61] or methyl [62] groups in the duodenum by digestive enzymes. As a rule, 
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the best-absorbed polyphenols in hurnans are isoflavones (in soybean-derived products) 
and gallic acid (in sumac and green tea), followed by catechins (in green tea), flavanones 
(in citrus), and quercetin glucosides (in onions), whereas the least absorbed are 
proanthocyanidins and anthocyanins (in berries), galloylated tea catechins, and stilbenes. 
Whereas aglycones are normally weIl absorbed by the small intestine, nutritional 
polyphenols are more commonly detected in the form of glycosides, esters and 
polymers, which cannot be efficiently assimilated in the upper portion of the gut. 
Molecules not absorbed in the upper gastrointestinal tract continue to the colon to 
become substrates to the gut microbiota, responsible for a very wide array of reactions, 
sorne of which yield monomers from polymers or aglycones from glycosylated 
polyphenols [see for review ref 63]. SmaIler, better-absorbed phenolic acids may also be 
produced by the gut microbiota. For example, quercetin microbiotic degradation mainly 
generates 3,4-dihydroxyphenylacetic, 3-methoxy-4-hydroxyphenylacetic (homovanillic 
acid), and 3-hydroxyphenylacetic acids [64]. Among volunteers challenged with 75 mg 
of rutin, a quercetin glycoside, the total urinary excretion of microbial metabolites 
accounted for as much as 50% of the ingested dose [65]. Importantly, the sum of these 
gastrointestinal transformations and food matrix interactions can either mcrease or 
decrease the absorption of the resulting metabolites in the bloodstream. 
3.3 Plasma bioavailability, transformations and cellular uptake 
Once in the blood, drug-metabolizing enzymes mainly found in the liver and 
kidneys further modify polyphenols into various conjugated forms, a process that serves 
to detoxify potentially harmful substances. Molecules are rendered more hydrophilic in 
order to facilitate their urinary elimination, which usually lowers bioavailability [66, 67]. 
To date, the green tea polyphenol EGCG remains the only known molecule 
to abundantly persist in a free form in the human plasma (up to 90%) [68]. 
While metabolites usually constitute the greatest fraction of circulating polyphenolic 
species, sorne forms undergo enterohepatic recirculation via biliary secretion, followed 
by deconjugation into free polyphenols by the gut microbiota and reabsorption in the 
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colon [69, 70] . Additional hepatic reactions may also occur thus reverting circulating 
metabolites back to their free form [71-73], as is the case for the conversion of 
resveratrol sulphates to bioactive resveratrol by human-expressed sulphatases [73]. 
Moreover, glucuronide and sulphate metabolites were found to retain sorne of their 
beneficial effects in vitro [74, 75]. Chronic administration of polyphenols may be an 
efficient strategy to increase plasma bioavailability in humans, as reported for EGCG 
[76]. 
As the finality of drug administration consists in cellular uptake, the notion of 
bioavailability encompasses the accessibility of polyphenols to target cells, which 
depends not only on their aforementioned metabolism but also on their complexation 
with plasma molecules such as proteins, fatty acids and lipoproteins [77]. In fact, the 
bioefficacy of therapeutic agents heavily relies on their capacity to bind such serum 
transporters [78]. Taking resveratrol for example, its lipophilic nature requires it to be 
conjugated into a more hydrophilic form, by sulphation or glucuronidation, or to be 
bound to proteins in order to circulate in high concentrations, making its passive 
unbound transport in the plasma rather arduous [79]. Complexation of resveratrol to 
transporter proteins, principally albumin [80-82] and lipoproteins [83-86], occurs at the 
expense of its aptitude to be taken up by cells [79]. Fatty acids are also known to 
improve the ability of resveratrol to bind transporter proteins [87]. 
While the binding of polyphenols by transporter proteins may diminish the 
former's availability in the free form , it is thought to provide a reservoir, playing a focal 
role in the systemic distribution of bound species [77]. Sorne studies have even proposed 
that these complexes could be retained at the cell membrane by albumin and lipoprotein 
receptors, offering a carrier-mediated mechanism by which polyphenols may gain entry 
to cells [77] aside from passive diffusion [79]. There remains the possibility that 
polyphenols need not enter cells to have an effect, as is the case when free resveratrol 
binds integrin aV~3 [88] to fulfill part of its angiosuppressive effects and its ability to 
trigger p53-dependent apoptosis ofbreast cancer cells [89]. 
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3.4 Accumulation in the brain parenchyma 
Drugs targeted to the brain must ultimately be able to accumulate in the 
parenchyma, both in a biologically active form and in sufficient concentrations. 
Three important obstacles stand in the way of brain penetration: the blood-brain barrier 
(BBB), efflux transporters, and multidrug resistance-associated proteins [90, 91]. 
y oudim and colleagues were the first to demonstrate polyphenols crossing through the 
BBB in an in vitro model, describing superior permeation of lipophilic molecules 
(methylated conjugates) in comparison to hydrophilic ones (sulphated or glucuronidated) 
[92, 93]. Another team identified a stereoselective process in the passage of flavonoid 
catechins across the BBB [94] . Yet, elucidation of the exact mechanisms used by 
polyphenols to penetrate the brain in vivo, either by simple diffusion or by transporters 
at the BBB, remains to be achieved. 
Although information on brain permeation 1S limited compared to plasma 
availability, an increasing number of studies have directly detected polyphenols and 
their metabolites in the brains of rodents and even pigs [95], as reviewed elsewhere 
[90, 96, 97]. CNS penetration of the most commonly studied polyphenols has been 
recurrently confirmed in vivo, as is the case for resveratrol [67, 98-101], EGCG 
[102, 103] and quercetin [93, 104-106]. 
For example, tritiated resveratrol was administered orally to rats (50 mg/kg b.w.) 
and levels after 2 ho urs were found to reach 1.7% of the ingested dose in the plasma 
and below 0.1% in the brain [67]. Interestingly, 18 hours following administration, 
the CNS retained 43% of the concentration measured at 2 h, mainly in the form of free 
resveratrol. Despite its persistence in the brai n, resveratrol nonetheless permeates the 
brain lowest compared to liver, kidney, testicle and 1ung tissues as confirmed by high-
performance liquid chromatography (HPLC) [99]. Despite evidence of entry into the 
brain, another study was unable to detect the polyphenol or its metabolites in the 
brains of rats fed a 0.2% resveratrol diet for 45 days using a HPLC assay with 
a detection limit of 0.5 pmol/ml/mg of tissue [107]. Other teams also used 
chromatographic quantification in rat brains using different protocols. In one study, 
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15 mg/kg b.w. ofresveratrol were administered intravenously (i.v.) - which by this route 
constitutes a high dose - and brain tissue concentrations reached -0.17 nmol/g 
90 minutes after injections [99]. Another team administered escalating oral doses of 
resveratrol (100-400 mg/kg b.w.) for 3 days allowing the detection of -l.7 nmol/g of 
brain tissue by liquid chromatography-mass spectrometry [100]. Evidently, the detection 
ofpolypheno1s in the brain is sensitive to methodo10gical disparities and caution must be 
exercised when drawing conclusions from these studies. 
Sorne polypheno1s are extensively transformed before they reach the brain, 
which possibly dampens their bioavailability, as discussed above. As an example, 
curcumin is highly lipophilic and, in theory, should easily gain entry to the brain [108]. 
However, before reaching the BBB, the free form of curcumin is very rapidly 
conjugated, rende ring it only sparingly bioavailable in the CNS [109]. Conversely, 
catechins efficiently cross the BBB after oral administration, but are found in 
glucuronidated and 3' -O-methyl glucuronidated forms in the brain tissue [102, 11 0]. 
To date, it remains unclear whether conjugation occurs before or after entry into the 
brain. Nevertheless, strategies exist to boost CNS concentrations of the aglycone form, 
for example by continuous administration aimed at promoting tissue accumulation [103]. 
Following 24 hours of continuous intragastric administration, EGCG levels in the 
CNS reached 5-10% of concentrations measured in the plasma [103]. These results 
imply, however, that a very high plasma concentration is needed for EGCG to 
accumulate in therapeutically reasonable concentrations in the brain. The necessity of 
maintaining high circulating concentrations may raise questions regarding the safety and 
tolerability of polyphenols. 
3.5 Synergistic effects 
Sorne polyphenols interact beneficially wh en administered in combination. 
Synergistic pharmacokinetics are at the basis of emerging multi-drug therapies 
[111-113] developed to surmount shortcomings such as low efficacy, acquired resistance 
and undesirable side effects in standalone treatments. Polyphenols exert synergy by 
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multiple means, extensively reviewed elsewhere [114-116]. Although synergistic 
chemosensitization properties of polyphenols are well appreciated, for example with 
respect to EGCG-induced downregulation of the endoplasmic reticulum stress response 
elements that renders temozolomide treatments synergistically more efficient in a mouse 
model of glioma [117] , what follows will concentrate solely on neuroprotective 
mechanisms. 
Perhaps at the basis of herb and extract efficacies, different polyphenols may 
concurrently regulate identical or separate targets in cells, resulting in a concerted 
agonistic effect. For instance, combinations of resveratrol and quercetin [118, 119] or 
epicatechin and quercetin [120] afford synergistic protection against amyloid-like 
aggregation, oxidative stress and oxygen-glucose deprivation in vitro. An earlier report 
of synergy between polyphenols showed that treatment of neuronal PC12 cells with 
subliminal doses of resveratrol in combination with catechin conferred greater protection 
against A~ toxicity than the sum of their individual actions [121]. However, when 
measuring their direct free radical scavenging capacity, the authors found their 
combined antioxidative effect to be merely additive, suggesting that their synergistic 
neuroprotective competences at combined subliminal doses must depend on other 
cellular mechanisms [121]. Very few studies have addressed neuroprotective synergy in 
vivo though a combination of polyphenols was found to synergistically rescue 
photoreceptors in an animal model ofretinal degeneration [122]. 
Synergy can also occur between polyphenols and drugs. Many in vitro reports 
support this, as is the case for the potentiation of neurite outgrowth by a subeffective 
dose of brain-derived neurotrophic factor (BDNF) in conjunction with green tea 
catechins [123 , 124], as weIl as for the protection of primary neurons and astrocytes by 
a cocktail of subliminal doses of resveratrol and melatonin via upregulation of heme 
ox ygenase-l [125]. One of the first reports of pol yphenol-drug synergy in rodents 
showed EGCG to favorably interact with rasagiline, an irreversible inhibitor of 
dopamine-metabolizing monoamme oxidase B (MAO-B) undergoing clinical 
investigations for the treatment of Parkinson's disease [126, 127]. When administered 
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alone in subliminal doses, neither EGCG nor rasagiline were capable of rescuing 
nigrostriatal neurons in a 1,2,3,6-tetrahydropyridine (MPTP)-injured mouse model of 
Parkinson's disease [128]. However, a combination of these agents at the se subeffective 
doses promoted the survival of the dopaminergic nigrostriatal pathway, demonstrating 
their synergistic effect. Interestingly, rasagiline's ability to promote the expression of 
BDNF in concert with EGCG-induced augmentations of prote in kinase C at the 
membrane appeared to produce a sum agonistic effect converging at their downstream 
effector Akt/protein kinase B, thought to account for their neuroprotective action. 
Other polyphenol-drug synergies exist for valproate and resveratrol in ischemic stroke 
[129] as weil as for glatiramer acetate and EGCG in experimental autoimmune 
encephalomyelitis [130], among others. 
Many polyphenols readily regulate absorption in the gastrointestinal tract, 
clearance at the level of the kidneys, and detoxification in the liver by modulating the 
activity of transport proteins or drug-metabolizing enzymes, which may improve their 
own oral bioavailability or that of other agents. In this respect, the flavonoid EGCG 
bears promising potential for use in Parkinson's disease owing to its ability to minimize 
levodopa methylation in the liver by inhibiting hum an catechol-O-methyl transferase 
(COMT), thereby enhancing bioavailability of the drug [131] . Flavonoids in general are 
also known to be potent inhibitors of cytochrome P450 (CYP) drug-metabolizing 
enzymes [132, 133] whose aforementioned activity reduces polyphenol bioavailability. 
This potential to enhance bioavailability of metabolism-sensitive drugs constitutes a 
clear example of polyphenol synergy that may be possible to harness in humans. 
4. Safety and tolerability 
Beyond favorable pharrnacokinetics, polyphenols must be safe and well-tolerated 
when employed in humans in the proposed conditions and posology. Several 
investigations have already addressed safety and tolerability issues in humans [see for 
review refs 134-137]. What follows will summarize these findings . 
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4.1 Side effects from dosage and chronicity 
Virtually ail human investigations perfonued with a wide array of polyphenol 
preparations demonstrate that they are safe and tolerable on the short [138, 139], 
medium [46, 140] and long tenu [141-143]. Generally, side effects are uncommon, mi Id 
and transient, expressing themselves as minor gastrointestinal troubles and, more rarely, 
in the fonu of headaches, dizziness and rashes. In a phase II trial , 24 Alzheimer's 
patients were administered 2 or 4 g of curcuminoids daily for 48 weeks and 3 withdrew 
due to minor gastrointestinal issues [143]. A study using a single 5 g/70 kg b.w. intake 
of resveratrol, representing 1/40 of the nephrotoxic dose and 1/4 of the highest dose 
reported to be safe in rats [144], did not uncover any serious adverse effects [138]. 
A great number of investigations have also addressed the safety of specific diets 
enriched in polyphenol-rich functional foods. Of particular interest, black cohosh, soy, 
and red clover regimens aimed at reducing menopausal symptoms in women have 
proven to be safe, with occasional manifestations of mi Id gastrointestinal issues, 
musculoskeletal and connective tissue troubles, as weil as weight gain [see for review 
ref 134]. 
4.2 Adverse pharmacological interactions 
While a consensus has been reached for the safety and tolerability of polyphenols 
in most individuals, certain contexts preclude their use. The case of grapefruit juice is a 
notorious example of the possible noxious effects of polyphenols in specific settings. 
In 1998, Bailey et al. demonstrated that grapefruit juice potently inhibits drug-
detoxifying enzymes, explicitlY members of the CYP family responsible for the 
metabolism of several prescribed drugs [145, 146]. Apigenin, naringenin, nobiletin and 
hesperetin contained in citrus fruits are thought to be the principal culprits [132, 147, 
148]. Interestingly, enzymatic inhibition is apparently irreversible following the 
ingestion of 200-300 mL of juice, leading to increased drug bioavailability and toxicity 
for up to 24 hours after intake. With this knowledge, medical professionals are now 
mindful of the risks of consuming grapefruit juice in individuals already taking 
antidepressants such as buspirone (Buspar) and sertraline (Zoloft), beta-blockers, 
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anti-cancer agents, fexofenadine (Allegra), or certain statins (atorvastatin) among many 
other drugs [149-152] . Several other adverse interactions exist between polyphenols and 
drugs [153,154] and have been extensively discussed elsewhere [136]. 
4.3 Turnorigenicity 
As previously discussed, certain polyphenols, termed phytoestrogens, owe part 
of their biofunctionality to their resemblance to steroid hormones. Members of the 
flavonoid and stilbene subclasses indeed possess the capacity to bind ERs [155] and 
testosterone receptors [156] , albeit with much lower affinities than endogenous ligands. 
Many studies find phytoestrogens to be safe with respect to incidences of cancers 
[157, 158], and support their role in inhibiting aberrant cell proliferation [159-165]. 
Nevertheless, a few publications draw attention to the possible carcinogenic actions of 
sorne phytoestrogens that should not be disregarded [166]. In particular, soy genistein 
and daidzein (0.001-10 )lM) may stimulate the growth of malignant breast tumors, both 
in vitro and in vivo [166, 167]. 
In the case of the stilbene resveratrol, studies confirmed its ability to bind both 
ERs equally [168] , however with 7000 times less affinity than estradiol [33]. 
Interestingly, its effects are ostensible for select EREs regulated by ERu, but not for 
EREs dependent on ER~ activation. Unlike other ERu agonists, resveratrol does not 
appear to provoke mammary or uterine tissue proliferation in rats [169] and even 
promotes neuronal differentiation in vitro [170]. In light of this, resveratrol's favorable 
effects may in fact partially hinge on tissue-specific expression profiles of ERu and ER~ 
[171] . More recently, an eloquent study delineated the discriminatory ability of 
resveratrol to impede inflammation without promoting cell proliferation through 
pathway-selective ERu activation [172]. Crystallographic renderings of the ligand-
binding domain revealed resveratrol to bind in an opposite orientation compared to 
estradiol, which may be at the core of its pathway selectivity and its proven safety in 
humans [135] , especially concerning risks of carcinogenesis. 
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5. A portrait of clinicat progress 
The therapeutic potential of polyphenols is hardly contestable when taking into 
account the overwhelming body of lite rature supporting their beneficial effects in 
countless preclinical disease settings [see for review refs 16, 17]. N otwithstanding the 
weight of epidemiological, anecdotal and fundamental evidence, translation from 
bench-to-bedside has proven extremely challenging despite relentless efforts to test 
polyphenols in clinical trials [see for review ref 90] . As of yet, a single trial addressing 
polyphenols in neurodegenerative diseases has reached phase III clinic,al testing [173]. 
In this prospective, randomized, double-blind, placebo-controlled parallel group study, 
disease progression will be assessed after 48 weeks of daily oral EGCG treatments in 
multiple system atrophy patients. Results are still pending as of July 201 8. 
The case of standardized Ginkgo biloba extracts, rich in flavonoids, yielded 
particularly disappointing results in light of nurnerous failed phase l trials with respect to 
the high hopes he Id by many [106, 174-176]. These studies addressed dementia 
prevention in large cohorts of healthy or mildly cognitively impaired elderly individuals 
administered oral Ginkgo biloba twice daily for several years [177], but no reduction in 
the incidence of cognitive decline or Alzheimer's disease was found between groups 
[178-182]. Other phase l and II clinical attempts have also been unsuccessful in 
confirming the putative positive effects of curcumin in Alzheimer's disease patients 
[143 , 183]. The reasons behind these discrepant results are not understood: have 
preclinical models failed to fulfill their predictive purpose or are the clinical trials simply 
incapable of detecting the beneficial effects of polyphenols due to a flawed approach? 
What is important to keep in mind is that successful clinical trials are not common, on 
account of the Inherent difficulty of translating drug applications between rodent 
paradigms and humans. Poor choice of participants, administration strategies or clinical 
endpoints will inexorably undermine the outcomes of these studies. As such, lack of 
positive results may not in themselves imply invalid preclinical evidence. 
In that respect, the required enrolment profile for testing Ginkgo biloba extracts 
was re-evaluated, yielding positive results in a new round of clinical trials, this time 
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performed in full-blown Alzheimer's disease and vascular dementia. These trials 
successfully uncovered the benefits of several months of a daily Ginkgo biloba treatment 
on cognition and neuropsychiatric symptoms [141, 142]. Changing the endpoints and 
focusing on prefrontal dopaminergic functions in elderly humans with self-reported mild 
cognitive decline was another fruitful strategy to expose the beneficial effects of Ginkgo 
biloba [184]. Nevertheless, the cholinesterase inhibitor rivastigmine, commercially 
known as Exelon, has been shown to be more efficient than Ginkgo biloba in treating 
Alzheimer's disease and remains the drug of choice to ameliorate cognitive impairment 
in mi Id to moderate forms of the disease [185]. 
Regarding other phase l trials, several have been successful in confirming discrete 
positive effects in healthy individuals. A variety of polyphenols, including resveratrol, 
were found to increase cerebral blood flow without, however, improving cognitive 
performances in young adults, whether administered in a single dose [186-188] or 
chronically over 28 days [189]. However, other groups found that longer chronic 
interventions in elderly humans using either cocoa flavanols or resveratrol enhanced 
dentate gyrus-related cognitive functions [190] or hippocampal-related memory 
functions [191], respectively. In Alzheimer's disease patients, resveratrol reached phase 
II investigations on the basis of its modulatory role on neuroinflammation, cognitive 
decline, and cerebrospinal fluid (CSF) levels of A~40 [192, 193]. Following a twice-
daily oral regime for one year, resveratrol and its metabolites were discovered in the 
CSF, validating its ability to cross the BBB in humans [192]. Despite its relatively low 
bioavailability, resveratrol maintains the hopes of the scientific community towards its 
potential use in human neurodegenerative diseases. 
6. Future strategies for pharmaceutical development 
Polyphenols hold interesting properties that justify the intense scientific efforts 
devoted to translating their purported neuroprotective effects in humans. However, 
their questionable bioavailability, their mode st effects in humans and the impossibility 
of applying exclusive patent protection on natural molecules strips dietary polyphenols 
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of their appeal for pharmaceutical expansion. Nevertheless, several strategies espoused 
by drug developing teams in recent years have tackled these issues. 
6.1 Alternative formulations 
Engineering of novel structural analogues inspired by existing polyphenols or 
formulating specific preparations of polyphenols, such as the well-defined Ginkgo 
Biloba extract 761 , may be patentable options. Among the latest innovations, chemical 
engineering of pro-drug polyphenolic structures has shown promising results. 
For instance, acetylation of EGCG or resveratrol via esterification of their hydroxyl 
moieties yields stable pro-drugs in vivo whose acetyl groups can be hydrolyzed 
intracellularly by esterases to release the free polyphenol within the cell [194-196]. 
This strategy minimizes polyphenol auto-oxidation and allows better lipophilicity-
dependent cellular uptake [197-199]. Production of conjugates with improved 
bioefficacy has also been a good experimental approach to promote polyphenol 
absorption and activity. For example, the glutamoyl diester of curcumin is a more pote nt 
neuroprotective agent than is curcurnin alone [200]. Similar efforts have been deployed 
for resveratrol [201-203]. 
6.2 Alternative drug delivery systems 
One of the more hopeful avenues employed by several teams is the development 
of novel encapsulation technologies. Progress in vehicle formulation made by 
pharmaceutical companies have allowed the preparation of polyphenols captured in lipid 
nanocapsules [204-206] , nanoparticles [206, 207], exosomes [208], nanocomposites 
[209], emulsified formulations [206,210,211] or in gel form [212]. Promisingly, several 
reports demonstrate increased bioavailability in rodents administered encapsulated 
polyphenols [see for review ref 213] . Another unusual packaging approach consists in 
the administration of biologically compatible carbon nanotubes [214] grafted with 
pol yphenols, such as gallic acid [215]. This method was shown to enhance the 
antioxidative properties of grafted agents [215] and to improve their ability to traverse 
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biological barriers [214, 216], although the application of such conjugates lS still 
not common and the outcome of using them has not been sufficiently addressed. 
Possible health concerns arising from the peculiar physicochemical properties of carbon 
nanotubes also warrant further investigations [214, 217]. Another simple tactic consists 
in improving a polyphenol's solubility in circulation, such as for the lipophilic 
resveratrol [218], via complexation with cyclodextrins whose capacity to form inclusion 
complexes has already been exploited in other drug delivery strategies [219]. On the 
who le, each of these methods possesses its own advantages and disadvantages, but brain 
accessibility is generally augrnented owing to improved BBB infiltration by lipophilic 
vehicles, brain targeting by functionalized capsules, and efficient evasion of metabolism 
[220]. 
6.3 Alternative administration routes 
In order to target the human brain with more efficiency, the administration route is 
another variable that can be altered, as long as it remains easy to market. Likely the most 
interesting of these alternative options is intranasal administration, usually paired 
with one of the previously mentioned encapsulation technologies, which has produced 
successful results with brain-bound drugs in humans, at least when considering 
bioavailability and the capacity to avoid peripheral side effects as c1inical endpoints 
[221 , 222]. Notable examples are the administration of insulin for the treatment of 
Alzheimer' s disease [223] and apomorphine for the treatment of Parkinson' s disease 
[224]. The me chanis ms by which drugs are delivered to the brain parenchyma have only 
begun to be elucidated. It would appear that drugs administered nasally either enter the 
brain through retrograde axonal transport at the level of the olfactory sensory cells, or by 
their penetration into the CSF across the nasal epithelium [225]. Although studies with 
polyphenols are scarce in preclinical models [226-228], intranasal curcumin 
administration has gained much attention [see for review ref 229] due to its very poor 
oral bioavailability [230] yet promising neuroprotective actions. Curcumin, which is 
highly lipophilic, may easily cross the BBB [108] if it is efficiently incorporated in the 
bloodstream and preserved from enzymatic modifications [231]. While it is recognized 
430 
as a very safe route, intranasal administration sometimes leads to minor adverse effects, 
principally nasal irritation, constituting a potential roadblock in the development of 
intranasal polyphenol administration [224, 232]. Less discussed administration systems 
verified preclinically with polyphenols include rectal suppositories for efficient systemic 
distribution, bone-marrow administration to improve immunomodulatory effects in situ 
and controlled-release implant strategies for direct targeting of tumors, although 
intrathecal administration for direct distribution in the CSF remains the only other 
interesting yet invasive option for brain targeting [see for review ref 229]. 
7. On the topic of dose-response 
The previous sections have highlighted studies focused on improving polyphenol 
bioavailability for their therapeutic use. While bioavai lability remains a core issue 
regarding their therapeutic potential, little is known about the actual dosage required for 
polyphenols to wield beneficial effects in humans. This constant struggle to prove that 
polyphenols can accumulate in high-enough concentrations in target tissues is likely 
deeply rooted in a history of earlier reports that lent these molecules potent antioxidative 
properties in vitro [233, 234]. 
More recently, the physiological significance of polyphenols' direct antioxidative 
actions is met with much skepticism, particularly with regard to the brain, due to their 
modest gastrointestinal absorption, propensity to undergo heavy biotransformations and 
rapid excretion by the kidneys [97,235]. On the one hand, H-atom transfer must always 
occur faster th an at least one of the reactions of free-radical-production cascades 
(e.g., the limiting propagation step in lipid peroxidation), and this is improbable [236] . 
On the other, polyphenol concentrations, which rarely exceed micromolar concentrations 
in plasma or tissues at any given time [237], are substantially inferior to those of 
endogenous antioxidants such as ascorbate (30-100 !-lM) and urate (140-200 !-lM) [238]. 
Consequently, it is argued that their contribution to plasma's total antioxidative capacity 
never exceeds 2% and may therefore be irrelevant in a physiological context [235, 239]. 
In fact, direct antioxidative effects of polyphenols have not been measured in the brain 
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and sorne recommend assuming the "absence of evidence as evidence of absence" [97]. 
Studies demonstrating the anti-inflammatory properties of polyphenol analogues devoid 
of direct antioxidative capacities challenges the idea by which their health virtues stem 
from their ability to hamper oxidative stress [201 , 202]. 
Nowadays, it is acknowledged that high circulating concentrations of polyphenols 
may not be required to achieve certain clinical endpoints. Indeed, by interacting with 
various enzymatic targets, for instance Keapl , very small doses of polyphenols may 
bene fit from the cascades of events that ensue in cells. Despite this, efforts continue to 
foc us on enhancing bioavailability rather than on identifying an adequate dose-response 
framework that could predict the behavior of this class of molecules. This oversight may 
partly account for the apparent difficulty of translating preclinical findings into actual 
positive outcomes in humans. Where disappointingly mode st clinical benefits have been 
shown, is increasing the dose always a judicious strategy? The answer may not be as 
obvious as once thought. 
Sensible explanations have been proposed to explain the bioefficacy of 
polyphenols at very low doses. One of these is that polyphenols exert their biological 
effects in a non-linear fashion, more precisely by abiding to the kinetics of a biphasic 
dose-response profile. One such model predicts dose-response curves in the shape of a 
J or an inverted U depending on the endpoint quantified [240, 241]. The biphasic theory 
stipulates low-dose stimulatory and high-dose inhibitory effects [242, 243]. It describes 
an agent's direct stimulatory effects at low concentrations followed by the organism 's 
overcompensation riposte at higher doses [244]. In neuroprotection, hormesis predicts 
very low doses to be beneficial and higher doses to be potentially harmful. 
The application of this theory is thus intimately linked with whether polyphenols are 
indeed stressors that induce a defense response in cells. This has yet to be confirmed. 
Today, the biphasic hypothesis to explain polyphenols ' bioefficacy at very low 
doses is gaining momentum, resveratrol constituting the best example. A wealth of 
reports lends resveratrol hormetic properties in various fields of application, ranging 
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from cancer to neuroscience research, extensively reviewed elsewhere [245]. In sorne 
instances, resveratrol stimulates cancer cell proliferation at very low doses, but inhibits 
carcinogenesis in higher concentrations [246]. Other reports show resveratrol 
inducing atherosclerotic les ions at high doses, while it remains cardioprotective at 
lower concentrations [247]. In neurons, resveratrol promotes survival at very low 
concentrations, but is neurotoxic at higher doses [121 , 248]. One study performed in 
mice and primary cortical neurons proposed a mechanism possibly underlying the 
biphasic response of energy-depleted neurons to resveratrol, showing protection at low 
doses and toxicity at higher doses [249] . The authors explained resveratrol' s bimodal 
effects via its stirnulatory action on silent mating type information regulation 2 homo log 
1 (SIRT1), whose low-grade activity can suppress oxidative stress [250] . However, 
wh en stimulated by greater doses of resveratrol, SIRT1 expends too much reduced 
nicotinamide adenine dinucleotide (N AD+) where neurons are already energeticall y 
depleted, causing energy failure. During an ischemic event, resveratrol administration 
could either be beneficial or detrimental, depending on dosage and timing to which the 
bioenergetic status of neurons is sensitive. 
For now, these studies are more often than not performed in pre-clinical models 
and do not necessarily reflect what could occur in humans. The best-documented 
evidence of biphasic dose-responses in humans pertain to radiation events, for instance 
in cancer treatments or in atomic bomb survivors [251, 252]. However, reservations 
dwell on the significance of such a dose-response relationship in polyphenols applied to 
the hum an brain, seeing as it is highly unlikely that treatments could ever afford to 
increase their bioavailability in the parenchyma beyond very low concentrations. 
This could mean that the observed bioefficacy of polyphenols may already be optimal 
where mode st benefits are found in trials. Indeed, one distinct feature of the 
biphasic hypothesis provides that low dose beneficial effects stem from cellular 
overcompensation mechanisms in response to the stress charged by polyphenols [253]. 
Beyond the optimal concentration at which maximal benefits are yielded, this 
compensation reaction is slowly overwhelmed by the increasing stress polyphenols 
directly exert on the cell. Even at the optimal concentration, these beneficial effects are 
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thus thought to be at best partial. If this theory holds true, this could explain the 
mitigated results clinical trials have harvested to date, even upon increasing dosages. 
8. Concluding remarks 
In theory, polyphenols hold a very attractive therapeutic potential. Their structure 
confers them metal-chelating, fibril-destabilizing, estrogen-like, enzyme-binding and 
indirect antioxidative competences supporting their usefulness in neurodegenerative 
diseases. Epidemiological evidence shows a strong association between their 
consumption and a reduced occurrence of various neurodegenerative diseases. 
Preclinical models lend them neuroprotective properties. Sorne clinical trials have even 
been successful in revealing small but noticeable improvements in human health and 
have confirmed their safety in various settings. Nevertheless, the limited bioavailability 
of polyphenols faced with their apparent bioefficacy remains an under-explored 
dimension of their employment In diseases. To achieve clinical dissemination, 
investigators must demonstrate that polyphenols exert significant health benefits, 
fulfilling fixed endpoints. However, in neurodegenerative diseases, polyphenol trials 
consistently faU through in early clinical testing phases. To overcome this, researchers 
must optimize the design of their trials, with respect to the subjects (disease stage, 
participant profile, cohort age, medical history), the administration paradigm 
(polyphenol formulation, route, dosage, frequency, duration) and endpoints (motor 
symptoms, cognitive decline, neuroinflammation, neuron integrity, CNS vascular health, 
etc.). This should logically require a clear notion of the relationship between doses and 
outcomes in very specific human disease settings, as well as the extent to which 
beneficial effects should be expected to manifest themselves. Indeed, as reviewed here, 
polyphenols are sensitive to a great number of physiological conditions that impinge on 
their bioavailability and biofunctionality, which may account for the markedly high 
interindividual variation observed in clinical investigations. Even biphasic dose-response 
theories cannot explain this variability. 
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Despite having collected a large amount of information from many pre-clinical 
models and applications, the scientific community still cannot agree on a working 
theoretical framework that could aid in predicting outcomes in humans. Until then, 
optimization of clinical trials remains an exercise of futile guessing. A priority would 
consist in determining the maximal health benefits that could be achieved from 
polyphenol monotherapies as they most usually stand in trials. Can we really expect 
standalone treatments to fui fi Il hard-to-reach clinical endpoints? If epidemiological 
evidence is strong for the protective effects of consuming complex mixtures of 
polyphenols in food, it may be precarious to expect single molecules to be as effective. 
Perhaps concentrating on the concerted effects between polyphenols with each other or 
with other drugs that show partial benefits, such as the MAO-B inhibitor rasagiline [127] 
or levodopa [131], ma y overcome the as of yet modest effects in humans. Evaluating 
polyphenols in preventive clinical paradigms may also constitute a more realistic 
strategy. Future research should cease to avoid addressing the limitations of polyphenols 
employed in neurodegenerative diseases; it should rather clearly define and hamess 
these frontiers in emitting educated projections of their true therapeutic potential in 
human health. 
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Full chapter in English: Prevention of neuroinflammation by resveratrol: focus on 
experimental models and molecular mechanisms 
Abstract 
The central nervous system (CNS) is normally protected by the blood brain barrier 
(BBB) from systemic inflammation, and the role of immunity is fulfilled by its resident 
cells, mainly microglia. Resveratrol, trans-3,5,4'-trihydroxystilbene, has long been 
acknowledged as a dietary polyphenol bearing potent anti-oxidative and neuroprotective 
properties in experimental paradigms of neurodegenerative diseases with a component 
of neuroinflammation, such as Parkinson's disease (PD) and Alzheimer's disease (AD). 
Nowadays, a growing number of studies indicate that resveratrol is implicated in 
slowing or altering the pathological progression of neurodegeneration by modulating 
specifie cellular pathways and parameters of neuroinflammation. Here, we present a 
global portrait of this polyphenol's role in the neural environ ment with a specifie 
emphasis on the experimental paradigms demonstrating resveratrol's molecular and 
cellular action on neuroinflammation. 
1. Introduction: neuroinflammation 
For a long time, the central nervous system (CNS) was considered an immune 
privileged region of the organism. This apparent state of retreat was attributed to the 
presence of tight junctions at the boundary between the endothelial membrane and nerve 
cells named the blood-brain barrier (BBB), and the relatively low expression of major 
histocompatibility complex (MHC) molecules. Today, we know this paradigm to be 
inaccurate as major evidence demonstrates support dynamic crosstalk between central 
and peripheral immunity as established by cytokine-mediated coordination of the 
inflammatory reaction (1), active immune surveillance by intruding cells of the 
peripheral immunity (2-4), and even the newfound demonstration of a lymphatic 
drainage system (5,6). 
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The CNS remams immunologically specialized inasmuch as resident cells 
accomplish the bulk of surveillance, defense, and reparation tasks. The principal 
antigen-presenting immune cells of the CNS are microglia that, in their resting ramified 
state, monitor their environrnent for disruptions of the fragile homeostasis required for 
the proper functioning of nerve cells (7-9). Vpon activation, microglia partake in 
neuroinflarnrnation by secreting inflarnrnatory mediators, producing toxic reactive 
species, and by executing reparation tasks through phagocytosis of debris (10,11). 
Astrocytes, which constitute up to 70% of glial cells, also actively participate during the 
inflammatory reaction by becoming hypertrophic, proliferating (astrogliosis), presenting 
antigens, expressing both pro- and anti-inflarnrnatory molecules, producing neurotrophic 
factors, and confining the lesion through the production of a glial scar (12,13) . Just as 
important is the presence of neurons that constitutive express transforming growth 
factor-beta (TGF-~), soluble fractalkine, and fas ligand (FasL), thus helping to contain 
inflammation (14,15). As such, all resident cells of the CNS are capable of fulfilling pro-
and anti-inflammatory tasks depending on their expression phenotype that greatly 
depends on surrounding soluble and cellular signaIs. 
Sustained and uncontrolled neuroinflarnrnation can easily take on auto-destructive 
proportions as observed in several neurodegenerative diseases such as Alzheimer's 
disease (AD) or Parkinson's disease (PD) (16,17). As such, strategies aiming to 
modulate neuroinflammation are of great interest in the development of neuroprotective 
therapies for various neurological pathologies. 
2. Resveratrol in neuroinflammation 
With respect to their proven anti-inflarnrnatory properties, an expanding number of 
studies have addressed the potential neuroprotective effects of dietary polyphenols in the 
CNS, especially regarding neurodegenerative diseases (18-20). Among the most 
promising anti-inflammatory polyphenols, resveratrol (trans-3 ,5,4'-trihydroxystilbene), 
a stilbenoid found in important quantities in the roots of Polygonum cuspidatum 
(Fallopiajaponica) and to a lesser extent in red wine, grapes, peanuts, and berries (21), 
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has attracted much attention over the past twenty years since its anticancer properties 
were first brought to light (22). Resveratrol has also been shown to possess broad 
anti-oxidative (23), cardioprotective (24), and anti-inflammatory (25,26) effects. 
Its neuroprotective actions in a wealth of in vitro and in vivo models (recently reviewed 
in 27 and 28), together with its sufficient bioavailability, oral safety, and ability to cross 
the BBB (29,30-36), earn resveratrol a prime role for its potential to counteract 
neuroinflammation in a pathological context. The following sections review the advance 
made in the characterization of resveratrol's neuroprotective properties pertaining to its 
anti-inflammatory actions, with a particular focus on experimental models and the latest 
proposed molecular mechanisms. 
2.1 Resveratrol and neuroinflammation: In vitro models 
2.1.1 Microglia monocultures 
Resveratrol's anti-inflammatory effects have been tested repeatedly ln 
monocultures of microglial cell lines or primary cultures treated with pro-inflammatory 
molecules such as the endotoxin lipopolysaccharide (LPS), a component of gram-
negative bacteria outer membranes. LPS elicits a potent inflammatory response by 
binding toll-like receptor 4 (TLR4), which leads to receptor homodimerization and 
activation that ultimately enhance transcription of pro-inflammatory proteins. 
Using BV2 microglial cells treated with LPS, resveratrol attenuated the release of 
pro-inflammatory cytokines such as interleukin- l ~ (IL-l~) and tumor necrosis factor-a 
(TNF-a) (37), as weil as it lowered levels (mRNA and protein) of the pro-inflammatory 
enzymes inducible nitric oxide (iNOS) and cyclooxygenase-2 (COX-2) alongside 
their products, nitric oxide (NO) and prostaglandin E2 (PGE2), respectively (38). 
Both mRNA and protein levels of the pro-inflammatory transcription factor K-light-
chain-enhancer of activated B cells subunit RelA (NF-KB/RelA) were reduced as a result 
of resveratrol's inhibitory effect on upstream regulators, in particular the prevention of 
mitogen-activated prote in kinases (MAPKs) phosphorylation (38). Of importance, these 
anti-inflammatory effects were fully or partially impaired by a treatment with 
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rapamycin, meaning that the mechanistic target of rapamycin (mTOR) was required to 
fulfill resveratrol ' s beneficial effects (38). Wh en used as a co-treatment in the 
LPS-activated N9 micro glial celIs, resveratrol was also shown to be anti-inflammatory 
by reducing iNOS expression and TNF-a release by acting through inhibition of 
p38 MAPK phosphorylation (39). More recently, comparable anti-inflammatory effects 
were observed in the N13 microglial celI line treated with LPS wherein resveratrol 
upregulated suppressor of cytokine signaling-l (SOCS-l), a regulator of inflammation 
that drives a negative feedback loop to temper cytokine production (40). Remarkably, 
resveratrol was found to inhibit aIl three pathways downstream of TLR4 activation, 
namely the MAPK, NF-KB pathway, and janus kinase (JAK)/signal transducer and 
activator of transcription (ST AT) axes, leading to hampered cytokine production. 
Noteworthy, silencing the expression of SOCS-l impaired resveratrol's pleiotropic anti-
inflammatory actions, suggesting a pivotaI role for this regulatory switch in mediating 
this polyphenol ' s beneficial effects. 
In pnmary rat microglia treated with LPS, resveratrol reported to prevent 
microglial activation not only by inhibiting the activity of cyclooxygenases (COXs), 
but also through the downregulation of the transcription and expression of the inducible 
microsomal PGE synthase-l (mPGES-l) known to be importantly involved in 
LPS-activation (41). This observation was not accompanied by altered COX expression 
nor modulated by COX-l inhibitors, suggesting that resveratrol's newfound inhibitory 
effect on mPGES-1 expression is independent of its action on COX-l. 
The use of A~ in mediating glial activation has become an increasingly popular 
tool in mimicking neuroinflammation in light of discoveries that demonstrate a clear-cut 
link between AD and inflammation (42). One study compared the potential of 
resveratrol to antagonize pro-inflammatory events in BV2 microglial celIs activated by 
either A~ or LPS (43). Resveratrol inhibited the NF-KB pathway in both models, 
and apparently interfered with TLR4 oligodimerization upon activation by LPS as 
shown by co-immunoprecipitation experiments in homogenates from murine bone 
marrow-derived pro-B Ba/F3 celIs coexpressing two differently tagged versions of 
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TLR4. Although there is no doubt that resveratrol blocked downstream TLR4 pathways, 
direct interference with TLR4 oligomerization is unlikely given that this polyphenol 
does not possess the structural motif to perform Michael addition on the receptor (44). 
Very recently, another group employed oligomeric A~ instead of A~ monomers to 
activate BV2 microglial ceIls and found that resveratrol successfully mitigated 
microgliosis and production of cytokines, NO, and reactive oxygen species (ROS) (45). 
In addition, resveratrol was shown to reduce mRNA and prote in levels of nicotinamide 
adenine dinucleotide phosphate oxidase (NADPH oxidase) subunits p47phox and 
gp91 phox, thereby explaining the decrease in ROS formation. 
2.1.2 Astrocyte monocultures 
As astrocytes are the most abundant type of nerve ceIl in the CNS, their regulatory 
role in neuroinflammation cannot be ignored. In the C6 astroglial cell strain derived 
from a rat glial tumor, resveratrol revoked activation of the NF-KB pathway and 
impeded the expression of downstream target genes COX-2 and iNOS, foIlowing LPS 
activation (47). Similarly, in primary murine astrocyte cultures activated by LPS, 
resveratrol was found to reduce levels of several pro-inflammatory cytokines including 
regulators of T cell polarization, IL-12 subunit ~ (IL-12p40) and IL-23, and the 
chemokine monocyte chemotactic protein-l (MCP-I) (48). Moreover, another study 
used pharmacological inhibitors of the inducible heme oxygenase-l (HO-I), ERKl/2, 
and p38, in primary rat astrocytes, to show that HO-I was necessary to mediate 
resveratrol's beneficial effects (49). Of note, HO-I is a known inhibitor of NF-KB 
nuclear translocation and of iNOS activity (50). Comparable results were obtained in 
primary rat astrocyte cultures activated by A~, sustaining a role for resveratrol ln 
diminishing COX-2 and iNOS protein levels as weIl as in impeding astrogliosis (51). 
In a comparative study using primary murine microglia and astrocytes as weIl as 
the N9 microglial ceIl, resveratrol precluded the activation of NF-KB in ail cell types, 
but it only successfully inhibited activator protein 1 (AP-I), another key pro-
inflammatory transcription factor, in microglia thereby offering a reasonable explanation 
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for resveratrol's less potent anti-inflammatory response in astrocytes (52). Interestingly, 
resveratrol had no effect on the phosphorylation levels of ail three members of the 
MAPK family, contrary to other data collected albeit from different experimental 
models (38-40,53-55). Another comparative study using primary hippocampal astrocyte 
cultures from newbom, adult, and aged Wistar rats, revealed that pro-inflammatory 
cytokine production was slightly though significantly more elevated in astrocyte cultures 
derived from older rats, while expression levels of the anti-oxidant enzyme glutathione 
synthase and its product, glutathione, were consistently lower (56). Remarkably, 
resveratrol was able to decrease levels of inflammatory markers and ameliorate the 
glutathione anti-oxidant response in each one of these unchallenged astrocyte cultures. 
2.1.3 Glia-neuron co-cultures 
As inflammatory reactions rely heavily on crosstalk between the multiple actors of 
immunity, co-cultures have emerged as very useful tools to study these interactions. 
Using LPS-challenged mixed primary cortical cultures, one group showed that 
resveratrol can reduce microglial activation as demonstrated by a decrease in levels of 
ionized calcium-binding adapter molecule 1 (Thal), a marker of activated microglia, and 
concomitant drops in TNF-a, IL-lB, and NO secretion (57). Similar results were found 
in mesencephalic mixed primary cultures where resveratrol protected dopaminergic 
neurons against LPS toxicity (58). The same group further revealed that resveratrol 
could impair NADPH oxidase activation, an enzyme that like MPO is responsible for 
respiratory burst, thereby preventing the production of ROS. This was likely due to the 
inhibition of MAPK phosphorylation, in particular extracellular signal-regulated kinase 
(ERKI /2), a known activator of NADPH oxidase. Similar NADPH oxidase-inhibition 
effects for resveratrol had also been previously reported in AB-chaUenged BV2 
microglia (45). Moreover, resveratrol could not protect the dopaminergic neurons 
in mixed cultures from NADPH oxidase-deficient mice, implying that its anti-
inflammatory properties may require the inhibition ofthis ROS-producing enzyme. 
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It should be noted, however, that mixed cultures cannot distinctively detect 
interactions that are solely based on paracrine signaling in the absence of cell-cell 
contact, as is the case for sorne cellular relationships seen in inflammation. To palliate 
this problem, the use of conditioned medium was developed as a method for the 
compartmentalization of cellular populations. Wang and colleagues (59) demonstrated in 
a conditioned medium experiment that secreted soluble factors from LPS-activated 
primary microglia reduce the viability of primary hippocampal neurons while resveratrol 
co-treatment afforded anti-inflammatory effects, leading to decreased secretion of 
cytokines, lower expression of iNOS, and repression of the NF-tcB pathway. Of interest, 
resveratrol preserved the physiology of the primary neurons treated with conditioned 
medium on the basis of numbers of growth cones, dendrites, and spines. Ye and 
colleagues also administered cytokine-rich conditioned medium from LPS-activated 
BV2 microglia monocultures as a toxic treatment on separate native PC12 cells (60). 
Resveratrol treatrnents were performed either on the BV2 microglial or PC12 cell 
population, resulting in protection against LPS-induced PC12 apoptosis, decreased 
microglial cytokine release, and all-around increased expression of silent mating type 
information regulation 2 homologue 1 (SIRTl), a deacetylase with pleiotropic beneficial 
effects. 
While the use of conditioned medium does solve the compartmentalization 
problems that arise from employing mixeq cultures, this method still bears important 
drawbacks. Indeed, in conditioned medium, the communication occurs unidirectionally 
instead of bidirectionally, secreted factors become diluted as they diffuse over time, 
and short-lived molecules, such as ROS that often go hand in hand with inflammatory 
reactions, decay before the conditioned medium is even transferred to the second 
population of cells. Currently, insert co-culture systems solve several of these problems. 
Our group tested the neuroinflammatory paradigm using LPS-activated N9 microglia 
grown in cell culture inserts overlaid in wells containing nerve growth factor-
differentiated dopaminergic PC12 neurons (61). Secreted cytokines diffused through the 
micropores of the inserts and triggered the apoptotic cascade of the neuronal PC 12 
neurons underneath, events that were counteracted by a resveratrol pre-treatment. 
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Similar results were found in the same co-culture neuroinflammation system using the 
parkinsonian neurotoxin I-methyl-4-phenylpyridiniurn (MPP+) to activate the microglial 
cellline (62). 
One group used an array of co-culture techniques to demonstrate the link between 
resveratrol neuroprotection and the expression of myeloperoxidase (MPO), a peroxidase 
enzyme necessary during micro glial respiratory burst (46). Resveratrol succeeded to 
prevent rotenone-induced increases in MPO activity and expression while other anti-
inflammatory drugs could not. Remarkably, in a mixed culture of MPO-deficient glial 
cells, resveratrol greatly ameliorated the impaired inflammatory response to rotenone-
induced production of nitrite and transcriptional up-regulation pro-inflammatory 
markers. In the same study, the authors reported that neurons cultured without microglia, 
were much more susceptible to rotenone toxicity despite being treated with resveratrol, 
suggesting that this polyphenol's mode of action may rely at least partly on MPO 
inhibition. Similar results were also obtained by Zhang et al. showing that solely mixed 
primary cultures containing microglia were protected against MPP+ by resveratrol 
administration (58) . 
One of the earliest studies employing A~ as a pro-inflammatory insult showed that 
resveratrol could prevent the activation of the NF-KB axis in a mixed culture of cortical 
neurons and glia (63) . Concomitantly, expression of the deacetylase SIRTl , a known 
inhibitor ofNF-KB activation, was significantly increased. Either overexpressing SIRTI 
or treating the mixed culture with resveratrol could suppress increased levels of 
cathepsin Band iNOS, two effectors of neuronal injury in AD, suggesting a role for this 
deacetylase in resveratrol 's anti-inflammatory actions. 
2.1.4 Organotypic slice cultures 
Organotypic slice cultures offer interesting advantages over other in vitro 
platforms such as preservation of tissue architecture, maintenance of intact local 
synaptic circuitry, and pharmacological accessibility (64). In that respect, resveratrol's 
470 
anti-inflammatory potential was investigated in rat hippocampal slice cultures stimulated 
by A~ (65). Resveratrol administered both in a free form or loaded in lipid-core 
nanocapsules was found to diminish cytokine release and ROS formation, thereby 
protecting the slice cultures against cell death. Remarkably, resveratrol-Ioaded lipid-core 
nanocapsules were further able to increase the release of IL-lO, an anti-inflammatory 
cytokine. On the other hand, free form resveratrol was less effective than lipid-core 
nanocapsules in mediating all-around anti-inflammatory effects and was unable to 
stimulate IL-10 release, which opens the way for the improvement of administration 
routes for this polyphenol in pre-clinical experimental models. 
Another set of interesting studies employing organotypic rat hippocampal slice 
cultures · have shown the noxious effects of the neurotransmitter glutamate and the 
neurotoxic viral protein Tat, derived from the human immunodeficiency virus-l (HIV -1) 
(54,55). Tat is actively secreted by HIV -infected immune cells and is known to be 
elevated in the CNS of patients suffering from HIV -associated dementia (HAD) (66), 
whereas glutamate plays a role in several neurological diseases with a component of 
excitotoxicity such as AD but also in HAD (66,67). Both toxic treatments increased the 
expression of pro-inflammatory MCP-l, however they acted through different 
mechanisms. Whereas glutamate required ERK1/2-induced IL-l ~ production to 
mediate its pro-inflammatory action (54), Tat rather necessitated activation of both 
ERK1I2 and tyrosine kinase (TK) to promote TNF-a release (55). In these paradigms, 
resveratrol exerted anti-inflammatory protective effects through preventing ERK1I2 
phosphorylation and subsequently mitigating cytokine production and ultimately led 
to decreased expression of MCP-l, as shown previously (48,52). Noteworthy, 
pharmacological manipulations ruled out the implication of any of the two other 
MAPKs, which reiterates the pivotai function that ERK1I2 holds in mediating 
resveratrol's anti-inflammatory effects in these models and others (38-40,53). 
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2.2 Resveratrol and neuroinflammation: In vivo models 
2.2.1 Neurodegenerative disease models 
The most common neurodegenerative diseases and brain injuries are attended by 
inflammatory events that participate either in their ons et or progression. In the two most 
common neurodegenerative disease, AD and PD, neuroinflammation has been broadly 
characterized ever since seminal work by McGeer and colleagues exposed the existence 
of unusually elevated levels of MHC class II molecules on the surface of activated 
microglia in post-mortem brains of PD patients (68). 
Experiments perforrned in rodents challenged with LPS have substantiated 
resveratrol ' s general potential to prevent neuroinflammation by improving CNS levels 
of oxidative markers and pro-inflammatory cytokines, as weIl as ameliorating locomotor 
and cognitive behaviors (37,69). Further experimenting using the well-known MPTP 
mouse model of PD revealed that orally-administered resveratrol could reduce glial 
activation and dopaminergic neuronal death in the substantia nigra pars compacta, 
the key region targeted by neurodegeneration in PD. (70). In particular, resveratrol 
upregulated the transcription and expression of SOCS-l , reduced cytokines release and 
lowed transcription levels of their respective receptors. In 6-hydroxydopamine 
(6-0HDA)-treated rats, another rodent model of PD, resveratrol administered per os 
showed similar anti-inflammatory effects alongside improving dopaminergic neuronal 
morphology, such as chromatin condensation, mitochondrial tumefaction, and 
vacuolization (71). Noteworthy, resveratrol was able to attenuate the characteristic 
apomorphine-induced tuming behavior observed in these rats. 
Resveratrol's anti-inflammatory properties have further been supported in models 
of AD. Indeed, resveratrol was shown to diminish plaque area in correlation with 
impeded microglial activation in the hippocampus of APP/PS 1 transgenic mice, a well-
documented model of early onset AD (43). Resveratrol mixed in the diet and fed to the 
mice for a period of one year was found to significantly reduce A~ plaque density in the 
cortex, caudate-putamen, and hippocampus (72), and concurrent micro glial activation 
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was hampered in these brain regions. In rats infused with A~ intracerebroventricularly, 
resveratrol loaded in lipid-core nanocapsules was shown to improve hippocampal 
synaptic integrity and gliosis (73) by inhibiting c-Jun N-terminal kinases (JNK) MAPK 
and the ~-catenin pathway through rescuing glycogen synthase kinase 3~ (GSK-3 ~) 
phosphorylation. In addition, improvement of spatial working memory and long-term 
recognition memory was observed following treatment with resveratrol-Ioaded lipid-
core nanocapsules (65). Zaky and colleagues reported that resveratrol could reduce 
NF-KB activation and cytokine production and plaque formation in a rodent model 
administered with alup1inum chloride (74). Besides, resveratrol was able to increase the 
levels of A~40 peptide, a potentially protective form of A~40 and rescued the expression 
of apurinic/apyramidic endonuclease 1/redox factor-I (APE 1/Ref-I), an important 
player in DNA repair and a redox regulator of transcription factors su ch as NF-KB and 
AP-l. 
2.2.2 Brain in jury models 
Traumatic brain injuries (TBI) represent the importance of controlled and 
well-steered neuroinflammation intended to effectively repair CNS lesions. TBI implies 
glial activation, cytokine production, debris clearance, and even the recruitment of 
a substantial cast of blood-derived inflammatory effectors due to loss of BBB integrity 
(75-77). Thus, it is of prime importance to tackle the inflammatory component of TBI to 
limit neuronallesions and dysfunction. 
Resveratrol administered post-in jury m a munne model of mild TB l, indeed 
displayed anti-inflammatory actions by attenuating microgliosis in the corpus callosum, 
cerebral cortex, and dentate gyms (78), and elevated levels of IL-6 and IL-I2 observed 
in the hippocampus following the injury were rescued by resveratrol administration. 
As for TB l, patients with spinal cord injuries (SCI) sustain ongoing inflammatory 
damage long after the traumatic event (75). In a rat model of acute SCI, resveratrol 
administered post-in jury improved the extent of damages in the CNS by reducing 
necrosis, hemorrhage, oxidative stress, and edema, as well as by rescuing neuronal 
morphology and apoptosis (79). Alongside the se observations, pro-inflammatory 
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cytokine production and MPO expression were hampered. On the other side, resveratrol 
also reduced levels of anti-inflammatory IL-l 0, suggesting an all-around buffering effect 
of inflammatory signaling. Remarkably, rats treated with resveratrol displayed improved 
locomotor activity. 
Following an ischemic event, reperfusion is a key contributor to the up rai se in 
robust neuroinflammation (76). A pre-treatrnent of resveratrol in rats challenged with 
global cerebral ischemia/reperfusion remarkably attenuated glial activation particularly 
in the CAl hippocampal region (80). In parallel, NF-KB and JNK activation were 
hampered, leading to decreased production of COX-2 and iNOS. 
Status epilepticus (SE), a state of persistent seizure and a known cause of CNS 
injury, may implicate neuroinflammation (77). Resveratrol ' s anti-inflammatory potential 
has been tested in a rat model of SE, particularly regarding its possible effect on 
mTOR (81). Indeed, resveratrol could downregulate the activity of mTOR shown to be 
increased in SE rats, leading to the impediment of the NF-KB pathway and reduction of 
the classical downstream gene targets. Similar results were obtained with the mTOR 
inhibitor rapamycin. Remarkably, resveratrol enhanced the levels of mTOR antagonists 
5' adenosine monophosphate-activated protein kinase (AMPK) and SIRTI. However, 
further experiments showed that pharmacological inhibition of AMPK but not SIRTI 
could reverse resveratrol's beneficial effects, implying a role for AMPK activation in 
this polyphenol's mTOR-inhibitory and anti-inflammatory actions. This is in opposition 
to results obtained in vitro where resveratrol rather activated mTOR (38). 
3. Molecular mechanisms of resveratrol action in neuroinflammation 
It is undeniable that resveratrol possesses potent anti-inflammatory properties in 
light of the compelling in vitro and in vivo evidence that has pointed out its potential to 
downregulate distinct pathways implicated in inflammation, in particular the NF -KB, 
AMPKlSIRTl , and MAPKs axes, as weil as pivotai actors such as MPO, NADPH 
oxidase, and HO-l, to name a few. Figure 1 presents an overview of the potential key 
molecular axes underlying resveratrol's anti-inflammatory benefits. 
474 
resveratrol 
activating mechanism 
inhibitory mechanism 
indirect mechanism ~ other targets? 
direct targets of resveratrol r OH ::'---- -
l 
i S'AMP 
cAMP 
1 
H '" 1 ~ I: ~ OH 
i NAD+ 
NADH 
~ 
................ / ! 
: pro-inflammatory pro-inflammatory v ,. 
factors , cytokines and microglial 
, enzymes respiratory burst 
" 1 ~ ~~ 
" J, I~~~ ~~~ 
~ ...... V' 
neuroinflammation 
Figure 1 Possible mechanisms by which resveratrol affords its anti-
inflammatory actions, particularly in microglia activated by LPS. 
Firstly, resveratrol is suggested to directly inhibit phosphodiesterases 
(PDEs) or to activate si lent mating type information regulation (Sir) 2 
homolog 1 (SIRT 1). Both targets are responsible for triggering multiple 
intracellular cascades, sorne of which depicted herein, leading to the 
activation of adenosine monophosphate kinase (AMPK). Thereafter, 
AMPK is capable of inhibiting nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-K13) activation. Similarly, SIRTI deacetylates 
both NF-teE and activator proteinl (AP-l), thereby preventing their 
activation. Moreover, resveratrol has been demonstrated to directly 
activate heme oxygenase-l (HO-l), an inhibitor of NF-K13, and to 
475 
stabilize KH-type splicing regulator protein (KSRP), a protein responsible 
for the degradation of pro-inflammatory mRNAs. As weil, resveratrol 
is a known inhibitor of apurinic/apyramidic endonuclease lIredox 
factor-l (APElIRef-1), which potentiates NF-KB- and AP-l-mediated 
transcription, and of pro-inflammatory enzymes such as cyclooxygenases 
(COXs) and leukotriene A4 hydrolase (LTA4H), which respectively 
synthesize the pro-inflammatory mediators prostaglandin E2 (POE2) and 
leukotriene B4. Finally, resveratrol's role in directly modulating estrogen 
receptors (ERs) has also been highlighted as a potential anti-inflammatory 
pathway. This aU-inclusive schematic demonstrates a convergence in the 
multiple pathways activated or inhibited by resveratrol that ultimately 
lead to the offset of pro-inflammatory processes in microglia. EPAC, 
exchange factor directly activated by cyclic adenosine monophosphate 1; 
LKB 1, liver kinase BI ; LPS, lipopolysaccharide; MAPK, mitogen-
activated prote in kinase; MPO, myeloperoxidase; NADPH, nicotinamide 
adenine dinucleotide phosphate; TLR4, toll-like receptor 4. 
3.1 Pro-inflammatory enzymes 
COXs are convincingly sorne of the most probable direct targets of resveratrol ' s 
attention. Both COX -1 and COX -2 catalyze the conversion of arachidonic acid to pro-
inflammatory prostaglandins. Pezzuto ' s group proved resveratrol 's inhibitory effect on 
both COX isoforms, with regard to its anti-cancer potential (22), and these observations 
have been reinstated in recent days (82). Another inflammation-related protein, 
leukotriene 4A hydrolase (LTA4H), has recently been shown to be directly inhibited by 
resveratrol (83). LT A4H catalyzes the final step of the neutrophil chemoattractant 
leukotriene B4 synthesis pathway. Nonetheless, thwarting results showing LT A4H to 
de grade another neutrophil chernoattractant, proline glycine proline peptide (POP), make 
it difficult to predict the SUffi anti-inflammatory effect of inhibiting this hydrolase 
(84,85). 
3.2 Pro-inflammatory mRNAs 
More recently, resveratrol has also emerged as a potent disruptor of pro-
inflammatory mRNAs. lndeed, using a target-fishing method, resveratrol was found to 
bind KH-type splicing regulator prote in (KSRP) whose main activity in the cell consists 
in binding inherently instable mRNAs, such as the ones encoding pro-inflammatory 
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proteins IL-8, iNOS, and TNF-a, and recruiting decay machinery (86). Accordingly, 
resveratrol was able to increase KSRP stability and to concurrently reduce the life of 
pro-inflammatory mRNAs. In primary cells from mice in which KSRP was inactivated, 
resveratrol displayed significantly lower anti-inflammatory aptitudes. Interestingly, these 
effects were observed independently of SIRTI involvement. 
3.3 APElIRefl 
Resveratrol's anti-inflammatory actions could furthermore operate by inhibiting 
APElIRef-l (74,87-89), a DNA repair prote in that also comprises a redox sensitive 
catalytic activity, the Ref-l domain, known to bind to pro-inflammatory factors AP-l 
and NF-KB and to activate their transcriptional activity. It would appear that resveratrol 
not only acts through modulating the cell's redox environment, but also by directly 
binding pockets located in the redox domain (90). Interestingly, APElIRef-l has also 
been linked to neurodegenerative diseases and holds a special place among the most 
recent emerging therapeutic targets (91,92). Conversely, previous work has rather shown 
that resveratrol may be responsible for increasing APE lIRef-l levels, though evidence 
of direct binding was not provided (74) . 
3.4 ERs 
Another indirect mechanism by which resveratro1 could mediate its anti-
inflammatory effects in the CNS is through activation of estrogen receptors (ERs), 
which it is weil known to directly bind (93,94). More recently, resveratrol was 
successfully crystalized in a complex with ERa, and was found to bind the receptor in a 
unique orientation that would explain why it do es not behave like estrogen in several 
cell types (95). In fact, this "flipped" binding orientation explains why resveratrol acts as 
a pathway-selective ERa activator, since it perturbs the receptor's coactivator-binding 
surfaces. In the same published data, resveratrol was proven to require ERa to inhibit 
IL-6 expression. 
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3.5 AMPKlSIRTl 
The most reputable aXIs renowned to be activated by resveratrol is the 
AMPKlSIRTl pathway. AMPK is a metabolic power player that is thought to afford 
several of resveratrol's pleiotropic effects, not only pertaining to inflammation. AMPK 
integrates information on the intracellular energy status, thus acting as an A TP:AMP 
sensor. Upon ATP depletion, AMPK is activated and increases the NAD+/NADH ratio, 
itself leading to SIRTI activation. SIRTI is also in itself an indirect activator of AMPK 
as it deacetylates liver kinase B 1 (LKB 1) that in tum phosphorylates and activates 
the kinase. Whether resveratrol binds and activates SIRTI or whether it inhibits 
phosphodiesterases (PDEs), which eventually leading to AMPK activation, is still a 
debated topic (see 27 for a detailed review on this topic), as findings in different 
models and at different concentrations have yielded confounding results (96-103). 
The activation of the AMPKlSIRTI axis may well explain resveratrol's anti-
inflammatory effects through 1) deacetylation of AP-l and NF-KB (104) and 2) NADPH 
oxidase inactivation by AMPK (105-107). 
4. Summary and perspectives 
Resveratrol remains today the center of much scientific attention in the global 
effort to develop therapeutic options to improve or cure neurological diseases, most of 
which comprise a neuroinflammatory facet. As it has been demonstrated in countless 
models, resveratrol possesses a very large number of possible modes of action that 
explain its promiscuity in exerting such a wide range of physiological effects. 
This chapter has reviewed in details the experimental paradigms that contribute to 
improve our knowledge of the possible molecular mechanisms of resveratrol action on 
neuroinflammation. Even if the key direct interactions between resveratrol and its 
possible molecular target are still under investigation (reviewed recently in 109), 
resveratrol has been demonstrated as a promising therapeutic strategy in ameliorating 
neuroinflammation and other pathological expressions with a component of 
inflammation. 
478 
To temper our fervor, it should be reiterated that ail the promlsmg anti-
inflammatory pathways elicited by resveratrol in nerve cells and reported in this article, 
derive from cell culture or small animal model systems with no report on resveratrol 
action on hurnan health or alternate animal models. Indeed, translation of resveratrol 
body of work from basic sciences to the clinics is still difficult, and the scarce data 
obtained in controlled studies are disappointing and controversial, especially so with 
respect to the human response to different doses of resveratrol (reported in 110). 
It appears capital to us that the next efforts of the resveratrol community should 
accurately study the molecular target of resveratrol as weil as improve the application of 
pre-clinical advances in large animal models in order to proper understand the 
unambiguous anti-inflammatory effects, safety and efficacy of resveratrol and any more 
potential benefits it may have in humans. 
Acknowledgments 
This work was funded by a Natural Sciences and Engineering Research Council 
(NSERC) Canada grant to MGM. JR is a NSERC-Vanier student fellow. 
479 
References 
1. Galic MA, Riazi K, Pittman QJ. Cytokines and brain excitability. Front 
Neuroendocrino12012 ; 33 : 116-25. 
2. Ousman SS, Kubes P. Immune surveillance In the central nervous system. 
Nat Neurosci 2013 ; 15: 1096-101. 
3. Reboldi A, Coisne C, Baurnjohann D, Benvenuto F, Bottinelli D, Lira S, Uccelli 
A, Lanzavecchia A, Engelhardt B, Sallusto F. C-C chemokine receptor 6-
regulated entry of TH-17 cells into the CNS through the choroid plexus is 
required for the initiation ofEAE. Nat Immuno12009; 10: 514-23. 
4. Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune 
surveillance in the central nervous system. Nat Rev Immuno12012 ; 12: 623-35. 
5. Louveau A, Smimov l , Keyes TJ, Eccles ID, Rouhani SJ, Peske JD, Derecki NC, 
Castle D, Mandell JW, Lee KS, Harris TH, Kipnis 1. Structural and functional 
features of central nervous system lymphatic vessels. Nature 2015. 
6. Aspelund A, Antila S, Proulx ST, Karlsen TV, Karaman S, Detmar M, Wiig H, 
Alitalo K. A duraI lymphatic vascular system that drains brain interstitial fluid 
and macromolecules . J Exp Med 2015; 212 : 991-9. 
7. Kreutzberg GW. Microglia: a sens or for pathological events in the CNS. Trends 
Neurosci 1996; 19: 312-18. 
8. Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells 
in the normal and pathologic brain. Nat Neurosci 2007; 10: 1387-94. 
9. Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, 
Dustin ML, Gan WB. A TP mediates rapid micro glial response to local brain 
injury in vivo. Nat Neurosci 2005 ; 8: 752-8. 
10. Tremblay M-E, Stevens B, Sierra A, Wake H, Bessis A, Nimmerjanh A. The role 
of microglia in the healthy brain. J Neurosci 20 Il ; 31 : 16064-9. 
Il. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the 
molecular mechanisms. Nat Rev Neurosci 2007; 8: 57-69. 
12. Farina C, Aloisi F, Meinl E. Astrocytes are active players in cerebral innate 
immunity. Trends Immuno12007; 28: 138-45. 
480 
13. Jager A, Dardalhon Y, Sobel RA, Bettelli E, Kuchroo. Thl, Thl7, and Th9 
effector cells induce experimental auto immune encephalomyelitis with different 
pathological phenotypes. J Immunol 2009; 183: 7169-77. 
14. Giemsa U, Mitchison NA, Brunner-Weinzierl MC. Immune privilege as an 
intrinsic CNS property: astrocytes protect the CNS against T -cell-mediated 
neuroinflammation. Mediators Inflamm 2013; 2013: 320519. 
15. Boche D, Cunningham C, Docagne F, Scott H, Perry YH. TGFbetal regulates the 
inflammatory response during chronic neurodegeneration. Neurobiol Dis 2006; 
22: 638-50. 
16. Amor S, Puentes F, Baker D, van der Yalk P. Inflammation in neurodegenerative 
diseases. Immuno12010; 129: 154-69. 
17. Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease-a double-
edged sword. Neuron 2002; 35 : 419-32. 
18. Bhullar KS, Rupasinghe HP. Polyphenols: multipotent therapeutic agents m 
neurodegenerative diseases. Oxid Med Cell Longev 2013; 891748. 
19. Reglodi D, Renaud J, Tamas A, Tizabi Y, Sodas B, Del-Bel E, 
Raisman-Yozari R. Novel tactics for neuroprotection in Parkinson's disease: Role 
of antibiotics, polyphenols and neuropeptides. Prog Neurobiol 2015; pii: S0301-
0082( 15)00 128-8. 
20. Rubio-Perez JM, Morillas-Ruiz JM. A review: inflammatory process m 
Alzheimer's disease, role of cytokines. Scientific World Journal 2012: 756357. 
21. Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: food 
sources and bioavailability. Am J Clin Nutr 2004; 79: 727-47. 
22. Jang M, Cai L, Udeani GO, Slowing KY, Thomas CF, Beecher CW, Fong HH, 
Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM. Cancer 
chemopreventive activity of resveratrol, a natural product derived from grapes. 
Science 1997; 275: 218-20. 
23 . Leonard SS, Xia C, Jiang BH, Stinefelt B, Klandorf H, Harris GK, Shi X. 
Resveratrol scavenges reactive oxygen species and effects radical-induced 
cellular responses. Biochem Biophys Res Commun 2003; 309: 1017-26. 
481 
24. Wu JM, Hsieh TC, Wang Z. Cardioprotection by resveratrol: a review of 
effects/targets in cultured cells and animal tissues. Am J Cardiovasc Dis 20 Il ; 
1: 38-47. 
25. Svajger U, Jeras M. Anti-inflammatory effects of resveratrol and its potential use 
in therapy of immune-mediated diseases. Int Rev Immuno12012 ; 31 : 202-22. 
26. Das S, Das DK. Anti-inflammatory responses of resveratrol. Inflamm Allergy 
Drug Targets 2007; 6: 168-73. 
27. Renaud J, Martinoli MG. Resveratrol as a protective molecule for 
neuroinflammation: a reVlew of mechanisms. Curr Pharrn Biotechnol 2014; 
15: 318-29. 
28. Bastianetto S, Menard C, Quirion R. Neuroprotective actions of resveratrol. 
Biochim Biophys Acta 2015; 1852: 1195-1201. 
29. Cottart CH, Nivet-Antoine V, Laguillier-Morizot C, Beaudeux JL. Resveratrol 
bioavailability and toxicity in hurnans. Mol Nutr Food Res 2010; 54: 7-16. 
30. Wang Q, Xu J, Rottinghaus GE, Simonyi A, Lubahn D, Sun GY, Sun A Y: 
Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res 
2002; 958: 439-47. 
31. Vingtdeux V, Giliberto L, Zhao H, Chandakkar P, Wu Q, Simon JE, Janle EM, 
Lobo J, Ferruzzi MG, Davies P, Marambaud P.AMP-activated prote in kinase 
signaling activation by resveratrol modulates amyloid-beta peptide metabolism. 
J Biol Chem 2010; 285: 9100-13. 
32. Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beai MF, Gibson GE. Dietary 
supplementation with resveratrol reduces plaque pathology in a transgenicmodel 
of Alzheimer's disease. Neurochem Int 2009; 54: 111-8. 
33 . Mokni M, Elkahoui S, Limam F, Amri M, Aouani E: Effect of resveratrol on 
antioxidant enzyme activities in the brain of healthy rat. Neurochem Res 2007; 
32: 981-987. 
34. Asensi M, Medina l, Ortega A, Carretero J, Bano MC, Obrador E, Estrela JM. 
Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free 
Radic Biol Med 2002; 33 : 387-98. 
482 
35. Abd El-Mohsen M, Bayele H, Kuhnle G, Gibson G, Debnam E, Kaila Srai S, 
Rice-Evans C, Spencer JP. Distribution of [3H]trans-resveratrol in rat tissues 
following oral administration. Br J Nutr 2006; 96: 62-70. 
36. Juan ME, Maijo M, Planas JM. Quantification of trans-resveratrol and its 
metabolites in rat plasma and tissues by HPLC. J Pharmaceut Biomed Anal 201 0; 
51: 391-98. 
37. Abraham J, Johnson RW. Consuming a di et supplemented with resveratrol 
reduced infection-related neuroinflammation and deficits in working memory in 
aged mice. Rejuvenation Res 2009; 12: 445-43. 
38. Zhong LM, Zong Y, Sun L, Guo JZ, Zhang W, He Y, Song R, Wang WM, 
Xiao CJ, Lu D. Resveratro1 inhibits inflammatory responses via the mammalian 
target of rapamycin signaling pathway in cultured LPS-stimulated microglial 
cells. PLoS One 2012; 7: e32195 . 
39. Bi XL, Yang JY, Dong YX, Wang JM, Cui YH, Ikeshima T, Zhao YQ, 
Wu CF. Resveratrol inhibits nitric oxide and TNP-alpha production by 
lipopolysaccharide-activated microglia. Int. Immunopharmacol 2005; 5: 185-93. 
40. Dragone T, Cianciulli A, Calvello R, Porro C, Trotta T, Panaro MA. Resveratrol 
counteracts lipopolysaccharide-mediated micro glial inflammation by modulating 
a SOCS-l dependent signaling pathway. Toxicol In Vitro 2014; 28: 1126-35. 
41. Candelario-Jalil E, de Oliveira AC, Graf S, Bhatia HS, Hüll M, Mufioz E, 
Fiebich BL. Resveratrol potently reduces prostaglandin E2 production and free 
radical formation in lipopolysaccharide-activated primary rat microglia. 
J Neuroinflammation 2007; 10: 4-25. 
42. McGeer PL, McGeer EG. The amyloid cascade-inflammatory hypothesis 
of Alzheimer disease: implications for therapy. Acta Neuropathol 2013; 126: 
479-97. 
43. Capiralla H, Vingtdeux V, Zhao H, Sankowski R, Al-Abed Y, Davies P, 
Marambaud P. Resveratrol mitigates lipopolysaccharide- and A~-mediated 
microglial inflammation by inhibiting theTLR4/NF-ill/STAT signaling cascade. 
JNeurochem 2012; 120: 461-72. 
44. Zhao L, Lee JY, Hwang DH. Inhibition of pattern recognition receptor-mediated 
inflammation by bioactive phytochemicals. Nutr Rev 20 Il ; 69: 310-20. 
483 
45 . Yao Y, Li J, Niu Y, Yu JQ, Yan L, Miao ZH, Zhao XX, Li YJ, Yao WX, 
Zheng P, Li WQ. Resveratrol inhibits oligomeric A~-induced microglial 
activation via NADPH oxidase. Mol Med Rep 2015; 12: 6133-9. 
46. Chang CY, Choi DK, Lee DK, Hong YJ, Park El Resveratrol confers protection 
against rotenone-induced neurotoxicity by modulating myeloperoxidase levels in 
glial cells. PLoS One 2013; 8: e60654. 
47. Kim Y A, Kim GY, Park KY, Choi YH. Resveratrol inhibits nitric oxide and 
prostaglandin E2 production by lipopolysaccharide-activated C6 microglia. 
J Med. Food 2007; 10: 218-24. 
48. Wight RD, Tull CA, Deel MW, Stroope BL, Eubanks AG, Chavis JA, Drew PD, 
Hensley LL. Resveratrol effects on astrocyte function: relevance to 
neurodegenerative diseases. Biochem Biophys Res Commun 2012; 426: 112-5. 
49. Bellaver B, Souza DG, Bobermin LD, Souza DO, Gonçalves CA, Quincozes-
Santos A. Resveratrol Protects Hippocampal Astrocytes Against LPS-Induced 
Neurotoxicity Through HO-l , p38 and ERK Pathways. Neurochem Res 2015; 
40: 1600-8. 
50. Wakabayashi N, Slocum SL, Skoko JJ, Shin S, Kensler TW. When NRF2 talks, 
who's listening? Antioxid Redox Signal 2010; 13: 1649-63. 
51. Scuderi C, Stecca C, Bronzuoli MR, Rotili D, Valente S, Mai A, Steardo L. 
Sirtuin modulators control reactive gliosis in an in vitro model of Alzheimer's 
disease. Front Pharmacol 2014; 5: 89. 
52. Lu X, Ma L, Ruan L, Kong Y, Mou H, Zhang Z, Wang Z, Wang JM, Le Y. 
Resveratrol differentially modulates inflarnrnatory responses of microglia and 
astrocytes. J Neuroinflarnrnation 2010; 7: 46. 
53. Zhang F, Shi JS, Zhou H, Wilson B, Hong JS, Gao HM. Resveratrol protects 
dopamine neurons against lipopolysaccharide-induced neurotoxicity through its 
anti-inflarnrnatory actions. Mol Pharmacol 2010; 78: 466-77. 
54. Lee EO, Park HJ, Kang JL, Kim HS, Chong YH. Resveratrol reduces glutamate-
mediated monocyte chemotactic protein-1 expression via inhibition of 
extracellular signal-regulated kinase 1/2 pathway in rat hippocampal slice 
cultures. J Neurochem 2010; 112: 1477-87. 
484 
55. Lee EO, Kim SE, Park HK, Kang JL, Chong YH. Extracellular HIV-1 Tat 
upregulates TNF-a dependent MCP-lICCL2 production via activation ofERK1I2 
pathway in rat hippocampal slice cultures: inhibition by resveratrol, a 
polyphenolic phytostilbene. Exp Neurol 20 Il; 229: 399-408. 
56. Bellaver B, Souza DG, Souza DO, Quincozes-Santos A. Resveratrol increases 
antioxidant defenses and decreases proinflammatory cytokines in hippocampal 
astrocyte cultures from newbom, adult and aged Wistar rats. Toxicol ln Vitro 
2014; 28: 479-84. 
57. Zhang F, Wang H, Wu Q, Lu Y, Nie J, Xie X, Shi 1. Resveratrol protects cortical 
neurons against microglia-mediated neuroinflammation. Phytother Res 2013; 
27: 344-9. 
58. Zhang F, Shi JS, Zhou H, Wilson B, Hong JS, Gao HM. Resveratrol protects 
dopamine neurons against lipopolysaccharide-induced neurotoxicity through its 
a!lti-inflammatory actions. Mol Pharmacol2010; 78: 466-77. 
59. Wang F, Cui N, Yang L, Shi L, Li Q, Zhang G, Wu J, Zheng J, Jiao B. 
Resveratrol Rescues the Impairments of Hippocampal Neurons Stimulated by 
Microglial Over-Activation ln Vitro. Cell Mol Neurobiol2015; 35: 1003-15 . 
60. Ye J, Liu Z, Wei J, Lu L, Huang Y, Luo L, Xie H. Protective effect ofSIRTl on 
toxicity of microglial-derived factors induced by LPS to PC12 cells via the 
p53-caspase-3-dependent apoptotic pathway. Neurosci Lett 2013 ; 553: 72-7. 
6l. Bureau G, Longpré F, Martinoli MG. Resveratrol and quercetin, two natural 
polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. 
J Neurosci Res 2008; 86: 403-10. 
62. Boumival J, Plouffe M, Renaud J, Provencher C, Martinoli MG. Quercetin and 
sesamin prote ct dopaminergic cells from MPP+-induced neuroinflammation in a 
microglial (N9)-neuronal (PC12) coculture system. Oxid Med Cell Longev 2012; 
2012: 921941. 
63. Chen J, Zhou Y, Mueller-Steiner S, Chen LF, Kwon H, Yi S, Mucke L, Gan L. 
SIRT1 protects against microglia-dependent amyloid-beta toxicity through 
inhibiting NF-kappaB signaling. J Biol Chem 2005; 280: 40364-74. 
64. Cho S, Wood A, Bowlby MR. Brain slices as models for neurodegenerative 
disease and screening platforms to identify novel therapeutics. CUIT 
Neuropharmacol2007; 5: 19-33 . 
485 
65. Frozza RL, Bernardi A, Hoppe JB, Meneghetti AB, Battastini AM, 
Pohlmann AR, Guterres SS, Salbego C. Lipid-core nanocapsules improve the 
effects of resveratrol against Abeta-induced neuroinflammation. J Biomed 
NanotechnoI2013 ; 9 : 2086-104. 
66. Hudson L, Liu J, Nath A, Jones M, Raghavan R, Narayan 0 , Male D, Everall I. 
Detection of the human immunodeficiency virus regulatory prote in tat in 
CNS tissues. J Neurovirol2000; 6: 145-55. 
67. Bellizzi MJ, Lu SM, Gelbard HA. Protecting the synapse: evidence for a rational 
strategy to treat HIV-l associated neurologic disease. J Neuroimmune Pharmacol 
2006; 1: 20-31. 
68. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive 
for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease 
brains. Neurology 1988; 38: 1285-91. 
69. Sebai H, Gadacha W, Sani M, Aouani E, Ghanem-Boughanmi N, Ben-Attia M. 
Protective effect of resveratrol against lipopolysaccharide-induced oxidative 
stress in rat brain. Brain Inj 2009; 23: 1089-94. 
70. Lofrurnento DD, Nicolardi G, Cianciulli A, De Nuccio F, La Pesa V, 
Carofiglio V, Dragone T, Calvello R, Panaro MA. Neuroprotective effects 
of resveratrol in an MPTP mouse model ofParkinson's-like disease: Possible role 
of SOCS-l in reducing pro-inflammatory responses. Innate Immun 2013 ; 
20: 249-60. 
71. Jin F, Wu Q, Lu YF, Gong QH, Shi JS. Neuroprotective effect of resveratrol on 
6-0HDA-induced Parkinson's disease in rats. Eur J Pharmacol2008; 600: 78-82. 
72. Solberg NO, Chamberlin R, Vigil JR, Deck LM, Heidrich JE, Brown DC, 
Brady CI, Vander Jagt TA, Garwood M, Bisoffi M, Severns V, Vander Jagt DL, 
Sillerud LO. Optical and SPION-Enhanced MR Imaging Shows that trans-
Stilbene Inhibitors of NF-KB Concomitantly Lower Alzheimer's Disease Plaque 
Formation and Microglial Activation in ABPP/PS-l Transgenic Mouse Brain. 
J Alzheimers Dis 2014; 40: 191-212. 
73. Frozza RL, Bernardi A, Hoppe JB, Meneghetti AB, Matté A, Battastini AM, 
Pohlmann AR, Guterres SS, Salbego C. Neuroprotective effects of resveratrol 
against AB administration in rats are improved by lipid-core nanocapsules. 
Mol Neurobiol2013 ; 47: 1066-80. 
486 
74. Zaky A, Mohammad B, Moftah M, Kandeel KM, Bassiouny AR. 
Apurinic/apyrimidinic endonuclease 1 is a key modulator of aluminum-induced 
neuroinflammation. BMC Neurosci 2013; 14: 26. 
75. David S, L6pez-Vales R, Wee Yong V. Harmful and beneficial effects of 
inflammation after spinal cord injury: potential therapeutic implications. 
Handb Clin Neuro12012; 109: 485-502. 
76. Amantea D, Nappi G, Bemardi G, Bagetta G, Corasaniti MT. Post-ischemic brain 
damage: pathophysiology and role of inflammatory mediators. FEBS J 2009; 
276: 13-26. 
77. Janigro D, Iffland PH 2nd, Marchi N, Granata T. A role for inflammation in 
status epilepticus is revealed by a review of CUITent therapeutic approaches. 
Epilepsia 2013 ; 54: 30-2. 
78. Gatson JW, Liu MM, Abdelfattah K, Wigginton JG, Smith S, Wolf S, Minei JP. 
Resveratrol decreases inflammation in the brain of mice with mild traumatic brain 
injury. J Trauma Acute Care Surg 2013 ; 74: 470-4; discussion 474-5. 
79. Liu C, Shi Z, Fan L, Zhang C, Wang K, Wang B. Resveratrol irnproves neuron 
protection and functional recovery in rat model of spinal cord injury. Brain Res 
2011; 1374: 100-9. 
80. Simao FI , Matté A, Pagnussat AS, Netto CA, Salbego CG. Resveratrol 
preconditioning modulates inflammatory response in the rat hippocampus 
following global cerebral ischemia. Neurochem Int 2012; 61 : 659-65. 
81. Wang SJ, Bo QY, Zhao XH, Yang X, Chi ZF, Liu XW. Resveratrol pre-treatment 
reduces early inflammatory responses induced by status epilepticus via mTOR 
signaling. Brain Res 2013; 1492: 122-9. 
82. Zykova TA, Zhu F, Zhai X, Ma WY, Ermakova SP, Lee KW, Bode AM, Dong Z. 
Resveratrol directly targets COX-2 to inhibit carcinogenesis. Mol Carcinog 2008; 
47: 797-805. 
83 . Oi N, Jeong CH, Nadas J, Cho YY, Pugliese A, Bode AM, Dong Z. Resveratrol, a 
red wine polyphenol, suppresses pancreatic cancer by inhibiting leukotriene A(4) 
hydrolase. Cancer Res 2010; 70: 9755-64. 
84. Snelgrove RJ, Jackson PL, Hardison MT, Noerager BD, Kinloch A, Gaggar A, 
Shastry S, Rowe SM, Shim YM, Hussell T, Blalock JE. A critical role for 
LTA( 4)H in limiting chronic pulmonary neutrophilic inflammation. Science 
2010; 330: 90-4. 
487 
85. Davies DR, Mamat B, Magnusson OT, Christensen J, Haraldsson MH, Mishra R, 
Pease B, Hansen E, Singh J, Zembower D, Kim H, KiseIyov AS, Burgin AB, 
Gurney ME, Stewart LJ. Discovery of leukotriene A4 hydrolase inhibitors using 
metabolomics biased fragment crystallography. J Med Chem 2009; 52: 4694-715 . 
86. Bollmann F, Art J, Henke J, Schrick K, Besche V, Bros M, Li H, Siuda D, 
Handler N, Bauer F, Erker T, Behnke F, M6nch B, HardIe L, Hoffmann M, Chen 
CY, F6rstermann U, Dirsch VM, Werz 0 , Kleinert H, Pautz A. Resveratrol post-
transcriptionally regulates pro-inflammatory gene expression via regulation of 
KSRP RNA binding activity. Nucleic Acids Res 2014; 42: 12555-69. 
87. Yang S, Irani K, Heffron SE, Jurnak F, Meyskens FL Jr. Alterations in 
the expression of the apurinic/apyrimidinic endonuclease-l/redox factor-l 
(APE/Ref-l) in human melanoma and identification of the therapeutic potential of 
resveratrol as an APE/Ref-l inhibitor. Mol Cancer Ther 2005; 4: 1923-35. 
88. Raffoul 11, Heydari AR, Hillman GG. DNA Repair and Cancer Therapy: 
Targeting APEl/Ref-1 Using Dietary Agents. J Onco12012; 2012: 370481. 
89. Thakur S, Sarkar B, Cholia RP, Gautam N, Dhiman M, Mantha AK. APEI /Ref-i 
as an emerging therapeutic target for various human diseases: phytochemical 
modulation ofits functions . Exp Mol Med 2014; 46: el06. 
90. Yang S, Irani K, Heffron SE, Jurnak F, Meyskens FL Jr. Alterations in 
the expression of the apurinic/apyrimidinic endonuclease-l/redox factor-l 
(APE/Ref-l) in human melanoma and identification of the therapeutic potential of 
resveratrol as an APE/Ref-l inhibitor. Mol Cancer Ther 2005; 4: 1923-35. 
91. Shaikh A Y, Martin LJ. DNA base-excision repair enzyme apurinic/apyrimidinic 
endonuclease/redox factor-l is increased and competent in the brain and spinal 
cord of individuals with amyotrophic lateral sclerosis. Neuromolecular Med 
2002; 2: 47-60. 
92. Tan Z, Shi L, Schreiber SS. DifferentiaI expression of redox factor-l associated 
with beta-amyloid-mediated neurotoxicity. Open Neurosci J 2009; 3: 26-34. 
93 . Gehm BD, McAndrews JM, Chien PY, Jameson JL. Resveratrol, a polyphenolic 
compound found in grapes and wine, is an agonist for the estrogen receptor. 
Proc Nat Acad Sci USA 1997; 94: 14138-43. 
94. Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM. Resveratroi acts as a 
mixed agonistlantagonist for estrogen receptors alpha and beta. Endocrinology 
2000; 141: 3657-67. 
488 
95. Nwachukwu JC, Srinivasan S, Bruno NE, Parent AA, Hughes TS, Pollock JA, 
Gjyshi 0 , Cavett V, Nowak J, Garcia-Ordonez RD, Houtman R, Griffin PR, 
Kojetin DJ, Katzenellenbogen JA, Conkright MD, Nettles KW. Resveratrol 
modulates the inflammatory response via an estrogen receptor-signal integration 
network. Elife 2014; 25: e02057. 
96. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, 
Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA. 
Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. 
Nature 2003; 425: 191-6. 
97. Dai H, Kustigian L, Camey D, Case A, Considine T, Hubbard BP, Pemi RB, 
Riera TV, Szczepankiewicz B, Vlasuk GP, Stein RL. SIRTI activation by small 
molecules: kinetic and biophysical evidence for direct interaction of enzyme and 
activator. J Biol Chem 2010; 285: 32695-703. 
98. Beher D, Wu J, Cumine S, Kim KW, Lu SC, Atangan L, Wang M. Resveratrol 
is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 2009; 
74: 619-24. 
99. Lakshminarasimhan M, Rauh D, Schutkowski M, Steegbom C. Sirt1 activation 
by resveratrol is substrate sequence-selective. Aging (Albany NY) 2013; 
5: 151-4. 
100. Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, Ke H, Rehmann H, 
Taussig R, Brown AL, Kim MK, Beaven MA, Burgin AB, Manganiello V, 
Chung JH. Resveratrol ameliorates aging-related metabolic phenotypes by 
inhibiting cAMP phosphodiesterases. Ce1l2012; 148: 421-33. 
101. Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, Elliott PJ, 
Puigserver P, Auwerx 1. AMPK regulates energy expenditure by modulating 
NAD+ metabolism and SIRT1 activity. Nature 2009; 458: 1056-60. 
102. Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ, 
Agarwal B, Ye L, Ramadori G, Teodoro JS , Hubbard BP, Vare\a AT, Davis JG, 
Varamini B, Hafner A, Moaddel R, Rolo AP, Coppari R, Palmeira CM, 
de Cabo R, Baur JA, Sinclair DA. SIRTI is required for AMPK activation and the 
beneficial effects of resveratrol on mitochondrial function. Cell Metab 2012; 
15: 675-90. 
103. Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS, 
Griffith D, Griffor M, Loulakis P, Pabst B, Qiu X, Stockman B, Thanabal 
V,Varghese A, Ward J, Withka J, Ahn K. SRTl720, SRT2183 , SRT1460, and 
resveratrol are not direct activators ofSIRTI. J Biol Chem 2010; 285 : 8340-51. 
489 
104. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW. 
Modulation ofNF-kappaB-dependent transcription and cell survival by the SIRTI 
deacetylase. EMBO J 2004; 23 : 2369-80. 
105. McCarty MF, Barroso-Aranda J, Contreras F. AMP-activated kinase may 
suppress NADPH oxidase activation in vascular tissues. Med Hypotheses 2009; 
72: 468-70. 
106. Song P, Zou MH. Regulation ofNAD(P)H oxidases by AMPK in cardiovascular 
systems. Free Radic Biol Med 2012; 52: 1607-19. 
107. Tang H, Pan CS, Mao XW, Liu YY, Yan L, Zhou CM, Fan JY, Zhang SV, 
Han JY. Role of NAD PH Oxidase in Total Salvianolic Acid Injection Attenuating 
Ischemia-Reperfusion Impaired Cerebral Microcirculation and Neurons: 
Implication of AMPKlAkt/PKC. Microcirculation 2014; 21: 615-27. 
108. Yamamori T, DeRicco J, Naqvi A, Hoffman TA, Mattagajasingh I, Kasuno K, 
Jung SB, Kim CS, !rani K. SIRTI deacetylates APEI and regulates cellular base 
excision repair. Nucleic Acids Res 2010; 38: 832-45. 
109. Britton RG, Kovoor C, Brown K. Direct molecular targets of resveratrol : 
identifying key interactions to unlock complex mechanisms. Ann N Y Acad Sci 
2015; 1348: 124-33. 
110. Tang PC-TT, Ng Y-F, Ho S, Gyda M, Chan S-W,. Resveratrol and cardiovascular 
health- promising therapeutic or hopeless illusion? Pharmacol Res 2014; 
90: 88-115. 

APPENDIXD 
THE LINKBETWEEN PARKINSON'S DISEASE AND ATTENTION-DEFICIT 
HYPERACTIVITY DISORDER: AN ACCOUNT OF THE EVIDENCE 
In this thesis, the nicotinamide-streptozotocin model of long-term hyperglycaemia 
was employed to demonstrate the selective vulnerability of the nigrostriatal pathway to a 
supplementary source of oxidative stress. In achieving this goal, we were arrested by the 
remarkably singular behaviours manifested by our model: not only did long-term 
hyperglycaemic rats display bradykinesia and gait abnormalities, they were also 
paradoxically hyper-reactive in contexts of social novelty. 
Given the paucity of literature addressing behavioural alterations ansmg from 
sustained hyperglycaemia, we were solely supplied with our own data and cIues from 
seemingly unrelated neuropsychiatric models on the quest to untangle this enigma. 
On the one hand, we knew that the dorsal striatum of our model was poorly supplied 
with dopamine at baseline. On the other hand, the social behaviour of our 
hyperglycaemic rats bore a striking likeness with that of attention-deficit hyperactivity 
disorder models. Seeking to sharpen our understanding of this disease, we discovered 
that attention-deficit hyperactivity disorder and Parkinson ' s disease share a common 
dopaminergic neuropathological element. Even more striking is the implication of the 
nigrostriatal pathway in both disorders. As mentioned in the discussion, patients with 
attention-deficit hyperactivity disorder present alterations at the level of the substantia 
nigra pars compacta (deI Campo et al. , 2013 ; Romanos et al. , 2010) and of the dorsal 
striatum (Badgaiyan et al., 2015 ; Sikstrom and Soderlund, 2007). 
While these two neuropathologies appear to be quite distinct, at least by virtue of 
their symptomatic signatures, it is reasonable to question the possibility that they are 
more intimately linked than first appearances would allow. In this view, the aim of this 
appendix is to briefly recount the evidence supporting such an association. 
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1. Nigral morphology 
We mentioned that the substantia nigra pars compacta is altered in patients with 
attention-deficit hyperactivity disorder (deI Campo et al. , 2013; Romanos et al. , 2010). 
In fact, these abnormalities were identified with various kinds of imaging techniques 
more commonly employed in parkinsonian patients, such as transcranial sonography and 
positron emission tomography. 
Figure 1 Transcranial sonographies of the midbrain in patients with attention-
deficit hyperactivity disorder and Parkinson 's disease. 
In aIl transcranial sono graphies, the midbrain is circled by the dotted line 
and the echogenic area of the substantia nigra is traced with a full white 
line. Top: In patients with attention-deficit hyperactivity disorder (B), 
the echogenic area is enlarged compared with control individuals (A). 
(From Romanos et al. , 2010.) Bottom: Similar findings of an enlarged 
echogenic substantia nigra pars compacta can be observed in patients with 
Parkinson's disease (right) in comparison with healthy individuals (Ieft) . 
(From Gaenslen et al., 2008.) 
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ln particular, evidence of an enhanced echogenicity was gathered in children 
with attention-deficit hyperactivity disorder (Romanos et al. , 2010), a pathological sign 
linked to increased iron content paired with a susceptibility for nigrostriatal dysfunction 
(Becker et al., 1995; Berg et al. , 2002; Gaenslen et al. , 2008). Remarkably, the same 
pattern of echogenicity can be observed in parkinsonian patients (Figure 1). 
These important findings launched investigations aimed at uncovering the role of 
oxidative stress, perhaps linked to nigral iron contents, in this neuropsychiatric condition 
(Hess et al., 2017). It is unc1ear how iron contents are linked to neuropathogenicity in 
both these diseases. 
2. Animal models 
Looking into animal models also provides sorne indications of a possible link 
between the se pathologies. Quite teIling is the existence of a longstanding model of 
attention-deficit hyperactivity disorder, used for sorne 40 years now, that employs 
6-0HDA. ln neonate rats, this parkinsonian toxin destroys the near totality of 
nigrostriatal neurons, sparing the ventral tegmental area, and causes a compensatory 
serotoninergic hyperinnervation of the striatum that is thought to underlie behavioural 
aberrations (Breese et al. , 2005; Kostrzewa et al. , 2004, 2006). The exact underpinnings 
of the hyper-reactive phenotype remains ill understood. Noteworthy, total depletion of 
dorsostriatal dopamine is likely not physiologicaIly relevant in patients with attention-
deficit hyperactivity disorder. The hypotonic and hyperphasic aspects thought to 
underlie this illness are therefore not represented therein (Badgaiyan et al., 2015; 
Sikstrom and Soderlund, 2007). 
More recently, in an attempt to model Parkinson's disease, one group uncovered 
a hyper-reactive phenotype resulting from subeffective treatments. lndeed, primates 
treated with varying chronic doses of the parkinsonian toxin MPTP displayed early 
premotor social alterations, inc1uding enhanced aggressive and affiliative behaviours, 
highly correlated with dorsostriatal denervation. ln the later phase of the pathology 
wherein aIl evaluated dopamine-related cortical and subcortical structures were 
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fully degenerated, these hyper-reactive behaviours were drastically decreased and 
conspicuous motor symptoms emerged. This study actually sheds light on a possible 
continuum of nigrostriatal dopaminergic manifestations, ranging from hyper-reactivity at 
low levels of neurodegeneration to apathy and motor impairments at high degrees of 
denervation (Durand et al. , 2015). In relation to our own findings, we reiterate the 
possibility that long-term hyperglycaemic rats examined between 3 and 6 months 
display mixed moderate behaviours representative of both ends of the continuum. It is 
tempting to propose that sorne forms of attention-deficit hyperactivity disorder and 
Parkinson's disease may overlap. 
3. Epidemiological evidence 
Last, we can address existing epidemiological data suggesting a link between 
attention-deficit hyperactivity disorder and Parkinson's disease or related pathologies. 
Indeed, a growing body of literature has addressed the relationship between early-life 
attention-deficit hyperactivity disorder or its symptoms and late-life parkinsonism 
(Golimstok et al., 2011; Kim et al., 2013; Walitza et al., 2007). Interestingly, 
Parkinson's disease and attention-deficit hyperactivity disorder may share certain 
genetic underpinnings. Specifically, PARK2, a causative gene in Parkinson's disease 
encoding parkin, was found to be associated with attention-deficit hyperactivity disorder 
(Jarick et al., 2014). For sorne researchers, this invites the interrogation ofwhether both 
diseases are in fact the early- and late-life continuum of a single dopaminergic pathology 
(Golimstok et al., 2011). We wish to stress, however, that in this setting it is 
unclear whether treatments addressing attention-deficit hyperactivity disorder, like 
methylphenidate, may in fact contribute to overt nigrostriatal neurodegeneration found 
in Parkinson's disease (Sadasivan et al., 2012). 
Although any conclusions based on this scanty yet evocative evidence would be 
deemed premature, the relationship between attention-deficit hyperactivity disorder and 
Parkinson's disease does merit to be addressed by serious investigations aiming to 
expose any possible overlapping neurobiological mechanisms. It remains that no study 
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has appropriately accounted for the history of hyperactivity, aggression or impulsivity in 
large cohorts of parkinsonian patients. 
These findings do, however, provide novel insight into often overlooked 
non-motor behavioural alterations that may arise from nigrostriatal dopaminergic 
neurodegeneration. Indeed, the nigrostriatal pathway is just leaving the shadow of the 
mesocorticolimbic circuit as a regulator of social interactions (Burke et al. , 2010; 
King-Casas et al. , 2005; Lamichhane et al. , 2014; Ong et al. , 2011 ; Palme ri et al., 2017; 
Plavén-Sigray et al. , 2014; Stoeckel et al., 2014). Impaired social aptitudes recognized 
to dim the quality of life of parkinsonian patients - even besides the well-appreciated 
impulse control disorders that ensue from dopaminergic treatments (Cilia, 2012) - are 
gaining attention in the scientific community (Schrag et al., 2000; Yoshimura et al., 
2005; PeU et al. , 2006). Granted this era of neuroscientists is shining a powerful 
limelight on non-motor symptoms in Parkinson's disease, there is hope that these 
interrogations will soon be addressed. 
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